<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31437950</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>264</Volume><PubDate><Year>2019</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Detecting Systemic Data Quality Issues in Electronic Health Records.</ArticleTitle><Pagination><StartPage>383</StartPage><EndPage>387</EndPage><MedlinePgn>383-387</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI190248</ELocationID><Abstract><AbstractText>Secondary analysis of electronic health records for clinical research faces significant challenges due to known data quality issues in health data observationally collected for clinical care and the data biases caused by standard healthcare processes. In this manuscript, we contribute methodology for data quality assessment by plotting domain-level (conditions (diagnoses), drugs, and procedures) aggregate statistics and concept-level temporal frequencies (i.e., annual prevalence rates of clinical concepts). We detect common temporal patterns in concept frequencies by normalizing and clustering annual concept frequencies using K-means clustering. We apply these methods to the Columbia University Irving Medical Center Observational Medical Outcomes Partnership database. The resulting domain-aggregate and cluster plots show a variety of patterns. We review the patterns found in the condition domain and investigate the processes that shape them. We find that these patterns suggest data quality issues influenced by system-wide factors that affect individual concept frequencies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ta</LastName><ForeName>Casey N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008680</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT3 TR002027</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012895</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068598" MajorTopicYN="Y">Data Accuracy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cluster Analysis</Keyword><Keyword MajorTopicYN="N">Data Accuracy</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31437950</ArticleId><ArticleId IdType="mid">NIHMS1058602</ArticleId><ArticleId IdType="pmc">PMC6857180</ArticleId><ArticleId IdType="doi">10.3233/SHTI190248</ArticleId><ArticleId IdType="pii">SHTI190248</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hripcsak G, and Albers DJ, Next-generation pheno-typing of electronic health records, J Am Med Inform Assoc 20 (2013), 117&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555337</ArticleId><ArticleId IdType="pubmed">22955496</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, and Lieu T, Data enclaves for sharing information derived from clinical and administrative data, JAMA (2018), E1&#x2013;E2.</Citation><ArticleIdList><ArticleId IdType="pubmed">30083726</ArticleId></ArticleIdList></Reference><Reference><Citation>Botsis T, Hartvigsen G, Chen F, and Weng C, Secondary use of EHR: data quality issues and informatics opportunities, Summit on Translat Bioinforma 2010 (2010), 1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041534</ArticleId><ArticleId IdType="pubmed">21347133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharrazi H, Wang C, and Scharfstein D, Prospective EHR-based clinical trials: the challenge of missing data, J Gen Intern Med 29 (2014), 976&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4061350</ArticleId><ArticleId IdType="pubmed">24839057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharrazi H et al., Comparing population-based risk-stratification model performance using demographic, diagnosis and medication data extracted from outpatient electronic health records versus administrative claims, Med Care 55 (2017), 789&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">28598890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G et al., Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers, Stud Health Technol Inform 216 (2015), 574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG et al., A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data, EGEMS (Wash DC) 4 (2016), 1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5051581</ArticleId><ArticleId IdType="pubmed">27713905</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall GC et al., Guidelines for good database selection and use in pharmacoepidemiology research, Pharmacoepidemiology and Drug Safety 21 (2012), 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">22069180</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J, Kahn M, and Toh S, Data quality assessment for comparative effectiveness research in distributed data networks, Med Care 51 (2013), S22&#x2013;S29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306391</ArticleId><ArticleId IdType="pubmed">23793049</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharrazi H et al., A proposed national research and development agenda for population health informatics: summary recommendations from a national expert workshop, J Am Med Inform Assoc 24 (2017), 2&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5201177</ArticleId><ArticleId IdType="pubmed">27018264</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oostrom SH et al., Time trends in prevalence of chronic diseases and multimorbidity not only due to aging: data from general practices and health surveys, PLoS One 11 (2016), e0160264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970764</ArticleId><ArticleId IdType="pubmed">27482903</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartigan JA, and Wong MA, Algorithm AS 136: a K-means clustering algorithm, Journal of the Royal Statistical Society. Series C (Applied Statistics) 28 (1979), 100&#x2013;108.</Citation></Reference><Reference><Citation>Johnson SG, Speedie S, Simon G, Kumar V, and Westra BL, Application of an Ontology for Characterizing Data Quality for a Secondary Use of EHR Data, Appl Clin Inform 07 (2016), 69&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4817336</ArticleId><ArticleId IdType="pubmed">27081408</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R, Walther G, and Hastie T, Estimating the number of clusters in a data set via the gap statistic, Journal of the Royal Statistical Society: Series B (Statistical Methodology) 63 (2001), 411&#x2013;423.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31438202</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>264</Volume><PubDate><Year>2019</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Augmenting Medical Device Evaluation Using a Reusable Unique Device Identifier Interoperability Solution Based on the OHDSI Common Data Model.</ArticleTitle><Pagination><StartPage>1502</StartPage><EndPage>1503</EndPage><MedlinePgn>1502-1503</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI190505</ELocationID><Abstract><AbstractText>The objective of the study is to augment safety and effectiveness evaluation of medical devices through building a reusable unique device identifier (UDI) interoperability solution. We propose a framework for building a UDI research database for medical device evaluation using the OHDSI common data model (CDM). As a pilot study, we design, develop and evaluate a UDI vocabulary, which would enable tackling challenges of data islands and standardization for medical device evaluation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Guoqian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kingsbury</LastName><ForeName>Paul R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nilay</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Controlled Vocabulary</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">Equipment Safety</Keyword><Keyword MajorTopicYN="N">Reference Standards</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31438202</ArticleId><ArticleId IdType="doi">10.3233/SHTI190505</ArticleId><ArticleId IdType="pii">SHTI190505</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31438258</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>264</Volume><PubDate><Year>2019</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Characterizing VA Users with the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>1614</StartPage><EndPage>1615</EndPage><MedlinePgn>1614-1615</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI190561</ELocationID><Abstract><AbstractText>In 2015, the VA Informatics and Computing Infrastructure, a resource center of the Department of Veterans Affairs, began to transform parts of its Corporate Data Warehouse (CDW) into the Observational Medical Outcomes Partnership) Common Data Model for use by its research and operations communities. Using the hierarchical relationships within the clinical vocabularies in OMOP we found differences in visits, disease prevalence, and medications prescribed between male and female veterans seen between VA fiscal years 2000-17.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Viernes</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>South</LastName><ForeName>Brett</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coronado</LastName><ForeName>Gregorio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014493" MajorTopicYN="Y">United States Department of Veterans Affairs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="Y">Veterans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Electronic health ecords</Keyword><Keyword MajorTopicYN="N">systematized nomenclature of medicine</Keyword><Keyword MajorTopicYN="N">veterans</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31438258</ArticleId><ArticleId IdType="doi">10.3233/SHTI190561</ArticleId><ArticleId IdType="pii">SHTI190561</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31438365</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>264</Volume><PubDate><Year>2019</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Standardized Observational Cancer Research Using the OMOP CDM Oncology Module.</ArticleTitle><Pagination><StartPage>1831</StartPage><EndPage>1832</EndPage><MedlinePgn>1831-1832</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI190670</ELocationID><Abstract><AbstractText>Observational research in cancer requires substantially more detail than most other therapeutic areas. Cancer conditions are defined through histology, affected anatomical structures, staging and grading, and biomarkers, and are treated with complex therapies. Here, we show a new cancer module as part of the OMOP CDM, allowing manual and automated abstraction and standardized analytics. We tested the model in EHR and registry data against a number of typical use cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Belenkaya</LastName><ForeName>Rimma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>OHDSI Oncology Workgroup, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurley</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical and Translational Sciences Institute, Northwestern University, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dymshyts</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Odysseus Data Science Inc, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araujo</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Real World Analytics Solution, IQVIA, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Maine Medical Center Research Institute, Center for Outcomes Research and Evaluation, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>RuiJun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Department, Columbia University Medical Center, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real World Analytics Solution, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="Y">Research</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Oncology</Keyword><Keyword MajorTopicYN="N">Research</Keyword><Keyword MajorTopicYN="N">Standardized</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31438365</ArticleId><ArticleId IdType="doi">10.3233/SHTI190670</ArticleId><ArticleId IdType="pii">SHTI190670</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31438371</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>264</Volume><PubDate><Year>2019</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Genomic Common Data Model for Biomedical Data in Clinical Practice.</ArticleTitle><Pagination><StartPage>1843</StartPage><EndPage>1844</EndPage><MedlinePgn>1843-1844</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI190676</ELocationID><Abstract><AbstractText>A common data model for clinical NGS panel data that is used in a distributed research network to achieve large scale to make evidence for improving patient care should be developed. This study developed OMOP-CDM extension for NGS panel data and confirmed the feasibility of the model by finding the differences between a database generated by research-purpose and clinical practice. We believe this data model can be used in distributed research model and will facilitate the usage of the clinical NGS data in patient care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Seo Jeong</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roh</LastName><ForeName>Jin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, Ajou University Hospital, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yu Rang</ForeName><Initials>YR</Initials><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="Y">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data Analysis</Keyword><Keyword MajorTopicYN="N">High-Throughput Nucleotide Sequencing</Keyword><Keyword MajorTopicYN="N">Observational Study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31438371</ArticleId><ArticleId IdType="doi">10.3233/SHTI190676</ArticleId><ArticleId IdType="pii">SHTI190676</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31445247</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8243</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of medical informatics</Title><ISOAbbreviation>Int J Med Inform</ISOAbbreviation></Journal><ArticleTitle>Automatic trial eligibility surveillance based on unstructured clinical data.</ArticleTitle><Pagination><StartPage>13</StartPage><EndPage>19</EndPage><MedlinePgn>13-19</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijmedinf.2019.05.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-5056(18)31052-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Insufficient patient enrollment in clinical trials remains a serious and costly problem and is often considered the most critical issue to solve for the clinical trials community. In this project, we assessed the feasibility of automatically detecting a patient's eligibility for a sample of breast cancer clinical trials by mapping coded clinical trial eligibility criteria to the corresponding clinical information automatically extracted from text in the EHR.</AbstractText><AbstractText Label="METHODS">Three open breast cancer clinical trials were selected by oncologists. Their eligibility criteria were manually abstracted from trial descriptions using the OHDSI ATLAS web application. Patients enrolled or screened for these trials were selected as 'positive' or 'possible' cases. Other patients diagnosed with breast cancer were selected as 'negative' cases. A selection of the clinical data and all clinical notes of these 229 selected patients was extracted from the MUSC clinical data warehouse and stored in a database implementing the OMOP common data model. Eligibility criteria were extracted from clinical notes using either manually crafted pattern matching (regular expressions) or a new natural language processing (NLP) application. These extracted criteria were then compared with reference criteria from trial descriptions. This comparison was realized with three different versions of a new application: rule-based, cosine similarity-based, and machine learning-based.</AbstractText><AbstractText Label="RESULTS">For eligibility criteria extraction from clinical notes, the machine learning-based NLP application allowed for the highest accuracy with a micro-averaged recall of 90.9% and precision of 89.7%. For trial eligibility determination, the highest accuracy was reached by the machine learning-based approach with a per-trial AUC between 75.5% and 89.8%.</AbstractText><AbstractText Label="CONCLUSION">NLP can be used to extract eligibility criteria from EHR clinical notes and automatically discover patients possibly eligible for a clinical trial with good accuracy, which could be leveraged to reduce the workload of humans screening patients for trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meystre</LastName><ForeName>St&#xe9;phane M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC, United States; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, United States. Electronic address: meystre@musc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heider</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Youngjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aruch</LastName><ForeName>Daniel B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Britten</LastName><ForeName>Carolyn D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 CA210962</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 CA189848</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA210963</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 CA138313</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Med Inform</MedlineTA><NlmUniqueID>9711057</NlmUniqueID><ISSNLinking>1386-5056</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001331" MajorTopicYN="N">Automation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073458" MajorTopicYN="N">Data Warehousing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004608" MajorTopicYN="Y">Eligibility Determination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="N">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016526" MajorTopicYN="N">Workload</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Eligibility criteria</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Natural language processing</Keyword></KeywordList><CoiStatement>COMPETING INTERESTS STATEMENT. The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31445247</ArticleId><ArticleId IdType="mid">NIHMS1530600</ArticleId><ArticleId IdType="pmc">PMC6717538</ArticleId><ArticleId IdType="doi">10.1016/j.ijmedinf.2019.05.018</ArticleId><ArticleId IdType="pii">S1386-5056(18)31052-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung NS, Crowley WF, Genel M, Salber P, Sandy L, Sherwood LM, et al. Central challenges facing the national clinical research enterprise. JAMA. 2003. March 12;289(10):1278&#x2013;1287.</Citation><ArticleIdList><ArticleId IdType="pubmed">12633190</ArticleId></ArticleIdList></Reference><Reference><Citation>Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001. March 15;19(6):1728&#x2013;1733.</Citation><ArticleIdList><ArticleId IdType="pubmed">11251003</ArticleId></ArticleIdList></Reference><Reference><Citation>Somkin CP, Ackerson L, Husson G, Gomez V, Kolevska T, Goldstein D, et al. Effect of medical oncologists&#x2019; attitudes on accrual to clinical trials in a community setting. J Oncol Pract 2013. November;9(6):e275&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5706122</ArticleId><ArticleId IdType="pubmed">24151327</ArticleId></ArticleIdList></Reference><Reference><Citation>Penberthy L, Brown R, Puma F, Dahman B. Automated matching software for clinical trials eligibility: measuring efficiency and flexibility. Contemp Clin Trials 2010. May;31(3):207&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4387843</ArticleId><ArticleId IdType="pubmed">20230913</ArticleId></ArticleIdList></Reference><Reference><Citation>Thadani SR, Weng C, Bigger JT, Ennever JF, Wajngurt D. Electronic screening improves efficiency in clinical trial recruitment. Journal of the American Medical Informatics Association Oxford University Press; 2009. November;16(6):869&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3002129</ArticleId><ArticleId IdType="pubmed">19717797</ArticleId></ArticleIdList></Reference><Reference><Citation>Embi PJ, Jain A, Clark J, Harris CM. Development of an electronic health record-based Clinical Trial Alert system to enhance recruitment at the point of care. AMIA Annu Symp Proc 2005;:231&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1560758</ArticleId><ArticleId IdType="pubmed">16779036</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinemann S, Th&#xfc;ring S, Wedeken S, Sch&#xe4;fer T, Scheidt-Nave C, Ketterer M, et al. A clinical trial alert tool to recruit large patient samples and assess selection bias in general practice research. BMC Med Res Methodol BioMed Central; 2011. February 15;11(1):16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047292</ArticleId><ArticleId IdType="pubmed">21320358</ArticleId></ArticleIdList></Reference><Reference><Citation>Meystre SM, Savova GK, Kipper-Schuler KC, Hurdle JF. Extracting information from textual documents in the electronic health record: a review of recent research. Yearb Med Inform 2008:128&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">18660887</ArticleId></ArticleIdList></Reference><Reference><Citation>Demner-Fushman D, Elhadad N. Aspiring to Unintended Consequences of Natural Language Processing: A Review of Recent Developments in Clinical and Consumer-Generated Text Processing. Yearb Med Inform 2016:224&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5171557</ArticleId><ArticleId IdType="pubmed">27830255</ArticleId></ArticleIdList></Reference><Reference><Citation>Richesson RL, Sun J, Pathak J, Kho A. A survey of clinical phenotyping in selected national networks: demonstrating the need for high-throughput, portable, and computational methods. Artificial Intelligence in Medicine 2016;71:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480212</ArticleId><ArticleId IdType="pubmed">27506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Savova GK, Tseytlin E, Finan S, Castine M, Miller T, Medvedeva O, et al. DeepPhe: A Natural Language Processing System for Extracting Cancer Phenotypes from Clinical Records. Cancer Res. 2017. November 1;77(21):e115&#x2013;e118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5690492</ArticleId><ArticleId IdType="pubmed">29092954</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpern Y, Horng S, Choi Y, Sontag D. Electronic medical record phenotyping using the anchor and learn framework. J Am Med Inform Assoc 2016; 23(4):731&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4926745</ArticleId><ArticleId IdType="pubmed">27107443</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Wu X, Luo Z, Boland MR, Theodoratos D, Johnson SB. EliXR: an approach to eligibility criteria extraction and representation. J Am Med Inform Assoc 2011;18 Suppl 1(Supplement 1):i116&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241167</ArticleId><ArticleId IdType="pubmed">21807647</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Tu SW, Carini S, Sim I, Weng C. EliXR-TIME: A Temporal Knowledge Representation for Clinical Research Eligibility Criteria. AMIA Summits Transl Sci Proc 2012;2012:71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392056</ArticleId><ArticleId IdType="pubmed">22779055</ArticleId></ArticleIdList></Reference><Reference><Citation>Duryea R, Danese MD. Human Readable Expression of Structured Algorithms for Describing and Storing Clinical Study Criteria and for Generating and Visualizing Queries. AMIA Summits Transl Sci Proc 2015:1&#x2013;5.</Citation></Reference><Reference><Citation>Levy-fix G, Yaman A, Weng C. Structuring Clinical Trial Eligibility Criteria with the Common Data Model. AMIA Summits Transl Sci Proc 2015.</Citation></Reference><Reference><Citation>Ni Y, Wright J, Perentesis J, Lingren T, Deleger L, Kaiser M, et al. Increasing the efficiency of trial-patient matching: automated clinical trial eligibility Pre-screening for pediatric oncology patients. BMC Med Inform Decis Mak; 2015;15(1):28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4407835</ArticleId><ArticleId IdType="pubmed">25881112</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivade C, Hebert C, Lopetegui M, de Marneffe M-C, Fosler-Lussier E, Lai AM. Textual inference for eligibility criteria resolution in clinical trials. J Biomed Inform 2015. December;58 Suppl:S211&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978353</ArticleId><ArticleId IdType="pubmed">26376462</ArticleId></ArticleIdList></Reference><Reference><Citation>NLM. Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery. 2013. 
Available from: https://clinicaltrials.gov/ct2/show/NCT01872975</Citation></Reference><Reference><Citation>NLM. Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy. 2013. 
Available from: https://clinicaltrials.gov/ct2/show/NCT01901094</Citation></Reference><Reference><Citation>NLM. Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery. 2013. 
Available from: https://clinicaltrials.gov/ct2/show/NCT01953588</Citation></Reference><Reference><Citation>de Castilho RE, Mujdricza-Maydt E. A web-based tool for the integrated annotation of semantic and syntactic structures. Proceedings of the Workshop on Language Technology Resources and Tools for Digital Humanities; Osaka, Japan; 2016:76&#x2013;84.</Citation></Reference><Reference><Citation>Si Y, Weng C. An OMOP CDM-Based Relational Database of Clinical Research Eligibility Criteria. Stud Health Technol Inform 2017;245:950&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5893219</ArticleId><ArticleId IdType="pubmed">29295240</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI) - Opportunities for Observational Researchers. Stud Health Technol Inform 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>ClinicalTrials.gov. Available from: https://clinicaltrials.gov</Citation></Reference><Reference><Citation>Regenstrief Institute. Logical observation identifier names and codes (LOINC). Available from: http://loinc.org/</Citation></Reference><Reference><Citation>NLM. SNOMED Clinical Terms&#xae; (SNOMED-CT&#xae;). Available from: http://www.nlm.nih.gov/research/umls/Snomed/snomed_main.html</Citation></Reference><Reference><Citation>Apache. UIMA (Unstructured Information Management Architecture). Available from: http://uima.apache.org/</Citation></Reference><Reference><Citation>Kim Y, Riloff E, Hurdle JF. A Study of Concept Extraction Across Different Types of Clinical Notes. AMIA Annu Symp Proc 2015:737&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765588</ArticleId><ArticleId IdType="pubmed">26958209</ArticleId></ArticleIdList></Reference><Reference><Citation>Lafferty JD, McCallum A, Pereira F. Conditional random fields: Probabilistic models for segmenting and labeling sequence data. Proc. 18th International Conf. on Machine Learning 2001;:282&#x2013;289.</Citation></Reference><Reference><Citation>Fan R-E, Chang K-W, Hsieh C-J, Wang X-R, Lin C-J. LIBLINEAR: A Library for Large Linear Classification. JMLR 2008;9(Aug):1871&#x2013;1874.</Citation></Reference><Reference><Citation>van Rijsbergen CJ. Information Retrieval. Butterworth; 1979.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31456304</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>12</Issue><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.</ArticleTitle><Pagination><StartPage>1620</StartPage><EndPage>1628</EndPage><MedlinePgn>1620-1628</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.4887</ELocationID><Abstract><AbstractText Label="PURPOSE">To compare the incidence of diabetic ketoacidosis (DKA) among patients with type 2 diabetes mellitus (T2DM) who were new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) versus other classes of antihyperglycemic agents (AHAs).</AbstractText><AbstractText Label="METHODS">Patients were identified from four large US claims databases using broad (all T2DM patients) and narrow (intended to exclude patients with type 1 diabetes or secondary diabetes misclassified as T2DM) definitions of T2DM. New users of SGLT2i and seven groups of comparator AHAs were matched (1:1) on exposure propensity scores to adjust for imbalances in baseline covariates. Cox proportional hazards regression models, conditioned on propensity score-matched pairs, were used to estimate hazard ratios (HRs) of DKA for new users of SGLT2i versus other AHAs. When I<sup>2</sup> &lt;40%, a combined HR across the four databases was estimated.</AbstractText><AbstractText Label="RESULTS">Using the broad definition of T2DM, new users of SGLT2i had an increased risk of DKA versus sulfonylureas (HR [95% CI]: 1.53 [1.31-1.79]), DPP-4i (1.28 [1.11-1.47]), GLP-1 receptor agonists (1.34 [1.12-1.60]), metformin (1.31 [1.11-1.54]), and insulinotropic AHAs (1.38 [1.15-1.66]). Using the narrow definition of T2DM, new users of SGLT2i had an increased risk of DKA versus sulfonylureas (1.43 [1.01-2.01]). New users of SGLT2i had a lower risk of DKA versus insulin and a similar risk as thiazolidinediones, regardless of T2DM definition.</AbstractText><AbstractText Label="CONCLUSIONS">Increased risk of DKA was observed for new users of SGLT2i versus several non-SGLT2i AHAs when T2DM was defined broadly. When T2DM was defined narrowly to exclude possible misclassified patients, an increased risk of DKA with SGLT2i was observed compared with sulfonylureas.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Pharmacoepidemiology &amp; Drug Safety Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7225-9407</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hester</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-5824-2040</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Don</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alba</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lind</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meininger</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berlin</LastName><ForeName>Jesse A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Raritan, New Jersey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067757">Glucagon-Like Peptide-1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000067575" MajorTopicYN="N">Administrative Claims, Healthcare</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016883" MajorTopicYN="N">Diabetic Ketoacidosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067757" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="N">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SGLT2 inhibitor</Keyword><Keyword MajorTopicYN="N">diabetic ketoacidosis</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31456304</ArticleId><ArticleId IdType="pmc">PMC6916409</ArticleId><ArticleId IdType="doi">10.1002/pds.4887</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gosmanov AR, Gosmanova EO, Dillard&#x2010;Cannon E. Management of adult diabetic ketoacidosis. Diabetes Metab Syndr Obes. 2014;7:255&#x2010;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4085289</ArticleId><ArticleId IdType="pubmed">25061324</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335&#x2010;1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2699725</ArticleId><ArticleId IdType="pubmed">19564476</ArticleId></ArticleIdList></Reference><Reference><Citation>International Diabetes Federation . IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017.</Citation></Reference><Reference><Citation>Fazeli Farsani S, Brodovicz K, Soleymanlou N, Marquard J, Wissinger E, Maiese BA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review. BMJ Open. 2017;7(7):e016587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5642652</ArticleId><ArticleId IdType="pubmed">28765134</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang ZH, Kihl&#x2010;Selstam E, Eriksson JW. Ketoacidosis occurs in both Type 1 and Type 2 diabetes&#x2014;a population&#x2010;based study from Northern Sweden. Diabet Med. 2008;25(7):867&#x2010;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">18644074</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen ML, Persson F, Andersen GS, et al. Incidence of ketoacidosis in the Danish type 2 diabetes population before and after introduction of sodium&#x2010;glucose cotransporter 2 inhibitors&#x2014;a nationwide, retrospective cohort study, 1995&#x2010;2014. Diabetes Care. 2017;40(5):e57&#x2010;e58.</Citation><ArticleIdList><ArticleId IdType="pubmed">28283564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YG, Jeon JY, Han SJ, Kim DJ, Lee KW, Kim HJ. Sodium&#x2010;glucose co&#x2010;transporter&#x2010;2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: a nationwide population&#x2010;based cohort study. Diabetes Obes Metab. 2018;20(8):1852&#x2010;1858.</Citation><ArticleIdList><ArticleId IdType="pubmed">29569427</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam KS, Chow CC, Tan KC, et al. Practical considerations for the use of sodium&#x2010;glucose co&#x2010;transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Curr Med Res Opin. 2016;32(6):1097&#x2010;1108.</Citation><ArticleIdList><ArticleId IdType="pubmed">26933918</ArticleId></ArticleIdList></Reference><Reference><Citation>INVOKANA&#xae; (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2018.</Citation></Reference><Reference><Citation>Invokana (canagliflozin hemihydrate) [package insert]. Italy: Janssen&#x2010;Cilag SpA; n.d.</Citation></Reference><Reference><Citation>FARXIGA&#xae; (dapagliflozin) [package insert]. Wilmington, DE AstraZeneca Pharmaceuticals; October 2017.</Citation></Reference><Reference><Citation>Forxiga (dapagliflozin) [package insert]. Germany: AstraZeneca GmbH; n.d.</Citation></Reference><Reference><Citation>JARDIANCE&#xae; (empagliflozin) [package insert]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals; December 2017.</Citation></Reference><Reference><Citation>Jardiance (empagliflozin) [package insert]. Germany: Boehringer Ingelheim Pharma GmbH &amp; Co. KG; n.d.</Citation></Reference><Reference><Citation>STEGLATRO&#x2122; (ertugliflozin) [package insert]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; December 2017.</Citation></Reference><Reference><Citation>Steglatro (ertugliflozin) [packet insert]. Belgium: Schering&#x2010;Plough Labo NV; n.d.</Citation></Reference><Reference><Citation>
Food and Drug Administration
. FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf. Accessed March 22, 2018.</Citation></Reference><Reference><Citation>
European Medicines Agency
. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. Healthcare professionals should be aware of possible atypical cases. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/European_Commission_final_decision/WC500202393.pdf. Accessed June 19, 2017.</Citation></Reference><Reference><Citation>Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680&#x2010;1686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542268</ArticleId><ArticleId IdType="pubmed">26203064</ArticleId></ArticleIdList></Reference><Reference><Citation>Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644&#x2010;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">28605608</ArticleId></ArticleIdList></Reference><Reference><Citation>Jabbour S, Seufert J, Scheen A, Bailey CJ, Karup C, Langkilde AM. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from Phase 2b/3 clinical trials. Diabetes Obes Metab. 2017;20(3):620&#x2010;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5836959</ArticleId><ArticleId IdType="pubmed">28950419</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380(4):347&#x2010;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">30415602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I&#x2010;III clinical trials. Adv Ther. 2017;34(7):1707&#x2010;1726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504200</ArticleId><ArticleId IdType="pubmed">28631216</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117&#x2010;2128.</Citation><ArticleIdList><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E. Effects of SGLT&#x2010;2 inhibitors on diabetic ketoacidosis: a meta&#x2010;analysis of randomised controlled trials. Diabetes Res Clin Pract. 2017;130:53&#x2010;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">28570924</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H, Li D, Wang T, Zhai S, Song Y. Effect of sodium&#x2010;glucose cotransporter 2 inhibitors on diabetic ketoacidosis among patients with type 2 diabetes: a meta&#x2010;analysis of randomized controlled trials. Diabetes Care. 2016;39(8):e123&#x2010;e124.</Citation><ArticleIdList><ArticleId IdType="pubmed">27311492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Desai M, Ryan PB, et al. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. Diabetes Res Clin Pract. 2017;128:83&#x2010;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">28448895</ArticleId></ArticleIdList></Reference><Reference><Citation>Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med. 2017;376(23):2300&#x2010;2302.</Citation><ArticleIdList><ArticleId IdType="pubmed">28591538</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(3):553&#x2010;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>
R Core Team
. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: https://www.R-project.org/.</Citation></Reference><Reference><Citation>Genkin A, Lewis DD, Madigan D. Large&#x2010;scale bayesian logistic regression for text categorization. Technometrics. 2007;49(3):291&#x2010;304.</Citation></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the lasso. J Royal Statistical Soc, Series B (Methodological). 1996;58(1):267&#x2010;228.</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23(1):1&#x2010;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One&#x2010;to&#x2010;many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 2):69&#x2010;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">22552982</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Optimal caliper widths for propensity&#x2010;score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150&#x2010;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120982</ArticleId><ArticleId IdType="pubmed">20925139</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p&#x2010;values. Stat Med. 2014;33(2):209&#x2010;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta&#x2010;analysis in clinical trials. Control Clin Trials. 1986;7(3):177&#x2010;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hine J, Paterson H, Abrol E, Russell&#x2010;Jones D, Herring R. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol. 2015;3(7):503&#x2010;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">26025388</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M, McKenna MJ, Crowley RK. Diabetic ketoacidosis in patients with type 2 diabetes recently commenced on Sglt&#x2010;2 inhibitors: an ongoing concern. Endocr Pract. 2017;23(4):506&#x2010;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">28437153</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell DSH. Re: diabetic ketoacidosis in patients with type 2 diabetes on Sglt&#x2010;2 inhibitors: an ongoing concern. Endocr Pract. 2018;24(1):126.</Citation><ArticleIdList><ArticleId IdType="pubmed">29368970</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31483279</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>267</Volume><PubDate><Year>2019</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Moving Towards an EHR Data Quality Framework: The MIRACUM Approach.</ArticleTitle><Pagination><StartPage>247</StartPage><EndPage>253</EndPage><MedlinePgn>247-253</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI190834</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Data quality (DQ) is an important prerequisite for secondary use of electronic health record (EHR) data in clinical research, particularly with regards to progressing towards a learning health system, one of the MIRACUM consortium's goals. Following the successful integration of the i2b2 research data repository in MIRACUM, we present a standardized and generic DQ framework.</AbstractText><AbstractText Label="STATE OF THE ART" NlmCategory="BACKGROUND">Already established DQ evaluation methods do not cover all of MIRACUM's requirements.</AbstractText><AbstractText Label="CONCEPT" NlmCategory="METHODS">A data quality analysis plan was developed to assess common data quality dimensions for demographic-, condition-, procedure- and department-related variables of MIRACUM's research data repository.</AbstractText><AbstractText Label="IMPLEMENTATION" NlmCategory="METHODS">A data quality analysis (DQA) tool was developed using R scripts packaged in a Docker image with all the necessary dependencies and R libraries for easy distribution. It integrates with the i2b2 data repository at each MIRACUM site, executes an analysis on the data and generates a DQ report.</AbstractText><AbstractText Label="LESSONS LEARNED" NlmCategory="CONCLUSIONS">Our DQA tool brings the analysis to the data and thus meets the MIRACUM data protection requirements. It evaluates established DQ dimensions of data repositories in a standardized and easily distributable way. This analysis allowed us to reveal and revise inconsistencies in earlier versions of the ETL jobs. The framework is portable, easy to deploy across different sites and even further adaptable to other database schemes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The presented framework provides the first step towards a unified, standardized and harmonized EHR DQ assessment in MIRACUM. DQ issues can now be systematically identified by individual hospitals to subsequently implement site- or consortium-wide feedback loops to increase data quality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kapsner</LastName><ForeName>Lorenz A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Center of Medical Information and Communication Technology, University Hospital Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kampf</LastName><ForeName>Marvin O</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Center of Medical Information and Communication Technology, University Hospital Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seuchter</LastName><ForeName>Susanne A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Center of Medical Information and Communication Technology, University Hospital Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamdje-Wabo</LastName><ForeName>Gaetan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics of the Heinrich-Lanz-Center, Mannheim University Medicine, Ruprecht-Karls-University Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gradinger</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics of the Heinrich-Lanz-Center, Mannheim University Medicine, Ruprecht-Karls-University Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganslandt</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics of the Heinrich-Lanz-Center, Mannheim University Medicine, Ruprecht-Karls-University Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mate</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Medical Information and Communication Technology, University Hospital Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruendner</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Friedrich-Alexander University Erlangen-N&#xfc;rnberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraska</LastName><ForeName>Detlef</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center of Medical Information and Communication Technology, University Hospital Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokosch</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials><AffiliationInfo><Affiliation>Center of Medical Information and Communication Technology, University Hospital Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Friedrich-Alexander University Erlangen-N&#xfc;rnberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D000068598" MajorTopicYN="Y">Data Accuracy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data analysis</Keyword><Keyword MajorTopicYN="N">clinical research</Keyword><Keyword MajorTopicYN="N">data quality</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31483279</ArticleId><ArticleId IdType="doi">10.3233/SHTI190834</ArticleId><ArticleId IdType="pii">SHTI190834</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31494719</PMID><DateCompleted><Year>2020</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1573-689X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>07</Day></PubDate></JournalIssue><Title>Journal of medical systems</Title><ISOAbbreviation>J Med Syst</ISOAbbreviation></Journal><ArticleTitle>Feasibility of Mapping Austrian Health Claims Data to the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>314</StartPage><MedlinePgn>314</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">314</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10916-019-1436-9</ELocationID><Abstract><AbstractText>The Main Association of Austrian Social Security Institutions collects pseudonymized claims data from Austrian social security institutions and information about hospital stays in a database for research purposes. For new studies the same data are repeatedly reprocessed and it is difficult to compare different study results even though the data is already preprocessed and prepared in a proprietary data model. Based on a study on adverse drug events in relation to inappropriate medication in geriatric patients the suitability of the Observational Medical Outcomes Partnership (OMOP) common data model (CDM) is analyzed and data is transformed into the OMOP CDM. 1,023 (99.7%) of drug codes and 3,812 (99.2%) of diagnoses codes coincide with the OMOP vocabularies. The biggest obstacles are missing mappings for the Local Vocabularies like the Austrian pharmaceutical registration numbers and the Socio-Economic Index to the OMOP vocabularies. OMOP CDM is a promising approach for the standardization of Austrian claims data. In the long run, the benefits of standardization and reproducibility of research should outweigh this initial drawback.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haberson</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2138-9732</Identifier><AffiliationInfo><Affiliation>Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. a.haberson@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinner</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xf6;berl</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gall</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Syst</MedlineTA><NlmUniqueID>7806056</NlmUniqueID><ISSNLinking>0148-5598</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N" Type="Geographic">Austria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005853" MajorTopicYN="N">Geriatrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="N">Insurance Claim Review</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063487" MajorTopicYN="N">Prescription Drug Misuse</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Claims data</Keyword><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Drug safety</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Secondary use</Keyword><Keyword MajorTopicYN="N">Standardized health data</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31494719</ArticleId><ArticleId IdType="pmc">PMC6732152</ArticleId><ArticleId IdType="doi">10.1007/s10916-019-1436-9</ArticleId><ArticleId IdType="pii">10.1007/s10916-019-1436-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ohlmeier C, Leverkus F, Kloss S, Basic E, Ble&#xdf; H-H. Estimating the incidence of venous thromboembolism (VTE) using various types of routine data of the German healthcare system. Z f Evidenz, Fortbild. und Qualitat Im Gesundheitswesen. 2018;139:46&#x2013;52. doi: 10.1016/j.zefq.2018.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.zefq.2018.11.005</ArticleId><ArticleId IdType="pubmed">30477975</ArticleId></ArticleIdList></Reference><Reference><Citation>Safran C, Bloomrosen M, Hammond WE, Labkoff S, Markel-Fox S, Tang PC, Detmer DE, Expert P. Toward a national framework for the secondary use of health data: An American medical informatics association white paper. J. Am. Med. Inform. Assoc. 2007;14:1):1&#x2013;1):9. doi: 10.1197/jamia.M2273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M2273</ArticleId><ArticleId IdType="pmc">PMC2329823</ArticleId><ArticleId IdType="pubmed">17077452</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisinger SJ, Ryan PB, O'Hara DJ, Powell GE, Painter JL, Pattishall EN, Morris JA. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. J. Am. Med. Inform. Assoc. 2010;17(6):652&#x2013;662. doi: 10.1136/jamia.2009.002477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.002477</ArticleId><ArticleId IdType="pmc">PMC3000752</ArticleId><ArticleId IdType="pubmed">20962127</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Zhou X, Suehs BT, Hartzema AG, Kahn MG, Moride Y, Sauer BC, Liu Q, Moll K, Pasquale MK, Nair VP, Bate A. A comparative assessment of observational medical outcomes partnership and mini-sentinel common data models and analytics: Implications for active drug safety surveillance. Drug Saf. 2015;38(8):749&#x2013;765. doi: 10.1007/s40264-015-0297-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0297-5</ArticleId><ArticleId IdType="pubmed">26055920</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinner C, Gezgin D, Wendl C, Gall W. A clinical data warehouse based on OMOP and i2b2 for Austrian health claims data. Stud. Health Technol. Inform. 2018;248:94&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">29726424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Choi J, Jang I, Quach J, Ohno-Machado L. Feasibility of representing data from published nursing research using the OMOP common data model. AMIA Annu. Symp. Proc. 2016;2016:715&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333244</ArticleId><ArticleId IdType="pubmed">28269868</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, Herrmann T, Haverkamp C, Horki P, Laufer J, Berger F, Honing G, Fritsch HW, Schuttler J, Ganslandt T, Prokosch HU, Sedlmayr M. Towards implementation of OMOP in a German University hospital consortium. Appl. Clin. Inform. 2018;9(1):54&#x2013;61. doi: 10.1055/s-0037-1617452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31542521</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Making work visible for electronic phenotype implementation: Lessons learned from the eMERGE network.</ArticleTitle><Pagination><StartPage>103293</StartPage><MedlinePgn>103293</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2019.103293</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(19)30212-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Implementation of phenotype algorithms requires phenotype engineers to interpret human-readable algorithms and translate the description (text and flowcharts) into computable phenotypes - a process that can be labor intensive and error prone. To address the critical need for reducing the implementation efforts, it is important to develop portable algorithms.</AbstractText><AbstractText Label="METHODS">We conducted a retrospective analysis of phenotype algorithms developed in the Electronic Medical Records and Genomics (eMERGE) network and identified common customization tasks required for implementation. A novel scoring system was developed to quantify portability from three aspects: Knowledge conversion, clause Interpretation, and Programming (KIP). Tasks were grouped into twenty representative categories. Experienced phenotype engineers were asked to estimate the average time spent on each category and evaluate time saving enabled by a common data model (CDM), specifically the Observational Medical Outcomes Partnership (OMOP) model, for each category.</AbstractText><AbstractText Label="RESULTS">A total of 485 distinct clauses (phenotype criteria) were identified from 55 phenotype algorithms, corresponding to 1153 customization tasks. In addition to 25 non-phenotype-specific tasks, 46 tasks are related to interpretation, 613 tasks are related to knowledge conversion, and 469 tasks are related to programming. A score between 0 and 2 (0 for easy, 1 for moderate, and 2 for difficult portability) is assigned for each aspect, yielding a total KIP score range of 0 to 6. The average clause-wise KIP score to reflect portability is 1.37&#x202f;&#xb1;&#x202f;1.38. Specifically, the average knowledge (K) score is 0.64&#x202f;&#xb1;&#x202f;0.66, interpretation (I) score is 0.33&#x202f;&#xb1;&#x202f;0.55, and programming (P) score is 0.40&#x202f;&#xb1;&#x202f;0.64. 5% of the categories can be completed within one hour (median). 70% of the categories take from days to months to complete. The OMOP model can assist with vocabulary mapping tasks.</AbstractText><AbstractText Label="CONCLUSION">This study presents firsthand knowledge of the substantial implementation efforts in phenotyping and introduces a novel metric (KIP) to measure portability of phenotype algorithms for quantifying such efforts across the eMERGE Network. Phenotype developers are encouraged to analyze and optimize the portability in regards to knowledge, interpretation and programming. CDMs can be used to improve the portability for some 'knowledge-oriented' tasks.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Luke V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ta</LastName><ForeName>Casey N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caroll</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benoit</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Research Information Science and Computing, Partners Healthcare, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lingren</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dikilitas</LastName><ForeName>Ozan</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mentch</LastName><ForeName>Frank D</ForeName><Initials>FD</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrell</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Wei-Qi</ForeName><Initials>WQ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gainer</LastName><ForeName>Vivian S</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Research Information Science and Computing, Partners Healthcare, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kullo</LastName><ForeName>Iftikhar J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacheco</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hakonarson</LastName><ForeName>Hakon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walunas</LastName><ForeName>Theresa L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Northwestern University Feinberg School of Medicine, Chicago, IL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denny</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiley</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Human Genome Research Institute, NIH, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Shawn N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Research Information Science and Computing, Partners Healthcare, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States; Medical Informatics Services, NewYork-Presbyterian Hospital, New York, NY, United States. Electronic address: hripcsak@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States. Electronic address: chunhua@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HG008676</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008657</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008672</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008684</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008673</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008701</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008666</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL133786</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG006388</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008680</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG006379</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Electronic health records</Keyword><Keyword MajorTopicYN="N">Phenotyping</Keyword><Keyword MajorTopicYN="N">Portability</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31542521</ArticleId><ArticleId IdType="mid">NIHMS1544840</ArticleId><ArticleId IdType="pmc">PMC6894517</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2019.103293</ArticleId><ArticleId IdType="pii">S1532-0464(19)30212-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liao KP, Cai T, Savova GK, et al. Development of phenotype algorithms using electronic medical records and incorporating natural language processing. BMJ 2015;350:h1885. doi:10.1136/bmj.h1885</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.h1885</ArticleId><ArticleId IdType="pmc">PMC4707569</ArticleId><ArticleId IdType="pubmed">25911572</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty CA, Chisholm RL, Chute CG, et al. The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics 2011;4:13. doi:10.1186/1755-8794-4-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1755-8794-4-13</ArticleId><ArticleId IdType="pmc">PMC3038887</ArticleId><ArticleId IdType="pubmed">21269473</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway M, Berg RL, Carrell D, et al. Analyzing the Heterogeneity and Complexity of Electronic Health Record Oriented Phenotyping Algorithms. AMIA Annu Symp Proc 2011;2011:274&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243189</ArticleId><ArticleId IdType="pubmed">22195079</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton KM, Peissig PL, Kho AN, et al. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. J Am Med Inform Assoc 2013;20:e147&#x2013;54. doi:10.1136/amiajnl-2012-000896</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000896</ArticleId><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W-Q, Denny JC. Extracting research-quality phenotypes from electronic health records to support precision medicine. Genome Med 2015;7:41. doi:10.1186/s13073-015-0166-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-015-0166-y</ArticleId><ArticleId IdType="pmc">PMC4416392</ArticleId><ArticleId IdType="pubmed">25937834</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM, Seneviratne M, Hernandez-Boussard T, et al. Advances in Electronic Phenotyping: From Rule-Based Definitions to Machine Learning Models. Annu Rev Biomed Data Sci 2018;1:53&#x2013;68. doi:10.1146/annurev-biodatasci-080917-013315</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biodatasci-080917-013315</ArticleId><ArticleId IdType="pmc">PMC6583807</ArticleId><ArticleId IdType="pubmed">31218278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kho AN, Hayes MG, Rasmussen-Torvik L, et al. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. J Am Med Inform Assoc 2012;19:212&#x2013;8. doi:10.1136/amiajnl-2011-000439</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000439</ArticleId><ArticleId IdType="pmc">PMC3277617</ArticleId><ArticleId IdType="pubmed">22101970</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim U, Kim H-N, Sung Y-A, et al. Pathway Analysis of Metabolic Syndrome Using a Genome-Wide Association Study of Korea Associated Resource (KARE) Cohorts. Genomics Inform 2014;12:195&#x2013;202. doi:10.5808/GI.2014.12.4.195</Citation><ArticleIdList><ArticleId IdType="doi">10.5808/GI.2014.12.4.195</ArticleId><ArticleId IdType="pmc">PMC4330254</ArticleId><ArticleId IdType="pubmed">25705158</ArticleId></ArticleIdList></Reference><Reference><Citation>Kullo IJ, Ding K, Jouni H, et al. A genome-wide association study of red blood cell traits using the electronic medical record. PloS One 2010;5. doi:10.1371/journal.pone.0013011</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013011</ArticleId><ArticleId IdType="pmc">PMC2946914</ArticleId><ArticleId IdType="pubmed">20927387</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford DC, Crosslin DR, Tromp G, et al. eMERGEing progress in genomics&#x2014;the first seven years. Front Genet 2014;5. doi:10.3389/fgene.2014.00184</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2014.00184</ArticleId><ArticleId IdType="pmc">PMC4060012</ArticleId><ArticleId IdType="pubmed">24987407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby JC, Speltz P, Rasmussen LV, et al. PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc 2016;23:1046&#x2013;52. doi:10.1093/jamia/ocv202</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv202</ArticleId><ArticleId IdType="pmc">PMC5070514</ArticleId><ArticleId IdType="pubmed">27026615</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson O, Hurdle JF. Document Clustering of Clinical Narratives: a Systematic Study of Clinical Sublanguages. AMIA Annu Symp Proc 2011;2011:1099&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243234</ArticleId><ArticleId IdType="pubmed">22195171</ArticleId></ArticleIdList></Reference><Reference><Citation>Studer R, Benjamins VR, Fensel D. Knowledge engineering: Principles and methods. Data Knowl Eng 1998;25:161&#x2013;97. doi:10.1016/S0169-023X(97)00056-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-023X(97)00056-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Aylett RS, Doniat C. Supporting the Domain expert in planning domain construction. In: Proceedings of the AIPS&#x2019;02 Workshop on Knowledge Engineering Tools and Techniques for AI Planning. Citeseer 2002.</Citation></Reference><Reference><Citation>Alonso F, Mat&#xe9; JL, Pazos J. Knowledge engineering versus software engineering. Data Knowl Eng 1990;5:79&#x2013;91. doi:10.1016/0169-023X(90)90005-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0169-023X(90)90005-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ. High-fidelity phenotyping: richness and freedom from bias. J Am Med Inform Assoc doi:10.1093/jamia/ocx110</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocx110</ArticleId><ArticleId IdType="pmc">PMC7282504</ArticleId><ArticleId IdType="pubmed">29040596</ArticleId></ArticleIdList></Reference><Reference><Citation>Richesson RL, Sun J, Pathak J, et al. Clinical phenotyping in selected national networks: demonstrating the need for high-throughput, portable, and computational methods. Artif Intell Med 2016;71:57&#x2013;61. doi:10.1016/j.artmed.2016.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.artmed.2016.05.005</ArticleId><ArticleId IdType="pmc">PMC5480212</ArticleId><ArticleId IdType="pubmed">27506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ, Thompson WK, Eyler AE, et al. Portability of an algorithm to identify rheumatoid arthritis in electronic health records. J Am Med Inform Assoc 2012;19:e162&#x2013;9. doi:10.1136/amiajnl-2011-000583</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000583</ArticleId><ArticleId IdType="pmc">PMC3392871</ArticleId><ArticleId IdType="pubmed">22374935</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Crawford DC, Ritchie MD, et al. Variants Near FOXE1 Are Associated with Hypothyroidism and Other Thyroid Conditions: Using Electronic Medical Records for Genome- and Phenome-wide Studies. Am J Hum Genet 2011;89:529&#x2013;42. doi:10.1016/j.ajhg.2011.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2011.09.008</ArticleId><ArticleId IdType="pmc">PMC3188836</ArticleId><ArticleId IdType="pubmed">21981779</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson WK, Rasmussen LV, Pacheco JA, et al.
An evaluation of the NQF Quality Data Model for representing Electronic Health Record driven phenotyping algorithms. In: AMIA. Citeseer
2012. 
http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.453.993&amp;rep=rep1&amp;type=pdf (accessed 1 Mar 2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540514</ArticleId><ArticleId IdType="pubmed">23304366</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo H, Thompson WK, Rasmussen LV, et al. Desiderata for computable representations of electronic health records-driven phenotype algorithms. J Am Med Inform Assoc 2015;22:1220&#x2013;30. doi:10.1093/jamia/ocv112</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv112</ArticleId><ArticleId IdType="pmc">PMC4639716</ArticleId><ArticleId IdType="pubmed">26342218</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco JA, Rasmussen LV, Kiefer RC, et al. A case study evaluating the portability of an executable computable phenotype algorithm across multiple institutions and electronic health record environments. J Am Med Inform Assoc 2018;25:1540&#x2013;6. doi:10.1093/jamia/ocy101</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy101</ArticleId><ArticleId IdType="pmc">PMC6213083</ArticleId><ArticleId IdType="pubmed">30124903</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen LV, Thompson WK, Pacheco JA, et al. Design patterns for the development of electronic health record-driven phenotype extraction algorithms. J Biomed Inform 2014;51:280&#x2013;6. doi:10.1016/j.jbi.2014.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2014.06.007</ArticleId><ArticleId IdType="pmc">PMC4194216</ArticleId><ArticleId IdType="pubmed">24960203</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, et al. Facilitating phenotype transfer using a common data model. J Biomed Inform Accepted.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang N, Weng C, Hripcsak G. A Method for Enhancing the Portability of Electronic Phenotyping Algorithms: An eMERGE Pilot Study. 2016.</Citation></Reference><Reference><Citation>Hripcsak G, Ludemann P, Pryor TA, et al. Rationale for the Arden Syntax. Comput Biomed Res 1994;27:291&#x2013;324. doi:10.1006/cbmr.1994.1023</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cbmr.1994.1023</ArticleId><ArticleId IdType="pubmed">7956129</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G Writing Arden Syntax medical logic modules. Comput Biol Med 1994;24:331&#x2013;63. doi:10.1016/0010-4825(94)90002-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0010-4825(94)90002-7</ArticleId><ArticleId IdType="pubmed">7705066</ArticleId></ArticleIdList></Reference><Reference><Citation>Samwald M, Fehre K, de Bruin J, et al. The Arden Syntax standard for clinical decision support: Experiences and directions. J Biomed Inform 2012;45:711&#x2013;8. doi:10.1016/j.jbi.2012.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2012.02.001</ArticleId><ArticleId IdType="pubmed">22342733</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. ATLAS. http://www.ohdsi.org/web/atlas (accessed 28 May 2019).</Citation></Reference><Reference><Citation>Yuan C, Ryan PB, Ta C, et al. Criteria2Query: a natural language interface to clinical databases for cohort definition. J Am Med Inform Assoc 2019;26:294&#x2013;305. doi:10.1093/jamia/ocy178</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy178</ArticleId><ArticleId IdType="pmc">PMC6402359</ArticleId><ArticleId IdType="pubmed">30753493</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Spickard A, Johnson KB, et al. Evaluation of a method to identify and categorize section headers in clinical documents. J Am Med Inform Assoc JAMIA 2009;16:806&#x2013;15. doi:10.1197/jamia.M3037</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M3037</ArticleId><ArticleId IdType="pmc">PMC3002123</ArticleId><ArticleId IdType="pubmed">19717800</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu H, Stenner SP, Doan S, et al. MedEx: a medication information extraction system for clinical narratives. J Am Med Inform Assoc 2010;17:19&#x2013;24. doi:10.1197/jamia.M3378</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M3378</ArticleId><ArticleId IdType="pmc">PMC2995636</ArticleId><ArticleId IdType="pubmed">20064797</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny JC, Smithers JD, Miller RA, et al. &#x201c;Understanding&#x201d; medical school curriculum content using KnowledgeMap. J Am Med Inform Assoc JAMIA 2003;10:351&#x2013;62. doi:10.1197/jamia.M1176</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M1176</ArticleId><ArticleId IdType="pmc">PMC181986</ArticleId><ArticleId IdType="pubmed">12668688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci D, Lally A. UIMA: an architectural approach to unstructured information processing in the corporate research environment. Nat Lang Eng 2004;10:327&#x2013;48. doi:10.1017/S1351324904003523</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1351324904003523</ArticleId></ArticleIdList></Reference><Reference><Citation>Savova GK, Masanz JJ, Ogren PV, et al. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. J Am Med Inform Assoc 2010;17:507&#x2013;13. doi:10.1136/jamia.2009.001560</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.001560</ArticleId><ArticleId IdType="pmc">PMC2995668</ArticleId><ArticleId IdType="pubmed">20819853</ArticleId></ArticleIdList></Reference><Reference><Citation>Kullo IJ, Fan J, Pathak J, et al. Leveraging informatics for genetic studies: use of the electronic medical record to enable a genome-wide association study of peripheral arterial disease. J Am Med Inform Assoc 2010;17:568&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995686</ArticleId><ArticleId IdType="pubmed">20819866</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Bielinski SJ, Sohn S, et al. An Information Extraction Framework for Cohort Identification Using Electronic Health Records. AMIA Summits Transl Sci Proc 2013;2013:149&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3845757</ArticleId><ArticleId IdType="pubmed">24303255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo H, Pacheco JA, Rasmussen LV, et al. A Prototype for Executable and Portable Electronic Clinical Quality Measures Using the KNIME Analytics Platform. AMIA Summits Transl Sci Proc 2015;2015:127&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525225</ArticleId><ArticleId IdType="pubmed">26306254</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman C, Alderson PO, Austin JH, et al. A general natural-language text processor for clinical radiology. J Am Med Inform Assoc JAMIA 1994;1:161&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC116194</ArticleId><ArticleId IdType="pubmed">7719797</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31545380</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Comparison of the cohort selection performance of Australian Medicines Terminology to Anatomical Therapeutic Chemical mappings.</ArticleTitle><Pagination><StartPage>1237</StartPage><EndPage>1246</EndPage><MedlinePgn>1237-1246</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocz143</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Electronic health records are increasingly utilized for observational and clinical research. Identification of cohorts using electronic health records is an important step in this process. Previous studies largely focused on the methods of cohort selection, but there is little evidence on the impact of underlying vocabularies and mappings between vocabularies used for cohort selection. We aim to compare the cohort selection performance using Australian Medicines Terminology to Anatomical Therapeutic Chemical (ATC) mappings from 2 different sources. These mappings were taken from the Observational Medical Outcomes Partnership Common Data Model (OMOP-CDM) and the Pharmaceutical Benefits Scheme (PBS) schedule.</AbstractText><AbstractText Label="MATERIALS AND METHODS">We retrieved patients from the electronic Practice Based Research Network data repository using 3 ATC classification groups (A10, N02A, N06A). The retrieved patients were further verified manually and pooled to form a reference standard which was used to assess the accuracy of mappings using precision, recall, and F measure metrics.</AbstractText><AbstractText Label="RESULTS">The OMOP-CDM mappings identified 2.6%, 15.2%, and 24.4% more drugs than the PBS mappings in the A10, N02A and N06A groups respectively. Despite this, the PBS mappings generally performed the same in cohort selection as OMOP-CDM mappings except for the N02A Opioids group, where a significantly greater number of patients were retrieved. Both mappings exhibited variable recall, but perfect precision, with all drugs found to be correctly identified.</AbstractText><AbstractText Label="CONCLUSION">We found that 1 of the 3 ATC groups had a significant difference and this affected cohort selection performance. Our findings highlighted that underlying terminology mappings can greatly impact cohort selection accuracy. Clinical researchers should carefully evaluate vocabulary mapping sources including methodologies used to develop those mappings.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2019. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Guan N</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Centre for eHealth, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonnagaddala</LastName><ForeName>Jitendra</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Centre for eHealth, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farshid</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Lister Hill National Centre for Biomedical Communications, National Library of Medicine National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IQVIA, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liaw</LastName><ForeName>Siaw-Teng</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Centre for eHealth, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="N">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="Y">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039061" MajorTopicYN="N">Systematized Nomenclature of Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="Y">Terminology as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="Y">Vocabulary, Controlled</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Australian Medicines Terminology</Keyword><Keyword MajorTopicYN="N">anatomical therapeutic chemical classification</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">cohort selection</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31545380</ArticleId><ArticleId IdType="pmc">PMC7647230</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocz143</ArticleId><ArticleId IdType="pii">5572827</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Charles D, Gabriel M, Furukawa MF.. Adoption of electronic health record systems among US non-federal acute care hospitals: 2008&#x2013;2012. ONC Data Brief 2013; 9: 1&#x2013;9.</Citation></Reference><Reference><Citation>Safran C. Using routinely collected data for clinical research. Stat Med 1991; 104: 559&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">1905417</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan S, van Weel C.. The use of routinely collected computer data for research in primary care: opportunities and challenges. Fam Pract 2006; 232: 253&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">16368704</ArticleId></ArticleIdList></Reference><Reference><Citation>Concato J, Shah N, Horwitz RI.. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 34225: 1887&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1557642</ArticleId><ArticleId IdType="pubmed">10861325</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence&#x2014;what is it and what can it tell us. N Engl J Med 2016; 37523: 2293&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman O, Kuivaniemi H, Tromp G, et al. The electronic medical records and genomics (eMERGE) network: past, present, and future. Genet Med 2013; 1510: 761..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795928</ArticleId><ArticleId IdType="pubmed">23743551</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM, Halpern Y, Sontag D, et al. Electronic phenotyping with APHRODITE and the Observational Health Sciences and Informatics (OHDSI) data network. AMIA Joint Summits on Translational Science proceedings. AMIA Jt Summits Transl Sci 2017; 2017: 48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543379</ArticleId><ArticleId IdType="pubmed">28815104</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo H, Thompson WK, Rasmussen LV, et al. Desiderata for computable representations of electronic health records-driven phenotype algorithms. J Am Med Inform Assoc 2015; 226: 1220&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639716</ArticleId><ArticleId IdType="pubmed">26342218</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W-Q, Teixeira PL, Mo H, et al. Combining billing codes, clinical notes, and medications from electronic health records provides superior phenotyping performance. J Am Med Inform Assoc 2016; 23 (e1): e20&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4954637</ArticleId><ArticleId IdType="pubmed">26338219</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PB, Jensen LJ, Brunak S.. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet 2012; 136: 395..</Citation><ArticleIdList><ArticleId IdType="pubmed">22549152</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivade C, Raghavan P, Fosler-Lussier E, et al. A review of approaches to identifying patient phenotype cohorts using electronic health records. J Am Med Inform Assoc 2014; 212: 221&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932460</ArticleId><ArticleId IdType="pubmed">24201027</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao KP, Cai T, Gainer V, et al. Electronic medical records for discovery research in rheumatoid arthritis. Arthritis Care Res 2010; 628: 1120&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121049</ArticleId><ArticleId IdType="pubmed">20235204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Levine ME, Shang N, et al. Effect of vocabulary mapping for conditions on phenotype cohorts. J Am Med Inform Assoc 2018; 25 (12): 1618&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289550</ArticleId><ArticleId IdType="pubmed">30395248</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan PB, Stang PE, et al. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform 2012; 454: 689&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">22683994</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonnagaddala J, Dai H-J, Ray P, et al. Mining electronic health records to guide and support clinical decision support systems In: Siaw-Teng Liaw, Andrew Nunn, Tony Sahama, eds. Improving Health Management through Clinical Decision Support Systems. Pennsylvania, USA: IGI Global; 2016: 252&#x2013;69.</Citation></Reference><Reference><Citation>WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo: WHO; 2005.</Citation></Reference><Reference><Citation>Natsch S, Hekster YA, Jong R, et al. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis 1998; 171: 20&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9512177</ArticleId></ArticleIdList></Reference><Reference><Citation>Basger BJ, Chen TF, Moles RJ.. Application of a prescribing indicators tool to assist in identifying drug-related problems in a cohort of older Australians. Int J Pharm Pract 2012; 203: 172&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">22554160</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrows RC Jr, Cimino JJ, Clayton PD. Mapping clinically useful terminology to a controlled medical vocabulary. In: Proceedings of the Annual Symposium on Computer Application in Medical Care. November 5&#x2013;9, 1994; Washington, DC. Pennsylvania: Hanley &amp; Belfus, Inc.</Citation></Reference><Reference><Citation>Humphreys BL, Lindberg D.. The UMLS project: making the conceptual connection between users and the information they need. Bull Med Libr Assoc 1993; 812: 170..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC225759</ArticleId><ArticleId IdType="pubmed">8472002</ArticleId></ArticleIdList></Reference><Reference><Citation>Caughey GE, Roughead EE, Vitry AI, et al. Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts. Diabetes Res Clin Pract 2010; 873: 385&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">19923032</ArticleId></ArticleIdList></Reference><Reference><Citation>Inacio MC, Hansen C, Pratt NL, et al. Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study. BMJ Open 2016; 64: e010664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4853994</ArticleId><ArticleId IdType="pubmed">27130165</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitry AI, Roughead EE, Preiss AK, et al. Influence of comorbidities on therapeutic progression of diabetes treatment in Australian veterans: a cohort study. PLoS One 2010; 511: e14024..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2984440</ArticleId><ArticleId IdType="pubmed">21103337</ArticleId></ArticleIdList></Reference><Reference><Citation>Pahor M, Chrischilles E, Guralnik J, et al. Drug data coding and analysis in epidemiologic studies. Eur J Epidemiol 1994; 104: 405&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">7843344</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber CA, Szucs TD, Rapold R, et al. Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications. BMC Public Health 2013; 131: 1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840632</ArticleId><ArticleId IdType="pubmed">24172142</ArticleId></ArticleIdList></Reference><Reference><Citation>Peissig PL, Costa VS, Caldwell MD, et al. Relational machine learning for electronic health record-driven phenotyping. J Biomed Inform 2014; 52: 260&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4261015</ArticleId><ArticleId IdType="pubmed">25048351</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Ma Y, Gronsbell J, et al. Enabling phenotypic big data with PheNorm. J Am Med Inform Assoc 2018; 251: 54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6251688</ArticleId><ArticleId IdType="pubmed">29126253</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitwal H, Qing D, Jones S, et al. Cross-terminology mapping challenges: a demonstration using medication terminological systems. J Biomed Inform 2012; 454: 613&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4398308</ArticleId><ArticleId IdType="pubmed">22750536</ArticleId></ArticleIdList></Reference><Reference><Citation>Defalco FJ, Ryan PB, Soledad Cepeda M.. Applying standardized drug terminologies to observational healthcare databases: a case study on opioid exposure. Health Serv Outcomes Res Method 2013; 131: 58&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566397</ArticleId><ArticleId IdType="pubmed">23396660</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y, Jung C, Chae Y, et al. Comparison of validity of mapping between drug indications and ICD-10. Methods Inf Med 2014; 533: 195&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">24727865</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H-T, Lu D.-F, Konicek D, et al. Nursing interventions classification in systematized nomenclature of medicine clinical terms: a cross-mapping validation. Comput Inform Nurs 2007; 254: 198&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">17625400</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung KW, Bodenreider O, Aronson AR, et al. Combining lexical and semantic methods of inter-terminology mapping using the UMLS. Stud Health Technol Inform 2007; 129 (Pt 1): 605..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430093</ArticleId><ArticleId IdType="pubmed">17911788</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg DM, Fine J, Chappell R.. Sample size for positive and negative predictive value in diagnostic research using case-control designs. Biostatistics 2008; 101: 94&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668447</ArticleId><ArticleId IdType="pubmed">18556677</ArticleId></ArticleIdList></Reference><Reference><Citation>Burt T, Button KS, Thom HHZ, et al. The burden of the &#x201c;false-negatives&#x201d; in clinical development: analyses of current and alternative scenarios and corrective measures. Clin Transl Sci 2017; 106: 470&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402187</ArticleId><ArticleId IdType="pubmed">28675646</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz S, Rodrigues JM, Rector A, et al. Interface terminologies, reference terminologies and aggregation terminologies: a strategy for better integration. Stud Health Technol Inform 2017; 245: 940&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295238</ArticleId></ArticleIdList></Reference><Reference><Citation>Chute CG. Clinical classification and terminology: some history and current observations. J Am Med Inform Assoc 2000; 73: 298&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61433</ArticleId><ArticleId IdType="pubmed">10833167</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman SE. Coordination of SNOMED-CT and ICD-10: Getting the Most Out of Electronic Health Record Systems. J AHIMA 2005; 767: 60&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">16097126</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MF, Hwang JC, Alexander CY, et al. Reliability of SNOMED-CT coding by three physicians using two terminology browsers. AMIA Annu Symp Proc 2006; 2006: 131&#x2013;5; Washington, DC.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839418</ArticleId><ArticleId IdType="pubmed">17238317</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization. Classification of diseases (ICD). 2018. 
https://www.who.int/classifications/icd/en/. Accessed December 23, 2018.</Citation></Reference><Reference><Citation>Jonnagaddala J, Hu F. Automatic coding of death certificates to ICD-10 terminology. In: Linda Cappellato, Nicola Ferro, Lorraine Goeuriot, Thomas Mandl, eds. CLEF (Working Notes) Dublin, Ireland: Sun SITE Central Europe; 2017.</Citation></Reference><Reference><Citation>
National Clinical Terminology Service. Australian medicines terminology fact sheet. 2016. 
https://www.digitalhealth.gov.au/using-the-my-health-record-system/digital-health-training-resources/guides/australian-medicines-terminology-amt-fact-sheet. Accessed November 14, 2018.</Citation></Reference><Reference><Citation>
International Health Terminology Standards Development Organisation. SNOMED CT July 2018 International Edition&#x2014;SNOMED International Release notes. 2018. 
https://confluence.ihtsdotools.org/display/RMT/SNOMED+CT+July+2018+International+Edition+-+SNOMED+International+Release+notes. Accessed December 11, 2018.</Citation></Reference><Reference><Citation>Bodenreider O, Rodriguez LM.. Analyzing U.S. prescription lists with RxNorm and the ATC/DDD Index. AMIA Annu Symp Proc 2014; 2014: 297&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419961</ArticleId><ArticleId IdType="pubmed">25954332</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Wilcox A.. Reference standards, judges, and comparison subjects: roles for experts in evaluating system performance. J Am Med Inform Assoc 2002; 91: 1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC349383</ArticleId><ArticleId IdType="pubmed">11751799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Friedman C, Alderson PO, et al. Unlocking clinical data from narrative reports: a study of natural language processing. Ann Intern Med 1995; 1229: 681&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7702231</ArticleId></ArticleIdList></Reference><Reference><Citation>
ePBRN
. ePBRN/AMT-Study-JAMIA. 2019. 
https://github.com/ePBRN/AMT-Study-JAMIA. Accessed June 5, 2019.</Citation></Reference><Reference><Citation>
Pharmaceutical Benefits Scheme. PBS publications archive. 2018. 
http://www.pbs.gov.au/info/publication/schedule/archive. Accessed December 11, 2018.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>
US National Library of Medicine. RxNorm release notes. 2013. 
https://www.nlm.nih.gov/research/umls/rxnorm/docs/2013/rxnorm_releasenotes_full_08052013.html. Accessed December 11, 2018.</Citation></Reference><Reference><Citation>
Observational Health Data Sciences and Informatics. Release notes 2017-09-06. 2017. 
https://github.com/OHDSI/OMOP-Standardized-Vocabularies/blob/master/Release%20Notes%202017-09-06.txt. Accessed November 10, 2018.</Citation></Reference><Reference><Citation>
Observational Health Data Sciences and Informatics. Athena&#x2014;OHDSI Vocabularies Repository. 2015. 
http://athena.ohdsi.org/search-terms/terms/43351380. Accessed December 10, 2018.</Citation></Reference><Reference><Citation>Taggart J, Liaw ST, Yu H.. Structured data quality reports to improve EHR data quality. Int J Med Inform 2015; 8412: 1094&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26480872</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle D, Rafael N.. BioGrid Australia and GRHANITE&#x2122;: privacy-protecting subject matching. Stud Health Technol Inform 2011; 168: 24&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">21893908</ArticleId></ArticleIdList></Reference><Reference><Citation>Liaw S-T, Boyle D. Secure data linkage and information sharing with GRHANITE. In: Heather Grain, ed. HISA Health Informatics Conference (HIC) 2008. Melbourne: Health Informatics Society of Australia; August 31&#x2013;September 2 2008, pp. 159&#x2013;165.</Citation></Reference><Reference><Citation>
Farshid S, Jonnagaddala J, Guo GN, Wu M, Liaw, S.-T. Harmonising primary care data using international standard vocabularies for observational research; 2018. https://zenodo.org/record/1401691#.XUF9n-gzaUn. Accessed December 10, 2018.</Citation></Reference><Reference><Citation>Kohler F, Liaw S-T, Pennock R, et al. Integrated health care&#x2014;a population health approach in South Western Sydney. Int J Integr Care 2014; 149.</Citation></Reference><Reference><Citation>Royal Australian College of General Practitioners. RACGP Standards for General Practices 5th ed. East Melbourne, Australia: RACGP. 2017.</Citation></Reference><Reference><Citation>Meystre S, Haug PJ.. Natural language processing to extract medical problems from electronic clinical documents: performance evaluation. J Biomed Inform 2006; 396: 589&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">16359928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Rothschild AS.. Agreement, the F-measure, and reliability in information retrieval. J Am Med Inform Assoc 2005; 123: 296&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1090460</ArticleId><ArticleId IdType="pubmed">15684123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohavi R. A study of cross-validation and bootstrap for accuracy estimation and model selection. In: International Joint Conference on Artificial Intelligence, 1995.</Citation></Reference><Reference><Citation>Tilson L, Bennett K, Barry M.. Prescribing trends for nicotine replacement therapy in primary care. Irish Med J 2004; 979: 270&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">15568584</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MV, Costello D, Yonkers KA.. Clinical correlates of prescription opioid analgesic use in pregnancy. Matern Child Health J 2015; 193: 548&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272915</ArticleId><ArticleId IdType="pubmed">24951127</ArticleId></ArticleIdList></Reference><Reference><Citation>Handal M, Engeland A, R&#xf8;nning M, et al. Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during, and after pregnancy: a population-based cohort study. Eur J Clin Pharmacol 2011; 679: 953..</Citation><ArticleIdList><ArticleId IdType="pubmed">21484468</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale O, Borchgrevink PC, Fredheim OMS, et al. Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: impact of gender, age, exercise and prescription of opioids. BMC Public Health 2015; 151: 461..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428499</ArticleId><ArticleId IdType="pubmed">25934132</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasselstr&#xf6;m J, Liu-Palmgren J, Rasj&#xf6;-Wr&#xe5;&#xe5;k G.. Prevalence of pain in general practice. Eur J Pain 2002; 65: 375&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">12160512</ArticleId></ArticleIdList></Reference><Reference><Citation>Australian Bureau of Statistics. 4364.0.55.001&#x2014;National Health Survey: First Results, 2014&#x2013;15 2015. Canberra, Australia: Australian Bureau of Statistics.</Citation></Reference><Reference><Citation>Dhombres F, Charlet J.. As ontologies reach maturity, artificial intelligence starts being fully efficient: findings from the section on knowledge representation and management for the yearbook 2018. Yearb Med Inform 2018; 2701: 140&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6115232</ArticleId><ArticleId IdType="pubmed">30157517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamunen K, Laitinen-Parkkonen P, Paakkari P, et al. What do different databases tell about the use of opioids in seven European countries in 2002? Eur J Pain 2008; 126: 705&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">18162422</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31553307</PMID><DateRevised><Year>2021</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>29</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and Initial Evaluation.</ArticleTitle><Pagination><StartPage>e14325</StartPage><MedlinePgn>e14325</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e14325</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/14325</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The phecode system was built upon the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) for phenome-wide association studies (PheWAS) using the electronic health record (EHR).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The goal of this paper was to develop and perform an initial evaluation of maps from the International Classification of Diseases, 10th Revision (ICD-10) and the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes to phecodes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We mapped ICD-10 and ICD-10-CM codes to phecodes using a number of methods and resources, such as concept relationships and explicit mappings from the Centers for Medicare &amp; Medicaid Services, the Unified Medical Language System, Observational Health Data Sciences and Informatics, Systematized Nomenclature of Medicine-Clinical Terms, and the National Library of Medicine. We assessed the coverage of the maps in two databases: Vanderbilt University Medical Center (VUMC) using ICD-10-CM and the UK Biobank (UKBB) using ICD-10. We assessed the fidelity of the ICD-10-CM map in comparison to the gold-standard ICD-9-CM phecode map by investigating phenotype reproducibility and conducting a PheWAS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We mapped &gt;75% of ICD-10 and ICD-10-CM codes to phecodes. Of the unique codes observed in the UKBB (ICD-10) and VUMC (ICD-10-CM) cohorts, &gt;90% were mapped to phecodes. We observed 70-75% reproducibility for chronic diseases and &lt;10% for an acute disease for phenotypes sourced from the ICD-10-CM phecode map. Using the ICD-9-CM and ICD-10-CM maps, we conducted a PheWAS with a Lipoprotein(a) genetic variant, rs10455872, which replicated two known genotype-phenotype associations with similar effect sizes: coronary atherosclerosis (ICD-9-CM: P&lt;.001; odds ratio (OR) 1.60 [95% CI 1.43-1.80] vs ICD-10-CM: P&lt;.001; OR 1.60 [95% CI 1.43-1.80]) and chronic ischemic heart disease (ICD-9-CM: P&lt;.001; OR 1.56 [95% CI 1.35-1.79] vs ICD-10-CM: P&lt;.001; OR 1.47 [95% CI 1.22-1.77]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study introduces the beta versions of ICD-10 and ICD-10-CM to phecode maps that enable researchers to leverage accumulated ICD-10 and ICD-10-CM data for PheWAS in the EHR.</AbstractText><CopyrightInformation>&#xa9;Patrick Wu, Aliya Gifford, Xiangrui Meng, Xue Li, Harry Campbell, Tim Varley, Juan Zhao, Robert Carroll, Lisa Bastarache, Joshua C Denny, Evropi Theodoratou, Wei-Qi Wei. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 29.11.2019.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wu</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1437-6688</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program, Vanderbilt University School of Medicine, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Gifford</LastName><ForeName>Aliya</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8931-8362</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Meng</LastName><ForeName>Xiangrui</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-4889-4640</Identifier><AffiliationInfo><Affiliation>Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xue</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-6880-2577</Identifier><AffiliationInfo><Affiliation>Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-6169-6262</Identifier><AffiliationInfo><Affiliation>Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varley</LastName><ForeName>Tim</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6106-568X</Identifier><AffiliationInfo><Affiliation>Public Health and Intelligence Strategic Business Unit, National Services Scotland, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Juan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1429-0662</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carroll</LastName><ForeName>Robert</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3802-8183</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bastarache</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3020-447X</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denny</LastName><ForeName>Joshua C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-3049-7332</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theodoratou</LastName><ForeName>Evropi</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5887-9132</Identifier><AffiliationInfo><Affiliation>Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Wei-Qi</ForeName><Initials>WQ</Initials><Identifier Source="ORCID">0000-0003-4985-056X</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>22804</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>T15 LM007450</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM010685</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL133786</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007347</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 GM115305</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data science</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword><Keyword MajorTopicYN="N">genome-wide association study</Keyword><Keyword MajorTopicYN="N">medical informatics applications</Keyword><Keyword MajorTopicYN="N">phenome-wide association study</Keyword><Keyword MajorTopicYN="N">phenotyping</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31553307</ArticleId><ArticleId IdType="pmc">PMC6911227</ArticleId><ArticleId IdType="doi">10.2196/14325</ArticleId><ArticleId IdType="pii">v7i4e14325</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kirby JC, Speltz P, Rasmussen LV, Basford M, Gottesman O, Peissig PL, Pacheco JA, Tromp G, Pathak J, Carrell DS, Ellis SB, Lingren T, Thompson WK, Savova G, Haines J, Roden DM, Harris PA, Denny JC. PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc. 2016 Nov;23(6):1046&#x2013;1052. doi: 10.1093/jamia/ocv202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv202</ArticleId><ArticleId IdType="pmc">PMC5070514</ArticleId><ArticleId IdType="pubmed">27026615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamazon ER, Segr&#xe8; Ayellet V, van de Bunt M, Wen X, Xi HS, Hormozdiari F, Ongen H, Konkashbaev A, Derks EM, Aguet F, Quan J, GTEx Consortium. Nicolae DL, Eskin E, Kellis M, Getz G, McCarthy MI, Dermitzakis ET, Cox NJ, Ardlie KG. Using an atlas of gene regulation across 44 human tissues to inform complex disease- and trait-associated variation. Nat Genet. 2018 Jul;50(7):956&#x2013;967. doi: 10.1038/s41588-018-0154-4.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0154-4</ArticleId><ArticleId IdType="pmc">PMC6248311</ArticleId><ArticleId IdType="pubmed">29955180</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, Herron TJ, McCarthy S, Schmidt EM, Sveinbjornsson G, Surakka I, Mathis MR, Yamazaki M, Crawford RD, Gabrielsen ME, Skogholt AH, Holmen OL, Lin M, Wolford BN, Dey R, Dalen H, Sulem P, Chung JH, Backman JD, Arnar DO, Thorsteinsdottir U, Baras A, O'Dushlaine C, Holst AG, Wen X, Hornsby W, Dewey FE, Boehnke M, Kheterpal S, Mukherjee B, Lee S, Kang HM, Holm H, Kitzman J, Shavit JA, Jalife J, Brummett CM, Teslovich TM, Carey DJ, Gudbjartsson DF, Stefansson K, Abecasis GR, Hveem K, Willer CJ. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat Genet. 2018 Sep;50(9):1234&#x2013;1239. doi: 10.1038/s41588-018-0171-3.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0171-3</ArticleId><ArticleId IdType="pmc">PMC6530775</ArticleId><ArticleId IdType="pubmed">30061737</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonti CN, Vernot B, Bastarache L, Bottinger E, Carrell DS, Chisholm RL, Crosslin DR, Hebbring SJ, Jarvik GP, Kullo IJ, Li R, Pathak J, Ritchie MD, Roden DM, Verma SS, Tromp G, Prato JD, Bush WS, Akey JM, Denny JC, Capra JA. The phenotypic legacy of admixture between modern humans and Neandertals. Science. 2016 Feb 12;351(6274):737&#x2013;41. doi: 10.1126/science.aad2149.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aad2149</ArticleId><ArticleId IdType="pmc">PMC4849557</ArticleId><ArticleId IdType="pubmed">26912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Diogo D, Bastarache L, Liao KP, Graham RR, Fulton RS, Greenberg JD, Eyre S, Bowes J, Cui J, Lee A, Pappas DA, Kremer JM, Barton A, Coenen MJH, Franke B, Kiemeney LA, Mariette X, Richard-Miceli C, Canh&#xe3;o Helena, Fonseca JE, de Vries N, Tak PP, Crusius JBA, Nurmohamed MT, Kurreeman F, Mikuls TR, Okada Y, Stahl EA, Larson DE, Deluca TL, O'Laughlin M, Fronick CC, Fulton LL, Kosoy R, Ransom M, Bhangale TR, Ortmann W, Cagan A, Gainer V, Karlson EW, Kohane I, Murphy SN, Martin J, Zhernakova A, Klareskog L, Padyukov L, Worthington J, Mardis ER, Seldin MF, Gregersen PK, Behrens T, Raychaudhuri S, Denny JC, Plenge RM. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS One. 2015;10(4):e0122271. doi: 10.1371/journal.pone.0122271.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0122271</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0122271</ArticleId><ArticleId IdType="pmc">PMC4388675</ArticleId><ArticleId IdType="pubmed">25849893</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastegar-Mojarad M, Ye Z, Kolesar JM, Hebbring SJ, Lin SM. Opportunities for drug repositioning from phenome-wide association studies. Nat Biotechnol. 2015 Apr;33(4):342&#x2013;5. doi: 10.1038/nbt.3183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3183</ArticleId><ArticleId IdType="pubmed">25850054</ArticleId></ArticleIdList></Reference><Reference><Citation>Millard LAC, Davies NM, Timpson NJ, Tilling K, Flach PA, Davey Smith G. MR-PheWAS: hypothesis prioritization among potential causal effects of body mass index on many outcomes, using Mendelian randomization. Sci Rep. 2015 Nov 16;5:16645. doi: 10.1038/srep16645. doi: 10.1038/srep16645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep16645</ArticleId><ArticleId IdType="doi">10.1038/srep16645</ArticleId><ArticleId IdType="pmc">PMC4644974</ArticleId><ArticleId IdType="pubmed">26568383</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehm MG, Aponte JL, Chiano MN, Yerges-Armstrong LM, Johnson T, Barker JN, Cook SF, Gupta A, Hinds DA, Li L, Nelson MR, Simpson MA, Tian C, McCarthy LC, Rajpal DK, Waterworth DM. Phenome-wide association study using research participants' self-reported data provides insight into the Th17 and IL-17 pathway. PLoS One. 2017;12(11):e0186405. doi: 10.1371/journal.pone.0186405.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0186405</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0186405</ArticleId><ArticleId IdType="pmc">PMC5665418</ArticleId><ArticleId IdType="pubmed">29091937</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Ye Z, Mayer JG, Hoch BA, Green C, Rolak L, Cold C, Khor S, Zheng X, Miyagawa T, Tokunaga K, Brilliant MH, Hebbring SJ. Phenome-wide association study maps new diseases to the human major histocompatibility complex region. J Med Genet. 2016 Oct;53(10):681&#x2013;9. doi: 10.1136/jmedgenet-2016-103867.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2016-103867</ArticleId><ArticleId IdType="pmc">PMC5035188</ArticleId><ArticleId IdType="pubmed">27287392</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuraz A, Chouchana L, Malamut G, Le Beller C, Roche D, Beaune P, Degoulet P, Burgun A, Loriot M, Avillach P. Phenome-wide association studies on a quantitative trait: application to TPMT enzyme activity and thiopurine therapy in pharmacogenomics. PLoS Comput Biol. 2013;9(12):e1003405. doi: 10.1371/journal.pcbi.1003405.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003405</ArticleId><ArticleId IdType="doi">10.1371/journal.pcbi.1003405</ArticleId><ArticleId IdType="pmc">PMC3873228</ArticleId><ArticleId IdType="pubmed">24385893</ArticleId></ArticleIdList></Reference><Reference><Citation>Doshi-Velez F, Ge Y, Kohane I. Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis. Pediatrics. 2014 Jan;133(1):e54&#x2013;63. doi: 10.1542/peds.2013-0819.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2013-0819</ArticleId><ArticleId IdType="pmc">PMC3876178</ArticleId><ArticleId IdType="pubmed">24323995</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Meng X, Spiliopoulou A, Timofeeva M, Wei W, Gifford A, Shen X, He Y, Varley T, McKeigue P, Tzoulaki I, Wright AF, Joshi P, Denny JC, Campbell H, Theodoratou E. MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank. Ann Rheum Dis. 2018 Jul;77(7):1039&#x2013;1047. doi: 10.1136/annrheumdis-2017-212534.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212534</ArticleId><ArticleId IdType="pmc">PMC6029646</ArticleId><ArticleId IdType="pubmed">29437585</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics. 2014 Aug 15;30(16):2375&#x2013;6. doi: 10.1093/bioinformatics/btu197.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu197</ArticleId><ArticleId IdType="pmc">PMC4133579</ArticleId><ArticleId IdType="pubmed">24733291</ArticleId></ArticleIdList></Reference><Reference><Citation>PheWAS Catalog.  [2019-07-14].  Phecode Map 1.2 with ICD-9 Codes.  https://phewascatalog.org/phecodes.</Citation></Reference><Reference><Citation>Steindel SJ. International classification of diseases, 10th edition, clinical modification and procedure coding system: descriptive overview of the next generation HIPAA code sets. J Am Med Inform Assoc. 2010;17(3):274&#x2013;82. doi: 10.1136/jamia.2009.001230.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.001230</ArticleId><ArticleId IdType="pmc">PMC2995704</ArticleId><ArticleId IdType="pubmed">20442144</ArticleId></ArticleIdList></Reference><Reference><Citation>Topaz M, Shafran-Topaz L, Bowles KH. ICD-9 to ICD-10: evolution, revolution, and current debates in the United States. Perspect Health Inf Manag. 2013;10:1d.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692324</ArticleId><ArticleId IdType="pubmed">23805064</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung KW, Richesson R, Smerek M, Pereira KC, Green BB, Patkar A, Clowse M, Bauck A, Bodenreider O. Preparing for the ICD-10-CM Transition: Automated Methods for Translating ICD Codes in Clinical Phenotype Definitions. EGEMS (Wash DC) 2016;4(1):1211. doi: 10.13063/2327-9214.1211.  </Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1211</ArticleId><ArticleId IdType="pmc">PMC4862764</ArticleId><ArticleId IdType="pubmed">27195309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder V.  NLM Technical Bulletin. US National Library of Medicine; 2018. May,  [2019-07-16].  UMLS 2018AA Release Available.  https://www.nlm.nih.gov/pubs/techbull/mj18/mj18_umls_2018aa_release.html.</Citation></Reference><Reference><Citation>Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, Field JR, Pulley JM, Ramirez AH, Bowton E, Basford MA, Carrell DS, Peissig PL, Kho AN, Pacheco JA, Rasmussen LV, Crosslin DR, Crane PK, Pathak J, Bielinski SJ, Pendergrass SA, Xu H, Hindorff LA, Li R, Manolio TA, Chute CG, Chisholm RL, Larson EB, Jarvik GP, Brilliant MH, McCarty CA, Kullo IJ, Haines JL, Crawford DC, Masys DR, Roden DM. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013 Dec;31(12):1102&#x2013;10. doi: 10.1038/nbt.2749.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2749</ArticleId><ArticleId IdType="pmc">PMC3969265</ArticleId><ArticleId IdType="pubmed">24270849</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Bastarache LA, Carroll RJ, Marlo JE, Osterman TJ, Gamazon ER, Cox NJ, Roden DM, Denny JC. Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS One. 2017;12(7):e0175508. doi: 10.1371/journal.pone.0175508.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0175508</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0175508</ArticleId><ArticleId IdType="pmc">PMC5501393</ArticleId><ArticleId IdType="pubmed">28686612</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015 Mar;12(3):e1001779. doi: 10.1371/journal.pmed.1001779.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001779</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1001779</ArticleId><ArticleId IdType="pmc">PMC4380465</ArticleId><ArticleId IdType="pubmed">25826379</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Medicare &amp; Medicaid Services  CMS.gov. 2017. Aug 11,  [2019-07-05].  2018 ICD-10-CM and GEMs.  https://www.cms.gov/Medicare/Coding/ICD10/2018-ICD-10-CM-and-GEMs.html.</Citation></Reference><Reference><Citation>US National Library of Medicine. 2018. Jan 26,  [2019-04-06].  SNOMED CT to ICD-9-CM Rule Based Mapping to Support Reimbursement.  https://www.nlm.nih.gov/research/umls/mapping_projects/snomedct_to_icd9cm_reimburse.html.</Citation></Reference><Reference><Citation>Fung KW, Bodenreider O. Utilizing the UMLS for semantic mapping between terminologies. AMIA Annu Symp Proc. 2005:266&#x2013;70.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC1560893</ArticleId><ArticleId IdType="pubmed">16779043</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. 2016. Jun 04,  [2019-07-17].  ICD9CM.  https://www.ohdsi.org/web/wiki/doku.php?id=documentation:vocabulary:icd9cm.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van der Lei Johan, Pratt N, Nor&#xe9;n G Niklas, Li Y, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuse DA. Supporting communication in an integrated patient record system. AMIA Annu Symp Proc. 2003:1065.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC1480157</ArticleId><ArticleId IdType="pubmed">14728568</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordestgaard BG, Chapman MJ, Ray K, Bor&#xe9;n Jan, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen M, Tokg&#xf6;zoglu Lale, Tybj&#xe6;rg-Hansen Anne, European Atherosclerosis Society Consensus Panel  Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010 Dec;31(23):2844&#x2013;53. doi: 10.1093/eurheartj/ehq386.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehq386</ArticleId><ArticleId IdType="pmc">PMC3295201</ArticleId><ArticleId IdType="pubmed">20965889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Feng Q, Wu P, Warner JL, Denny JC, Wei W. Using topic modeling via non-negative matrix factorization to identify relationships between genetic variants and disease phenotypes: A case study of Lipoprotein(a) (LPA) PLoS One. 2019;14(2):e0212112. doi: 10.1371/journal.pone.0212112.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212112</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0212112</ArticleId><ArticleId IdType="pmc">PMC6374022</ArticleId><ArticleId IdType="pubmed">30759150</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Li X, Feng Q, Kubo M, Kullo IJ, Peissig PL, Karlson EW, Jarvik GP, Lee MTM, Shang N, Larson EA, Edwards T, Shaffer CM, Mosley JD, Maeda S, Horikoshi M, Ritchie M, Williams MS, Larson EB, Crosslin DR, Bland ST, Pacheco JA, Rasmussen-Torvik LJ, Cronkite D, Hripcsak G, Cox NJ, Wilke RA, Stein CM, Rotter JI, Momozawa Y, Roden DM, Krauss RM, Denny JC. LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins. Circulation. 2018 Oct 23;138(17):1839&#x2013;1849. doi: 10.1161/CIRCULATIONAHA.117.031356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.031356</ArticleId><ArticleId IdType="pmc">PMC6202211</ArticleId><ArticleId IdType="pubmed">29703846</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, Masys DR. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008 Sep;84(3):362&#x2013;9. doi: 10.1038/clpt.2008.89.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2008.89</ArticleId><ArticleId IdType="pmc">PMC3763939</ArticleId><ArticleId IdType="pubmed">18500243</ArticleId></ArticleIdList></Reference><Reference><Citation>PheWAS  GitHub.  [2019-10-04].  PheWAS R Package.  https://github.com/PheWAS/PheWAS.</Citation></Reference><Reference><Citation>Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, LeFaive J, VandeHaar P, Gagliano SA, Gifford A, Bastarache LA, Wei W, Denny JC, Lin M, Hveem K, Kang HM, Abecasis GR, Willer CJ, Lee S. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat Genet. 2018 Sep;50(9):1335&#x2013;1341. doi: 10.1038/s41588-018-0184-y.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-018-0184-y</ArticleId><ArticleId IdType="pmc">PMC6119127</ArticleId><ArticleId IdType="pubmed">30104761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaganti S, Mawn LA, Kang H, Egan J, Resnick SM, Beason-Held LL, Landman BA, Lasko T. Electronic Medical Record Context Signatures Improve Diagnostic Classification Using Medical Image Computing. IEEE J Biomed Health Inform. 2019 Sep;23(5):2052&#x2013;2062. doi: 10.1109/JBHI.2018.2890084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/JBHI.2018.2890084</ArticleId><ArticleId IdType="pmc">PMC6844192</ArticleId><ArticleId IdType="pubmed">30602428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Feng Q, Wu P, Lupu RA, Wilke RA, Wells QS, Denny JC, Wei W. Learning from Longitudinal Data in Electronic Health Record and Genetic Data to Improve Cardiovascular Event Prediction. Sci Rep. 2019 Jan 24;9(1):717. doi: 10.1038/s41598-018-36745-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-36745-x</ArticleId><ArticleId IdType="pmc">PMC6345960</ArticleId><ArticleId IdType="pubmed">30679510</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M, ElTayeby O, Zolnoori M, Yao L. Public Opinions Toward Diseases: Infodemiological Study on News Media Data. J Med Internet Res. 2018 May 08;20(5):e10047. doi: 10.2196/10047.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/10047</ArticleId><ArticleId IdType="pmc">PMC5964307</ArticleId><ArticleId IdType="pubmed">29739741</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi X, Li X, Cai T. Spherical Regression under Mismatch Corruption with Application to Automated Knowledge Translation. arXiv preprint. 2019 Sep 04;  </Citation></Reference><Reference><Citation>Bastarache L, Hughey JJ, Hebbring S, Marlo J, Zhao W, Ho WT, Van Driest SL, McGregor TL, Mosley JD, Wells QS, Temple M, Ramirez AH, Carroll R, Osterman T, Edwards T, Ruderfer D, Velez Edwards DR, Hamid R, Cogan J, Glazer A, Wei W, Feng Q, Brilliant M, Zhao ZJ, Cox NJ, Roden DM, Denny JC. Phenotype risk scores identify patients with unrecognized Mendelian disease patterns. Science. 2018 Mar 16;359(6381):1233&#x2013;1239. doi: 10.1126/science.aal4043.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aal4043</ArticleId><ArticleId IdType="pmc">PMC5959723</ArticleId><ArticleId IdType="pubmed">29590070</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Healthcare Research and Quality  Healthcare Cost and Utilization Project (HCUP) 2012. Jan,  [2019-07-15].  HCUP CCS Fact Sheet.  https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccsfactsheet.jsp.</Citation></Reference><Reference><Citation>Sabbatini AK, Kocher KE, Basu A, Hsia RY. In-Hospital Outcomes and Costs Among Patients Hospitalized During a Return Visit to the Emergency Department. JAMA. 2016 Feb 16;315(7):663&#x2013;71. doi: 10.1001/jama.2016.0649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0649</ArticleId><ArticleId IdType="pubmed">26881369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Hao S, Jin B, Shin AY, Zhu C, Huang M, Wang Y, Zheng L, Dai D, Culver DS, Alfreds ST, Rogow T, Stearns F, Sylvester KG, Widen E, Ling X. Online Prediction of Health Care Utilization in the Next Six Months Based on Electronic Health Record Information: A Cohort and Validation Study. J Med Internet Res. 2015 Sep 22;17(9):e219. doi: 10.2196/jmir.4976.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.4976</ArticleId><ArticleId IdType="pmc">PMC4642374</ArticleId><ArticleId IdType="pubmed">26395541</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Healthcare Research and Quality  Healthcare Cost and Utilization Project (HCUP) 2019. Sep,  [2019-07-05].  Clinical Classifications Software (CCS) for ICD-10-PCS (beta version).  https://www.hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp.</Citation></Reference><Reference><Citation>Hripcsak G, Levine ME, Shang N, Ryan PB. Effect of vocabulary mapping for conditions on phenotype cohorts. J Am Med Inform Assoc. 2018 Dec 01;25(12):1618&#x2013;1625. doi: 10.1093/jamia/ocy124.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy124</ArticleId><ArticleId IdType="pmc">PMC6289550</ArticleId><ArticleId IdType="pubmed">30395248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31581246</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>KETOS: Clinical decision support and machine learning as a service - A training and deployment platform based on Docker, OMOP-CDM, and FHIR Web Services.</ArticleTitle><Pagination><StartPage>e0223010</StartPage><MedlinePgn>e0223010</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0223010</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0223010</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE">To take full advantage of decision support, machine learning, and patient-level prediction models, it is important that models are not only created, but also deployed in a clinical setting. The KETOS platform demonstrated in this work implements a tool for researchers allowing them to perform statistical analyses and deploy resulting models in a secure environment.</AbstractText><AbstractText Label="METHODS">The proposed system uses Docker virtualization to provide researchers with reproducible data analysis and development environments, accessible via Jupyter Notebook, to perform statistical analysis and develop, train and deploy models based on standardized input data. The platform is built in a modular fashion and interfaces with web services using the Health Level 7 (HL7) Fast Healthcare Interoperability Resources (FHIR) standard to access patient data. In our prototypical implementation we use an OMOP common data model (OMOP-CDM) database. The architecture supports the entire research lifecycle from creating a data analysis environment, retrieving data, and training to final deployment in a hospital setting.</AbstractText><AbstractText Label="RESULTS">We evaluated the platform by establishing and deploying an analysis and end user application for hemoglobin reference intervals within the University Hospital Erlangen. To demonstrate the potential of the system to deploy arbitrary models, we loaded a colorectal cancer dataset into an OMOP database and built machine learning models to predict patient outcomes and made them available via a web service. We demonstrated both the integration with FHIR as well as an example end user application. Finally, we integrated the platform with the open source DataSHIELD architecture to allow for distributed privacy preserving data analysis and training across networks of hospitals.</AbstractText><AbstractText Label="CONCLUSION">The KETOS platform takes a novel approach to data analysis, training and deploying decision support models in a hospital or healthcare setting. It does so in a secure and privacy-preserving manner, combining the flexibility of Docker virtualization with the advantages of standardized vocabularies, a widely applied database schema (OMOP-CDM), and a standardized way to exchange medical data (FHIR).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gruendner</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7204-5329</Identifier><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg (FAU), Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwachhofer</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg (FAU), Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sippl</LastName><ForeName>Phillip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg (FAU), Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg (FAU), Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erpenbeck</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg (FAU), Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gulden</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg (FAU), Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapsner</LastName><ForeName>Lorenz A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0003-1866-860X</Identifier><AffiliationInfo><Affiliation>Medical Centre for Information and Communication Technology, Universit&#xe4;tsklinikum Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zierk</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Centre for Information and Communication Technology, Universit&#xe4;tsklinikum Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics and Adolescent Medicine, Universit&#xe4;tsklinikumErlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mate</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1389-3384</Identifier><AffiliationInfo><Affiliation>Medical Centre for Information and Communication Technology, Universit&#xe4;tsklinikum Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xfc;rzl</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Division of Molecular and Experimental Surgery, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg (FAU), Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croner</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of General, Visceral, Vascular and Graft Surgery, University Hospital, Magdeburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokosch</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg (FAU), Erlangen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Centre for Information and Communication Technology, Universit&#xe4;tsklinikum Erlangen, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toddenroth</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Chair of Medical Informatics, Friedrich-Alexander-University Erlangen-N&#xfc;rnberg (FAU), Erlangen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>PLoS One. 2019 Nov 13;14(11):e0225442</RefSource><PMID Version="1">31721815</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="N">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020000" MajorTopicYN="Y">Decision Support Systems, Clinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="Y">Health Information Interoperability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="Y">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018907" MajorTopicYN="N">Privacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014584" MajorTopicYN="N">User-Computer Interface</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31581246</ArticleId><ArticleId IdType="pmc">PMC6776354</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0223010</ArticleId><ArticleId IdType="pii">PONE-D-19-12555</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wehling M. Translational medicine: science or wishful thinking? J Transl Med. 2008;6:31 Epub 2008/06/19. 10.1186/1479-5876-6-31</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-6-31</ArticleId><ArticleId IdType="pmc">PMC2442586</ArticleId><ArticleId IdType="pubmed">18559092</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow RE, Emmons KM. How can we increase translation of research into practice? Types of evidence needed. Annu Rev Public Health. 2007;28:413&#x2013;33. Epub 2006/12/08. 10.1146/annurev.publhealth.28.021406.144145 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.publhealth.28.021406.144145</ArticleId><ArticleId IdType="pubmed">17150029</ArticleId></ArticleIdList></Reference><Reference><Citation>Horig H, Marincola E, Marincola FM. Obstacles and opportunities in translational research. Nat Med. 2005;11(7):705&#x2013;8. Epub 2005/07/15. 10.1038/nm0705-705 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0705-705</ArticleId><ArticleId IdType="pubmed">16015353</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto GES J. A. EPOCH and ePRISM: A web-based translational framework for bridging outcomes research and clinical practice. Computers in Cardiology. 2007; 10.1109/CIC.2007.4745457:4</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/CIC.2007.4745457:4</ArticleId></ArticleIdList></Reference><Reference><Citation>Velickovski F, Ceccaroni L, Roca J, Burgos F, Galdiz JB, Marina N, et al. Clinical Decision Support Systems (CDSS) for preventive management of COPD patients. J Transl Med. 2014;12 Suppl 2:S9 Epub 2014/12/05. 10.1186/1479-5876-12-S2-S9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-12-S2-S9</ArticleId><ArticleId IdType="pmc">PMC4255917</ArticleId><ArticleId IdType="pubmed">25471545</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldow C, Salentin S, Schroeder M, Roeder I, Glauche I. MAGPIE: Simplifying access and execution of computational models in the life sciences. PLoS Comput Biol. 2017;13(12):e1005898 Epub 2017/12/16. 10.1371/journal.pcbi.1005898</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1005898</ArticleId><ArticleId IdType="pmc">PMC5747461</ArticleId><ArticleId IdType="pubmed">29244826</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson E, Li W, Sudre C, Fidon L, Shakir DI, Wang G, et al. NiftyNet: a deep-learning platform for medical imaging. Comput Methods Programs Biomed. 2018;158:113&#x2013;22. Epub 2018/03/17. 10.1016/j.cmpb.2018.01.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2018.01.025</ArticleId><ArticleId IdType="pmc">PMC5869052</ArticleId><ArticleId IdType="pubmed">29544777</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalilia M, Choi M, Henderson A, Iyengar S, Braunstein M, Sun J. Clinical Predictive Modeling Development and Deployment through FHIR Web Services. AMIA Annu Symp Proc. 2015;2015:717&#x2013;26. Epub 2015/01/01.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765683</ArticleId><ArticleId IdType="pubmed">26958207</ArticleId></ArticleIdList></Reference><Reference><Citation>GT-FHIR: OMOP on FHIR Project [Internet]. 2018 [cited 2019 Sep 3]. Available from: https://github.com/gt-health/GT-FHIR.</Citation></Reference><Reference><Citation>HL7.org. HL7 FHIR [Internet]. [cited 2019 Sep 3]. Available from: https://www.hl7.org/fhir/.</Citation></Reference><Reference><Citation>Definition and DDLs for the OMOP Common Data Model (CDM) [Internet]. [cited 2019 Sep 3]. Available from: https://github.com/OHDSI/CommonDataModel.</Citation></Reference><Reference><Citation>Semler SC, Wissing F, Heyder R. German Medical Informatics Initiative. Methods Inf Med. 2018;57(S 01):e50&#x2013;e6. Epub 2018/07/18. 10.3414/ME18-03-0003</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME18-03-0003</ArticleId><ArticleId IdType="pmc">PMC6178199</ArticleId><ArticleId IdType="pubmed">30016818</ArticleId></ArticleIdList></Reference><Reference><Citation>Winter A, Staubert S, Ammon D, Aiche S, Beyan O, Bischoff V, et al. Smart Medical Information Technology for Healthcare (SMITH). Methods Inf Med. 2018;57(S 01):e92&#x2013;e105. Epub 2018/07/18. 10.3414/ME18-02-0004</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME18-02-0004</ArticleId><ArticleId IdType="pmc">PMC6193398</ArticleId><ArticleId IdType="pubmed">30016815</ArticleId></ArticleIdList></Reference><Reference><Citation>Haarbrandt B, Schreiweis B, Rey S, Sax U, Scheithauer S, Rienhoff O, et al. HiGHmed&#x2014;An Open Platform Approach to Enhance Care and Research across Institutional Boundaries. Methods Inf Med. 2018;57(S 01):e66&#x2013;e81. Epub 2018/07/18. 10.3414/ME18-02-0002</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME18-02-0002</ArticleId><ArticleId IdType="pmc">PMC6193407</ArticleId><ArticleId IdType="pubmed">30016813</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasser F, Kohlbacher O, Mansmann U, Bauer B, Kuhn KA. Data Integration for Future Medicine (DIFUTURE). Methods Inf Med. 2018;57(S 01):e57&#x2013;e65. Epub 2018/07/18. 10.3414/ME17-02-0022</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME17-02-0022</ArticleId><ArticleId IdType="pmc">PMC6178202</ArticleId><ArticleId IdType="pubmed">30016812</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8. Epub 2015/08/12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes N, Rijnbeek P, Van Speybroeck M. The European Health Data and Evidence Network (EHDEN) [Internet]. Liberating Evidence via Harmonisation of EU Real world data. Rotterdam: European ODHSI Symposium;  [cited 2019 Sep 3]. Available from: http://www.ohdsi-europe.org/images/symposium-2018/posters/24-Nigel-Hughes.pdf.</Citation></Reference><Reference><Citation>Prokosch HU, Acker T, Bernarding J, Binder H, Boeker M, Boerries M, et al. MIRACUM: Medical Informatics in Research and Care in University Medicine. Methods Inf Med. 2018;57(S 01):e82&#x2013;e91. Epub 2018/07/18. 10.3414/ME17-02-0025</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME17-02-0025</ArticleId><ArticleId IdType="pmc">PMC6178200</ArticleId><ArticleId IdType="pubmed">30016814</ArticleId></ArticleIdList></Reference><Reference><Citation>Project Jupyter. jupyter [Internet]. 2018 [cited 2019 Sep 3]. Available from: http://jupyter.org/.</Citation></Reference><Reference><Citation>Fortier I, Burton PR, Robson PJ, Ferretti V, Little J, L'Heureux F, et al. Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies. Int J Epidemiol. 2010;39(5):1383&#x2013;93. Epub 2010/09/04. 10.1093/ije/dyq139</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyq139</ArticleId><ArticleId IdType="pmc">PMC2972444</ArticleId><ArticleId IdType="pubmed">20813861</ArticleId></ArticleIdList></Reference><Reference><Citation>Laursen SO. [SNOMED (Systematized Nomenclature of Medicine)&#x2014;multiaxial data registration]. Ugeskr Laeger. 1981;143(17):1081&#x2013;3. Epub 1981/04/20. .</Citation><ArticleIdList><ArticleId IdType="pubmed">7245387</ArticleId></ArticleIdList></Reference><Reference><Citation>Vreeman DJ, McDonald CJ, Huff SM. LOINC(R)&#x2014;A Universal Catalog of Individual Clinical Observations and Uniform Representation of Enumerated Collections. Int J Funct Inform Personal Med. 2010;3(4):273&#x2013;91. Epub 2010/01/01. 10.1504/IJFIPM.2010.040211</Citation><ArticleIdList><ArticleId IdType="doi">10.1504/IJFIPM.2010.040211</ArticleId><ArticleId IdType="pmc">PMC3418707</ArticleId><ArticleId IdType="pubmed">22899966</ArticleId></ArticleIdList></Reference><Reference><Citation>Rishi Kanth S. Fast Health Interoperability Resources (FHIR): Current Status in the Healthcare System. International Journal of E-Health and Medical Communications (IJEHMC). 2019;10(1):76&#x2013;93. 10.4018/IJEHMC.2019010105</Citation><ArticleIdList><ArticleId IdType="doi">10.4018/IJEHMC.2019010105</ArticleId></ArticleIdList></Reference><Reference><Citation>ATLAS [Internet]. 2018 [cited 2019 Sep 3]. Available from: https://github.com/OHDSI/Atlas.</Citation></Reference><Reference><Citation>Grundner J, Prokosch HU, Sturzl M, Croner R, Christoph J, Toddenroth D. Predicting Clinical Outcomes in Colorectal Cancer Using Machine Learning. Stud Health Technol Inform. 2018;247:101&#x2013;5. Epub 2018/04/22. .</Citation><ArticleIdList><ArticleId IdType="pubmed">29677931</ArticleId></ArticleIdList></Reference><Reference><Citation>Logemann T. General Data Protection Regulation GDPR [Internet]. [cited 2019 14.01.2019]. Available from: https://gdpr-info.eu/.</Citation></Reference><Reference><Citation>Zierk J, Arzideh F, Haeckel R, Rauh M, Metzler M, Ganslandt T, et al. Indirect determination of hematology reference intervals in adult patients on Beckman Coulter UniCell DxH 800 and Abbott CELL-DYN Sapphire devices. Clin Chem Lab Med. 2018. Epub 2018/10/28. 10.1515/cclm-2018-0771 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2018-0771</ArticleId><ArticleId IdType="pubmed">30367783</ArticleId></ArticleIdList></Reference><Reference><Citation>Arzideh F. Reference Limit Estimator [Internet]. https://www.dgkl.de/fileadmin/Verbandsarbeit/Entscheidungsgrenzen/RLE49.zip2018 [cited 2019 Sep 3]. Available from: https://www.dgkl.de/fileadmin/Verbandsarbeit/Entscheidungsgrenzen/RLE49.zip.</Citation></Reference><Reference><Citation>Povey S, Lovering R, Bruford E, Wright M, Lush M, Wain H. The HUGO Gene Nomenclature Committee (HGNC). Hum Genet. 2001;109(6):678&#x2013;80. Epub 2002/01/26. 10.1007/s00439-001-0615-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-001-0615-0</ArticleId><ArticleId IdType="pubmed">11810281</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BBaMLaLKaJSaJRaESaGCaZM. mlr: Machine Learning in R. Journal of Machine Learning Research. 2016;17(170):1&#x2013;5.</Citation></Reference><Reference><Citation>Kuhn M. The caret Package.</Citation></Reference><Reference><Citation>Gruendner J, Prokosch HU, Schindler S, Lenz S, Binder H. A Queue-Poll Extension and DataSHIELD: Standardised, Monitored, Indirect and Secure Access to Sensitive Data. Stud Health Technol Inform. 2019;258:115&#x2013;9. Epub 2019/04/04. .</Citation><ArticleIdList><ArticleId IdType="pubmed">30942726</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisch F, Dimitriadou E. mlbench: Machine Learning Benchmark Problems [Internet]. 2012.  [cited 2019 Aug 27]. Available from: https://cran.r-project.org/web/packages/mlbench/index.html.</Citation></Reference><Reference><Citation>Dua D, Graff C. Machine Learning Repository [Internet]. 2019.  [cited 2019 Aug 27]. Available from: http://archive.ics.uci.edu/ml.</Citation></Reference><Reference><Citation>HL7. HL7 FHIR&#x2014;Version History [Internet]. 2018 [cited 2019 Aug 13]. Available from: http://hl7.org/fhir/history.html.</Citation></Reference><Reference><Citation>Google. Cloud Healthcare API [Internet]. 2019 [cited 2019 Aug 14]. Available from: https://cloud.google.com/healthcare/.</Citation></Reference><Reference><Citation>Microsoft. Azure API for FHIR. [Internet]. 2019. Available from: https://azure.microsoft.com/en-us/services/azure-api-for-fhir/.</Citation></Reference><Reference><Citation>Apple. Accessing Health Records [Internet]. 2019 [cited 2019 Aug 14]. Available from: https://developer.apple.com/documentation/healthkit/samples/accessing_health_records.</Citation></Reference><Reference><Citation>Posnack S, Barker W. Heat Wave: The U.S. is Poised to Catch FHIR in 2019 [Internet]. 2018.  [cited 2019 Sep 3 ]. Available from: https://www.healthit.gov/buzz-blog/interoperability/heat-wave-the-u-s-is-poised-to-catch-fhir-in-2019.</Citation></Reference><Reference><Citation>Medizininformatik-Initiative. Medizininformatik-Initiative beschlie&#xdf;t Verwendung von FHIR. [Internet]. 2019 [cited 2019 Aug 17]. Available from: https://www.medizininformatik-initiative.de/de/medizininformatik-initiative-beschliesst-verwendung-von-fhir.</Citation></Reference><Reference><Citation>Gaye A, Marcon Y, Isaeva J, LaFlamme P, Turner A, Jones EM, et al. DataSHIELD: taking the analysis to the data, not the data to the analysis. Int J Epidemiol. 2014;43(6):1929&#x2013;44. Epub 2014/09/30. 10.1093/ije/dyu188</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyu188</ArticleId><ArticleId IdType="pmc">PMC4276062</ArticleId><ArticleId IdType="pubmed">25261970</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, et al. Towards Implementation of OMOP in a German University Hospital Consortium. Appl Clin Inform. 2018;9(1):54&#x2013;61. Epub 2018/01/25. 10.1055/s-0037-1617452</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1617452</ArticleId><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel JC, Kreda DA, Mandl KD, Kohane IS, Ramoni RB. SMART on FHIR: a standards-based, interoperable apps platform for electronic health records. J Am Med Inform Assoc. 2016;23(5):899&#x2013;908. Epub 2016/02/26. 10.1093/jamia/ocv189</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv189</ArticleId><ArticleId IdType="pmc">PMC4997036</ArticleId><ArticleId IdType="pubmed">26911829</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31592524</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Leaf: an open-source, model-agnostic, data-driven web application for cohort discovery and translational biomedical research.</ArticleTitle><Pagination><StartPage>109</StartPage><EndPage>118</EndPage><MedlinePgn>109-118</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocz165</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Academic medical centers and health systems are increasingly challenged with supporting appropriate secondary use of clinical data. Enterprise data warehouses have emerged as central resources for these data, but often require an informatician to extract meaningful information, limiting direct access by end users. To overcome this challenge, we have developed Leaf, a lightweight self-service web application for querying clinical data from heterogeneous data models and sources.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Leaf utilizes a flexible biomedical concept system to define hierarchical concepts and ontologies. Each Leaf concept contains both textual representations and SQL query building blocks, exposed by a simple drag-and-drop user interface. Leaf generates abstract syntax trees which are compiled into dynamic SQL queries.</AbstractText><AbstractText Label="RESULTS">Leaf is a successful production-supported tool at the University of Washington, which hosts a central Leaf instance querying an enterprise data warehouse with over 300 active users. Through the support of UW Medicine (https://uwmedicine.org), the Institute of Translational Health Sciences (https://www.iths.org), and the National Center for Data to Health (https://ctsa.ncats.nih.gov/cd2h/), Leaf source code has been released into the public domain at https://github.com/uwrit/leaf.</AbstractText><AbstractText Label="DISCUSSION">Leaf allows the querying of single or multiple clinical databases simultaneously, even those of different data models. This enables fast installation without costly extraction or duplication.</AbstractText><AbstractText Label="CONCLUSIONS">Leaf differs from existing cohort discovery tools because it does not specify a required data model and is designed to seamlessly leverage existing user authentication systems and clinical databases in situ. We believe Leaf to be useful for health system analytics, clinical research data warehouses, precision medicine biobanks, and clinical studies involving large patient cohorts.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2019. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dobbins</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Medical Education, UW Medicine Research IT, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spital</LastName><ForeName>Clifford H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>UW Medicine Research IT, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Population Health Analytics, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>Jason M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Clinical Research Informatics, St. Jude's Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Veer</LastName><ForeName>Bas</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>UW Medicine Research IT, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zampino</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UW Medicine Research IT, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Robert D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Disease, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Britt</LastName><ForeName>Bethene D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>UW Medicine Analytics, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Kari A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilcox</LastName><ForeName>Adam B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarczy-Hornoch</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mooney</LastName><ForeName>Sean D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002319</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073458" MajorTopicYN="Y">Data Warehousing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019992" MajorTopicYN="N">Databases as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="N">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="N">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057170" MajorTopicYN="Y">Translational Research, Biomedical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017432" MajorTopicYN="N">Unified Medical Language System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014584" MajorTopicYN="Y">User-Computer Interface</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="Y">Vocabulary, Controlled</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">biomedical informatics</Keyword><Keyword MajorTopicYN="N">cloud computing</Keyword><Keyword MajorTopicYN="N">cohort discovery</Keyword><Keyword MajorTopicYN="N">data integration</Keyword><Keyword MajorTopicYN="N">leaf</Keyword><Keyword MajorTopicYN="N">observational health data sciences and informatics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31592524</ArticleId><ArticleId IdType="pmc">PMC6913227</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocz165</ArticleId><ArticleId IdType="pii">5583724</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Berner ES, Moss J.. Informatics challenges for the impending patient information explosion. J Am Med Inform Assoc 2005; 12 (6): 614&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1294032</ArticleId><ArticleId IdType="pubmed">16049224</ArticleId></ArticleIdList></Reference><Reference><Citation>Shameer K, Badgeley MA, Miotto R, et al. Translational bioinformatics in the era of real-time biomedical, health care and wellness data streams. Brief Bioinform 2017; 18 (1): 105&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5221424</ArticleId><ArticleId IdType="pubmed">26876889</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty CA, Chisholm RL, Chute CG, et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics 2011; 4 (1): 13..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038887</ArticleId><ArticleId IdType="pubmed">21269473</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)&#x2014;a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (2): 377&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700030</ArticleId><ArticleId IdType="pubmed">18929686</ArticleId></ArticleIdList></Reference><Reference><Citation>
Norman DA, Draper SW.. 
User Centered System Design|New Perspectives on Human-Computer Interaction. 
Abingdon, United Kingdom: 
Taylor &amp; Francis; 1986. 
https://www.taylorfrancis.com/books/e/9781482229639 Accessed April 6, 2019.</Citation></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, et al. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2). J Am Med Inform Assoc 2010; 17 (2): 124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferranti JM, Gilbert W, McCall J, et al. The design and implementation of an open-source, data-driven cohort recruitment system: the Duke integrated subject cohort and enrollment research network (DISCERN). J Am Med Inform Assoc 2012; 19 (e1): e68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392865</ArticleId><ArticleId IdType="pubmed">21946237</ArticleId></ArticleIdList></Reference><Reference><Citation>Penberthy L, Brown R, Puma F, Dahman B.. Automated matching software for clinical trials eligibility: measuring efficiency and flexibility. Contemp Clin Trials 2010; 31 (3): 207&#x2013;17 .</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4387843</ArticleId><ArticleId IdType="pubmed">20230913</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson N, Abend A, Mandel A, et al. Implementation of a deidentified federated data network for population-based cohort discovery. J Am Med Inform Assoc 2012; 19 (e1): e60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392860</ArticleId><ArticleId IdType="pubmed">21873473</ArticleId></ArticleIdList></Reference><Reference><Citation>TriNetX. https://www.trinetx.com/ Accessed April 30, 2019.</Citation></Reference><Reference><Citation>Dyb&#xe5; T, Dings&#xf8;yr T.. Empirical studies of agile software development: a systematic review. Inform Softw Technol 2008; 50 (9&#x2013;10): 833&#x2013;59.</Citation></Reference><Reference><Citation>Carine F, Parrent N.. Improving patient identification data on the patient master index. Health Inf Manage 1999; 29 (1): 14&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10977163</ArticleId></ArticleIdList></Reference><Reference><Citation>Pautasso C. RESTful web services: principles, patterns, emerging technologies In: Web Services Foundations. New York, NY: Springer; 2014: 31&#x2013;51.</Citation></Reference><Reference><Citation>Office for Civil Rights (OCR). Methods for de-identification of PHI. https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html Accessed April 29, 2019.</Citation></Reference><Reference><Citation>OMOP Common Data Model&#x2013;OHDSI. https://www.ohdsi.org/data-standardization/the-common-data-model/ Accessed April 6, 2019.</Citation></Reference><Reference><Citation>Epic. https://www.epic.com/ Accessed April 6, 2019.</Citation></Reference><Reference><Citation>Johnson AEW, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database. Sci Data 2016; 3 (1): 160035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4878278</ArticleId><ArticleId IdType="pubmed">27219127</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider O. The unified medical language system (UMLS): integrating biomedical terminology. Nucleic Acids Res 2004; 32 (Database issue): D267&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308795</ArticleId><ArticleId IdType="pubmed">14681409</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann JG, Abend A, Raghavan VA, Mandl KD, Murphy SN.. Data interchange using i2b2. J Am Med Inform Assoc 2016; 23 (5): 909..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997035</ArticleId><ArticleId IdType="pubmed">26911824</ArticleId></ArticleIdList></Reference><Reference><Citation>
Klensin J, Saint-Andre P. Uniform Resource Names (URNs). https://tools.ietf.org/html/rfc8141 Accessed April 6, 2019.</Citation></Reference><Reference><Citation>Bender D, Sartipi K. HL7 FHIR: an agile and RESTful approach to healthcare information exchange; In: Proceedings of the 26th IEEE International Symposium on Computer-Based Medical Systems; 2013: 326&#x2013;31.</Citation></Reference><Reference><Citation>Morcos M, Lood C, Hughes G.. Demographic, clinical and immunologic correlates among a cohort of 50 cocaine users demonstrating anti-neutrophil cytoplasmic antibodies. J Rheumatol 2019; 46 (9): 1151&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">31092720</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomason J, Lood C, Hughes G.. The interferon gamma release assay is a novel predictor of disease activity in systemic Lupus erythematosus. Arthritis Rheumatol 2017; 69 (suppl 10).</Citation></Reference><Reference><Citation>Bartek MA, Kessler GL, Talbott JM, Nguyen J, Shalhub S.. Washington State abdominal aortic aneurysm mortality shows a steady decline between 1996 and 2016. J Vasc Surg 2019. Mar 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6728234</ArticleId><ArticleId IdType="pubmed">30850292</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang C, Bartek MA, Shalhub S, et al. PC040. disease-based observational cohort study of patients with thoracoabdominal aortic aneurysm. J Vasc Surg 2018; 67 (6): e183&#x2013;4.</Citation></Reference><Reference><Citation>Taylor AP, Freeman RV, Bartek MA, Shalhub S.. Left ventricular hypertrophy is a possible biomarker for early mortality after type B aortic dissection. J Vasc Surg 2019; 69 (6): 1710&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548621</ArticleId><ArticleId IdType="pubmed">30552040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartek MA, Aldea G, Nguyen J, et al. IP003. Aortic dissection-related mortality in Washington State remains unchanged from 1996 to 2016. J Vasc Surg 2018; 67 (6): e89&#x2013;90.</Citation></Reference><Reference><Citation>Kang C, Bartek MA, Shalhub S, et al. Disease-based observation cohort study of patients with thoracoabdominal aortic aneurysm. J Vasc Surg 2018; 68 (3): e35&#x2013;6.</Citation></Reference><Reference><Citation>Bartek MA, Talbot J, Nguyen J, et al. Trends in Washington state aortic-related deaths over a 21-year period, 1996-2016. J Vasc Surg 2017; 66 (3): e54.</Citation></Reference><Reference><Citation>Thornblade LW, Verdial FC, Bartek MA, et al. The safety of expectant management for adhesive small bowel obstruction: a systematic review. J Gastrointest Surg 2019; 23 (4): 846&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988581</ArticleId><ArticleId IdType="pubmed">30788717</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang I, Liew J, Morcos B, Zuo S, Crawford C, Bays AM.. A pharmacist managed titration of urate-lowering therapy to streamline gout management. Arthritis Rheumatol 2019; 39 (9): 1637&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">31147732</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Veldtman G, Bouma B, et al. Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation. Are they safe? Open Heart2019; 6 (1): e000985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6560660</ArticleId><ArticleId IdType="pubmed">31245011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills B, Muller E, Feinstein B, et al. Differences in injury circumstances and outcomes between firearm injuries transported via EMS and private vehicle. In: proceedings from the Society for the Advancement of Violence and Injury Research Annual Meeting; April 1&#x2013;3, 2019; Cincinnati, OH.</Citation></Reference><Reference><Citation>Powelson L. Chronic pain after trauma. In: proceedings from the UW Medicine Anesthesiology and Pain Medicine Grand Rounds; June 27, 2018; Seattle, WA.</Citation></Reference><Reference><Citation>Amin TM, Schorn M, Krashin D, et al. Frequency of opioid use for migraines in the ED. In: proceedings from the World Congress on Pain; September 12&#x2013;16, 2018; Boston, MA.</Citation></Reference><Reference><Citation>INSIGHT Program Awarded Federal Research Education Grant. http://depts.washington.edu/hiprc/insight-program-awarded-federal-research-education-grant/ Accessed April 6, 2019.</Citation></Reference><Reference><Citation>HealthLink, UW Medicine. UW Medicine warns of danger to kids around a lawnmower. https://www.king5.com/article/news/health/uw-medicine-warns-of-danger-to-kids-around-a-lawnmower/281-576066862 Accessed April 6, 2019.</Citation></Reference><Reference><Citation>
Malcolm K, Hurst A. More bike sharing, fewer helmets. Are head injuries on the rise? https://kuow.org/stories/more-bike-sharing-fewer-helmets-are-head-injuries-on-the-rise/ Accessed April 6, 2019.</Citation></Reference><Reference><Citation>Sweeney L. K-anonymity: a model for protecting privacy. Int J Uncertain Fuzz Knowl Based Syst 2002; 10 (5): 557&#x2013;70.</Citation></Reference><Reference><Citation>El Elam K, Jonker E, Arbuckle L, Malin B.. A systematic review of re-identification attacks on health data. PLoS One 10 (4): e0126772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4400170</ArticleId><ArticleId IdType="pubmed">25880057</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31596493</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence.</ArticleTitle><Pagination><StartPage>e1912869</StartPage><MedlinePgn>e1912869</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1912869</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2019.12869</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Although randomized clinical trials are considered to be the criterion standard for generating clinical evidence, the use of real-world evidence to evaluate the efficacy and safety of medical interventions is gaining interest. Whether observational data can be used to address the same clinical questions being answered by traditional clinical trials is still unclear.</AbstractText><AbstractText Label="OBJECTIVE">To identify the number of clinical trials published in high-impact journals in 2017 that could be feasibly replicated using observational data from insurance claims and/or electronic health records (EHRs).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">In this cross-sectional analysis, PubMed was searched to identify all US-based clinical trials, regardless of randomization, published between January 1, 2017, and December 31, 2017, in the top 7 highest-impact general medical journals of 2017. Trials were excluded if they did not involve human participants, did not use end points that represented clinical outcomes among patients, were not characterized as clinical trials, and had no recruitment sites in the United States.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcomes were the number and percentage of trials for which the intervention, indication, trial inclusion and exclusion criteria, and primary end points could be ascertained from insurance claims and/or EHR data.</AbstractText><AbstractText Label="RESULTS">Of the 220 US-based trials analyzed, 33 (15.0%) could be replicated using observational data because their intervention, indication, inclusion and exclusion criteria, and primary end points could be routinely ascertained from insurance claims and/or EHR data. Of the 220 trials, 86 (39.1%) had an intervention that could be ascertained from insurance claims and/or EHR data. Among the 86 trials, 62 (72.1%) had an indication that could be ascertained. Forty-five (72.6%) of 62 trials had at least 80% of inclusion and exclusion criteria data that could be ascertained. Of these 45 studies, 33 (73.3%) had at least 1 primary end point that could be ascertained.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study found that only 15% of the US-based clinical trials published in high-impact journals in 2017 could be feasibly replicated through analysis of administrative claims or EHR data. This finding suggests the potential for real-world evidence to complement clinical trials, both by examining the concordance between randomized experiments and observational studies and by comparing the generalizability of the trial population with the real-world population of interest.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bartlett</LastName><ForeName>Victoria L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhruva</LastName><ForeName>Sanket S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California, San Francisco School of Medicine, San Francisco.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiology, San Francisco Veterans Affairs Health Care System, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nilay D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Division of Health Care Policy &amp; Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), Department of Biomedical Informatics, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Joseph S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Section of General Internal Medicine and the National Clinician Scholars Program, Yale School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T35 HL007649</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015706" MajorTopicYN="Y">Bibliometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007348" MajorTopicYN="N">Insurance, Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="Y">Reproducibility of Results</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Shah reported receiving grants from the US Food and Drug Administration (FDA), Agency for Healthcare Research and Quality (AHRQ), Center for Medicare and Medicaid Innovation (CMMI), National Heart, Lung and Blood Institute of the National Institutes of Health (NHLBI/NIH), National Science Foundation, and Patient Centered Outcomes Research Institute (PCORI) outside the submitted work and receiving research support through Mayo Clinic from the FDA to establish the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program. Dr Ryan reported being an employee of Janssen Research and Development and a shareholder of Johnson &amp; Johnson. Dr Ross reported receiving grants from the FDA, the Centers for Medicare &amp; Medicaid Services, Medtronic Inc, Blue Cross Blue Shield Association, AHRQ, NHLBI/NIH, and Laura and John Arnold Foundation outside the submitted work and receiving research support through Yale University from Johnson &amp; Johnson. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31596493</ArticleId><ArticleId IdType="pmc">PMC6802419</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.12869</ArticleId><ArticleId IdType="pii">2752575</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sherman RE, Anderson SA, Dal Pan GJ, et al. . Real-world evidence&#x2014;what is it and what can it tell us? N Engl J Med. 2016;375(23):-. doi:10.1056/NEJMsb1609216</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb1609216</ArticleId><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine Forum on Drug Discovery, Development, and Translation Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington, DC:National Academies Press; 2010.</Citation></Reference><Reference><Citation>Dhruva SS, Ross JS, Desai NR. Real-world evidence: promise and peril for medical product evaluation. P T. 2018;43(8):464-472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6065494</ArticleId><ArticleId IdType="pubmed">30100687</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration  Use of real-world evidence to support regulatory decision-making for medical devices: guidance for industry and Food and Drug Administration staff. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm513027.pdf. Published August 2017. Accessed August 31, 2019.</Citation></Reference><Reference><Citation>National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Drug Discovery, Development, and Translation. Real-World Evidence Generation and Evaluation of Therapeutics: Proceedings of a Workshop Washington, DC: National Academies Press; 2017.</Citation></Reference><Reference><Citation>Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv. 2008;1(3):211-217. doi:10.1016/j.jcin.2008.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2008.01.008</ArticleId><ArticleId IdType="pubmed">19463302</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc. 2014;21(4):578-582. doi:10.1136/amiajnl-2014-002747</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002747</ArticleId><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowie MR, Blomster JI, Curtis LH, et al. . Electronic health records to facilitate clinical research. Clin Res Cardiol. 2017;106(1):1-9. doi:10.1007/s00392-016-1025-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-016-1025-6</ArticleId><ArticleId IdType="pmc">PMC5226988</ArticleId><ArticleId IdType="pubmed">27557678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesselheim AS, Avorn J. New &#x201c;21st Century Cures&#x201d; legislation: speed and ease vs science. JAMA. 2017;317(6):581-582. doi:10.1001/jama.2016.20640</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.20640</ArticleId><ArticleId IdType="pubmed">28056124</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration  Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act. Accessed August 31, 2019.</Citation></Reference><Reference><Citation>Thomson Reuters. InCites Journal Citation Reports. https://jcr.clarivate.com. Accessed June 30, 2018.</Citation></Reference><Reference><Citation>Dhruva SS, Ross JS, Schulz WL, Krumholz HM. Fulfilling the promise of unique device identifiers. Ann Intern Med. 2018;169(3):183-185. doi:10.7326/M18-0526</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M18-0526</ArticleId><ArticleId IdType="pubmed">29868760</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine 
https://clinicaltrials.gov. Accessed October 8, 2018.</Citation></Reference><Reference><Citation>Resnic FS, Majithia A, Marinac-Dabic D, et al. . Registry-based prospective, active surveillance of medical-device safety. N Engl J Med. 2017;376(6):526-535. doi:10.1056/NEJMoa1516333</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1516333</ArticleId><ArticleId IdType="pmc">PMC6145132</ArticleId><ArticleId IdType="pubmed">28121489</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Thompson WK, Herr TM, et al. . Natural language processing for EHR-based pharmacovigilance: a structured review. Drug Saf. 2017;40(11):1075-1089. doi:10.1007/s40264-017-0558-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-017-0558-6</ArticleId><ArticleId IdType="pubmed">28643174</ArticleId></ArticleIdList></Reference><Reference><Citation>Moses H III, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA. 2015;313(2):174-189. doi:10.1001/jama.2014.15939</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2014.15939</ArticleId><ArticleId IdType="pubmed">25585329</ArticleId></ArticleIdList></Reference><Reference><Citation>DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&amp;D costs. J Health Econ. 2016;47:20-33. doi:10.1016/j.jhealeco.2016.01.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhealeco.2016.01.012</ArticleId><ArticleId IdType="pubmed">26928437</ArticleId></ArticleIdList></Reference><Reference><Citation>Pease AM, Krumholz HM, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ. 2017;357:j1680. doi:10.1136/bmj.j1680</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j1680</ArticleId><ArticleId IdType="pmc">PMC5421452</ArticleId><ArticleId IdType="pubmed">28468750</ArticleId></ArticleIdList></Reference><Reference><Citation>Downing NS, Shah ND, Aminawung JA, et al. . Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA. 2017;317(18):1854-1863. doi:10.1001/jama.2017.5150</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.5150</ArticleId><ArticleId IdType="pmc">PMC5815036</ArticleId><ArticleId IdType="pubmed">28492899</ArticleId></ArticleIdList></Reference><Reference><Citation>Darrow JJ, Avorn J, Kesselheim AS. New FDA breakthrough-drug category&#x2013;implications for patients. N Engl J Med. 2014;370(13):1252-1258. doi:10.1056/NEJMhle1311493</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMhle1311493</ArticleId><ArticleId IdType="pubmed">24670173</ArticleId></ArticleIdList></Reference><Reference><Citation>Mess&#xe9; SR, Kent DM. Still no closure on the question of PFO closure. N Engl J Med. 2013;368(12):1152-1153. doi:10.1056/NEJMe1301680</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe1301680</ArticleId><ArticleId IdType="pmc">PMC4420155</ArticleId><ArticleId IdType="pubmed">23514293</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb S. FDA budget matters: a cross-cutting data enterprise for real world evidence. FDA Voices.https://www.fda.gov/NewsEvents/Newsroom/FDAVoices/ucm614669.htm. Published June 10, 2018. Accessed November 11, 2018.</Citation></Reference><Reference><Citation>US Food and Drug Administration  Framework for FDA&#x2019;s real-world evidence program. https://www.fda.gov/media/120060/download. Published December 2018. Accessed August 31, 2019.</Citation></Reference><Reference><Citation>Guimar&#xe3;es PO, Krishnamoorthy A, Kaltenbach LA, et al. . Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction: a secondary analysis of the TRANSLATE-ACS study. JAMA Cardiol. 2017;2(7):750-757. doi:10.1001/jamacardio.2017.1460</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2017.1460</ArticleId><ArticleId IdType="pmc">PMC5710613</ArticleId><ArticleId IdType="pubmed">28538984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99-104. doi:10.1016/j.ahj.2004.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2004.02.013</ArticleId><ArticleId IdType="pubmed">15215798</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" VersionID="2" Owner="NLM"><PMID Version="2">31633087</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2574-2531</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Apr</Month></PubDate></JournalIssue><Title>JAMIA open</Title><ISOAbbreviation>JAMIA Open</ISOAbbreviation></Journal><ArticleTitle>ROMOP: a light-weight R package for interfacing with OMOP-formatted electronic health record data.</ArticleTitle><Pagination><StartPage>10</StartPage><EndPage>14</EndPage><MedlinePgn>10-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamiaopen/ooy059</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Electronic health record (EHR) data are increasingly used for biomedical discoveries. The nature of the data, however, requires expertise in both data science and EHR structure. The Observational Medical Out-comes Partnership (OMOP) common data model (CDM) standardizes the language and structure of EHR data to promote interoperability of EHR data for research. While the OMOP CDM is valuable and more attuned to research purposes, it still requires extensive domain knowledge to utilize effectively, potentially limiting more widespread adoption of EHR data for research and quality improvement.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We have created ROMOP: an R package for direct interfacing with EHR data in the OMOP CDM format.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ROMOP streamlines typical EHR-related data processes. Its functions include exploration of data types, extraction and summarization of patient clinical and demographic data, and patient searches using any CDM vocabulary concept.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">ROMOP is freely available under the Massachusetts Institute of Technology (MIT) license and can be obtained from GitHub (http://github.com/BenGlicksberg/ROMOP). We detail instructions for setup and use in the Supplementary Materials. Additionally, we provide a public sandbox server containing synthesized clinical data for users to explore OMOP data and ROMOP (http://romop.ucsf.edu).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glicksberg</LastName><ForeName>Benjamin S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskotsky</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pediatrics Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giangreco</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Departments of Biomedical Informatics, Systems Biology, and Medicine, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thangaraj</LastName><ForeName>Phyllis M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Departments of Biomedical Informatics, Systems Biology, and Medicine, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudrapatna</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pediatrics Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Datta</LastName><ForeName>Debajyoti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pediatrics Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frazier</LastName><ForeName>Remi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Academic Research Systems, Department of Enterprise Data Warehouse University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Nelson</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Academic Research Systems, Department of Enterprise Data Warehouse University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsen</LastName><ForeName>Rick</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Academic Research Systems, Department of Enterprise Data Warehouse University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatonetti</LastName><ForeName>Nicholas P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Departments of Biomedical Informatics, Systems Biology, and Medicine, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butte</LastName><ForeName>Atul J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Pediatrics Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F30 HL140946</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMIA Open</MedlineTA><NlmUniqueID>101730643</NlmUniqueID><ISSNLinking>2574-2531</ISSNLinking></MedlineJournalInfo><CoiStatement>Conflict of interest statement. None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31633087</ArticleId><ArticleId IdType="mid">NIHMS1052565</ArticleId><ArticleId IdType="pmc">PMC6800657</ArticleId><ArticleId IdType="doi">10.1093/jamiaopen/ooy059</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blumenthal D, Tavenner M.. The &#x201c;meaningful use&#x201d; regulation for electronic health records. N Engl J Med 2010; 3636: 501&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">20647183</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen PB, Jensen LJ, Brunak S.. Mining electronic health records: towards better research applications and clinical care. Nat Rev Genet 2012; 136: 395&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">22549152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res 2004; 32: D267&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308795</ArticleId><ArticleId IdType="pubmed">14681409</ArticleId></ArticleIdList></Reference><Reference><Citation>Huser V, DeFalco FJ, Schuemie M, et al. Multisite evaluation of a data quality tool for patient-level clinical data sets. EGEMS (Wash DC) 2016; 41: 1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5226382</ArticleId><ArticleId IdType="pubmed">28154833</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaddox TR, Ryan PB, Schuemie MJ, Madigan D, Suchard MA.. Hierarchical models for multiple, rare outcomes using massive observational healthcare databases. Stat Anal Data Min 2016; 94: 260&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5423675</ArticleId><ArticleId IdType="pubmed">28503249</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Ryan PB, Suchard MA, et al. Risk of angioedema associated with levetiracetam compared with phenytoin: findings of the observational health data sciences and informatics research network. Epilepsia 2017; 588: e101&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632067</ArticleId><ArticleId IdType="pubmed">28681416</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN.. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform 2016; 64: 333&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajkomar A, Oren E, Chen K, et al. Scalable and accurate deep learning with electronic health records. NPJ Digit Med 2018; 11: 18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6550175</ArticleId><ArticleId IdType="pubmed">31304302</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Shah N.. Learning effective treatment pathways for type-2 diabetes from a clinical data warehouse. AMIA Annu Symp Proc 2016; 2016: 2036&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333256</ArticleId><ArticleId IdType="pubmed">28269963</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wickham H, Danenberg P, Eugster M.. 
roxygen2: in-source documentation for R
https://cran.r-project.org/package=roxygen2 (version 6.0.1)2013; 3(0).</Citation></Reference><Reference><Citation>
Dowle M, Srinivasan A, Gorecki J,
et al.
Package &#x2018;data.table&#x2019;
2018. 
https://cran.r-project.org/web/packages/data.table/data.table.pdf (version 1.11.8)</Citation></Reference><Reference><Citation>
James D.
DBI: R database interface (2009); 2012. 
https://cran.r-project.org/web/packages/DBI/index.html (version 1.0.0).</Citation></Reference><Reference><Citation>
Wickham H, Francois R, Henry L, M&#xfc;ller K.. 
dplyr: A Grammar of Data Manipulation. R package version 0.5.0. Vienna: R Core Development Team; 2016. 
https://cran.r-project.org/web/packages/dplyr/dplyr.pdf (version 0.7.8)</Citation></Reference><Reference><Citation>
Hester J, Wickham H. odbc: connect to ODBC compatible databases (using the DBI interface). CRAN; 2018. 
https://cran.r-project.org/web/packages/odbc/odbc.pdf (version 1.1.5)</Citation></Reference><Reference><Citation>
Ooms J, James D, DebRoy S, Wickham H, Horner J.. 
RMySQL: Database Interface and MySQL Driver for R.
https://cran.r-project.org/web/packages/RMySQL/index.html (version 0.10.15); 3.</Citation></Reference><Reference><Citation>
Scheumie M, Suchard M.. 
DatabaseConnector: Connecting to Various Database Platforms
https://cran.r-project.org/web/packages/DatabaseConnector/index.html (version 2.2.0). 2018.</Citation></Reference><Reference><Citation>
Scheumie M, Suchard M.. 
DatabaseConnectorJars: JAR Dependencies for the &#x2018;DatabaseConnector&#x2019; Package
https://cran.r-project.org/web/packages/DatabaseConnectorJars/index.html (version 1.0.0). 2018.</Citation></Reference><Reference><Citation>
Scheumie M, Suchard M.. 
SqlRender: Rendering Parameterized SQL and Translation to Dialects
https://cran.r-project.org/web/packages/SqlRender/index.html (version 1.5.2). 2018.</Citation></Reference><Reference><Citation>
Wickham H, Chang W.. 
devtools: Tools to Make Developing R Packages Easier
https://cran.r-project.org/web/packages/devtools/index.html (version 1.13.6). 2016.</Citation></Reference><Reference><Citation>
Chang W, Cheng J, Allaire JJ, Xie Y, McPherson J.. 
Shiny: Web Application Framework for R.
https://cran.r-project.org/web/packages/shiny/index.html (version 1.1.0); 1 (4): 106.</Citation></Reference><Reference><Citation>
Schloerke B, Allaire J, Borges B.. 
learnr: Interactive Tutorials for R.
https://cran.rstudio.com/web/packages/learnr/index.html (version 0.9.2.1)
2018.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31642211</PMID><DateRevised><Year>2020</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1738-5520</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Korean circulation journal</Title><ISOAbbreviation>Korean Circ J</ISOAbbreviation></Journal><ArticleTitle>Comparison of First-Line Dual Combination Treatments in Hypertension: Real-World Evidence from Multinational Heterogeneous Cohorts.</ArticleTitle><Pagination><StartPage>52</StartPage><EndPage>68</EndPage><MedlinePgn>52-68</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4070/kcj.2019.0173</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">2018 ESC/ESH Hypertension guideline recommends 2-drug combination as initial anti-hypertensive therapy. However, real-world evidence for effectiveness of recommended regimens remains limited. We aimed to compare the effectiveness of first-line anti-hypertensive treatment combining 2 out of the following classes: angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor blocker (A), calcium channel blocker (C), and thiazide-type diuretics (D).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Treatment-na&#xef;ve hypertensive adults without cardiovascular disease (CVD) who initiated dual anti-hypertensive medications were identified in 5 databases from US and Korea. The patients were matched for each comparison set by large-scale propensity score matching. Primary endpoint was all-cause mortality. Myocardial infarction, heart failure, stroke, and major adverse cardiac and cerebrovascular events as a composite outcome comprised the secondary measure.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 987,983 patients met the eligibility criteria. After matching, 222,686, 32,344, and 38,513 patients were allocated to A+C vs. A+D, C+D vs. A+C, and C+D vs. A+D comparison, respectively. There was no significant difference in the mortality during total of 1,806,077 person-years: A+C vs. A+D (hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.97-1.20; p=0.127), C+D vs. A+C (HR, 0.93; 95% CI, 0.87-1.01; p=0.067), and C+D vs. A+D (HR, 1.18; 95% CI, 0.95-1.47; p=0.104). A+C was associated with a slightly higher risk of heart failure (HR, 1.09; 95% CI, 1.01-1.18; p=0.040) and stroke (HR, 1.08; 95% CI, 1.01-1.17; p=0.040) than A+D.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There was no significant difference in mortality among A+C, A+D, and C+D combination treatment in patients without previous CVD. This finding was consistent across multi-national heterogeneous cohorts in real-world practice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020. The Korean Society of Cardiology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Sungjae</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8266-0480</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MediBloc Inc., Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel N</ForeName><Initials>JN</Initials><Identifier Source="ORCID">0000-0001-9491-2737</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><Identifier Source="ORCID">0000-0002-9727-2138</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>Department of Biomathematics, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seongwon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0547-6492</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Jaehyeong</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7213-5033</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2664-7614</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, NewYork-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea. veritas@ajou.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sungha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5362-478X</Identifier><AffiliationInfo><Affiliation>Division of Cardiology, Severance Cardiovascular Hospital and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea. shpark0530@yuhs.ac.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HI16C0992</GrantID><Acronym>KCDC</Acronym><Agency>Korea Centers for Disease Control &amp; Prevention</Agency><Country>Korea</Country></Grant><Grant><GrantID>IIS 1251151</GrantID><Acronym>NSF</Acronym><Agency>National Science Foundation</Agency><Country>United States of America</Country></Grant><Grant><GrantID>MPSS-FireSafety-2015-80</GrantID><Agency>National Fire Agency</Agency><Country>United States of America</Country></Grant><Grant><GrantID>HI16C0992</GrantID><Acronym>MHW</Acronym><Agency>Ministry of Health and Welfare</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Korean Circ J</MedlineTA><NlmUniqueID>101247141</NlmUniqueID><ISSNLinking>1738-5520</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Angiotensin receptor antagonists</Keyword><Keyword MajorTopicYN="N">Antihypertensive agents</Keyword><Keyword MajorTopicYN="N">Calcium channel blockers</Keyword><Keyword MajorTopicYN="N">Diuretics</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword></KeywordList><CoiStatement>The authors declare the following disclosures: Mr. Swerdel, Dr. Ryan, and Dr. Schuemie are employees of Janssen Research &amp; Development. The rest of the authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31642211</ArticleId><ArticleId IdType="pmc">PMC6923236</ArticleId><ArticleId IdType="doi">10.4070/kcj.2019.0173</ArticleId><ArticleId IdType="pii">50.e2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659&#x2013;1724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5388856</ArticleId><ArticleId IdType="pubmed">27733284</ArticleId></ArticleIdList></Reference><Reference><Citation>Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022&#x2013;2031.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207952</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) J Clin Hypertens (Greenwich) 2002;4:393&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">12461301</ArticleId></ArticleIdList></Reference><Reference><Citation>Basile JN, Bloch MJ. Analysis of recent papers in hypertension. Initial combination therapy provides more prompt blood pressure control and reduces cardiovascular events but remains underutilized. J Clin Hypertens (Greenwich) 2013;15:523&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">23889711</ArticleId></ArticleIdList></Reference><Reference><Citation>Gradman AH, Paris&#xe9; H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013;61:309&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">23184383</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59:1124&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3425944</ArticleId><ArticleId IdType="pubmed">22566499</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021&#x2013;3104.</Citation><ArticleIdList><ArticleId IdType="pubmed">30165516</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417&#x2013;2428.</Citation><ArticleIdList><ArticleId IdType="pubmed">19052124</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogihara T, Saruta T, Rakugi H, et al. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens. 2014;32:2054&#x2013;2063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4166009</ArticleId><ArticleId IdType="pubmed">24999799</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805&#x2013;2816.</Citation><ArticleIdList><ArticleId IdType="pubmed">14657064</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber MA, Jamerson K, Bakris GL, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013;381:537&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">23219284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017;46:e15.</Citation><ArticleIdList><ArticleId IdType="pubmed">26822938</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47:2005&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23:10.1145/2414416.2414791</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168:49&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">12663327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2017;66:72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci U S A. 2018;115:2571&#x2013;2577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H, Park S, Kim HC. Temporal and geospatial trends of hypertension management in Korea: a nationwide study 2002&#x2013;2016. Korean Circ J. 2019;49:514&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6554585</ArticleId><ArticleId IdType="pubmed">30808085</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki M, Ogihara T, Umemoto S, et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens. 2011;29:1649&#x2013;1659.</Citation><ArticleIdList><ArticleId IdType="pubmed">21610513</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi C, Tai C, Bai B, et al. Angiotensin system blockade combined with calcium channel blockers is superior to other combinations in cardiovascular protection with similar blood pressure reduction: a meta-analysis in 20,451 hypertensive patients. J Clin Hypertens (Greenwich) 2016;18:801&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">26778747</ArticleId></ArticleIdList></Reference><Reference><Citation>Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534&#x2013;2544.</Citation><ArticleIdList><ArticleId IdType="pubmed">12759325</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens. 2015;33:1321&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">26039526</ArticleId></ArticleIdList></Reference><Reference><Citation>Wassertheil-Smoller S, Psaty B, Greenland P, et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA. 2004;292:2849&#x2013;2859.</Citation><ArticleIdList><ArticleId IdType="pubmed">15598916</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J. 2008;29:2669&#x2013;2680.</Citation><ArticleIdList><ArticleId IdType="pubmed">18852183</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26:819&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">18327094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">20026768</ArticleId></ArticleIdList></Reference><Reference><Citation>Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol. 2018;71:1474&#x2013;1482.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598869</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Zeng D. On the relative efficiency of using summary statistics versus individual-level data in meta-analysis. Biometrika. 2010;97:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3412575</ArticleId><ArticleId IdType="pubmed">23049122</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31645076</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>Incrementally Transforming Electronic Medical Records into the Observational Medical Outcomes Partnership Common Data Model: A Multidimensional Quality Assurance Approach.</ArticleTitle><Pagination><StartPage>794</StartPage><EndPage>803</EndPage><MedlinePgn>794-803</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0039-1697598</ELocationID><Abstract><AbstractText Label="BACKGROUND">The development and adoption of health care common data models (CDMs) has addressed some of the logistical challenges of performing research on data generated from disparate health care systems by standardizing data representations and leveraging standardized terminology to express clinical information consistently. However, transforming a data system into a CDM is not a trivial task, and maintaining an operational, enterprise capable CDM that is incrementally updated within a data warehouse is challenging.</AbstractText><AbstractText Label="OBJECTIVES">To develop a quality assurance (QA) process and code base to accompany our incremental transformation of the Department of Veterans Affairs Corporate Data Warehouse health care database into the Observational Medical Outcomes Partnership (OMOP) CDM to prevent incremental load errors.</AbstractText><AbstractText Label="METHODS">We designed and implemented a multistage QA) approach centered on completeness, value conformance, and relational conformance data-quality elements. For each element we describe key incremental load challenges, our extract, transform, and load (ETL) solution of data to overcome those challenges, and potential impacts of incremental load failure.</AbstractText><AbstractText Label="RESULTS">Completeness and value conformance data-quality elements are most affected by incremental changes to the CDW, while updates to source identifiers impact relational conformance. ETL failures surrounding these elements lead to incomplete and inaccurate capture of clinical concepts as well as data fragmentation across patients, providers, and locations.</AbstractText><AbstractText Label="CONCLUSION">Development of robust QA processes supporting accurate transformation of OMOP and other CDMs from source data is still in evolution, and opportunities exist to extend the existing QA framework and tools used for incremental ETL QA processes.</AbstractText><CopyrightInformation>Georg Thieme Verlag KG Stuttgart &#xb7; New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>VA Salt Lake City Health Care System, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deppen</LastName><ForeName>Stephen A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>VA Salt Lake City Health Care System, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viernes</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VA Salt Lake City Health Care System, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, Utah, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Aize</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Nashville, Tennessee, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanchrow</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hewa</LastName><ForeName>Kushan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greaves</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Vanderbilt University Medical Center, Nashville, Tennessee, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Nashville, Tennessee, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011785" MajorTopicYN="Y">Quality Assurance, Health Care</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31645076</ArticleId><ArticleId IdType="pmc">PMC6811349</ArticleId><ArticleId IdType="doi">10.1055/s-0039-1697598</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Voss E A, Makadia R, Matcho A et al.Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(03):553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xf6;rg T, DeBloch S.Towards generating ETL processes for incremental loadingIn: ACM International Conference Proceeding Series; September 10&#x2013;12, 2008; Coimbra, Portugal. pp. 101&#x2013;110</Citation></Reference><Reference><Citation>Post A R, Ai M, Kalsanka Pai A, Overcash M, Stephens D S. Architecting the data loading process for an i2b2 research data warehouse: full reload versus incremental updating. AMIA Annu Symp Proc. 2018;2017:1411&#x2013;1420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977612</ArticleId><ArticleId IdType="pubmed">29854210</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn M G, Brown J S, Chun A T et al.Transparent reporting of data quality in distributed data networks. EGEMS (Wash DC) 2015;3(01):1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434997</ArticleId><ArticleId IdType="pubmed">25992385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn M G, Callahan T J, Barnard J et al.A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS (Wash DC) 2016;4(01):1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5051581</ArticleId><ArticleId IdType="pubmed">27713905</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh W R, Cimino J, Payne P R et al.Recommendations for the use of operational electronic health record data in comparative effectiveness research. EGEMS (Wash DC) 2013;1(01):1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371471</ArticleId><ArticleId IdType="pubmed">25848563</ArticleId></ArticleIdList></Reference><Reference><Citation>Qualls L G, Phillips T A, Hammill B G et al.Evaluating foundational data quality in the National Patient-Centered Clinical Research Network (PCORnet&#xae;) EGEMS (Wash DC) 2018;6(01):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983028</ArticleId><ArticleId IdType="pubmed">29881761</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke J D, Shah N H et al.Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Available at:https://www.ohdsi.org. Accessed August 30, 2019</Citation></Reference><Reference><Citation>Makadia R, Ryan P B. Transforming the premier perspective hospital database into the Observational Medical Outcomes Partnership (OMOP) common data model. EGEMS (Wash DC) 2014;2(01):1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. 2014;37(11):945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwalm M, Raoul T, Chu D et al.PRM59 - Conversion of a French electronic medical record (EMR) database into the Observational Medical Outcomes Partnership common data model. Value Health. 2017;20(09):A741.</Citation></Reference><Reference><Citation>Maier C, Lang L, Storf H et al.Towards implementation of OMOP in a German university hospital consortium. Appl Clin Inform. 2018;9(01):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann J G, Joss M AH, Embree K, Murphy S N. Data model harmonization for the All Of Us Research Program: transforming i2b2 data into the OMOP common data model. PLoS One. 2019;14(02):e0212463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn E K, Park M Y et al.Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016;22(01):54&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>You S C, Lee S, Cho S Y et al.Conversion of national health insurance service-national sample cohort (NHIS-NSC) database into Observational Medical Outcomes Partnership-common data model (OMOP-CDM) Stud Health Technol Inform. 2017;245:467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Resnic F S, Robbins S L et al.Creating a common data model for comparative effectiveness with the Observational Medical Outcomes Partnership. Appl Clin Inform. 2015;6(03):536&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Department of Veterans Affairs. National center for veterans analysis and statistics [11/13/2017]. Available at:https://www.va.gov/vetdata/Utilization.asp. Accessed August 30, 2019</Citation></Reference><Reference><Citation>Fihn S D, Francis J, Clancy C et al.Insights from advanced analytics at the Veterans Health Administration. Health Aff (Millwood) 2014;33(07):1203&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">25006147</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R, Singh S. A description of classification of causes of data quality problems in data warehousing. International Journal of Computer Science Issues. 2010;7(03):41&#x2013;49.</Citation></Reference><Reference><Citation>Rupali G, Singh J. A review of contemporary data quality issues in data warehouse ETL environment. Journal on Today's Ideas &#x2013; Tomorrow's Technologies. 2014;2(02):153&#x2013;160.</Citation></Reference><Reference><Citation>Weiskopf N G, Bakken S, Hripcsak G, Weng C. A data quality assessment guideline for electronic health record data reuse. EGEMS (Wash DC) 2017;5(01):14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983018</ArticleId><ArticleId IdType="pubmed">29881734</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31651956</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Imputation and characterization of uncoded self-harm in major mental illness using machine learning.</ArticleTitle><Pagination><StartPage>136</StartPage><EndPage>146</EndPage><MedlinePgn>136-146</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocz173</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We aimed to impute uncoded self-harm in administrative claims data of individuals with major mental illness (MMI), characterize self-harm incidence, and identify factors associated with coding bias.</AbstractText><AbstractText Label="MATERIALS AND METHODS">The IBM MarketScan database (2003-2016) was used to analyze visit-level self-harm in 10&#xa0;120&#xa0;030 patients with &#x2265;2 MMI codes. Five machine learning (ML) classifiers were tested on a balanced data subset, with XGBoost selected for the full dataset. Classification performance was validated via random data mislabeling and comparison with a clinician-derived "gold standard." The incidence of coded and imputed self-harm was characterized by year, patient age, sex, U.S. state, and MMI diagnosis.</AbstractText><AbstractText Label="RESULTS">Imputation identified 1&#xa0;592&#xa0;703 self-harm events vs 83&#xa0;113 coded events, with areas under the curve &gt;0.99 for the balanced and full datasets, and 83.5% agreement with the gold standard. The overall coded and imputed self-harm incidence were 0.28% and 5.34%, respectively, varied considerably by age and sex, and was highest in individuals with multiple MMI diagnoses. Self-harm undercoding was higher in male than in female individuals and increased with age. Substance abuse, injuries, poisoning, asphyxiation, brain disorders, harmful thoughts, and psychotherapy were the main features used by ML to classify visits.</AbstractText><AbstractText Label="DISCUSSION">Only 1 of 19 self-harm events was coded for individuals with MMI. ML demonstrated excellent performance in recovering self-harm visits. Male individuals and seniors with MMI are particularly vulnerable to self-harm undercoding and may be at risk of not getting appropriate psychiatric care.</AbstractText><AbstractText Label="CONCLUSIONS">ML can effectively recover unrecorded self-harm in claims data and inform psychiatric epidemiological and observational studies.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2019. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Praveen</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Global Health, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University of New Mexico, Albuquerque, New Mexico, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nestsiarovich</LastName><ForeName>Anastasiya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Global Health, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Stuart J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Department of Clinical Research &amp; Leadership, George Washington University, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerner</LastName><ForeName>Berit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkins</LastName><ForeName>Douglas J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Center for Global Health, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Christophe G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Center for Global Health, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, University of New Mexico, Albuquerque, New Mexico, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02893371</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002965" MajorTopicYN="N">Classification</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059019" MajorTopicYN="N">Clinical Coding</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016728" MajorTopicYN="N">Self-Injurious Behavior</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059020" MajorTopicYN="Y">Suicidal Ideation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coding</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">self-harm</Keyword><Keyword MajorTopicYN="N">suicide</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31651956</ArticleId><ArticleId IdType="pmc">PMC7647246</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocz173</ArticleId><ArticleId IdType="pii">5607248</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WISQARS Leading Causes of Death Reports. https://webappa.cdc.gov/sasweb/ncipc/leadcaus10_us.html. Accessed March 26, 2019.</Citation></Reference><Reference><Citation>WISQARS Fatal Injury Reports. https://webappa.cdc.gov/sasweb/ncipc/mortrate10_us.html. Accessed March 26, 2019.</Citation></Reference><Reference><Citation>Crosby AE, Han B, Ortega LAG, et al. Suicidal thoughts and behaviors among adults aged &#x2265;18 years&#x2013;United States, 2008-2009. MMWR Surveill Summ 2011; 60: 1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">22012169</ArticleId></ArticleIdList></Reference><Reference><Citation>Crandall C, Fullerton-Gleason L, Aguero R, et al. Subsequent suicide mortality among emergency department patients seen for suicidal behavior. Acad Emerg Med 2006; 13 (4): 435&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16531601</ArticleId></ArticleIdList></Reference><Reference><Citation>Andover MS, Gibb BE.. Non-suicidal self-injury, attempted suicide, and suicidal intent among psychiatric inpatients. Psychiatry Res 2010; 178 (1): 101&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20444506</ArticleId></ArticleIdList></Reference><Reference><Citation>Canner JK, Giuliano K, Selvarajah S, et al. Emergency department visits for attempted suicide and self harm in the USA: 2006-2013. Epidemiol Psychiatr Sci 2018; 27 (1): 94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6999001</ArticleId><ArticleId IdType="pubmed">27852333</ArticleId></ArticleIdList></Reference><Reference><Citation>Olfson M, Marcus SC, Bridge JA.. Emergency treatment of deliberate self-harm. Arch Gen Psychiatry 2012; 69 (1): 80&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21893643</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus SC, Bridge JA, Olfson M.. Payment source and emergency management of deliberate self-harm. Am J Public Health 2012; 102 (6): 1145&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3483957</ArticleId><ArticleId IdType="pubmed">22515853</ArticleId></ArticleIdList></Reference><Reference><Citation>Bethell J, Rhodes AE.. Identifying deliberate self-harm in emergency department data. Health Rep 2009; 20 (2): 35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">19728584</ArticleId></ArticleIdList></Reference><Reference><Citation>LeMier M, Cummings P, West TA.. Accuracy of external cause of injury codes reported in Washington State hospital discharge records. Inj Prev 2001; 7 (4): 334&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1730776</ArticleId><ArticleId IdType="pubmed">11770664</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemball RS, Gasgarth R, Johnson B, et al. Unrecognized suicidal ideation in ED patients: are we missing an opportunity? Am J Emerg Med 2008; 26 (6): 701&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746995</ArticleId><ArticleId IdType="pubmed">18606326</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson HD, Pace WD, Brandt E, et al. Monitoring suicidal patients in primary care using electronic health records. J Am Board Fam Med 2015; 28 (1): 65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">25567824</ArticleId></ArticleIdList></Reference><Reference><Citation>
Abellera J, Annest JL, Conn JM, 
et al. How states are collecting and using cause of injury data: 2004 update to the 1997 report. 2005. 
http://www.cste2.org/webpdfs/ECodeFinal3705.pdf Accessed August 30, 2017.</Citation></Reference><Reference><Citation>Annest JL, Fingerhut LA, Gallagher SS, et al. Strategies to improve external cause-of-injury coding in state-based hospital discharge and emergency department data systems: recommendations of the CDC Workgroup for Improvement of External Cause-of-Injury Coding. MMWR Recomm Rep 2008; 57 (RR-1): 1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">18368008</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson KF, Nugent SM, Grill J, et al. Accuracy of external cause-of-injury coding in VA polytrauma patient discharge records. J Rehabil Res Dev 2010; 47 (8): 689&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">21110244</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CY, Stewart C, Ahmed AT, et al. How complete are E-codes in commercial plan claims databases? Pharmacoepidemiol Drug Saf 2014; 23 (2): 218&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4100538</ArticleId><ArticleId IdType="pubmed">24453020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman GJ, Hays RD, Shapiro MF, et al. Claims-based identification methods and the cost of fall-related injuries among US older adults. Med Care 2016; 54 (7): 664&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4907826</ArticleId><ArticleId IdType="pubmed">27057747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting SA, Sullivan AF, Miller I, et al. Multicenter study of predictors of suicide screening in emergency departments. Acad Emerg Med 2012; 19 (2): 239&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3664554</ArticleId><ArticleId IdType="pubmed">22288721</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulin C, Shiner B, Thompson P, et al. Predicting the risk of suicide by analyzing the text of clinical notes. PLoS One 2014; 9 (1): e85733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904866</ArticleId><ArticleId IdType="pubmed">24489669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler RC, Warner CH, Ivany C, et al. Predicting suicides after psychiatric hospitalization in US Army soldiers: the Army Study to Assess Risk and rEsilience in Servicemembers (Army STARRS). JAMA Psychiatry 2015; 72 (1): 49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286426</ArticleId><ArticleId IdType="pubmed">25390793</ArticleId></ArticleIdList></Reference><Reference><Citation>Barak-Corren Y, Castro VM, Javitt S, et al. Predicting suicidal behavior from longitudinal electronic health records. Am J Psychiatry 2017; 174 (2): 154&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">27609239</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat HS, Goldman-Mellor SJ. Predicting adolescent suicide attempts with neural networks. arXiv 2017 Dec 1 [E-pub ahead of print].</Citation></Reference><Reference><Citation>Walsh CG, Ribeiro JD, Franklin JC.. Predicting risk of suicide attempts over time through machine learning. Clin Psychol Sci 2017; 5 (3): 457&#x2013;69.</Citation></Reference><Reference><Citation>Simon GE, Johnson E, Lawrence JM, et al. Predicting suicide attempts and suicide deaths following outpatient visits using electronic health records. Am J Psychiatry 2018; 175 (10): 951&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6167136</ArticleId><ArticleId IdType="pubmed">29792051</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh CG, Ribeiro JD, Franklin JC.. Predicting suicide attempts in adolescents with longitudinal clinical data and machine learning. J Child Psychol Psychiatry 2018; 59 (12): 1261&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">29709069</ArticleId></ArticleIdList></Reference><Reference><Citation>DelPozo-Banos M, John A, Petkov N, et al. Using neural networks with routine health records to identify suicide risk: feasibility study. JMIR Ment Health 2018; 5 (2): e10144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035342</ArticleId><ArticleId IdType="pubmed">29934287</ArticleId></ArticleIdList></Reference><Reference><Citation>Haerian K, Salmasian H, Friedman C.. Methods for identifying suicide or suicidal ideation in EHRs. AMIA Annu Symp Proc 2012; 2012: 1244&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540459</ArticleId><ArticleId IdType="pubmed">23304402</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh J, Yun K, Hwang J-H, et al. Classification of suicide attempts through a machine learning algorithm based on multiple systemic psychiatric scales. Front Psychiatry 2017; 8: 192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5632514</ArticleId><ArticleId IdType="pubmed">29038651</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Q-Y, Mittal LP, Nathan MD, et al. Use of natural language processing in electronic medical records to identify pregnant women with suicidal behavior: towards a solution to the complex classification problem. Eur J Epidemiol 2019; 34 (2): 153&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6370493</ArticleId><ArticleId IdType="pubmed">30535584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes AC, Dutta R, Velupillai S, et al. Identifying suicide ideation and suicidal attempts in a psychiatric clinical research database using natural language processing. Sci Rep 2018; 8 (1): 7426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5943451</ArticleId><ArticleId IdType="pubmed">29743531</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick AR, Miller M, Barber CW, et al. Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded. Pharmacoepidem Drug Safe 2010; 19 (12): 1263&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992076</ArticleId><ArticleId IdType="pubmed">20922709</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc 2015; 22 (3): 553&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>ETL-CDMBuilder. Github
https://github.com/OHDSI/ETL-CDMBuilder Accessed March 26, 2019.</Citation></Reference><Reference><Citation>Chen T, Guestrin C.. XGBoost: A scalable tree boosting system In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. New York, NY: ACM; 2016: 785&#x2013;94.</Citation></Reference><Reference><Citation>Matthews BW. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim Biophys Acta 1975; 405 (2): 442&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">1180967</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: machine learning in python. J Mach Learn Res 2011; 12: 2825&#x2013;30.</Citation></Reference><Reference><Citation>Baker SP, Hu G, Wilcox HC, et al. Increase in suicide by hanging/suffocation in the U.S., 2000-2010. Am J Prev Med 2013; 44 (2): 146&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553495</ArticleId><ArticleId IdType="pubmed">23332330</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawton K, Bergen H, Cooper J, et al. Suicide following self-harm: findings from the multicentre study of self-harm in England, 2000-2012. J Affect Disord 2015; 175: 147&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">25617686</ArticleId></ArticleIdList></Reference><Reference><Citation>WISQARS (Web-based Injury Statistics Query and Reporting System. 2019. https://www.cdc.gov/injury/wisqars/index.html. Accessed June 5, 2019.</Citation></Reference><Reference><Citation>McAllister M. Multiple meanings of self harm: a critical review. Int J Ment Health Nurs 2003; 12 (3): 177&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">17393644</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh WR, Weiner MG, Embi PJ, et al. Caveats for the use of operational electronic health record data in comparative effectiveness research. Med Care 2013; 51: S30&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748381</ArticleId><ArticleId IdType="pubmed">23774517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fliege H, Lee J-R, Grimm A, et al. Risk factors and correlates of deliberate self-harm behavior: a systematic review. J Psychosom Res 2009; 66 (6): 477&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">19446707</ArticleId></ArticleIdList></Reference><Reference><Citation>Angst J, Hengartner MP, Rogers J, et al. Suicidality in the prospective Zurich study: prevalence, risk factors and gender. Eur Arch Psychiatry Clin Neurosci 2014; 264 (7): 557&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">24682244</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Luo M, Wang W, et al. Association between nonmedical use of opioids or sedatives and suicidal behavior among Chinese adolescents: an analysis of sex differences. Aust N Z J Psychiatry 2019; 53 (6): 559&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">30525916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawton K, Saunders K, Topiwala A, et al. Psychiatric disorders in patients presenting to hospital following self-harm: a systematic review. J Affect Disord 2013; 151 (3): 821&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">24091302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31668726</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>394</Volume><Issue>10211</Issue><PubDate><Year>2019</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.</ArticleTitle><Pagination><StartPage>1816</StartPage><EndPage>1826</EndPage><MedlinePgn>1816-1826</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(19)32317-7</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(19)32317-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Uncertainty remains about the optimal monotherapy for hypertension, with current guidelines recommending any primary agent among the first-line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calcium channel blockers, in the absence of comorbid indications. Randomised trials have not further refined this choice.</AbstractText><AbstractText Label="METHODS">We developed a comprehensive framework for real-world evidence that enables comparative effectiveness and safety evaluation across many drugs and outcomes from observational data encompassing millions of patients, while minimising inherent bias. Using this framework, we did a systematic, large-scale study under a new-user cohort design to estimate the relative risks of three primary (acute myocardial infarction, hospitalisation for heart failure, and stroke) and six secondary effectiveness and 46 safety outcomes comparing all first-line classes across a global network of six administrative claims and three electronic health record databases. The framework addressed residual confounding, publication bias, and p-hacking using large-scale propensity adjustment, a large set of control outcomes, and full disclosure of hypotheses tested.</AbstractText><AbstractText Label="FINDINGS">Using 4&#xb7;9 million patients, we generated 22&#x2008;000 calibrated, propensity-score-adjusted hazard ratios (HRs) comparing all classes and outcomes across databases. Most estimates revealed no effectiveness differences between classes; however, thiazide or thiazide-like diuretics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardial infarction (HR 0&#xb7;84, 95% CI 0&#xb7;75-0&#xb7;95), hospitalisation for heart failure (0&#xb7;83, 0&#xb7;74-0&#xb7;95), and stroke (0&#xb7;83, 0&#xb7;74-0&#xb7;95) risk while on initial treatment. Safety profiles also favoured thiazide or thiazide-like diuretics over angiotensin-converting enzyme inhibitors. The non-dihydropyridine calcium channel blockers were significantly inferior to the other four classes.</AbstractText><AbstractText Label="INTERPRETATION">This comprehensive framework introduces a new way of doing observational health-care science at scale. The approach supports equivalence between drug classes for initiating monotherapy for hypertension-in keeping with current guidelines, with the exception of thiazide or thiazide-like diuretics superiority to angiotensin-converting enzyme inhibitors and the inferiority of non-dihydropyridine calcium channel blockers.</AbstractText><AbstractText Label="FUNDING">US National Science Foundation, US National Institutes of Health, Janssen Research &amp; Development, IQVIA, South Korean Ministry of Health &amp; Welfare, Australian National Health and Medical Research Council.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA; Department of Biomathematics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA. Electronic address: msuchard@ucla.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, USA; Epidemiology Analytics, Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Yale University School of Medicine, New Haven, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>RuiJun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, University of South Australia, Adelaide, SA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Real World Analytics Solutions, IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Georgia Tech Research Institute, Georgia Tech College of Computing, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA; Medical Informatics Services, New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, NJ, USA; Department of Biomedical Informatics, Columbia University Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI135995</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004232">Diuretics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2019 Nov 16;394(10211):1782-1784</RefSource><PMID Version="1">31668725</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Am J Nurs. 2020 Mar;120(3):67</RefSource><PMID Version="1">32079803</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057186" MajorTopicYN="N">Comparative Effectiveness Research</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004232" MajorTopicYN="N">Diuretics</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31668726</ArticleId><ArticleId IdType="mid">NIHMS1546136</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pii">S0140-6736(19)32317-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018;138(17):e426&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">30354655</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">30165516</ArticleId></ArticleIdList></Reference><Reference><Citation>The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">12479763</ArticleId></ArticleIdList></Reference><Reference><Citation>Reboussin DM, Allen NB, Griswold ME, et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018;138(17):e595&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">30354656</ArticleId></ArticleIdList></Reference><Reference><Citation>Musini VM, Gueyffier F, Puil L, Salzwedel DM, Wright JM. Pharmacotherapy for hypertension in adults aged 18 to 59 years. Cochrane Database Syst Rev [Internet] 2017;Available from: 10.1002/14651858.cd008276.pub2 (accessed on 21 July 2019)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.cd008276.pub2</ArticleId><ArticleId IdType="pmc">PMC6483466</ArticleId><ArticleId IdType="pubmed">28813123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf 2013;36 Suppl 1:S59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol 2016;183(8):758&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>ACCORD Study Group, Cushman WC, Evans GW, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1575&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123215</ArticleId><ArticleId IdType="pubmed">20228401</ArticleId></ArticleIdList></Reference><Reference><Citation>SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373(22):2103&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4689591</ArticleId><ArticleId IdType="pubmed">26551272</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for Causal Effects. Biometrika 1983;70(1):41.</Citation></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol 2018;47(6):2005&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med 2013;33(2):209&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust empirical calibration of p-values using observational data. Stat Med 2016;35(22):3883&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="pubmed">27592566</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform 2017;66:72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proceedings of the National Academy of Sciences 2018;115(11):2571&#x2013;2577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A, Patrick Lauer, et al. A tool for assessing the feasibility of comparative effectiveness research. Comparative Effectiveness Research 2013;3:11&#x2013;20.</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model. ACM Trans Model Comput Simul 2013;23(1):10:1&#x2013;10:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Roland M, Torgerson DJ. What are pragmatic trials? BMJ 1998;316(7127):285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665488</ArticleId><ArticleId IdType="pubmed">9472515</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanchetti A, Crepaldi G, Bond MG, et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial. Stroke 2004;35(12):2807&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">15514192</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348(7):583&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584366</ArticleId></ArticleIdList></Reference><Reference><Citation>Rush CJ, Campbell RT, Jhund PS, Petrie MC, McMurray JJV. Association is not causation: treatment effects cannot be estimated from observational data in heart failure. Eur Heart J 2018;39(37):3417&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166137</ArticleId><ArticleId IdType="pubmed">30085087</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci [Internet] 2018;376(2128). Available from: 10.1098/rsta.2017.0356</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31721815</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>11</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Correction:&#xa0;KETOS: Clinical decision support and machine learning as a service - A training and deployment platform based on Docker, OMOP-CDM, and FHIR Web Services.</ArticleTitle><Pagination><StartPage>e0225442</StartPage><MedlinePgn>e0225442</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0225442</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0225442</ELocationID><Abstract><AbstractText>[This corrects the article DOI: 10.1371/journal.pone.0223010.].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gruendner</LastName><ForeName>Julian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schwachhofer</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sippl</LastName><ForeName>Phillip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Erpenbeck</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gulden</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kapsner</LastName><ForeName>Lorenz A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Zierk</LastName><ForeName>Jakob</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mate</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>St&#xfc;rzl</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Croner</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Prokosch</LastName><ForeName>Hans-Ulrich</ForeName><Initials>HU</Initials></Author><Author ValidYN="Y"><LastName>Toddenroth</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>PLoS One. 2019 Oct 3;14(10):e0223010</RefSource><PMID Version="1">31581246</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31721815</ArticleId><ArticleId IdType="pmc">PMC6853310</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0225442</ArticleId><ArticleId IdType="pii">PONE-D-19-30965</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gruendner J, Schwachhofer T, Sippl P, Wolf N, Erpenbeck M, Gulden C, et al. (2019) KETOS: Clinical decision support and machine learning as a service&#x2013;A training and deployment platform based on Docker, OMOP-CDM, and FHIR Web Services. PLoS ONE 14(10): e0223010 10.1371/journal.pone.0223010</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0223010</ArticleId><ArticleId IdType="pmc">PMC6776354</ArticleId><ArticleId IdType="pubmed">31581246</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31797639</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2335-6936</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing</Title><ISOAbbreviation>Pac Symp Biocomput</ISOAbbreviation></Journal><ArticleTitle>Robust-ODAL: Learning from heterogeneous health systems without sharing patient-level data.</ArticleTitle><Pagination><StartPage>695</StartPage><EndPage>706</EndPage><MedlinePgn>695-706</MedlinePgn></Pagination><Abstract><AbstractText>Electronic Health Records (EHR) contain extensive patient data on various health outcomes and risk predictors, providing an efficient and wide-reaching source for health research. Integrated EHR data can provide a larger sample size of the population to improve estimation and prediction accuracy. To overcome the obstacle of sharing patient-level data, distributed algorithms were developed to conduct statistical analyses across multiple clinical sites through sharing only aggregated information. However, the heterogeneity of data across sites is often ignored by existing distributed algorithms, which leads to substantial bias when studying the association between the outcomes and exposures. In this study, we propose a privacy-preserving and communication-efficient distributed algorithm which accounts for the heterogeneity caused by a small number of the clinical sites. We evaluated our algorithm through a systematic simulation study motivated by real-world scenarios and applied our algorithm to multiple claims datasets from the Observational Health Data Sciences and Informatics (OHDSI) network. The results showed that the proposed method performed better than the existing distributed algorithm ODAL and a meta-analysis method.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology &amp; Informatics, University of Pennsylvania, Philadelphia, PA,19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruowang</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Scheuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI130460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012607</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pac Symp Biocomput</MedlineTA><NlmUniqueID>9711271</NlmUniqueID><ISSNLinking>2335-6928</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="Y">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31797639</ArticleId><ArticleId IdType="mid">NIHMS1061510</ArticleId><ArticleId IdType="pmc">PMC6905508</ArticleId><ArticleId IdType="pii">9789811215636_0061</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Center for Devices and Radiological Health. Real-World Evidence to Support Regulatory Decision-Making for Devices. FDA Med Bull. www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices</Citation></Reference><Reference><Citation>Center for Drug Evaluation and Research. Submitting Documents Using Real-World Data and Real-World Evidence. FDA Med Bull. www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-documents-using-real-world-data-and-real-world-evidence-fda-drugs-andbiologics-guidance</Citation></Reference><Reference><Citation>Center for Drug Evaluation and Research. Use of Electronic Health Record Data in Clinical Investigations. FDA Med Bull. www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-health-record-data-clinical-investigations-guidance-industry</Citation></Reference><Reference><Citation>Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med. 2016;375: 2293&#x2013;2297.</Citation><ArticleIdList><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowens FM, Frye PA, Jones WA. Health information technology: integration of clinical workflow into meaningful use of electronic health records. Perspect Health Inf Manag. 2010;7: 1d.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966355</ArticleId><ArticleId IdType="pubmed">21063545</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman CP, Wong AK, Blumenthal D. Achieving a nationwide learning health system. Sci Transl Med. 2010;2: 57cm29.</Citation><ArticleIdList><ArticleId IdType="pubmed">21068440</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19: 54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest CB, Margolis PA, Bailey LC, Marsolo K, Del Beccaro MA, Finkelstein JA, et al. PEDSnet: a National Pediatric Learning Health System. J Am Med Inform Assoc. 2014;21: 602&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="pubmed">24821737</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Jiang X, Kim J, Ohno-Machado L. Grid Binary LOgistic REgression (GLORE): building shared models without sharing data. J Am Med Inform Assoc. 2012;19: 758&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422844</ArticleId><ArticleId IdType="pubmed">22511014</ArticleId></ArticleIdList></Reference><Reference><Citation>Seol Kwangsoo, et al. Privacy-preserving attribute-based access control model for XML-based electronic health record system. IEEE Access 6 (2018): 9114&#x2013;9128.</Citation></Reference><Reference><Citation>Kho Abel N., et al. Design and implementation of a privacy preserving electronic health record linkage tool in Chicago. Journal of the American Medical Informatics Association 225 (2015): 1072&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009931</ArticleId><ArticleId IdType="pubmed">26104741</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Lu-Chou, et al. Privacy preservation and information security protection for patients&#x2019; portable electronic health records. Computers in Biology and Medicine 399 (2009): 743&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pubmed">19589509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahi Muneeb Ahmed, et al. Privacy preservation in e-healthcare environments: State of the art and future directions. IEEE Access 6 (2017): 464&#x2013;478.</Citation></Reference><Reference><Citation>Dubovitskaya Alevtina, et al. A cloud-based ehealth architecture for privacy preserving data integration. IFIP International Information Security and Privacy Conference Springer, Cham, 2015.</Citation></Reference><Reference><Citation>G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113: 7329&#x2013;7336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Shahn Z, Madigan D, Hripcsak G, Tatonetti NP. Birth month affects lifetime disease risk: a phenome-wide method. J Am Med Inform Assoc. 2015;22: 1042&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4986668</ArticleId><ArticleId IdType="pubmed">26041386</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzan IL, Rudick RA. Time to integrate clinical and research informatics. Sci Transl Med. 2012;4: 162fs41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23197569</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DR. Regression Models and Life-Tables In: Kotz S, Johnson NL, editors. Breakthroughs in Statistics: Methodology and Distribution. New York, NY: Springer New York; 1992. pp. 527&#x2013;541.</Citation></Reference><Reference><Citation>Ohno-Machado L, Agha Z, Bell DS, Dahm L, Day ME, Doctor JN, et al. pSCANNER: Patient-centered scalable national network for effectiveness research. J Am Med Inform Assoc. BMJ Publishing Group; 2014;21: 621&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078293</ArticleId><ArticleId IdType="pubmed">24780722</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan R, Boland MR, Moore JH, Chen Y. ODAL: A one-shot distributed algorithm to perform logistic regressions on electronic health records data from multiple clinical sites. Pac Symp Biocomput. 2019;24: 30&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417819</ArticleId><ArticleId IdType="pubmed">30864308</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang KY. Extended Mantel-Haenszel estimating procedure for multivariate logistic regression models. Biometrics. 1987;43: 289&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">3607201</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H-DI. Effect of Ignoring Heterogeneity in Hazards Regression In: Balakrishnan N, Nikulin MS, Mesbah M, Limnios N, editors. Parametric and Semiparametric Models with Applications to Reliability, Survival Analysis, and Quality of Life. Boston, MA: Birkh&#xe4;user Boston; 2004. pp. 239&#x2013;250.</Citation></Reference><Reference><Citation>Forrest CB, Crandall WV, Bailey LC, et al. Effectiveness of anti-TNF&#x3b1; for Crohn disease: research in a pediatric learning health system. Pediatrics 2014; 134(1): 37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531278</ArticleId><ArticleId IdType="pubmed">24935993</ArticleId></ArticleIdList></Reference><Reference><Citation>Antunes O, Filippi J, H&#xe9;buterne X, Peyrin-Biroulet L. Treatment algorithms in Crohn&#x2019;s&#x2013;Up, down or something else? Best Practice &amp; Research Clinical Gastroenterology 2014; 28(3): 473&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">24913386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YS, Baek SH, Kim MJ, Lee YM, Lee Y, Choe YH. Efficacy of early infliximab treatment for pediatric Crohn&#x2019;s disease: a three-year follow-up. Pediatric Gastroenterology, Hepatology &amp; Nutrition 2012; 15(4): 243&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746055</ArticleId><ArticleId IdType="pubmed">24010094</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008;29: 932&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">18334475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation. 2007;115: 1067&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">17339564</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31837755</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1946-9837</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><PubDate><Year>2019</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Topics in companion animal medicine</Title><ISOAbbreviation>Top Companion Anim Med</ISOAbbreviation></Journal><ArticleTitle>Optimization of Electronic Medical Records for Data Mining Using a Common Data Model.</ArticleTitle><Pagination><StartPage>100364</StartPage><MedlinePgn>100364</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tcam.2019.100364</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1938-9736(19)30101-1</ELocationID><Abstract><AbstractText>The increasing use of electronic health records (EHRs) in veterinary medicine creates an opportunity to utilize the high volume of electronic patient data for mining and data-driven analytics with the goal of improving patient care and outcomes. A central focus of the Clinical and Translational Science Award One Health Alliance (COHA) is to integrate efforts across multiple disciplines to better understand shared diseases in animals and people. The ability to combine veterinary and human medical data provides a unique resource to study the interactions and relationships between animals, humans, and the environment. However, to effectively answer these questions, veterinary EHR data must first be prepared in the same way it is now commonly being done in human medicine to enable data mining and development of analytics to facilitate knowledge formation and solutions that advance our understanding of disease processes, with the ultimate goal of improving outcomes for veterinary patients and their owners. As a first step, COHA member institutions implemented a Common Data Model to standardize EHR data. Herein we present the approach executed within the COHA framework to prepare and optimize veterinary EHRs for data mining and knowledge formation based on the adoption of the Observational Health Data Sciences and Informatics' Observational Medical Outcomes Partnership Common Data Model.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwong</LastName><ForeName>Manlik</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tufts Medical Center, Boston, MA, USA. Electronic address: Mkwong@tuftsmedicalcenter.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardner</LastName><ForeName>Heather L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dieterle</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cummings School of Veterinary Medicine, Tufts University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentko</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Cummings School of Veterinary Medicine, Tufts University, Boston, MA, USA; Animal Bioscience Inc., Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Top Companion Anim Med</MedlineTA><NlmUniqueID>101465592</NlmUniqueID><ISSNLinking>1946-9837</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068598" MajorTopicYN="N">Data Accuracy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057225" MajorTopicYN="N">Data Mining</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014730" MajorTopicYN="N">Veterinary Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COHA</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword><Keyword MajorTopicYN="N">infrastructure</Keyword><Keyword MajorTopicYN="N">research</Keyword><Keyword MajorTopicYN="N">veterinary</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31837755</ArticleId><ArticleId IdType="mid">NIHMS1554946</ArticleId><ArticleId IdType="pmc">PMC7874511</ArticleId><ArticleId IdType="doi">10.1016/j.tcam.2019.100364</ArticleId><ArticleId IdType="pii">S1938-9736(19)30101-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hripcsak G, Albers DJ. Next-generation phenotyping of electronic health records. J Am Med Inform Assoc 20:117&#x2013;121, 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555337</ArticleId><ArticleId IdType="pubmed">22955496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellinger C, Mohomed Jabbar MS, Zaiane O, Osornio-Vargas A. A systematic review of data mining and machine learning for air pollution epidemiology. BMC Public Health 17:907,2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5704396</ArticleId><ArticleId IdType="pubmed">29179711</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyfroidt G, Guiza F, Ramon J, Bruynooghe M. Machine learning techniques to examine large patient databases. BestPract Res Clin Anaesthesiol 23:127&#x2013;143,2009</Citation><ArticleIdList><ArticleId IdType="pubmed">19449621</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Guo SL, Han LN, Li TL. Application and exploration of big data mining in clinical medicine. Chin Med J 129:731&#x2013;738, 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4804421</ArticleId><ArticleId IdType="pubmed">26960378</ArticleId></ArticleIdList></Reference><Reference><Citation>Yala A, Lehman C, Schuster T, Portnoi T, Barzilay R. A deep learning mammography-based model for improved breast cancer risk prediction. Radiology :182716,2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31063083</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty C, Camina S, White K, Orenstein G. The Path to Predictive Analytics and Machine Learning. 1 ed Sebastopol CA: O&#x2019;Reilly Media, Inc.; 2016</Citation></Reference><Reference><Citation>Law GC, Apfelbacher C, Posadzki PP, Kemp S, Tudor Car L. Choice of outcomes and measurement instruments in randomised trials on eLearning in medical education: a systematic mapping review protocol. SystRev 7:75,2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5960094</ArticleId><ArticleId IdType="pubmed">29776434</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonardi A, Clifford CJ, Hadar N. A Structured Approach Using the Systematic Review Data Repository (SRDR): building the evidence for oral health interventions in the population with intellectual and developmental disability. Eval Rev 41:111&#x2013;129,2017</Citation><ArticleIdList><ArticleId IdType="pubmed">27543432</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31851711</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>12</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Inferring disease severity in rheumatoid arthritis using predictive modeling in administrative claims databases.</ArticleTitle><Pagination><StartPage>e0226255</StartPage><MedlinePgn>e0226255</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0226255</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0226255</ELocationID><Abstract><AbstractText Label="BACKGROUND">Confounding by disease severity is an issue in pharmacoepidemiology studies of rheumatoid arthritis (RA), due to channeling of sicker patients to certain therapies. To address the issue of limited clinical data for confounder adjustment, a patient-level prediction model to differentiate between patients prescribed and not prescribed advanced therapies was developed as a surrogate for disease severity, using all available data from a US claims database.</AbstractText><AbstractText Label="METHODS">Data from adult RA patients were used to build regularized logistic regression models to predict current and future disease severity using a biologic or tofacitinib prescription claim as a surrogate for moderate-to-severe disease. Model discrimination was assessed using the area under the receiver (AUC) operating characteristic curve, tested and trained in Optum Clinformatics&#xae; Extended DataMart (Optum) and additionally validated in three external IBM MarketScan&#xae; databases. The model was further validated in the Optum database across a range of patient cohorts.</AbstractText><AbstractText Label="RESULTS">In the Optum database (n = 68,608), the AUC for discriminating RA patients with a prescription claim for a biologic or tofacitinib versus those without in the 90 days following index diagnosis was 0.80. Model AUCs were 0.77 in IBM CCAE (n = 75,579) and IBM MDCD (n = 7,537) and 0.75 in IBM MDCR (n = 36,090). There was little change in the prediction model assessing discrimination 730 days following index diagnosis (prediction model AUC in Optum was 0.79).</AbstractText><AbstractText Label="CONCLUSIONS">A prediction model demonstrated good discrimination across multiple claims databases to identify RA patients with a prescription claim for advanced therapies during different time-at-risk periods as proxy for current and future moderate-to-severe disease. This work provides a robust model-derived risk score that can be used as a potential covariate and proxy measure to adjust for confounding by severity in multivariable models in the RA population. An R package to develop the prediction model and risk score are available in an open source platform for researchers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Urmila</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-7183-3622</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>87LA6FU830</RegistryNumber><NameOfSubstance UI="C479163">tofacitinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="Y">Insurance Claim Review</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N">Pyrroles</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors are employees of Janssen Research and Development, a unit of Johnson and Johnson family of companies. The work on this study was part of their employment. All authors hold pension rights from the company and own stock options. The authors would like to declare the following patents associated with this research: Johnson &amp; Johnson holds marketing authorizations for REMICADE&#x2122; (infliximab) and SIMPONI&#x2122; (golimumab). This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31851711</ArticleId><ArticleId IdType="pmc">PMC6919633</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0226255</ArticleId><ArticleId IdType="pii">PONE-D-19-14036</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bernatsky S, Lix L,O'Donnell S, Lacaille D, Canrad Network. Consensus statements for the use of administrative health data in rheumatic disease research and surveillance. J Rheumatol. 2013; 40(1): 66&#x2013;73. 10.3899/jrheum.120835</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.120835</ArticleId><ArticleId IdType="pubmed">23118109</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht K, Zink A. Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies. Arthritis Research &amp; Therapy. 2017; 19: 68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5364634</ArticleId><ArticleId IdType="pubmed">28335797</ArticleId></ArticleIdList></Reference><Reference><Citation>Avina-Zubieta JA., Abrahamowicz M, Cho HK, Rahman MM, Sylvestre MP,Esdaile JM, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford). 2013; 52(1): 68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">23192907</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride S., Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA, Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis. J Rheumatol. 2011; 38(10): 2141&#x2013;9. 10.3899/jrheum.101195</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.101195</ArticleId><ArticleId IdType="pubmed">21844154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravi B, Croxford R, Austin PC, Hollands S, Paterson JM,Bogoch E.et al.Increased surgeon experience with rheumatoid arthritis reduces the risk of complications following total joint arthroplasty. Arthritis Rheumatol. 2014; 66(3): 488&#x2013;96. 10.1002/art.38205</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38205</ArticleId><ArticleId IdType="pubmed">24574207</ArticleId></ArticleIdList></Reference><Reference><Citation>Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J. et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013; 65(3): 353&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">22833532</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23(1). 10.1145/2414416.2414791</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Saag KG, Bridges SL Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2016;68(1):1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">26545825</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann of Rheum Dis. 2017;76(6):960&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">28264816</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018; 25(8):969&#x2013;75. 10.1093/jamia/ocy032</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54&#x2013;60. 10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(3):553&#x2013;64. 10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CP, Rohan P, Krishnaswami S, McPheeters ML. A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data. Vaccine. 2013;31 Suppl 10:K41&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24331074</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Tech Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>PatientLevelPrediction R package Available from: https://github.com/OHDSI/StudyProtocolSandbox/tree/master/RASeverity.</Citation></Reference><Reference><Citation>Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski ML, Farley JF. Predictors of treatment initiation with tumor necrosis factor-alpha inhibitors in patients with rheumatoid arthritis. J Manag Care Spec Pharm. 2014;20(11):1110&#x2013;20. 10.18553/jmcp.2014.20.11.1110</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2014.20.11.1110</ArticleId><ArticleId IdType="pubmed">25351972</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai RJ, Solomon DH, Weinblatt ME, Shadick N, Kim SC. An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. Arthritis Res Ther. 2015;17:83 10.1186/s13075-015-0599-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0599-0</ArticleId><ArticleId IdType="pmc">PMC4394559</ArticleId><ArticleId IdType="pubmed">25880932</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato M, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Avorn J, et al. The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther. 2006;8(3):R57 10.1186/ar1921</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar1921</ArticleId><ArticleId IdType="pmc">PMC1526615</ArticleId><ArticleId IdType="pubmed">16542499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis research &amp; therapy. 2008;10(4):R95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575609</ArticleId><ArticleId IdType="pubmed">18717997</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F, Michaud K, Simon T. Can severity be predicted by treatment variables in rheumatoid arthritis administrative data bases? J of Rheumatol. 2006;33(10):1952&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960927</ArticleId></ArticleIdList></Reference><Reference><Citation>Norgeot B, Glicksberg BS, Trupin L, Lituiev D, Gianfrancesco M, Oskotsky B, et al. Assessment of a Deep Learning Model Based on Electronic Health Record Data to Forecast Clinical Outcomes in Patients With Rheumatoid Arthritis. JAMA Netw Open. 2019;2(3):e190606 10.1001/jamanetworkopen.2019.0606</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.0606</ArticleId><ArticleId IdType="pmc">PMC6484652</ArticleId><ArticleId IdType="pubmed">30874779</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">31866433</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>102</Volume><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Adapting electronic health records-derived phenotypes to claims data: Lessons learned in using limited clinical data for phenotyping.</ArticleTitle><Pagination><StartPage>103363</StartPage><MedlinePgn>103363</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2019.103363</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(19)30283-7</ELocationID><Abstract><AbstractText>Algorithms for identifying patients of interest from observational data must address missing and inaccurate data and are desired to achieve comparable performance on both administrative claims and electronic health records data. However, administrative claims data do not contain the necessary information to develop accurate algorithms for disorders that require laboratory results, and this omission can result in insensitive diagnostic code-based algorithms. In this paper, we tested our assertion that the performance of a diagnosis code-based algorithm for chronic kidney disorder (CKD) can be improved by adding other codes indirectly related to CKD (e.g., codes for dialysis, kidney transplant, suspicious kidney disorders). Following the best practices from Observational Health Data Sciences and Informatics (OHDSI), we adapted an electronic health record-based gold standard algorithm for CKD and then created algorithms that can be executed on administrative claims data and account for related data quality issues. We externally validated our algorithms on four electronic health record datasets in the OHDSI network. Compared to the algorithm that uses CKD diagnostic codes only, positive predictive value of the algorithms that use additional codes was slightly increased (47.4% vs. 47.9-48.5% respectively). The algorithms adapted from the gold standard algorithm can be used to infer chronic kidney disorder based on administrative claims data. We succeeded in improving the generalizability and consistency of the CKD phenotypes by using data and vocabulary standardized across the OHDSI network, although performance variability across datasets remains. We showed that identifying and addressing coding and data heterogeneity can improve the performance of the algorithms.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, USA; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA, USA; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Raritan, NJ, USA; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, USA; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, USA; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA. Electronic address: hripicsak@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY, USA; Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA. Electronic address: chunhua@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008680</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic kidney disorder</Keyword><Keyword MajorTopicYN="N">Data quality</Keyword><Keyword MajorTopicYN="N">Observational Health Data Sciences and Informatics (OHDSI)</Keyword><Keyword MajorTopicYN="N">Phenotyping</Keyword><Keyword MajorTopicYN="N">Portability</Keyword><Keyword MajorTopicYN="N">Reproducibility</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31866433</ArticleId><ArticleId IdType="mid">NIHMS1548044</ArticleId><ArticleId IdType="pmc">PMC7390483</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2019.103363</ArticleId><ArticleId IdType="pii">S1532-0464(19)30283-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van der Lei J, Pratt N, Nor&#xe9;n GN, Li Y-C, Stang PE, Madigan D, Ryan PB, Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers, Stud Health Technol Inform 216 (2015) 574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI Data Network, (n.d.).
http://www.ohdsi.org/web/wiki/doku.php?id=resources:2018_data_network (accessed
May 21, 2019).</Citation></Reference><Reference><Citation>Page not found &#x2013; KDIGO, (n.d.).
https://kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf (accessed
July 11, 2019).</Citation></Reference><Reference><Citation>Levey AS, de Jong PE, Coresh J, M.E. l. Nahas, B.C. Astor, K. Matsushita, R.T. Gansevoort, B.L. Kasiske, K.-U. Eckardt, The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report, Kidney International. 80 (2011) 17&#x2013;28. 10.1038/ki.2010.483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2010.483</ArticleId><ArticleId IdType="pubmed">21150873</ArticleId></ArticleIdList></Reference><Reference><Citation>KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease&#x2013;Mineral and Bone Disorder (CKD-MBD), Kidney International Supplements. 7 (2017) 1&#x2013;59. 10.1016/j.kisu.2017.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kisu.2017.04.001</ArticleId><ArticleId IdType="pmc">PMC6341011</ArticleId><ArticleId IdType="pubmed">30681074</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman N, Halas G, Peeler W, Casaclang N, Williamson T, Katz A, From patient care to research: a validation study examining the factors contributing to data quality in a primary care electronic medical record database, BMC Family Practice 16 (2015). 10.1186/s12875-015-0223-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12875-015-0223-z</ArticleId><ArticleId IdType="pmc">PMC4324413</ArticleId><ArticleId IdType="pubmed">25649201</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadhim-Saleh A, Green M, Williamson T, Hunter D, Birtwhistle R, Validation of the diagnostic algorithms for 5 chronic conditions in the Canadian Primary Care Sentinel Surveillance Network (CPCSSN): a Kingston Practice-based Research Network (PBRN) report, J Am Board Fam Med. 26 (2013) 159&#x2013;167. 10.3122/jabfm.2013.02.120183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3122/jabfm.2013.02.120183</ArticleId><ArticleId IdType="pubmed">23471929</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleet JL, Dixon SN, Shariff SZ, Quinn RR, Nash DM, Harel Z, Garg AX, Detecting chronic kidney disease in population-based administrative databases using an algorithm of hospital encounter and physician claim codes, BMC Nephrology 14 (2013). 10.1186/1471-2369-14-81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2369-14-81</ArticleId><ArticleId IdType="pmc">PMC3637099</ArticleId><ArticleId IdType="pubmed">23560464</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronksley PE, Tonelli M, Quan H, Manns BJ, James MT, Clement FM, Samuel S, Quinn RR, Ravani P, Brar SS, Hemmelgarn BR, For the Alberta Kidney Disease Network, Validating a case definition for chronic kidney disease using administrative data, Nephrology Dialysis Transplantation. 27 (2012) 1826&#x2013;1831. 10.1093/ndt/gfr598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ndt/gfr598</ArticleId><ArticleId IdType="pubmed">22015442</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens LA, Fares G, Fleming J, Martin D, Murthy K, Qiu J, Stark PC, Uhlig K, Van Lente F, Levey AS, Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease, J. Am. Soc. Nephrol 16 (2005) 2439&#x2013;2448. 10.1681/ASN.2005020192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2005020192</ArticleId><ArticleId IdType="pubmed">15930090</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH, Identification of Individuals With CKD From Medicare Claims Data: A Validation Study, American Journal of Kidney Diseases. 46 (2005) 225&#x2013;232. 10.1053/j.ajkd.2005.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2005.04.029</ArticleId><ArticleId IdType="pubmed">16112040</ArticleId></ArticleIdList></Reference><Reference><Citation>KDIGO_2012_CKD_GL.pdf, (n.d.).
https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf (accessed
May 21, 2019).</Citation></Reference><Reference><Citation>KDIGO_2012_CKD_GL.pdf, (n.d.).
https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf (accessed
July 11, 2019).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31900133</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Treatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019.</ArticleTitle><Pagination><StartPage>4</StartPage><MedlinePgn>4</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-019-2418-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Understanding how patients are treated in the real-world is vital to identifying potential gaps in care. We describe the current pharmacologic treatment patterns for the treatment of depression.</AbstractText><AbstractText Label="METHODS">Patients with depression were identified from four large national claims databases during 1/1/2014-1/31/2019. Patients had &#x2265;2 diagnoses for depression or an inpatient hospitalization with a diagnosis of depression. Patients were required to have enrollment in the database &#x2265;1&#x2009;year prior to and 3 years following their first depression diagnosis. Treatment patterns were captured at the class level and included selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, other antidepressants, anxiolytics, hypnotics/sedatives, and antipsychotics. Treatment patterns were captured during all available follow-up.</AbstractText><AbstractText Label="RESULTS">We identified 269,668 patients diagnosed with depression. The proportion not receiving any pharmacological treatment during follow-up ranged from 29 to 52%. Of the treated, approximately half received &#x2265;2 different classes of therapy, a quarter received &#x2265;3 classes and more than 10% received 4 or more. SSRIs were the most common first-line treatment; however, many patients received an anxiolytic, hypnotic/sedative, or antipsychotic prior to any antidepressive treatment. Treatment with a combination of classes ranged from approximately 20% of first-line therapies to 40% of fourth-line.</AbstractText><AbstractText Label="CONCLUSIONS">Many patients diagnosed with depression go untreated and many others receive a non-antidepressant medication class as their first treatment. More than half of patients received more than one type of treatment class during the study follow up, suggesting that the first treatment received may not be optimal for most patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0001-5417-3925</Identifier><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Epidemiology, Titusville, NJ, 08560, USA. dkern2@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cepeda</LastName><ForeName>M Soledad</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Epidemiology, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defalco</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Epidemiology, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etropolski</LastName><ForeName>Mila</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Neuroscience TA, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>n/a</GrantID><Agency>Janssen Research and Development</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006993">Hypnotics and Sedatives</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000068760">Serotonin and Noradrenaline Reuptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="Y">Drug Prescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006993" MajorTopicYN="N">Hypnotics and Sedatives</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007344" MajorTopicYN="N">Insurance Claim Reporting</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068760" MajorTopicYN="N">Serotonin and Noradrenaline Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antidepressants</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Real-world evidence</Keyword><Keyword MajorTopicYN="N">Treatment patterns</Keyword></KeywordList><CoiStatement>All authors are employees of Janssen Research &amp; Development, LLC, which markets and develops treatments for depression, and are stockholders of Johnson &amp; Johnson, Janssen&#x2019;s parent company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31900133</ArticleId><ArticleId IdType="pmc">PMC6942399</ArticleId><ArticleId IdType="doi">10.1186/s12888-019-2418-7</ArticleId><ArticleId IdType="pii">10.1186/s12888-019-2418-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Institute of Mental Health. Major Depression 2019 [Last Accessed: September 9, 2019]. Available from: https://www.nimh.nih.gov/health/statistics/major-depression.shtml.</Citation></Reference><Reference><Citation>Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26(2):457&#x2013;494. doi: 10.1016/S0193-953X(02)00107-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0193-953X(02)00107-7</ArticleId><ArticleId IdType="pubmed">12778843</ArticleId></ArticleIdList></Reference><Reference><Citation>Adli M, Wiethoff K, Baghai TC, Fisher R, Seemuller F, Laakmann G, et al. How effective is algorithm-guided treatment for depressed inpatients? Results from the randomized controlled multicenter German algorithm project 3 trial. Int J Neuropsychopharmacol. 2017;20(9):721&#x2013;730. doi: 10.1093/ijnp/pyx043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyx043</ArticleId><ArticleId IdType="pmc">PMC5581493</ArticleId><ArticleId IdType="pubmed">28645191</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi MH, Kleiber BA. Algorithm for the treatment of chronic depression. J Clin Psychiatry. 2001;62(Suppl 6):22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">11310816</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75(1):57&#x2013;66. doi: 10.3949/ccjm.75.1.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.75.1.57</ArticleId><ArticleId IdType="pubmed">18236731</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Si T. Use of antipsychotics in the treatment of depressive disorders. Shanghai Arch Psychiatry. 2013;25(3):134&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4054548</ArticleId><ArticleId IdType="pubmed">24991148</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S-M, Han C, Lee S-J, Jun T-Y, Patkar AA, Masand PS, et al. Second generation antipsychotics in the treatment of major depressive disorder: an update. Chonnam Med J. 2016;52(3):159&#x2013;172. doi: 10.4068/cmj.2016.52.3.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.4068/cmj.2016.52.3.159</ArticleId><ArticleId IdType="pmc">PMC5040765</ArticleId><ArticleId IdType="pubmed">27689026</ArticleId></ArticleIdList></Reference><Reference><Citation>Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O'Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21(4):238&#x2013;245. doi: 10.1177/1062860606288243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1062860606288243</ArticleId><ArticleId IdType="pubmed">16849780</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46(10):1075&#x2013;1090. doi: 10.1016/0895-4356(93)90103-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(93)90103-8</ArticleId><ArticleId IdType="pubmed">8410092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Levine ME, Shang N, Ryan PB. Effect of vocabulary mapping for conditions on phenotype cohorts. J Am Med Inform Assoc. 2018;25(12):1618&#x2013;1625. doi: 10.1093/jamia/ocy124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy124</ArticleId><ArticleId IdType="pmc">PMC6289550</ArticleId><ArticleId IdType="pubmed">30395248</ArticleId></ArticleIdList></Reference><Reference><Citation>SNOMED CT. SNOMED CT 5-Step Briefing 2019. Available from: http://www.snomed.org/snomed-ct/five-step-briefing.</Citation></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600&#x2013;606. doi: 10.7326/0003-4819-153-9-201011020-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier G, Gu&#xe9;rin A, Zhdanava M, Jacobson W, Nomikos G, Merikle E, et al. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis. BMC Psychiatry. 2017;17(1):222. doi: 10.1186/s12888-017-1385-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-017-1385-0</ArticleId><ArticleId IdType="pmc">PMC5477263</ArticleId><ArticleId IdType="pubmed">28629442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329&#x2013;7336. doi: 10.1073/pnas.1510502113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Major Depressive Disorder 2010 [Last Accessed: August 19, 2019]. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.</Citation></Reference><Reference><Citation>Gelenberg AJ. A review of the current guidelines for depression treatment. J Clin Psychiatry. 2010;71(7):e15. doi: 10.4088/JCP.9078tx1c.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.9078tx1c</ArticleId><ArticleId IdType="pubmed">20667285</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyde J, Calnan M, Prior L, Lewis G, Kessler D, Sharp D. A qualitative study exploring how GPs decide to prescribe antidepressants. Br J Gen Pract. 2005;55(519):755&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1562347</ArticleId><ArticleId IdType="pubmed">16212850</ArticleId></ArticleIdList></Reference><Reference><Citation>Haw C, Stubbs J. Benzodiazepines--a necessary evil? A survey of prescribing at a specialist UK psychiatric hospital. J Psychopharmacol. 2007;21(6):645&#x2013;649. doi: 10.1177/0269881106072386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881106072386</ArticleId><ArticleId IdType="pubmed">17092967</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirdifield C, Anthierens S, Creupelandt H, Chipchase SY, Christiaens T, Siriwardena AN. General practitioners&#x2019; experiences and perceptions of benzodiazepine prescribing: systematic review and meta-synthesis. BMC Fam Pract. 2013;14(1):191. doi: 10.1186/1471-2296-14-191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2296-14-191</ArticleId><ArticleId IdType="pmc">PMC4028802</ArticleId><ArticleId IdType="pubmed">24330388</ArticleId></ArticleIdList></Reference><Reference><Citation>Brett J, Murnion B. Management of benzodiazepine misuse and dependence. Aust Prescr. 2015;38(5):152&#x2013;155. doi: 10.18773/austprescr.2015.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.18773/austprescr.2015.055</ArticleId><ArticleId IdType="pmc">PMC4657308</ArticleId><ArticleId IdType="pubmed">26648651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lader M. Benzodiazepines revisited--will we ever learn? Addiction. 2011;106(12):2086&#x2013;2109. doi: 10.1111/j.1360-0443.2011.03563.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1360-0443.2011.03563.x</ArticleId><ArticleId IdType="pubmed">21714826</ArticleId></ArticleIdList></Reference><Reference><Citation>Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95&#x2013;114. doi: 10.1016/j.drugalcdep.2019.02.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2019.02.033</ArticleId><ArticleId IdType="pmc">PMC6639084</ArticleId><ArticleId IdType="pubmed">31121495</ArticleId></ArticleIdList></Reference><Reference><Citation>Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and drug overdose mortality among individuals receiving opioid analgesics. Addict Sci Clin Pract. 2015;10(1):A48. doi: 10.1186/1940-0640-10-S1-A48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1940-0640-10-S1-A48</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760. doi: 10.1136/bmj.j760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j760</ArticleId><ArticleId IdType="pmc">PMC5421443</ArticleId><ArticleId IdType="pubmed">28292769</ArticleId></ArticleIdList></Reference><Reference><Citation>Olfson M, Blanco C, Marcus SC. Treatment of adult depression in the United States. JAMA Intern Med. 2016;176(10):1482&#x2013;1491. doi: 10.1001/jamainternmed.2016.5057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2016.5057</ArticleId><ArticleId IdType="pubmed">27571438</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda MS, Stang P, Makadia R. Depression is associated with high levels of C-reactive protein and low levels of fractional exhaled nitric oxide: results from the 2007-2012 National Health and nutrition examination surveys. J Clin Psychiatry. 2016;77(12):1666&#x2013;1671. doi: 10.4088/JCP.15m10267.</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.15m10267</ArticleId><ArticleId IdType="pubmed">27337107</ArticleId></ArticleIdList></Reference><Reference><Citation>Qaseem A, Barry MJ, Kansagara D. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;164(5):350&#x2013;359. doi: 10.7326/M15-2570.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M15-2570</ArticleId><ArticleId IdType="pubmed">26857948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda MS, Stang P, Blacketer C, Kent JM, Wittenberg GM. Clinical relevance of sleep duration: results from a cross-sectional analysis using NHANES. J Clin Sleep Med. 2016;12(6):813&#x2013;819. doi: 10.5664/jcsm.5876.</Citation><ArticleIdList><ArticleId IdType="doi">10.5664/jcsm.5876</ArticleId><ArticleId IdType="pmc">PMC4877313</ArticleId><ArticleId IdType="pubmed">26951419</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyloun KR, Hansen RN, Hepp Z, Gillard P, Thase ME, Devine EB. Adherence and persistence across antidepressant therapeutic classes: a retrospective claims analysis among insured US patients with major depressive disorder (MDD) CNS drugs. 2017;31(5):421&#x2013;432. doi: 10.1007/s40263-017-0417-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-017-0417-0</ArticleId><ArticleId IdType="pmc">PMC5425490</ArticleId><ArticleId IdType="pubmed">28378157</ArticleId></ArticleIdList></Reference><Reference><Citation>Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163(1):101&#x2013;108. doi: 10.1176/appi.ajp.163.1.101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.163.1.101</ArticleId><ArticleId IdType="pubmed">16390896</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagot JP, Cuerq A, Samson S, Fagot-Campagna A. Cohort of one million patients initiating antidepressant treatment in France: 12-month follow-up. Int J Clin Pract. 2016;70(9):744&#x2013;751. doi: 10.1111/ijcp.12850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.12850</ArticleId><ArticleId IdType="pubmed">27484351</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MJ, Kim N, Shin D, Rhee SJ, Park CHK, Kim H, et al. The epidemiology of antidepressant use in South Korea: does short-term antidepressant use affect the relapse and recurrence of depressive episodes? PLoS One. 2019;14(9):e0222791. doi: 10.1371/journal.pone.0222791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0222791</ArticleId><ArticleId IdType="pmc">PMC6760791</ArticleId><ArticleId IdType="pubmed">31553786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, et al. Influences on antidepressant prescribing trends in the UK: 1995-2011. Soc Psychiatry Psychiatr Epidemiol. 2017;52(2):193&#x2013;200. doi: 10.1007/s00127-016-1306-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00127-016-1306-4</ArticleId><ArticleId IdType="pmc">PMC5329088</ArticleId><ArticleId IdType="pubmed">27885400</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31910437</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network.</ArticleTitle><Pagination><StartPage>e0226718</StartPage><MedlinePgn>e0226718</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0226718</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0226718</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">Hemorrhagic transformation (HT) after cerebral infarction is a complex and multifactorial phenomenon in the acute stage of ischemic stroke, and often results in a poor prognosis. Thus, identifying risk factors and making an early prediction of HT in acute cerebral infarction contributes not only to the selections of therapeutic regimen but also, more importantly, to the improvement of prognosis of acute cerebral infarction. The purpose of this study was to develop and validate a model to predict a patient's risk of HT within 30 days of initial ischemic stroke.</AbstractText><AbstractText Label="METHODS">We utilized a retrospective multicenter observational cohort study design to develop a Lasso Logistic Regression prediction model with a large, US Electronic Health Record dataset which structured to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). To examine clinical transportability, the model was externally validated across 10 additional real-world healthcare datasets include EHR records for patients from America, Europe and Asia.</AbstractText><AbstractText Label="RESULTS">In the database the model was developed, the target population cohort contained 621,178 patients with ischemic stroke, of which 5,624 patients had HT within 30 days following initial ischemic stroke. 612 risk predictors, including the distance a patient travels in an ambulance to get to care for a HT, were identified. An area under the receiver operating characteristic curve (AUC) of 0.75 was achieved in the internal validation of the risk model. External validation was performed across 10 databases totaling 5,515,508 patients with ischemic stroke, of which 86,401 patients had HT within 30 days following initial ischemic stroke. The mean external AUC was 0.71 and ranged between 0.60-0.78.</AbstractText><AbstractText Label="CONCLUSIONS">A HT prognostic predict model was developed with Lasso Logistic Regression based on routinely collected EMR data. This model can identify patients who have a higher risk of HT than the population average with an AUC of 0.78. It shows the OMOP CDM is an appropriate data standard for EMR secondary use in clinical multicenter research for prognostic prediction model development and validation. In the future, combining this model with clinical information systems will assist clinicians to make the right therapy decision for patients with acute ischemic stroke.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-7225-5235</Identifier><AffiliationInfo><Affiliation>Biomedical Engineering School, Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin Feeney</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IQVIA, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, New Jersey, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Yuhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery, General Hospital of Southern Theatre Command, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, New Jersey, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>RuiJun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medical College, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development, Raritan, New Jersey, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan Stewart</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IQVIA, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tufts Medical Center, Institute for Clinical Research and Health Policy Studies, Boston, Massachusetts, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Zandt</LastName><ForeName>Mui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IQVIA, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Chas</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IQVIA, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vashisht</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfohl</LastName><ForeName>Stephen R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasthurirathne</LastName><ForeName>Suranga N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Indiana University Richard M. Fairbanks School of Public Health, Indianapolis, Indiana, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Biomedical Engineering School, Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IQVIA, Durham, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 LM012409</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002543" MajorTopicYN="N">Cerebral Hemorrhage</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Dr. Reps, Dr. Ryan, Ms. Voss and Dr. Rao are employees of Janssen Research and Development. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31910437</ArticleId><ArticleId IdType="pmc">PMC6946584</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0226718</ArticleId><ArticleId IdType="pii">PONE-D-19-25005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Paciaroni M, Bandini F, Agnelli G, Tsivgoulis G, Yaghi S, Furie KL, et al.
Hemorrhagic Transformation in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Time to Initiation of Oral Anticoagulant Therapy and Outcomes. J Am Heart Assoc [Internet]. 2018. 
November
20 [cited 2019 Apr 30];7(22). Available from: https://www.ahajournals.org/doi/10.1161/JAHA.118.010133</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.118.010133</ArticleId><ArticleId IdType="pmc">PMC6404429</ArticleId><ArticleId IdType="pubmed">30571487</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, et al.
Hemorrhagic Transformation in Acute Ischemic Stroke. Stroke [Internet]. 1999. 
July [cited 2019 Apr 30];30(7):1326&#x2013;32. Available from: https://www.ahajournals.org/doi/10.1161/01.STR.30.7.1326
</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.STR.30.7.1326</ArticleId><ArticleId IdType="pubmed">10390303</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Zhao R, Feng X, Shi Y, Wu Y, reports XS-S, et al. Rivaroxaban does not influence hemorrhagic transformation in a diabetes ischemic stroke and endovascular thrombectomy model. nature.com [Internet]. [cited 2019 Apr 30]; https://www.nature.com/articles/s41598-018-25820-y</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5943582</ArticleId><ArticleId IdType="pubmed">29743683</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y, Jiang X, Yang Y, Xi G. Hemorrhagic Transformation Induced by Acute Hyperglycemia in a Rat Model of Transient Focal Ischemia. In 2011.  [cited 2019 Apr 30]. p. 49&#x2013;54. http://www.springerlink.com/index/10.1007/978-3-7091-0693-8_9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-7091-0693-8_9</ArticleId><ArticleId IdType="pubmed">21725731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Hong K, Lee J, Kim Y, &#x2026; TS-C neurology and, 2018 undefined. Prediction of hemorrhagic transformation in patients with mild atrial fibrillation-associated stroke treated with early anticoagulation: post hoc analysis of the Triple AXEL. Elsevier [Internet]. [cited 2019 Apr 30]; https://www.sciencedirect.com/science/article/pii/S0303846718303457</Citation><ArticleIdList><ArticleId IdType="pubmed">30243187</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang N, Lin M, Wang B, &#x2026; WZ-ERM, 2016 undefined. Low level of low-density lipoprotein cholesterol is related with increased hemorrhagic transformation after acute ischemic cerebral infarction. europeanreview.org [Internet]. [cited 2019 May 1]; https://www.europeanreview.org/wp/wp-content/uploads/673-678.pdf</Citation><ArticleIdList><ArticleId IdType="pubmed">26957269</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardi K, Leys D, Eusebi P, &#x2026; CC-C, 2011 undefined. Influence of lipid profiles on the risk of hemorrhagic transformation after ischemic stroke: systematic review. karger.com [Internet]. [cited 2019 Apr 30]; https://www.karger.com/Article/Abstract/335014</Citation></Reference><Reference><Citation>Cordenier A, Smedt A De, &#x2026; RB-AN, 2011 undefined. Pre-stroke use of statins on stroke outcome: a meta-analysis of observational studies. actaneurologica.be [Internet]. [cited 2019 Apr 30]; http://www.actaneurologica.be/pdfs/2011-4/02-Cordenier%20et%20al.pdf</Citation><ArticleIdList><ArticleId IdType="pubmed">22368964</ArticleId></ArticleIdList></Reference><Reference><Citation>Montaner J, Bustamante A, S G-M, 2016.  undefined. Combination of thrombolysis and statins in acute stroke is safe: results of the STARS randomized trial (stroke treatment with acute reperfusion and simvastatin). Am Hear Assoc [Internet]. [cited 2019 Apr 30]; https://www.ahajournals.org/doi/abs/10.1161/strokeaha.116.014600</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/strokeaha.116.014600</ArticleId><ArticleId IdType="pubmed">27758944</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang O, Saver J, Liebeskind D, S S, 2007.  undefined. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. AAN Enterp [Internet]. [cited 2019 Apr 30]; https://n.neurology.org/content/68/10/737.short</Citation></Reference><Reference><Citation>Levent &#xd6;CEK, Derya G&#xdc;NER, &#x130;rem Fatma ULUDA&#x11e;, Bedile &#x130;rem T&#x130;FT&#x130;K&#xc7;&#x130;O&#x11e;LU and YZ. Risk Factors for Hemorrhagic transformation in patients with acute middle cerebral artery infarction. ncbi.nlm.nih.gov [Internet]. [cited 2019 Apr 30]; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353105/</Citation></Reference><Reference><Citation>Xu X, Li C, Wan T, Gu X, Zhu W, Hao J, et al.
Risk factors for hemorrhagic transformation after intravenous thrombolysis in acute cerebral infarction: a retrospective single-center study. Elsevier;  [Internet]. [cited 2019 Apr 30]; https://www.sciencedirect.com/science/article/pii/S1878875017301146</Citation></Reference><Reference><Citation>Landolfi A, Selvetella G, Cugino D, &#x2026; G G journal of, 2016.  undefined. Hemorrhagic transformation of acute ischemic stroke is limited in hypertensive patients with cardiac hypertrophy. Elsevier;  [Internet]. [cited 2019 Apr 30]; https://www.sciencedirect.com/science/article/pii/S0167527316310671</Citation><ArticleIdList><ArticleId IdType="pubmed">27352208</ArticleId></ArticleIdList></Reference><Reference><Citation>Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160&#x2013;236. 10.1161/STR.0000000000000024</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STR.0000000000000024</ArticleId><ArticleId IdType="pubmed">24788967</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciaroni M, Agnelli G, Caso V, Tsivgoulis G, Furie KL, Tadi P, et al.
Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema. Stroke [Internet]. 2017. 
March [cited 2019 Apr 30];48(3):726&#x2013;32. Available from: https://www.ahajournals.org/doi/10.1161/STROKEAHA.116.015770
</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.116.015770</ArticleId><ArticleId IdType="pubmed">28183856</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabay M. 21st century cures act. Hosp Pharm. 2017;52(4):264 10.1310/hpj5204-264</Citation><ArticleIdList><ArticleId IdType="doi">10.1310/hpj5204-264</ArticleId><ArticleId IdType="pmc">PMC5424829</ArticleId><ArticleId IdType="pubmed">28515504</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics,OMOP Common Data Model [Internet]. [cited 2019 Apr 17]. https://github.com/OHDSI/CommonDataModel/</Citation></Reference><Reference><Citation>FitzHenry F, Resnic FS, Robbins SL, Denton J, Nookala L, Meeker D, et al.
Creating a Common Data Model for Comparative Effectiveness with the Observational Medical Outcomes Partnership. Appl Clin Inform [Internet]. 2015. 
December
19 [cited 2019 May 1];06(03):536&#x2013;47. Available from: http://www.thieme-connect.de/DOI/DOI?10.4338/ACI-2014-12-CR-0121</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>A H Jr, Bendixen B, Kappelle L, J B, 1993.  undefined. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Am Hear Assoc [Internet]. [cited 2019 May 1]; https://www.ahajournals.org/doi/pdf/10.1161/str.24.1.7678184</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/str.24.1.7678184</ArticleId><ArticleId IdType="pubmed">7678184</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. WhiteRabbit [Internet]. github. [cited 2019 May 16]. https://github.com/OHDSI/WhiteRabbit</Citation></Reference><Reference><Citation>Clairblacketer. Definition and DDLs for the OMOP Common Data Model (CDM). 2019.</Citation></Reference><Reference><Citation>Reps J, Schuemie M, &#x2026; MS-J of the, 2018 undefined. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. academic.oup.com [Internet]. [cited 2019 May 1]; https://academic.oup.com/jamia/article-abstract/25/8/969/4989437</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie M, Collins G, Steyerberg E, &#x2026; V J of clinical, 2019 undefined. A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. Elsevier;  [Internet]. [cited 2019 May 1]; https://www.sciencedirect.com/science/article/pii/S0895435618310813</Citation><ArticleIdList><ArticleId IdType="pubmed">30763612</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB RP. OHDSI Patient Level Prediction Package [Internet]. https://github.com/OHDSI/PatientLevelPrediction</Citation></Reference><Reference><Citation>Kassambara A. Machine Learning Essentials: Practical Guide in R [Internet]. 2018 [cited 2019 May 1]. https://books.google.com/books?hl=zh-CN&amp;lr=&amp;id=745QDwAAQBAJ&amp;oi=fnd&amp;pg=PP2&amp;dq=Machine+Learning+Essentials:+Practical+Guide+in+R&amp;ots=5DNtzSS2Pp&amp;sig=vTw7xrJZfcAhBK-B-4Y6I8Mc1yAl</Citation></Reference><Reference><Citation>Rathmann W, Bongaerts B, Carius H-J, Kruppert S, Kostev K. Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther. 2018;56(10):459&#x2013;66. 10.5414/CP203320&#x2029;</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CP203320&#x2029;</ArticleId><ArticleId IdType="pubmed">30168417</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Heal care Sci. 2015;1(1):16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4729130</ArticleId><ArticleId IdType="pubmed">26819727</ArticleId></ArticleIdList></Reference><Reference><Citation>Camm AJ, Fox KAA. Strengths and weaknesses of &#x2018;real-world&#x2019;studies involving non-vitamin K antagonist oral anticoagulants. Open Hear. 2018;5(1):e000788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5922572</ArticleId><ArticleId IdType="pubmed">29713485</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Kiefer RC, Sharma DK, Prud&#x2019;hommeaux E, Solbrig HR. A consensus-based approach for harmonizing the OHDSI common data model with HL7 FHIR. Stud Health Technol Inform. 2017;245:887</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939955</ArticleId><ArticleId IdType="pubmed">29295227</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31914471</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>Transforming French Electronic Health Records into the Observational Medical Outcome Partnership's Common Data Model: A Feasibility Study.</ArticleTitle><Pagination><StartPage>13</StartPage><EndPage>22</EndPage><MedlinePgn>13-22</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0039-3402754</ELocationID><Abstract><AbstractText Label="BACKGROUND">Common data models (CDMs) enable data to be standardized, and facilitate data exchange, sharing, and storage, particularly when the data have been collected via distinct, heterogeneous systems. Moreover, CDMs provide tools for data quality assessment, integration into models, visualization, and analysis. The observational medical outcome partnership (OMOP) provides a CDM for organizing and standardizing databases. Common data models not only facilitate data integration but also (and especially for the OMOP model) extends the range of available statistical analyses.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to evaluate the feasibility of implementing French national electronic health records in the OMOP CDM.</AbstractText><AbstractText Label="METHODS">The OMOP's specifications were used to audit the source data, specify the transformation into the OMOP CDM, implement an extract-transform-load process to feed data from the French health care system into the OMOP CDM, and evaluate the final database.</AbstractText><AbstractText Label="RESULTS">Seventeen vocabularies corresponding to the French context were added to the OMOP CDM's concepts. Three French terminologies were automatically mapped to standardized vocabularies. We loaded nine tables from the OMOP CDM's "standardized clinical data" section, and three tables from the "standardized health system data" section. Outpatient and inpatient data from 38,730 individuals were integrated. The median (interquartile range) number of outpatient and inpatient stays per patient was 160 (19-364).</AbstractText><AbstractText Label="CONCLUSION">Our results demonstrated that data from the French national health care system can be integrated into the OMOP CDM. One of the main challenges was the use of international OMOP concepts to annotate data recorded in a French context. The use of local terminologies was an obstacle to conceptual mapping; with the exception of an adaptation of the International Classification of Diseases 10th Revision, the French health care system does not use international terminologies. It would be interesting to extend our present findings to the 65 million people registered in the French health care system.</AbstractText><CopyrightInformation>Georg Thieme Verlag KG Stuttgart &#xb7; New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lamer</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Depas</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doutreligne</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bureau Etat de Sant&#xe9; de la Population, Minist&#xe8;re des Affaires Sociales et de la Sant&#xe9;, Direction de la Recherche, des Etudes et des Statistiques - Observation de la Sant&#xe9; et de l'Assurance Maladie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parrot</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Descartes, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Web INnovation Donn&#xe9;es-Direction des Syst&#xe8;mes d'Information, Assistance Publique - H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verloop</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service Etudes et Statistiques, ARS Hauts-de-France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defebvre</LastName><ForeName>Marguerite-Marie</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Service Etudes et Statistiques, ARS Hauts-de-France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ficheur</LastName><ForeName>Gr&#xe9;goire</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chazard</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beuscart</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Appl Clin Inform. 2020 Jan;11(1):e1</RefSource><PMID Version="1">32162290</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D054869" MajorTopicYN="N">Clinical Audit</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010317" MajorTopicYN="Y">Partnership Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>G.F. reports grants from ARS Hauts-de-France, during the conduct of the study. E.C. reports grants from ARS Hauts-de-France, during the conduct of the study. A.L. reports grants from ARS Hauts-de-France, during the conduct of the study. M.M.D. reports grants from ARS Hauts-de-France, during the conduct of the study. J.B.B. reports grants from ARS Hauts-de-France, during the conduct of the study. M.D. reports personal fees from French Ministry of Health, (DREES), during the conduct of the study. N.D, reports grants from ARS Hauts-de-France, during the conduct of the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31914471</ArticleId><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="doi">10.1055/s-0039-3402754</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sentinel Initiativetp. Available at:www.mini-sentinel.org/. Accessed April 4, 2019</Citation></Reference><Reference><Citation>National Patient-Centered Clinical Research Network. PCORnet. Available at:https://pcornet.org/pcornet-common-data-model/. Accessed April 4, 2019</Citation></Reference><Reference><Citation>Chazard E, Merlin B, Ficheur G, Sarfati J-C, Beuscart R; PSIP Consortium.Detection of adverse drug events: proposal of a data model Stud Health Technol Inform 200914863&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">19745236</ArticleId></ArticleIdList></Reference><Reference><Citation>i2b2: Informatics for Integrating Biology &amp; the BedsideAvailable at:https://www.i2b2.org/. Accessed April 4, 2019</Citation></Reference><Reference><Citation>OHDSI&#x2014;Observational Health Data Sciences and Informatics. Available at:https://www.ohdsi.org/. Accessed April 4, 2019</Citation></Reference><Reference><Citation>Weeks J, Pardee R. Learning to share health care data: a brief timeline of influential common data models and distributed health data networks in U.S. health care research. EGEMS Wash DC. 2019;7(01):4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437693</ArticleId><ArticleId IdType="pubmed">30937326</ArticleId></ArticleIdList></Reference><Reference><Citation>Liyanage H, Liaw S-T, Jonnagaddala J, Hinton W, de Lusignan S. Common data models (CDMs) to enhance international big data analytics: a diabetes use case to compare three CDMs. Stud Health Technol Inform. 2018;255:60&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">30306907</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus M N. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>CDISC.Study Data Tabulation Model (SDTM)Available at:https://www.cdisc.org/standards/foundational/sdtm. Accessed April 4, 2019</Citation></Reference><Reference><Citation>Xu Y, Zhou X, Suehs B T et al.A comparative assessment of observational medical outcomes partnership and mini-sentinel common data models and analytics: implications for active drug safety surveillance. Drug Saf. 2015;38(08):749&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">26055920</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke J D, Shah N H et al.Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P B, Stang P E, Overhage J M et al.A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36 01:S143&#x2013;S158.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166231</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M J, Gini R, Coloma P M et al.Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. Drug Saf. 2013;36 01:S159&#x2013;S169.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166232</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H et al.Towards implementation of OMOP in a German university hospital consortium. Appl Clin Inform. 2018;9(01):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan P B. Transforming the premier perspective hospital database into the observational medical outcomes partnership (OMOP) common data model. EGEMS (Wash DC) 2014;2(01):1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>You S C, Lee S, Cho S-Y et al.Conversion of national health insurance service-national sample cohort (NHIS-NSC) database into observational medical outcomes partnership-common data model (OMOP-CDM) Stud Health Technol Inform. 2017;245:467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn E K, Park M Y et al.Conversion and data quality assessment of electronic health record data at a korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016;22(01):54&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Le dispositif Paerpa. Minist&#xe8;re des Solidarit&#xe9;s et de la Sant&#xe9;. Available at:https://solidarites-sante.gouv.fr/systeme-de-sante-et-medico-social/parcours-des-patients-et-des-usagers/le-parcours-sante-des-aines-paerpa/article/le-dispositif-paerpa. Accessed April 4, 2019</Citation></Reference><Reference><Citation>Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merli&#xe8;re Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58(04):286&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">20598822</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc J-L, Sailler L. French health insurance databases: what interest for medical research? Rev Med Interne. 2015;36(06):411&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">25547954</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI/Common Data Model.Definition and DDLs for the OMOP Common Data Model (CDM)Available at:https://github.com/OHDSI/CommonDataModel. Accessed April 4, 2019</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics.ELT creation best practicesAvailable at:http://www.ohdsi.org/web/wiki/doku.php?id=documentation:etl_best_practices. Accessed April 4, 2019</Citation></Reference><Reference><Citation>OHDSI/Achilles.Automated Characterization of Health Information at Large-scale Longitudinal Evidence Systems (ACHILLES) - descriptive statistics about a OMOP CDM database; 2019Available at:https://github.com/OHDSI/Achilles. Accessed October 17, 2019</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics.WhiteRabbitAvailable at:http://www.ohdsi.org/web/wiki/doku.php?id=documentation:software:whiterabbit. Accessed April 4, 2019</Citation></Reference><Reference><Citation>Open Source ETL&#x2014;Talend Open Studio for Data Integration.Talend real-time open source data integration softwareAvailable at:https://www.talend.com/products/data-integration/data-integration-open-studio/. Accessed April 4, 2019</Citation></Reference><Reference><Citation>Postgre SQL.The world's most advanced open source databaseAvailable at:https://www.postgresql.org/. Accessed April 4, 2019</Citation></Reference><Reference><Citation>Ubuntu.The leading operating system for PCs, IoT devices, servers and the cloudAvailable at:https://www.ubuntu.com/. Accessed April 4, 2019</Citation></Reference><Reference><Citation>Athena. Available at:http://athena.ohdsi.org/search-terms/terms. Accessed April 4, 2019</Citation></Reference><Reference><Citation>Lima D M, Rodrigues-Jr J F, Traina A JM, Pires F A, Gutierrez M A. Transforming two decades of ePR data to OMOP CDM for clinical research. Stud Health Technol Inform. 2019;264:233&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">31437920</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Resnic F S, Robbins S L et al.Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl Clin Inform. 2015;6(03):536&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Wang L, Miao S et al.Analysis of treatment pathways for three chronic diseases using OMOP CDM. J Med Syst. 2018;42(12):260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6244882</ArticleId><ArticleId IdType="pubmed">30421323</ArticleId></ArticleIdList></Reference><Reference><Citation>Viernes B, Lynch K E, South B, Coronado G, DuVall S L. Characterizing VA users with the OMOP common data model. Stud Health Technol Inform. 2019;264:1614&#x2013;1615.</Citation><ArticleIdList><ArticleId IdType="pubmed">31438258</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H et al.An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Saf. 2013;36(02):119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>European Health Data Evidence Network Available at:https://www.ehden.eu/. Accessed October 9, 2019</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31923062</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-233X</ISSN><JournalIssue CitedMedium="Internet"><Volume>135</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Obstetrics and gynecology</Title><ISOAbbreviation>Obstet Gynecol</ISOAbbreviation></Journal><ArticleTitle>Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users.</ArticleTitle><Pagination><StartPage>319</StartPage><EndPage>327</EndPage><MedlinePgn>319-327</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/AOG.0000000000003656</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To evaluate the relative risk of cervical neoplasms among copper intrauterine device (Cu IUD) and levonorgestrel-releasing intrauterine system (LNG-IUS) users.</AbstractText><AbstractText Label="METHODS">We performed a retrospective cohort analysis of 10,674 patients who received IUDs at Columbia University Medical Center. Our data were transformed to a common data model and are part of the Observational Health Data Sciences and Informatics network. The cohort patients and outcomes were identified by a combination of procedure codes, condition codes, and medication exposures in billing and claims data. We adjusted for confounding with propensity score stratification and propensity score 1:1 matching.</AbstractText><AbstractText Label="RESULTS">Before propensity score adjustment, the Cu IUD cohort included 8,274 patients and the LNG-IUS cohort included 2,400 patients. The median age for both cohorts was 29 years at IUD placement. More than 95% of the LNG-IUS cohort used a device with 52 mg LNG. Before propensity score adjustment, we identified 114 cervical neoplasm outcomes. Seventy-seven (0.9%) cervical neoplasms were in the Cu IUD cohort and 37 (1.5%) were in the LNG-IUS cohort. The propensity score matching analysis identified 7,114 Cu IUD and 2,174 LNG-IUS users, with covariate balance achieved over 16,827 covariates. The diagnosis of high-grade cervical neoplasia was 0.7% in the Cu IUD cohort and 1.8% in the LNG-IUS cohort (2.4 [95% CI 1.5-4.0] cases/1,000 person-years and 5.2 [95% CI 3.7-7.1] cases/1,000 person-years, respectively). The relative risk of high-grade cervical neoplasms among Cu IUD users was 0.38 (95% CI 0.16-0.78, P&lt;.02) compared with LNG-IUS users. By inspection, the Kaplan-Meier curves for each cohort diverged over time.</AbstractText><AbstractText Label="CONCLUSION">Copper IUD users have a lower risk of high-grade cervical neoplasms compared with LNG-IUS users. The relative risk of cervical neoplasms of LNG-IUS users compared with the general population is unknown.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Departments of Biomedical Informatics and Obstetrics and Gynecology, Columbia University Medical Center, Observational Health Data Sciences and Informatics, and Medical Informatics Services, New York-Presbyterian Hospital, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Westhoff</LastName><ForeName>Carolyn L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Obstet Gynecol</MedlineTA><NlmUniqueID>0401101</NlmUniqueID><ISSNLinking>0029-7844</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003271">Contraceptive Agents, Female</NameOfSubstance></Chemical><Chemical><RegistryNumber>5W7SIA7YZW</RegistryNumber><NameOfSubstance UI="D016912">Levonorgestrel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Obstet Gynecol. 2020 Jun;135(6):1486-1487</RefSource><PMID Version="1">32443070</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Obstet Gynecol. 2020 Jun;135(6):1487</RefSource><PMID Version="1">32443071</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003271" MajorTopicYN="N">Contraceptive Agents, Female</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007435" MajorTopicYN="N">Intrauterine Devices, Copper</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007436" MajorTopicYN="N">Intrauterine Devices, Medicated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016912" MajorTopicYN="N">Levonorgestrel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="N">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31923062</ArticleId><ArticleId IdType="pmc">PMC7012337</ArticleId><ArticleId IdType="doi">10.1097/AOG.0000000000003656</ArticleId><ArticleId IdType="pii">00006250-202002000-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cortessis VK, Barret M, Wade NQ, Enebish T, Perrigo JL, Tobin J, et al. Intrauterine device use and cervical cancer risk: a systematic review and meta-analysis. Obstet Gynecol 2017;130:1226&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">29112647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lekovich JP, Amrane S, Pangasa M, Pereira N, Frey MK, Varrey A, et al. Comparison of human papillomavirus infection and cervical cytology in women using copper-containing and levonorgestrel-containing intrauterine devices. Obstet Gynecol 2015;125:1101&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">25932838</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttinger A, Critchley HOD. Endometrial effects of intrauterine levonorgestrel. Contraception 2007;75:S93&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17531624</ArticleId></ArticleIdList></Reference><Reference><Citation>Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011;278:16&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">21087457</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. Med Care 2012;50(Suppl):S60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824370</ArticleId><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci USA 2016;113:7329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational health data sciences and Informatics (OHDSI) OMOP common data model V5.0. Available at: www.ohdsi.org/web/wiki/doku.php?id=documentation:cdm:single-page. Retrieved June 1, 2015.</Citation></Reference><Reference><Citation>Reich JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012;19:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Mohan S, Husain SA, Natarajan K. Expanding transplant outcomes research opportunities through the use of a common data model. Am J Transplant 2018;18:1321&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6070138</ArticleId><ArticleId IdType="pubmed">29687963</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Scheumie MJ, Krumholz HM, You SC, Chen R, Pratt N, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019; 394:1816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med 2014;33:209&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul 2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol 2018;47:2005&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. Drug approval package: Mirena (levonorgestrel-releasing intrauterine system). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-225_Mirena.cfm. Retrieved July 22, 2019.</Citation></Reference><Reference><Citation>Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8137626</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011;103:368&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3046952</ArticleId><ArticleId IdType="pubmed">21282563</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinney ES, The intrauterine device and the intrauterine system. Best Pract Res Clin Obstet Gynaecol 2014;28:807&#x2013; 24.</Citation><ArticleIdList><ArticleId IdType="pubmed">24947600</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips SJ, Hofler LG, Modest AM, Harvey LFB, Wu LH, Hacker MR, et al. Continuation of copper and levonorgestrel intrauterine devices: a retrospective cohort study. Am J Obstet Gynecol 2017;217:57.e1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5810132</ArticleId><ArticleId IdType="pubmed">28315664</ArticleId></ArticleIdList></Reference><Reference><Citation>Buhling KH, Zite NB, Lotke P, Black K; INTRA Writing Group. Worldwide use of intrauterine contraception: a review. Contraception 2014;89:162&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24369300</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31926440</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8332</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Lung cancer (Amsterdam, Netherlands)</Title><ISOAbbreviation>Lung Cancer</ISOAbbreviation></Journal><ArticleTitle>Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>8</EndPage><MedlinePgn>1-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lungcan.2019.12.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0169-5002(19)30791-3</ELocationID><Abstract><AbstractText Label="OBJECTIVES">stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) are a therapeutic option for Oligometastatic/Oligoprogressive (OM/OP) NSCLC. This retrospective multicentre analysis aims to analyse clinical outcomes and treatment related toxicity of patients treated to all sites of know disease with SRS and/or FSRT for OM/OP NSCLC in 8 Italian radiation oncology centres.</AbstractText><AbstractText Label="MATERIALS AND METHODS">From January 2016 to January 2017 198 OM/OP NSCLC patients (pts) were treated in 8 Centres. Inclusion criteria were as follows: 1-5 lesions at onset or after previous systemic treatment; Pts must have all metastatic lesions treated. Endpoints analysed were local progression free survival (LPFS); out-of-field recurrence free survival (OFPS); progression free survival (PFS); overall survival (OS). Time to New systemic Therapy free survival (TNT) and toxicity were also analysed.</AbstractText><AbstractText Label="RESULTS">At the time of radiotherapy, 119 pts (60 %) were treated for a single lesion, 49 (25 %) for 2 lesions, 30 (15 %) for 3-5 metastases. Total number of lesions treated was 333: 204 brain, 68 lung, 24 bone, 16 nodal, 12 adrenal, 8 liver and 1 soft tissue. 83/198 pts (41.8 %) had the primary tumour controlled at the time of the SRT. After a median follow-up of 18 months, median OS and PFS were 29.6 months and 10.6 months, respectively. One year LPFS and OPFS were 90 % and 47 %, respectively. Median TNT was 10 months. At univariate analysis factors associated with better OS were PS 0-1; controlled primary tumour, 1-2 lesions; extracranial metastasis. Multivariate analysis confirmed number of lesions &lt;3 and extracranial metastasis to be related with better survival (Relative Risk 0.4 and 0.41, respectively). Two cases of death possibly related to brain radionecrosis were observed.</AbstractText><AbstractText Label="CONCLUSION">OM/OP NSCLC pts treated with an ablative SRT to all metastatic sites have fair outcomes with acceptable toxicity. Better results might be achieved in case of low disease burden and extracranial possibly when primary tumour is controlled.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buglione</LastName><ForeName>Michela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University and Spedali Civili of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jereczek-Fossa</LastName><ForeName>Barbara Alicja</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-oncology University of Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bon&#xf9;</LastName><ForeName>Marco Lorenzo</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University and Spedali Civili of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franceschini</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fodor</LastName><ForeName>Andrei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanetti</LastName><ForeName>Isa Bossi</ForeName><Initials>IB</Initials><AffiliationInfo><Affiliation>Cyberknife Unit, Centro Diagnostico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerardi</LastName><ForeName>Marianna Alessandra</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology IEO, European Institute of Oncology IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borghetti</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University and Spedali Civili of Brescia, Brescia, Italy. Electronic address: paolobor82@yahoo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomasini</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University and Spedali Civili of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Muzio</LastName><ForeName>Nadia Gisella</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, San Raffaele Scientific Institute, Milan, Italy; Department of Radiotherapy, Universit&#xe0; Vita Salute S. Raffaele, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oneta</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-oncology University of Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scorsetti</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franzese</LastName><ForeName>Ciro</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romanelli</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology IEO, European Institute of Oncology IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catalano</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, IRCCS MultiMedica, Sesto S. Giovanni, MI, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dell'Oca</LastName><ForeName>Italo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beltramo</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cyberknife Unit, Centro Diagnostico Italiano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ivaldi</LastName><ForeName>Giovanni Battista</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology ICS Maugeri, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laudati</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, ASST Lariana, Como, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magrini</LastName><ForeName>Stefano Maria</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, University and Spedali Civili of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antognoni</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Ospedale di Circolo e Fondazione Macchi, ASST dei Sette Laghi, Varese, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Italian Society of Radiotherapy and Clinical Oncology &#x2013; Regional Group Lombardy (AIROL)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Lung Cancer</MedlineTA><NlmUniqueID>8800805</NlmUniqueID><ISSNLinking>0169-5002</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000077192" MajorTopicYN="N">Adenocarcinoma of Lung</DescriptorName><QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="N">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019583" MajorTopicYN="Y">Dose Fractionation, Radiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016634" MajorTopicYN="N">Radiosurgery</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ablative treatments</Keyword><Keyword MajorTopicYN="N">Non small cell lung cancer (NSCLC)</Keyword><Keyword MajorTopicYN="N">Oligometastasis</Keyword><Keyword MajorTopicYN="N">Stereotactic radiosurgery (SRS)</Keyword><Keyword MajorTopicYN="N">Stereotactic radiotherapy (SRT)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31926440</ArticleId><ArticleId IdType="doi">10.1016/j.lungcan.2019.12.019</ArticleId><ArticleId IdType="pii">S0169-5002(19)30791-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31937652</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>13</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Application of a Common Data Model (CDM) to rank the paediatric user and prescription prevalence of 15 different drug classes in South Korea, Hong Kong, Taiwan, Japan and Australia: an observational, descriptive study.</ArticleTitle><Pagination><StartPage>e032426</StartPage><MedlinePgn>e032426</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e032426</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2019-032426</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To measure the paediatric user and prescription prevalence in inpatient and ambulatory settings in South Korea, Hong Kong, Taiwan, Japan and Australia by age and gender. A further objective was to list the most commonly used drugs per drug class, per country.</AbstractText><AbstractText Label="DESIGN AND SETTING">Hospital inpatient and insurance paediatric healthcare data from the following databases were used to conduct this descriptive drug utilisation study: (i) the South Korean Ajou University School of Medicine database; (ii) the Hong Kong Clinical Data Analysis and Reporting System; (iii) the Japan Medical Data Center; (iv) Taiwan's National Health Insurance Research Database and (v) the Australian Pharmaceutical Benefits Scheme. Country-specific data were transformed into the Observational Medical Outcomes Partnership Common Data Model.</AbstractText><AbstractText Label="PATIENTS">Children (&#x2264;18 years) with at least 1 day of observation in any of the respective databases from January 2009 until December 2013 were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">For each drug class, we assessed the per-protocol overall user and prescription prevalence rates (per 1000 persons) per country and setting.</AbstractText><AbstractText Label="RESULTS">Our study population comprised 1 574 524 children (52.9% male). The highest proportion of dispensings was recorded in the youngest age category (&lt;2 years) for inpatients (45.1%) with a relatively high user prevalence of analgesics and antibiotics. Adrenergics, antihistamines, mucolytics and corticosteroids were used in 10%-15% of patients. For ambulatory patients, the highest proportion of dispensings was recorded in the middle age category (2-11 years, 67.1%) with antibiotics the most dispensed drug overall.</AbstractText><AbstractText Label="CONCLUSIONS">Country-specific paediatric drug utilisation patterns were described, ranked and compared between four East Asian countries and Australia. The widespread use of mucolytics in East Asia warrants further investigation.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brauer</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8934-347X</Identifier><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Ian Chi Kei</ForeName><Initials>ICK</Initials><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK i.wong@ucl.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Kenneth Kc</ForeName><Initials>KK</Initials><Identifier Source="ORCID">0000-0001-8645-1942</Identifier><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Soo-Yeon</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yu-Chuan Jack</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Graduate Institute of Biomedical Informatics, College of Medical Science and Technology, Taiwan Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Dermatology, Wan Fang Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Medical Informatics Association (IMIA), Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Usman</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>The International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Masters &amp; PhD Program in Global Health Department, College of Public Health, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Community Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Shaikh Zayed Medical Complex, Lahore, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Phung-Anh Alex</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>The International Center for Health Information Technology (ICHIT), Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="Y">Drug Utilization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000600" MajorTopicYN="N">supply &amp; distribution</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055656" MajorTopicYN="N">Prescriptions</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">clinical pharmacology</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">paediatrics</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31937652</ArticleId><ArticleId IdType="pmc">PMC7044847</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2019-032426</ArticleId><ArticleId IdType="pii">bmjopen-2019-032426</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong ICK, Murray ML. The potential of UK clinical databases in enhancing paediatric medication research. Br J Clin Pharmacol 2005;59:750&#x2013;5. 10.1111/j.1365-2125.2005.02450.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2005.02450.x</ArticleId><ArticleId IdType="pmc">PMC1884862</ArticleId><ArticleId IdType="pubmed">15948943</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashed AN, Wong ICK, Wilton L, et al. . Drug utilisation patterns in children admitted to a paediatric general medical ward in five countries. Drugs Real World Outcomes 2015;2:397&#x2013;410. 10.1007/s40801-015-0049-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40801-015-0049-y</ArticleId><ArticleId IdType="pmc">PMC4674526</ArticleId><ArticleId IdType="pubmed">26690854</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturkenboom MCJM, Verhamme KMC, Nicolosi A, et al. . Drug use in children: cohort study in three European countries. BMJ 2008;337:a2245 10.1136/bmj.a2245</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.a2245</ArticleId><ArticleId IdType="pmc">PMC2593449</ArticleId><ArticleId IdType="pubmed">19029175</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua KL, Soh SE, Ma S, et al. . Pediatric asthma mortality and hospitalization trends across Asia Pacific: relationship with asthma drug utilization patterns. World Allergy Organ J 2009;2:77&#x2013;82. 10.1097/WOX.0b013e3181a7c288</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WOX.0b013e3181a7c288</ArticleId><ArticleId IdType="pmc">PMC3651014</ArticleId><ArticleId IdType="pubmed">23283014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon S-M, Park S, Rhie SJ, et al. . Prescribing patterns of polypharmacy in Korean pediatric patients. PLoS One 2019;14:e0222781 10.1371/journal.pone.0222781</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0222781</ArticleId><ArticleId IdType="pmc">PMC6773215</ArticleId><ArticleId IdType="pubmed">31574095</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C-L, Kao Yang Y-H, Liu C-C, et al. . A retrospective study on the usage of cough and cold medications in viral respiratory tract infections in Taiwanese children. Pharmacoepidemiol Drug Saf 2014;23:36&#x2013;42. 10.1002/pds.3460</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3460</ArticleId><ArticleId IdType="pubmed">23712880</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai EC-C, Ryan P, Zhang Y, et al. . Applying a common data model to Asian databases for multinational pharmacoepidemiologic studies: opportunities and challenges. Clin Epidemiol 2018;10:875&#x2013;85. 10.2147/CLEP.S149961</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S149961</ArticleId><ArticleId IdType="pmc">PMC6067778</ArticleId><ArticleId IdType="pubmed">30100761</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen M, Bergman U, Choi N-K, et al. . The Asian pharmacoepidemiology network (aspen): promoting multi-national collaboration for pharmacoepidemiologic research in Asia. Pharmacoepidemiol Drug Saf 2013;22:700&#x2013;4. 10.1002/pds.3439</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3439</ArticleId><ArticleId IdType="pubmed">23653370</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan EW, Lau WCY, Leung WK, et al. . Prevention of Dabigatran-Related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology 2015;149:586&#x2013;95. 10.1053/j.gastro.2015.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.05.002</ArticleId><ArticleId IdType="pubmed">25960019</ArticleId></ArticleIdList></Reference><Reference><Citation>Chui CSL, Man KKC, Cheng C-L, et al. . An investigation of the potential association between retinal detachment and oral fluoroquinolones: a self-controlled case series study. J Antimicrob Chemother 2014;69:2563&#x2013;7. 10.1093/jac/dku145</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dku145</ArticleId><ArticleId IdType="pubmed">24833754</ArticleId></ArticleIdList></Reference><Reference><Citation>Man KKC, Chan EW, Coghill D, et al. . Methylphenidate and the risk of trauma. Pediatrics 2015;135:40&#x2013;8. 10.1542/peds.2014-1738</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2014-1738</ArticleId><ArticleId IdType="pubmed">25511122</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci 2015;1 10.1186/s40780-015-0016-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40780-015-0016-5</ArticleId><ArticleId IdType="pmc">PMC4729130</ArticleId><ArticleId IdType="pubmed">26819727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai EC-C, Man KKC, Chaiyakunapruk N, et al. . Brief report: databases in the Asia-Pacific region: the potential for a distributed network approach. Epidemiology 2015;26:815&#x2013;20. 10.1097/EDE.0000000000000325</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000325</ArticleId><ArticleId IdType="pubmed">26133022</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose K, St&#xf6;tter H. ICH E 11: clinical investigation of medicinal products in the paediatric population : Rose K, Guide to paediatric clinical research. Basel: KArger, 2007: 33&#x2013;7.</Citation></Reference><Reference><Citation>Woo Y, Kim HE, Chung S, et al. . Pediatric medication error reports in Korea adverse event reporting system database, 1989-2012: comparing with adult reports. J Korean Med Sci 2015;30:371&#x2013;7. 10.3346/jkms.2015.30.4.371</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2015.30.4.371</ArticleId><ArticleId IdType="pmc">PMC4366956</ArticleId><ArticleId IdType="pubmed">25829803</ArticleId></ArticleIdList></Reference><Reference><Citation>
Taiwan Food and Drugs Administration 
Taiwan food and drug administration annual report, 2016.  Available: http://www.fda.gov.tw/upload/ebook/AnnuaReport/2016 [Accessed October 2016].</Citation></Reference><Reference><Citation>Sato J. Global pediatric development: we are making progress. PMDA Perspective.: Japanese Pharmaceuticals and Medical Devices Agency (PMDA), 2014.</Citation></Reference><Reference><Citation>Mallet P, Mourdi N, Dubus J-C, et al. . Respiratory paradoxical adverse drug reactions associated with acetylcysteine and carbocysteine systemic use in paediatric patients: a national survey. PLoS One 2011;6:e22792 10.1371/journal.pone.0022792</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0022792</ArticleId><ArticleId IdType="pmc">PMC3144941</ArticleId><ArticleId IdType="pubmed">21818391</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Medicines Agency (EMA) 
Revised assessment report: ambroxol and bromhexine containing medicinal products. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Ambroxol_and_bromhexine_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500184106.pdf [Accessed 10 Sep 2015].</Citation></Reference><Reference><Citation>Schmiedl S, Fischer R, Ib&#xe1;&#xf1;ez L, et al. . Utilisation and off-label prescriptions of respiratory drugs in children. PLoS One 2014;9:e105110 10.1371/journal.pone.0105110</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0105110</ArticleId><ArticleId IdType="pmc">PMC4152124</ArticleId><ArticleId IdType="pubmed">25180704</ArticleId></ArticleIdList></Reference><Reference><Citation>Arakawa H, Hamasaki Y, Kohno Y, et al. . Japanese guidelines for childhood asthma 2017. Allergol Int 2017;66:190&#x2013;204. 10.1016/j.alit.2016.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.alit.2016.11.003</ArticleId><ArticleId IdType="pubmed">28108245</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Medicines Agency (EMA) 
Opinion of the paediatric Committee on the refusal of a paediatric investigation plan and on the granting of a product-specific waiver. Available: http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500095327.pdf [Accessed 27 Feb 2017].</Citation></Reference><Reference><Citation>
European Medicines Agency (EMA) 
Assessment report: codeine containing medicinal products for the treatment of cough and/or cold in paediatric patients. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Codeine_cough_or_cold_in_children/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500186522.pdf [Accessed 12 Mar 2015].</Citation></Reference><Reference><Citation>Ciszkowski C, Madadi P, Phillips MS, et al. . Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med 2009;361:827&#x2013;8. 10.1056/NEJMc0904266</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc0904266</ArticleId><ArticleId IdType="pubmed">19692698</ArticleId></ArticleIdList></Reference><Reference><Citation>
British National Formulary (BNF) 
Clarithromycin. Available: https://www.evidence.nhs.uk/formulary/bnf/current/5-infections/51-antibacterial-drugs/515-macrolides/clarithromycin [Accessed 30 Mar 2017].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31939079</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Developing Predictive Models to Determine Patients in End-of-Life Care in Administrative Datasets.</ArticleTitle><Pagination><StartPage>447</StartPage><EndPage>455</EndPage><MedlinePgn>447-455</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-020-00906-7</ELocationID><Abstract><AbstractText Label="INTRODUCTION">In observational studies with mortality endpoints, one needs to consider how to account for subjects whose interventions appear to be part of 'end-of-life' care.</AbstractText><AbstractText Label="OBJECTIVE">The objective of this study was to develop a diagnostic predictive model to identify those in end-of-life care at the time of a drug exposure.</AbstractText><AbstractText Label="METHODS">We used data from four administrative claims datasets from 2000 to 2017. The index date was the date of the first prescription for the last new drug subjects received during their observation period. The outcome of end-of-life care was determined by the presence of one or more codes indicating terminal or hospice care. Models were developed using regularized logistic regression. Internal validation was through examination of the area under the receiver operating characteristic curve (AUC) and through model calibration in a 25% subset of the data held back from model training. External validation was through examination of the AUC after applying the model learned on one dataset to the three other datasets.</AbstractText><AbstractText Label="RESULTS">The models showed excellent performance characteristics. Internal validation resulted in AUCs ranging from 0.918 (95% confidence interval [CI] 0.905-0.930) to 0.983 (95% CI 0.978-0.987) for the four different datasets. Calibration results were also very good, with slopes near unity. External validation also produced very good to excellent performance metrics, with AUCs ranging from 0.840 (95% CI 0.834-0.846) to 0.956 (95% CI 0.952-0.960).</AbstractText><AbstractText Label="CONCLUSION">These results show that developing diagnostic predictive models for determining subjects in end-of-life care at the time of a drug treatment is possible and may improve the validity of the risk profile for those treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel N</ForeName><Initials>JN</Initials><Identifier Source="ORCID">0000-0001-9491-2737</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, 920 Route 202, Raritan, NJ, 08869, USA. jswerdel@its.jnj.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), 622 West 168th Street, PH-20, New York, NY, 10032, USA. jswerdel@its.jnj.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA. jswerdel@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, 920 Route 202, Raritan, NJ, 08869, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), 622 West 168th Street, PH-20, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fife</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, 920 Route 202, Raritan, NJ, 08869, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, 920 Route 202, Raritan, NJ, 08869, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), 622 West 168th Street, PH-20, New York, NY, 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Columbia University, 622 West 168th Street, PH20, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008962" MajorTopicYN="Y">Models, Theoretical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013727" MajorTopicYN="Y">Terminal Care</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Joel Swerdel, Jenna M. Reps, Daniel Fife, and Patrick Ryan were full-time employees of Janssen Research &amp; Development LLC at the time the study was conducted. They own stock, stock options, and pension rights from the company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31939079</ArticleId><ArticleId IdType="pmc">PMC7165142</ArticleId><ArticleId IdType="doi">10.1007/s40264-020-00906-7</ArticleId><ArticleId IdType="pii">10.1007/s40264-020-00906-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Smith A, Murphy L, Bennett K, Barron TI. Patterns of statin initiation and continuation in patients with breast or colorectal cancer, towards end-of-life. Support Care Cancer. 2017;25(5):1629&#x2013;1637. doi: 10.1007/s00520-017-3576-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00520-017-3576-0</ArticleId><ArticleId IdType="pmc">PMC5378743</ArticleId><ArticleId IdType="pubmed">28101676</ArticleId></ArticleIdList></Reference><Reference><Citation>Arana A, Johannes CB, McQuay LJ, Varas-Lorenzo C, Fife D, Rothman KJ. Risk of out-of-hospital sudden cardiac death in users of domperidone, proton pump inhibitors, or metoclopramide: a population-based nested case-control study. Drug Saf. 2015;38(12):1187&#x2013;1199. doi: 10.1007/s40264-015-0338-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-015-0338-0</ArticleId><ArticleId IdType="pmc">PMC4659849</ArticleId><ArticleId IdType="pubmed">26350642</ArticleId></ArticleIdList></Reference><Reference><Citation>Varas-Lorenzo C, Arana A, Johannes CB, McQuay LJ, Rothman KJ, Fife D. Improving the identification of out-of-hospital sudden cardiac deaths in a general practice research database. Drugs Real World Outcomes. 2016;3(3):353&#x2013;358. doi: 10.1007/s40801-016-0086-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40801-016-0086-1</ArticleId><ArticleId IdType="pmc">PMC5042942</ArticleId><ArticleId IdType="pubmed">27747831</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulshof TA, Zuidema SU, Ostelo RW, Luijendijk HJ. The mortality risk of conventional antipsychotics in elderly patients: a systematic review and meta-analysis of randomized placebo-controlled trials. J Am Med Dir Assoc. 2015;16(10):817&#x2013;824. doi: 10.1016/j.jamda.2015.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2015.03.015</ArticleId><ArticleId IdType="pubmed">25933724</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal V, Podchiyska T, Banda JM, Goel V, Leung TI, Minty EP, et al. Learning statistical models of phenotypes using noisy labeled training data. J Am Med Inform Assoc. 2016;23(6):1166&#x2013;1173. doi: 10.1093/jamia/ocw028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocw028</ArticleId><ArticleId IdType="pmc">PMC5070523</ArticleId><ArticleId IdType="pubmed">27174893</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpern Y, Horng S, Choi Y, Sontag D. Electronic medical record phenotyping using the anchor and learn framework. J Am Med Inform Assoc. 2016;23(4):731&#x2013;740. doi: 10.1093/jamia/ocw011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocw011</ArticleId><ArticleId IdType="pmc">PMC4926745</ArticleId><ArticleId IdType="pubmed">27107443</ArticleId></ArticleIdList></Reference><Reference><Citation>Demirer E, Miller AC, Kunter E, Kartaloglu Z, Barnett SD, Elamin EM. Predictive models for tuberculous pleural effusions in a high tuberculosis prevalence region. Lung. 2012;190(2):239&#x2013;248. doi: 10.1007/s00408-011-9342-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-011-9342-z</ArticleId><ArticleId IdType="pubmed">22057296</ArticleId></ArticleIdList></Reference><Reference><Citation>Huertas-Fernandez I, Garcia-Gomez FJ, Garcia-Solis D, Benitez-Rivero S, Marin-Oyaga VA, Jesus S, et al. Machine learning models for the differential diagnosis of vascular parkinsonism and Parkinson&#x2019;s disease using [(123)I]FP-CIT SPECT. Eur J Nucl Med Mol Imaging. 2015;42(1):112&#x2013;119. doi: 10.1007/s00259-014-2882-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-014-2882-8</ArticleId><ArticleId IdType="pubmed">25120041</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams BA, Ladapo JA, Merhige ME. External validation of models for estimating pretest probability of coronary artery disease among individuals undergoing myocardial perfusion imaging. Int J Cardiol. 2015;182:534&#x2013;540. doi: 10.1016/j.ijcard.2015.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2015.01.015</ArticleId><ArticleId IdType="pubmed">25665971</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010;153(9):600&#x2013;606. doi: 10.7326/0003-4819-153-9-201011020-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>National Hospice and Palliative Care Organization. NHPCO&#x2019;s facts and figures hospice care in America. 2017. https://legacy.nhpco.org/sites/default/files/public/Statistics_Research/2017_Facts_Figures.pdf.</Citation></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373&#x2013;383. doi: 10.1016/0021-9681(87)90171-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14(1):15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810070</ArticleId><ArticleId IdType="pubmed">18197741</ArticleId></ArticleIdList></Reference><Reference><Citation>Welles CC, Whooley MA, Na B, Ganz P, Schiller NB, Turakhia MP. The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among patients with coronary heart disease: data from the Heart and Soul Study. Am Heart J. 2011;162(3):555&#x2013;561. doi: 10.1016/j.ahj.2011.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2011.05.023</ArticleId><ArticleId IdType="pmc">PMC3199107</ArticleId><ArticleId IdType="pubmed">21884876</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25(8):969&#x2013;975. doi: 10.1093/jamia/ocy032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B (Methodol) 1996;58(1):267&#x2013;288.</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23(1):1&#x2013;23. doi: 10.1145/2414416.2414791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ME, Langefeld CD, Tierney WM, Hui SL, McDonald CJ. Validation of probabilistic predictions. Med Decis Mak. 1993;13(1):49&#x2013;58. doi: 10.1177/0272989X9301300107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X9301300107</ArticleId><ArticleId IdType="pubmed">8433637</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO Definition of Palliative Care. 2017. http://www.who.int/cancer/palliative/definition/en/.</Citation></Reference><Reference><Citation>Hughes MT, Smith TJ. The growth of palliative care in the United States. Annu Rev Public Health. 2014;35:459&#x2013;475. doi: 10.1146/annurev-publhealth-032013-182406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-publhealth-032013-182406</ArticleId><ArticleId IdType="pubmed">24641562</ArticleId></ArticleIdList></Reference><Reference><Citation>Guadagnolo BA, Liao KP, Elting L, Giordano S, Buchholz TA, Shih YC. Use of radiation therapy in the last 30&#xa0;days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol. 2013;31(1):80&#x2013;87. doi: 10.1200/JCO.2012.45.0585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2012.45.0585</ArticleId><ArticleId IdType="pmc">PMC3530693</ArticleId><ArticleId IdType="pubmed">23169520</ArticleId></ArticleIdList></Reference><Reference><Citation>Huo J, Du XL, Lairson DR, Chan W, Jiang J, Buchholz TA, et al. Utilization of surgery, chemotherapy, radiation therapy, and hospice at the end of life for patients diagnosed with metastatic melanoma. Am J Clin Oncol. 2015;38(3):235&#x2013;241. doi: 10.1097/COC.0b013e31829378f9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COC.0b013e31829378f9</ArticleId><ArticleId IdType="pmc">PMC3796177</ArticleId><ArticleId IdType="pubmed">23648436</ArticleId></ArticleIdList></Reference><Reference><Citation>Miesfeldt S, Murray K, Lucas L, Chang CH, Goodman D, Morden NE. Association of age, gender, and race with intensity of end-of-life care for Medicare beneficiaries with cancer. J Palliat Med. 2012;15(5):548&#x2013;554. doi: 10.1089/jpm.2011.0310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jpm.2011.0310</ArticleId><ArticleId IdType="pmc">PMC3353746</ArticleId><ArticleId IdType="pubmed">22468739</ArticleId></ArticleIdList></Reference><Reference><Citation>Virnig BA, Kind S, McBean M, Fisher E. Geographic variation in hospice use prior to death. J Am Geriatr Soc. 2000;48(9):1117&#x2013;1125. doi: 10.1111/j.1532-5415.2000.tb04789.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2000.tb04789.x</ArticleId><ArticleId IdType="pubmed">10983913</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackan NA, Ostir GV, Freeman JL, Mahnken JD, Goodwin JS. Decreasing variation in the use of hospice among older adults with breast, colorectal, lung, and prostate cancer. Med Care. 2004;42(2):116&#x2013;122. doi: 10.1097/01.mlr.0000108765.86294.1b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mlr.0000108765.86294.1b</ArticleId><ArticleId IdType="pubmed">14734948</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeyer Z, Powers BW, Makar M, Keating NL, Cutler DM. Physician characteristics strongly predict patient enrollment in hospice. Health Aff (Millwood). 2015;34(6):993&#x2013;1000. doi: 10.1377/hlthaff.2014.1055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2014.1055</ArticleId><ArticleId IdType="pmc">PMC4852702</ArticleId><ArticleId IdType="pubmed">26056205</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindley LC, Edwards SL. Geographic variation in california pediatric hospice care for children and adolescents: 2007&#x2013;2010. Am J Hosp Palliat Care. 2018;35(1):15&#x2013;20. doi: 10.1177/1049909116678380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1049909116678380</ArticleId><ArticleId IdType="pmc">PMC5344704</ArticleId><ArticleId IdType="pubmed">27837156</ArticleId></ArticleIdList></Reference><Reference><Citation>Adsersen M, Thygesen LC, Jensen AB, Neergaard MA, Sjogren P, Groenvold M. Is admittance to specialised palliative care among cancer patients related to sex, age and cancer diagnosis? A nation-wide study from the Danish Palliative Care Database (DPD) BMC Palliat Care. 2017;16(1):21. doi: 10.1186/s12904-017-0194-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12904-017-0194-z</ArticleId><ArticleId IdType="pmc">PMC5363002</ArticleId><ArticleId IdType="pubmed">28330507</ArticleId></ArticleIdList></Reference><Reference><Citation>Avati A, Jung K, Harman S, Downing L, Ng A, Shah NH. Improving palliative care with deep learning. BMC Med Inform Decis Mak. 2018;18(Suppl 4):122. doi: 10.1186/s12911-018-0677-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-018-0677-8</ArticleId><ArticleId IdType="pmc">PMC6290509</ArticleId><ArticleId IdType="pubmed">30537977</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K, Sudat SEK, Kwon N, Stewart WF, Shah NH. Predicting need for advanced illness or palliative care in a primary care population using electronic health record data. J Biomed Inform. 2019;92:103115. doi: 10.1016/j.jbi.2019.103115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103115</ArticleId><ArticleId IdType="pmc">PMC6512802</ArticleId><ArticleId IdType="pubmed">30753951</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31943641</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5448</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Pediatric diabetes</Title><ISOAbbreviation>Pediatr Diabetes</ISOAbbreviation></Journal><ArticleTitle>Diabetic ketoacidosis at diagnosis among youth with type 1 and type 2 diabetes: Results from SEARCH (United States) and YDR (India) registries.</ArticleTitle><Pagination><StartPage>40</StartPage><EndPage>46</EndPage><MedlinePgn>40-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pedi.12979</ELocationID><Abstract><AbstractText Label="BACKGROUND">There is significant global variation in the prevalence of diabetic ketoacidosis (DKA) at diagnosis among youth with type 1 diabetes (T1D). However, data for youth with type 2 diabetes (T2D) are limited, even in developed countries. We compared the prevalence of DKA at diagnosis among individuals with T1D and T2D from the SEARCH for Diabetes in Youth (SEARCH) and the Registry of Youth Onset Diabetes in India (YDR) registries.</AbstractText><AbstractText Label="METHODS">We harmonized the SEARCH and YDR registries to the structure and terminology in the Observational Medical Outcome Partnership Common Data Model. Data used were from youth with T1D and T2D diagnosed before 20&#x2009;years and newly diagnosed between 2006 and 2012 in YDR and 2009 and 2012 in SEARCH.</AbstractText><AbstractText Label="RESULTS">There were 5366 US youth (4078 with T1D, 1288 with T2D) and 2335 Indian youth (2108 with T1D, 227 with T2D). More than one third of T1D youth enrolled in SEARCH had DKA at diagnosis which was significantly higher than in YDR (35.3% vs 28.7%, P&#x2009;&lt;&#x2009;.0001). The burden of DKA in youth with T1D was significantly higher among younger age groups; this relationship was similar across registries (P = .4). The prevalence of DKA among T2D in SEARCH and YDR were 5.5% and 6.6% respectively (P = .4).</AbstractText><AbstractText Label="CONCLUSIONS">There is significant burden of DKA at diagnosis with T1D among youth from United States and India, especially among the younger age groups. The reasons for this high prevalence are largely unknown but are critical to developing interventions to prevent DKA at diagnosis.</AbstractText><CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Praveen</LastName><ForeName>Pradeep A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hockett</LastName><ForeName>Christine W</ForeName><Initials>CW</Initials><Identifier Source="ORCID">0000-0002-1665-6763</Identifier><AffiliationInfo><Affiliation>Lifecourse Epidemiology of Adiposity and Diabetes Center, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Toan C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amutha</LastName><ForeName>Anandakumar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dr. Mohan's Diabetes Specialties Centre and Madras Diabetes Research Foundation, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isom</LastName><ForeName>Scott P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Elizabeth T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Viswanathan</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5038-6210</Identifier><AffiliationInfo><Affiliation>Dr. Mohan's Diabetes Specialties Centre and Madras Diabetes Research Foundation, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabelea</LastName><ForeName>Dana A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-9514-8929</Identifier><AffiliationInfo><Affiliation>Lifecourse Epidemiology of Adiposity and Diabetes Center, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Ralph B</ForeName><Initials>RB</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamman</LastName><ForeName>Richard F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Lifecourse Epidemiology of Adiposity and Diabetes Center, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer-Davis</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0003-3858-0517</Identifier><AffiliationInfo><Affiliation>Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Jean M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolan</LastName><ForeName>Lawrence M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhu</LastName><ForeName>Sri Venkata</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>University College of Medical Science, GTB Hospital, Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tandon</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4604-1986</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 DK057516</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006139</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000247</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000154</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U48/CCU819241-3</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000244</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000062</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006134</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002709</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP002708</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21DK105869-02</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006138</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U48/CCU519239</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002710</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR00423</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP006138</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK57516</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U48/CCU919219</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006138</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002714</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006134</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 Tr001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000248</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>00097</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP002714</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U48/CCU419249</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1U18DP002709</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U58/CCU019235-4</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP002710-01</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006136</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006131</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP-10-001</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 DK105869</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006139</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>200-2010-35171</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006133</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000077</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP-05-069</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK127208</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1U18DP006131</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000423</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006136</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP000247-06A1</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000250</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000246</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000254</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006133</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002708</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Pediatr Diabetes</MedlineTA><NlmUniqueID>100939345</NlmUniqueID><ISSNLinking>1399-543X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016883" MajorTopicYN="N">Diabetic Ketoacidosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SEARCH for Diabetes in Youth registry</Keyword><Keyword MajorTopicYN="N">YDR registry</Keyword><Keyword MajorTopicYN="N">diabetic ketoacidosis</Keyword><Keyword MajorTopicYN="N">type 1 diabetes</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList><CoiStatement><b>Disclosures:</b> None of the authors have any potential conflicts of interest relevant to the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31943641</ArticleId><ArticleId IdType="mid">NIHMS1648755</ArticleId><ArticleId IdType="pmc">PMC7748377</ArticleId><ArticleId IdType="doi">10.1111/pedi.12979</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eledrisi MS, Alshanti MS, Shah MF, Brolosy B, Jaha N. Overview of the diagnosis and management of diabetic ketoacidosis. Am J Med Sci. 2006;331(5):243&#x2013;251. http://www.ncbi.nlm.nih.gov/pubmed/16702793. Accessed
May 19, 2016.</Citation><ArticleIdList><ArticleId IdType="pubmed">16702793</ArticleId></ArticleIdList></Reference><Reference><Citation>Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association. Diabetes Care. 2018;41(12):2648&#x2013;2668. doi:10.2337/dci18-0052</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci18-0052</ArticleId><ArticleId IdType="pmc">PMC7732108</ArticleId><ArticleId IdType="pubmed">30425094</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge JA, Hawkins MM, Winter DL, Dunger DB. The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. Arch Dis Child. 2001;85(1):16&#x2013;22. http://www.ncbi.nlm.nih.gov/pubmed/11420189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1718828</ArticleId><ArticleId IdType="pubmed">11420189</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med. 2001;344(4):264&#x2013;269. doi:10.1056/NEJM200101253440404</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200101253440404</ArticleId><ArticleId IdType="pubmed">11172153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence SE, Cummings EA, Gaboury I, Daneman D. Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis. J Pediatr. 2005;146(5):688&#x2013;692. doi:10.1016/j.jpeds.2004.12.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2004.12.041</ArticleId><ArticleId IdType="pubmed">15870676</ArticleId></ArticleIdList></Reference><Reference><Citation>Duca LM, Wang B, Rewers M, Rewers A. Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes Predicts Poor Long-term Glycemic Control. Diabetes Care. 2017;40(9):1249&#x2013;1255. doi:10.2337/dc17-0558</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc17-0558</ArticleId><ArticleId IdType="pubmed">28667128</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalitin S, Fisher S, Yackbovitch-Gavan M, et al. Ketoacidosis at onset of type 1 diabetes is a predictor of long-term glycemic control. Pediatr Diabetes. 2018;19(2):320&#x2013;328. doi:10.1111/pedi.12546</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pedi.12546</ArticleId><ArticleId IdType="pubmed">28568379</ArticleId></ArticleIdList></Reference><Reference><Citation>Duca LM, Reboussin BA, Pihoker C, et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: The SEARCH for diabetes in youth study. Pediatr Diabetes. 2019;20(2):172&#x2013;179. doi:10.1111/pedi.12809</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pedi.12809</ArticleId><ArticleId IdType="pmc">PMC6361710</ArticleId><ArticleId IdType="pubmed">30556249</ArticleId></ArticleIdList></Reference><Reference><Citation>Usher-Smith JA, Thompson M, Ercole A, Walter FM. Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: a systematic review. Diabetologia. 2012;55(11):2878&#x2013;2894. doi:10.1007/s00125-012-2690-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-012-2690-2</ArticleId><ArticleId IdType="pmc">PMC3464389</ArticleId><ArticleId IdType="pubmed">22933123</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabelea D, Rewers A, Stafford JM, et al. Trends in the Prevalence of Ketoacidosis at Diabetes Diagnosis: The SEARCH for Diabetes in Youth Study. Pediatrics. 2014;133(4):e938&#x2013;e945. doi:10.1542/peds.2013-2795</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2013-2795</ArticleId><ArticleId IdType="pmc">PMC4074618</ArticleId><ArticleId IdType="pubmed">24685959</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamman RF, Bell RA, Dabelea D, et al. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care. 2014;37(12):3336&#x2013;3344. doi:10.2337/dc14-0574</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-0574</ArticleId><ArticleId IdType="pmc">PMC4237981</ArticleId><ArticleId IdType="pubmed">25414389</ArticleId></ArticleIdList></Reference><Reference><Citation>Praveen PA, Madhu SV, Mohan V, et al. Registry of Youth Onset Diabetes in India (YDR): Rationale, Recruitment, and Current Status. J Diabetes Sci Technol. May 2016. doi:10.1177/1932296816645121</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1932296816645121</ArticleId><ArticleId IdType="pmc">PMC5032954</ArticleId><ArticleId IdType="pubmed">27179010</ArticleId></ArticleIdList></Reference><Reference><Citation>Bui TP, Werther GA, Cameron FJ. Trends in diabetic ketoacidosis in childhood and adolescence: a 15-yr experience. Pediatr Diabetes. 2002;3(2):82&#x2013;88. doi:10.1034/j.1399-5448.2002.30204.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-5448.2002.30204.x</ArticleId><ArticleId IdType="pubmed">15016161</ArticleId></ArticleIdList></Reference><Reference><Citation>Hekkala A, Knip M, Veijola R. Ketoacidosis at Diagnosis of Type 1 Diabetes in Children in Northern Finland: Temporal changes over 20 years. Diabetes Care. 2007;30(4):861&#x2013;866. doi:10.2337/dc06-2281</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc06-2281</ArticleId><ArticleId IdType="pubmed">17392547</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;vy-Marchal C, Patterson CC, Green A, EURODIAB ACE Study Group. Europe and Diabetes. Geographical variation of presentation at diagnosis of type I diabetes in children: the EURODIAB study. European and Dibetes. Diabetologia. 2001;44
Suppl 3:B75&#x2013;80. http://www.ncbi.nlm.nih.gov/pubmed/11724421.</Citation><ArticleIdList><ArticleId IdType="pubmed">11724421</ArticleId></ArticleIdList></Reference><Reference><Citation>VanderWeele J, Pollack T, Oakes DJ, et al. Validation of data from electronic data warehouse in diabetic ketoacidosis: Caution is needed. J Diabetes Complications. 2018;32(7):650&#x2013;654. doi:10.1016/j.jdiacomp.2018.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2018.05.004</ArticleId><ArticleId IdType="pubmed">29903409</ArticleId></ArticleIdList></Reference><Reference><Citation>Varadarajan P Risk factors for mortality in children with diabetic keto acidosis from developing countries. World J Diabetes. 2014;5(6):932. doi:10.4239/wjd.v5.i6.932</Citation><ArticleIdList><ArticleId IdType="doi">10.4239/wjd.v5.i6.932</ArticleId><ArticleId IdType="pmc">PMC4265883</ArticleId><ArticleId IdType="pubmed">25512799</ArticleId></ArticleIdList></Reference><Reference><Citation>The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann N Y Acad Sci. 2008;1150(1):1&#x2013;13. doi:10.1196/annals.1447.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1447.062</ArticleId><ArticleId IdType="pmc">PMC2886800</ArticleId><ArticleId IdType="pubmed">19120261</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Rasoul M, Al-Mahdi M, Al-Qattan H, et al. Ketoacidosis at presentation of type 1 diabetes in children in Kuwait: frequency and clinical characteristics. Pediatr Diabetes. 2010;11(5):351&#x2013;356. doi:10.1111/j.1399-5448.2009.00600.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-5448.2009.00600.x</ArticleId><ArticleId IdType="pubmed">19821943</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferies C, Cutfield SW, Derraik JGB, et al. 15-year incidence of diabetic ketoacidosis at onset of type 1 diabetes in children from a regional setting (Auckland, New Zealand). Sci Rep. 2015;5(1):10358. doi:10.1038/srep10358</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep10358</ArticleId><ArticleId IdType="pmc">PMC4650806</ArticleId><ArticleId IdType="pubmed">25989414</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31951272</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Assessment of a Machine Learning Model Applied to Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation.</ArticleTitle><Pagination><StartPage>e1919396</StartPage><MedlinePgn>e1919396</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1919396</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2019.19396</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its early detection could lead to significant improvements in outcomes through the appropriate prescription of anticoagulation medication. Although a variety of methods exist for screening for AF, a targeted approach, which requires an efficient method for identifying patients at risk, would be preferred.</AbstractText><AbstractText Label="OBJECTIVE">To examine machine learning approaches applied to electronic health record data that have been harmonized to the Observational Medical Outcomes Partnership Common Data Model for identifying risk of AF.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This diagnostic study used data from 2&#x202f;252&#x202f;219 individuals cared for in the UCHealth hospital system, which comprises 3 large hospitals in Colorado, from January 1, 2011, to October 1, 2018. Initial analysis was performed in December 2018; follow-up analysis was performed in July 2019.</AbstractText><AbstractText Label="EXPOSURES">All Observational Medical Outcomes Partnership Common Data Model-harmonized electronic health record features, including diagnoses, procedures, medications, age, and sex.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Classification of incident AF in designated 6-month intervals, adjudicated retrospectively, based on area under the receiver operating characteristic curve and F1 statistic.</AbstractText><AbstractText Label="RESULTS">Of 2&#x202f;252&#x202f;219 individuals (1&#x202f;225&#x202f;533 [54.4%] women; mean [SD] age, 42.9 [22.3] years), 28&#x202f;036 (1.2%) developed incident AF during a designated 6-month interval. The machine learning model that used the 200 most common electronic health record features, including age and sex, and random oversampling with a single-layer, fully connected neural network provided the optimal prediction of 6-month incident AF, with an area under the receiver operating characteristic curve of 0.800 and an F1 score of 0.110. This model performed only slightly better than a more basic logistic regression model composed of known clinical risk factors for AF, which had an area under the receiver operating characteristic curve of 0.794 and an F1 score of 0.079.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Machine learning approaches to electronic health record data offer a promising method for improving risk prediction for incident AF, but more work is needed to show improvement beyond standard risk factors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tiwari</LastName><ForeName>Premanand</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Colorado Center for Personalized Medicine, University of Colorado School of Medicine, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colborn</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Colorado School of Public Health, Department of Biostatics and Informatics, University of Colorado Denver, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Derek E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Children's Hospital Colorado, Cancer Center Biostatistics Core, Department of Pediatrics, University of Colorado, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Fuyong</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Colorado School of Public Health, Department of Biostatics and Informatics, University of Colorado Denver, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Debashis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Colorado School of Public Health, Department of Biostatics and Informatics, University of Colorado Denver, Aurora.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Colorado Center for Personalized Medicine, University of Colorado School of Medicine, Aurora.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology and Cardiac Electrophysiology, University of Colorado School of Medicine, Aurora.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 HL127296</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31951272</ArticleId><ArticleId IdType="pmc">PMC6991266</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.19396</ArticleId><ArticleId IdType="pii">2758859</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart. 2001;86(3):-. doi:10.1136/heart.86.3.284</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heart.86.3.284</ArticleId><ArticleId IdType="pmc">PMC1729916</ArticleId><ArticleId IdType="pubmed">11514479</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin EJ, Blaha MJ, Chiuve SE, et al. ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee . Heart disease and stroke statistics, 2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146-e603. doi:10.1161/CIR.0000000000000485</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000485</ArticleId><ArticleId IdType="pmc">PMC5408160</ArticleId><ArticleId IdType="pubmed">28122885</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin EJ, Wolf PA, D&#x2019;Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952. doi:10.1161/01.CIR.98.10.946</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.98.10.946</ArticleId><ArticleId IdType="pubmed">9737513</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin EJ, Levy D, Vaziri SM, D&#x2019;Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271(11):840-844. doi:10.1001/jama.1994.03510350050036</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1994.03510350050036</ArticleId><ArticleId IdType="pubmed">8114238</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer DE, Hughes RA, Gress DR, et al. ; Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators . The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323(22):1505-1511. doi:10.1056/NEJM199011293232201</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199011293232201</ArticleId><ArticleId IdType="pubmed">2233931</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84(2):527-539. doi:10.1161/01.CIR.84.2.527</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.84.2.527</ArticleId><ArticleId IdType="pubmed">1860198</ArticleId></ArticleIdList></Reference><Reference><Citation>Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343(8899):687-691.</Citation><ArticleIdList><ArticleId IdType="pubmed">7907677</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1(8631):175-179. doi:10.1016/S0140-6736(89)91200-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(89)91200-2</ArticleId><ArticleId IdType="pubmed">2563096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezekowitz MD, Bridgers SL, James KE, et al. ; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators . Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327(20):1406-1412. doi:10.1056/NEJM199211123272002</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199211123272002</ArticleId><ArticleId IdType="pubmed">1406859</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18(2):349-355. doi:10.1016/0735-1097(91)90585-W</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0735-1097(91)90585-W</ArticleId><ArticleId IdType="pubmed">1856403</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-1457. doi:10.1001/archinte.1994.00420130036007</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1994.00420130036007</ArticleId><ArticleId IdType="pubmed">8018000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867. doi:10.7326/0003-4819-146-12-200706190-00007</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-146-12-200706190-00007</ArticleId><ArticleId IdType="pubmed">17577005</ArticleId></ArticleIdList></Reference><Reference><Citation>van Walraven C, Hart RG, Singer DE, et al. . Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288(19):2441-2448. doi:10.1001/jama.288.19.2441</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.288.19.2441</ArticleId><ArticleId IdType="pubmed">12435257</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med. 2006;166(12):1269-1275. doi:10.1001/archinte.166.12.1269</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.166.12.1269</ArticleId><ArticleId IdType="pubmed">16801509</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly SJ, Ezekowitz MD, Yusuf S, et al. ; RE-LY Steering Committee and Investigators . Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0905561</ArticleId><ArticleId IdType="pubmed">19717844</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MR, Mahaffey KW, Garg J, et al. ; ROCKET AF Investigators . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi:10.1056/NEJMoa1009638</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1009638</ArticleId><ArticleId IdType="pubmed">21830957</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly SJ, Eikelboom J, Joyner C, et al. ; AVERROES Steering Committee and Investigators . Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-817. doi:10.1056/NEJMoa1007432</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1007432</ArticleId><ArticleId IdType="pubmed">21309657</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaakkola J, Mustonen P, Kiviniemi T, et al. . Stroke as the first manifestation of atrial fibrillation. PLoS One. 2016;11(12):e0168010. doi:10.1371/journal.pone.0168010</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0168010</ArticleId><ArticleId IdType="pmc">PMC5148080</ArticleId><ArticleId IdType="pubmed">27936187</ArticleId></ArticleIdList></Reference><Reference><Citation>Curry SJ, Krist AH, Owens DK, et al. ; US Preventive Services Task Force . Screening for atrial fibrillation with electrocardiography: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(5):478-484. doi:10.1001/jama.2018.10321</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.10321</ArticleId><ArticleId IdType="pubmed">30088016</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonas DE, Kahwati LC, Yun JDY, Middleton JC, Coker-Schwimmer M, Asher GN. Screening for atrial fibrillation with electrocardiography: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(5):485-498. doi:10.1001/jama.2018.4190</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.4190</ArticleId><ArticleId IdType="pubmed">30088015</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman B, Camm J, Calkins H, et al. ; AF-Screen Collaborators . Screening for atrial fibrillation: a report of the AF-SCREEN international collaboration. Circulation. 2017;135(19):1851-1867. doi:10.1161/CIRCULATIONAHA.116.026693</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.116.026693</ArticleId><ArticleId IdType="pubmed">28483832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocher R, Emanuel EJ, DeParle NA. The Affordable Care Act and the future of clinical medicine: the opportunities and challenges. Ann Intern Med. 2010;153(8):536-539. doi:10.7326/0003-4819-153-8-201010190-00274</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-8-201010190-00274</ArticleId><ArticleId IdType="pubmed">20733178</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexheimer JW, Talbot TR, Sanders DL, Rosenbloom ST, Aronsky D. Prompting clinicians about preventive care measures: a systematic review of randomized controlled trials. J Am Med Inform Assoc. 2008;15(3):311-320. doi:10.1197/jamia.M2555</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M2555</ArticleId><ArticleId IdType="pmc">PMC2410011</ArticleId><ArticleId IdType="pubmed">18308989</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoughi F, Erfannia L. Health information system in a cloud computing context. Stud Health Technol Inform. 2017;236:290-297.</Citation><ArticleIdList><ArticleId IdType="pubmed">28508809</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen RE, Rothrock NE, DeWitt EM, et al. . The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. Med Care. 2015;53(2):153-159. doi:10.1097/MLR.0000000000000289</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000000289</ArticleId><ArticleId IdType="pmc">PMC4801509</ArticleId><ArticleId IdType="pubmed">25588135</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey JA, Schwartz BS, Stewart WF, Adler NE. Using electronic health records for population health research: a review of methods and applications. Annu Rev Public Health. 2016;37:61-81. doi:10.1146/annurev-publhealth-032315-021353</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-publhealth-032315-021353</ArticleId><ArticleId IdType="pmc">PMC6724703</ArticleId><ArticleId IdType="pubmed">26667605</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Lee J, Wang S, Sun J, Liu H, Jiang X. Privacy-preserving predictive modeling: harmonization of contextual embeddings from different sources. JMIR Med Inform. 2018;6(2):e33. doi:10.2196/medinform.9455</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/medinform.9455</ArticleId><ArticleId IdType="pmc">PMC5981054</ArticleId><ArticleId IdType="pubmed">29769172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Kiefer RC, Sharma DK, Prud&#x2019;hommeaux E, Solbrig HR. A consensus-based approach for harmonizing the OHDSI Common Data Model with HL7 FHIR. Stud Health Technol Inform. 2017;245:887-891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939955</ArticleId><ArticleId IdType="pubmed">29295227</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Evans J, Oniki TA, et al. . Harmonization of detailed clinical models with clinical study data standards. Methods Inf Med. 2015;54(1):65-74. doi:10.3414/ME13-02-0019</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME13-02-0019</ArticleId><ArticleId IdType="pubmed">25426730</ArticleId></ArticleIdList></Reference><Reference><Citation>Oca&#xf1;a K, de Oliveira D. Parallel computing in genomic research: advances and applications. Adv Appl Bioinform Chem. 2015;8:23-35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4655901</ArticleId><ArticleId IdType="pubmed">26604801</ArticleId></ArticleIdList></Reference><Reference><Citation>Korb O, Finn PW, Jones G. The cloud and other new computational methods to improve molecular modelling. Expert Opin Drug Discov. 2014;9(10):1121-1131. doi:10.1517/17460441.2014.941800</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17460441.2014.941800</ArticleId><ArticleId IdType="pubmed">25146114</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg MA, Samuel M, Thosani A, Zimetbaum PJ. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. Pacing Clin Electrophysiol. 2013;36(3):328-333. doi:10.1111/pace.12053</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pace.12053</ArticleId><ArticleId IdType="pmc">PMC3618372</ArticleId><ArticleId IdType="pubmed">23240827</ArticleId></ArticleIdList></Reference><Reference><Citation>Diederichsen SZ, Haugan KJ, K&#xf8;ber L, et al. . Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): rationale and design of a large randomized controlled trial. Am Heart J. 2017;187:122-132. doi:10.1016/j.ahj.2017.02.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2017.02.017</ArticleId><ArticleId IdType="pubmed">28454796</ArticleId></ArticleIdList></Reference><Reference><Citation>LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436-444. doi:10.1038/nature14539</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14539</ArticleId><ArticleId IdType="pubmed">26017442</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallkamp J, Schlipsing M, Salmen J, Igel C. Man vs. computer: benchmarking machine learning algorithms for traffic sign recognition. Neural Netw. 2012;32:323-332.</Citation><ArticleIdList><ArticleId IdType="pubmed">22394690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooi T, Litjens G, van Ginneken B, et al. . Large scale deep learning for computer aided detection of mammographic lesions. Med Image Anal. 2017;35:303-312. doi:10.1016/j.media.2016.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.media.2016.07.007</ArticleId><ArticleId IdType="pubmed">27497072</ArticleId></ArticleIdList></Reference><Reference><Citation>Minarro-Gim&#xe9;nez JA, Mar&#xed;n-Alonso O, Samwald M. Exploring the application of deep learning techniques on medical text corpora. Stud Health Technol Inform. 2014;205:584-588.</Citation><ArticleIdList><ArticleId IdType="pubmed">25160253</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Li X, Conesa A, Pereira C. GRAM-CNN: a deep learning approach with local context for named entity recognition in biomedical text. Bioinformatics. 2018;34(9):1547-1554. doi:10.1093/bioinformatics/btx815</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx815</ArticleId><ArticleId IdType="pmc">PMC5925775</ArticleId><ArticleId IdType="pubmed">29272325</ArticleId></ArticleIdList></Reference><Reference><Citation>Morav&#x10d;&#xed;k M, Schmid M, Burch N, et al. . DeepStack: expert-level artificial intelligence in heads-up no-limit poker. Science. 2017;356(6337):508-513. doi:10.1126/science.aam6960</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aam6960</ArticleId><ArticleId IdType="pubmed">28254783</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaeffer J, Burch N, Bj&#xf6;rnsson Y, et al. . Checkers is solved. Science. 2007;317(5844):1518-1522. doi:10.1126/science.1144079</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1144079</ArticleId><ArticleId IdType="pubmed">17641166</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver D, Huang A, Maddison CJ, et al. . Mastering the game of Go with deep neural networks and tree search. Nature. 2016;529(7587):484-489. doi:10.1038/nature16961</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature16961</ArticleId><ArticleId IdType="pubmed">26819042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez J, Monasterio V, Minchol&#xe9; A, et al. . Automatic SVM classification of sudden cardiac death and pump failure death from autonomic and repolarization ECG markers. J Electrocardiol. 2015;48(4):551-557. doi:10.1016/j.jelectrocard.2015.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jelectrocard.2015.04.002</ArticleId><ArticleId IdType="pubmed">25912974</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu-Jones BK, Greene CS; Pooled Resource Open-Access ALS Clinical Trials Consortium . Semi-supervised learning of the electronic health record for phenotype stratification. J Biomed Inform. 2016;64:168-178. doi:10.1016/j.jbi.2016.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.10.007</ArticleId><ArticleId IdType="pubmed">27744022</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Li Z, Guo H, et al. . Predicting congenital heart defects: a comparison of three data mining methods. PLoS One. 2017;12(5):e0177811. doi:10.1371/journal.pone.0177811</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0177811</ArticleId><ArticleId IdType="pmc">PMC5443514</ArticleId><ArticleId IdType="pubmed">28542318</ArticleId></ArticleIdList></Reference><Reference><Citation>Amini P, Ahmadinia H, Poorolajal J, Moqaddasi Amiri M. Evaluating the high risk groups for suicide: a comparison of logistic regression, support vector machine, decision tree and artificial neural network. Iran J Public Health. 2016;45(9):1179-1187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149472</ArticleId><ArticleId IdType="pubmed">27957463</ArticleId></ArticleIdList></Reference><Reference><Citation>Churpek MM, Yuen TC, Winslow C, Meltzer DO, Kattan MW, Edelson DP. Multicenter comparison of machine learning methods and conventional regression for predicting clinical deterioration on the wards. Crit Care Med. 2016;44(2):368-374. doi:10.1097/CCM.0000000000001571</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001571</ArticleId><ArticleId IdType="pmc">PMC4736499</ArticleId><ArticleId IdType="pubmed">26771782</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KW, Torres Soto J, Glicksberg BS, et al. . Artificial intelligence in cardiology. J Am Coll Cardiol. 2018;71(23):2668-2679. doi:10.1016/j.jacc.2018.03.521</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2018.03.521</ArticleId><ArticleId IdType="pubmed">29880128</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594. doi:10.1136/bmj.g7594</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g7594</ArticleId><ArticleId IdType="pubmed">25569120</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the Premier Perspective hospital database into the Observational Medical Outcomes Partnership (OMOP) Common Data Model. EGEMS (Wash DC). 2014;2(1):1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: synthetic minority over-sampling technique. J Artif Intell Res. 2002;16:321-357. doi:10.1613/jair.953</Citation><ArticleIdList><ArticleId IdType="doi">10.1613/jair.953</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai KE, Anthony S, Coiera E, Magrabi F. Using statistical text classification to identify health information technology incidents. J Am Med Inform Assoc. 2013;20(5):980-985. doi:10.1136/amiajnl-2012-001409</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-001409</ArticleId><ArticleId IdType="pmc">PMC3756261</ArticleId><ArticleId IdType="pubmed">23666777</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis J, Goadrich M. The relationship between precision-recall and ROC curves. In: ICML &#x2019;06 Proceedings of the 23rd International Conference on Machine Learning. New York, NY: Association for Computing Machinery; 2006:233-240. doi:10.1145/1143844.1143874</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/1143844.1143874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Rothschild AS. Agreement, the f-measure, and reliability in information retrieval. J Am Med Inform Assoc. 2005;12(3):296-298. doi:10.1197/jamia.M1733</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M1733</ArticleId><ArticleId IdType="pmc">PMC1090460</ArticleId><ArticleId IdType="pubmed">15684123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol. 2007;73(16):5261-5267. doi:10.1128/AEM.00062-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AEM.00062-07</ArticleId><ArticleId IdType="pmc">PMC1950982</ArticleId><ArticleId IdType="pubmed">17586664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansoor H, Elgendy IY, Segal R, Bavry AA, Bian J. Risk prediction model for in-hospital mortality in women with ST-elevation myocardial infarction: A machine learning approach. Heart Lung. 2017;46(6):405-411.</Citation><ArticleIdList><ArticleId IdType="pubmed">28992993</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu Y, Adam BL, Yasui Y, et al. . Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem. 2002;48(10):1835-1843.</Citation><ArticleIdList><ArticleId IdType="pubmed">12324514</ArticleId></ArticleIdList></Reference><Reference><Citation>Penny W, Frost D. Neural networks in clinical medicine. Med Decis Making. 1996;16(4):386-398. doi:10.1177/0272989X9601600409</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X9601600409</ArticleId><ArticleId IdType="pubmed">8912300</ArticleId></ArticleIdList></Reference><Reference><Citation>Agresti A, Coull BA. 
Approximate is better than &#x201c;exact&#x201d; for interval estimation of binomial proportions. Am Stat. 1998;52(2):119-126. http://users.stat.ufl.edu/~aa/articles/agresti_coull_1998.pdf. Accessed December 2, 2019.</Citation></Reference><Reference><Citation>Lakhani P, Langlotz CP. Automated detection of radiology reports that document non-routine communication of critical or significant results. J Digit Imaging. 2010;23(6):647-657. doi:10.1007/s10278-009-9237-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10278-009-9237-1</ArticleId><ArticleId IdType="pmc">PMC2978900</ArticleId><ArticleId IdType="pubmed">19826871</ArticleId></ArticleIdList></Reference><Reference><Citation>Nattel S, Shiroshita-Takeshita A, Brundel BJ, Rivard L. Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis. 2005;48(1):9-28. doi:10.1016/j.pcad.2005.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2005.06.002</ArticleId><ArticleId IdType="pubmed">16194689</ArticleId></ArticleIdList></Reference><Reference><Citation>Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335-2345. doi:10.1016/j.jacc.2014.02.555</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2014.02.555</ArticleId><ArticleId IdType="pubmed">24613319</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg MA, Manning WJ. Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circulation. 2012;126(19):2353-2362. doi:10.1161/CIRCULATIONAHA.112.113233</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.112.113233</ArticleId><ArticleId IdType="pubmed">23129702</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso A, Krijthe BP, Aspelund T, et al. . Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2(2):e000102. doi:10.1161/JAHA.112.000102</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.112.000102</ArticleId><ArticleId IdType="pmc">PMC3647274</ArticleId><ArticleId IdType="pubmed">23537808</ArticleId></ArticleIdList></Reference><Reference><Citation>Li DC, Hu SC, Lin LS, Yeh CW. Detecting representative data and generating synthetic samples to improve learning accuracy with imbalanced data sets. PLoS One. 2017;12(8):e0181853. doi:10.1371/journal.pone.0181853</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0181853</ArticleId><ArticleId IdType="pmc">PMC5542532</ArticleId><ArticleId IdType="pubmed">28771522</ArticleId></ArticleIdList></Reference><Reference><Citation>Colborn KL, Bronsert M, Amioka E, Hammermeister K, Henderson WG, Meguid R. Identification of surgical site infections using electronic health record data. Am J Infect Control. 2018;46(11):1230-1235. doi:10.1016/j.ajic.2018.05.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2018.05.011</ArticleId><ArticleId IdType="pubmed">29907448</ArticleId></ArticleIdList></Reference><Reference><Citation>Blagus R, Lusa L. SMOTE for high-dimensional class-imbalanced data. BMC Bioinformatics. 2013;14:106. doi:10.1186/1471-2105-14-106</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-106</ArticleId><ArticleId IdType="pmc">PMC3648438</ArticleId><ArticleId IdType="pubmed">23522326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JG, Jun S, Cho YW, et al. . Deep learning in medical imaging: general overview. Korean J Radiol. 2017;18(4):570-584. doi:10.3348/kjr.2017.18.4.570</Citation><ArticleIdList><ArticleId IdType="doi">10.3348/kjr.2017.18.4.570</ArticleId><ArticleId IdType="pmc">PMC5447633</ArticleId><ArticleId IdType="pubmed">28670152</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwalla S, Sarma KK. Machine learning based sample extraction for automatic speech recognition using dialectal Assamese speech. Neural Netw. 2016;78:97-111.</Citation><ArticleIdList><ArticleId IdType="pubmed">26783204</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Ghosh J, Bejan CA, et al. . Building bridges across electronic health record systems through inferred phenotypic topics. J Biomed Inform. 2015;55:82-93. doi:10.1016/j.jbi.2015.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.03.011</ArticleId><ArticleId IdType="pmc">PMC4464930</ArticleId><ArticleId IdType="pubmed">25841328</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham T, Tran T, Phung D, Venkatesh S. Predicting healthcare trajectories from medical records: a deep learning approach. J Biomed Inform. 2017;69:218-229. doi:10.1016/j.jbi.2017.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2017.04.001</ArticleId><ArticleId IdType="pubmed">28410981</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Pan Z, Tao Q. Robust and adaptive online time series prediction with long short-term memory. Comput Intell Neurosci. 2017;2017:9478952. doi:10.1155/2017/9478952</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/9478952</ArticleId><ArticleId IdType="pmc">PMC5748146</ArticleId><ArticleId IdType="pubmed">29391864</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z. Parametric regression model for survival data: Weibull regression model as an example. Ann Transl Med. 2016;4(24):484. doi:10.21037/atm.2016.08.45</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm.2016.08.45</ArticleId><ArticleId IdType="pmc">PMC5233524</ArticleId><ArticleId IdType="pubmed">28149846</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg MA, Maziarz M, Tan AY, et al. . Circulating fibrosis biomarkers and risk of atrial fibrillation: the Cardiovascular Health Study (CHS). Am Heart J. 2014;167(5):723-8.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4060155</ArticleId><ArticleId IdType="pubmed">24766983</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton KK, Ellinor PT, Heckbert SR, et al. . N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120(18):1768-1774. doi:10.1161/CIRCULATIONAHA.109.873265</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.873265</ArticleId><ArticleId IdType="pmc">PMC4132053</ArticleId><ArticleId IdType="pubmed">19841297</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg MA, Gottdiener JS, Heckbert SR, Mukamal KJ. Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. Eur Heart J. 2012;33(7):904-912. doi:10.1093/eurheartj/ehr378</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehr378</ArticleId><ArticleId IdType="pmc">PMC3345546</ArticleId><ArticleId IdType="pubmed">21990265</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31953884</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5448</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Pediatric diabetes</Title><ISOAbbreviation>Pediatr Diabetes</ISOAbbreviation></Journal><ArticleTitle>Clinical profile at diagnosis with youth-onset type 1 and type 2 diabetes in two pediatric diabetes registries: SEARCH (United States) and YDR (India).</ArticleTitle><Pagination><StartPage>22</StartPage><EndPage>30</EndPage><MedlinePgn>22-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pedi.12981</ELocationID><Abstract><AbstractText Label="BACKGROUND">Over the last decades, diabetes in youth has increased in both India and the United States, along with the burden of long-term complications and healthcare costs. However, there are limited standardized population-based data in contemporary youth cohorts for comparison of clinical and demographic characteristics of diabetes for both type 1 (T1D) and type 2 (T2D).</AbstractText><AbstractText Label="METHODS">In partnership, we harmonized demographic and clinical data from the SEARCH for Diabetes in Youth (SEARCH) registry in the United States and the Registry of People with Diabetes with Youth Age at Onset (YDR) in India to the structure and terminology of the Observational Medical Outcomes Partnership Common Data Model. Data were from youth with T1D and T2D, aged &lt;20&#x2009;years and newly diagnosed between 2006 and 2010. We compared key characteristics across registries using &#x3c7;<sup>2</sup> tests and t-tests.</AbstractText><AbstractText Label="RESULTS">In total, there were 9650 youth with T1D and 2406 youth with T2D from 2006 to 2012. SEARCH youth were diagnosed at younger ages than YDR youth for T1D and T2D (10.0 vs 10.5&#x2009;years, P&#x2009;&lt;&#x2009;.001 and 14.7 vs 16.1&#x2009;years, P&#x2009;&lt;&#x2009;.001, respectively). For T2D, SEARCH had a higher proportion of females and significantly lower proportion of youth of high socioeconomic status compared to YDR. For T1D and T2D, SEARCH youth had higher BMI, lower blood pressure, and lower A1c compared to YDR youth.</AbstractText><AbstractText Label="CONCLUSIONS">These data offer insights into the demographic and clinical characteristics of diabetes in youth across the two countries. Further research is needed to better understand why these differences exist.</AbstractText><CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hockett</LastName><ForeName>Christine W</ForeName><Initials>CW</Initials><Identifier Source="ORCID">0000-0002-1665-6763</Identifier><AffiliationInfo><Affiliation>Lifecourse Epidemiology of Adiposity and Diabetes Center, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Praveen</LastName><ForeName>Pradeep A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Endocrinology &amp; Metabolism, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Toan C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amutha</LastName><ForeName>Anandakumar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dr. Mohan's Diabetes Specialties Centre and Madras Diabetes Research Foundation, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isom</LastName><ForeName>Scott P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Elizabeth T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Ralph B</ForeName><Initials>RB</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamman</LastName><ForeName>Richard F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Lifecourse Epidemiology of Adiposity and Diabetes Center, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer-Davis</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0003-3858-0517</Identifier><AffiliationInfo><Affiliation>Department of Nutrition and Medicine, University of North Carolina, Chapel Hill, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Jean M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pihoker</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9074-7770</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, University of Washington, Seattle, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado, Aurora, Colorado.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Viswanathan</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5038-6210</Identifier><AffiliationInfo><Affiliation>Dr. Mohan's Diabetes Specialties Centre and Madras Diabetes Research Foundation, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tandon</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4604-1986</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology &amp; Metabolism, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabelea</LastName><ForeName>Dana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9514-8929</Identifier><AffiliationInfo><Affiliation>Lifecourse Epidemiology of Adiposity and Diabetes Center, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 DK057516</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006139</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000247</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002710</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP006138</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006138</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000154</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002714</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000248</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000244</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000062</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006134</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002709</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006131</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000077</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000423</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HIR 10-001</GrantID><Acronym>HX</Acronym><Agency>HSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 DK105869</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006136</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000250</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000246</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000254</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006133</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002708</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21DK105869-02</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Pediatr Diabetes</MedlineTA><NlmUniqueID>100939345</NlmUniqueID><ISSNLinking>1399-543X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">India</Keyword><Keyword MajorTopicYN="N">United States</Keyword><Keyword MajorTopicYN="N">data harmonization</Keyword><Keyword MajorTopicYN="N">early onset type 2 diabetes</Keyword><Keyword MajorTopicYN="N">registry</Keyword><Keyword MajorTopicYN="N">type 1 diabetes</Keyword></KeywordList><CoiStatement><b>Disclosures:</b> None of the authors have any potential conflicts of interest relevant to the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31953884</ArticleId><ArticleId IdType="mid">NIHMS1648761</ArticleId><ArticleId IdType="pmc">PMC7785282</ArticleId><ArticleId IdType="doi">10.1111/pedi.12981</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hamman RF, Bell RA, Dabelea D, et al. The SEARCH for Diabetes in Youth Study: Rationale, Findings, and Future Directions. Diabetes Care. 2014;37(12):3336&#x2013;3344. doi:10.2337/dc14-0574</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-0574</ArticleId><ArticleId IdType="pmc">PMC4237981</ArticleId><ArticleId IdType="pubmed">25414389</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson C, Guariguata L, Dahlquist G, Solt&#xe9;sz G, Ogle G, Silink M. Diabetes in the young &#x2013; a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Res Clin Pract. 2014;103(2):161&#x2013;175. doi:10.1016/j.diabres.2013.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2013.11.005</ArticleId><ArticleId IdType="pubmed">24331235</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer-Davis EJ, Dabelea D, Lawrence JM. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002&#x2013;2012. N Engl J Med. 2017;377(3):301. doi:10.1056/NEJMc1706291</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1706291</ArticleId><ArticleId IdType="pmc">PMC5639715</ArticleId><ArticleId IdType="pubmed">28723318</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettitt DJ, Talton J, Dabelea D, et al. Prevalence of Diabetes in U.S. Youth in 2009: The SEARCH for Diabetes in Youth Study. Diabetes Care. 2014;37(2):402&#x2013;408. doi:10.2337/dc13-1838</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-1838</ArticleId><ArticleId IdType="pmc">PMC3898760</ArticleId><ArticleId IdType="pubmed">24041677</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr. 2017;71(7):816&#x2013;824. doi:10.1038/ejcn.2017.40</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejcn.2017.40</ArticleId><ArticleId IdType="pubmed">28422124</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitti DB, Klingensmith GJ, Bell RA, et al. Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. J Pediatr. 2009;155(5):668&#x2013;672.e1-3. doi:10.1016/j.jpeds.2009.05.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2009.05.025</ArticleId><ArticleId IdType="pmc">PMC4689142</ArticleId><ArticleId IdType="pubmed">19643434</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabelea D, Stafford JM, Mayer-Davis EJ, et al. Association of Type 1 Diabetes vs Type 2 Diabetes Diagnosed During Childhood and Adolescence With Complications During Teenage Years and Young Adulthood. JAMA. 2017;317(8):825&#x2013;835. doi:10.1001/jama.2017.0686</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.0686</ArticleId><ArticleId IdType="pmc">PMC5483855</ArticleId><ArticleId IdType="pubmed">28245334</ArticleId></ArticleIdList></Reference><Reference><Citation>Soltesz G, Patterson CC, Dahlquist G, EURODIAB Study Group. Worldwide childhood type 1 diabetes incidence--what can we learn from epidemiology? Pediatr Diabetes. 2007;8 Suppl 6:6&#x2013;14. doi:10.1111/j.1399-5448.2007.00280.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-5448.2007.00280.x</ArticleId><ArticleId IdType="pubmed">17727380</ArticleId></ArticleIdList></Reference><Reference><Citation>Praveen PA, Madhu SV, Mohan V, et al. Registry of Youth Onset Diabetes in India (YDR). J Diabetes Sci Technol. 2016;10(5):1034&#x2013;1041. doi:10.1177/1932296816645121</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1932296816645121</ArticleId><ArticleId IdType="pmc">PMC5032954</ArticleId><ArticleId IdType="pubmed">27179010</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniar D, Chen L. Integrations of Data Warehousing, Data Mining and Database Technologies: Innovative Approaches. IGI Global; 2001. 
https://www.igi-global.com/book/integrations-data-warehousing-data-mining/45967.
Accessed March 5, 2019.</Citation></Reference><Reference><Citation>Definition and DDLs for the OMOP Common Data Model (CDM): OHDSI/CommonDataModel. Observational Health Data Sciences and Informatics; 2018. 
https://github.com/OHDSI/CommonDataModel.
Accessed December 6, 2018.</Citation></Reference><Reference><Citation>Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. Med Care. 2012;50 Suppl:S60&#x2013;67. doi:10.1097/MLR.0b013e318259bff4</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e318259bff4</ArticleId><ArticleId IdType="pmc">PMC3824370</ArticleId><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez BL, Dabelea D, Liese AD, et al. Prevalence and correlates of elevated blood pressure in youth with diabetes mellitus: the SEARCH for diabetes in youth study. J Pediatr. 2010;157(2):245&#x2013;251.e1. doi:10.1016/j.jpeds.2010.02.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2010.02.021</ArticleId><ArticleId IdType="pubmed">20394942</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO | The WHO Child Growth Standards. WHO; 
http://www.who.int/childgrowth/en/.
Accessed November 26, 2018.</Citation></Reference><Reference><Citation>de Onis M Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007;85(09):660&#x2013;667. doi:10.2471/BLT.07.043497</Citation><ArticleIdList><ArticleId IdType="doi">10.2471/BLT.07.043497</ArticleId><ArticleId IdType="pmc">PMC2636412</ArticleId><ArticleId IdType="pubmed">18026621</ArticleId></ArticleIdList></Reference><Reference><Citation>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555&#x2013;576.</Citation><ArticleIdList><ArticleId IdType="pubmed">15286277</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes&#x2014;2019. Diabetes Care. 2019;42(Supplement 1):S61&#x2013;S70. doi:10.2337/dc19-S006</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc19-S006</ArticleId><ArticleId IdType="pubmed">30559232</ArticleId></ArticleIdList></Reference><Reference><Citation>Unnikrishnan AG, Bhatia E, Bhatia V, et al. Type 1 diabetes versus type 2 diabetes with onset in persons younger than 20 years of age. Ann N Y Acad Sci. 2008;1150:239&#x2013;244. doi:10.1196/annals.1447.056</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1447.056</ArticleId><ArticleId IdType="pubmed">19120303</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia V, Arya V, Dabadghao P, et al. Etiology and Outcome of Childhood and Adolescent Diabetes Mellitus in North India. J Pediatr Endocrinol Metab. 2011;17(7):993&#x2013;1000. doi:10.1515/JPEM.2004.17.7.993</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/JPEM.2004.17.7.993</ArticleId><ArticleId IdType="pubmed">15301047</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchers AT, Uibo R, Gershwin ME. The geoepidemiology of type 1 diabetes. Autoimmun Rev. 2010;9(5):A355&#x2013;365. doi:10.1016/j.autrev.2009.12.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2009.12.003</ArticleId><ArticleId IdType="pubmed">19969107</ArticleId></ArticleIdList></Reference><Reference><Citation>Liese AD, Puett RC, Lamichhane AP, et al. Neighborhood level risk factors for type 1 diabetes in youth: the SEARCH case-control study. Int J Health Geogr. 2012;11:1. doi:10.1186/1476-072X-11-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-072X-11-1</ArticleId><ArticleId IdType="pmc">PMC3269381</ArticleId><ArticleId IdType="pubmed">22230476</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemiatycki J, Colle E, Campbell S, Dewar R, Aubert D, Belmonte MM. Incidence of IDDM in Montreal by ethnic group and by social class and comparisons with ethnic groups living elsewhere. Diabetes. 1988;37(8):1096&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">3391344</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W. Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health. 2000;54(3):173&#x2013;177. doi:10.1136/jech.54.3.173</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech.54.3.173</ArticleId><ArticleId IdType="pmc">PMC1731634</ArticleId><ArticleId IdType="pubmed">10746110</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins JM, Vaccarino V, Zhang H, Kasl SV. Socioeconomic status and diagnosed diabetes incidence. Diabetes Res Clin Pract. 2005;68(3):230&#x2013;236. doi:10.1016/j.diabres.2004.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2004.09.007</ArticleId><ArticleId IdType="pubmed">15936465</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulgaron ER, Delamater AM. Obesity and Type 2 Diabetes in Children: Epidemiology and Treatment. Curr Diab Rep. 2014;14(8):508. doi:10.1007/s11892-014-0508-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11892-014-0508-y</ArticleId><ArticleId IdType="pmc">PMC4099943</ArticleId><ArticleId IdType="pubmed">24919749</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohan V, Shanthirani S, Deepa R, et al. Intra-urban differences in the prevalence of the metabolic syndrome in southern India -- the Chennai Urban Population Study (CUPS No. 4). Diabet Med J Br Diabet Assoc. 2001;18(4):280&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">11437858</ArticleId></ArticleIdList></Reference><Reference><Citation>Mbanya JC, Ngogang J, Salah JN, Minkoulou E, Balkau B. Prevalence of NIDDM and impaired glucose tolerance in a rural and an urban population in Cameroon. Diabetologia. 1997;40(7):824&#x2013;829. doi:10.1007/s001250050755</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001250050755</ArticleId><ArticleId IdType="pubmed">9243104</ArticleId></ArticleIdList></Reference><Reference><Citation>abu Sayeed M, Ali L, Hussain MZ, Rumi MA, Banu A, Azad Khan AK. Effect of socioeconomic risk factors on the difference in prevalence of diabetes between rural and urban populations in Bangladesh. Diabetes Care. 1997;20(4):551&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">9096979</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen L, Williams J, Townsend N, et al. Socioeconomic status and non-communicable disease behavioural risk factors in low-income and lower-middle-income countries: a systematic review. Lancet Glob Health. 2017;5(3):e277&#x2013;e289. doi:10.1016/S2214-109X(17)30058-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(17)30058-X</ArticleId><ArticleId IdType="pmc">PMC5673683</ArticleId><ArticleId IdType="pubmed">28193397</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu WC, Araneta MRG, Kanaya AM, Chiang JL, Fujimoto W. BMI Cut Points to Identify At-Risk Asian Americans for Type 2 Diabetes Screening. Diabetes Care. 2015;38(1):150&#x2013;158. doi:10.2337/dc14-2391</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-2391</ArticleId><ArticleId IdType="pmc">PMC4392932</ArticleId><ArticleId IdType="pubmed">25538311</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JCN, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129&#x2013;2140. doi:10.1001/jama.2009.726</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.726</ArticleId><ArticleId IdType="pubmed">19470990</ArticleId></ArticleIdList></Reference><Reference><Citation>King GL, McNeely MJ, Thorpe LE, et al. Understanding and Addressing Unique Needs of Diabetes in Asian Americans, Native Hawaiians, and Pacific Islanders. Diabetes Care. 2012;35(5):1181&#x2013;1188. doi:10.2337/dc12-0210</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc12-0210</ArticleId><ArticleId IdType="pmc">PMC3329823</ArticleId><ArticleId IdType="pubmed">22517939</ArticleId></ArticleIdList></Reference><Reference><Citation>Flowers E, Lin F, Kandula NR, et al. Body Composition and Diabetes Risk in South Asians: Findings From the MASALA and MESA Studies. Diabetes Care. February 2019:dc181510. doi:10.2337/dc18-1510</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc18-1510</ArticleId><ArticleId IdType="pmc">PMC6489113</ArticleId><ArticleId IdType="pubmed">30796111</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977&#x2013;986. doi:10.1056/NEJM199309303291401</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199309303291401</ArticleId><ArticleId IdType="pubmed">8366922</ArticleId></ArticleIdList></Reference><Reference><Citation>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet Lond Engl. 1998;352(9131):837&#x2013;853.</Citation><ArticleIdList><ArticleId IdType="pubmed">9742976</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman WH, Dungan KM, Wolffenbuttel BHR, et al. Racial and Ethnic Differences in Mean Plasma Glucose, Hemoglobin A1c, and 1,5-Anhydroglucitol in Over 2000 Patients with Type 2 Diabetes. J Clin Endocrinol Metab. 2009;94(5):1689&#x2013;1694. doi:10.1210/jc.2008-1940</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2008-1940</ArticleId><ArticleId IdType="pubmed">19276235</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan CL, McFann K, Newnes L, Nadeau KJ, Zeitler PS, Kelsey M. Hemoglobin A1c Assay Variations and Implications for Diabetes Screening in Obese Youth. Pediatr Diabetes. 2014;15(8):557&#x2013;563. doi:10.1111/pedi.12132</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pedi.12132</ArticleId><ArticleId IdType="pmc">PMC4167160</ArticleId><ArticleId IdType="pubmed">24636682</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31956997</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model?: A Validation Study Based on Prescribing Codeine in Children.</ArticleTitle><Pagination><StartPage>915</StartPage><EndPage>925</EndPage><MedlinePgn>915-925</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.1785</ELocationID><Abstract><AbstractText>Exploring and combining results from more than one real-world data (RWD) source might be necessary in order to explore variability and demonstrate generalizability of the results or for regulatory requirements. However, the heterogeneous nature of RWD poses challenges when working with more than one source, some of which can be solved by analyzing databases converted into a common data model (CDM). The main objective of the study was to evaluate the implementation of the Observational Medical Outcome Partnership (OMOP) CDM on IQVIA Medical Research Data (IMRD)-UK data. A drug utilization study describing the prescribing of codeine for pain in children was used as a case study to be replicated in IMRD-UK and its corresponding OMOP CDM transformation. Differences between IMRD-UK source and OMOP CDM were identified and investigated. In IMRD-UK updated to May 2017, results were similar between source and transformed data with few discrepancies. These were the result of different conventions applied during the transformation regarding the date of birth for children younger than 15&#xa0;years and the start of the observation period, and of a misclassification of two drug treatments. After the initial analysis and feedback provided, a rerun of the analysis in IMRD-UK updated to September 2018 showed almost identical results for all the measures analyzed. For this study, the conversion to OMOP CDM was adequate. Although some decisions and mapping could be improved, these impacted on the absolute results but not on the study inferences. This validation study supports six recommendations for good practice in transforming to CDMs.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Candore</LastName><ForeName>Gianmario</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Business Data Department, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hedenmalm</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Business Data Department, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slattery</LastName><ForeName>Jim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharmacovigilance and Epidemiology Department, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cave</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmacovigilance and Epidemiology Department, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurz</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Pharmacovigilance and Epidemiology Department, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arlett</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pharmacovigilance and Epidemiology Department, European Medicines Agency, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical><Chemical><RegistryNumber>UX6OWY2V7J</RegistryNumber><NameOfSubstance UI="D003061">Codeine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003061" MajorTopicYN="N">Codeine</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079803" MajorTopicYN="N">Data Management</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>All authors declared no competing interests for this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31956997</ArticleId><ArticleId IdType="pmc">PMC7158210</ArticleId><ArticleId IdType="doi">10.1002/cpt.1785</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cave, A. , Kurz, X. &amp; Arlett, P. Real&#x2010;world data for regulatory decision making: challenges and possible solutions for Europe. Clin. Pharmacol. Ther. 106, 36&#x2013;39 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6617710</ArticleId><ArticleId IdType="pubmed">30970161</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)
. Chapter 4: approaches to data collection In ENCePP Guide on Methodological Standards in Pharmacoepidemiology. European Medicines Agency;  &lt;http://www.encepp.eu/standards_and_guidances/methodologicalGuide4.shtml&gt; Accessed August 26, 2019.</Citation></Reference><Reference><Citation>
European Commission
. Guideline on the format and content of applications for designation as orphan medicinal products and on the transfer of designations from one sponsor to another, 27.03.2014. Belgium: European Commission Health and Consumers Directorate&#x2010;General;  &lt;https://ec.europa.eu/health//sites/health/files/files/orphanmp/2014-03_guideline_rev4_final.pdf&gt; (2014).</Citation></Reference><Reference><Citation>
European Medicines Agency
. Orphan designation: Overview &lt;https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview&gt;.</Citation></Reference><Reference><Citation>Zhou, X. et al An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Saf. 36, 119&#x2013;134 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage, J.M. , Ryan, P.B. , Reich, C.G. , Hartzema, A.G. &amp; Stang, P.E. Validation of a common data model for active safety surveillance research. J. Am. Med. Inform. Assoc. 19, 54&#x2013;60 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, Y. et al A comparative assessment of observational medical outcomes partnership and mini&#x2010;sentinel common data models and analytics: implications for active drug safety surveillance. Drug Saf. 38, 749&#x2013;765 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26055920</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt, R.W. , Platt, R. , Brown, J.S. , Henry, D.A. , Klungel, O.H. &amp; Suissa, S. How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. Pharmacoepidemiol. Drug Saf. 29, 3&#x2013;7 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30648307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak, G. et al Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Studies Health Technol. Inform. 216, 574&#x2013;548 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI)
. Observational health data sciences and informatics &lt;https://www.ohdsi.org/&gt;.</Citation></Reference><Reference><Citation>Ball, R. , Robb, M. , Anderson, S.A. &amp; Dal Pan, G. The FDA's sentinel initiative&#x2013;a comprehensive approach to medical product surveillance. Clin. Pharmacol. Ther. 99, 265&#x2013;268 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26667601</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss, S. , Brown, J.S. , Bate, A. , Trifiro, G. &amp; Bartels, D.B. Choosing among common data models for real&#x2010;world data analyses fit for making decisions about the effectiveness of medical products. Clin. Pharmacol. Ther. 107: 827&#x2013;833 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31330042</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho, A. , Ryan, P. , Fife, D. &amp; Reich, C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. 37, 945&#x2013;959 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss, E.A. et al Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J. Am. Med. Inform. Assoc. 22, 553&#x2013;564 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberson, A. , Rinner, C. &amp; Gall, W. Standardizing Austrians claims data using the OMOP common data model: a feasibility study. Stud. Health Technol. Inform. 258, 151&#x2013;152 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30942734</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberson, A. , Rinner, C. , Schoberl, A. &amp; Gall, W. Feasibility of mapping Austrian health claims data to the OMOP common data model. J. Med. Syst. 43, 314 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6732152</ArticleId><ArticleId IdType="pubmed">31494719</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima, D.M. , Rodrigues, J.F. Jr , Traina, A.J.M. , Pires, F.A. &amp; Gutierrez, M.A. Transforming two decades of ePR data to OMOP CDM for clinical research. Stud. Health Technol. Inform. 264, 233&#x2013;237 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31437920</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier, C. et al Towards implementation of OMOP in a German University Hospital Consortium. Appl. Clin. Inform. 9, 54&#x2013;61 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia, R. &amp; Ryan, P.B. Transforming the premier perspective hospital database into the Observational Medical Outcomes Partnership (OMOP) common data model. EGEMS 2, 1110 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon, D. et al Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthcare Inform. Res. 22, 54&#x2013;58 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>You, S.C. et al Conversion of National Health Insurance Service&#x2010;National Sample Cohort (NHIS&#x2010;NSC) Database into Observational Medical Outcomes Partnership&#x2010;Common Data Model (OMOP&#x2010;CDM). Stud. Health Technol. Inform. 245, 467&#x2013;470 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnbeek, P.R. Converting to a common data model: what is lost in translation?: Commentary on "fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model". Drug Saf. 37, 893&#x2013;896 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25187018</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency (EMA)/350259/2013
. PRAC recommends restricting the use of codeine when used for pain relief in children London, United Kingdom &lt;http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Codeine_containing_medicinal_products/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500144445.pdf&gt; (2013).</Citation></Reference><Reference><Citation>
European Medicines Agency
. Restrictions on use of codeine for pain relief in children &#x2013; CMDh endorses PRAC recommendation London, United Kingdom &lt;http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001829.jsp%26mxml:id=WC0b01ac058004d5c1&gt; (2013).</Citation></Reference><Reference><Citation>European Medicines Agency (EMA)/H/A&#x2010;31/1342
. Assessment report for codeine&#x2010;containing medicinal products indicated in the management of pain in children 2013 [updated June 24, 2013. 1&#x2013;18] &lt;http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Codeine_containing_medicinal_products/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500147065.pdf&gt;.</Citation></Reference><Reference><Citation>Hedenmalm, K. et al A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. Pharmacoepidemiol. Drug Saf. 28, 1086&#x2013;1096 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6771637</ArticleId><ArticleId IdType="pubmed">31219227</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher, H. , Kostev, K. &amp; Schroder&#x2010;Bernhardi, D. Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int. J. Clin. Pharmacol. Ther. 47, 617&#x2013;626 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19825325</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvador Rosa, A. , Moreno Perez, J.C. , Sonego, D. , Garcia Rodriguez, L.A. &amp; de Abajo Iglesias, F.J. The BIFAP project: database for pharmaco&#x2010;epidemiological research in primary care. Aten. Primaria 30, 655&#x2013;661 (2002).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7679749</ArticleId><ArticleId IdType="pubmed">12525343</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett, E. et al Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int. J. Epidemiol. 44, 827&#x2013;836 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Blak, B.T. , Thompson, M. , Dattani, H. &amp; Bourke, A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Informatics Primary Care 19, 251&#x2013;255 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22828580</ArticleId></ArticleIdList></Reference><Reference><Citation>
OHDSI/CommonDataModel
&lt;https://github.com/OHDSI/CommonDataModel/wiki&gt;.</Citation></Reference><Reference><Citation>IQVIA . THIN Research Format Data Guide. Version 1809 (IQVIA, London, UK, 2018).</Citation></Reference><Reference><Citation>Kim, H.J. , Fay, M.P. , Feuer, E.J. &amp; Midthune, D.N. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19, 335&#x2013;351 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10649300</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Cancer Institute
. Joinpoint Regression Program, version 4.5.0.1 &#x2013; June 2017 &lt;https://surveillance.cancer.gov/joinpoint/&gt; (2017).</Citation></Reference><Reference><Citation>Fay, M.P. , Tiwari, R.C. , Feuer, E.J. &amp; Zou, Z. Estimating average annual percent change for disease rates without assuming constant change. Biometrics 62, 847&#x2013;854 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16984328</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales, D.R. , Slattery, J. , Pacurariu, A. , Pinheiro, L. , McGettigan, P. &amp; Kurz, X. Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone/corticosteroid therapy: population&#x2010;based nested case&#x2010;control study. Clin. Drug Investig. 39, 205&#x2013;213 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6394638</ArticleId><ArticleId IdType="pubmed">30465300</ArticleId></ArticleIdList></Reference><Reference><Citation>

Tranchard, S
. Revised IDMP standards to improve description of medicinal products worldwide &lt;https://www.iso.org/news/ref2234.html&gt; (2017).</Citation></Reference><Reference><Citation>Schneeweiss, S. &amp; Glynn, R.J. Real&#x2010;world data analytics fit for regulatory decision&#x2010;making. Am. J. Law Med. 44, 197&#x2013;217 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30106649</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbonari, D.M. et al Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Pharmacoepidemiol. Drug Saf. 24, 999&#x2013;1003 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26213344</ArticleId></ArticleIdList></Reference><Reference><Citation>Cave, A. Opportunities for 'big data' in medicines development and regulatory science. 34th International Conference of Pharmacoepidemiology &amp; Therapeutic Risk Management, Prague, Czech Republic, August 24, 2018.</Citation></Reference><Reference><Citation>
European Medicines Agency (EMA)/614680/2018
. A common data model for Europe? Why? Which? How? &lt;https://www.ema.europa.eu/en/documents/report/common-data-model-europe-why-which-how-workshop-report_en.pdf&gt; (2018).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31970824</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1746</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of gastroenterology and hepatology</Title><ISOAbbreviation>J Gastroenterol Hepatol</ISOAbbreviation></Journal><ArticleTitle>Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.</ArticleTitle><Pagination><StartPage>1325</StartPage><EndPage>1330</EndPage><MedlinePgn>1325-1330</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jgh.14983</ELocationID><Abstract><AbstractText Label="BACKGROUNDS AND AIM" NlmCategory="OBJECTIVE">There are potential concerns regarding infectious complications including Clostridium difficile infections (CDIs) among patients taking gastric acid suppressants. Furthermore, it is speculated that the stronger acid suppression by proton pump inhibitors (PPIs) potentially enhance infectious complications. This study aimed to compare the risk of CDI between PPIs and histamine-2 receptor antagonists (H2RAs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using the long-term database of the Kangdong Sacred Heart Hospital, converted to the Observational Medical Outcomes Partnership Common Data Model, we identified outpatients treated with PPIs and H2RAs for &#x2265;&#xa0;7&#xa0;days from January 1, 2004 through December 31, 2018. We conducted Cox regression analysis to examine the hazard ratio (HR) of CDI after propensity score matching.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During a median follow-up period of 1.2&#xa0;years (interquartile range, 0.2-3.2&#xa0;years), the initial CDI occurrence differed significantly between matched cohorts of patients taking PPIs and H2RAs [PPIs vs H2RAs, 88/31&#xa0;095 person years vs 47/32&#xa0;836 person years; HR, 2.22; 95% confidence interval (CI) 1.29-3.96; P&#xa0;=&#xa0;0.005]. Almost 50% of all events occurred within 1&#xa0;year of drug exposure. The risk of CDIs was significantly greater among groups receiving PPIs or H2RAs than in matched controls (PPIs vs control: HR, 2.65; 95% CI 1.28-5.79; P&#xa0;=&#xa0;0.011; and H2RAs vs control: HR 2.43; 95% CI 1.09-5.68; P&#xa0;=&#xa0;0.034].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In long-term hospital cohort, outpatient-based PPIs were associated with greater risk of CDI than H2RAs. It is necessary to be cautioned about complication of CDI in patients taking long-term PPI therapy.</AbstractText><CopyrightInformation>&#xa9; 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Seung In</ForeName><Initials>SI</Initials><Identifier Source="ORCID">0000-0003-4417-0135</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Chan Hyuk</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae Joon</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>You Sang</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yerim</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Jong Jin</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinseob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, Seoul National University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Woon Geon</ForeName><Initials>WG</Initials><Identifier Source="ORCID">0000-0002-9851-5576</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Liver and Digestive Diseases, Hallym University, Chuncheon, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HI19C0143</GrantID><Agency>Ministry of Health &amp; Welfare, Republic of Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>J Gastroenterol Hepatol</MedlineTA><NlmUniqueID>8607909</NlmUniqueID><ISSNLinking>0815-9319</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006635">Histamine H2 Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003015" MajorTopicYN="N">Clostridium Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078332" MajorTopicYN="N">Data Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006635" MajorTopicYN="N">Histamine H2 Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="N">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clostridium difficile infections</Keyword><Keyword MajorTopicYN="N">complications</Keyword><Keyword MajorTopicYN="N">histamine-2 receptor antagonists</Keyword><Keyword MajorTopicYN="N">hospital-based cohort</Keyword><Keyword MajorTopicYN="N">proton pump inhibitors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31970824</ArticleId><ArticleId IdType="doi">10.1111/jgh.14983</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Savarino V, Tosetti C, Benedetto E, Compare D, Nardone G. Appropriateness in prescribing PPIs: a position paper of the Italian Society of Gastroenterology (SIGE)-study section &#x201c;Digestive Diseases in Primary Care&#x201d;. Dig. Liver Dis. 2018; 50: 894-902.</Citation></Reference><Reference><Citation>Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat. Rev. Gastroenterol. Hepatol. 2017; 14: 697-710.</Citation></Reference><Reference><Citation>Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 2017; 153: 35-48.</Citation></Reference><Reference><Citation>Lessa FC, Mu Y, Bamberg WM et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 2015; 372: 825-834.</Citation></Reference><Reference><Citation>Gerding DN, Lessa FC. The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect. Dis. Clin. North Am. 2015; 29: 37-50.</Citation></Reference><Reference><Citation>Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 2005; 353: 2442-2449.</Citation></Reference><Reference><Citation>Reveles KR, Lawson KA, Mortensen EM et al. National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014. PLoS ONE 2017; 12: e0189227.</Citation></Reference><Reference><Citation>Yang BK, Do BJ, Kim EJ et al. The simple predictors of pseudomembranous colitis in patients with hospital-acquired diarrhea: a prospective observational study. Gut Liver 2014; 8: 41-48.</Citation></Reference><Reference><Citation>Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J. Clin. Gastroenterol. 2012; 46: 397-400.</Citation></Reference><Reference><Citation>Buendgens L, Bruensing J, Matthes M et al. Administration of proton pump inhibitors in critically ill medical patients is associated with increased risk of developing Clostridium difficile-associated diarrhea. J. Crit. Care 2014; 29 696.e11-5.</Citation></Reference><Reference><Citation>Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton pump inhibitors do not increase risk for Clostridium difficile infection in the intensive care unit. Am. J. Gastroenterol. 2016; 111: 1641-1648.</Citation></Reference><Reference><Citation>Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous? Dig. Liver Dis. 2016; 48: 851-859.</Citation></Reference><Reference><Citation>Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am. J. Gastroenterol. 2012; 107: 1001-1010.</Citation></Reference><Reference><Citation>Moayyedi P, Eikelboom JW, Bosch J et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2019; 157: 682-691.e2.</Citation></Reference><Reference><Citation>Gordon D, Young LR, Reddy S, Bergman C, Young JD. Incidence of Clostridium difficile infection in patients receiving high-risk antibiotics with or without a proton pump inhibitor. J. Hosp. Infect. 2016; 92: 173-177.</Citation></Reference><Reference><Citation>Park YH, Seong JM, Cho S et al. Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study. J. Gastroenterol. 2019.</Citation></Reference><Reference><Citation>Trifan A, Stanciu C, Girleanu I et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J. Gastroenterol. 2017; 23: 6500-6515.</Citation></Reference><Reference><Citation>Azab M, Doo L, Doo DH et al. Comparison of the hospital-acquired Clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: a systematic review and meta-analysis. Gut Lliver 2017; 11: 781-788.</Citation></Reference><Reference><Citation>Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterol. 2012; 107: 1011-1019.</Citation></Reference><Reference><Citation>MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern. Med. 2014; 174: 564-574.</Citation></Reference><Reference><Citation>Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-2995.</Citation></Reference><Reference><Citation>Dubberke ER, Reske KA, Olsen MA et al. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease. Arch. Intern. Med. 2007; 167: 1092-1097.</Citation></Reference><Reference><Citation>Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ. Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Aliment. Pharmacol. Ther. 2009; 29: 626-634.</Citation></Reference><Reference><Citation>Howell MD, Novack V, Grgurich P et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch. Intern. Med. 2010; 170: 784-790.</Citation></Reference><Reference><Citation>Yoon D, Ahn EK, Park MY et al. Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016; 22: 54-58.</Citation></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) Common Data Model. EGEMS (Washington, DC) 2014; 2: 1110.</Citation></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet (London, England) 2019; 394: 1816-1826.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud. Health Technol. Inform. 2015; 216: 574-578.</Citation></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A et al. Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the observational health data sciences and informatics initiative. JAMA Netw. Open 2018; 1: e181755.</Citation></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J. Am. Med. Inform. Assoc. 2015; 22: 553-564.</Citation></Reference><Reference><Citation>You SC, Lee S, Cho SY et al. Conversion of National Health Insurance Service-National Sample Cohort (NHIS-NSC) Database into Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM). Stud. Health Technol. Inform. 2017; 245: 467-470.</Citation></Reference><Reference><Citation>Imhann F, Bonder MJ, Vich Vila A et al. Proton pump inhibitors affect the gut microbiome. Gut 2016; 65: 740-748.</Citation></Reference><Reference><Citation>Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014; 2: 42.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32053653</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Wisdom of the CROUD:&#xa0; Development and validation of a patient-level prediction model for opioid use disorder using population-level claims data.</ArticleTitle><Pagination><StartPage>e0228632</StartPage><MedlinePgn>e0228632</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0228632</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0228632</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Some patients who are given opioids for pain could develop opioid use disorder. If it was possible to identify patients who are at a higher risk of opioid use disorder, then clinicians could spend more time educating these patients about the risks. We develop and validate a model to predict a person's future risk of opioid use disorder at the point before being dispensed their first opioid.</AbstractText><AbstractText Label="METHODS">A cohort study patient-level prediction using four US claims databases with target populations ranging between 343,552 and 384,424 patients. The outcome was recorded diagnosis of opioid abuse, dependency or unspecified drug abuse as a proxy for opioid use disorder from 1 day until 365 days after the first opioid is dispensed. We trained a regularized logistic regression using candidate predictors consisting of demographics and any conditions, drugs, procedures or visits prior to the first opioid. We then selected the top predictors and created a simple 8 variable score model.</AbstractText><AbstractText Label="RESULTS">We estimated the percentage of new users of opioids with reported opioid use disorder within a year to range between 0.04%-0.26% across US claims data. We developed an 8 variable Calculator of Risk for Opioid Use Disorder (CROUD) score, derived from the prediction models to stratify patients into higher and lower risk groups. The 8 baseline variables were age 15-29, medical history of substance abuse, mood disorder, anxiety disorder, low back pain, renal impairment, painful neuropathy and recent ER visit. 1.8% of people were in the high risk group for opioid use disorder and had a score &gt; = 23 with the model obtaining a sensitivity of 13%, specificity of 98% and PPV of 1.14% for predicting opioid use disorder.</AbstractText><AbstractText Label="CONCLUSIONS">CROUD could be used by clinicians to obtain personalized risk scores. CROUD could be used to further educate those at higher risk and to personalize new opioid dispensing guidelines such as urine testing. Due to the high false positive rate, it should not be used for contraindication or to restrict utilization.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna Marie</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development Titusville, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cepeda</LastName><ForeName>M Soledad</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Janssen Research and Development Titusville, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development Titusville, Titusville, NJ, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C564945">Neuropathy, Painful</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059350" MajorTopicYN="N">Chronic Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="N">Drug Prescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008487" MajorTopicYN="N">Medical History Taking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009293" MajorTopicYN="N">Opioid-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010523" MajorTopicYN="N">Peripheral Nervous System Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors are employees of and receive salary from Janssen Research &amp; Development, an affiliate of Janssen Pharmaceuticals Inc., which markets several analgesic drug products including opioids. This does not alter our adherence to PLOS ONE policies on sharing data and materials</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32053653</ArticleId><ArticleId IdType="pmc">PMC7017997</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0228632</ArticleId><ArticleId IdType="pii">PONE-D-19-11692</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hakkinen M, Vuori E, Ojanpera I. Prescription opioid abuse based on representative postmortem toxicology. Forensic Sci Int. 2014;245:121&#x2013;125. 10.1016/j.forsciint.2014.10.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.forsciint.2014.10.028</ArticleId><ArticleId IdType="pubmed">25447184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes A, Williams M, Lipari R, Bose J, Copello E, Kroutil L. Prescription drug use and misuse in the United States: Results from the 2015 National Survey on Drug Use and Health. NSDUH Data Review. 2016.</Citation></Reference><Reference><Citation>Heron M. Deaths: Leading causes for 2015 [USA]. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2017;66(5):1&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">29235984</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudd RA, Aleshire N, Zibbell JE, Matthew Gladden R. Increases in drug and opioid overdose deaths United States, 2000&#x2013;2014. Am J Transplant. 2016;16(4):1323&#x2013;1327.</Citation></Reference><Reference><Citation>Scholl L, Seth P, Kariisa M. Wilson N and Baldwin G, Drug and opioid-involved overdose deaths&#x2014;United States, 2013&#x2013;2017. Morbidity and Mortality Weekly Report, 2019;67(5152): 1419&#x2013;1427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6334822</ArticleId><ArticleId IdType="pubmed">30605448</ArticleId></ArticleIdList></Reference><Reference><Citation>White AG, Birnbaum HG, Schiller M, Tang J, Katz NP. Analytic models to identify patients at risk for prescription opioid abuse. Am J Manag Care. 2009;15(12):897&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pubmed">20001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Edlund MJ, Martin BC, Fan MY, Devries A, Braden JB, Sullivan MD. Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend. 2010;112(1):90&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967631</ArticleId><ArticleId IdType="pubmed">20634006</ArticleId></ArticleIdList></Reference><Reference><Citation>Exchange P. Understanding predictors of opioid abuse: predictive model development and validation. Am J Pharm. 2014;6(5):208&#x2013;216.</Citation></Reference><Reference><Citation>Ciesielski T, Iyengar R, Bothra A, Tomala D, Cislo G, Gage BF. A tool to assess risk of de novo opioid abuse or dependence. Am J Med. 2016;129(7):699&#x2013;705. 10.1016/j.amjmed.2016.02.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2016.02.014</ArticleId><ArticleId IdType="pmc">PMC5076552</ArticleId><ArticleId IdType="pubmed">26968469</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal H, Singla U, Grimsley EW. Identification of Opioid Abuse or Dependence: No Tool Is Perfect. Am J Med. 2017;130(3):e113 10.1016/j.amjmed.2016.09.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2016.09.022</ArticleId><ArticleId IdType="pubmed">28215952</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2011;19(1):54&#x2013;60. 10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(3):553&#x2013;564. 10.1093/jamia/ocu023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci USA. 2016;113(27):7329&#x2013;7336. 10.1073/pnas.1510502113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>IBM Watson Health, 2019. IBM MarketScan Research Databases for Heath Services Researchers. Date Accessed: 2019-08-07. &lt;https://www.ibm.com/downloads/cas/6KNYVVQ2&gt;</Citation></Reference><Reference><Citation>OPTUM, 2019. Real-World Data. Date Accessed: 2019-08-07. &lt;https://www.optum.com/solutions/life-sciences/explore-data/real-world.html&gt;</Citation></Reference><Reference><Citation>Reps J.M., Schuemie M.J., Suchard M.A., Ryan P.B. and Rijnbeek P.R. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018; 25(8):969&#x2013;975. 10.1093/jamia/ocy032</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy032</ArticleId><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M. A. and Simpson S. E. and Zorych I. and Ryan P. and Madigan D. Massive parallelization of serial inference algorithms for complex generalized linear models. ACM Transactions on Modeling and Computer Simulation.2013;23:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier L., Van De Geer S and B&#xfc;hlmann P. The group lasso for logistic regression. J R Stat Soc Series B Stat Methodol. 2008;70(1):53&#x2013;71.</Citation></Reference><Reference><Citation>CDC, 2019. Guideline for prescribing opioids for chronic pain. Date accessed 2019-08-07. &lt;https://www.cdc.gov/drugoverdose/pdf/Guidelines_Factsheet-a.pdf&gt;</Citation></Reference><Reference><Citation>FDA, 2018. FDA educational blueprint for health care providers involved in the treatment and monitoring of patients with pain. Date accessed: 2019-08-07. &lt;https://www.fda.gov/media/99496/download&gt;</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32065600</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>180</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension.</ArticleTitle><Pagination><StartPage>542</StartPage><EndPage>551</EndPage><MedlinePgn>542-551</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2019.7454</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Chlorthalidone is currently recommended as the preferred thiazide diuretic to treat hypertension, but no trials have directly compared risks and benefits.</AbstractText><AbstractText Label="OBJECTIVE">To compare the effectiveness and safety of chlorthalidone and hydrochlorothiazide as first-line therapies for hypertension in real-world practice.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This is a Large-Scale Evidence Generation and Evaluation in a Network of Databases (LEGEND) observational comparative cohort study with large-scale propensity score stratification and negative-control and synthetic positive-control calibration on databases spanning January 2001 through December 2018. Outpatient and inpatient care episodes of first-time users of antihypertensive monotherapy in the United States based on 2 administrative claims databases and 1 collection of electronic health records were analyzed. Analysis began June 2018.</AbstractText><AbstractText Label="EXPOSURES">Chlorthalidone and hydrochlorothiazide.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcomes were acute myocardial infarction, hospitalization for heart failure, ischemic or hemorrhagic stroke, and a composite cardiovascular disease outcome including the first 3 outcomes and sudden cardiac death. Fifty-one safety outcomes were measured.</AbstractText><AbstractText Label="RESULTS">Of 730&#x202f;225 individuals (mean [SD] age, 51.5 [13.3] years; 450&#x202f;100 women [61.6%]), 36&#x202f;918 were dispensed or prescribed chlorthalidone and had 149 composite outcome events, and 693&#x202f;337 were dispensed or prescribed hydrochlorothiazide and had 3089 composite outcome events. No significant difference was found in the associated risk of myocardial infarction, hospitalized heart failure, or stroke, with a calibrated hazard ratio for the composite cardiovascular outcome of 1.00 for chlorthalidone compared with hydrochlorothiazide (95% CI, 0.85-1.17). Chlorthalidone was associated with a significantly higher risk of hypokalemia (hazard ratio [HR], 2.72; 95% CI, 2.38-3.12), hyponatremia (HR, 1.31; 95% CI, 1.16-1.47), acute renal failure (HR, 1.37; 95% CI, 1.15-1.63), chronic kidney disease (HR, 1.24; 95% CI, 1.09-1.42), and type 2 diabetes mellitus (HR, 1.21; 95% CI, 1.12-1.30). Chlorthalidone was associated with a significantly lower risk of diagnosed abnormal weight gain (HR, 0.73; 95% CI, 0.61-0.86).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This study found that chlorthalidone use was not associated with significant cardiovascular benefits when compared with hydrochlorothiazide, while its use was associated with greater risk of renal and electrolyte abnormalities. These findings do not support current recommendations to prefer chlorthalidone vs hydrochlorothiazide for hypertension treatment in first-time users was found. We used advanced methods, sensitivity analyses, and diagnostics, but given the possibility of residual confounding and the limited length of observation periods, further study is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, NewYork-Presbyterian Hospital, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fielding School of Public Health, Department of Biostatistics, University of California, Los Angeles, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>David Geffen School of Medicine, Department of Biomathematics, University of California, Los Angeles, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shea</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>RuiJun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medical College, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fielding School of Public Health, Department of Biostatistics, University of California, Los Angeles, Los Angeles.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI135995</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0J48LPH2TH</RegistryNumber><NameOfSubstance UI="D006852">Hydrochlorothiazide</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q0MQD1073Q</RegistryNumber><NameOfSubstance UI="D002752">Chlorthalidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2020 Aug 1;180(8):1133</RefSource><PMID Version="1">32568361</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2020 Aug 1;180(8):1133-1134</RefSource><PMID Version="1">32568364</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2020 Aug 1;180(8):1132-1133</RefSource><PMID Version="1">32568375</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002752" MajorTopicYN="N">Chlorthalidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006852" MajorTopicYN="N">Hydrochlorothiazide</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Hripcsak reports grants from the National Library of Medicine during the conduct of the study and grants from Janssen Research outside the submitted work. Dr Suchard reports grants from the National Science Foundation and the National Institutes of Health during the conduct of the study and grants from Janssen Research and Development outside the submitted work. Dr Shea reports grants from the National Heart, Lung, and Blood Institute and the US Health Resources and Services Administration not directly relevant to the published work. Dr Madigan reports personal fees from Simon Greenstone Panatier; Williams Hart; Lanier Law Firm; Kazan, McClain, Satterley &amp; Greenwood; Shire; and Bayer outside the submitted work. Dr Krumholz reports personal fees from UnitedHealth, IBM Watson Health, Element Science, Aetna, Facebook, Siegfried &amp; Jenson Law Firm, Arnold &amp; Porter Law Firm, Ben C. Martin Law Firm, and the National Center for Cardiovascular Diseases (Beijing); cofounder of Hugo Health and Refactor Health; contracts with US Centers for Medicare &amp; Medicaid Services; and grants from Medtronic/US Food and Drug Administration, Medtronic/Johnson &amp; Johnson, and Shenzhen Center for Health Information outside the submitted work. Dr Ryan is an employee of Janssen Research and Development and shareholder of Johnson &amp; Johnson during the conduct of the study. Dr Schuemie is an employee and shareholder of Janssen Research and Development outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32065600</ArticleId><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2019.7454</ArticleId><ArticleId IdType="pii">2760777</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Whelton PK, Carey RM, Aronow WS, et al. . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task force on clinical practice guidelines. Hypertension. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYP.0000000000000066</ArticleId><ArticleId IdType="pubmed">29133354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederle FA, Cushman WC, Ferguson RE, Brophy MT, Fiore Md LD. Chlorthalidone Versus hydrochlorothiazide: a new kind of Veterans Affairs cooperative study. Ann Intern Med. 2016;165(9):663-664. doi:10.7326/M16-1208</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M16-1208</ArticleId><ArticleId IdType="pubmed">27538129</ArticleId></ArticleIdList></Reference><Reference><Citation>Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension. 2015;65(5):1033-1040. doi:10.1161/HYPERTENSIONAHA.114.05122</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.114.05122</ArticleId><ArticleId IdType="pubmed">25733241</ArticleId></ArticleIdList></Reference><Reference><Citation>Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59(6):1110-1117. doi:10.1161/HYPERTENSIONAHA.112.191106</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.112.191106</ArticleId><ArticleId IdType="pubmed">22526259</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhalla IA, Gomes T, Yao Z, et al. . Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med. 2013;158(6):447-455. doi:10.7326/0003-4819-158-6-201303190-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-158-6-201303190-00004</ArticleId><ArticleId IdType="pubmed">23552325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst ME, Carter BL, Goerdt CJ, et al. . Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352-358. doi:10.1161/01.HYP.0000203309.07140.d3</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000203309.07140.d3</ArticleId><ArticleId IdType="pubmed">16432050</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakris GL, Sica D, White WB, et al. . Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125(12):1229.e1-1229.e10. doi:10.1016/j.amjmed.2012.05.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2012.05.023</ArticleId><ArticleId IdType="pubmed">22939358</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47(6):2005-2014. doi:10.1093/ije/dyy120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci USA. 2018;115(11):2571-2577. doi:10.1073/pnas.1708282114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383-388. doi:10.1097/EDE.0b013e3181d61eeb</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181d61eeb</ArticleId><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci. 2018;376(2128):20170356. doi:10.1098/rsta.2017.0356</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574-578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. . Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816-1826. doi:10.1016/S0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(suppl 1):S59-S72. doi:10.1007/s40264-013-0099-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0099-6</ArticleId><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19(1):54-60. doi:10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758-764. doi:10.1093/aje/kwv254</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwv254</ArticleId><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-1251. doi:10.1016/0895-4356(94)90129-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-4356(94)90129-5</ArticleId><ArticleId IdType="pubmed">7722560</ArticleId></ArticleIdList></Reference><Reference><Citation>GitHub. OHDSI/CohortMethod: New-user cohort method with large scale propensity and outcome models. https://github.com/OHDSI/CohortMethod. Accessed January 13, 2020.</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23(1):10. doi:10.1145/2414416.2414791</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55. doi:10.1093/biomet/70.1.41</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/70.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AM, Patrick AR, Lauer MS, et al. . A tool for assessing the feasibility of comparative effectiveness research. Comp Effectiveness Res. 2013;3:11-20. doi:10.2147/CER.S40357</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CER.S40357</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2017;66:72-81. doi:10.1016/j.jbi.2016.12.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.12.005</ArticleId><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4: effects of various classes of antihypertensive drugs&#x2013;overview and meta-analyses. J Hypertens. 2015;33(2):195-211. doi:10.1097/HJH.0000000000000447</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000000447</ArticleId><ArticleId IdType="pubmed">25485720</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, et al. ; Task Force Members . 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. doi:10.1097/HJH.0000000000001940</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000001940</ArticleId><ArticleId IdType="pubmed">30234752</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57(4):689-694. doi:10.1161/HYPERTENSIONAHA.110.161505</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.110.161505</ArticleId><ArticleId IdType="pubmed">21383313</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen JP, Fleurence R, Devine B, et al. . Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417-428. doi:10.1016/j.jval.2011.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2011.04.002</ArticleId><ArticleId IdType="pubmed">21669366</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43(1):4-9. doi:10.1161/01.HYP.0000103632.19915.0E</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000103632.19915.0E</ArticleId><ArticleId IdType="pubmed">14638621</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59(6):1104-1109. doi:10.1161/HYPERTENSIONAHA.111.190637</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.111.190637</ArticleId><ArticleId IdType="pmc">PMC4930655</ArticleId><ArticleId IdType="pubmed">22547443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst ME, Carter BL, Zheng S, Grimm RH Jr. Meta-analysis of dose-response characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens. 2010;23(4):440-446. doi:10.1038/ajh.2010.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajh.2010.1</ArticleId><ArticleId IdType="pubmed">20111008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst ME, Neaton JD, Grimm RH Jr, et al. ; Multiple Risk Factor Intervention Trial Research Group . Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension. 2011;58(6):1001-1007. doi:10.1161/HYPERTENSIONAHA.111.181248</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.111.181248</ArticleId><ArticleId IdType="pmc">PMC3245686</ArticleId><ArticleId IdType="pubmed">22025372</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32133717</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Empirical assessment of case-based methods for drug safety alert identification in the French National Healthcare System database (SNDS): Methodology of the ALCAPONE project.</ArticleTitle><Pagination><StartPage>993</StartPage><EndPage>1000</EndPage><MedlinePgn>993-1000</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.4983</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To introduce the methodology of the ALCAPONE project.</AbstractText><AbstractText Label="BACKGROUND">The French National Healthcare System Database (SNDS), covering 99% of the French population, provides a potentially valuable opportunity for drug safety alert generation. ALCAPONE aimed to assess empirically in the SNDS case-based designs for alert generation related to four health outcomes of interest.</AbstractText><AbstractText Label="METHODS">ALCAPONE used a reference set adapted from observational medical outcomes partnership (OMOP) and Exploring and Understanding Adverse Drug Reactions (EU-ADR) project, with four outcomes-acute liver injury (ALI), myocardial infarction (MI), acute kidney injury (AKI), and upper gastrointestinal bleeding (UGIB)-and positive and negative drug controls. ALCAPONE consisted of four main phases: (1) data preparation to fit the OMOP Common Data Model and select the drug controls; (2) detection of the selected controls via three case-based designs: case-population, case-control, and self-controlled case series, including design variants (varying risk window, adjustment strategy, etc.); (3) comparison of design variant performance (area under the ROC curve, mean square error, etc.); and (4) selection of the optimal design variants and their calibration for each outcome.</AbstractText><AbstractText Label="RESULTS">Over 2009-2014, 5225 cases of ALI, 354&#x2009;109 MI, 12&#x2009;633 AKI, and 156&#x2009;057 UGIB were identified using specific definitions. The number of detectable drugs ranged from 61 for MI to 25 for ALI. Design variants generated more than 50&#x2009;000 points estimates. Results by outcome will be published in forthcoming papers.</AbstractText><AbstractText Label="CONCLUSIONS">ALCAPONE has shown the interest of the empirical assessment of pharmacoepidemiological approaches for drug safety alert generation and may encourage other researchers to do the same in other databases.</AbstractText><CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thurin</LastName><ForeName>Nicolas H</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0003-3589-0819</Identifier><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1219, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lassalle</LastName><ForeName>R&#xe9;gis</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;nichon</LastName><ForeName>Marine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagne</LastName><ForeName>Joshua J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rassen</LastName><ForeName>Jeremy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Aetion, Inc., New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benichou</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1181, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weill</LastName><ForeName>Alain</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8687-9092</Identifier><AffiliationInfo><Affiliation>Caisse Nationale de l'Assurance Maladie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blin</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1212-2817</Identifier><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1219, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Droz-Perroteau</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057225" MajorTopicYN="N">Data Mining</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009313" MajorTopicYN="N">National Health Programs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017891" MajorTopicYN="N">Pharmacoepidemiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="Y">Pharmacovigilance</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SNDS</Keyword><Keyword MajorTopicYN="N">calibration</Keyword><Keyword MajorTopicYN="N">case-population</Keyword><Keyword MajorTopicYN="N">claims database</Keyword><Keyword MajorTopicYN="N">method assessment</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32133717</ArticleId><ArticleId IdType="doi">10.1002/pds.4983</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Moore N. The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist. Eur J Clin Pharmacol. 2013;69(Suppl 1):33-41.</Citation></Reference><Reference><Citation>Trifiro G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18:1176-1184.</Citation></Reference><Reference><Citation>Trifiro G, Fourrier-Reglat A, Sturkenboom MC, Diaz Acedo C, Van Der Lei J, Group E-A. The EU-ADR project: preliminary results and perspective. Stud Health Technol Inform. 2009;148:43-49.</Citation></Reference><Reference><Citation>Trifiro G, Patadia V, Schuemie MJ, et al. EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Stud Health Technol Inform. 2011;166:25-30.</Citation></Reference><Reference><Citation>DuMouchel W, Ryan PB, Schuemie MJ, Madigan D. Evaluation of disproportionality safety signaling applied to healthcare databases. Drug Saf. 2013;36(Suppl 1):S123-S132.</Citation></Reference><Reference><Citation>Madigan D, Schuemie MJ, Ryan PB. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S73-S82.</Citation></Reference><Reference><Citation>Noren GN, Bergvall T, Ryan PB, Juhlin K, Schuemie MJ, Madigan D. Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S107-S121.</Citation></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S59-S72.</Citation></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Madigan D. Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S95-S106.</Citation></Reference><Reference><Citation>Schuemie MJ, Madigan D, Ryan PB. Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S133-S142.</Citation></Reference><Reference><Citation>Suchard MA, Zorych I, Simpson SE, Schuemie MJ, Ryan PB, Madigan D. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S83-S93.</Citation></Reference><Reference><Citation>Ryan P, Stang P, Overhage J, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(Suppl 1):S143-S158.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574-578.</Citation></Reference><Reference><Citation>Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954-962.</Citation></Reference><Reference><Citation>Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013;36:135-144.</Citation></Reference><Reference><Citation>Moore N, Gulmez SE, Larrey D, et al. Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. Pharmacoepidemiol Drug Saf. 2013;22:160-167.</Citation></Reference><Reference><Citation>Theophile H, Laporte JR, Moore N, Martin KL, Begaud B. The case-population study design: an analysis of its application in pharmacovigilance. Drug Saf. 2011;34:861-868.</Citation></Reference><Reference><Citation>Moore N, Gulmez SE, Blin P, et al. Relative risks from case-population data. Epidemiology. 2013;24:935-936.</Citation></Reference><Reference><Citation>Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.</Citation></Reference><Reference><Citation>Abbing-Karahagopian V, Kurz X, de Vries F, et al. Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project. Curr Clin Pharmacol. 2014;9:130-138.</Citation></Reference><Reference><Citation>Castellsague J, Riera-Guardia N, Calingaert B, et al. Safety of non-steroidal anti-inflammatory drugs P. individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35:1127-1146.</Citation></Reference><Reference><Citation>Gulmez SE, Larrey D, Pageaux GP, et al. Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the study of acute liver transplant (SALT). Eur J Clin Pharmacol. 2013;69:605-616.</Citation></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(Suppl 1):S33-S47.</Citation></Reference><Reference><Citation>Coloma PM, Avillach P, Salvo F, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36:13-23.</Citation></Reference><Reference><Citation>Reich C, Ryan P, Schuemie MJ. Alternative outcome definitions and their effect on the performance of methods for observational outcome studies. Drug Saf. 2013;36(Suppl 1):S181-S193.</Citation></Reference><Reference><Citation>Duong M, Salvo F, Pariente A, et al. Usage patterns of 'over-the-counter&#x2019; vs. prescription-strength nonsteroidal anti-inflammatory drugs in France. Br J Clin Pharmacol. 2014;77:887-895.</Citation></Reference><Reference><Citation>Bezin J, Pariente A, Lassalle R, et al. Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France. Eur J Clin Pharmacol. 2014;70(4):429-436.</Citation></Reference><Reference><Citation>Rapsomaniki E, Thuresson M, Yang E, et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes. 2016;2(3):172-183.</Citation></Reference><Reference><Citation>Blin P, Dureau-Pournin C, Lassalle R, Abouelfath A, Droz-Perroteau C, Moore N. A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. Br J Clin Pharmacol. 2016;81:569-578.</Citation></Reference><Reference><Citation>Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: preliminary results from the EPIHAM study. Pharmacoepidemiol Drug Saf. 2018;27:1174-1181.</Citation></Reference><Reference><Citation>Moore N, Duret S, Grolleau A, et al. Previous drug exposure in patients hospitalised for acute liver injury: a case-population study in the French national healthcare data system. Drug Saf. 2019;42(4):559-572.</Citation></Reference><Reference><Citation>Armstrong B. A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies. Am J Epidemiol. 1987;126:356-358.</Citation></Reference><Reference><Citation>Whitaker H, Farrington C, Spiessens B, Musonda P. Tutorail in biostatistics: the self-controlled case series method. Stat Med. 2006;25:1768-1797.</Citation></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33:209-218.</Citation></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust empirical calibration of p-values using observational data. Stat Med. 2016;35:3883-3888.</Citation></Reference><Reference><Citation>Gruber S, Tchetgen Tchetgen E. Limitations of empirical calibration of p-values using observational data. Stat Med. 2016;35:3869-3882.</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. The Book of OHDSI; 2019.</Citation></Reference><Reference><Citation>Schuemie M, Soledad C, Suchard M, Tian Y, Schuler A, Ryan P, Hripcsak G. Empirical evaluation of the OHDSI methods library. OHDSI Symposium 2017. https://www.ohdsi.org/past-events/2017-ohdsi-symposium-materials/.</Citation></Reference><Reference><Citation>Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol. 1976;103:226-235.</Citation></Reference><Reference><Citation>Miettinen OS. Estimation of relative risk from individually matched series. Biometrics. 1970;26:75-86.</Citation></Reference><Reference><Citation>Schneeweiss S, Suissa S. Discussion of Schuemie et al: "a plea to stop using the case-control design in retrospective database studies". Stat Med. 2019;38:4209-4212.</Citation></Reference><Reference><Citation>Ibanez L, Ballarin E, Vidal X, Laporte JR. Agranulocytosis associated with calcium dobesilate clinical course and risk estimation with the case-control and the case-population approaches. Eur J Clin Pharmacol. 2000;56:763-767.</Citation></Reference><Reference><Citation>Keisu M, Ekman E, Wiholm BE. Comparing risk estimates of sulphonamide-induced agranulocytosis from the Swedish drug monitoring system and a case-control study. Eur J Clin Pharmacol. 1992;43:211-214.</Citation></Reference><Reference><Citation>Laporte JR, Ibanez L, Ballarin E, Perez E, Vidal X. Fatal aplastic anaemia associated with nifedipine. Lancet. 1998;352:619-620.</Citation></Reference><Reference><Citation>Laporte JR, Vidal X, Ballarin E, Ibanez L. Possible association between ocular chloramphenicol and aplastic anaemia-the absolute risk is very low. Br J Clin Pharmacol. 1998;46:181-184.</Citation></Reference><Reference><Citation>Hauben M, Aronson JK, Ferner RE. Evidence of misclassification of drug-event associations classified as gold standard 'Negative controls&#x2019; by the observational medical outcomes partnership (OMOP). Drug Saf. 2016;39:421-432.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32134536</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5448</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Pediatric diabetes</Title><ISOAbbreviation>Pediatr Diabetes</ISOAbbreviation></Journal><ArticleTitle>Treatment regimens and glycosylated hemoglobin levels in youth with Type 1 and Type 2 diabetes: Data from SEARCH (United States) and YDR (India) registries.</ArticleTitle><Pagination><StartPage>31</StartPage><EndPage>39</EndPage><MedlinePgn>31-39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pedi.13004</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To compare treatment regimens and glycosylated hemoglobin (A1c) levels in Type 1 (T1D) and Type 2 diabetes (T2D) using diabetes registries from two countries-U.S. SEARCH for Diabetes in Youth (SEARCH) and Indian Registry of youth onset diabetes in India (YDR).</AbstractText><AbstractText Label="METHODS">The SEARCH and YDR data were harmonized to the structure and terminology in the Observational Medical Outcomes Partnership Common Data Model. Data used were from T1D and T2D youth diagnosed &lt;20&#x2009;years between 2006-2012 for YDR, and 2006, 2008, and 2012 for SEARCH. We compared treatment regimens and A1c levels across the two registries.</AbstractText><AbstractText Label="RESULTS">There were 4003 T1D (SEARCH = 1899; YDR = 2104) and 611 T2D (SEARCH = 384; YDR = 227) youth. The mean A1c was higher in YDR compared to SEARCH (T1D:11.0%&#x2009;&#xb1;&#x2009;2.9% vs 7.8% &#xb1;&#x2009;1.7%, P&#x2009;&lt;&#x2009;.001; T2D:9.9%&#x2009;&#xb1;&#x2009;2.8% vs 7.2%&#x2009;&#xb1;&#x2009;2.1%, P&#x2009;&lt;&#x2009;.001). Among T1D youth in SEARCH, 65.1% were on a basal/bolus regimen, whereas in YDR, 52.8% were on once/twice daily insulin regimen. Pumps were used by 16.2% of SEARCH and 1.5% of YDR youth with T1D. Among T2D youth, in SEARCH and YDR, a majority were on metformin only (43.0% vs 30.0%), followed by insulin&#x2009;+&#x2009;any oral hypoglycemic agents (26.3% vs 13.7%) and insulin only (12.8% vs 18.9%), respectively.</AbstractText><AbstractText Label="CONCLUSION">We found significant differences between SEARCH and YDR in treatment patterns in T1D and T2D. A1c levels were higher in YDR than SEARCH youth, for both T1D and T2D, irrespective of the regimens used. Efforts to achieve better glycemic control for youth are urgently needed to reduce the risk of long-term complications.</AbstractText><CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amutha</LastName><ForeName>Anandakumar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Madras Diabetes Research Foundation &amp; Dr. Mohan's Diabetes Specialties Centre, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Praveen</LastName><ForeName>Pradeep A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Endocrinology &amp; Metabolism, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hockett</LastName><ForeName>Christine W</ForeName><Initials>CW</Initials><Identifier Source="ORCID">0000-0002-1665-6763</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Toan C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Elizabeth T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Wake Forest School of Medicine, Winston Salem, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isom</LastName><ForeName>Scott P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Wake Forest School of Medicine, Winston Salem, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Ralph B Jr</ForeName><Initials>RBJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Wake Forest School of Medicine, Winston Salem, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamman</LastName><ForeName>Richard F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer-Davis</LastName><ForeName>Elizabeth J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0003-3858-0517</Identifier><AffiliationInfo><Affiliation>Department of Nutrition and Medicine, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadwa</LastName><ForeName>Raj Paul</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Jean M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pihoker</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9074-7770</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabelea</LastName><ForeName>Dana</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9514-8929</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tandon</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4604-1986</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology &amp; Metabolism, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Viswanathan</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5038-6210</Identifier><AffiliationInfo><Affiliation>Department of Diabetology, Madras Diabetes Research Foundation &amp; Dr. Mohan's Diabetes Specialties Centre, Chennai, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 DK057516</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006139</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002710</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP006138</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006138</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000154</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002714</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000244</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000062</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006134</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002709</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006131</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP006131</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000423</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HIR 10-001</GrantID><Acronym>HX</Acronym><Agency>HSRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000247</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP006139</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000248</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP006136</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 DK105869</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000077</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP006134</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006136</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000250</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP006133</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000246</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000254</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006133</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002708</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21DK105869-02</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Pediatr Diabetes</MedlineTA><NlmUniqueID>100939345</NlmUniqueID><ISSNLinking>1399-543X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">A1c levels</Keyword><Keyword MajorTopicYN="N">Type 1 diabetes</Keyword><Keyword MajorTopicYN="N">diabetes registry</Keyword><Keyword MajorTopicYN="N">youth onset Type 2 diabetes</Keyword></KeywordList><CoiStatement><b>Disclosures:</b> None of the authors have any potential conflicts of interest relevant to the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32134536</ArticleId><ArticleId IdType="mid">NIHMS1648764</ArticleId><ArticleId IdType="pmc">PMC7744104</ArticleId><ArticleId IdType="doi">10.1111/pedi.13004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amutha A, Datta M, Unnikrishnan IR, Anjana RM, Rema M, Narayan KM, Mohan V. Clinical profile of diabetes in the young seen between 1992 and 2009 at a specialist diabetes centre in south India. Prim Care Diabetes. 2011. December;5(4):223&#x2013;9. doi: 10.1016/j.pcd.2011.04.003. Epub 2011 May 23. PubMed PMID: 21601548</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcd.2011.04.003</ArticleId><ArticleId IdType="pubmed">21601548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran A, Snehalatha C, Ma RC. Diabetes in South-East Asia: an update. Diabetes Res Clin Pract 2014;103(2):231&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">24300015</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabelea D, DeGroat J, Sorrelman C, Glass M, Percy CA, Avery C, Hu D, D&#x2019;Agostino RB Jr, Beyer J, Imperatore G, Testaverde L, Klingensmith G, Hamman RF; SEARCH for Diabetes in Youth Study Group. Diabetes in Navajo youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study. Diabetes Care. 2009. March;32 Suppl 2:S141&#x2013;7. doi: 10.2337/dc09-S206. PubMed PMID: 19246579; PubMed Central PMCID: PMC2647690.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc09-S206</ArticleId><ArticleId IdType="pmc">PMC2647690</ArticleId><ArticleId IdType="pubmed">19246579</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, Bell R, Badaru A, Talton J, Crume T, Liese AD, Merchant AT, Lawrence JM, Reynolds K, Dolan L, Liu LL, Hamman RF, for the SEARCH for Diabetes in Youth Study. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. Journal of the American Medical Association 2014;311(17):1778&#x2013;1786. PMID: 24794371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4368900</ArticleId><ArticleId IdType="pubmed">24794371</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence JM, Imperatore G, Dabelea D, Mayer-Davis EJ, Linder B, Saydah S, Klingensmith GJ, Dolan L, Standiford DA, Pihoker C, Pettitt DJ, Talton JW, Thomas J, Bell RA, D&#x2019;Agostino RB Jr; SEARCH for Diabetes in Youth Study Group. Trends in incidence of type 1 diabetes among non-Hispanic white youth in the U.S., 2002&#x2013;2009. Diabetes. 2014. November;63(11):3938&#x2013;45. doi: 10.2337/db13-1891. Epub 2014. Jun 4. PubMed PMID: 24898146; PubMed Central PMCID: PMC4207387.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-1891</ArticleId><ArticleId IdType="pmc">PMC4207387</ArticleId><ArticleId IdType="pubmed">24898146</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, Imperatore G, Linder B, Marcovina S, Pettitt DJ, Pihoker C, Saydah S, Wagenknecht L, SEARCH for Diabetes in Youth Study. Incidence Trends of Type 1 and Type 2 Diabetes Among Youths, 2002&#x2013;2012. The New England Journal of Medicine 2017; 376:1419&#x2013;1429. PMID: 28402773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5592722</ArticleId><ArticleId IdType="pubmed">28402773</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh K, Saligram PS, Hort K. What explains regulatory failure? Analysing the architecture of health care regulation in two Indian states. Health Policy Plan 2015; 30(1): 39&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">24342742</ArticleId></ArticleIdList></Reference><Reference><Citation>The U.S. Health Care System: An International Perspective - DPEAFLCIO". dpeajlcio.org.</Citation></Reference><Reference><Citation>Fast Facts on US Hospitals". Aha.org. Retrieved December
1, 2016</Citation></Reference><Reference><Citation>Pihoker C, Badaru A, Anderson A, Morgan T, Dolan L, Dabelea D, Imperatore G, Linder B, Marcovina S, Mayer-Davis E, Reynolds K, Klingensmith GJ; SEARCH for Diabetes in Youth Study Group. Insulin regimens and clinical outcomes in a type 1 diabetes cohort: the SEARCH for Diabetes in Youth study. Diabetes Care. 2013. January;36(1):27&#x2013;33. doi: 10.2337/dc12-0720. Epub 2012 Sep 6. PubMed PMID: 22961571; PubMed Central PMCID: PMC3526205.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc12-0720</ArticleId><ArticleId IdType="pmc">PMC3526205</ArticleId><ArticleId IdType="pubmed">22961571</ArticleId></ArticleIdList></Reference><Reference><Citation>Badaru A, Klingensmith GJ, Dabelea D, Mayer-Davis EJ, Dolan L, Lawrence JM, Marcovina S, Beavers D, Rodriguez BL, Imperatore G, Pihoker C. Correlates of treatment patterns among youth with type 2 diabetes. Diabetes Care. 2014;37(1):64&#x2013;72. doi: 10.2337/dc13-1124. Epub 2013 Sep 11. PubMed PMID: 24026554; PubMed Central PMCID: PMC3867996.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-1124</ArticleId><ArticleId IdType="pmc">PMC3867996</ArticleId><ArticleId IdType="pubmed">24026554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamman RF, Bell RA, Dabelea D, D'Agostino RB Jr, Dolan L, Imperatore G, Lawrence JM, Linder B, Marcovina SM, Mayer-Davis EJ, Pihoker C, Rodriguez BL, Saydah S; SEARCH for Diabetes in Youth Study Group. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care. 2014. December;37(12):3336&#x2013;44. doi: 10.2337/dc14-0574. Review. PubMed PMID: 25414389; PubMed Central PMCID: PMC4237981.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-0574</ArticleId><ArticleId IdType="pmc">PMC4237981</ArticleId><ArticleId IdType="pubmed">25414389</ArticleId></ArticleIdList></Reference><Reference><Citation>Praveen PA, Madhu SV, Mohan V, Das S, Kakati S, Shah N, Chaddha M, Bhadada SK, Das AK, Shukla DK, Kaur T, Tandon N. Registry of Youth Onset Diabetes in India (YDR): Rationale, Recruitment, and Current Status. J Diabetes Sci Technol. 2016. August 22;10(5):1034&#x2013;41. doi: 10.1177/1932296816645121. Print 2016 Sep. PubMed PMID: 27179010; PubMed Central PMCID: PMC5032954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1932296816645121</ArticleId><ArticleId IdType="pmc">PMC5032954</ArticleId><ArticleId IdType="pubmed">27179010</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO &#x2223; The WHO Child Growth Standards. WHO; 
http://www.who.int/childgrowth/en/
Accessed November 26, 2018.</Citation></Reference><Reference><Citation>Rewers MJ, Pillay K, de Beaufort C, et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2014;15(Suppl. 20):102&#x2013;114 pmid:25182311.</Citation><ArticleIdList><ArticleId IdType="pubmed">25182311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanungo A, Jhingan A, Sahay RK, Muruganathan A, Das AK; Diabetes Consensus Group. Consensus evidence-based guidelines for insulin therapy in patients with type 1 diabetes mellitus as per Indian clinical practice. J Assoc Physicians India. 2014. July;62(7 Suppl):26&#x2013;33. Review. PubMed PMID: 25668934.</Citation><ArticleIdList><ArticleId IdType="pubmed">25668934</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013;36:S11&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3537269</ArticleId><ArticleId IdType="pubmed">23264422</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE. Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults, 2012. 
http://www.nice.org.uk/nicemedia/live/10944/29390/29390.pdf Last accessed on February 18, 2014.</Citation></Reference><Reference><Citation>Cheng AY, Lau DC. The Canadian diabetes association 2013 clinical practice guidelines raising the bar and setting higher standards. Can J Diabetes 2013;37:137&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">24070834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesavadev J, Das AK, Unnikrishnan R 1st, Joshi SR, Ramachandran A, Shamsudeen J, Krishnan G, Jothydev S, Mohan V. Use of insulin pumps in India: suggested guidelines based on experience and cultural differences. Diabetes Technol Ther. 2010. October;12(10):823&#x2013;31. doi: 10.1089/dia.2010.0027. PubMed PMID: 20807118; PubMed Central PMCID: PMC2956384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dia.2010.0027</ArticleId><ArticleId IdType="pmc">PMC2956384</ArticleId><ArticleId IdType="pubmed">20807118</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudhakaran C, Anjana RM, Rao K, Unnikrishnan R 1st, Suresh T, Mohan V. Role of continuous subcutaneous insulin infusion in patients with recalcitrant diabetes in South India. Diabetes Technol Ther. 2009. November;11(11):733&#x2013;7. doi: 10.1089/dia.2009.0066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/dia.2009.0066</ArticleId><ArticleId IdType="pubmed">19905890</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris CA, Imperatore G, Klingensmith G, Petitti D, Rodriguez B, Anderson AM, Schwartz ID, Standiford DA, Pihoker C. Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for Diabetes in Youth study. J Pediatr. 2009. August;155(2):183&#x2013;9.e1. doi: 10.1016/j.jpeds.2009.01.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2009.01.063</ArticleId><ArticleId IdType="pubmed">19394043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012. June 14;366(24):2247&#x2013;56. doi: 10.1056/NEJMoa1109333. Epub 2012 Apr 29. PubMed PMID: 22540912; PubMed Central PMCID: PMC3478667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1109333</ArticleId><ArticleId IdType="pmc">PMC3478667</ArticleId><ArticleId IdType="pubmed">22540912</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen SG, Hoekstra JB, DeVries JH. Insulin therapy for type 2 diabetes. Diabetes Care. 2009. November;32 Suppl 2:S253&#x2013;9. doi: 10.2337/dc09-S318. Review. PubMed PMID: 19875560; PubMed Central PMCID: PMC2811456.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc09-S318</ArticleId><ArticleId IdType="pmc">PMC2811456</ArticleId><ArticleId IdType="pubmed">19875560</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008. October 9;359(15):1577&#x2013;89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10. PubMed PMID: 18784090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0806470</ArticleId><ArticleId IdType="pubmed">18784090</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury S. Puberty and type 1 diabetes. Indian journal of endocrinology and metabolism, 2015. 19(Suppl 1), S51&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4413391</ArticleId><ArticleId IdType="pubmed">25941652</ArticleId></ArticleIdList></Reference><Reference><Citation>Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatric Diabetes 2009: 10 (Suppl. 12): 71&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">19754620</ArticleId></ArticleIdList></Reference><Reference><Citation>George MM, &amp; Copeland KC Current treatment options for type 2 diabetes mellitus in youth: today&#x2019;s realities and lessons from the TODAY study. Current diabetes reports, 2013. 13(1), 72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3545061</ArticleId><ArticleId IdType="pubmed">23065368</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007. April;30(4):790&#x2013;4. PubMed PMID: 17392540.</Citation><ArticleIdList><ArticleId IdType="pubmed">17392540</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidyanathan J, Choe S, Sahajwalla CG. Type 2 diabetes in pediatrics and adults: thoughts from a clinical pharmacology perspective. Journal of pharmaceutical sciences. 2012;101(5):1659&#x2013;1671.</Citation><ArticleIdList><ArticleId IdType="pubmed">22383396</ArticleId></ArticleIdList></Reference><Reference><Citation>Unnikrishnan R, Anjana RM, Deepa M, et al. Glycemic control among individuals with self-reported diabetes in India--the ICMR-INDIAB Study. Diabetes Technol Ther. 2014;16(9):596&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135327</ArticleId><ArticleId IdType="pubmed">25101698</ArticleId></ArticleIdList></Reference><Reference><Citation>Clements MA, Foster NC, Maahs DM, Schatz DA, Olson BA, Tsalikian E, Lee JM, Burt-Solorzano CM, Tamborlane WV, Chen V, Miller KM, Beck RW; T1D Exchange Clinic Network. Hemoglobin A1c (HbA1c) changes over time among adolescent and young adult participants in the T1D exchange clinic registry. Pediatr Diabetes. 2016. August;17(5):327&#x2013;36. doi: 10.1m/pedi.12295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1m/pedi.12295</ArticleId><ArticleId IdType="pubmed">26153338</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, Maahs DM, Tamborlane WV; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015. June;38(6):971&#x2013;8. doi: 10.2337/dc15-0078. PubMed PMID: 25998289.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc15-0078</ArticleId><ArticleId IdType="pubmed">25998289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahkoska AR, Shay CM, Crandell J, et al. Association of Race and Ethnicity With Glycemic Control and Hemoglobin A1c Levels in Youth With Type 1 Diabetes. JAMA Netw Open. 2018;1(5):e181851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6203341</ArticleId><ArticleId IdType="pubmed">30370425</ArticleId></ArticleIdList></Reference><Reference><Citation>Copeland KC, Zeitler P, Geffner M, et al.; TODAY Study Group. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011; 96:159&#x2013;167</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038479</ArticleId><ArticleId IdType="pubmed">20962021</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellers EAC, Yung G, Dean HJ. Dyslipidemia and other cardiovascular risk factors in a Canadian First Nation pediatric population with type 2 diabetes mellitus. Pediatr Diabetes 2007; 8:384&#x2013;390</Citation><ArticleIdList><ArticleId IdType="pubmed">18036065</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadeau KJ, Anderson BJ, Berg EG, Chiang JL, Chou H, Copeland KC, Hannon TS, Huang TT, Lynch JL, Powell J, Sellers E, Tamborlane WV, Zeitler P. Youth-Onset Type 2 Diabetes Consensus Report: Current Status, Challenges, and Priorities. Diabetes Care. 2016. September;39(9):1635&#x2013;42. doi: 10.2337/dc16-1066.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc16-1066</ArticleId><ArticleId IdType="pmc">PMC5314694</ArticleId><ArticleId IdType="pubmed">27486237</ArticleId></ArticleIdList></Reference><Reference><Citation>Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA. Earlier onset of complications in youth with type 2 diabetes. Diabetes Care 2014; 37:436&#x2013;443</Citation><ArticleIdList><ArticleId IdType="pubmed">24130346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci 2015; 1353:113&#x2013;137 22.</Citation><ArticleIdList><ArticleId IdType="pubmed">26448515</ArticleId></ArticleIdList></Reference><Reference><Citation>Dabelea D, Stafford JM, Mayer-Davis EJ, D&#x2019;Agostino R Jr, Dolan L, Imperatore G, Linder B, Lawrence JM, Marcovina SM, Mottl AK, Black MH, Pop-Busui R, Saydah S, Hamman RF, Pihoker C, SEARCH for Diabetes in Youth Research Group. Association of Type 1 Diabetes Vs Type 2 Diabetes Diagnosed During Childhood and Adolescence with Complications During Teenage Years and Young Adulthood. JAMA 2017;317:825&#x2013;835. PMID: 28245334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5483855</ArticleId><ArticleId IdType="pubmed">28245334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32134687</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Treatment Patterns for Chronic Comorbid Conditions in Patients With Cancer Using a Large-Scale Observational Data Network.</ArticleTitle><Pagination><StartPage>171</StartPage><EndPage>183</EndPage><MedlinePgn>171-183</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">CCI.19.00107</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI.19.00107</ELocationID><Abstract><AbstractText Label="PURPOSE">Patients with cancer are predisposed to developing chronic, comorbid conditions that affect prognosis, quality of life, and mortality. While treatment guidelines and care variations for these comorbidities have been described for the general noncancer population, less is known about real-world treatment patterns in patients with cancer. We sought to characterize the prevalence and distribution of initial treatment patterns across a large-scale data network for depression, hypertension, and type II diabetes mellitus (T2DM) among patients with cancer.</AbstractText><AbstractText Label="METHODS">We used the Observational Health Data Sciences and Informatics network, an international collaborative implementing the Observational Medical Outcomes Partnership Common Data Model to standardize more than 2 billion patient records. For this study, we used 8 databases across 3 countries-the United States, France, and Germany-with 295,529,655 patient records. We identified patients with cancer using SNOMED (Systematized Nomenclature of Medicine) codes validated via manual review. We then characterized the treatment patterns of these patients initiating treatment of depression, hypertension, or T2DM with persistent treatment and at least 365 days of observation.</AbstractText><AbstractText Label="RESULTS">Across databases, wide variations exist in treatment patterns for depression (n = 1,145,510), hypertension (n = 3,178,944), and T2DM (n = 886,766). When limited to 6-node (6-drug) sequences, we identified 61,052 unique sequences for depression, 346,067 sequences for hypertension, and 40,629 sequences for T2DM. These variations persisted across sites, databases, countries, and conditions, with the exception of metformin (73.8%) being the most common initial T2DM treatment. The most common initial medications were sertraline (17.5%) and escitalopram (17.5%) for depression and hydrochlorothiazide (20.5%) and lisinopril (19.6%) for hypertension.</AbstractText><AbstractText Label="CONCLUSION">We identified wide variations in the treatment of common comorbidities in patients with cancer, similar to the general population, and demonstrate the feasibility of conducting research on patients with cancer across a large-scale observational data network using a common data model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ruijun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medical College, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crew</LastName><ForeName>Katherine D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Medicine and the Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IQVIA, Cambridge, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vashisht</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, Stanford University, Palo Alto, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randhawa</LastName><ForeName>Gurvaneet</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Health Systems and Interventions Research Branch, Healthcare Delivery Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, Stanford University, Palo Alto, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterian Hospital, New York, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011369</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/cci/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). PATRICK RYAN: <b>Employment:</b> Janssen Research &amp; Development <b>Stock and Other Ownership Interests:</b> Johnson &amp; Johnson NIGAM H. SHAH: <b>Leadership:</b> Prealize Health <b>Stock and Other Ownership Interests:</b> Apixio <b>Consulting or Advisory Role:</b> Apixio <b>Research Funding:</b> Google (Inst) <b>Travel, Accommodations, Expenses:</b> Apixio GEORGE HRIPCSAK: <b>Research Funding:</b> Janssen Research &amp; Development No other potential conflicts of interest were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32134687</ArticleId><ArticleId IdType="pmc">PMC7113074</ArticleId><ArticleId IdType="doi">10.1200/CCI.19.00107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Edwards BK, Noone A-M, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3999205</ArticleId><ArticleId IdType="pubmed">24343171</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;gaard M, Thomsen RW, Bossen KS, et al. The impact of comorbidity on cancer survival: A review. Clin Epidemiol. 2013;5(suppl 1):3&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820483</ArticleId><ArticleId IdType="pubmed">24227920</ArticleId></ArticleIdList></Reference><Reference><Citation>Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">8256968</ArticleId></ArticleIdList></Reference><Reference><Citation>Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29:1335&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084001</ArticleId><ArticleId IdType="pubmed">21357791</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003;103:792&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">12516101</ArticleId></ArticleIdList></Reference><Reference><Citation>Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the &#x201c;silver tsunami&#x201d;: Prevalence trajectories and comorbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev. 2016;25:1029&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4933329</ArticleId><ArticleId IdType="pubmed">27371756</ArticleId></ArticleIdList></Reference><Reference><Citation>Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000;35:181&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">10960800</ArticleId></ArticleIdList></Reference><Reference><Citation>Chochinov HM. Depression in cancer patients. Lancet Oncol. 2001;2:499&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">11905726</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon L, Yin H, Suissa S, et al. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control. 2014;25:329&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pubmed">24384808</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen BL, DeRubeis RJ, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: An American Society of Clinical Oncology guideline adaptation. J Clin Oncol. 2014;32:1605&#x2013;1619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090422</ArticleId><ArticleId IdType="pubmed">24733793</ArticleId></ArticleIdList></Reference><Reference><Citation>McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry. 1995;52:89&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">7848055</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirl WF. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr. 2004;2004:32&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">15263039</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman E, Messerli FH, Boyko V, et al. Is there an association between hypertension and cancer mortality? Am J Med. 2002;112:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">11959059</ArticleId></ArticleIdList></Reference><Reference><Citation>Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">18842611</ArticleId></ArticleIdList></Reference><Reference><Citation>Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103:763&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086879</ArticleId><ArticleId IdType="pubmed">21527770</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA. 2000;284:2907&#x2013;2911.</Citation><ArticleIdList><ArticleId IdType="pubmed">11147988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: A meta-analysis. Am J Hypertens. 2010;23:460&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">20186127</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol. 2008;9:117&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">18221915</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton PK, Carey RM, Aronow WS, et al: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71:1269-1324, 2018 [Errata: Hypertension 71:e136-e139, 2018; Hypertension 72:e33, 2018] PubMed.</Citation><ArticleIdList><ArticleId IdType="pubmed">29133354</ArticleId></ArticleIdList></Reference><Reference><Citation> Work Group on Major Depressive Disorder.  https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.</Citation></Reference><Reference><Citation>American Diabetes Association 8. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2018. Diabetes Care. 2018;41(suppl 1):S73&#x2013;S85.</Citation><ArticleIdList><ArticleId IdType="pubmed">29222379</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160&#x2013;1167.</Citation><ArticleIdList><ArticleId IdType="pubmed">15191933</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, Lieu T. Data enclaves for sharing information derived from clinical and administrative data. JAMA. 2018;320:753&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">30083726</ArticleId></ArticleIdList></Reference><Reference><Citation>Randhawa GS, Slutsky JR. Building sustainable multi-functional prospective electronic clinical data systems. Med Care. 2012;50(suppl):S3&#x2013;S6.</Citation><ArticleIdList><ArticleId IdType="pubmed">22692255</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  Mission, vision &amp; values.  https://www.ohdsi.org/who-we-are/mission-vision-values/</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci USA. 2016;113:7329&#x2013;7336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan P, Belenkaya R, et al.  OMOP Common Data Model v5.3 Specifications.  https://github.com/OHDSI/CommonDataModel</Citation></Reference><Reference><Citation> Observational Health Data Sciences and Informatics: Treatment Pathways in Patients With Cancer.  https://www.ohdsi.org/web/wiki/doku.php?id=research:treatment_pathways_in_cancer_12mo.</Citation></Reference><Reference><Citation> Observational Health Data Sciences and Informatics: Common Data Model.  https://github.com/OHDSI/CommonDataModel/wiki.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7320306</ArticleId><ArticleId IdType="pubmed">32530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst. 1999;91:542&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088625</ArticleId></ArticleIdList></Reference><Reference><Citation>Barone BB, Yeh H-C, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA. 2008;300:2754&#x2013;2764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3093051</ArticleId><ArticleId IdType="pubmed">19088353</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Poll-Franse LV, Houterman S, Janssen-Heijnen MLG, et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: A large population based analysis. Int J Cancer. 2007;120:1986&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">17230509</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating NL, O&#x2019;Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448&#x2013;4456.</Citation><ArticleIdList><ArticleId IdType="pubmed">16983113</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: A consensus report. Diabetes Care. 2010;33:1674&#x2013;1685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890380</ArticleId><ArticleId IdType="pubmed">20587728</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32162290</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>Erratum: Transforming French Electronic Health Records into the Observational Medical Outcome Partnership's Common Data Model: A Feasibility Study.</ArticleTitle><Pagination><StartPage>e1</StartPage><MedlinePgn>e1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0040-1702166</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lamer</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Depas</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doutreligne</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bureau Etat de Sant&#xe9; de la Population, Minist&#xe8;re des Affaires Sociales et de la Sant&#xe9;, Direction de la Recherche, des Etudes et des Statistiques - Observation de la Sant&#xe9; et de l'Assurance Maladie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parrot</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris Descartes, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Web INnovation Donn&#xe9;es-Direction des Syst&#xe8;mes d'Information, Assistance Publique - H&#xf4;pitaux de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verloop</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service Etudes et Statistiques, ARS Hauts-de-France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defebvre</LastName><ForeName>Marguerite-Marie</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Service Etudes et Statistiques, ARS Hauts-de-France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ficheur</LastName><ForeName>Gr&#xe9;goire</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chazard</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beuscart</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, ULR 2694-METRICS: &#xc9;valuation des Technologies de Sant&#xe9; et des Pratiques M&#xe9;dicales, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>Appl Clin Inform. 2020 Jan;11(1):13-22</RefSource><PMID Version="1">31914471</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32162290</ArticleId><ArticleId IdType="pmc">PMC7065979</ArticleId><ArticleId IdType="doi">10.1055/s-0040-1702166</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32162687</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-1167</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Epilepsia</Title><ISOAbbreviation>Epilepsia</ISOAbbreviation></Journal><ArticleTitle>Analysis of antiseizure drug-related adverse reactions from the electronic health record using the common data model.</ArticleTitle><Pagination><StartPage>610</StartPage><EndPage>616</EndPage><MedlinePgn>610-616</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/epi.16472</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Antiseizure drugs (ASDs) are known to cause a wide range of adverse drug reactions (ADRs). Recently, electronic health care data using the common data model (CDM) have been introduced and commonly adopted in pharmacovigilance research. We aimed to analyze ASD-related ADRs using CDM and to assess the feasibility of CDM analysis in monitoring ADR in a single tertiary hospital.</AbstractText><AbstractText Label="METHODS">We selected five ASDs: oxcarbazepine (OXC), lamotrigine (LTG), levetiracetam (LEV), valproic acid (VPA), and topiramate (TPM). Patients diagnosed with epilepsy and exposed to monotherapy with one of the ASDs before age 18&#xa0;years were included. We measured four ADR outcomes: (1) hematologic abnormality, (2) hyponatremia, (3) elevation of liver enzymes, and (4) subclinical hypothyroidism. We performed a subgroup analysis to exclude the effects of concomitant medications.</AbstractText><AbstractText Label="RESULTS">From the database, 1344 patients were included for the study. Of the 1344 patients, 436 were receiving OXC, 293 were receiving LTG, 275 were receiving LEV, 180 were receiving VPA, and 160 were receiving TPM. Thrombocytopenia developed in 14.1% of patients taking VPA. Hyponatremia occurred in 10.5% of patients taking OXC. Variable ranges of liver enzyme elevation were detected in 19.3% of patients taking VPA. Subclinical hypothyroidism occurred in approximately 21.5% to 28% of patients with ASD monotherapy, which did not significantly differ according to the type of ASD. In a subgroup analysis, we observed similar ADR tendencies, but with less thrombocytopenia in the TPM group.</AbstractText><AbstractText Label="SIGNIFICANCE">The incidence and trends of ADRs that were evaluated by CDM were similar to the previous literature. CDM can be a useful tool for analyzing ASD-related ADRs in a multicenter study. The strengths and limitations of CDM should be carefully addressed.</AbstractText><CopyrightInformation>Wiley Periodicals, Inc. &#xa9; 2020 International League Against Epilepsy.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sun Ah</ForeName><Initials>SA</Initials><Identifier Source="ORCID">0000-0001-6164-8706</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hunmin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6689-3495</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4996-8613</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8620-4925</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Soyoung</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0845-0981</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Yonghoon</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0024-6890</Identifier><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Hee</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-7964-1630</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ki Joong</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0002-0849-125X</Identifier><AffiliationInfo><Affiliation>Departement of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>18-2018-014</GrantID><Agency>Seoul National University Bundang Hospital Research Fund</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Epilepsia</MedlineTA><NlmUniqueID>2983306R</NlmUniqueID><ISSNLinking>0013-9580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0H73WJJ391</RegistryNumber><NameOfSubstance UI="D000077236">Topiramate</NameOfSubstance></Chemical><Chemical><RegistryNumber>44YRR34555</RegistryNumber><NameOfSubstance UI="D000077287">Levetiracetam</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VZI5B1W380</RegistryNumber><NameOfSubstance UI="D000078330">Oxcarbazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065709" MajorTopicYN="Y">Common Data Elements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077287" MajorTopicYN="N">Levetiracetam</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078330" MajorTopicYN="N">Oxcarbazepine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077236" MajorTopicYN="N">Topiramate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse drug reaction</Keyword><Keyword MajorTopicYN="N">antiseizure drugs</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">epilepsy</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32162687</ArticleId><ArticleId IdType="doi">10.1111/epi.16472</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology. 1995;45:456-60.</Citation></Reference><Reference><Citation>Handoko KB, Souverein PC, van Staa TP, et al. Risk of aplastic anemia in patients using antiepileptic drugs. Epilepsia. 2006;47:1232-6.</Citation></Reference><Reference><Citation>Inacia P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83:227-46.</Citation></Reference><Reference><Citation>Srba J, Descikova V, Vlcek J. Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009. Eur J Clin Pharmacol. 2012;68:1057-63.</Citation></Reference><Reference><Citation>Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013;69:237-44.</Citation></Reference><Reference><Citation>Isler C, Kucukyuruk B, Ozkara C, et al. Comparison of clinical features and surgical outcome in focal cortical dysplasia type 1 and type 2. Epilepsy Res. 2017;136:130-6.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Health Technol Inform. 2015;216:574-8.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54-60.</Citation></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, et al. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Saf. 2013;36(2):119-34.</Citation></Reference><Reference><Citation>National Cancer Center Institute of the National Institutes of Health. Common termsinology criteria for adverse events (CTCAE) v5.0; 2017. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed January 15, 2020.</Citation></Reference><Reference><Citation>Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guideliness for diagnosis and management. JAMA. 2004;291:228-38.</Citation></Reference><Reference><Citation>Verrotti A, Scaparrotta A, Grosso S, Chiarelli F, Coppola G. Anticonvulsant drugs and hematological disease. Neurol Sci. 2014;35:983-93.</Citation></Reference><Reference><Citation>Barr RD, Copeland SA, Stockwell ML, Morris N, Kelton JC. Valproic acid and immune thrombocytopenia. Arch Dis Child. 1982;57(9):681-4.</Citation></Reference><Reference><Citation>Neophytides AN, Nutt JG, Lodish JR. Thrombocytopenia associated with sodium valproate treatment. Ann Neurol. 1979;5:389-90.</Citation></Reference><Reference><Citation>Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2007;49(3):438-45.</Citation></Reference><Reference><Citation>Conley EL, Coley KC, Pollock BG, Dapos SV, Maxwell R, Branch RA. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital. Pharmacotherapy. 2001;21(11):1325-30.</Citation></Reference><Reference><Citation>Buoli M, Serati M, Botturi A, Altamura AC. The risk of thrombocytopenia during valproic acid therapy: a critical summary of available clinical data. Drugs R D. 2018;18(1):1-5.</Citation></Reference><Reference><Citation>May R, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia. 1993;34:1098-101.</Citation></Reference><Reference><Citation>Bauer J, Ben-Menachem E, Kramer G, Fryze W, Da Silva S, Kasteleijn-Nolst Trenite DGA. Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand. 2006;114:169-76.</Citation></Reference><Reference><Citation>Chang LR, Chang HC, Lin YH. Quetiapine- and valproate-associated neutropenia and thrombocytopenia after lamotrigine-induced Steven-Johnson syndrome. J Clin Psychopharmacol. 2012;32:133-4.</Citation></Reference><Reference><Citation>Hung WC, Hsieh MH. Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients. J Clin Psychopharmacol. 2012;32:416-7.</Citation></Reference><Reference><Citation>Rahman A, Mican LM, Fischer C, Campbell AH. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother. 2009;43:822-30.</Citation></Reference><Reference><Citation>Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551-63.</Citation></Reference><Reference><Citation>Berghuis B, van der Palen J, Haan G-J, et al. Carbamazepine- and oxcarbazepine-induced hyponatremia in people with epilepsy. Epilepsia. 2017;58:1227-33.</Citation></Reference><Reference><Citation>Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323-38.</Citation></Reference><Reference><Citation>Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology. 1989;39:201-7.</Citation></Reference><Reference><Citation>Scheffner D, Konig S, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia. 1988;29:530-42.</Citation></Reference><Reference><Citation>Koenig SA, Buesing D, Longin E, et al. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia. 2006;47:2027-31.</Citation></Reference><Reference><Citation>Eiris-Punal J, Rio-Garma MD, Rio-Garma MCD, Lojo-Rocamonde S, Novo-Rodriguez I, Castro-Gago M. Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia. 1999;40:1761-6.</Citation></Reference><Reference><Citation>Isojarvi JIT, Parkarinen AJ, Myllyla VV. Thyroid function in epileptic patients treated with carbamazepine. Arch Neurol. 1989;46:1175-8.</Citation></Reference><Reference><Citation>Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatr Neurol. 2001;25:43-6.</Citation></Reference><Reference><Citation>Yilmaz U, Yilmaz TS, Akinci G, Korkmaz HA, Tekgul H. The effect of antiepileptic drugs on thyroid function in children. Seizure. 2014;23:29-35.</Citation></Reference><Reference><Citation>Sahu JK, Gulati S, Kabra M, et al. Evaluation of subclinical hypothyroidism in ambulatory children with controlled epilepsy on valproate monotherapy. J Child Neurol. 2012;27:594-7.</Citation></Reference><Reference><Citation>Ilic V, Bogicevic D, Miljkovic B, et al. Duration of valproic acid monotherapy correlates with subclinical thyroid dysfunction in children with epilepsy. Epileptic Disord. 2016;18:181-6.</Citation></Reference><Reference><Citation>Harpaz R, DuMochel W, Shah NH. Big data and adverse drug reaction detection. Clin Pharmacol Ther. 2016;99:268-70.</Citation></Reference><Reference><Citation>Montastruc F, Bagheri H, Lacroix I, et al. Adverse drug reaction reports received through the mobile app, VigiBIP: a comparison with classical methods of reporting. Drug Saf. 2018;41:511-4.</Citation></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. 2014;37(11):945-59.</Citation></Reference><Reference><Citation>Hripcsak G, Levine ME, Shang N, Ryan PB. Effect of vocabulary mapping for conditions on phenotype cohorts. J Am Med Inform Assoc. 2018;25(12):1618-25.</Citation></Reference><Reference><Citation>Li Y, Ryan PB, Wei Y, Friedman C. A method to combine signals from spontaneous reporting systems and observational healthcare data to detect adverse drug reactions. Drug Saf. 2015;38:895-908.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32196874</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5448</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Pediatric diabetes</Title><ISOAbbreviation>Pediatr Diabetes</ISOAbbreviation></Journal><ArticleTitle>Comparison of the incidence of diabetes in United States and Indian youth: An international harmonization of youth diabetes registries.</ArticleTitle><Pagination><StartPage>8</StartPage><EndPage>14</EndPage><MedlinePgn>8-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pedi.13009</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Incidence of youth-onset diabetes in India has not been well described. Comparison of incidence, across diabetes registries, has the potential to inform hypotheses for risk factors. We sought to compare the incidence of diabetes in the U.S.-based registry of youth onset diabetes (SEARCH) to the Registry of Diabetes with Young Age at Onset (YDR-Chennai and New Delhi regions) in India.</AbstractText><AbstractText Label="METHODS">We harmonized data from both SEARCH and YDR to the Observational Medical Outcomes Partnership (OMOP) Common Data Model. Data were from youth registered with incident diabetes (2006-2012). Denominators were from census and membership data. We calculated diabetes incidence by averaging the total cases across the entire follow-up period and dividing this by the estimated census population corresponding to the source population for case ascertainment. Incidence was calculated for each of the registries and compared by type and within age and sex categories using a 2-sided, skew-corrected inverted score test.</AbstractText><AbstractText Label="RESULTS">Incidence of type 1 was higher in SEARCH (21.2 cases/100&#x2009;000 [95% CI: 19.9, 22.5]) than YDR (4.9 cases/100&#x2009;000 [95% CI: 4.3, 5.6]). Incidence of type 2 diabetes was also higher in SEARCH (5.9 cases/100&#x2009;000 [95% CI: 5.3, 6.6] in SEARCH vs 0.5/cases/100&#x2009;000 [95% CI: 0.3, 0.7] in YDR). The age distribution of incident type 1 diabetes cases was similar across registries, whereas type 2 diabetes incidence was higher at an earlier age in SEARCH. Sex differences existed in SEARCH only, with a higher rate of type 2 diabetes among females.</AbstractText><AbstractText Label="CONCLUSION">The incidence of youth-onset type 1 and 2 diabetes was significantly different between registries. Additional data are needed to elucidate whether the differences observed represent diagnostic delay, differences in genetic susceptibility, or differences in distribution of risk factors.</AbstractText><CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>Elizabeth T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabelea</LastName><ForeName>Dana A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-9514-8929</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Praveen</LastName><ForeName>Pradeep A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Metabolism and Diabetes, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amutha</LastName><ForeName>Anandakumar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dr. Mohan's Diabetes Specialties Centre and Madras Diabetes Research Foundation, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hockett</LastName><ForeName>Christine W</ForeName><Initials>CW</Initials><Identifier Source="ORCID">0000-0002-1665-6763</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isom</LastName><ForeName>Scott P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Data Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Toan C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Viswanathan</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-7939-6295</Identifier><AffiliationInfo><Affiliation>Dr. Mohan's Diabetes Specialties Centre and Madras Diabetes Research Foundation, Chennai, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Biostatistics and Data Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kahn</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamman</LastName><ForeName>Richard F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wadwa</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolan</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Jean M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhu</LastName><ForeName>S V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Centre for Diabetes, Endocrinology and Metabolism, University College of Medical Science, GTB Hospital, Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhokar</LastName><ForeName>Reshmi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Metabolism and Diabetes, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goel</LastName><ForeName>Komal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Metabolism and Diabetes, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tandon</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4604-1986</Identifier><AffiliationInfo><Affiliation>Department of Endocrinology, Metabolism and Diabetes, All India Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer-Davis</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3858-0517</Identifier><AffiliationInfo><Affiliation>Department of Nutrition and Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 DK057516</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006139</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000247</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002710</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP006138</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006138</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000154</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002714</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000248</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000244</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000062</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006134</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002709</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006131</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000077</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UC4 DK108173</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 DK105869</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK127208</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000423</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006136</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000250</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000246</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DP000254</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18DP006133</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U18 DP002708</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21DK105869-02</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Pediatr Diabetes</MedlineTA><NlmUniqueID>100939345</NlmUniqueID><ISSNLinking>1399-543X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">India</Keyword><Keyword MajorTopicYN="N">United States</Keyword><Keyword MajorTopicYN="N">descriptive epidemiology of diabetes</Keyword><Keyword MajorTopicYN="N">diabetes in youth; incidence</Keyword></KeywordList><CoiStatement><b>Disclosures:</b> None of the authors have any potential conflicts of interest relevant to the manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32196874</ArticleId><ArticleId IdType="mid">NIHMS1648766</ArticleId><ArticleId IdType="pmc">PMC7748376</ArticleId><ArticleId IdType="doi">10.1111/pedi.13009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amed S, Islam N, Sutherland J, Reimer K. Incidence and prevalence trends of youth-onset type 2 diabetes in a cohort of Canadian youth: 2002&#x2013;2013. Pediatric diabetes. 2018;19(4):630&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">29280255</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox DA, Islam N, Sutherland J, Reimer K, Amed S. Type 1 diabetes incidence and prevalence trends in a cohort of Canadian children and youth. Pediatric diabetes. 2018;19(3):501&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">28857360</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer-Davis EJ, Dabelea D, Lamichhane AP, et al. Breast-feeding and type 2 diabetes in the youth of three ethnic groups: the SEARCh for diabetes in youth case-control study. Diabetes Care. 2008;31(3):470&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">18071004</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazeli Farsani S, Souverein PC, van der Vorst MM, et al. Increasing trends in the incidence and prevalence rates of type 1 diabetes among children and adolescents in the Netherlands. Pediatric diabetes. 2016;17(1):44&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">25377748</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson CC, Harjutsalo V, Rosenbauer J, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989&#x2013;2013: a multicentre prospective registration study. Diabetologia. 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">30483858</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss LD, Hosking J, Metcalf BS, Jeffery AN, Fremeaux AE, Wilkin TJ. Metabolic risk in contemporary children is unrelated to socio-economic status: longitudinal study of a UK urban population (EarlyBird 42). Pediatric diabetes. 2014;15(3):244&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">24827703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolahdooz F, Nader F, Daemi M, Jang SL, Johnston N, Sharma S. Prevalence of Known Risk Factors for Type 2 Diabetes Mellitus in Multiethnic Urban Youth in Edmonton: Findings From the WHY ACT NOW Project. Canadian journal of diabetes. 2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">30551935</ArticleId></ArticleIdList></Reference><Reference><Citation>Praveen PA, Madhu SV, Mohan V, et al. Registry of Youth Onset Diabetes in India (YDR): Rationale, Recruitment, and Current Status. Journal of diabetes science and technology. 2016;10(5):1034&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5032954</ArticleId><ArticleId IdType="pubmed">27179010</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamman RF, Bell RA, Dabelea D, et al. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care. 2014;37(12):3336&#x2013;3344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237981</ArticleId><ArticleId IdType="pubmed">25414389</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002&#x2013;2012. N Engl J Med. 2017;376(15):1419&#x2013;1429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5592722</ArticleId><ArticleId IdType="pubmed">28402773</ArticleId></ArticleIdList></Reference><Reference><Citation>Verlato G, Muggeo M. Capture-recapture method in the epidemiology of type 2 diabetes: a contribution from the Verona Diabetes Study. Diabetes Care. 2000;23(6):759&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">10840992</ArticleId></ArticleIdList></Reference><Reference><Citation>Commissioner OotRGaC. 2011; http://www.censusindia.gov.in/2011census/censusdata2k11.aspx. Accessed
9.1.2018, 2018.</Citation></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association : JAMIA. 2015;22(3):553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra A, Sattar N, Tandon N, et al. Clinical management of type 2 diabetes in south Asia. The lancet Diabetes &amp; endocrinology. 2018;6(12):979&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">30287103</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980&#x2013;2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2014;384(9945):766&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624264</ArticleId><ArticleId IdType="pubmed">24880830</ArticleId></ArticleIdList></Reference><Reference><Citation>Somera LP, Lee HR, Badowski G, Cassel K. Health Information Seeking, Source Trust, and Culture: A Comparative Analysis of Health Information Trends and Needs Between Guam and the United States. Journal of health communication. 2016;21(4):469&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4905759</ArticleId><ArticleId IdType="pubmed">26983674</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar N, Gill JMR. Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management. The Lancet Diabetes &amp; Endocrinology. 2015;3(12):1004&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">26489808</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra A, Tandon N, Ebrahim S, et al. Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. Bmj. 2017;357:j1420.</Citation><ArticleIdList><ArticleId IdType="pubmed">28400361</ArticleId></ArticleIdList></Reference><Reference><Citation>Harron KL, Feltbower RG, McKinney PA, Bodansky HJ, Campbell FM, Parslow RC. Rising rates of all types of diabetes in south Asian and non-south Asian children and young people aged 0&#x2013;29 years in West Yorkshire, U.K., 1991&#x2013;2006. Diabetes Care. 2011;34(3):652&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041200</ArticleId><ArticleId IdType="pubmed">21278139</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayashree M, Singhi S. Diabetic ketoacidosis: predictors of outcome in a pediatric intensive care unit of a developing country. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2004;5(5):427&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">15329157</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran A, Snehalatha C, Vijay V, King H. Impact of poverty on the prevalence of diabetes and its complications in urban southern India. Diabet Med. 2002;19(2):130&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">11874429</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskind IG, Patil SS, Haard&#xf6;rfer R, Cunningham SA. UNHEALTHY WEIGHT IN INDIAN FAMILIES: THE ROLE OF THE FAMILY ENVIRONMENT IN THE CONTEXT OF THE NUTRITION TRANSITION. Population research and policy review. 2018;37(2):157&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6023548</ArticleId><ArticleId IdType="pubmed">29962562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32220411</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-6483</ISSN><JournalIssue CitedMedium="Internet"><Volume>112S</Volume><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of substance abuse treatment</Title><ISOAbbreviation>J Subst Abuse Treat</ISOAbbreviation></Journal><ArticleTitle>Service utilization and chronic condition outcomes among primary care patients with substance use disorders and co-occurring chronic conditions.</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>55</EndPage><MedlinePgn>49-55</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jsat.2020.02.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0740-5472(19)30594-X</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients with a substance use disorder (SUD) often present with co-occurring chronic conditions in primary care. Despite the high co-occurrence of chronic medical conditions and SUD, little is known about whether chronic condition outcomes or related service utilization in primary care varies between patients with versus without documented SUDs. This study examined whether having a SUD influenced the use of primary care services and common chronic condition outcomes for patients with diabetes, hypertension, and obesity.</AbstractText><AbstractText Label="METHODS">A longitudinal cohort observational study examined electronic health record data from 21 primary care clinics in Washington and Idaho to examine differences in service utilization and clinical outcomes for diabetes, hypertension, and obesity in patients with and without a documented SUD diagnosis. Differences between patients with and without documented SUD diagnoses were compared over a three-year window for clinical outcome measures, including hemoglobin A1c, systolic and diastolic blood pressure, and body mass index, as well as service outcome measures, including number of encounters with primary care and co-located behavioral health providers, and orders for prescription opioids. Adult patients (N&#xa0;=&#xa0;10,175) diagnosed with diabetes, hypertension, or obesity before the end of 2014, and who had &#x2265;2 visits across a three-year window including at least one visit in 2014 (baseline) and at least one visit occurring 12&#xa0;months or longer after the 2014 visit (follow-up) were examined.</AbstractText><AbstractText Label="RESULTS">Patients with SUD diagnoses and co-occurring chronic conditions were seen by providers more frequently than patients without SUD diagnoses (p's&#xa0;&lt;&#xa0;0.05), and patients with SUD diagnoses were more likely to be prescribed opioid medications. Chronic condition outcomes were no different for patients with versus without SUD diagnoses.</AbstractText><AbstractText Label="DISCUSSION">Despite the higher visit rates to providers in primary care, a majority of patients with SUD diagnoses and chronic medical conditions in primary care did not get seen by co-located behavioral health providers, who can potentially provide and support evidence informed care for both SUD and chronic conditions. Patients with chronic medical conditions also were more likely to get prescribed opioids if they had an SUD diagnosis. Care pathway innovations for SUDs that include greater utilization of evidence-informed co-treatment of SUDs and chronic conditions within primary care settings may be necessary for improving care overall for patients with comorbid SUDs and chronic conditions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Kari A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, University of Washington, Seattle, WA, United States of America; Department of Psychiatry &amp; Behavioral Sciences, University of Washington, Seattle, WA, United States of America; Department of Biomedical Informatics &amp; Medical Education, University of Washington, Seattle, WA, United States of America. Electronic address: kstephen@uw.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Imara I</ForeName><Initials>II</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, University of Washington, Seattle, WA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hallgren</LastName><ForeName>Kevin A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, University of Washington, Seattle, WA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mollis</LastName><ForeName>Brenda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, University of Washington, Seattle, WA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Kris</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Behavioral Sciences, University of Washington, Seattle, WA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donovan</LastName><ForeName>Dennis M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Alcohol &amp; Drug Abuse Institute, University of Washington, Seattle, WA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuvek</LastName><ForeName>Brenda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Alcohol &amp; Drug Abuse Institute, University of Washington, Seattle, WA, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Laura-Mae</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, University of Washington, Seattle, WA, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AA024796</GrantID><Acronym>AA</Acronym><Agency>NIAAA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 DA013714</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UG1 DA013714</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002319</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Subst Abuse Treat</MedlineTA><NlmUniqueID>8500909</NlmUniqueID><ISSNLinking>0740-5472</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="Y">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014861" MajorTopicYN="N" Type="Geographic">Washington</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chronic condition</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Hypertension</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword><Keyword MajorTopicYN="N">Primary care</Keyword><Keyword MajorTopicYN="N">Substance use</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32220411</ArticleId><ArticleId IdType="mid">NIHMS1594316</ArticleId><ArticleId IdType="pmc">PMC7274163</ArticleId><ArticleId IdType="doi">10.1016/j.jsat.2020.02.008</ArticleId><ArticleId IdType="pii">S0740-5472(19)30594-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ashman JJ, Rui P, Schappert SM, &amp; Strashny A (2017). Characteristics of visits to primary care physicians by adults diagnosed with hypertension. National Health Statistics Reports, Number 106 Retrieved from https://www.cdc.gov/nchs/data/nhsr/nhsr106.pdf</Citation><ArticleIdList><ArticleId IdType="pubmed">29155688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazemore AW, Cottrell EK, Gold R, Hughes LS, Phillips RL, Angier H, &#x2026; DeVoe JE (2016). &#x201c;Community vital signs&#x201d;: Incorporating geocoded social determinants into electronic records to promote patient and population health. Journal of the American Medical Informatics Association, 23(2), 407&#x2013;412. doi:10.1093/jamia/ocv088</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv088</ArticleId><ArticleId IdType="pubmed">26174867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bray JW, Del Boca FK, McRee BG, Hayashi SW, &amp; Babor TF (2017). Screening, brief intervention and referral to treatment (sbirt): Rationale, program overview and cross-site evaluation. Addiction, 112 Suppl 2, 3&#x2013;11. doi:10.1111/add.13676</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/add.13676</ArticleId><ArticleId IdType="pubmed">28074566</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler DC, Petterson S, Phillips RL, &amp; Bazemore AW (2013). Measures of social deprivation that predict health care access and need within a rational area of primary care service delivery. Health Services Research, 48(2pt1), 539&#x2013;559. doi:10.1111/j.1475-6773.2012.01449.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1475-6773.2012.01449.x</ArticleId><ArticleId IdType="pmc">PMC3626349</ArticleId><ArticleId IdType="pubmed">22816561</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler M, Kane RL, McAlpine D, Kathol RG, Fu SS, Hagedorn H, &amp; Wilt TJ (2008). Integration of mental health/substance abuse and primary care. Evid Rep Technol Assess (Full Rep)(173), 1&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4781124</ArticleId><ArticleId IdType="pubmed">19408966</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Behavioral Health Statistics and Quality. (2016). Key substance use and mental health indicators in the united states: Results from the 2015 national survey on drug use and health. (HHS Publication No. SMA 16&#x2013;4984, NSDUH Series H-51). Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2015/NSDUH-FFR1-2015/NSDUH-FFR1-2015.pdf</Citation></Reference><Reference><Citation>Center for Behavioral Health Statistics and Quality. (2017). 2016 national survey on drug use and health: Detailed table. Retrieved from https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.pdf</Citation></Reference><Reference><Citation>Cole AM, Stephens KA, Keppel GA, Estiri H, &amp; Baldwin LM (2016). Extracting electronic health record data in a practice-based research network: Processes to support translational research across diverse practice organizations. EGEMS (Wash DC), 4(2), 1206. doi:10.13063/2327-9214.1206</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1206</ArticleId><ArticleId IdType="pmc">PMC4827782</ArticleId><ArticleId IdType="pubmed">27141519</ArticleId></ArticleIdList></Reference><Reference><Citation>DARTNet Institute. (2019). About dartnet institute. Retrieved from http://www.dartnet.info/AboutDI.htm</Citation></Reference><Reference><Citation>Dowell D, Haegerich TM, &amp; Chou R (2016). Prescribing opioids for chronic pain--reply. JAMA, 316(7), 774&#x2013;775. doi:10.1001/jama.2016.9242</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.9242</ArticleId><ArticleId IdType="pubmed">27533172</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham K, Cheng J, Bernards S, Wells S, Rehm J, &amp; Kurdyak P (2017). How much do mental health and substance use/addiction affect use of general medical services? Extent of use, reason for use, and associated costs. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie, 62(1), 48&#x2013;56. doi:10.1177/0706743716664884</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0706743716664884</ArticleId><ArticleId IdType="pmc">PMC5302109</ArticleId><ArticleId IdType="pubmed">27543084</ArticleId></ArticleIdList></Reference><Reference><Citation>Gryczynski J, McNeely J, Wu LT, Subramaniam GA, Svikis DS, Cathers LA, &#x2026; Schwartz RP (2017). Validation of the taps-1: A four-item screening tool to identify unhealthy substance use in primary care. Journal of General Internal Medicine, 32(9), 990&#x2013;996. doi:10.1007/s11606-017-4079-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-017-4079-x</ArticleId><ArticleId IdType="pmc">PMC5570743</ArticleId><ArticleId IdType="pubmed">28550609</ArticleId></ArticleIdList></Reference><Reference><Citation>Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, &amp; Anis AH (2009). The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health, 9, 88&#x2013;88. doi:10.1186/1471-2458-9-88</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-9-88</ArticleId><ArticleId IdType="pmc">PMC2667420</ArticleId><ArticleId IdType="pubmed">19320986</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallgren KA, Witwer E, West I, &amp; Baldwin LM, Donovan D, Stuvek B, Keppel GA, Mollis B, &amp; Stephens KA (2020). Prevelance of documented alcohol and opioid use disorder diagnoses and treatments in a regional primary care practice-based research network. Journal of Substance Abuse Treatment, 110, 18&#x2013;27. doi:10.1016/j.jsat.2019.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsat.2019.11.008</ArticleId><ArticleId IdType="pmc">PMC7255441</ArticleId><ArticleId IdType="pubmed">31952624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes SL, Salzberg CA, McCarthy D, Radley DC, Abrams MK, Shah T, &amp; Anderson GF (August
2016). High-need, high-cost patients: Who are they and how do they use health care&#x2014;a population-based comparison of demographics, health care use, and expenditures,&#x2026; Retrieved from https://www.commonwealthfund.org/publications/issue-briefs/2016/aug/high-need-high-cost-patients-who-are-they-and-how-do-they-use</Citation><ArticleIdList><ArticleId IdType="pubmed">27571599</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Wei X, Wu T, Chen R, &amp; Guo A (2013). Collaborative care for patients with depression and diabetes mellitus: A systematic review and meta-analysis. BMC Psychiatry, 13, 260&#x2013;260. doi:10.1186/1471-244X-13-260</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-244X-13-260</ArticleId><ArticleId IdType="pmc">PMC3854683</ArticleId><ArticleId IdType="pubmed">24125027</ArticleId></ArticleIdList></Reference><Reference><Citation>Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, &#x2026; Chou R (2017). Primary care-based models for the treatment of opioid use disorder: A scoping review. Annals of Internal Medicine, 166(4), 268&#x2013;278. doi:10.7326/m16-2149</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m16-2149</ArticleId><ArticleId IdType="pmc">PMC5504692</ArticleId><ArticleId IdType="pubmed">27919103</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlowska O, Solomons L, Cuzner D, Ahmed S, McManners J, Tan GD, &#x2026; Rea R (2017). Diabetes care: Closing the gap between mental and physical health in primary care. The British journal of general practice : the journal of the Royal College of General Practitioners, 67(663), 471&#x2013;472. doi:10.3399/bjgp17X692993</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp17X692993</ArticleId><ArticleId IdType="pmc">PMC5604824</ArticleId><ArticleId IdType="pubmed">28963429</ArticleId></ArticleIdList></Reference><Reference><Citation>LaBelle CT, Han SC, Bergeron A, &amp; Samet JH (2016). Office-based opioid treatment with buprenorphine (obot-b): Statewide implementation of the massachusetts collaborative care model in community health centers. Journal of Substance Abuse Treatment, 60, 6&#x2013;13. doi:10.1016/j.jsat.2015.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsat.2015.06.010</ArticleId><ArticleId IdType="pmc">PMC4682362</ArticleId><ArticleId IdType="pubmed">26233698</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayhew M, DeBar LL, Deyo RA, Kerns RD, Goulet JL, Brandt CA, &amp; Von Korff M (2019). Development and assessment of a crosswalk between icd-9-cm and icd-10-cm to identify patients with common pain conditions. The journal of pain : official journal of the American Pain Society, 20(12), 1429&#x2013;1445. doi:10.1016/j.jpain.2019.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpain.2019.05.006</ArticleId><ArticleId IdType="pmc">PMC6874733</ArticleId><ArticleId IdType="pubmed">31129316</ArticleId></ArticleIdList></Reference><Reference><Citation>Merikangas KR, &amp; McClair VL (2012). Epidemiology of substance use disorders. Human Genetics, 131(6), 779&#x2013;789. doi:10.1007/s00439-012-1168-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-012-1168-0</ArticleId><ArticleId IdType="pmc">PMC4408274</ArticleId><ArticleId IdType="pubmed">22543841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills S, Torrance N, &amp; Smith BH (2016). Identification and management of chronic pain in primary care: A review. Current psychiatry reports, 18(2), 22&#x2013;22. doi:10.1007/s11920-015-0659-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11920-015-0659-9</ArticleId><ArticleId IdType="pmc">PMC4731442</ArticleId><ArticleId IdType="pubmed">26820898</ArticleId></ArticleIdList></Reference><Reference><Citation>Morasco BJ, Gritzner S, Lewis L, Oldham R, Turk DC, &amp; Dobscha SK (2011). Systematic review of prevalence, correlates, and treatment outcomes for chronic non-cancer pain in patients with comorbid substance use disorder. Pain, 152(3), 488&#x2013;497. doi:10.1016/j.pain.2010.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pain.2010.10.009</ArticleId><ArticleId IdType="pmc">PMC3053013</ArticleId><ArticleId IdType="pubmed">21185119</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Drug Abuse (NIH). (2014). Principles of adolescent substance use disorder treatment: A research-based guide. Retrieved from https://www.drugabuse.gov/publications/principles-adolescent-substance-use-disorder-treatment-research-based-guide/introduction</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics (OHDSI). (2019). Omop common data model. Data Standardization. Retrieved from https://www.ohdsi.org/data-standardization/the-common-data-model/</Citation></Reference><Reference><Citation>Ornstein SM, Nietert PJ, Jenkins RG, &amp; Litvin CB (2013). The prevalence of chronic diseases and multimorbidity in primary care practice: A pprnet report. Journal of the American Board of Family Medicine, 26(5), 518&#x2013;524. doi:10.3122/jabfm.2013.05.130012</Citation><ArticleIdList><ArticleId IdType="doi">10.3122/jabfm.2013.05.130012</ArticleId><ArticleId IdType="pubmed">24004703</ArticleId></ArticleIdList></Reference><Reference><Citation>Parchman ML, Penfold RB, Ike B, Tauben D, Von Korff M, Stephens M, &#x2026; Baldwin LM (2019). Team-based clinic redesign of opioid medication management in primary care: Effect on opioid prescribing. Annals of Family Medicine, 17(4), 319&#x2013;325. doi:10.1370/afm.2390</Citation><ArticleIdList><ArticleId IdType="doi">10.1370/afm.2390</ArticleId><ArticleId IdType="pmc">PMC6827656</ArticleId><ArticleId IdType="pubmed">31285209</ArticleId></ArticleIdList></Reference><Reference><Citation>Petterson S, McNellis R, Kilink K, Meyers DS, &amp; Bazemore A (January
2018). The state of primary care in the united states: A chartbook of facts and statistics. Retrieved from https://www.graham-center.org/content/dam/rgc/documents/publications-reports/reports/PrimaryCareChartbook.pdf</Citation></Reference><Reference><Citation>Polydorou S, Gunderson EW, &amp; Levin FR (2008). Training physicians to treat substance use disorders. Current psychiatry reports, 10(5), 399&#x2013;404. doi:10.1007/s11920-008-0064-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11920-008-0064-8</ArticleId><ArticleId IdType="pmc">PMC2741399</ArticleId><ArticleId IdType="pubmed">18803913</ArticleId></ArticleIdList></Reference><Reference><Citation>Poudel A, &amp; Gautam S (2017). Age of onset of substance use and psychosocial problems among individuals with substance use disorders. BMC Psychiatry, 17(1), 10. doi:10.1186/s12888-016-1191-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-016-1191-0</ArticleId><ArticleId IdType="pmc">PMC5225546</ArticleId><ArticleId IdType="pubmed">28077106</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert Graham Center. (2019). Social deprivation index (sdi). Retrieved from https://www.graham-center.org/rgc/maps-data-tools/sdi/social-deprivation-index.html</Citation></Reference><Reference><Citation>Saitz R, &amp; Daaleman TP (2017). Now is the time to address substance use disorders in primary care. Annals of Family Medicine, 15(4), 306&#x2013;308. doi:10.1370/afm.2111</Citation><ArticleIdList><ArticleId IdType="doi">10.1370/afm.2111</ArticleId><ArticleId IdType="pmc">PMC5505446</ArticleId><ArticleId IdType="pubmed">28694263</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro B, Coffa D, &amp; McCance-Katz EF (2013). A primary care approach to substance misuse. American Family Physician, 88(2), 113&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">23939642</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens KA, Anderson N, Lin CP, &amp; Estiri H (2016). Implementing partnership-driven clinical federated electronic health record data sharing networks. International Journal of Medical Informatics, 93, 26&#x2013;33. doi:10.1016/j.ijmedinf.2016.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2016.05.008</ArticleId><ArticleId IdType="pmc">PMC6790180</ArticleId><ArticleId IdType="pubmed">27435944</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens KA, Lin CP, Baldwin LM, Echo-Hawk A, Keppel GA, Buchwald D, &#x2026; Tarczy-Hornoch P (2012). Lc data quest: A technical architecture for community federated clinical data sharing. AMIA Jt Summits Transl Sci Proc, 2012, 57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392065</ArticleId><ArticleId IdType="pubmed">22779052</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins KE, Ober AJ, Lamp K, Lind M, Setodji C, Osilla KC, &#x2026; Pincus HA (2017). Collaborative care for opioid and alcohol use disorders in primary care: The summit randomized clinical trial. JAMA Intern Med, 177(10), 1480&#x2013;1488. doi:10.1001/jamainternmed.2017.3947</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2017.3947</ArticleId><ArticleId IdType="pmc">PMC5710213</ArticleId><ArticleId IdType="pubmed">28846769</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams EC, Gupta S, Rubinsky AD, Glass JE, Jones-Webb R, Bensley KM, &amp; Harris AHS (2017). Variation in receipt of pharmacotherapy for alcohol use disorders across racial/ethnic groups: A national study in the u.S. Veterans health administration. Drug and Alcohol Dependence, 178, 527&#x2013;533. doi:10.1016/j.drugalcdep.2017.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2017.06.011</ArticleId><ArticleId IdType="pubmed">28728114</ArticleId></ArticleIdList></Reference><Reference><Citation>Winhusen T, Theobald J, Kaelber DC, &amp; Lewis D (2019). Medical complications associated with substance use disorders in patients with type 2 diabetes and hypertension: Electronic health record findings. Addiction, 114(8), 1462&#x2013;1470. doi:10.1111/add.14607</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/add.14607</ArticleId><ArticleId IdType="pmc">PMC6626564</ArticleId><ArticleId IdType="pubmed">30851217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L-T, McNeely J, Subramaniam GA, Brady KT, Sharma G, VanVeldhuisen P, &#x2026; Schwartz RP (2017). Dsm-5 substance use disorders among adult primary care patients: Results from a multisite study. Drug and Alcohol Dependence, 179, 42&#x2013;46. doi:10.1016/j.drugalcdep.2017.05.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2017.05.048</ArticleId><ArticleId IdType="pmc">PMC5599360</ArticleId><ArticleId IdType="pubmed">28753480</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu LT, Ghitza UE, Zhu H, Spratt S, Swartz M, &amp; Mannelli P (2018). Substance use disorders and medical comorbidities among high-need, high-risk patients with diabetes. Drug and Alcohol Dependence, 186, 86&#x2013;93. doi:10.1016/j.drugalcdep.2018.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2018.01.008</ArticleId><ArticleId IdType="pmc">PMC5959045</ArticleId><ArticleId IdType="pubmed">29554592</ArticleId></ArticleIdList></Reference><Reference><Citation>WWAMI Rural Health Research Center (RUCA). (2019). Ruca data. Zip code ruca approximation. Retrieved from https://depts.washington.edu/uwruca/ruca-contact.php</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32229499</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2632-1009</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>BMJ health &amp; care informatics</Title><ISOAbbreviation>BMJ Health Care Inform</ISOAbbreviation></Journal><ArticleTitle>Extending an open-source tool to measure data quality: case report on Observational Health Data Science and Informatics (OHDSI).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e100054</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjhci-2019-100054</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">As the health system seeks to leverage large-scale data to inform population outcomes, the informatics community is developing tools for analysing these data. To support data quality assessment within such a tool, we extended the open-source software Observational Health Data Sciences and Informatics (OHDSI) to incorporate new functions useful for population health.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed and tested methods to measure the completeness, timeliness and entropy of information. The new data quality methods were applied to over 100&#x2009;million clinical messages received from emergency department information systems for use in public health syndromic surveillance systems.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">While completeness and entropy methods were implemented by the OHDSI community, timeliness was not adopted as its context did not fit with the existing OHDSI domains. The case report examines the process and reasons for acceptance and rejection of ideas proposed to an open-source community like OHDSI.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dixon</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0002-1121-0607</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Indiana University Richard M Fairbanks School of Public Health, Indianapolis, Indiana, USA bedixon@regenstrief.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute Inc, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute Inc, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>French</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute Inc, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute Inc, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Center for Health Analytics and Informatics, Georgia Tech Research Institute, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grannis</LastName><ForeName>Shaun J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute Inc, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Family Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 HS025502</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 LM012219</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Health Care Inform</MedlineTA><NlmUniqueID>101745500</NlmUniqueID><ISSNLinking>2632-1009</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000068598" MajorTopicYN="Y">Data Accuracy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="Y">Data Science</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="Y">Information Storage and Retrieval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">information systems</Keyword><Keyword MajorTopicYN="N">medical informatics</Keyword><Keyword MajorTopicYN="N">public health</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32229499</ArticleId><ArticleId IdType="mid">NIHMS1590928</ArticleId><ArticleId IdType="pmc">PMC7254131</ArticleId><ArticleId IdType="doi">10.1136/bmjhci-2019-100054</ArticleId><ArticleId IdType="pii">bmjhci-2019-100054</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dixon BE, Whipple EC, Lajiness JM, et al. . Utilizing an integrated infrastructure for outcomes research: a systematic review. Health Info Libr J 2016;33:7&#x2013;32.10.1111/hir.12127</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hir.12127</ArticleId><ArticleId IdType="pubmed">26639793</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine Digital infrastructure for the learning health system: the foundation for continuous improvement in health and health care: workshop series summary. Washington, DC: The National Academies Press, 2011.</Citation></Reference><Reference><Citation>Dixon BE, Rosenman M, Xia Y, et al. . A vision for the systematic monitoring and improvement of the quality of electronic health data. Stud Health Technol Inform 2013;192:884&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23920685</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Bakken S, Hripcsak G, et al. . A data quality assessment guideline for electronic health record data reuse. EGEMS 2017;5:14.10.5334/egems.218</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/egems.218</ArticleId><ArticleId IdType="pmc">PMC5983018</ArticleId><ArticleId IdType="pubmed">29881734</ArticleId></ArticleIdList></Reference><Reference><Citation>Liaw S-T, Chen H-Y, Maneze D, et al. . Health reform: is routinely collected electronic information fit for purpose? Emerg Med Australas 2012;24:57&#x2013;63.10.1111/j.1742-6723.2011.01486.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-6723.2011.01486.x</ArticleId><ArticleId IdType="pubmed">22313561</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon BE, Siegel JA, Oemig TV, et al. . Electronic health information quality challenges and interventions to improve public health surveillance data and practice. Public Health Rep 2013;128:546&#x2013;53.10.1177/003335491312800614</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/003335491312800614</ArticleId><ArticleId IdType="pmc">PMC3804098</ArticleId><ArticleId IdType="pubmed">24179266</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin EG, Law J, Ran W, et al. . Evaluating the quality and usability of open data for public health research: a systematic review of data Offerings on 3 open data platforms. J Public Health Manag Pract 2017;23:e5&#x2013;13.10.1097/PHH.0000000000000388</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHH.0000000000000388</ArticleId><ArticleId IdType="pubmed">26910872</ArticleId></ArticleIdList></Reference><Reference><Citation>Botts N, Bouhaddou O, Bennett J, et al. . Data quality and Interoperability challenges for eHealth exchange participants: observations from the Department of Veterans Affairs' virtual lifetime electronic record health pilot phase. AMIA Annu Symp Proc 2014;2014:307&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419918</ArticleId><ArticleId IdType="pubmed">25954333</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman C, Rubin J, Brown J, et al. . Toward a science of learning systems: a research agenda for the high-functioning learning health system. J Am Med Inform Assoc 2015;22:43&#x2013;50.10.1136/amiajnl-2014-002977</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002977</ArticleId><ArticleId IdType="pmc">PMC4433378</ArticleId><ArticleId IdType="pubmed">25342177</ArticleId></ArticleIdList></Reference><Reference><Citation>A Learning Health System Activity; Roundtable on Value and Science-Driven Health Care; Institute of Medicine Observational studies in a learning health system: workshop summary. Washington (DC: National Academies Press (US), 2013.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. . Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, et al. . Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012;19:54&#x2013;60.10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al. . Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med 2010;153:600&#x2013;6.10.7326/0003-4819-153-9-201011020-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Ryan PB, Suchard MA, et al. . Risk of angioedema associated with levetiracetam compared with phenytoin: findings of the observational health data sciences and informatics research network. Epilepsia 2017;58:e101&#x2013;6.10.1111/epi.13828</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.13828</ArticleId><ArticleId IdType="pmc">PMC6632067</ArticleId><ArticleId IdType="pubmed">28681416</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Shahn Z, Madigan D, et al. . Birth month affects lifetime disease risk: a phenome-wide method. J Am Med Inform Assoc 2015;22:1042&#x2013;53.10.1093/jamia/ocv046</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv046</ArticleId><ArticleId IdType="pmc">PMC4986668</ArticleId><ArticleId IdType="pubmed">26041386</ArticleId></ArticleIdList></Reference><Reference><Citation>Huser V, DeFalco FJ, Schuemie M, et al. . Multisite evaluation of a data quality tool for patient-level clinical data sets. EGEMS 2016;4:24.10.13063/2327-9214.1239</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1239</ArticleId><ArticleId IdType="pmc">PMC5226382</ArticleId><ArticleId IdType="pubmed">28154833</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn MG, Callahan TJ, Barnard J, et al. . A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data. EGEMS 2016;4:18&#x2013;44.10.13063/2327-9214.1244</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1244</ArticleId><ArticleId IdType="pmc">PMC5051581</ArticleId><ArticleId IdType="pubmed">27713905</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon BE, Rahurkar S. Public Health Informatics : Hoyt RE, Hersh WR, Health informatics: practical guide. 7th edn Lulu, 2018.</Citation></Reference><Reference><Citation>Williams KS, Shah GH. Electronic health records and meaningful use in local health departments: updates from the 2015 NACCHO informatics assessment survey. J Public Health Manag Pract 2016;22 Suppl 6, Public Health Informatics:S27&#x2013;33.10.1097/PHH.0000000000000460</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHH.0000000000000460</ArticleId><ArticleId IdType="pmc">PMC5050007</ArticleId><ArticleId IdType="pubmed">27684614</ArticleId></ArticleIdList></Reference><Reference><Citation>Doroshenko A, Cooper D, Smith G, et al. . Evaluation of syndromic surveillance based on national health service direct derived data-England and Wales. MMWR Morb Mortal Wkly Rep 2005;54:117&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16177702</ArticleId></ArticleIdList></Reference><Reference><Citation>Buehler JW, Sonricker A, Paladini M, et al. . Syndromic surveillance practice in the United States: findings from a survey of state, territorial, and selected local health departments. Advances in Disease Surveillance 2008;6:1&#x2013;20.</Citation></Reference><Reference><Citation>Ong M-S, Magrabi F, Coiera E. Syndromic surveillance for health information system failures: a feasibility study. J Am Med Inform Assoc 2013;20:506&#x2013;12.10.1136/amiajnl-2012-001144</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-001144</ArticleId><ArticleId IdType="pmc">PMC3628054</ArticleId><ArticleId IdType="pubmed">23184193</ArticleId></ArticleIdList></Reference><Reference><Citation>Grannis S, Wade M, Gibson J, et al. . The Indiana public health emergency surveillance system: ongoing progress, early findings, and future directions. AMIA Annu Symp Proc 2006:304&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1839268</ArticleId><ArticleId IdType="pubmed">17238352</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon BE, Lai PTS, Grannis SJ. Variation in information needs and quality: implications for public health surveillance and biomedical informatics. AMIA Annu Symp Proc 2013;2013:670&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900209</ArticleId><ArticleId IdType="pubmed">24551368</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI 
Welcome to OHDSI: observational health data sciences and informatics community, 2017.  Available: http://www.ohdsi.org/web/wiki/doku.php?id=welcome [Accessed 5 Dec 2017].</Citation></Reference><Reference><Citation>Wen C.
Add observation.row_created_db_time column: GitHub, 2017.  Available: https://github.com/OHDSI/CommonDataModel/issues/104 [Accessed 22 Dec 2017].</Citation></Reference><Reference><Citation>Wang RY, Strong DM. Beyond accuracy: what data quality means to data consumers. J Manag Inf Syst 1996;12:5&#x2013;33.10.1080/07421222.1996.11518099</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07421222.1996.11518099</ArticleId></ArticleIdList></Reference><Reference><Citation>Batini C, Cappiello C, Francalanci C, et al. . Methodologies for data quality assessment and improvement. ACM Comput Surv 2009;41:1&#x2013;52.10.1145/1541880.1541883</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/1541880.1541883</ArticleId></ArticleIdList></Reference><Reference><Citation>Holden RJ, Voida S, Savoy A, et al. . Human Factors Engineering and Human&#x2013;Computer Interaction: Supporting User Performance and Experience : Finnell JT, Dixon BE, Clinical informatics study guide: text and review. Zurich: Springer International Publishing, 2016: 287&#x2013;307.</Citation></Reference><Reference><Citation>The Book of OHDSI Observational health data sciences and informatics, ED.: observational health data sciences and informatics 2019.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32293578</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study.</ArticleTitle><Pagination><StartPage>e15124</StartPage><MedlinePgn>e15124</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e15124</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/15124</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Observational Health Data Sciences and Informatics (OHDSI) network is an international collaboration established to apply open-source data analytics to a large network of health databases, including the Korean common data model (K-CDM) network.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study is to analyze the effect that age at diagnosis has on the prognosis of inflammatory bowel disease (IBD) in Korea using a CDM network database.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed the K-CDM network database from 2005 to 2015. We transformed the electronic medical record into the CDM version 5.0 used in OHDSI. A worsened IBD prognosis was defined as the initiation of therapy with biologic agents, including infliximab and adalimumab. To evaluate the effect that age at diagnosis had on the prognosis of IBD, we divided the patients into an early-onset (EO) IBD group (age at diagnosis &lt;40 years) and a late-onset (LO) IBD group (age at diagnosis &#x2265;40 years) with the cutoff value of age at diagnosis as 40 years, which was calculated using the Youden index method. We then used the logrank test and Cox proportional hazards model to analyze the effect that age at diagnosis (EO group vs LO group) had on the prognosis in patients with IBD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 3480 patients were enrolled. There was 2017 patients with ulcerative colitis (UC) and 1463 with Crohn's disease (CD). The median follow up period was 109.5 weeks. The EO UC group was statistically significant and showed less event-free survival (ie, experiences of biologic agents) than the LO UC group (P&lt;.001). In CD, the EO CD group showed less event-free survival (ie, experiences of biologic agents) than the LO CD group. In the Cox proportional hazard analysis, the odds ratio (OR) of the EO UC group on experiences of biologic agents compared with the LO UC group was 2.3 (95% CI 1.3-3.8, P=.002). The OR of the EO CD group on experiences of biologic agents compared with the LO CD group was 5.4 (95% CI 1.9-14.9, P=.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The EO IBD group showed a worse prognosis than the LO IBD group in Korean patients with IBD. In addition, this study successfully verified the CDM model in gastrointestinal research.</AbstractText><CopyrightInformation>&#xa9;Youn I Choi, Yoon Jae Kim, Jun-Won Chung, Kyoung Oh Kim, Hakki Kim, Rae Woong Park, Dong Kyun Park. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 15.04.2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Youn I</ForeName><Initials>YI</Initials><Identifier Source="ORCID">0000-0001-6561-6752</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Gil Medical Center, Gachon University College of Internal Medicine, Incheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kim</LastName><ForeName>Yoon Jae</ForeName><Initials>YJ</Initials><Identifier Source="ORCID">0000-0001-8477-6823</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Gil Medical Center, Gachon University College of Internal Medicine, Incheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Jun-Won</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0002-0869-7661</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Gil Medical Center, Gachon University College of Internal Medicine, Incheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kyoung Oh</ForeName><Initials>KO</Initials><Identifier Source="ORCID">0000-0002-5365-2550</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Gil Medical Center, Gachon University College of Internal Medicine, Incheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hakki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3361-8232</Identifier><AffiliationInfo><Affiliation>Health IT Research Center, Gil Medical Center, Gachon University, Incheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Ajou Medical Center, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Dong Kyun</ForeName><Initials>DK</Initials><Identifier Source="ORCID">0000-0002-2862-6641</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Gil Medical Center, Gachon University College of Internal Medicine, Incheon, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Crohn&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">early-onset</Keyword><Keyword MajorTopicYN="N">late-onset</Keyword><Keyword MajorTopicYN="N">ulcerative colitis</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32293578</ArticleId><ArticleId IdType="pmc">PMC7191339</ArticleId><ArticleId IdType="doi">10.2196/15124</ArticleId><ArticleId IdType="pii">v8i4e15124</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720&#x2013;7. doi: 10.1038/nrgastro.2015.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2015.150</ArticleId><ArticleId IdType="pubmed">26323879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima Martins A, Volpato RA, Zago-Gomes MDP. The prevalence and phenotype in Brazilian patients with inflammatory bowel disease. BMC Gastroenterol. 2018 Jun 18;18(1):87. doi: 10.1186/s12876-018-0822-y.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12876-018-0822-y</ArticleId><ArticleId IdType="doi">10.1186/s12876-018-0822-y</ArticleId><ArticleId IdType="pmc">PMC6006948</ArticleId><ArticleId IdType="pubmed">29914399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018 Dec 23;390(10114):2769&#x2013;2778. doi: 10.1016/S0140-6736(17)32448-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32448-0</ArticleId><ArticleId IdType="pubmed">29050646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamm MA. Rapid changes in epidemiology of inflammatory bowel disease. Lancet. 2018 Dec 23;390(10114):2741&#x2013;2742. doi: 10.1016/S0140-6736(17)32669-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32669-7</ArticleId><ArticleId IdType="pubmed">29050647</ArticleId></ArticleIdList></Reference><Reference><Citation>Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46&#x2013;54.e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.10.001</ArticleId><ArticleId IdType="pubmed">22001864</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng SC, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV, Tysk C, O'Morain C, Moum B, Colombel J. Geographical variability and environmental risk factors in inflammatory bowel disease. Gut. 2013 Apr;62(4):630&#x2013;49. doi: 10.1136/gutjnl-2012-303661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2012-303661</ArticleId><ArticleId IdType="pubmed">23335431</ArticleId></ArticleIdList></Reference><Reference><Citation>Salgado VCL, Luiz RR, Boechat N, Schorr BC, Le&#xe3;o IS, Nunes T, Zaltman C. Crohn's disease environmental factors in the developing world: a case-control study in a statewide catchment area in Brazil. World J Gastroenterol. 2017 Aug 14;23(30):5549&#x2013;5556. doi: 10.3748/wjg.v23.i30.5549.  </Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i30.5549</ArticleId><ArticleId IdType="pmc">PMC5558118</ArticleId><ArticleId IdType="pubmed">28852314</ArticleId></ArticleIdList></Reference><Reference><Citation>Ol&#xe9;n O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, Ekbom A, Malmborg P, Ludvigsson JF. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ. 2017 Sep 20;358:j3951. doi: 10.1136/bmj.j3951.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.j3951</ArticleId><ArticleId IdType="pmc">PMC5605779</ArticleId><ArticleId IdType="pubmed">28931512</ArticleId></ArticleIdList></Reference><Reference><Citation>Klement E, Lysy J, Hoshen M, Avitan M, Goldin E, Israeli E. Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2008 Jul;103(7):1775&#x2013;82. doi: 10.1111/j.1572-0241.2008.01905.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2008.01905.x</ArticleId><ArticleId IdType="pubmed">18557710</ArticleId></ArticleIdList></Reference><Reference><Citation>Everhov &#xc5;H, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, S&#xf6;derling J, Ekbom A, Neovius M, Ludvigsson JF, Askling J, Ol&#xe9;n O. Incidence and treatment of patients diagnosed with&#xa0;inflammatory bowel diseases at 60 years or older&#xa0;in&#xa0;Sweden. Gastroenterology. 2018 Feb;154(3):518&#x2013;528.e15. doi: 10.1053/j.gastro.2017.10.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.10.034</ArticleId><ArticleId IdType="pubmed">29102619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009 Feb;15(2):182&#x2013;9. doi: 10.1002/ibd.20628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ibd.20628</ArticleId><ArticleId IdType="pubmed">18668678</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV, Kane S, Sands BE, Colombel J, Sandborn WJ, Lasch K, Cao C. Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn's&#xa0;disease. Gastroenterology. 2018 Sep;155(3):687&#x2013;695.e10. doi: 10.1053/j.gastro.2018.05.039.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.05.039</ArticleId><ArticleId IdType="pmc">PMC6419724</ArticleId><ArticleId IdType="pubmed">29857091</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan NH, Almukhtar RM, Cole EB, Abbas AM. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease - a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014 Aug;40(4):374&#x2013;81. doi: 10.1111/apt.12834. doi: 10.1111/apt.12834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12834</ArticleId><ArticleId IdType="doi">10.1111/apt.12834</ArticleId><ArticleId IdType="pubmed">24961751</ArticleId></ArticleIdList></Reference><Reference><Citation>Baars JE, Kuipers EJ, van Haastert M, Nicola&#xef; JJ, Poen AC, van der Woude CJ. Age at diagnosis of inflammatory bowel disease influences early development of colorectal cancer in inflammatory bowel disease patients: a nationwide, long-term survey. J Gastroenterol. 2012 Dec;47(12):1308&#x2013;22. doi: 10.1007/s00535-012-0603-2.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-012-0603-2</ArticleId><ArticleId IdType="pmc">PMC3523115</ArticleId><ArticleId IdType="pubmed">22627504</ArticleId></ArticleIdList></Reference><Reference><Citation>Israeli E, Ryan JD, Shafer L, Bernstein CN. Younger age at diagnosis is associated with panenteric, but not more aggressive, Crohn's disease. Clin Gastroenterol Hepatol. 2014 Jan;12(1):72&#x2013;79.e1. doi: 10.1016/j.cgh.2013.06.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2013.06.027</ArticleId><ArticleId IdType="pubmed">23880115</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MZ, Thompson CB, Yates B, Zimmerman L, Pullen CH. Implementing common data elements across studies to advance research. Nurs Outlook. 2015;63(2):181&#x2013;8. doi: 10.1016/j.outlook.2014.11.006.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.outlook.2014.11.006</ArticleId><ArticleId IdType="pmc">PMC4361774</ArticleId><ArticleId IdType="pubmed">25771192</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehan J, Hirschfeld S, Foster E, Ghitza U, Goetz K, Karpinski J, Lang L, Moser RP, Odenkirchen J, Reeves D, Rubinstein Y, Werner E, Huerta M. Improving the value of clinical research through the use of Common Data Elements. Clin Trials. 2016 Dec;13(6):671&#x2013;676. doi: 10.1177/1740774516653238.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774516653238</ArticleId><ArticleId IdType="pmc">PMC5133155</ArticleId><ArticleId IdType="pubmed">27311638</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, Suchard MA, Park RW, Wong ICK, Rijnbeek PR, van der Lei J, Pratt N, Nor&#xe9;n GN, Li Y, Stang PE, Madigan D, Ryan PB. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, Suchard MA, Schuemie MJ, DeFalco FJ, Perotte A, Banda JM, Reich CG, Schilling LM, Matheny ME, Meeker D, Pratt N, Madigan D. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. 2016 Dec 05;113(27):7329&#x2013;36. doi: 10.1073/pnas.1510502113.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C, Bate A. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Saf. 2013 Feb;36(2):119&#x2013;34. doi: 10.1007/s40264-012-0009-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-012-0009-3</ArticleId><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P, Cheng C, Kaddi CD, Venugopalan J, Hoffman R, Wang MD. -Omic and Electronic Health Record Big Data Analytics for Precision Medicine. IEEE Trans Biomed Eng. 2017 Feb;64(2):263&#x2013;273. doi: 10.1109/TBME.2016.2573285.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TBME.2016.2573285</ArticleId><ArticleId IdType="pmc">PMC5859562</ArticleId><ArticleId IdType="pubmed">27740470</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenkaya R, Gurley M, Dymshyts D, Araujo S, Williams A, Chen R, Reich C. Standardized observational cancer research using the OMOP CDM oncology module. Stud Health Technol Inform. 2019 Aug 21;264:1831&#x2013;1832. doi: 10.3233/SHTI190670.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI190670</ArticleId><ArticleId IdType="pubmed">31438365</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung Y, Hwangbo Y, Yoon SM, Koo HS, Shin HD, Shin JE, Moon HS, Kang SB, Lee JR, Huh KC. Predictive factors for differentiating between Crohn's disease and intestinal tuberculosis in Koreans. Am J Gastroenterol. 2016 Aug;111(8):1156&#x2013;64. doi: 10.1038/ajg.2016.212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.212</ArticleId><ArticleId IdType="pubmed">27296940</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Liao W, Yu C, Tu Y, Pan X, Chen Y, Lv N, Zhu X. Differences in clinical features of Crohn's disease and intestinal tuberculosis. World J Gastroenterol. 2015 Mar 28;21(12):3650&#x2013;6. doi: 10.3748/wjg.v21.i12.3650.  </Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i12.3650</ArticleId><ArticleId IdType="pmc">PMC4375590</ArticleId><ArticleId IdType="pubmed">25834333</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumla A, George A, Sharma V, Herbert RHN, Baroness Masham of Ilton. Oxley A, Oliver M. The WHO 2014 global tuberculosis report&#x2014;further to go. Lancet Glob Health. 2015 Jan;3(1):e10&#x2013;2. doi: 10.1016/S2214-109X(14)70361-4.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(14)70361-4</ArticleId><ArticleId IdType="pubmed">25539957</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ES, Kim WH. Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver. 2010 Mar;4(1):1&#x2013;14. doi: 10.5009/gnl.2010.4.1.1.  </Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl.2010.4.1.1</ArticleId><ArticleId IdType="pmc">PMC2871616</ArticleId><ArticleId IdType="pubmed">20479907</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Im JP, Han K, Kim J, Lee HJ, Chun J, Kim JS. Changes in direct healthcare costs before and after the diagnosis of inflammatory bowel disease: a nationwide population-based study. Gut Liver. 2020 Jan 15;14(1):89&#x2013;99. doi: 10.5009/gnl19023.  </Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl19023</ArticleId><ArticleId IdType="pmc">PMC6974324</ArticleId><ArticleId IdType="pubmed">31158951</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek S, Lee KY, Song KH, Yu CS. Current status and trends in inflammatory bowel disease surgery in Korea: analysis of data in a nationwide registry. Ann Coloproctol. 2018 Dec;34(6):299&#x2013;305. doi: 10.3393/ac.2018.07.21.  </Citation><ArticleIdList><ArticleId IdType="doi">10.3393/ac.2018.07.21</ArticleId><ArticleId IdType="pmc">PMC6347339</ArticleId><ArticleId IdType="pubmed">30630303</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019 Dec;68(Suppl 3):s1&#x2013;s106. doi: 10.1136/gutjnl-2019-318484.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-318484</ArticleId><ArticleId IdType="pmc">PMC6872448</ArticleId><ArticleId IdType="pubmed">31562236</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019 Mar;114(3):384&#x2013;413. doi: 10.14309/ajg.0000000000000152.</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000000152</ArticleId><ArticleId IdType="pubmed">30840605</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018 Apr;113(4):481&#x2013;517. doi: 10.1038/ajg.2018.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2018.27</ArticleId><ArticleId IdType="pubmed">29610508</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JJ, Yang S, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H. Second Korean guidelines for the management of Crohn's disease. Intest Res. 2017 Jan;15(1):38&#x2013;67. doi: 10.5217/ir.2017.15.1.38.  </Citation><ArticleIdList><ArticleId IdType="doi">10.5217/ir.2017.15.1.38</ArticleId><ArticleId IdType="pmc">PMC5323307</ArticleId><ArticleId IdType="pubmed">28239314</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JW, Im JP, Cheon JH, Kim YS, Kim JS, Han DS. Inflammatory bowel disease cohort studies in Korea: present and future. Intest Res. 2015 Jul;13(3):213&#x2013;8. doi: 10.5217/ir.2015.13.3.213.  </Citation><ArticleIdList><ArticleId IdType="doi">10.5217/ir.2015.13.3.213</ArticleId><ArticleId IdType="pmc">PMC4479735</ArticleId><ArticleId IdType="pubmed">26130995</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017 Jan;15(1):7&#x2013;37. doi: 10.5217/ir.2017.15.1.7.  </Citation><ArticleIdList><ArticleId IdType="doi">10.5217/ir.2017.15.1.7</ArticleId><ArticleId IdType="pmc">PMC5323310</ArticleId><ArticleId IdType="pubmed">28239313</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong SJ, Cho SM, Choe B, Jang HJ, Choi KH, Kang B, Kim JE, Hwang JH. Characteristics and incidence trends for pediatric inflammatory bowel disease in Daegu-Kyungpook province in Korea: a multi-center study. J Korean Med Sci. 2018 Apr 30;33(18):e132. doi: 10.3346/jkms.2018.33.e132.  </Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2018.33.e132</ArticleId><ArticleId IdType="pmc">PMC5920122</ArticleId><ArticleId IdType="pubmed">29713253</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobore I, Li J, Yuhang L, Al-Handarish Y, Kandwal A, Nie Z, Wang L. Deep learning intervention for health care challenges: some biomedical domain considerations. JMIR Mhealth Uhealth. 2019 Aug 02;7(8):e11966. doi: 10.2196/11966.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/11966</ArticleId><ArticleId IdType="pmc">PMC6696854</ArticleId><ArticleId IdType="pubmed">31376272</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiske A, Prainsack B, Buyx A. Data work: meaning-making in the era of data-rich medicine. J Med Internet Res. 2019 Jul 09;21(7):e11672. doi: 10.2196/11672.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/11672</ArticleId><ArticleId IdType="pmc">PMC6647753</ArticleId><ArticleId IdType="pubmed">31290397</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Sun S, Mukkamala RR, Vatrapu R, Ordieres-Mer&#xe9; J. Accelerating health data sharing: a solution based on the Internet of Things and distributed ledger technologies. J Med Internet Res. 2019 Jun 06;21(6):e13583. doi: 10.2196/13583.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13583</ArticleId><ArticleId IdType="pmc">PMC6592507</ArticleId><ArticleId IdType="pubmed">31172963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavragani A, Ochoa G. Google trends in infodemiology and infoveillance: methodology framework. JMIR Public Health Surveill. 2019 May 29;5(2):e13439. doi: 10.2196/13439.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13439</ArticleId><ArticleId IdType="pmc">PMC6660120</ArticleId><ArticleId IdType="pubmed">31144671</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbonnel F, Ninot G. Identifying frameworks for validation and monitoring of consensual behavioral intervention technologies: narrative review. J Med Internet Res. 2019 Oct 16;21(10):e13606. doi: 10.2196/13606.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13606</ArticleId><ArticleId IdType="pmc">PMC6822061</ArticleId><ArticleId IdType="pubmed">31621638</ArticleId></ArticleIdList></Reference><Reference><Citation>Katapally TR. The SMART framework: integration of citizen science, community-based participatory research, and systems science for population health science in the digital age. JMIR Mhealth Uhealth. 2019 Aug 30;7(8):e14056. doi: 10.2196/14056.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14056</ArticleId><ArticleId IdType="pmc">PMC6743262</ArticleId><ArticleId IdType="pubmed">31471963</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HH, Kim B, Joo S, Shin S, Cha HS, Park YR. Why do data users say health care data are difficult to use? a cross-sectional survey study. J Med Internet Res. 2019 Aug 06;21(8):e14126. doi: 10.2196/14126.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14126</ArticleId><ArticleId IdType="pmc">PMC6701164</ArticleId><ArticleId IdType="pubmed">31389335</ArticleId></ArticleIdList></Reference><Reference><Citation>McPadden J, Durant TJ, Bunch DR, Coppi A, Price N, Rodgerson K, Torre CJ, Byron W, Hsiao AL, Krumholz HM, Schulz WL. Health care and precision medicine research: analysis of a scalable data science platform. J Med Internet Res. 2019 Apr 09;21(4):e13043. doi: 10.2196/13043.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/13043</ArticleId><ArticleId IdType="pmc">PMC6477571</ArticleId><ArticleId IdType="pubmed">30964441</ArticleId></ArticleIdList></Reference><Reference><Citation>Mavragani A, Ochoa G, Tsagarakis KP. Assessing the methods, tools, and statistical approaches in Google trends research: systematic review. J Med Internet Res. 2018 Nov 06;20(11):e270. doi: 10.2196/jmir.9366.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.9366</ArticleId><ArticleId IdType="pmc">PMC6246971</ArticleId><ArticleId IdType="pubmed">30401664</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Solbrig HR, Prud'hommeaux E, Tao C, Weng C, Chute CG. Quality assurance of cancer study Common Data Elements using a post-coordination approach. AMIA Annu Symp Proc. 2015;2015:659&#x2013;68.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765658</ArticleId><ArticleId IdType="pubmed">26958201</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Hicks RR, Johnson VE, Bergstrom DA, Cummings DM, Noble LJ, Hovda D, Whalen M, Ahlers ST, LaPlaca M, Tortella FC, Duhaime A, Dixon CE. Pre-clinical traumatic brain injury Common Data Elements: toward a common language across laboratories. J Neurotrauma. 2015 Nov 15;32(22):1725&#x2013;35. doi: 10.1089/neu.2014.3861.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2014.3861</ArticleId><ArticleId IdType="pmc">PMC4651035</ArticleId><ArticleId IdType="pubmed">26058402</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell MJ, Kochanek PM. Pediatric traumatic brain injury in 2012: the year with new guidelines and common data elements. Crit Care Clin. 2013 Apr;29(2):223&#x2013;38. doi: 10.1016/j.ccc.2012.11.004.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccc.2012.11.004</ArticleId><ArticleId IdType="pmc">PMC3632392</ArticleId><ArticleId IdType="pubmed">23537673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M, Shin S, Kang M, Yi B, Chang DK. Developing a standardization algorithm for categorical laboratory tests for clinical big data research: retrospective study. JMIR Med Inform. 2019 Aug 29;7(3):e14083. doi: 10.2196/14083.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14083</ArticleId><ArticleId IdType="pmc">PMC6740165</ArticleId><ArticleId IdType="pubmed">31469075</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue JK, Vassar MJ, Lingsma HF, Cooper SR, Okonkwo DO, Valadka AB, Gordon WA, Maas AIR, Mukherjee P, Yuh EL, Puccio AM, Schnyer DM, Manley GT, TRACK-TBI Investigators  Transforming research and clinical knowledge in traumatic brain injury pilot: multicenter implementation of the common data elements for traumatic brain injury. J Neurotrauma. 2013 Nov 15;30(22):1831&#x2013;44. doi: 10.1089/neu.2013.2970.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2013.2970</ArticleId><ArticleId IdType="pmc">PMC3814815</ArticleId><ArticleId IdType="pubmed">23815563</ArticleId></ArticleIdList></Reference><Reference><Citation>Amre DK, Lambrette P, Law L, Krupoves A, Chotard V, Costea F, Grimard G, Israel D, Mack D, Seidman EG. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn's disease: a case-control study. Am J Gastroenterol. 2006 May;101(5):1005&#x2013;11. doi: 10.1111/j.1572-0241.2006.00526.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00526.x</ArticleId><ArticleId IdType="pubmed">16573775</ArticleId></ArticleIdList></Reference><Reference><Citation>Panaccio MP, Cummins G, Wentworth C, Lanes S, Reynolds SL, Reynolds MW, Miao R, Koren A. A common data model to assess cardiovascular hospitalization and mortality in atrial fibrillation patients using administrative claims and medical records. Clin Epidemiol. 2015;7:77&#x2013;90. doi: 10.2147/CLEP.S64936. doi: 10.2147/CLEP.S64936.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S64936</ArticleId><ArticleId IdType="doi">10.2147/CLEP.S64936</ArticleId><ArticleId IdType="pmc">PMC4296911</ArticleId><ArticleId IdType="pubmed">25624771</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaty HM, Sansgiry S, Artinyan A, Hou JK. Time trends, clinical characteristics, and risk factors of chronic anal fissure among a national cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2016 Mar;61(3):861&#x2013;4. doi: 10.1007/s10620-015-3930-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-015-3930-3</ArticleId><ArticleId IdType="pubmed">26514675</ArticleId></ArticleIdList></Reference><Reference><Citation>Gower-Rousseau C, Dauchet L, Vernier-Massouille G, Tilloy E, Brazier F, Merle V, Dupas J, Savoye G, Bald&#xe9; M, Marti R, Lerebours E, Cortot A, Salomez J, Turck D, Colombel J. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 2009 Aug;104(8):2080&#x2013;8. doi: 10.1038/ajg.2009.177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2009.177</ArticleId><ArticleId IdType="pubmed">19436273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32308871</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2019</Volume><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>Considerations for Improving the Portability of Electronic Health Record-Based Phenotype Algorithms.</ArticleTitle><Pagination><StartPage>755</StartPage><EndPage>764</EndPage><MedlinePgn>755-764</MedlinePgn></Pagination><Abstract><AbstractText>With the increased adoption of electronic health records, data collected for routine clinical care is used for health outcomes and population sciences research, including the identification of phenotypes. In recent years, research networks, such as eMERGE, OHDSI and PCORnet, have been able to increase statistical power and population diversity by combining patient cohorts. These networks share phenotype algorithms that are executed at each participating site. Here we observe experiences with phenotype algorithm portability across seven research networks and propose a generalizable framework for phenotype algorithm portability. Several strategies exist to increase the portability of phenotype algorithms, reducing the implementation effort needed by each site. These include using a common data model, standardized representation of the phenotype algorithm logic, and technical solutions to facilitate federated execution of queries. Portability is achieved by tradeoffs across three domains: Data, Authoring and Implementation, and multiple approaches were observed in representing portable phenotype algorithms. Our proposed framework will help guide future research in operationalizing phenotype algorithm portability at scale.</AbstractText><CopyrightInformation>&#xa9;2019 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Luke V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandt</LastName><ForeName>Pascal S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Guoqian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiefer</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacheco</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adekkanattu</LastName><ForeName>Prakash</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ancker</LastName><ForeName>Jessica S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhenxing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>Jyotishman</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Northwestern University, Chicago, IL.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM105688</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008673</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065709" MajorTopicYN="N">Common Data Elements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003195" MajorTopicYN="N">Computer Communication Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32308871</ArticleId><ArticleId IdType="pmc">PMC7153055</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pathak J, Kho AN, Denny JC. Electronic health records-driven phenotyping: challenges, recent advances, and perspectives. Journal of the American Medical Informatics Association : JAMIA. 2013;20(e2):e206&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861925</ArticleId><ArticleId IdType="pubmed">24302669</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM, Seneviratne M, Hernandez-Boussard T, Shah NH. Advances in Electronic Phenotyping: From Rule-Based Definitions to Machine Learning Models. Annual Review of Biomedical Data Science. 2018;1(1):53&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583807</ArticleId><ArticleId IdType="pubmed">31218278</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt TM, Elston-Lafata J, Tolsma D, Greene SM. The role of research in integrated healthcare systems: the HMO Research Network. Am J Manag Care. 2004;10(9):643&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15515997</ArticleId></ArticleIdList></Reference><Reference><Citation>McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data. Pharmacoepidemiology and Drug Safety. 2012;21:18&#x2013;22. Suppl 1.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262589</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med. 2013;15(10):761&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795928</ArticleId><ArticleId IdType="pubmed">23743551</ArticleId></ArticleIdList></Reference><Reference><Citation>Califf RM. The Patient-Centered Outcomes Research Network: a national infrastructure for comparative effectiveness research. North Carolina Medical Journal. 2014;75(3):204&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">24830497</ArticleId></ArticleIdList></Reference><Reference><Citation>NCATS. Welcome to the ACT Network! 2019 [March 13, 2019].  Available from: http://www.actnetwork.us.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Studies in health technology and informatics. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>De Moor G, Sundgren M, Kalra D, Schmidt A, Dugas M, Claerhout B, et al. Using electronic health records for clinical research: the case of the EHR4CR project. Journal of Biomedical Informatics. 2015;53:162&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">25463966</ArticleId></ArticleIdList></Reference><Reference><Citation>Richesson RL, Sun J, Pathak J, Kho AN, Denny JC. Clinical phenotyping in selected national networks: demonstrating the need for high-throughput, portable, and computational methods. Artificial Intelligence in Medicine. 2016;71:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480212</ArticleId><ArticleId IdType="pubmed">27506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby JC, Speltz P, Rasmussen LV, Basford M, Gottesman O, Peissig PL, et al. PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. Journal of the American Medical Informatics Association : JAMIA. 2016;23(6):1046&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070514</ArticleId><ArticleId IdType="pubmed">27026615</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. National Library of Medicine. Home -ClinicalTrials.gov 2019 [March 13, 2019].  Available from: https://clinicaltrials.gov/</Citation></Reference><Reference><Citation>Newton KM, Peissig PL, Kho AN, Bielinski SJ, Berg RL, Choudhary V, et al. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. Journal of the American Medical Informatics Association : JAMIA. 2013;20(e1):e147&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivade C, Raghavan P, Fosler-Lussier E, Embi PJ, Elhadad N, Johnson SB, et al. A review of approaches to identifying patient phenotype cohorts using electronic health records. Journal of the American Medical Informatics Association : JAMIA. 2014;21(2):221&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932460</ArticleId><ArticleId IdType="pubmed">24201027</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohane IS, Churchill SE, Murphy SN. A translational engine at the national scale: informatics for integrating biology and the bedside. Journal of the American Medical Informatics Association: JAMIA. 2012;19(2):181&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277623</ArticleId><ArticleId IdType="pubmed">22081225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sentinel Coordinating Center. Sentinel Common Data Model 2019 [March 13, 2019].  Available from:  https://www.sentinelinitiative.org/sentinel/data/distributed-database-common-data-model.</Citation></Reference><Reference><Citation>FitzHenry F, Resnic FS, Robbins SL, Denton J, Nookala L, Meeker D, et al. Creating a Common Data Model for Comparative Effectiveness with the Observational Medical Outcomes Partnership. Applied Clinical Informatics. 2015;6(3):536&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Data Interchange Standards Consortium. Study Data Tabulation Model 2018 [March 13, 2019].  Available from:  https://www.cdisc.org/standards/foundational/sdtm.</Citation></Reference><Reference><Citation>Platt R, Davis R, Finkelstein J, Go AS, Gurwitz JH, Roblin D, et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. Pharmacoepidemiology and Drug Safety. 2001;10(5):373&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">11802579</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross TR, Ng D, Brown JS, Pardee R, Hornbrook MC, Hart G, et al. EGEMS. 1. Vol. 2. Washington,DC: 2014. The HMO Research Network Virtual Data Warehouse: A Public Data Model to Support Collaboration. p. 1049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371424</ArticleId><ArticleId IdType="pubmed">25848584</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. Journal of Biomedical Informatics. 2016;64:333&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S.Department of Health and Human Services. Harmonization of Various Common Data Models and Open Standards for Evidence Generation 2017 [July 10, 2019]  Available from: https://aspe.hhs.gov/harmonization-various-common-data-models-and-open-standards-evidence-generation.</Citation></Reference><Reference><Citation>Clinical Data Interchange Standards Consortium.  BRIDG 2019. 2019 Jul 10; Available from:  https://www.cdisc.org/standards/domain-information-module/bridg.</Citation></Reference><Reference><Citation>Rasmussen LV, Kiefer RC, Mo H, Speltz P, Thompson WK, Jiang G, et al. A Modular Architecture for Electronic Health Record-Driven Phenotyping. AMIA Joint Summits on Translational Science proceedings AMIA Joint Summits on Translational Science. 2015;2015:147&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525215</ArticleId><ArticleId IdType="pubmed">26306258</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco JA, Rasmussen LV, Kiefer RC, Campion TR, Speltz P, Carroll RJ, et al. A case study evaluating the portability of an executable computable phenotype algorithm across multiple institutions and electronic health record environments. Journal of the American Medical Informatics Association : JAMIA. 2018;25(11):1540&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6213083</ArticleId><ArticleId IdType="pubmed">30124903</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Szolovits P, editors. Implementing a Portable Clinical NLP System with a Common Data Model -- a Lisp Perspective. 2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) 2018 Dec 3-6; 2018.</Citation></Reference><Reference><Citation>Bache R, Miles S, Taweel A. An adaptable architecture for patient cohort identification from diverse data sources. Journal of the American Medical Informatics Association : JAMIA. 2013;20(e2):e327&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861920</ArticleId><ArticleId IdType="pubmed">24064442</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI.  OHDSI/PhenotypeLibrary: A repository to store validated phenotype cohort definitions, with all associated source code, documentation, and validation results. 2019. 2019 Mar 13; Available from: https://github.com/OHDSI/PhenotypeLibrary.</Citation></Reference><Reference><Citation>McMurry AJ, Murphy SN, MacFadden D, Weber G, Simons WW, Orechia J, et al. SHRINE: Enabling Nationally Scalable Multi-Site Disease Studies. PLOS ONE. 2013;8(3):e55811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3591385</ArticleId><ArticleId IdType="pubmed">23533569</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo H, Jiang G, Pacheco JA, Kiefer R, Rasmussen LV, Pathak J, et al. A Decompositional Approach to Executing Quality Data Model Algorithms on the i2b2 Platform. AMIA Joint Summits on Translational Science proceedings AMIA Joint Summits on Translational Science. 2016;2016:167&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001760</ArticleId><ArticleId IdType="pubmed">27570665</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson R. Project management: cost, time and quality, two best guesses and a phenomenon, its time to accept other success criteria. International Journal of Project Management. 1999;17(6):337&#x2013;42.</Citation></Reference><Reference><Citation>Jackson KL, Mbagwu M, Pacheco JA, Baldridge AS, Viox DJ, Linneman JG, et al. Performance of an electronic health record-based phenotype algorithm to identify community associated methicillin-resistant Staphylococcus aureus cases and controls for genetic association studies. BMC Infectious Diseases. 2016</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114817</ArticleId><ArticleId IdType="pubmed">27855652</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo H, Thompson WK, Rasmussen LV, Pacheco JA, Jiang G, Kiefer R, et al. Desiderata for computable representations of electronic health records-driven phenotype algorithms. Journal of the American Medical Informatics Association : JAMIA. 2015;22(6):1220&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4639716</ArticleId><ArticleId IdType="pubmed">26342218</ArticleId></ArticleIdList></Reference><Reference><Citation>Girardeau Y, Doods J, Zapletal E, Chatellier G, Daniel C, Burgun A, et al. Leveraging the EHR4CR platform to support patient inclusion in academic studies: challenges and lessons learned. BMC medical research methodology. 2017;17(1):36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5329914</ArticleId><ArticleId IdType="pubmed">28241798</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Kiefer RC, Sharma DK, Prud&#x2019;hommeaux E, Solbrig HR. A Consensus-based Approach for Harmonizing the OHDSI Common Data Model with HL7 FHIR. Studies in health technology and informatics. 2017;245:887&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939955</ArticleId><ArticleId IdType="pubmed">29295227</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei WQ, Leibson CL, Ransom JE, Kho AN, Caraballo PJ, Chai HS, et al. Impact of data fragmentation across healthcare centers on the accuracy of a high-throughput clinical phenotyping algorithm for specifying subjects with type 2 diabetes mellitus. Journal of the American Medical Informatics Association : JAMIA. 2012;19(2):219&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277630</ArticleId><ArticleId IdType="pubmed">22249968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim Choi Keung SN, Zhao L, Tyler E, Taweel A, Delaney B, Peterson KA, et al. Cohort identification for clinical research: querying federated electronic healthcare records using controlled vocabularies and semantic types. AMIA Joint Summits on Translational Science proceedings AMIA Joint Summits on Translational Science. 2012;2012:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392063</ArticleId><ArticleId IdType="pubmed">22779039</ArticleId></ArticleIdList></Reference><Reference><Citation>National Patient-Centered Clinical Research Network (PCORnet). ADAPTABLETRIAL/PHENOTYPE: Eligibility phenotype for potential participant identification 2017. 2019 Mar 13; Available from:  https://github.com/ADAPTABLETRIAL/PHENOTYPE.</Citation></Reference><Reference><Citation>Liao KP, Cai T, Savova GK, Murphy SN, Karlson EW, Ananthakrishnan AN, et al. Development of phenotype algorithms using electronic medical records and incorporating natural language processing. BMJ : British Medical Journal. 2015;350:h1885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707569</ArticleId><ArticleId IdType="pubmed">25911572</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho JC, Ghosh J, Steinhubl SR, Stewart WF, Denny JC, Malin BA, et al. Limestone: High-throughput candidate phenotype generation via tensor factorization. Journal of Biomedical Informatics. 2014;52:199&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6563906</ArticleId><ArticleId IdType="pubmed">25038555</ArticleId></ArticleIdList></Reference><Reference><Citation>Farjah F, Halgrim S, Buist DS, Gould MK, Zeliadt SB, Loggers ET, et al. EGEMS 2016. 1. Washington,DC; 2016. An Automated Method for Identifying Individuals with a Lung Nodule Can Be Feasibly Implemented Across Health Systems. p. 1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013935</ArticleId><ArticleId IdType="pubmed">27668266</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ, Thompson WK, Eyler AE, Mandelin AM, Cai T, Zink RM, et al. Portability of an algorithm to identify rheumatoid arthritis in electronic health records. Journal of the American Medical Informatics Association: JAMIA. 2012;19(e1):e162&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392871</ArticleId><ArticleId IdType="pubmed">22374935</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrell DS, Schoen RE, Leffler DA, Morris M, Rose S, Baer A, et al. Challenges in adapting existing clinical natural language processing systems to multiple, diverse health care settings. Journal of the American Medical Informatics Association : JAMIA. 2017;24(5):986&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080843</ArticleId><ArticleId IdType="pubmed">28419261</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan B, Ramage D. Google AI Blog. [Internet] 2017 Available from:  https://ai.googleblog.com/2017/04/federated-learning-collaborative.html.</Citation></Reference><Reference><Citation>Brisimi TS, Chen R, Mela T, Olshevsky A, Paschalidis IC, Shi W. Federated learning of predictive models from federated Electronic Health Records. International Journal of Medical Informatics. 2018;112:59&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5836813</ArticleId><ArticleId IdType="pubmed">29500022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32313838</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2379-6146</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Learning health systems</Title><ISOAbbreviation>Learn Health Syst</ISOAbbreviation></Journal><ArticleTitle>The European medical information framework: A novel ecosystem for sharing healthcare data across Europe.</ArticleTitle><Pagination><StartPage>e10214</StartPage><MedlinePgn>e10214</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e10214</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/lrh2.10214</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The European medical information framework (EMIF) was an Innovative Medicines Initiative project jointly supported by the European Union and the European Federation of Pharmaceutical Industries and Associations, that generated a common technology and governance framework to identify, assess and (re)use healthcare data, to facilitate real-world data research. The objectives of EMIF included providing a unified platform to support a wide range of studies within two verification programmes-Alzheimer's disease (EMIF-AD), and metabolic consequences of obesity (EMIF-MET).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The EMIF platform was built around two main data-types: electronic health record data and research cohort data, and the platform architecture composed of a set of tools designed to enable data discovery and characterisation. This included the EMIF catalogue, which allowed users to find relevant data sources, including the data-types collected. Data harmonisation via a common data model were central to the project especially for population data sources. EMIF also developed an ethical code of practice to ensure data protection, patient confidentiality and compliance with the European Data Protection Directive, and GDPR.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Currently 18 population-based disease agnostic and 60 cohort-based Alzheimer's data partners from across 14 countries are contained within the catalogue, and this will continue to expand. The work conducted in EMIF-AD and EMIF-MET includes standardizing cohorts, summarising baseline characteristics of patients, developing diagnostic algorithms, epidemiological studies, identifying and validating novel biomarkers and selecting potential patient samples for pharmacological intervention.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">EMIF was designed to provide a sustainable model as demonstrated by the sustainability plans for EMIF-AD. Although network-wide studies using EMIF were not conducted during this project to evaluate its sustainability, learning from EMIF will be used in the follow-on IMI-2 project, European Health Data and Evidence Network (EHDEN). Furthermore, EMIF has facilitated collaborations between partners and continues to promote a wider adoption of principles, technology and architecture through some of its continued work.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Learning Health Systems published by Wiley Periodicals, Inc. on behalf of the University of Michigan.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lovestone</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurodegeneration, Janssen R&amp;D, Janssen Pharmaceutica, Beerse, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EMIF Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Learn Health Syst</MedlineTA><NlmUniqueID>101708071</NlmUniqueID><ISSNLinking>2379-6146</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EMIF</Keyword><Keyword MajorTopicYN="N">EMIF&#x2010;AD</Keyword><Keyword MajorTopicYN="N">EMIF&#x2010;MET</Keyword><Keyword MajorTopicYN="N">catalogue</Keyword><Keyword MajorTopicYN="N">use case</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest in the publication of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32313838</ArticleId><ArticleId IdType="pmc">PMC7156868</ArticleId><ArticleId IdType="doi">10.1002/lrh2.10214</ArticleId><ArticleId IdType="pii">LRH210214</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pacurariu A, Plueschke K, McGettigan P, et al. Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. BMJ Open. 2018;8(9):e023090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6129090</ArticleId><ArticleId IdType="pubmed">30185579</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturkenboom MC. Other databases in Europe for the analytic evaluation of drug effects Pharmacovigilance. 2nd ed; 2006:361&#x2010;373.</Citation></Reference><Reference><Citation>Miranda ML, Ferranti J, Strauss B, Neelon B, Califf RM. Geographic health information systems: a platform to support the 'triple aim'. Health Aff. 2013;32(9):1608&#x2010;1615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4076782</ArticleId><ArticleId IdType="pubmed">24019366</ArticleId></ArticleIdList></Reference><Reference><Citation>Floridi L, Luetge C, Pagallo U, et al. Key ethical challenges in the European medical information framework. Mind Mach. 2018;29:355&#x2010;371.</Citation></Reference><Reference><Citation>Singh G, Schulthess D, Hughes N, Vannieuwenhuyse B, Kalra D. Real world big data for clinical research and drug development. Drug Discov Today. 2018;23(3):652&#x2010;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">29294362</ArticleId></ArticleIdList></Reference><Reference><Citation>Bos I, Vos S, Vandenberghe R, et al. The EMIF&#x2010;AD multimodal biomarker discovery study: design, methods and cohort characteristics. Alzheimer Res Ther. 2018;10(1):64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035398</ArticleId><ArticleId IdType="pubmed">29980228</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Streffer JR, Lovestone S. A European medical information framework for Alzheimer's disease (EMIF&#x2010;AD). Alzheimer Dement. 2014;10(4):P799.</Citation></Reference><Reference><Citation>Silva LB, Trifan A, Oliveira JL. An agile architecture for data publishing and discovery. Comput Methods Prog Biomed. 2018;160:33&#x2010;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">29728244</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva LB, Dias C, Oliveira JL. Architecture to summarize patient&#x2010;level data across borders and countries. Stud Health Technol Inform. 2015;216:687&#x2010;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">26262139</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Schuemie MJ, Trifiro G, et al. Combining electronic healthcare databases in Europe to allow for large&#x2010;scale drug safety monitoring: the EU&#x2010;ADR project. Pharmacoepidemiol Drug Saf. 2011;20(1):1&#x2010;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21182150</ArticleId></ArticleIdList></Reference><Reference><Citation>
Rijnbeek PR, Mv Speybroeck, Tramontan L, et al. Implementation of the OMOP CDM and OHDSI tools in the European Medical Information Framework (EMIF). http://www.emif.eu/wp-content/uploads/2018/12/emif-ohdsi-symposium-23-september-2016-200916.pdf
2016: Accessed May 25, 2018.</Citation></Reference><Reference><Citation>
Informatics OHDSI. OMOP Common Data Model
2018. 
https://www.ohdsi.org/data-standardization/the-common-data-model/.</Citation></Reference><Reference><Citation>Ehrenstein V, Antonsen S, Pedersen L. Existing data sources for clinical epidemiology: Aarhus University prescription database. Clin Epidemiol. 2010;2:273&#x2010;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2998817</ArticleId><ArticleId IdType="pubmed">21152254</ArticleId></ArticleIdList></Reference><Reference><Citation>Gini R, Francesconi P, Mazzaglia G, et al. Chronic disease prevalence from Italian administrative databases in the VALORE project: a validation through comparison of population estimates with general practice databases and national survey. BMC Public Health. 2013;13:15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551838</ArticleId><ArticleId IdType="pubmed">23297821</ArticleId></ArticleIdList></Reference><Reference><Citation>Cricelli C, Mazzaglia G, Samani F, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self&#x2010;report and primary care databases. J Public Health Med. 2003;25(3):254&#x2010;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">14575204</ArticleId></ArticleIdList></Reference><Reference><Citation>Avillach P, Coloma PM, Gini R, et al. Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU&#x2010;ADR project. J Am Med Inform Assoc. 2013;20(1):184&#x2010;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555316</ArticleId><ArticleId IdType="pubmed">22955495</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer MA, Furlong LI, Torre P, et al. Reuse of EHRs to support clinical research in a Hospital of Reference. Stud Health Technol Inform. 2015;210:224&#x2010;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991136</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolibar B, Fina Aviles F, Morros R, et al. SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research. Med Clin. 2012;138(14):617&#x2010;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">22444996</ArticleId></ArticleIdList></Reference><Reference><Citation>Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of the health improvement network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care. 2011;19(4):251&#x2010;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">22828580</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitsalu L, Haller T, Esko T, et al. Cohort profile: estonian biobank of the estonian genome center, University of Tartu. Int J Epidemiol. 2015;44(4):1137&#x2010;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">24518929</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlug AE, van der Lei J, Mosseveld BM, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med. 1999;38(4&#x2013;5):339&#x2010;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">10805025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunningham JA, Van Speybroeck M, Kalra D, Verbeeck R. Nine principles of semantic harmonization. AMIA Ann Symp Proc. 2016;2016:451&#x2010;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333211</ArticleId><ArticleId IdType="pubmed">28269840</ArticleId></ArticleIdList></Reference><Reference><Citation>
Jelle P. EMIF AD cohort explorer reaches maturity
2017. 
http://www.emif.eu/news?news_news=12. Accessed August 1, 2018</Citation></Reference><Reference><Citation>Christoph J, Knell C, Bosserhoff A, et al. Usability and suitability of the omics&#x2010;integrating analysis platform tranSMART for translational research and education. App Clin Informat. 2017;8(4):1173&#x2010;1183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5802312</ArticleId><ArticleId IdType="pubmed">29270954</ArticleId></ArticleIdList></Reference><Reference><Citation>Canuel V, Rance B, Avillach P, Degoulet P, Burgun A. Translational research platforms integrating clinical and omics data: a review of publicly available solutions. Brief Bioinform. 2015;16(2):280&#x2010;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364065</ArticleId><ArticleId IdType="pubmed">24608524</ArticleId></ArticleIdList></Reference><Reference><Citation>Szalma S, Koka V, Khasanova T, Perakslis ED. Effective knowledge management in translational medicine. J Transl Med. 2010;8:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2914663</ArticleId><ArticleId IdType="pubmed">20642836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tudorache T, Nyulas C, Noy NF, Musen MA. WebProtege: a collaborative ontology editor and knowledge acquisition tool for the web. Semantic Web. 2013;4(1):89&#x2010;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691821</ArticleId><ArticleId IdType="pubmed">23807872</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander M, Loomis AK, Fairburn&#x2010;Beech J, et al. Real&#x2010;world data reveal a diagnostic gap in non&#x2010;alcoholic fatty liver disease. BMC Med. 2018;16:130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6088429</ArticleId><ArticleId IdType="pubmed">30099968</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera G, Pedersen L, Ansel D, et al. Dementia prevalence and incidence in a federation of European Electronic Health Record databases: the European medical Informatics framework resource. Alzheimer Dement. 2018;14(2):130&#x2010;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">28734783</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiandaca MS, Mapstone ME, Cheema AK, Federoff HJ. The critical need for defining preclinical biomarkers in Alzheimer's disease. Alzheimer Dement. 2014;10(3 Suppl):S196&#x2010;S212.</Citation><ArticleIdList><ArticleId IdType="pubmed">24924671</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander M, Perera G, Ford L, et al. Age&#x2010;stratified prevalence of mild cognitive impairment and dementia in European populations: a systematic review. J Alzheimer Dis. 2015;48(2):355&#x2010;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">26401999</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta&#x2010;analysis. JAMA. 2015;313(19):1924&#x2010;1938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486209</ArticleId><ArticleId IdType="pubmed">25988462</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller M, Kuiperij HB, Versleijen AA, et al. Validation of microRNAs in cerebrospinal fluid as biomarkers for different forms of dementia in a multicenter study. J Alzheimer Dis. 2016;52(4):1321&#x2010;1333.</Citation><ArticleIdList><ArticleId IdType="pubmed">27104900</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Verhey F, Frolich L, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain. 2015;138(Pt 5):1327&#x2010;1338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5013930</ArticleId><ArticleId IdType="pubmed">25693589</ArticleId></ArticleIdList></Reference><Reference><Citation>
E&#x2010;NSUo Cambridge. EPIC&#x2010;Norfolk Study, University of Cambridge, UK, 2018. 
http://www.srl.cam.ac.uk/epic/. Accessed December 24, 2018.</Citation></Reference><Reference><Citation>Cambridge MEUUo. Fenland Study. http://www.mrc-epid.cam.ac.uk/research/studies/fenland/. Accessed December 24, 2018</Citation></Reference><Reference><Citation>Laakso M, Kuusisto J, Stancakova A, et al. The metabolic syndrome in men study: a resource for studies of metabolic and cardiovascular diseases. J Lipid Res. 2017;58(3):481&#x2010;493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5335588</ArticleId><ArticleId IdType="pubmed">28119442</ArticleId></ArticleIdList></Reference><Reference><Citation>Arner P, Sahlqvist AS, Sinha I, et al. The epigenetic signature of systemic insulin resistance in obese women. Diabetologia. 2016;59(11):2393&#x2010;2405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5506095</ArticleId><ArticleId IdType="pubmed">27535281</ArticleId></ArticleIdList></Reference><Reference><Citation>Loomis AK, Kabadi S, Preiss D, et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. J Clin Endocrinol Metab. 2016;101(3):945&#x2010;952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4803162</ArticleId><ArticleId IdType="pubmed">26672639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotta LA, Abbasi A, Sharp SJ, et al. Definitions of metabolic health and risk of future type 2 diabetes in body mass index categories: a systematic review and network meta&#x2010;analysis. Diabetes Care. 2015;38(11):2177&#x2010;2187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826609</ArticleId><ArticleId IdType="pubmed">26494809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotta LA, Scott RA, Sharp SJ, et al. Genetic predisposition to an impaired metabolism of the branched&#x2010;chain amino acids and risk of type 2 diabetes: a Mendelian randomisation analysis. PLoS Med. 2016;13(11):e1002179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127513</ArticleId><ArticleId IdType="pubmed">27898682</ArticleId></ArticleIdList></Reference><Reference><Citation>Mardinoglu A, Stancakova A, Lotta LA, et al. Plasma mannose levels are associated with incident type 2 diabetes and cardiovascular disease. Cell Metab. 2017;26(2):281&#x2010;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">28768165</ArticleId></ArticleIdList></Reference><Reference><Citation>Yki&#x2010;Jarvinen H. Nutritional modulation of non&#x2010;alcoholic fatty liver disease and insulin resistance. Nutrients. 2015;7(11):9127&#x2010;9138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4663582</ArticleId><ArticleId IdType="pubmed">26556368</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Llaurado G, Oresic M, Hyotylainen T, Orho&#x2010;Melander M, Yki&#x2010;Jarvinen H. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. J Hepatol. 2015;62(3):657&#x2010;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">25457209</ArticleId></ArticleIdList></Reference><Reference><Citation>
Royal Statistical Society
Research on trust in data and attitudes toward data use/data sharing
2014. 
http://www.rss.org.uk/Images/PDF/influencing-change/rss-data-trust-deficit-Ipsos-Mori-RSS-charts-slides-2014.pdf. Accessed May 28, 2018.</Citation></Reference><Reference><Citation>
Agency EM. The ENCePP Code of Conduct. European Medicines Agency, Amsterdam, The Netherlands, 2018. 
http://www.encepp.eu/code_of_conduct/documents/ENCePPCodeofConduct.pdf. Accessed October 20, 2018.</Citation></Reference><Reference><Citation>
Agency EM. Checklist of the ENCePP Code of Conduct for ENCePP Seal studies 2018. 
http://www.encepp.eu/code_of_conduct/documents/Annex 2_Checklist.pdf. Accessed October 20, 2018.</Citation></Reference><Reference><Citation>
WMA Declaration of Helsinki &#x2013; Ethical Principles for Medical Research Involving Human Subjects
2013. 
https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ Accessed October 20, 2018.</Citation></Reference><Reference><Citation>Bahr A, Schl&#xfc;nder I. Code of practice on secondary use of medical data in European scientific research projects1. Int Data Privacy Law. 2015;5(4):279&#x2010;291.</Citation></Reference><Reference><Citation>
Perkins R, Yeoman A, Ammour N, et al. Electronic Health Records for Clinical Research: Deliverable 1.4 EHR4CR final scenarios, standard operating rules for the EHR4CR platform, and overall learning outcomes from the pilots
2016. 
https://www.i-hd.eu/i-HD/assets/File/EHR4CR/deliverables/115189_EHR4CR_D1_4%20-%20final%20scenarios,%20standard%20operating%20rules%20for%20the%20EHR4CR%20-%20COMPLETE.pdf. Accessed October 20, 2018</Citation></Reference><Reference><Citation>
Project YUODAY. Policies &amp; Procedures to Guide External Investigator Access to Clinical Trial Data. Yale University, United States, 2018. 
http://yoda.yale.edu/policies-procedures-guide-external-investigator-access-clinical-trial-data. Accessed October 20, 2018</Citation></Reference><Reference><Citation>
Singleton P, Kalra D. Electronic Health Records for Clinical Research: D9.17 The EHR4CR Consent Model and Trust Model
2015. 
https://www.i-hd.eu/i-HD/assets/File/EHR4CR/deliverables/115189_EHR4CR_D9_17%20-%20The%20EHR4CR%20Consent%20and%20Trust%20Model.pdf. Accessed October 20, 2018</Citation></Reference><Reference><Citation>
Standardization IOf
. ISO/TR 22221:2006 Health Informatics &#x2010; Good Principles and Practices for a Clinical Data Warehouse. ISO Geneva, Switzerland, 2006. 
https://www.iso.org/standard/40783.html. Accessed October 20, 2018</Citation></Reference><Reference><Citation>
UK MRC
. MRC Policy and Guidance on Sharing of Research Data from Population and Patient Studies. UK Medical Research Council, London, UK, 2011. 
https://mrc.ukri.org/publications/browse/mrc-policy-and-guidance-on-sharing-of-research-data-from-population-and-patient-studies/. Accessed October 20, 2018</Citation></Reference><Reference><Citation>
Use ICoHoTRfRoPfH
. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2)
2015. 
https://www.ema.europa.eu/en/iche6-r2-good-clinical-practice. Accessed October 20, 2018</Citation></Reference><Reference><Citation>Kalra D, Stroetmann V, Sundgren M, et al. The European Institute for Innovation through health data. Learn Health Syst. 2017;1(1):e10008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6516723</ArticleId><ArticleId IdType="pubmed">31245550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lea NC, Nicholls J, Dobbs C, et al. Data safe havens and trust: toward a common understanding of trusted research platforms for governing secure and ethical Health Research. Med Inf. 2016;4(2):e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4933798</ArticleId><ArticleId IdType="pubmed">27329087</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes N, Rijnbeek P, Speybroeck MV. The European Health Data and Evidence Network (EHDEN) &#x2013; Liberating Evidence Via Harmonisation of EU Real World Data. Janssen Pharmaceutica NV, Beerse, Belgium, 2018.</Citation></Reference><Reference><Citation>Lopes P, Silva LB, Oliveira JL. Challenges and opportunities for exploring patient&#x2010;level data. Biomed Res Int. 2015;2015:150435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4609340</ArticleId><ArticleId IdType="pubmed">26504779</ArticleId></ArticleIdList></Reference><Reference><Citation>
IMI
. Introduction to the IMI2 Big Data for Big Outcome Programme (BD4BO) 2016. 
https://intranet.imim.es/files/news/Topic_Feb2016_BD4BO_DataDN.pdf. Accessed July 4, 2018</Citation></Reference><Reference><Citation>James G, Reisberg S, Lepik K, et al. An exploratory phenome wide association study linking asthma and liver disease genetic variants to electronic health records from the Estonian biobank. PLoS ONE. 2019;14(4):e0215026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6461350</ArticleId><ArticleId IdType="pubmed">30978214</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberto G, Leal I, Sattar N, et al. Identifying cases of type 2 diabetes in heterogeneous data sources: strategy from the EMIF Project. PLoS ONE. 2016;11(8):e0160648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5006970</ArticleId><ArticleId IdType="pubmed">27580049</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32335224</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Deep phenotyping: Embracing complexity and temporality-Towards scalability, portability, and interoperability.</ArticleTitle><Pagination><StartPage>103433</StartPage><MedlinePgn>103433</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2020.103433</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(20)30061-7</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA. Electronic address: chunhua@columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Medicine - Biomedical Informatics Research, Stanford University, Stanford, CA, USA. Electronic address: nigam@stanford.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA. Electronic address: gh13@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011369</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HG008680</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013061</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012895</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32335224</ArticleId><ArticleId IdType="pmc">PMC7179504</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2020.103433</ArticleId><ArticleId IdType="pii">S1532-0464(20)30061-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>In Clinical Data as the Basic Staple of Health Learning: Creating and Protecting a Public Good: Workshop Summary. Washington (DC), 2010.</Citation></Reference><Reference><Citation>Newton K.M. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. J. Am. Med. Inform. Assoc. 2013;20(e1):e147&#x2013;e154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak J., Kho A.N., Denny J.C. Electronic health records-driven phenotyping: challenges, recent advances, and perspectives. J. Am. Med. Inform. Assoc. 2013;20(e2):e206&#x2013;e211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861925</ArticleId><ArticleId IdType="pubmed">24302669</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson P.N. Deep phenotyping for precision medicine. Hum. Mutat. 2012;33(5):777&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">22504886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G. Unlocking clinical data from narrative reports: a study of natural language processing. Ann. Intern. Med. 1995;122(9):681&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">7702231</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutillo C.M. Machine intelligence in healthcare-perspectives on trustworthiness, explainability, usability, and transparency. NPJ Digit Med. 2020;3:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7099019</ArticleId><ArticleId IdType="pubmed">32258429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G., Albers D.J. High-fidelity phenotyping: richness and freedom from bias. J. Am. Med. Inform. Assoc. 2018;25(3):289&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282504</ArticleId><ArticleId IdType="pubmed">29040596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagholikar K.B. Extending i2b2 into a framework for semantic abstraction of EHR to facilitate rapid development and portability of Health IT applications. AMIA Jt. Summits Transl. Sci. Proc. 2019;2019:370&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568124</ArticleId><ArticleId IdType="pubmed">31258990</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohrabi C. World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19) Int. J. Surg. 2020;76:71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7105032</ArticleId><ArticleId IdType="pubmed">32112977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong H.Y.F. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. Radiology. 2019</Citation></Reference><Reference><Citation>Yoon S.H. Chest radiographic and CT findings of the 2019 novel coronavirus disease (COVID-19): analysis of nine patients treated in Korea. Kor. J. Radiol. 2020;21(4):494&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7082662</ArticleId><ArticleId IdType="pubmed">32100485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J. Disruptions of the olfactory and default mode networks in Alzheimer's disease. Brain Behav. 2019;9(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625464</ArticleId><ArticleId IdType="pubmed">31165582</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J. Supervised patient similarity measure of heterogeneous patient records. ACM SIGKDD Explorat. Newsletter. 2012;2012(14):16&#x2013;24.</Citation></Reference><Reference><Citation>Datta S., Bernstam E.V., Roberts K. A frame semantic overview of NLP-based information extraction for cancer-related EHR notes. J. Biomed. Inform. 2019;100</Citation><ArticleIdList><ArticleId IdType="pubmed">31589927</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q. Symptom-based patient stratification in mental illness using clinical notes. J. Biomed. Inform. 2019;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783390</ArticleId><ArticleId IdType="pubmed">31499185</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyudovyk O. Pathway analysis of genomic pathology tests for prognostic cancer subtyping. J. Biomed. Inform. 2019;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136846</ArticleId><ArticleId IdType="pubmed">31499184</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C. Ensembles of natural language processing systems for portable phenotyping solutions. J. Biomed. Inform. 2019;100</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6899194</ArticleId><ArticleId IdType="pubmed">31655273</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong N. Developing a FHIR-based EHR phenotyping framework: a case study for identification of patients with obesity and multiple comorbidities from discharge summaries. J. Biomed. Inform. 2019;99</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6990976</ArticleId><ArticleId IdType="pubmed">31622801</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang N. Making work visible for electronic phenotype implementation: Lessons learned from the eMERGE network. J. Biomed. Inform. 2019;99</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6894517</ArticleId><ArticleId IdType="pubmed">31542521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G. Facilitating phenotype transfer using a common data model. J. Biomed. Inform. 2019;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets A. Adapting electronic health records-derived phenotypes to claims data: lessons learned in using limited clinical data for phenotyping. J. Biomed. Inform. 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390483</ArticleId><ArticleId IdType="pubmed">31866433</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J.M., Rijnbeek P.R., Ryan P.B. Supplementing claims data analysis using self-reported data to develop a probabilistic phenotype model for current smoking status. J. Biomed. Inform. 2019;97</Citation><ArticleIdList><ArticleId IdType="pubmed">31386904</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel J.N., Hripcsak G., Ryan P.B. PheValuator: development and evaluation of a phenotype algorithm evaluator. J. Biomed. Inform. 2019;97</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736922</ArticleId><ArticleId IdType="pubmed">31369862</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner J.L. HemOnc: a new standard vocabulary for chemotherapy regimen representation in the OMOP common data model. J. Biomed. Inform. 2019;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697579</ArticleId><ArticleId IdType="pubmed">31238109</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen F. HPO2Vec+: leveraging heterogeneous knowledge resources to enrich node embeddings for the Human Phenotype Ontology. J. Biomed. Inform. 2019;96</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6710011</ArticleId><ArticleId IdType="pubmed">31255713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracy J.M. Investigating voice as a biomarker: deep phenotyping methods for early detection of Parkinson's disease. J. Biomed. Inform. 2019</Citation><ArticleIdList><ArticleId IdType="pubmed">31866434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mate S. A method for the graphical modeling of relative temporal constraints. J. Biomed. Inform. 2019;100</Citation><ArticleIdList><ArticleId IdType="pubmed">31629921</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng W. Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer. J. Biomed. Inform. 2019;100</Citation><ArticleIdList><ArticleId IdType="pubmed">31689549</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J. Detecting time-evolving phenotypic topics via tensor factorization on electronic health records: cardiovascular disease case study. J. Biomed. Inform. 2019;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783385</ArticleId><ArticleId IdType="pubmed">31445983</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X. Phenotypic similarity for rare disease: ciliopathy diagnoses and subtyping. J. Biomed. Inform. 2019;100</Citation><ArticleIdList><ArticleId IdType="pubmed">31622800</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z. Identifying sub-phenotypes of acute kidney injury using structured and unstructured electronic health record data with memory networks. J. Biomed. Inform. 2020;102</Citation><ArticleIdList><ArticleId IdType="pubmed">31911172</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L. Automated grouping of medical codes via multiview banded spectral clustering. J. Biomed. Inform. 2019;100</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261410</ArticleId><ArticleId IdType="pubmed">31672532</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P. Deep representation learning for individualized treatment effect estimation using electronic health records. J. Biomed. Inform. 2019;100</Citation><ArticleIdList><ArticleId IdType="pubmed">31610264</ArticleId></ArticleIdList></Reference><Reference><Citation>Demner-Fushman D., Rogers W.J., Aronson A.R. MetaMap Lite: an evaluation of a new Java implementation of MetaMap. J. Am. Med. Inform. Assoc. 2017;24(4):841&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080672</ArticleId><ArticleId IdType="pubmed">28130331</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman C. A general natural-language text processor for clinical radiology. J. Am. Med. Inform. Assoc. 1994;1(2):161&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC116194</ArticleId><ArticleId IdType="pubmed">7719797</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisseroth C.A. ClinPhen extracts and prioritizes patient phenotypes directly from medical records to expedite genetic disease diagnosis. Genet. Med. 2019;21(7):1585&#x2013;1593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6551315</ArticleId><ArticleId IdType="pubmed">30514889</ArticleId></ArticleIdList></Reference><Reference><Citation>Savova G.K. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. J. Am. Med. Inform. Assoc. 2010;17(5):507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995668</ArticleId><ArticleId IdType="pubmed">20819853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W.Q. Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record. PLoS ONE. 2017;12(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5501393</ArticleId><ArticleId IdType="pubmed">28686612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32338068</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-4877</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Current medical research and opinion</Title><ISOAbbreviation>Curr Med Res Opin</ISOAbbreviation></Journal><ArticleTitle>Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.</ArticleTitle><Pagination><StartPage>1117</StartPage><EndPage>1124</EndPage><MedlinePgn>1117-1124</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/03007995.2020.1761312</ELocationID><Abstract><AbstractText><b>Objective:</b> Observational evidence suggests that patients with type 2 diabetes mellitus (T2DM) are at increased risk for acute pancreatitis (AP) versus those without T2DM. A small number of AP events were reported in clinical trials of the sodium glucose co-transporter 2 inhibitor canagliflozin, though no imbalances were observed between treatment groups. This observational study evaluated risk of AP among new users of canagliflozin compared with new users of six classes of other antihyperglycemic agents (AHAs).<b>Methods:</b> Three US claims databases were analyzed based on a prespecified protocol approved by the European Medicines Agency. Propensity score adjustment controlled for imbalances in baseline covariates. Cox regression models estimated the hazard ratio of AP with canagliflozin compared with other AHAs using on-treatment (primary) and intent-to-treat approaches. Sensitivity analyses assessed robustness of findings.<b>Results:</b> Across the three databases, there were between 12,023-80,986 new users of canagliflozin; the unadjusted incidence rates of AP (per 1000 person-years) were between 1.5-2.2 for canagliflozin and 1.1-6.6 for other AHAs. The risk of AP was generally similar for new users of canagliflozin compared with new users of glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sulfonylureas, thiazolidinediones, insulin, and other AHAs, with no consistent between-treatment differences observed across databases. Intent-to-treat and sensitivity analysis findings were qualitatively consistent with on-treatment findings.<b>Conclusions:</b> In this large observational study, incidence rates of AP in patients with T2DM treated with canagliflozin or other AHAs were generally similar, with no evidence suggesting that canagliflozin is associated with increased risk of AP compared with other AHAs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research &amp; Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research &amp; Development, LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research &amp; Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hester</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research &amp; Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research &amp; Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research &amp; Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freedman</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Global Medical Safety, Janssen Research &amp; Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research &amp; Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Epidemiology, Janssen Research &amp; Development, LLC, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Rose</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cardiovascular and Metabolism, Janssen Research &amp; Development, LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiovascular and Metabolism, Janssen Research &amp; Development, LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meininger</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Cardiovascular and Metabolism, Janssen Research &amp; Development, LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berlin</LastName><ForeName>Jesse A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Epidemiology, Johnson &amp; Johnson, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Norman</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Cardiovascular and Metabolism, Janssen Research &amp; Development, LLC, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Med Res Opin</MedlineTA><NlmUniqueID>0351014</NlmUniqueID><ISSNLinking>0300-7995</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0SAC974Z85</RegistryNumber><NameOfSubstance UI="D000068896">Canagliflozin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068896" MajorTopicYN="N">Canagliflozin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="N">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute pancreatitis</Keyword><Keyword MajorTopicYN="N">canagliflozin</Keyword><Keyword MajorTopicYN="N">observational study</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32338068</ArticleId><ArticleId IdType="doi">10.1080/03007995.2020.1761312</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32374408</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Development and validation of phenotype classifiers across multiple sites in the observational health data sciences and informatics network.</ArticleTitle><Pagination><StartPage>877</StartPage><EndPage>883</EndPage><MedlinePgn>877-883</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocaa032</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Accurate electronic phenotyping is essential to support collaborative observational research. Supervised machine learning methods can be used to train phenotype classifiers in a high-throughput manner using imperfectly labeled data. We developed 10 phenotype classifiers using this approach and evaluated performance across multiple sites within the Observational Health Data Sciences and Informatics (OHDSI) network.</AbstractText><AbstractText Label="MATERIALS AND METHODS">We constructed classifiers using the Automated PHenotype Routine for Observational Definition, Identification, Training and Evaluation (APHRODITE) R-package, an open-source framework for learning phenotype classifiers using datasets in the Observational Medical Outcomes Partnership Common Data Model. We labeled training data based on the presence of multiple mentions of disease-specific codes. Performance was evaluated on cohorts derived using rule-based definitions and real-world disease prevalence. Classifiers were developed and evaluated across 3 medical centers, including 1 international site.</AbstractText><AbstractText Label="RESULTS">Compared to the multiple mentions labeling heuristic, classifiers showed a mean recall boost of 0.43 with a mean precision loss of 0.17. Performance decreased slightly when classifiers were shared across medical centers, with mean recall and precision decreasing by 0.08 and 0.01, respectively, at a site within the USA, and by 0.18 and 0.10, respectively, at an international site.</AbstractText><AbstractText Label="DISCUSSION AND CONCLUSION">We demonstrate a high-throughput pipeline for constructing and sharing phenotype classifiers across sites within the OHDSI network using APHRODITE. Classifiers exhibit good portability between sites within the USA, however limited portability internationally, indicating that classifier generalizability may have geographic limitations, and, consequently, sharing the classifier-building recipe, rather than the pretrained classifiers, may be more useful for facilitating collaborative observational research.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kashyap</LastName><ForeName>Mehr</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seneviratne</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banda</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, Georgia State University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Borim</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Office of eHealth and Business, Seoul National University Bundang Hospital, Gyeonggi-do, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth and Business, Seoul National University Bundang Hospital, Gyeonggi-do, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG059307</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011369</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002965" MajorTopicYN="N">Classification</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="N">Data Science</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069553" MajorTopicYN="Y">Supervised Machine Learning</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cohort identification</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">electronic phenotyping</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">phenotype</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32374408</ArticleId><ArticleId IdType="pmc">PMC7309227</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocaa032</ArticleId><ArticleId IdType="pii">5831103</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banda JM, Seneviratne M, Hernandez-Boussard T, et al. Advances in electronic phenotyping: from rule-based definitions to machine learning models. Annu Rev Biomed Data Sci. 2018; 1 (1): 53&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583807</ArticleId><ArticleId IdType="pubmed">31218278</ArticleId></ArticleIdList></Reference><Reference><Citation>Richesson RL, Hammond WE, Nahm M, et al. Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory. J Am Med Inform Assoc. 2013; 20 (e2): e226&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861929</ArticleId><ArticleId IdType="pubmed">23956018</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Albers DJ.. Next-generation phenotyping of electronic health records. J Am Med Inform Assoc. 2013; 20 (1): 117&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555337</ArticleId><ArticleId IdType="pubmed">22955496</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak J, Kho AN, Denny JC.. Electronic health records-driven phenotyping: challenges, recent advances, and perspectives. J Am Med Inform Assoc. 2013; 20 (e2): e206&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861925</ArticleId><ArticleId IdType="pubmed">24302669</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivade C, Raghavan P, Fosler-Lussier E, et al. A review of approaches to identifying patient phenotype cohorts using electronic health records. J Am Med Inform Assoc. 2014; 21 (2): 221&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932460</ArticleId><ArticleId IdType="pubmed">24201027</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby JC, Speltz P, Rasmussen LV, et al. PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc. 2016; 23 (6): 1046&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070514</ArticleId><ArticleId IdType="pubmed">27026615</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco JA, Rasmussen LV, Kiefer RC, et al. A case study evaluating the portability of an executable computable phenotype algorithm across multiple institutions and electronic health record environments. J Am Med Inform Assoc. 2018; 25 (11): 1540&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6213083</ArticleId><ArticleId IdType="pubmed">30124903</ArticleId></ArticleIdList></Reference><Reference><Citation>Denaxas SC, George J, Herrett E, et al. Data resource profile: cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER). Int J Epidemiol. 2012; 41 (6): 1625&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535749</ArticleId><ArticleId IdType="pubmed">23220717</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton KM, Peissig PL, Kho AN, et al. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. J Am Med Inform Assoc. 2013; 20 (e1): e147&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Heal Technol Inform. 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohane IS, Churchill SE, Murphy SN.. A translational engine at the national scale: informatics for integrating biology and the bedside. J Am Med Inform Assoc. 2012; 19 (2): 181&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277623</ArticleId><ArticleId IdType="pubmed">22081225</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, et al. Facilitating phenotype transfer using a common data model. J Biomed Inform. 2019; 96: 103253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian TY, Zlateva I, Anderson DR.. Using electronic health records data to identify patients with chronic pain in a primary care setting. J Am Med Inform Assoc. 2013; 20 (e2): e275&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861913</ArticleId><ArticleId IdType="pubmed">23904323</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ, Eyler AE, Denny JC.. Na&#xef;ve Electronic Health Record phenotype identification for rheumatoid arthritis. AMIA Annu Symp Proc. 2011; 2011: 189&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3243261</ArticleId><ArticleId IdType="pubmed">22195070</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll RJ, Thompson WK, Eyler AE, et al. Portability of an algorithm to identify rheumatoid arthritis in electronic health records. J Am Med Inform Assoc. 2012; 19 (e1): e162&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392871</ArticleId><ArticleId IdType="pubmed">22374935</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Carroll RJ, Hinz ERM, et al. Applying active learning to high-throughput phenotyping algorithms for electronic health records data. J Am Med Inform Assoc. 2013; 20 (e2): e253&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3861916</ArticleId><ArticleId IdType="pubmed">23851443</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal V, Podchiyska T, Banda JM, et al. Learning statistical models of phenotypes using noisy labeled training data. J Am Med Inform Assoc. 2016; 23 (6): 1166&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070523</ArticleId><ArticleId IdType="pubmed">27174893</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpern Y, Choi Y, Horng S, et al. Using anchors to estimate clinical state without labeled data. AMIA Annu Symp Proc. 2014; 2014: 606&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419996</ArticleId><ArticleId IdType="pubmed">25954366</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpern Y, Horng S, Choi Y, et al. Electronic medical record phenotyping using the anchor and learn framework. J Am Med Inform Assoc. 2016; 23 (4): 731&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4926745</ArticleId><ArticleId IdType="pubmed">27107443</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu-Jones BK, Greene CS.. Consortium PRO-AALSCT. Semi-supervised learning of the electronic health record for phenotype stratification. J Biomed Inform. 2016; 64: 168&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">27744022</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Chakrabortty A, Liao KP, et al. Surrogate-assisted feature extraction for high-throughput phenotyping. J Am Med Inform Assoc. 2017; 24 (e1): e143&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6080726</ArticleId><ArticleId IdType="pubmed">27632993</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray SG, Avati A, Schmajuk G, et al. Automated and flexible identification of complex disease: building a model for systemic lupus erythematosus using noisy labeling. J Am Med Informatics Assoc. 2019; 26 (1): 61&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6308013</ArticleId><ArticleId IdType="pubmed">30476175</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon HU. General bounds on the number of examples needed for learning probabilistic concepts. J Comput Syst Sci. 1996; 52 (2): 239&#x2013;54.</Citation></Reference><Reference><Citation>Banda JM, Halpern Y, Sontag D, et al. Electronic phenotyping with APHRODITE and the Observational Health Sciences and Informatics (OHDSI) data network. AMIA Jt Summits Transl Sci Proc. 2017; 2017: 48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5543379</ArticleId><ArticleId IdType="pubmed">28815104</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Hripcsak G, Ryan PB.. PheValuator: development and evaluation of a phenotype algorithm evaluator. J Biomed Inform. 2019; 97: 103258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736922</ArticleId><ArticleId IdType="pubmed">31369862</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32375693</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>06</Day></PubDate></JournalIssue><Title>BMC medical research methodology</Title><ISOAbbreviation>BMC Med Res Methodol</ISOAbbreviation></Journal><ArticleTitle>Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation.</ArticleTitle><Pagination><StartPage>102</StartPage><MedlinePgn>102</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12874-020-00991-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">To demonstrate how the Observational Healthcare Data Science and Informatics (OHDSI) collaborative network and standardization can be utilized to scale-up external validation of patient-level prediction models by enabling validation across a large number of heterogeneous observational healthcare datasets.</AbstractText><AbstractText Label="METHODS">Five previously published prognostic models (ATRIA, CHADS<sub>2</sub>, CHADS<sub>2</sub>VASC, Q-Stroke and Framingham) that predict future risk of stroke in patients with atrial fibrillation were replicated using the OHDSI frameworks. A network study was run that enabled the five models to be externally validated across nine observational healthcare datasets spanning three countries and five independent sites.</AbstractText><AbstractText Label="RESULTS">The five existing models were able to be integrated into the OHDSI framework for patient-level prediction and they obtained mean c-statistics ranging between 0.57-0.63 across the 6 databases with sufficient data to predict stroke within 1&#x2009;year of initial atrial fibrillation diagnosis for females with atrial fibrillation. This was comparable with existing validation studies. The validation network study was run across nine datasets within 60&#x2009;days once the models were replicated. An R package for the study was published at https://github.com/OHDSI/StudyProtocolSandbox/tree/master/ExistingStrokeRiskExternalValidation.</AbstractText><AbstractText Label="CONCLUSION">This study demonstrates the ability to scale up external validation of patient-level prediction models using a collaboration of researchers and a data standardization that enable models to be readily shared across data sites. External validation is necessary to understand the transportability or reproducibility of a prediction model, but without collaborative approaches it can take three or more years for a model to be validated by one independent researcher. In this paper we show it is possible to both scale-up and speed-up external validation by showing how validation can be done across multiple databases in less than 2&#x2009;months. We recommend that researchers developing new prediction models use the OHDSI network to externally validate their models.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-2970-0778</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA. jreps@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>O'Brien Institute for Public Health, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Hong-Seok</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Ajou University Medical Centre, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM011369</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HI16C0992</GrantID><Agency>Health Promotion Administration, Ministry of Health and Welfare (TW)</Agency><Country>International</Country></Grant><Grant><GrantID>806968</GrantID><Agency>Innovative Medicines Initiative Joint Undertaking</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Res Methodol</MedlineTA><NlmUniqueID>100968545</NlmUniqueID><ISSNLinking>1471-2288</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Collaborative network</Keyword><Keyword MajorTopicYN="N">External validation</Keyword><Keyword MajorTopicYN="N">Patient-level prediction</Keyword><Keyword MajorTopicYN="N">Prognostic model</Keyword><Keyword MajorTopicYN="N">Transportability</Keyword></KeywordList><CoiStatement>Jenna Reps is an employee of Janssen Research &amp; Development and shareholder of Johnson &amp; Johnson. Patrick Ryan is an employee of Janssen Research &amp; Development and shareholder of Johnson &amp; Johnson. Peter Rijnbeek works for a research group who received unconditional research grants from Boehringer-Ingelheim, GSK, Janssen Research &amp; Development, Novartis, Pfizer, Yamanouchi, Servier. None of these grants result in a conflict of interest to the content of this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32375693</ArticleId><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="doi">10.1186/s12874-020-00991-3</ArticleId><ArticleId IdType="pii">10.1186/s12874-020-00991-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siontis GC, Tzoulaki I, Castaldi PJ, et al. External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination. J Clin Epidemiol. 2015;68(1):25&#x2013;34. doi: 10.1016/j.jclinepi.2014.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2014.09.007</ArticleId><ArticleId IdType="pubmed">25441703</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeyer Z, Emanuel EJ. Predicting the future&#x2014;big data, machine learning, and clinical medicine. N Engl J Med. 2016;375(13):1216. doi: 10.1056/NEJMp1606181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1606181</ArticleId><ArticleId IdType="pmc">PMC5070532</ArticleId><ArticleId IdType="pubmed">27682033</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: a review of contemporary guidance and literature. JRSM Cardiovasc Dis. 2017;6:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5331469</ArticleId><ArticleId IdType="pubmed">28286646</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Calster B, Wynants L, Timmerman D, Steyerberg EW, Collins GS. Predictive analytics in health care: how can we know it works? J Am Med Inform Assoc. 2019;26(12):1651&#x2013;1654. doi: 10.1093/jamia/ocz130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocz130</ArticleId><ArticleId IdType="pmc">PMC6857503</ArticleId><ArticleId IdType="pubmed">31373357</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman DG, Vergouwe Y, Royston P, et al. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;338:b605. doi: 10.1136/bmj.b605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b605</ArticleId><ArticleId IdType="pubmed">19477892</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, Ryan PB, Rijnbeek PR. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc. 2018;25(8):969&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013;2(3):e000250. doi: 10.1161/JAHA.113.000250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.113.000250</ArticleId><ArticleId IdType="pmc">PMC3698792</ArticleId><ArticleId IdType="pubmed">23782923</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham heart study. JAMA. 2003;290(8):1049&#x2013;1056. doi: 10.1001/jama.290.8.1049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.290.8.1049</ArticleId><ArticleId IdType="pubmed">12941677</ArticleId></ArticleIdList></Reference><Reference><Citation>Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of atrial fibrillation. JAMA. 2001;285(22):2864&#x2013;2870. doi: 10.1001/jama.285.22.2864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.285.22.2864</ArticleId><ArticleId IdType="pubmed">11401607</ArticleId></ArticleIdList></Reference><Reference><Citation>Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263&#x2013;272. doi: 10.1378/chest.09-1584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.09-1584</ArticleId><ArticleId IdType="pubmed">19762550</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ. 2013;346:f2573. doi: 10.1136/bmj.f2573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.f2573</ArticleId><ArticleId IdType="pmc">PMC3641809</ArticleId><ArticleId IdType="pubmed">23641033</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Ham HA, Klungel OH, Singer DE, et al. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database. J Am Coll Cardiol. 2015;66(17):1851&#x2013;1859. doi: 10.1016/j.jacc.2015.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.08.033</ArticleId><ArticleId IdType="pubmed">26493655</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspberg S, Chang Y, Atterman A, et al. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J. 2016;37(42):3203&#x2013;3210. doi: 10.1093/eurheartj/ehw077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw077</ArticleId><ArticleId IdType="pubmed">26941204</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao TF, Liu CJ, Tuan TC, et al. Comparisons of CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in atrial fibrillation: which scoring system should be used for Asians? Heart Rhythm. 2016;13(1):46&#x2013;53. doi: 10.1016/j.hrthm.2015.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2015.08.017</ArticleId><ArticleId IdType="pubmed">26277496</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar P, Krishnamurthi R, Ikram MA, et al. The stroke Riskometer&#x2122; app: validation of a data collection tool and stroke risk predictor. Int J Stroke. 2015;10(2):231&#x2013;244. doi: 10.1111/ijs.12411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijs.12411</ArticleId><ArticleId IdType="pmc">PMC4335600</ArticleId><ArticleId IdType="pubmed">25491651</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011;9(1):39&#x2013;48. doi: 10.1111/j.1538-7836.2010.04085.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2010.04085.x</ArticleId><ArticleId IdType="pubmed">21029359</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32399991</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Nintedanib and ischemic colitis: Signal assessment with the integrated use of two types of real-world evidence, spontaneous reports of suspected adverse drug reactions, and observational data from large health-care databases.</ArticleTitle><Pagination><StartPage>951</StartPage><EndPage>957</EndPage><MedlinePgn>951-957</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.5022</ELocationID><Abstract><AbstractText Label="PURPOSE">Statistical screening of Vigibase, the global database of individual case safety reports, highlighted an association between the MedDRA Preferred Term (PT) "colitis" and nintedanib. Nintedanib is a protein kinase inhibitor authorized in accelerated regulatory procedures for the treatment of idiopathic pulmonary fibrosis (IPF). The aim of this report is to describe the integration of two types of real-world evidence, spontaneous reports of adverse drug reactions (ADR), and observational health data (OHD) in the assessment of a post-authorization safety signal of ischemic colitis.</AbstractText><AbstractText Label="METHODS">Assessment of the statistical signal of "nintedanib - colitis" was undertaken using data from VigiBase, OHD from the Observational Heath Data Sciences and Informatics (OHDSI) collaborative, published literature, and openly available regulatory documents. Evidence synthesis was performed to support Bradford Hill criteria in causality assessment.</AbstractText><AbstractText Label="RESULTS">Evidence for strength of association, specificity, consistency, and analogy was found upon review of the case series. OHD was used to calculate incidence rates of colitis in new users of nintedanib across multiple populations, supportive of consistency, and further evidence for strength of association. Literature review identified support for biological plausibility and analogy. Signal assessment was supplemented with characterization of real-world users and exploration of potential risk factors using OHD.</AbstractText><AbstractText Label="CONCLUSIONS">An integrated approach using two forms of real-world data, spontaneous reports of ADRs and data from observational databases allowed a comprehensive and efficient signal assessment of nintedanib and colitis. Further exploration of the complementary use of real-time OHD in signal assessment could inform more efficient approaches to current signal management practices.</AbstractText><CopyrightInformation>&#xa9; 2020 Uppsala Monitoring Centre. Pharmacoepidemiology and Drug Safety published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chandler</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials><Identifier Source="ORCID">0000-0002-9334-9046</Identifier><AffiliationInfo><Affiliation>Uppsala Monitoring Centre, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>G6HRD2P839</RegistryNumber><NameOfSubstance UI="C530716">nintedanib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001208" MajorTopicYN="N" Type="Geographic">Asia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017091" MajorTopicYN="N">Colitis, Ischemic</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="N">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">real-world evidence</Keyword><Keyword MajorTopicYN="N">signal detection</Keyword></KeywordList><CoiStatement>The opinions expressed in this piece are not necessarily those of the national pharmacovigilance centers of the WHO Program for International Drug Monitoring or of the WHO. The author has no conflicts of interest that are directly relevant to the content of this piece.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32399991</ArticleId><ArticleId IdType="pmc">PMC7496543</ArticleId><ArticleId IdType="doi">10.1002/pds.5022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
European Medicines Agency
. Ofev. Assessment report. Procedure No. EMEA/H/C/003821/0000. Available at: https://www.ema.europa.eu/en/documents/assessment-report/ofev-epar-public-assessment-report_en.pdf. Accessed January 16, 2020.</Citation></Reference><Reference><Citation>
FDA
. Highlights of Prescribing Information. Ofev. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205832s012lbl.pdf. Accessed January 16, 2020.</Citation></Reference><Reference><Citation>Trotter JM, Peter MB. Ischaemic colitis. BMJ. 2016;355:i6600.</Citation><ArticleIdList><ArticleId IdType="pubmed">28007701</ArticleId></ArticleIdList></Reference><Reference><Citation>Caster O, Juhlin K, Watson S, Nor&#xe9;n GN. Improved statistical signal detection in pharmacovigilance by combining multiple strength&#x2010;of&#x2010;evidence aspects in VigiRank. Drug Saf. 2014;37(8):617&#x2010;628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134478</ArticleId><ArticleId IdType="pubmed">25052742</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrio M, Voss S, Shakir SA. Application of the Bradford Hill criteria to assess the causality of cisapride&#x2010;induced arrhythmia: a model for assessing causal association in pharmacovigilance. Drug Saf. 2007;30(4):333&#x2010;346.</Citation><ArticleIdList><ArticleId IdType="pubmed">17408310</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2010;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis LM, Hicklin DL. VEGF&#x2010;targeted therapy: mechanisms of anti&#x2010;tumour activity. Nat Rev Cancer. 2008;8:579&#x2010;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">18596824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamba T, Tam BY, Hashizume H, et al. VEGF&#x2010;dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol. 2006;290(2):H560&#x2010;H5766.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172168</ArticleId></ArticleIdList></Reference><Reference><Citation>Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007;14:1860&#x2010;1869.</Citation><ArticleIdList><ArticleId IdType="pubmed">17356952</ArticleId></ArticleIdList></Reference><Reference><Citation>Batteux B, Gras V, Mahboud Y, et al. Ischemic colitis associated with intravitreal administration of aflibercept: a first case report. Br J Clin Pharmacol. 2019;4:845&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6422656</ArticleId><ArticleId IdType="pubmed">30610744</ArticleId></ArticleIdList></Reference><Reference><Citation>Onoda Y, Shiba T, Hori Y, Maeno T, Takahashi M. Two cases of acute abdomen after an intravitreal injection of bevacizumab. Case Rep Ophthalmol. 2015;6(1):110&#x2010;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4410506</ArticleId><ArticleId IdType="pubmed">25960733</ArticleId></ArticleIdList></Reference><Reference><Citation>Patadia VK, Coloma P, Schuemie MJ, et al. Using real&#x2010;world healthcare data for pharmacovigilance signal detection &#x2010; the experience of the EU&#x2010;ADR project. Expert Rev Clin Pharmacol. 2015;8(1):95&#x2010;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">25487079</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, Vilar S, Dumouchel W, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2018;20:413&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628045</ArticleId><ArticleId IdType="pubmed">23118093</ArticleId></ArticleIdList></Reference><Reference><Citation>Star K, Watson S, Sandberg L, Johansson J, Edwards IR. Longitudinal medical records as a complement to routine drug safety signal analysis. Pharmacoepidemiol Drug Saf. 2015;24(5):486&#x2010;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024044</ArticleId><ArticleId IdType="pubmed">25623045</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifir&#xf2; G, Sultana J, Bate A. From big data to smart data for pharmacovigilance: the role of healthcare databases and other emerging sources. Drug Saf. 2018;41(2):143&#x2010;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">28840504</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32411828</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-6352</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>NPJ digital medicine</Title><ISOAbbreviation>NPJ Digit Med</ISOAbbreviation></Journal><ArticleTitle>Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations.</ArticleTitle><Pagination><StartPage>67</StartPage><MedlinePgn>67</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">67</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41746-020-0277-8</ELocationID><Abstract><AbstractText>Randomized controlled trials (RCTs) are regarded as the most reputable source of evidence. In some studies, factors beyond the intervention itself may contribute to the measured effect, an occurrence known as heterogeneity of treatment effect (HTE). If the RCT population differs from the real-world population on factors that induce HTE, the trials effect will not replicate. The RCTs eligibility criteria should identify the sub-population in which its evidence will replicate. However, the extent to which the eligibility criteria identify the appropriate population is unknown, which raises concerns for generalizability. We compared reported data from RCTs with real-world data from the electronic health records of a large, academic medical center that was curated according to RCT eligibility criteria. Our results show fundamental differences between the RCT population and our observational cohorts, which suggests that eligibility criteria may be insufficient for identifying the applicable real-world population in which RCT evidence will replicate.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Averitt</LastName><ForeName>Amelia J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0003-1221-1123</Identifier><AffiliationInfo><Affiliation>1Department of Biomedical Informatics, Columbia University, New York, NY USA.</Affiliation><Identifier Source="ISNI">0000000419368729</Identifier><Identifier Source="GRID">grid.21729.3f</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9624-0214</Identifier><AffiliationInfo><Affiliation>1Department of Biomedical Informatics, Columbia University, New York, NY USA.</Affiliation><Identifier Source="ISNI">0000000419368729</Identifier><Identifier Source="GRID">grid.21729.3f</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1Department of Biomedical Informatics, Columbia University, New York, NY USA.</Affiliation><Identifier Source="ISNI">0000000419368729</Identifier><Identifier Source="GRID">grid.21729.3f</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>2Janssen Research and Development, Titusville, NJ USA.</Affiliation><Identifier Source="ISNI">0000 0004 0389 4927</Identifier><Identifier Source="GRID">grid.497530.c</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perotte</LastName><ForeName>Adler</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1Department of Biomedical Informatics, Columbia University, New York, NY USA.</Affiliation><Identifier Source="ISNI">0000000419368729</Identifier><Identifier Source="GRID">grid.21729.3f</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Digit Med</MedlineTA><NlmUniqueID>101731738</NlmUniqueID><ISSNLinking>2398-6352</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Communication and replication</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Outcomes research</Keyword><Keyword MajorTopicYN="N">Randomized controlled trials</Keyword></KeywordList><CoiStatement>Competing interestsP.R. is an employee of Janssen Research and Development and a shareholder of Johnson &amp; Johnson. All other authors have no relevant conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32411828</ArticleId><ArticleId IdType="pmc">PMC7214444</ArticleId><ArticleId IdType="doi">10.1038/s41746-020-0277-8</ArticleId><ArticleId IdType="pii">277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong, V. C. &amp; Steiner P. M. Replication designs for causal inference. EdPolicyWorks Working Paper Series. 2018 [cited 2019 Mar 26]. Available from: http://curry.virginia.edu/uploads/epw/62_Replication_Designs.pdfhttp://curry.virginia.edu/edpolicyworks/wp</Citation></Reference><Reference><Citation>Djulbegovic, B. &amp; Guyatt, G. H. Progress in evidence-based medicine: a quarter century on. Lancet390, 415&#x2013;423 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28215660</ArticleId></ArticleIdList></Reference><Reference><Citation>Djulbegovic, B. &amp; Guyatt G. in Users Guide to Medical Literature. 3rd edn. (McGraw-Hill Education, 1976).</Citation></Reference><Reference><Citation>Djulbegovic, B., Guyatt, G. H. &amp; Ashcroft, R. E. Epistemologic inquiries in evidence-based medicine. Cancer Cont.16, 158&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">19337202</ArticleId></ArticleIdList></Reference><Reference><Citation>Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn&#x2019;t. BMJ. 1996;312:71&#x2013;72. doi: 10.1136/bmj.312.7023.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.312.7023.71</ArticleId><ArticleId IdType="pmc">PMC2349778</ArticleId><ArticleId IdType="pubmed">8555924</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JPA. How to make more published research true. PLoS Med. 2014;11:e1001747. doi: 10.1371/journal.pmed.1001747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001747</ArticleId><ArticleId IdType="pmc">PMC4204808</ArticleId><ArticleId IdType="pubmed">25334033</ArticleId></ArticleIdList></Reference><Reference><Citation>Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JPA. Life cycle of translational research for medical interventions. Science. 2008;321:1298&#x2013;1299. doi: 10.1126/science.1160622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1160622</ArticleId><ArticleId IdType="pubmed">18772421</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent DM, et al. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. Int. J. Epidemiol. 2016;45:dyw118. doi: 10.1093/ije/dyw118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw118</ArticleId><ArticleId IdType="pmc">PMC5841614</ArticleId><ArticleId IdType="pubmed">27375287</ArticleId></ArticleIdList></Reference><Reference><Citation>Fredriksson P, Johansson P. Dynamic treatment assignment. J. Bus. Econ. Stat. 2008;26:435&#x2013;445. doi: 10.1198/073500108000000033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1198/073500108000000033</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Brand JE, Jann B. Estimating heterogeneous treatment effects with observational data. Socio. Methodol. 2012;42:314&#x2013;347. doi: 10.1177/0081175012452652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0081175012452652</ArticleId><ArticleId IdType="pmc">PMC3591476</ArticleId><ArticleId IdType="pubmed">23482633</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell DT, Stanley JC. Experimental and Quasi-experimental Designs for Research. Boston: Houghton Mifflin Company; 1963.</Citation></Reference><Reference><Citation>Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast. Reconstr. Surg. 2011;128:305&#x2013;310. doi: 10.1097/PRS.0b013e318219c171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PRS.0b013e318219c171</ArticleId><ArticleId IdType="pmc">PMC3124652</ArticleId><ArticleId IdType="pubmed">21701348</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell, D. T. &amp; Stanley, J. C. Handbook of Research on Teaching. 1&#x2013;84 (Houghton Mifflin Company, Boston, 1963).</Citation></Reference><Reference><Citation>Hyman, R. Quasi-Experimentation: Design and Analysis Issues for Field Settings. Vol. 46, 96&#x2013;97 (Houghton Mifflin, 1982).</Citation></Reference><Reference><Citation>Anderson-Cook, C. M. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Vol. 100 (Wiley, 2005).</Citation></Reference><Reference><Citation>Velasco, E. in Encyclopedia of Research Design (ed. Salkind, N) (SAGE, Thousand Oaks Publications, 2010).</Citation></Reference><Reference><Citation>Wales JA, Palmer RL, Fairburn CG. Can treatment trial samples be representative? Behav. Res. Ther. 2009;47:893&#x2013;896. doi: 10.1016/j.brat.2009.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brat.2009.06.019</ArticleId><ArticleId IdType="pmc">PMC2764388</ArticleId><ArticleId IdType="pubmed">19647815</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int. J. Technol. Assess. Health Care. 1996;12:195&#x2013;208. doi: 10.1017/S0266462300009570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0266462300009570</ArticleId><ArticleId IdType="pubmed">8707495</ArticleId></ArticleIdList></Reference><Reference><Citation>Britton A, et al. Threats to applicability of randomised trials: exclusions and selective participation. J. Heal. Serv. Res. Policy. 1999;4:112&#x2013;121. doi: 10.1177/135581969900400210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135581969900400210</ArticleId><ArticleId IdType="pubmed">10387403</ArticleId></ArticleIdList></Reference><Reference><Citation>Karanis, Y. B., Canta, F. A. B., Mitrofan, L., Mistry, H. &amp; Anger, C. &#x2018;Research&#x2019; vs &#x2018;real world&#x2019; patients: the representativeness of clinical trial participants. Ann. Oncol. (2016) 10.1093/annonc/mdw392.51/2800468/Research-vs-real-world-patients-the</Citation></Reference><Reference><Citation>Stuart EA, Bradshaw CP, Leaf PJ. Assessing the generalizability of randomized trial results to target populations. Prev. Sci. 2015;16:475&#x2013;485. doi: 10.1007/s11121-014-0513-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11121-014-0513-z</ArticleId><ArticleId IdType="pmc">PMC4359056</ArticleId><ArticleId IdType="pubmed">25307417</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman RE, et al. Real-world evidence &#x2014; what is it and what can it tell us? N. Engl. J. Med. 2016;375:2293&#x2013;2297. doi: 10.1056/NEJMsb1609216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb1609216</ArticleId><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. doi: 10.1186/s13063-015-1023-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-015-1023-4</ArticleId><ArticleId IdType="pmc">PMC4632358</ArticleId><ArticleId IdType="pubmed">26530985</ArticleId></ArticleIdList></Reference><Reference><Citation>Badano LP, et al. Patients with chronic heart failure encountered in daily clinical practice are different from the &#x201c;typical&#x201d; patient enrolled in therapeutic trials. Ital. Hear. J. 2003;41:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">12762270</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch X, et al. Causes of ineligibility in randomized controlled trials and long-term mortality in patients with non-ST-segment elevation acute coronary syndromes. Int. J. Cardiol. 2008;124:86&#x2013;91. doi: 10.1016/j.ijcard.2006.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2006.12.027</ArticleId><ArticleId IdType="pubmed">17408780</ArticleId></ArticleIdList></Reference><Reference><Citation>Collet JP, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J. Am. Coll. Cardiol. 2003;41:8&#x2013;14. doi: 10.1016/S0735-1097(02)02664-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(02)02664-5</ArticleId><ArticleId IdType="pubmed">12570937</ArticleId></ArticleIdList></Reference><Reference><Citation>Costantino G, et al. Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice. Intern. Emerg. Med. 2009;4:117&#x2013;122. doi: 10.1007/s11739-008-0180-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-008-0180-9</ArticleId><ArticleId IdType="pubmed">18690492</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhruva SS, Redberg RF. Variations between clinical trial participants and medicare beneficiaries in evidence used for medicare national coverage decisions. Arch. Intern. Med. 2008;168:136. doi: 10.1001/archinternmed.2007.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2007.56</ArticleId><ArticleId IdType="pubmed">18227358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezekowitz JA, et al. Acute heart failure. Circ. Hear. Fail. 2012;5:735&#x2013;741. doi: 10.1161/CIRCHEARTFAILURE.112.968974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.112.968974</ArticleId><ArticleId IdType="pubmed">23032196</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb BA, et al. The older the better: are elderly study participants more non-representative? A cross-sectional analysis of clinical trial and observational study samples. BMJ Open. 2012;2:e000833. doi: 10.1136/bmjopen-2012-000833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2012-000833</ArticleId><ArticleId IdType="pmc">PMC3533104</ArticleId><ArticleId IdType="pubmed">23242479</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchinson-Jaffe AB, et al. Comparison of baseline characteristics, management and outcome of patients with non&#x2013;ST-segment elevation acute coronary syndrome in versus not in clinical trials. Am. J. Cardiol. 2010;106:1389&#x2013;1396. doi: 10.1016/j.amjcard.2010.06.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2010.06.070</ArticleId><ArticleId IdType="pubmed">21059426</ArticleId></ArticleIdList></Reference><Reference><Citation>Melloni C, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ. Cardiovasc. Qual. Outcomes. 2010;3:135&#x2013;142. doi: 10.1161/CIRCOUTCOMES.110.868307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.110.868307</ArticleId><ArticleId IdType="pubmed">20160159</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg BA, et al. Global outcomes of ST-elevation myocardial infarction: comparisons of the enoxaparin and thrombolysis reperfusion for acute myocardial infarction treatment-thrombolysis in myocardial infarction study 25 (ExTRACT-TIMI 25) registry and trial. Am. Heart J. 2007;154:54&#x2013;61. doi: 10.1016/j.ahj.2007.03.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2007.03.047</ArticleId><ArticleId IdType="pubmed">17584551</ArticleId></ArticleIdList></Reference><Reference><Citation>Uijen AA, Bakx JC, Mokkink HGA, van Weel C. Hypertension patients participating in trials differ in many aspects from patients treated in general practices. J. Clin. Epidemiol. 2007;60:330&#x2013;335. doi: 10.1016/j.jclinepi.2006.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2006.05.015</ArticleId><ArticleId IdType="pubmed">17346605</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals. JAMA. 2007;297:1233. doi: 10.1001/jama.297.11.1233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.297.11.1233</ArticleId><ArticleId IdType="pubmed">17374817</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi: 10.1136/bmj.c332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c332</ArticleId><ArticleId IdType="pmc">PMC2844940</ArticleId><ArticleId IdType="pubmed">20332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Furler J, Magin P, Pirotta M, van Driel M. Participant demographics reported in &#x201c;Table 1&#x201d; of randomised controlled trials: a case of &#x201c;inverse evidence&#x201d;? Int. J. Equity Health. 2012;11:14. doi: 10.1186/1475-9276-11-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-9276-11-14</ArticleId><ArticleId IdType="pmc">PMC3379950</ArticleId><ArticleId IdType="pubmed">22429574</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw. Open. 2019;2:e1912869. doi: 10.1001/jamanetworkopen.2019.12869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2019.12869</ArticleId><ArticleId IdType="pmc">PMC6802419</ArticleId><ArticleId IdType="pubmed">31596493</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001;345:861&#x2013;869. doi: 10.1056/NEJMoa011161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa011161</ArticleId><ArticleId IdType="pubmed">11565518</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamerson, K. et al. Benazepril plus Amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417&#x2013;2428 (2008) http://www.nejm.org/doi/abs/10.1056/NEJMoa0806182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0806182</ArticleId><ArticleId IdType="pubmed">19052124</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon CP, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004;350:1495&#x2013;1504. doi: 10.1056/NEJMoa040583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa040583</ArticleId><ArticleId IdType="pubmed">15007110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley P. Efficacy and tolerability of sitagliptin compared with glimepiride in elderly patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, non-inferiority trial. Drugs Aging. 2015;32:469&#x2013;476. doi: 10.1007/s40266-015-0271-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40266-015-0271-z</ArticleId><ArticleId IdType="pubmed">26041585</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32443071</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-233X</ISSN><JournalIssue CitedMedium="Internet"><Volume>135</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Obstetrics and gynecology</Title><ISOAbbreviation>Obstet Gynecol</ISOAbbreviation></Journal><ArticleTitle>In Reply.</ArticleTitle><Pagination><StartPage>1487</StartPage><MedlinePgn>1487</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/AOG.0000000000003912</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Westhoff</LastName><ForeName>Carolyn L</ForeName><Initials>CL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Obstet Gynecol</MedlineTA><NlmUniqueID>0401101</NlmUniqueID><ISSNLinking>0029-7844</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5W7SIA7YZW</RegistryNumber><NameOfSubstance UI="D016912">Levonorgestrel</NameOfSubstance></Chemical><Chemical><RegistryNumber>789U1901C5</RegistryNumber><NameOfSubstance UI="D003300">Copper</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Obstet Gynecol. 2020 Feb;135(2):319-327</RefSource><PMID Version="1">31923062</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Obstet Gynecol. 2020 Jun;135(6):1486-1487</RefSource><PMID Version="1">32443070</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003300" MajorTopicYN="Y">Copper</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016912" MajorTopicYN="N">Levonorgestrel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32443071</ArticleId><ArticleId IdType="doi">10.1097/AOG.0000000000003912</ArticleId><ArticleId IdType="pii">00006250-202006000-00037</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCE</Title><Reference><Citation>Spotnitz ME, Natarajan K, Ryan PB, Westhoff CL. Relative risk of cervical neoplasms among copper and levonorgestrel-releasing intrauterine system users. Obstet Gynecol 2020;135:319&#x2013;27.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32458499</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Real-world data in Saudi Arabia: Current situation and challenges for regulatory decision-making.</ArticleTitle><Pagination><StartPage>1303</StartPage><EndPage>1306</EndPage><MedlinePgn>1303-1306</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.5025</ELocationID><Abstract><AbstractText Label="PURPOSE">To present the process of establishing a pharmacoepidemiological database in Saudi Arabia, challenges and models used.</AbstractText><AbstractText Label="METHODS">The database establishment has started in 2017 by piloting the conversion of electronic health records of one hospital to the Observational Health Data Sciences and Informatics (OHDSI), Observational Medical Outcomes Partnership's Common Data Model (OMOP).</AbstractText><AbstractText Label="RESULTS">During the pilot phase we have faced several challenges such as limited contribution in providing data by local medical institution due to uncertainty about data governance, diversity of systems used by hospitals, inconsistent coding of medical information, and limited awareness about data structure from participating hospital. The pilot phase was completed in 2019 containing information about patient attributes, medical care, therapies, and other additional services for around 130&#x2009;000 patients in Saudi Arabia. The majority of patients were below the age of 50&#x2009;years (89%), and acute respiratory infections were the most frequent diagnosis. The data quality was acceptable and no major anomalies were detected during the conversion.</AbstractText><AbstractText Label="CONCLUSIONS">We demonstrated a successful creation of a pilot database using OHDSI Common Data Model. Our experience with the pilot database could be extended to other institutions to create a national dataset that could be used to generate real-world evidence.</AbstractText><CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alnofal</LastName><ForeName>Fatemah A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Research Department, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alrwisan</LastName><ForeName>Adel A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-9422-7390</Identifier><AffiliationInfo><Affiliation>Research Department, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0002-5630-2468</Identifier><AffiliationInfo><Affiliation>Research Department, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="Y">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006761" MajorTopicYN="N">Hospitals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017891" MajorTopicYN="N">Pharmacoepidemiology</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012529" MajorTopicYN="N" Type="Geographic">Saudi Arabia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Saudi Arabia</Keyword><Keyword MajorTopicYN="N">database</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">real-world data</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32458499</ArticleId><ArticleId IdType="doi">10.1002/pds.5025</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Heikinheimo O, Bitzer J, Garcia RL. Real-world research and the role of observational data in the field of gynaecology-a practical review. Eur J Contracept Reprod Health Care. 2017;22(4):250-259.</Citation></Reference><Reference><Citation>OECD. New Health Technologies, Managing Access, Value and Sustainability [Internet]; 2017. https://www.oecd.org/publications/managing-new-technologies-in-health-care-9789264266438-en.htm.</Citation></Reference><Reference><Citation>OHDSI. OMOP Common Data Model - OHDSI [Internet]; 2019. https://www.ohdsi.org/data-standardization/the-common-data-model.</Citation></Reference><Reference><Citation>Si Y, Weng C. An OMOP CDM-based relational database of clinical research eligibility criteria. Stud Health Technol Inform. 2017;245:950-954.</Citation></Reference><Reference><Citation>Haberson A, Rinner C, Gall W. Standardizing Austrians claims data using the OMOP common data model: a feasibility study. Stud Health Technol Inform. 2019;258:151-152.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32470694</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>Converting clinical document architecture documents to the common data model for incorporating health information exchange data in observational health studies: CDA to CDM.</ArticleTitle><Pagination><StartPage>103459</StartPage><MedlinePgn>103459</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2020.103459</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(20)30087-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Utilization of standard health information exchange (HIE) data is growing due to the high adoption rate and interoperability of electronic health record (EHR) systems. However, integration of HIE data into an EHR system is not yet fully adopted in clinical research. In addition, data quality should be verified for the secondary use of these data. Thus, the aims of this study were to convert referral documents in a Health Level 7 (HL7) clinical document architecture (CDA) to the common data model (CDM) to facilitate HIE data availability for longitudinal data analysis, and to identify data quality levels for application in future clinical studies.</AbstractText><AbstractText Label="METHODS">A total of 21,492 referral CDA documents accumulated for over 10&#xa0;years in a tertiary general hospital in South Korea were analyzed. To convert CDA documents to the Observational Medical Outcomes Partnership (OMOP) CDM, processes such as CDA parsing, data cleaning, standard vocabulary mapping, CDA-to-CDM mapping, and CDM conversion were performed. The quality of CDM data was then evaluated using the Achilles Heel and visualized with the Achilles tool.</AbstractText><AbstractText Label="RESULTS">Mapping five CDA elements (document header, problem, medication, laboratory, and procedure) into an OMOP CDM table resulted in population of 9 CDM tables (person, visit_occurrence, condition_occurrence, drug_exposure, measurement, observation, procedure_occurrence, care_site, and provider). Three CDM tables (drug_era, condition_era, and observation_period) were derived from the converted table. From vocabulary mapping codes in CDA documents according to domain, 98.6% of conditions, 68.8% of drugs, 35.7% of measurements, 100% of observation, and 56.4% of procedures were mapped as standard concepts. The conversion rates of the CDA to the OMOP CDM were 96.3% for conditions, 97.2% for drug exposure, 98.1% for procedure occurrence, 55.1% for measurements, and 100% for observation.</AbstractText><AbstractText Label="CONCLUSIONS">We examined the possibility of CDM conversion by defining mapping rules for CDA-to-CDM conversion using the referral CDA documents collected from clinics in actual medical practice. Although mapping standard vocabulary for CDM conversion requires further improvement, the conversion could facilitate further research on the usage patterns of medical resources and referral patterns.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Hyerim</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Soyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Hee</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Republic of Korea; Department of Pediatrics, Seoul National University Bundang Hospital, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jeong-Whun</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Seoul National University Bundang Hospital, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Republic of Korea. Electronic address: yoosoo0@snubh.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066275" MajorTopicYN="Y">Health Information Exchange</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012017" MajorTopicYN="N">Referral and Consultation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical document architecture</Keyword><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">Referral documents</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32470694</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2020.103459</ArticleId><ArticleId IdType="pii">S1532-0464(20)30087-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32477256</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2295</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Frontiers in neurology</Title><ISOAbbreviation>Front Neurol</ISOAbbreviation></Journal><ArticleTitle>Characterization of Anti-seizure Medication Treatment Pathways in Pediatric Epilepsy Using the Electronic Health Record-Based Common Data Model.</ArticleTitle><Pagination><StartPage>409</StartPage><MedlinePgn>409</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">409</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fneur.2020.00409</ELocationID><Abstract><AbstractText>The purpose of this pilot study was to analyze treatment pathways of pediatric epilepsy using the common data model (CDM) based on electronic health record (EHR) data. We also aimed to reveal whether CDM analysis was feasible and applicable to epilepsy research. We analyzed the treatment pathways of pediatric epilepsy patients from our institute who underwent antiseizure medication (ASM) treatment for at least 2 years, using the Observational Medical Outcomes Partnership (OMOP)-CDM. Subgroup analysis was performed for generalized or focal epilepsy, varying age of epilepsy onset, and specific epilepsy syndromes. Changes in annual prescription patterns were also analyzed to reveal the different trends. We also calculated the proportion of drug-resistant epilepsy by applying the definition of seizure persistence after application of two ASMs for a sufficient period of time (more than 6 months). We identified 1,192 patients who underwent treatment for more than 2 years (mean &#xb1; standard deviation: 6.5 &#xb1; 3.2 years). In our pediatric epilepsy cohort, we identified 313 different treatment pathways. Drug resistance, calculated as the application of more than three ASMs during the first 2 years of treatment, was 23.8%. Treatment pathways and ASM resistance differed between subgroups of generalized vs. focal epilepsy, different onset age of epilepsy, and specific epilepsy syndromes. The frequency of ASM prescription was similar between onset groups of different ages; however, phenobarbital was frequently used in children with epilepsy onset &lt; 4 years. Ninety-one of 344 cases of generalized epilepsy and 187 of 835 cases of focal epilepsy were classified as medically intractable epilepsy. The percentage of drug resistance was markedly different depending on the specific electro-clinical epilepsy syndrome [79.0% for Lennox-Gastaut syndrome (LGS), 7.1% for childhood absence epilepsy (CAE), and 9.0% for benign epilepsy with centrotemporal spikes (BECTS)]. We could visualize the annual trend and changes of ASM prescription for pediatric epilepsy in our institute from 2004 to 2017. We revealed that CDM analysis was feasible and applicable for epilepsy research. The strengths and limitations of CDM analysis should be carefully considered when planning the analysis, result extraction, and interpretation of results.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Kim, Yoo, Jeon, Yi, Kim, Choi, Hwang and Kim.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hunmin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healthcare ICT Research Center, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Yonghoon</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Healthcare ICT Research Center, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Soyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healthcare ICT Research Center, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healthcare ICT Research Center, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sun Ah</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Ewha Woman's University Medical Center, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Hee</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ki Joong</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Pediatric, Seoul National University Children's Hospital, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Neurol</MedlineTA><NlmUniqueID>101546899</NlmUniqueID><ISSNLinking>1664-2295</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common Data Model (CDM)</Keyword><Keyword MajorTopicYN="N">antiseizure medications</Keyword><Keyword MajorTopicYN="N">drug-resistant epilepsy</Keyword><Keyword MajorTopicYN="N">epilepsy</Keyword><Keyword MajorTopicYN="N">treatment pathway</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32477256</ArticleId><ArticleId IdType="pmc">PMC7235379</ArticleId><ArticleId IdType="doi">10.3389/fneur.2020.00409</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ. (2014) 348:g254. 10.1136/bmj.g254</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g254</ArticleId><ArticleId IdType="pubmed">24583319</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejada J, Costa KM, Bertti P, Garcia-Cairasco N. The epilepsies: complex challenges needing complex solutions. Epilepsy Behav. (2013) 26:212&#x2013;28. 10.1016/j.yebeh.2012.09.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yebeh.2012.09.029</ArticleId><ArticleId IdType="pubmed">23146364</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirtz D, Berg A, Bettis D, Camfield C, Camfield P, Crumrine P, et al. . Practice parameter: treatment of the child with a first unprovoked seizure: report of the quality standards subcommittee of the American academy of neurology and the practice committee of the child neurology society. Neurology. (2003) 60:166&#x2013;75. 10.1212/01.WNL.0000033622.27961.B6</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000033622.27961.B6</ArticleId><ArticleId IdType="pubmed">12552027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt D. Drug treatment of epilepsy: options and limitations. Epilepsy Behav. (2009) 15:56&#x2013;65. 10.1016/j.yebeh.2009.02.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yebeh.2009.02.030</ArticleId><ArticleId IdType="pubmed">19236951</ArticleId></ArticleIdList></Reference><Reference><Citation>Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. (2005) 7:1&#x2013;64. 10.1016/j.yebeh.2005.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yebeh.2005.06.001</ArticleId><ArticleId IdType="pubmed">16102515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol. (2005) 20:S1&#x2013;S56. 10.1177/088307380502000101</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/088307380502000101</ArticleId><ArticleId IdType="pubmed">16615562</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolin K, Berggren F, Berling P, Morberg S, Gauffin H, Landtblom A. Patterns of antiepileptic drug prescription in Sweden: a register-based approach. Acta Neurol Scand. (2017) 136:521&#x2013;7. 10.1111/ane.12776</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12776</ArticleId><ArticleId IdType="pubmed">28585316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. . Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A. (2016) 113:7329&#x2013;36. 10.1073/pnas.1510502113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1510502113</ArticleId><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubota K, Kamijima Y, Yang YHK, Kimura S, Lai ECC, Man KK, et al. . Penetration of new antidiabetic medications in east Asian countries and the United States: a cross-national comparative study. PloS One. (2018) 13:e0208796. 10.1371/journal.pone.0208796</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0208796</ArticleId><ArticleId IdType="pmc">PMC6291148</ArticleId><ArticleId IdType="pubmed">30540837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. . Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. (2015) 216:574&#x2013;8. 10.3233/978-1-61499-564-7-574</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/978-1-61499-564-7-574</ArticleId><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. . Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. (2010) 51:1069&#x2013;77. 10.1111/j.1528-1167.2009.02397.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2009.02397.x</ArticleId><ArticleId IdType="pubmed">19889013</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinnar S, Vining EP, Mellits ED, D'Souza BJ, Holden K, Baumgardner RA, et al. . Discontinuing antiepileptic medication in children with epilepsy after two years without seizures: a prospective study. N Engl J Med. (1985) 313:976&#x2013;80. 10.1056/NEJM198510173131603</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198510173131603</ArticleId><ArticleId IdType="pubmed">4047105</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulac O, Leppik I, Chadwick D, Specchio L. Starting stopping treatment In: Engel J, Pedley TA, Aicardi J, editors. Epilepsy: A Comprehensive Textbook, Vol. 2 Philadelphia, PA: Lippincott-Raven; (1997). p. 1301&#x2013;10.</Citation></Reference><Reference><Citation>Tomson T, Battino D. Teratogenicity of antiepileptic drugs: state of the art. Curr Opin Neurol. (2005) 18:135&#x2013;40. 10.1097/01.wco.0000162854.67767.06</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wco.0000162854.67767.06</ArticleId><ArticleId IdType="pubmed">15791143</ArticleId></ArticleIdList></Reference><Reference><Citation>Meo R, Bilo L. Polycystic ovary syndrome and epilepsy. Drugs. (2003) 63:1185&#x2013;227. 10.2165/00003495-200363120-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200363120-00002</ArticleId><ArticleId IdType="pubmed">12790692</ArticleId></ArticleIdList></Reference><Reference><Citation>Ijff DM, Aldenkamp AP. Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol. (2013) 111:707&#x2013;18. 10.1016/B978-0-444-52891-9.00073-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-52891-9.00073-7</ArticleId><ArticleId IdType="pubmed">23622218</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerts A, Arts WF, Stroink H, Peeters E, Brouwer O, Peters B, et al. . Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch study of epilepsy in childhood. Epilepsia. (2010) 51:1189&#x2013;97. 10.1111/j.1528-1167.2010.02546.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2010.02546.x</ArticleId><ArticleId IdType="pubmed">20557350</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg AT, Rychlik K, Levy SR, Testa FM. Complete remission of childhood-onset epilepsy: stability and prediction over two decades. Brain. (2014) 137:3213&#x2013;22. 10.1093/brain/awu294</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu294</ArticleId><ArticleId IdType="pmc">PMC4240301</ArticleId><ArticleId IdType="pubmed">25338950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sillanp&#xe4;&#xe4; M, Schmidt D. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain. (2009) 132:989&#x2013;98. 10.1093/brain/awn357</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn357</ArticleId><ArticleId IdType="pubmed">19153149</ArticleId></ArticleIdList></Reference><Reference><Citation>Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia. (1979) 20:729&#x2013;37. 10.1111/j.1528-1157.1979.tb04857.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1157.1979.tb04857.x</ArticleId><ArticleId IdType="pubmed">499118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cockerell OC, Sander J, Hart YM, Shorvon SD, Johnson A. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet. (1995) 346:140&#x2013;4. 10.1016/S0140-6736(95)91208-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(95)91208-8</ArticleId><ArticleId IdType="pubmed">7603228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. (2000) 342:314&#x2013;9. 10.1056/NEJM200002033420503</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200002033420503</ArticleId><ArticleId IdType="pubmed">10660394</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue-Ping W, Hai-Jiao W, Li-Na Z, Xu D, Ling L. Risk factors for drug-resistant epilepsy: a systematic review and meta-analysis. Medicine (Baltimore). (2019) 98:e16402. 10.1097/MD.0000000000016402</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000016402</ArticleId><ArticleId IdType="pmc">PMC6708813</ArticleId><ArticleId IdType="pubmed">31348240</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Lizana J, Rodriguez-Lucenilla MI, Aguilera-L&#xf3;pez P, Aguirre-Rodr&#xed;guez J, Cassinello-Garc&#xed;a E. A study of drug-resistant childhood epilepsy testing the new ILAE criteria. Seizure. (2012) 21:266&#x2013;72. 10.1016/j.seizure.2012.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.seizure.2012.01.009</ArticleId><ArticleId IdType="pubmed">22333178</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. . ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. (2017) 58:512&#x2013;21. 10.1111/epi.13709</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.13709</ArticleId><ArticleId IdType="pmc">PMC5386840</ArticleId><ArticleId IdType="pubmed">28276062</ArticleId></ArticleIdList></Reference><Reference><Citation>Fejerman N, Caraballo R, Tenembaum SN. Atypical evolutions of benign localization-related epilepsies in children: are they predictable? Epilepsia. (2000) 41:380&#x2013;90. 10.1111/j.1528-1157.2000.tb00177.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1157.2000.tb00177.x</ArticleId><ArticleId IdType="pubmed">10756401</ArticleId></ArticleIdList></Reference><Reference><Citation>Willmore LJ. Valproate. In: Nordli DR, Pellock JM, Sankar R, Wheless JW, editors. Pellock's Pediatric Epilepsy: Diagnosis Therapy. 4th ed New York, NY: Demos Medical Publishing; (2016). p. 941&#x2013;56.</Citation></Reference><Reference><Citation>Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. . Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. (2013) 54:551&#x2013;63. 10.1111/epi.12074</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.12074</ArticleId><ArticleId IdType="pubmed">23350722</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord. (2007) 9:353&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">18077226</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson RH, Cramer JA, Collins JF, Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group . A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Eng J Med. (1992) 327:765&#x2013;71. 10.1056/NEJM199209103271104</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199209103271104</ArticleId><ArticleId IdType="pubmed">1298221</ArticleId></ArticleIdList></Reference><Reference><Citation>Willmore LJ, Shu V, Wallin B. Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. The M88-194 study group. Neurology. (1996) 46:49&#x2013;53. 10.1212/WNL.46.1.49</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.46.1.49</ArticleId><ArticleId IdType="pubmed">8559420</ArticleId></ArticleIdList></Reference><Reference><Citation>Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The paediatric EPITEG collaborative group. Dev Med Child Neurol. (1995) 37:97&#x2013;108. 10.1111/j.1469-8749.1995.tb11978.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-8749.1995.tb11978.x</ArticleId><ArticleId IdType="pubmed">7851677</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Ryan PB, Suchard MA, Hripcsak G, Jin P, Reich C, et al. . Risk of angioedema associated with levetiracetam compared with phenytoin: findings of the observational health data sciences and informatics research network. Epilepsia. (2017) 58:e101&#x2013;6. 10.1111/epi.13828</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.13828</ArticleId><ArticleId IdType="pmc">PMC6632067</ArticleId><ArticleId IdType="pubmed">28681416</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32477631</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2153-4063</ISSN><JournalIssue CitedMedium="Print"><Volume>2020</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science</Title><ISOAbbreviation>AMIA Jt Summits Transl Sci Proc</ISOAbbreviation></Journal><ArticleTitle>Comparative Analysis and Evaluation of State-of-the-Art Medication Mapping Tools to Transform a Local Medication Terminology to RxNorm.</ArticleTitle><Pagination><StartPage>126</StartPage><EndPage>135</EndPage><MedlinePgn>126-135</MedlinePgn></Pagination><Abstract><AbstractText>Mapping local terminologies to standardized terminologies facilitates secondary use of electronic health records (EHR). Penn Medicine comprises multiple hospitals and facilities within the Philadelphia Metropolitan area providing services from primary to quaternary care. Our Penn Medicine (PennMed) data include medications collected during both inpatient and outpatient encounters at multiple facilities. Our goal was to map 941,198 unique medication terms to RxNorm, a standardized drug nomenclature from the National Library of Medicine (NLM). We chose three popular tools for mapping: NLM's RxMix and RxNav-in-a-Box, OHDSI's Usagi and Mayo Clinic's MedXN. We manually reviewed 400 mappings obtained from each tool and evaluated their performance for drug name, strength, form, and route. RxMix performed the best with an F1 score of 90% for drug name versus Usagi's 82% and MedXN's 74%. We discuss the strengths and limitations of each method and tips for other institutions seeking to map a local terminology to RxNorm.</AbstractText><CopyrightInformation>&#xa9;2020 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Biomedical Informatics, University of Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Excellence in Environmental Toxicology, University of Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Mary Regina</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Biomedical Informatics, University of Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Excellence in Environmental Toxicology, University of Pennsylvania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Jt Summits Transl Sci Proc</MedlineTA><NlmUniqueID>101539486</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32477631</ArticleId><ArticleId IdType="pmc">PMC7233099</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>U.S. National Library of Medicine. RxNorm overview [Internet]  Available from:  https://www.nlm.nih.gov/research/umls/rxnorm/overview.html.</Citation></Reference><Reference><Citation>Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc [Internet] 2011;18(4):441&#x2013;8. Available from:  http://www.ncbi.nlm.nih.gov/pubmed/21515544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128404</ArticleId><ArticleId IdType="pubmed">21515544</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitwal H, Qing D, Jones S, Bernstam E V., Chute CG, Johnson TR. Cross-terminology mapping challenges: A demonstration using medication terminological systems. J Biomed Inform [Internet] 2012 Aug 1;45(4):613&#x2013;25. Available from:  https://www.sciencedirect.com/science/article/pii/S1532046412000950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4398308</ArticleId><ArticleId IdType="pubmed">22750536</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider O, Peters L. RxMix &#x2013; Use of NLM drug APIs by non-programmers. 2017:2291.</Citation></Reference><Reference><Citation>U.S. National Library of Medicine. Approximate matching in the RxNorm API [Internet] 2015 Available from:  https://rxnav.nlm.nih.gov/RxNormApproxMatch.html.</Citation></Reference><Reference><Citation>Peters L, Kapusnik-Uner JE, Bodenreider O. Methods for managing variation in clinical drug names. AMIA Annu Symp Proc [Internet] 2010;2010:637. Available from:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041346/pdf/amia-2010_sympproc_0637.pdf.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041346</ArticleId><ArticleId IdType="pubmed">21347056</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters L, Rice R, Bodenreider O. RxNav-in-a-Box &#x2013; A locally-installable version of RxNav and related APIs. 2018;2102</Citation></Reference><Reference><Citation>Sohn S, Clark C, Halgrim SR, Murphy SP, Chute CG, Liu H. MedXN: An open source medication extraction and normalization tool for clinical text. J Am Med Informatics Assoc. 2014;21(5):858&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4147619</ArticleId><ArticleId IdType="pubmed">24637954</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Informatics Assoc [Internet] 2012 Jan 1;19(1):54&#x2013;60. Available from:  https://academic.oup.com/jamia/article-lookup/doi/10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI/Usagi [Internet]  Available from:  https://github.com/OHDSI/Usagi.</Citation></Reference><Reference><Citation>Kopacka I. Basic regular expressions in R: Cheat sheet [Internet] 2016 Available from:  https://www.rstudio.com/wp-content/uploads/2016/09/RegExCheatsheet.pdf.</Citation></Reference><Reference><Citation>Common medical abbreviations [Internet] 2002 Available from:  http://dhss.alaska.gov/dph/Emergency/Documents/ems/assets/Downloads/Common_Med_Abbrev.pdf.</Citation></Reference><Reference><Citation>List of abbreviations used in medical prescriptions [Internet]  Available from:  https://en.wikipedia.org/wiki/List_of_abbreviations_used_in_medical_prescriptions.</Citation></Reference><Reference><Citation>American Speech-Language Hearing Association. Common medical abbreviations [Internet]  Available from:  https://www.asha.org/uploadedfiles/slp/healthcare/medicalabbreviations.pdf.</Citation></Reference><Reference><Citation>100 most popular american last names [Internet]  Available from:  https://www.rong-chang.com/namesdict/100_last_names.htm.</Citation></Reference><Reference><Citation>Butler R. Most common last names for blacks in the U.S. [Internet]  Available from:  https://names.mongabay.com/data/black.html.</Citation></Reference><Reference><Citation>Spitzer Y. Most common jewish names [Internet] 2012 Available from:  https://yannayspitzer.net/2012/07/24/most-common-jewish-names/</Citation></Reference><Reference><Citation>Pallmann P, Hothorn LA. Analysis of means: A generalized approach using R. J Appl Stat. 2016;43(8):1541&#x2013;60.</Citation></Reference><Reference><Citation>Boland MR, Alur-Gupta S, Levine L, Gabriel P, Gonzalez-Hernandez G. Disease associations depend on visit type: results from a visit-wide association study. BioData Min [Internet] 2019 Dec 11;12(1):15. Available from:  https://biodatamining.biomedcentral.com/articles/10.1186/s13040-019-0203-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13040-019-0203-2</ArticleId><ArticleId IdType="pmc">PMC6625053</ArticleId><ArticleId IdType="pubmed">31338127</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. National Library of Medicine. Abbreviations and acronyms in RxNorm normalization [Internet]  Available from:  https://rxnav.nlm.nih.gov/Abbreviations.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32477663</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2153-4063</ISSN><JournalIssue CitedMedium="Print"><Volume>2020</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science</Title><ISOAbbreviation>AMIA Jt Summits Transl Sci Proc</ISOAbbreviation></Journal><ArticleTitle>Mapping Local Biospecimen Records to the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>422</StartPage><EndPage>429</EndPage><MedlinePgn>422-429</MedlinePgn></Pagination><Abstract><AbstractText>Research to support precision medicine for leukemia patients requires integration of biospecimen and clinical data. The Observational Medical Outcomes Partnership common data model (OMOP CDM) and its Specimen table presents a potential solution. Although researchers have described progress and challenges in mapping electronic health record (EHR) data to populate the OMOP CDM, to our knowledge no studies have described populating the OMOP CDM with biospecimen data. Using biobank data from our institution, we mapped 26% of biospecimen records to the OMOP Specimen table. Records failed mapping due to local codes for time point that were incompatible with the OMOP reference terminology. We recommend expanding allowable codes to encompass research data, adding foreign keys to leverage additional OMOP tables with data from other sources or to store additional specimen details, and considering a new table to represent processed samples and inventory.</AbstractText><CopyrightInformation>&#xa9;2020 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michael</LastName><ForeName>Chelsea L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Health Informatics, Memorial Sloan Kettering Cancer Center, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Healthcare Policy &amp; Research, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sholle</LastName><ForeName>Evan T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Information Technologies &amp; Services Department, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wulff</LastName><ForeName>Regina T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roboz</LastName><ForeName>Gail J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campion</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Healthcare Policy &amp; Research, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Information Technologies &amp; Services Department, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Translational Science Center, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Jt Summits Transl Sci Proc</MedlineTA><NlmUniqueID>101539486</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32477663</ArticleId><ArticleId IdType="pmc">PMC7233045</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atlanta, GA: American Cancer Society; 2019. Key statistics for acute myeloid leukemia (AML) [Internet]. [cited 2019 Jul 20]. Available from:  https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html.</Citation></Reference><Reference><Citation>Cancer stat facts: leukemia [Internet] National Cancer Institute. 2019.  [cited 2019 Apr 3]. Available from:  https://seer.cancer.gov/statfacts/html/leuks.html.</Citation></Reference><Reference><Citation>Myelodysplastic syndromes treatment (PDQ&#xae;)&#x2013;patient version [Internet] National Cancer Institute.  [updated 2019 Mar 28; cited 2019 Jul 29]. Available from:  https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq.</Citation></Reference><Reference><Citation>Adult acute myeloid leukemia treatment (PDQ&#xae;)&#x2013;patient version [Internet]. National Cancer Institute.  [updated 2019 Jul 23; cited 2019 Jul 22]. Available from:  https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq#_1.</Citation></Reference><Reference><Citation>Paradiso AV, Daidone MG, Canzonieri V, Zito A. Biobanks and scientists: supply and demand. Journal of translational medicine. 2018;16(1):136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5963141</ArticleId><ArticleId IdType="pubmed">29783984</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Studies in health technology and informatics. 2015;(216):574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisinger SJ, Ryan PB, O"Hara DJ, Powell GE, Painter JL, Pattishall EN, et al. Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. Journal of the American Medical Informatics Association : JAMIA. 2010;17(6):652&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000752</ArticleId><ArticleId IdType="pubmed">20962127</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. Journal of the American Medical Informatics Association : JAMIA. 2012;19(1):54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association : JAMIA. 2015;22(3):553&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H, Vormstein P, Bieber R, Bernarding J, et al. Towards implementation of OMOP in a German university hospital consortium. Applied clinical informatics. 2018;9(1):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinner C, Gezgin D, Wendl C, Gall W. A clinical data warehouse based on OMOP and i2b2 for Austrian health claims data. Studies in health technology and informatics. 2018;248:94&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29726424</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Levine ME, Shang N, Ryan PB. Effect of vocabulary mapping for conditions on phenotype cohorts. Journal of the American Medical Informatics Association : JAMIA. 2018;25(12):1618&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289550</ArticleId><ArticleId IdType="pubmed">30395248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wulff RT, Sholle ET, Roboz GJ, Kraemer DA, Campion TR. Evaluating generalizability of a biospecimen informatics approach: support for local requirements and best practices. AMIA Joint Summits on Translational Science proceedings AMIA Joint Summits on Translational Science. 2018;2017:55&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961803</ArticleId><ArticleId IdType="pubmed">29888041</ArticleId></ArticleIdList></Reference><Reference><Citation>Sholle ET, Kabariti J, Johnson SB, Leonard JP, Pathak J, Varughese VI, et al. Secondary use of patients" electronic records (SUPER): an approach for meeting specific data needs of clinical and translational researchers. AMIA Annual Symposium proceedings AMIA Symposium. 2017;(2017):1581&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977622</ArticleId><ArticleId IdType="pubmed">29854228</ArticleId></ArticleIdList></Reference><Reference><Citation>Specimen [Internet]  Observational Health Data Sciences and Informatics; [updated 11 Oct 2018; cited 2019 Jul 29]. Available from:  https://github.com/OHDSI/CommonDataModel/wiki/SPECIMEN.</Citation></Reference><Reference><Citation>Peripheral blood specimen [Internet]  Odysseus Data Services, Inc.; [updated 2018 Dec 28; cited 2019 Jul 29]. Available from:  http://athena.ohdsi.org/search-terms/terms/4047495.</Citation></Reference><Reference><Citation>Blood specimen [Internet]  Odysseus Data Services, Inc.; [updated 2018 Dec 28; cited 2019 Jul 29]. Available from:  http://athena.ohdsi.org/search-terms/terms/4001225.</Citation></Reference><Reference><Citation>Blood specimen with EDTA [Internet]  Odysseus Data Services, Inc.; [updated 2018 Dec 28; cited 2019 Jul 29]. Available from:  http://athena.ohdsi.org/search-terms/terms/40482922.</Citation></Reference><Reference><Citation>Blood specimen submitted in heparinized collection tube [Internet]  Odysseus Data Services, Inc. ; [updated 2018 Dec 28; cited 2019 Jul 29]. Available from:  http://athena.ohdsi.org/search-terms/terms/40486989.</Citation></Reference><Reference><Citation>Bone marrow specimen [Internet]  Odysseus Data Services, Inc.; [updated 2018 Dec 28; cited 2019 Jul 29]. Available from:  http://athena.ohdsi.org/search-terms/terms/4000623.</Citation></Reference><Reference><Citation>Venous structure [Internet]  Odysseus Data Services, Inc.; [updated 2018 Dec 28; cited 2019 Jul 29]. Available from:  http://athena.ohdsi.org/search-terms/terms/4104340.</Citation></Reference><Reference><Citation>Bone marrow structure [Internet]  Odysseus Data Services, Inc.; [updated 2018 Dec 28; cited 2019 Aug 12]. Available from:  http://athena.ohdsi.org/search-terms/terms/4029619.</Citation></Reference><Reference><Citation>Normal [Internet]  Odysseus Data Services, Inc.; [updated 2018 Dec 28; cited 2019 Aug 14]. Available from:  http://athena.ohdsi.org/search-terms/terms/4069590.</Citation></Reference><Reference><Citation>Abnormal [Internet].  Odysseus Data Services, Inc.; [updated 2018 Dec 28; cited 2019 Aug 14]. Available from:  http://athena.ohdsi.org/search-terms/terms/4135493.</Citation></Reference><Reference><Citation>Malignant [Internet]  Odysseus Data Services, Inc.; [updated 2018 Dec 28; cited 2019 Aug 14]. Available from:  http://athena.ohdsi.org/search-terms/terms/4066212.</Citation></Reference><Reference><Citation>Research administration [Internet]  Odysseus Data Services, Inc.; [updated 2018 Dec 28; cited 2019 Aug 14]. Available from:  http://athena.ohdsi.org/search-terms/terms/ext-link&gt;44803476.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32477694</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2153-4063</ISSN><JournalIssue CitedMedium="Print"><Volume>2020</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science</Title><ISOAbbreviation>AMIA Jt Summits Transl Sci Proc</ISOAbbreviation></Journal><ArticleTitle>Integrating Electronic Health Record Data into the ADEpedia-on-OHDSI Platform for Improved Signal Detection: A Case Study of Immune-related Adverse Events.</ArticleTitle><Pagination><StartPage>710</StartPage><EndPage>719</EndPage><MedlinePgn>710-719</MedlinePgn></Pagination><Abstract><AbstractText>With widespread adoption of electronic health records (EHRs), Real World Data and Real World Evidence (RWE) have been increasingly used by FDA for evaluating drug safety and effectiveness. However, integration of heterogeneous drug safety data sources and systems remains an impediment for effective pharmacovigilance studies. In an ongoing project, we have developed a next generation pharmacovigilance signal detection framework known as ADEpedia-on-OHDSI using the OMOP common data model (CDM). The objective of the study is to demonstrate the feasibility of the framework for integrating both spontaneous reporting data and EHR data for improved signal detection with a case study of immune-related adverse events. We first loaded the OMOP CDM with both recent and legacy FAERS (FDA Adverse Event Reporting System) data (from the time period between Jan. 2004 and Dec. 2018). We also integrated the clinical data from the Mayo Clinic EHR system for six oncological immunotherapy drugs. We implemented a signal detection algorithm and compared the timelines of positive signals detected from both FAERS and EHR data. We found that the signals detected from EHRs are 4 months earlier than signals detected from FAERS database (depending on the signal detection methods used) for the ipilimumab-induced hypopituitarism. Our CDM-based approach would be useful to provide a scalable solution to integrate both drug safety data and EHR data to generate RWE for improved signal detection.</AbstractText><CopyrightInformation>&#xa9;2020 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruddy</LastName><ForeName>Kathryn J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Oncology, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zong</LastName><ForeName>Nansu</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Shintaro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nilay D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Guoqian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Jt Summits Transl Sci Proc</MedlineTA><NlmUniqueID>101539486</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32477694</ArticleId><ArticleId IdType="pmc">PMC7233056</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Corrigan-Curay J, Sacks L, Woodcock J. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. JAMA. 2018;320(9):867&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">30105359</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Real World Evidence.  Available from:  https://www.fda.gov/ScienceResearch/SpecialTopics/RealWorldEvidence/default.htm.</Citation></Reference><Reference><Citation>Poole KG., Jr Patient-Experience Data and Bias - What Ratings Don"t Tell Us. N Engl J Med. 2019;380(9):801&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">30811905</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA, Framework for FDA&#x2019;s Real-World Evidence Program. 2018</Citation></Reference><Reference><Citation>Wang L, Rastegar-Mojarad M, Ji Z, Liu S, Liu K, Moon S, et al. Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis. Front Pharmacol. 2018;9:875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6090179</ArticleId><ArticleId IdType="pubmed">30131701</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H, Solti I, Kirkendall E, Zhai H, Lingren T, Meller J, et al. Leveraging Food and Drug Administration Adverse Event Reports for the Automated Monitoring of Electronic Health Records in a Pediatric Hospital. Biomed Inform Insights. 2017;9:1178222617713018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467704</ArticleId><ArticleId IdType="pubmed">28634427</ArticleId></ArticleIdList></Reference><Reference><Citation>Patadia VK, Schuemie MJ, Coloma P, Herings R, van der Lei J, Straus S, et al. Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. Int J Clin Pharm. 2015;37(1):94&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">25488315</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer SV, Harpaz R, LePendu P, Bauer-Mehren A, Shah NH. Mining clinical text for signals of adverse drug-drug interactions. J Am Med Inform Assoc. 2014;21(2):353&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932451</ArticleId><ArticleId IdType="pubmed">24158091</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarker A., Ginn R., Nikfarjam A., O&#x2019;Connor K., Smith K., Jayaraman S., Upadhaya T., Gonzalez G. Utilizing social media data for pharmacovigilance: a review. Journal of biomedical informatics. 2015;54:202&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4408239</ArticleId><ArticleId IdType="pubmed">25720841</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder S., Norman G., Loke Y.K. Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. British journal of clinical pharmacology. 2015;80(4):878&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4594731</ArticleId><ArticleId IdType="pubmed">26271492</ArticleId></ArticleIdList></Reference><Reference><Citation>Lardon J., Abdellaoui R., Bellet F., Asfari H., Souvignet J., Texier N., Jaulent M.C., Beyens M.N., Burgun A., Bousquet C. Adverse drug reaction identification and extraction in social media: a scoping review. Journal of medical Internet research. 2015;17(7):e171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526988</ArticleId><ArticleId IdType="pubmed">26163365</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI.  Available from:  https://www.ohdsi.org/</Citation></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, et al. Characterizing treatment pathways at scale using the OHDSI network. P Natl Acad Sci USA. 2016;113(27):7329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH. All of Us Research Program.  Available from:  https://allofus.nih.gov/</Citation></Reference><Reference><Citation>Vanderbilt University. eMERGE Network.  Available from:  https://emerge.mc.vanderbilt.edu/.</Citation></Reference><Reference><Citation>McCarty CA, Chisholm RL, Chute CG, Kullo IJ, Jarvik GP, Larson EB, et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics. 2011;4:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038887</ArticleId><ArticleId IdType="pubmed">21269473</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31(30):4401&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">23015364</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, Banda JM, Park RW, Jin S, et al. Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin: Analysis From the Observational Health Data Sciences and Informatics Initiative. JAMA Netw Open. 2018;1(4):e181755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Ruddy KJ, Hong N, Tsuji S, Wen A, Shah ND, et al. ADEpedia-on-OHDSI: A Next Generation Pharmacovigilance Signal Detection Platform Using the OHDSI Common Data Model. J Biomed Inform. 2019:103119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6432939</ArticleId><ArticleId IdType="pubmed">30738946</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Jiang G. ADEpedia-on-OHDSI.  Available from:  https://github.com/adepedia/adepedia-on-ohdsi.</Citation></Reference><Reference><Citation>FDA. FDA Adverse Event Reporting System (FAERS)  Available from:  https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm.</Citation></Reference><Reference><Citation>NIH. Drug Label: YERVOY- ipilimumab injection.  Available from:  https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66.</Citation></Reference><Reference><Citation>Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV. Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest. 2015;38(11):1159&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">25957829</ArticleId></ArticleIdList></Reference><Reference><Citation>Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582059</ArticleId></ArticleIdList></Reference><Reference><Citation>McClellan M. Drug safety reform at the FDA - Pendulum swing of systematic improvement? New Engl J Med. 2007;356(17):1700&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">17435081</ArticleId></ArticleIdList></Reference><Reference><Citation>Patadia VK, Schuemie MJ, Coloma PM, Herings R, van der Lei J, Sturkenboom M, et al. Can Electronic Health Records Databases Complement Spontaneous Reporting System Databases? A Historical-Reconstruction of the Association of Rofecoxib and Acute Myocardial Infarction. Frontiers in Pharmacology. 2018:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5997784</ArticleId><ArticleId IdType="pubmed">29928230</ArticleId></ArticleIdList></Reference><Reference><Citation>Patadia VK, Coloma P, Schuemie MJ, Herings R, Gini R, Mazzaglia G, et al. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project. Expert Rev Clin Pharmacol. 2015;8(1):95&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">25487079</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32479175</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-3704</ISSN><JournalIssue CitedMedium="Internet"><Volume>172</Volume><Issue>11 Suppl</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>Annals of internal medicine</Title><ISOAbbreviation>Ann Intern Med</ISOAbbreviation></Journal><ArticleTitle>Research and Reporting Considerations for Observational Studies Using Electronic Health Record Data.</ArticleTitle><Pagination><StartPage>S79</StartPage><EndPage>S84</EndPage><MedlinePgn>S79-S84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7326/M19-0873</ELocationID><Abstract><AbstractText>Electronic health records (EHRs) are an increasingly important source of real-world health care data for observational research. Analyses of data collected for purposes other than research require careful consideration of data quality as well as the general research and reporting principles relevant to observational studies. The core principles for observational research in general also apply to observational research using EHR data, and these are well addressed in prior literature and guidelines. This article provides additional recommendations for EHR-based research. Considerations unique to EHR-based studies include assessment of the accuracy of computer-executable cohort definitions that can incorporate unstructured data from clinical notes and management of data challenges, such as irregular sampling, missingness, and variation across time and place. Principled application of existing research and reporting guidelines alongside these additional considerations will improve the quality of EHR-based observational studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, School of Medicine, Stanford University (A.C., N.H.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Center for Biomedical Informatics Research, School of Medicine, Stanford University (A.C., N.H.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jonathan H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Division of Hospital Medicine, School of Medicine, Stanford University (J.H.C.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 ES026837</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011369</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Intern Med</MedlineTA><NlmUniqueID>0372351</NlmUniqueID><ISSNLinking>0003-4819</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32479175</ArticleId><ArticleId IdType="mid">NIHMS1608040</ArticleId><ArticleId IdType="pmc">PMC7413106</ArticleId><ArticleId IdType="doi">10.7326/M19-0873</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chute CG. Invited commentary: observational research in the age of the electronic health record. Am J Epidemiol. 2014;179:759&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">24488512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence&#x2014;what is it and what can it tell us? N Engl J Med. 2016;375:2293&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett VL, Dhruva SS, Shah ND, Ryan P, Ross JS. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw Open. 2019;2:e1912869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802419</ArticleId><ArticleId IdType="pubmed">31596493</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12:e1001885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4595218</ArticleId><ArticleId IdType="pubmed">26440803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JH, Hom J, Richman I, Asch SM, Podchiyska T, Johansen NA. Effect of opioid prescribing guidelines in primary care. Medicine. 2016;95:e4760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5008612</ArticleId><ArticleId IdType="pubmed">27583928</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, et al. Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the Observational Health Data Sciences and Informatics initiative. JAMA Netw Open. 2018;1:e181755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton KM, Peissig PL, Kho AN, et al. Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. J Am Med Inform Assoc. 2013;20:e147&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivade C, Raghavan P, Fosler-Lussier E, et al. A review of approaches to identifying patient phenotype cohorts using electronic health records. J Am Med Inform Assoc. 2013;21:221&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932460</ArticleId><ArticleId IdType="pubmed">24201027</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells BJ, Chagin KM, Nowacki AS, Kattan MW. Strategies for handling missing data in electronic health record derived data. EGEMS (Wash DC). 2013;1:1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371484</ArticleId><ArticleId IdType="pubmed">25848578</ArticleId></ArticleIdList></Reference><Reference><Citation>Madden JM, Lakoma MD, Rusinak D, Lu CY, Soumerai SB. Missing clinical and behavioral health data in a large electronic health record (EHR) system. J Am Med Inform Assoc. 2016;23:1143&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070522</ArticleId><ArticleId IdType="pubmed">27079506</ArticleId></ArticleIdList></Reference><Reference><Citation>Agniel D, Kohane IS, Weber GM. Biases in electronic health record data due to processes within the healthcare system: retrospective observational study. BMJ. 2018;361:k1479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5925441</ArticleId><ArticleId IdType="pubmed">29712648</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariharan J, Lamb GC, Neuner JM. Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med. 2007;22:485&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829426</ArticleId><ArticleId IdType="pubmed">17372797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright A, McCoy AB, Hickman TT, et al. Problem list completeness in electronic health records: a multi-site study and assessment of success factors. Int J Med Inform. 2015;84:784&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549158</ArticleId><ArticleId IdType="pubmed">26228650</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher ES, Whaley FS, Krushat WM, et al. The accuracy of Medicare&#x2019;s hospital claims data: progress has been made, but problems remain. Am J Public Health. 1992;82:243&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1694279</ArticleId><ArticleId IdType="pubmed">1739155</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei WQ, Teixeira PL, Mo H, Cronin RM, Warner JL, Denny JC. Combining billing codes, clinical notes, and medications from electronic health records provides superior phenotyping performance. J Am Med Inform Assoc. 2016;23:e20&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4954637</ArticleId><ArticleId IdType="pubmed">26338219</ArticleId></ArticleIdList></Reference><Reference><Citation>Reker DM, Hamilton BB, Duncan PW, Yeh SC, Rosen A. Stroke: who&#x2019;s counting what? J Rehabil Res Dev. 2001;38:281&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11392661</ArticleId></ArticleIdList></Reference><Reference><Citation>Chescheir N, Meints L. Prospective study of coding practices for cesarean deliveries. Obstet Gynecol. 2009. August;114(2 Pt 1):217&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622980</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Achkar M, Kengeri-Srikantiah S, Yamane BM, Villasmil J, Busha ME, Gebke KB. Billing by residents and attending physicians in family medicine: the effects of the provider, patient, and visit factors. BMC Med Educ. 2018;18:136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5998502</ArticleId><ArticleId IdType="pubmed">29895287</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrell DS, Cronkite D, Palmer RE, et al. Using natural language processing to identify problem usage of prescription opioids. Int J Med Inform. 2015;84:1057&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">26456569</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning CD, Sch&#xfc;tze H. Foundations of Statistical Natural Language Processing. Cambridge, MA: MIT Pr; 1999.</Citation></Reference><Reference><Citation>Levinson W, Born K, Wolfson D. Choosing Wisely campaigns: a work in progress. JAMA. 2018;319:1975&#x2013;6. Accessed at https://jamanetwork.com/journals/jama/fullarticle/2679354?utm_source=silverchair&amp;utm_medium=email&amp;utm_campaign=article_aler-tjama&amp;utm_content=olf&amp;utm_term=041918 on
19 April 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">29710232</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Hom J, Balasubramanian S, et al. Prevalence and predictability of low-yield inpatient laboratory diagnostic tests. JAMA Netw Open. 2019;2:e1910967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6739729</ArticleId><ArticleId IdType="pubmed">31509205</ArticleId></ArticleIdList></Reference><Reference><Citation>Richesson RL, Sun J, Pathak J, Kho AN, Denny JC. Clinical phenotyping in selected national networks: demonstrating the need for high-throughput, portable, and computational methods. Artif Intell Med. 2016. July;71:57&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480212</ArticleId><ArticleId IdType="pubmed">27506131</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM, Seneviratne M, Hernandez-Boussard T, Shah NH. Advances in Electronic phenotyping: from rule-based definitions to machine learning models. Annu Rev Biomed Data Sci. 2018;1:53&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583807</ArticleId><ArticleId IdType="pubmed">31218278</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdahl CT, Moran GJ, McBride O, Santini AM, Verzhbinsky IA, Schriger DL. Concordance between electronic clinical documentation and physicians&#x2019; observed behavior. JAMA Netw Open. 2019;2:e1911390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6751766</ArticleId><ArticleId IdType="pubmed">31532513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschtick RE. A piece of my mind. Copy-and-paste. JAMA. 2006;295:2335&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720812</ArticleId></ArticleIdList></Reference><Reference><Citation>Marafino BJ, Dudley RA, Shah NH, Chen JH. Accurate and interpretable intensive care risk adjustment for fused clinical data with generalized additive models. AMIA Jt Summits Transl Sci Proc. 2018;2017:166&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961794</ArticleId><ArticleId IdType="pubmed">29888065</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Manning CD, Raghavan P, Schutze H, eds. Evaluation in information retrieval In: Introduction to Information Retrieval. Cambridge, UK: Cambridge Univ Pr; 2008.</Citation></Reference><Reference><Citation>Kirby JC, Speltz P, Rasmussen LV, et al. PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc. 2016;23:1046&#x2013;52. Accessed at 10.1093/jamia/ocv202</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv202</ArticleId><ArticleId IdType="pmc">PMC5070514</ArticleId><ArticleId IdType="pubmed">27026615</ArticleId></ArticleIdList></Reference><Reference><Citation>Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ. 2013;347:f6409.</Citation><ArticleIdList><ArticleId IdType="pubmed">24217206</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart EA, DuGoff E, Abrams M, Salkever D, Steinwachs D. Estimating causal effects in observational studies using electronic health data: challenges and (some) solutions. EGEMS (Wash DC). 2013;1 Accessed at 10.13063/2327-9214.1038</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1038</ArticleId><ArticleId IdType="pmc">PMC4049166</ArticleId><ArticleId IdType="pubmed">24921064</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci. 2010;25:1&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943670</ArticleId><ArticleId IdType="pubmed">20871802</ArticleId></ArticleIdList></Reference><Reference><Citation>Cafri G, Wang W, Chan PH, Austin PC. A review and empirical comparison of causal inference methods for clustered observational data with application to the evaluation of the effectiveness of medical devices. Stat Methods Med Res. 2019;28:3142&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">30203707</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearl J Causal inference in statistics: an overview. Stat Surv. 2009;3:96&#x2013;146.</Citation></Reference><Reference><Citation>Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33:1057&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285163</ArticleId><ArticleId IdType="pubmed">24123228</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh S, Garc&#xed;a Rodr&#xed;guez LA, Hern&#xe1;n MA. Confounding adjustment via a semiautomated high-dimensional propensity score algorithm: an application to electronic medical records. Pharmacoepidemiol Drug Saf. 2011;20:849&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3222935</ArticleId><ArticleId IdType="pubmed">21717528</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbogast PG, Ray WA. Performance of disease risk scores, propensity scores, and traditional multivariable outcome regression in the presence of multiple confounders. Am J Epidemiol. 2011;174:613&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">21749976</ArticleId></ArticleIdList></Reference><Reference><Citation>Biondi-Zoccai G, Romagnoli E, Agostoni P, et al. Are propensity scores really superior to standard multivariable analysis? Contemp Clin Trials. 2011;32:731&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">21616172</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins NJ, Cole SR, Harel O, et al. Principled approaches to missing data in epidemiologic studies. Am J Epidemiol. 2018;187:568&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5860376</ArticleId><ArticleId IdType="pubmed">29165572</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu-Jones BK, Lavage DR, Snyder JW, Moore JH, Pendergrass SA, Bauer CR. Characterizing and managing missing structured data in electronic health records: data analysis. JMIR Med Inform. 2018;6:e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5845101</ArticleId><ArticleId IdType="pubmed">29475824</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials. 2004;1:368&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">16279275</ArticleId></ArticleIdList></Reference><Reference><Citation>Eekhout I, de Boer RM, Twisk JW, de Vet HC, Heymans MW. Missing data: a systematic review of how they are reported and handled. Epidemiology. 2012;23:729&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">22584299</ArticleId></ArticleIdList></Reference><Reference><Citation>Averill RF, Goldfield N, Hughes JS, et al.
All patient refined diagnosis related groups (APR-DRGs)
Version 20.0. Methodology overview. Wallingford, CT: 3M Health Information Systems; 2003. 
Accessed at www.hcup-us.ahrq.gov/db/nation/nis/APR-DRGsV20MethodologyOverviewandBibliography.pdf</Citation></Reference><Reference><Citation>Chen JH, Alagappan M, Goldstein MK, Asch SM, Altman RB. Decaying relevance of clinical data towards future decisions in data-driven inpatient clinical order sets. Int J Med Inform. 2017;102:71&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5459355</ArticleId><ArticleId IdType="pubmed">28495350</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbluth G, Jacolbia R, Milev D, Auerbach AD. Half-life of a printed handoff document. BMJ Qual Saf. 2016;25:324&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26558826</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung K, Shah NH. Implications of non-stationarity on predictive modeling using EHRs. J Biomed Inform. 2015;58:168&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684770</ArticleId><ArticleId IdType="pubmed">26483171</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Torres JG, Raeder T, Alaiz-Rodr&#xed;guez R, Chawla NV, Herrera F. A unifying view on dataset shift in classification. Pattern Recognit. 2012;45:521&#x2013;30.</Citation></Reference><Reference><Citation>Lindenauer PK, Lagu T, Shieh M-S, Pekow PS, Rothberg MB. Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003&#x2013;2009. JAMA. 2012;307:1405&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">22474204</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh CG, Sharman K, Hripcsak G. Beyond discrimination: a comparison of calibration methods and clinical usefulness of predictive models of readmission risk. J Biomed Inform. 2017;76:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5716927</ArticleId><ArticleId IdType="pubmed">29079501</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel JC, Kreda DA, Mandl KD, Kohane IS, Ramoni RB. SMART on FHIR: a standards-based, interoperable apps platform for electronic health records. J Am Med Inform Assoc. 2016. Sep;23(5):899&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997036</ArticleId><ArticleId IdType="pubmed">26911829</ArticleId></ArticleIdList></Reference><Reference><Citation>CommonDataModel. Github; 
Accessed at https://github.com/OHDSI/CommonDataModel on
16 October 2019.</Citation></Reference><Reference><Citation>Huser V, DeFalco FJ, Schuemie M, et al. Multisite evaluation of a data quality tool for patient-level clinical data sets. EGEMS (Wash DC). 2016;4:1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5226382</ArticleId><ArticleId IdType="pubmed">28154833</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JS, Kahn M, Toh S. Data quality assessment for comparative effectiveness research in distributed data networks. Med Care. 2013. August;51(8 Suppl 3):S22&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4306391</ArticleId><ArticleId IdType="pubmed">23793049</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan TJ, Bauck AE, Bertoch D, et al. A comparison of data quality assessment checks in six data sharing networks. EGEMS (Wash DC). 2017;5:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5982846</ArticleId><ArticleId IdType="pubmed">29881733</ArticleId></ArticleIdList></Reference><Reference><Citation>Huser V, Kahn MG, Brown JS, Gouripeddi R. Methods for examining data quality in healthcare integrated data repositories. Pac Symp Biocomput. 2018;23:628&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">29218922</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M, Saunders R, Stuckhardt L, McGinnis JM. Best care at lower cost: the path to continuously learning health care in America. Washington DC: Institute of Medicine, Committee on the Learning Health Care System in America; 2012.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32484782</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2369-2960</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>JMIR public health and surveillance</Title><ISOAbbreviation>JMIR Public Health Surveill</ISOAbbreviation></Journal><ArticleTitle>The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms.</ArticleTitle><Pagination><StartPage>e19773</StartPage><MedlinePgn>e19773</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e19773</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/19773</ELocationID><Abstract><AbstractText Label="BACKGROUND">Routinely recorded primary care data have been used for many years by sentinel networks for surveillance. More recently, real world data have been used for a wider range of research projects to support rapid, inexpensive clinical trials. Because the partial national lockdown in the United Kingdom due to the coronavirus disease (COVID-19) pandemic has resulted in decreasing community disease incidence, much larger numbers of general practices are needed to deliver effective COVID-19 surveillance and contribute to in-pandemic clinical trials.</AbstractText><AbstractText Label="OBJECTIVE">The aim of this protocol is to describe the rapid design and development of the Oxford Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID) and its first two platforms. The Surveillance Platform will provide extended primary care surveillance, while the Trials Platform is a streamlined clinical trials platform that will be integrated into routine primary care practice.</AbstractText><AbstractText Label="METHODS">We will apply the FAIR (Findable, Accessible, Interoperable, and Reusable) metadata principles to a new, integrated digital health hub that will extract routinely collected general practice electronic health data for use in clinical trials and provide enhanced communicable disease surveillance. The hub will be findable through membership in Health Data Research UK and European metadata repositories. Accessibility through an online application system will provide access to study-ready data sets or developed custom data sets. Interoperability will be facilitated by fixed linkage to other key sources such as Hospital Episodes Statistics and the Office of National Statistics using pseudonymized data. All semantic descriptors (ie, ontologies) and code used for analysis will be made available to accelerate analyses. We will also make data available using common data models, starting with the US Food and Drug Administration Sentinel and Observational Medical Outcomes Partnership approaches, to facilitate international studies. The Surveillance Platform will provide access to data for health protection and promotion work as authorized through agreements between Oxford, the Royal College of General Practitioners, and Public Health England. All studies using the Trials Platform will go through appropriate ethical and other regulatory approval processes.</AbstractText><AbstractText Label="RESULTS">The hub will be a bottom-up, professionally led network that will provide benefits for member practices, our health service, and the population served. Data will only be used for SQUIRE (surveillance, quality improvement, research, and education) purposes. We have already received positive responses from practices, and the number of practices in the network has doubled to over 1150 since February 2020. COVID-19 surveillance has resulted in tripling of the number of virology sites to 293 (target 300), which has aided the collection of the largest ever weekly total of surveillance swabs in the United Kingdom as well as over 3000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology samples. Practices are recruiting to the PRINCIPLE (Platform Randomised trial of INterventions against COVID-19 In older PeopLE) trial, and these participants will be followed up through ORCHID. These initial outputs demonstrate the feasibility of ORCHID to provide an extended national digital health hub.</AbstractText><AbstractText Label="CONCLUSIONS">ORCHID will provide equitable and innovative use of big data through a professionally led national primary care network and the application of FAIR principles. The secure data hub will host routinely collected general practice data linked to other key health care repositories for clinical trials and support enhanced in situ surveillance without always requiring large volume data extracts. ORCHID will support rapid data extraction, analysis, and dissemination with the aim of improving future research and development in general practice to positively impact patient care.</AbstractText><AbstractText Label="INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)">DERR1-10.2196/19773.</AbstractText><CopyrightInformation>&#xa9;Simon de Lusignan, Nicholas Jones, Jienchi Dorward, Rachel Byford, Harshana Liyanage, John Briggs, Filipa Ferreira, Oluwafunmi Akinyemi, Gayatri Amirthalingam, Chris Bates, Jamie Lopez Bernal, Gavin Dabrera, Alex Eavis, Alex J Elliot, Michael Feher, Else Krajenbrink, Uy Hoang, Gary Howsam, Jonathan Leach, Cecilia Okusi, Brian Nicholson, Philip Nieri, Julian Sherlock, Gillian Smith, Mark Thomas, Nicholas Thomas, Manasa Tripathy, William Victor, John Williams, Ian Wood, Maria Zambon, John Parry, Shaun O&#x2019;Hanlon, Mark Joy, Chris Butler, Martin Marshall, FD Richard Hobbs. Originally published in JMIR Public Health and Surveillance (http://publichealth.jmir.org), 02.07.2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Lusignan</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8553-2641</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Jones</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0352-3785</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorward</LastName><ForeName>Jienchi</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6072-1430</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byford</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4792-8995</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liyanage</LastName><ForeName>Harshana</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9738-6349</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Briggs</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9832-5430</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Filipa</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7717-8486</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akinyemi</LastName><ForeName>Oluwafunmi</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-0401-0145</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amirthalingam</LastName><ForeName>Gayatri</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2078-0975</Identifier><AffiliationInfo><Affiliation>Public Health England, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bates</LastName><ForeName>Chris</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0113-2593</Identifier><AffiliationInfo><Affiliation>TPP SystmOne, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez Bernal</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-1301-5653</Identifier><AffiliationInfo><Affiliation>Public Health England, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dabrera</LastName><ForeName>Gavin</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4606-5945</Identifier><AffiliationInfo><Affiliation>Public Health England, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eavis</LastName><ForeName>Alex</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3525-2198</Identifier><AffiliationInfo><Affiliation>EMIS Group, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliot</LastName><ForeName>Alex J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-6414-3065</Identifier><AffiliationInfo><Affiliation>Real-time Syndromic Surveillance Team, Field Service, Public Health England, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feher</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0631-6199</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krajenbrink</LastName><ForeName>Else</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6563-9441</Identifier><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoang</LastName><ForeName>Uy</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-8428-5140</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howsam</LastName><ForeName>Gary</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-6699-5504</Identifier><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leach</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5142-4506</Identifier><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okusi</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5575-8527</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Brian</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-0661-7362</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nieri</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0478-0190</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherlock</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7427-1936</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Gillian</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4257-0568</Identifier><AffiliationInfo><Affiliation>Real-time Syndromic Surveillance Team, Field Service, Public Health England, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6290-3948</Identifier><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0460-6870</Identifier><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathy</LastName><ForeName>Manasa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9840-3876</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Victor</LastName><ForeName>William</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-3660-6517</Identifier><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6118-0434</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Ian</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-0080-6624</Identifier><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EMIS Group, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zambon</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8897-7881</Identifier><AffiliationInfo><Affiliation>Public Health England, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parry</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0190-1121</Identifier><AffiliationInfo><Affiliation>TPP SystmOne, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Hanlon</LastName><ForeName>Shaun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0731-5211</Identifier><AffiliationInfo><Affiliation>EMIS Group, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joy</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4974-3724</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Chris</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0102-3453</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8575-5442</Identifier><AffiliationInfo><Affiliation>Royal College of General Practitioners, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hobbs</LastName><ForeName>F D Richard</ForeName><Initials>FDR</Initials><Identifier Source="ORCID">0000-0001-7976-7172</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Public Health Surveill</MedlineTA><NlmUniqueID>101669345</NlmUniqueID><ISSNLinking>2369-2960</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058006" MajorTopicYN="N">General Practice</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016347" MajorTopicYN="Y">Medical Records Systems, Computerized</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062486" MajorTopicYN="Y">Public Health Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">adaptive clinical trials</Keyword><Keyword MajorTopicYN="N">clinical trials as a topic</Keyword><Keyword MajorTopicYN="N">general practice</Keyword><Keyword MajorTopicYN="N">medical record systems, computerized</Keyword><Keyword MajorTopicYN="N">primary health care</Keyword><Keyword MajorTopicYN="N">public health surveillance</Keyword><Keyword MajorTopicYN="N">sentinel surveillance</Keyword><Keyword MajorTopicYN="N">severe acute respiratory syndrome coronavirus 2</Keyword></KeywordList><CoiStatement>Conflicts of Interest: CB and JP are employees of TPP, and that AE, IW, and SH are employees of EMIS. Both TPP and EMIS are commercial partner organisations for this project.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32484782</ArticleId><ArticleId IdType="pmc">PMC7333793</ArticleId><ArticleId IdType="doi">10.2196/19773</ArticleId><ArticleId IdType="pii">v6i3e19773</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>de Lusignan S, Correa A, Smith GE, Yonova I, Pebody R, Ferreira F, Elliot AJ, Fleming D. RCGP Research and Surveillance Centre: 50 years&#x2019; surveillance of influenza, infections, and respiratory conditions. Br J Gen Pract. 2017 Sep 29;67(663):440&#x2013;441. doi: 10.3399/bjgp17x692645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp17x692645</ArticleId><ArticleId IdType="pmc">PMC5604796</ArticleId><ArticleId IdType="pubmed">28963401</ArticleId></ArticleIdList></Reference><Reference><Citation>gov.uk.  [2020-06-02].  Life Sciences Industrial Strategy &#x2013; A report to the Government from the life sciences sector https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/650447/LifeSciencesIndustrialStrategy_acc2.pdf.</Citation></Reference><Reference><Citation>Moltu C, Stefansen J, Svisdahl M, Veseth M. Negotiating the coresearcher mandate - service users' experiences of doing collaborative research on mental health. Disabil Rehabil. 2012;34(19):1608&#x2013;16. doi: 10.3109/09638288.2012.656792.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/09638288.2012.656792</ArticleId><ArticleId IdType="pubmed">22489612</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook DJ, Marshall JC, Fowler RA. Critical Illness in Patients With COVID-19: Mounting an Effective Clinical and Research Response. JAMA. 2020 Apr 06; doi: 10.1001/jama.2020.5775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.5775</ArticleId><ArticleId IdType="pubmed">32250408</ArticleId></ArticleIdList></Reference><Reference><Citation>GoFAIR.  [2020-06-02].   https://www.go-fair.org/</Citation></Reference><Reference><Citation>Royal College of General Practitioners.  [2020-06-02].  Public Health Data https://www.rcgp.org.uk/clinical-and-research/our-programmes/research-and-surveillance-centre-new/public-health-data.aspx.</Citation></Reference><Reference><Citation>gov.uk. 2020. Mar 20,  [2020-04-15].  Staying at home and away from others (social distancing) https://www.gov.uk/government/publications/full-guidance-on-staying-at-home-and-away-from-others.</Citation></Reference><Reference><Citation>Butler C, Ogburn E, Allen J, Bongard E, Swazye H, Tonner D. ISRCTN Registry. 2020. Mar 20,  [2020-04-10].  ISRCTN86534580: A trial evaluating treatments for suspected coronavirus infection in people aged 50 years and above with pre-existing conditions and those aged 65 years and above http://www.isrctn.com/ISRCTN86534580.</Citation></Reference><Reference><Citation>Wilkinson MD, Dumontier M, Aalbersberg IJJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten J, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O, Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJG, Groth P, Goble C, Grethe JS, Heringa J, 't Hoen PAC, Hooft R, Kuhn T, Kok R, Kok J, Lusher SJ, Martone ME, Mons A, Packer AL, Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone S, Schultes E, Sengstag T, Slater T, Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A, Wittenburg P, Wolstencroft K, Zhao J, Mons B. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016 Mar 15;3:160018. doi: 10.1038/sdata.2016.18.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.18</ArticleId><ArticleId IdType="pmc">PMC4792175</ArticleId><ArticleId IdType="pubmed">26978244</ArticleId></ArticleIdList></Reference><Reference><Citation>Correa A, Hinton W, McGovern A, van Vlymen J, Yonova I, Jones S, de Lusignan S. Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open. 2016 Apr 20;6(4):e011092. doi: 10.1136/bmjopen-2016-011092.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-011092</ArticleId><ArticleId IdType="pmc">PMC4838708</ArticleId><ArticleId IdType="pubmed">27098827</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan S, Correa A, Pathirannehelage S, Byford R, Yonova I, Elliot AJ, Lamagni T, Amirthalingam G, Pebody R, Smith G, Jones S, Rafi I. RCGP Research and Surveillance Centre Annual Report 2014&#x2013;2015: disparities in presentations to primary care. Br J Gen Pract. 2016 Dec 19;67(654):e29&#x2013;e40. doi: 10.3399/bjgp16x688573.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp16x688573</ArticleId><ArticleId IdType="pmc">PMC5198624</ArticleId><ArticleId IdType="pubmed">27993900</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  GitHub. 2020. Apr 16,  [2020-06-02].  The Book of OHDSI https://ohdsi.github.io/TheBookOfOhdsi/</Citation></Reference><Reference><Citation>HL7 International.  [2020-06-04].   https://www.hl7.org/</Citation></Reference><Reference><Citation>de Lusignan S, Navarro R, Chan T, Parry G, Dent-Brown K, Kendrick T. Detecting referral and selection bias by the anonymous linkage of practice, hospital and clinic data using Secure and Private Record Linkage (SAPREL): case study from the evaluation of the Improved Access to Psychological Therapy (IAPT) service. BMC Med Inform Decis Mak. 2011 Oct 13;11:61. doi: 10.1186/1472-6947-11-61.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-11-61</ArticleId><ArticleId IdType="doi">10.1186/1472-6947-11-61</ArticleId><ArticleId IdType="pmc">PMC3204226</ArticleId><ArticleId IdType="pubmed">21995837</ArticleId></ArticleIdList></Reference><Reference><Citation>Last J, Adelaide DPH. The iceberg: 'completing the clinical picture' in general practice. Int J Epidemiol. 2013 Dec;42(6):1608&#x2013;13. doi: 10.1093/ije/dyt113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyt113</ArticleId><ArticleId IdType="pubmed">24415602</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor MJ. Legal Bases for Disclosing Confidential Patient Information for Public Health: Distinguishing Between Health Protection and Health Improvement. Med Law Rev. 2015;23(3):348&#x2013;74. doi: 10.1093/medlaw/fwv018.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/medlaw/fwv018</ArticleId><ArticleId IdType="pmc">PMC4533707</ArticleId><ArticleId IdType="pubmed">25995294</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidoff F, Batalden P, Stevens D, Ogrinc G, Mooney S, SQUIRE Development Group  Publication guidelines for quality improvement in health care: evolution of the SQUIRE project. Qual Saf Health Care. 2008 Oct;17 Suppl 1:i3&#x2013;9. doi: 10.1136/qshc.2008.029066.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/qshc.2008.029066</ArticleId><ArticleId IdType="pmc">PMC2773518</ArticleId><ArticleId IdType="pubmed">18836063</ArticleId></ArticleIdList></Reference><Reference><Citation>de SM, Dasler R, Ashton J. DataCite. 2019.  [2020-05-04].  DataCite Metadata Schema Documentation for the Publication and Citation of Research Data https://schema.datacite.org/meta/kernel-4.3/doc/DataCite-MetadataKernel_v4.3.pdf.</Citation></Reference><Reference><Citation>Clinical Informatics.  [2020-06-03].  RCGP RSC COVID-19 Surveillance https://clininf.eu/index.php/cov-19/</Citation></Reference><Reference><Citation>The Nuffield Department of Primary Care Health Sciences  Primary Care Clinical Trials Unit. 2020.  [2020-10-04].  The PRINCIPLE Trial: Evaluating potential treatments for COVID-19 infection in older people http://www.principletrial.org/</Citation></Reference><Reference><Citation>Marmot M. Social determinants of health inequalities. Lancet. 2005 Mar 25;365(9464):1099&#x2013;1104. doi: 10.1016/s0140-6736(05)74234-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(05)74234-3</ArticleId><ArticleId IdType="pubmed">15781105</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldacre B, Smeeth L, Bacon S. OpenSAFELY.  [2020-05-25].   https://opensafely.org/</Citation></Reference><Reference><Citation>Lemanska A, Byford RC, Correa A, Cruickshank C, Dearnaley DP, Griffin C, Hall E, de Lusignan S, Faithfull S. Linking CHHiP prostate cancer RCT with GP records: A study proposal to investigate the effect of co-morbidities and medications on long-term symptoms and radiotherapy-related toxicity. Tech Innov Patient Support Radiat Oncol. 2017 Jun;2:5&#x2013;12. doi: 10.1016/j.tipsro.2017.06.001.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tipsro.2017.06.001</ArticleId><ArticleId IdType="pmc">PMC7033766</ArticleId><ArticleId IdType="pubmed">32095558</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Nellore A. Cloud computing for genomic data analysis and collaboration. Nat Rev Genet. 2018 Jan 30;19(4):208&#x2013;219. doi: 10.1038/nrg.2017.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg.2017.113</ArticleId><ArticleId IdType="pmc">PMC6452449</ArticleId><ArticleId IdType="pubmed">29379135</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Kuo Y, Liu M. A health informatics transformation model based on intelligent cloud computing - exemplified by type 2 diabetes mellitus with related cardiovascular diseases. Comput Methods Programs Biomed. 2020 Feb 25;191:105409. doi: 10.1016/j.cmpb.2020.105409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2020.105409</ArticleId><ArticleId IdType="pubmed">32143073</ArticleId></ArticleIdList></Reference><Reference><Citation>Ping P, Hermjakob H, Polson JS, Benos PV, Wang W. Biomedical Informatics on the Cloud. Circ Res. 2018 Apr 27;122(9):1290&#x2013;1301. doi: 10.1161/circresaha.117.310967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circresaha.117.310967</ArticleId><ArticleId IdType="pmc">PMC6192708</ArticleId><ArticleId IdType="pubmed">29700073</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg JE. Time to tackle unwarranted variations in practice. BMJ. 2011 Mar 17;342:d1513. doi: 10.1136/bmj.d1513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d1513</ArticleId><ArticleId IdType="pubmed">21415111</ArticleId></ArticleIdList></Reference><Reference><Citation>Schols AM, Dinant G, Cals JW. Point-of-care testing in general practice: just what the doctor ordered? Br J Gen Pract. 2018 Jul 26;68(673):362&#x2013;363. doi: 10.3399/bjgp18x698033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp18x698033</ArticleId><ArticleId IdType="pmc">PMC6058637</ArticleId><ArticleId IdType="pubmed">30049755</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan S, Hoang U, Liyanage H, Yonova I, Ferreira F, Diez-Domingo J, Clark T. Feasibility of Point-of-Care Testing for Influenza Within a National Primary Care Sentinel Surveillance Network in England: Protocol for a Mixed Methods Study. JMIR Res Protoc. 2019 Nov 11;8(11):e14186. doi: 10.2196/14186.  </Citation><ArticleIdList><ArticleId IdType="doi">10.2196/14186</ArticleId><ArticleId IdType="pmc">PMC6878097</ArticleId><ArticleId IdType="pubmed">31710303</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanton N, Francis NA, Butler CC. Reducing uncertainty in managing respiratory tract infections in primary care. Br J Gen Pract. 2010 Dec 01;60(581):e466&#x2013;e475. doi: 10.3399/bjgp10x544104.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp10x544104</ArticleId><ArticleId IdType="pmc">PMC2991763</ArticleId><ArticleId IdType="pubmed">21144191</ArticleId></ArticleIdList></Reference><Reference><Citation>Ison M, Portsmouth S, Yoshida Y, Shishido T, Hayden F, Uehara T. LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study) Open Forum Infect Dis. 2018 Nov;5(Suppl 1):S764&#x2013;S765. doi: 10.1093/ofid/ofy229.2190.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofy229.2190</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lusignan Simon, Chan Tom, Theadom Alice, Dhoul Neil. The roles of policy and professionalism in the protection of processed clinical data: a literature review. Int J Med Inform. 2007 Apr;76(4):261&#x2013;8. doi: 10.1016/j.ijmedinf.2005.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2005.11.003</ArticleId><ArticleId IdType="pubmed">16406791</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlebois K, Palmour N, Knoppers BM. The Adoption of Cloud Computing in the Field of Genomics Research: The Influence of Ethical and Legal Issues. PLoS One. 2016;11(10):e0164347. doi: 10.1371/journal.pone.0164347.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164347</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0164347</ArticleId><ArticleId IdType="pmc">PMC5068798</ArticleId><ArticleId IdType="pubmed">27755563</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire AL, Majumder MA, Villanueva AG, Bardill J, Bollinger JM, Boerwinkle E, Bubela T, Deverka PA, Evans BJ, Garrison NA, Glazer D, Goldstein MM, Greely HT, Kahn SD, Knoppers BM, Koenig BA, Lambright JM, Mattison JE, O'Donnell C, Rai AK, Rodriguez LL, Simoncelli T, Terry SF, Thorogood AM, Watson MS, Wilbanks JT, Cook-Deegan R. Importance of Participant-Centricity and Trust for a Sustainable Medical Information Commons. J Law Med Ethics. 2019 Mar;47(1):12&#x2013;20. doi: 10.1177/1073110519840480.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073110519840480</ArticleId><ArticleId IdType="pmc">PMC6738947</ArticleId><ArticleId IdType="pubmed">30994067</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32492716</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>EHR-Independent Predictive Decision Support Architecture Based on OMOP.</ArticleTitle><Pagination><StartPage>399</StartPage><EndPage>404</EndPage><MedlinePgn>399-404</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0040-1710393</ELocationID><Abstract><AbstractText Label="BACKGROUND">The increasing availability of molecular and clinical data of cancer patients combined with novel machine learning techniques has the potential to enhance clinical decision support, example, for assessing a patient's relapse risk. While these prediction models often produce promising results, a deployment in clinical settings is rarely pursued.</AbstractText><AbstractText Label="OBJECTIVES">In this study, we demonstrate how prediction tools can be integrated generically into a clinical setting and provide an exemplary use case for predicting relapse risk in melanoma patients.</AbstractText><AbstractText Label="METHODS">To make the decision support architecture independent of the electronic health record (EHR) and transferable to different hospital environments, it was based on the widely used Observational Medical Outcomes Partnership (OMOP) common data model (CDM) rather than on a proprietary EHR data structure. The usability of our exemplary implementation was evaluated by means of conducting user interviews including the thinking-aloud protocol and the system usability scale (SUS) questionnaire.</AbstractText><AbstractText Label="RESULTS">An extract-transform-load process was developed to extract relevant clinical and molecular data from their original sources and map them to OMOP. Further, the OMOP WebAPI was adapted to retrieve all data for a single patient and transfer them into the decision support Web application for enabling physicians to easily consult the prediction service including monitoring of transferred data. The evaluation of the application resulted in a SUS score of 86.7.</AbstractText><AbstractText Label="CONCLUSION">This work proposes an EHR-independent means of integrating prediction models for deployment in clinical settings, utilizing the OMOP CDM. The usability evaluation revealed that the application is generally suitable for routine use while also illustrating small aspects for improvement.</AbstractText><CopyrightInformation>Georg Thieme Verlag KG Stuttgart &#xb7; New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Unberath</LastName><ForeName>Philipp</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokosch</LastName><ForeName>Hans Ulrich</ForeName><Initials>HU</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gr&#xfc;ndner</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erpenbeck</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christoph</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Friedrich-Alexander-Universit&#xe4;t Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020000" MajorTopicYN="Y">Decision Support Systems, Clinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32492716</ArticleId><ArticleId IdType="pmc">PMC7269719</ArticleId><ArticleId IdType="doi">10.1055/s-0040-1710393</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Luo W, Phung D, Tran T et al.Guidelines for developing and reporting machine learning predictive models in biomedical research: a multidisciplinary view. J Med Internet Res. 2016;18(12):e323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5238707</ArticleId><ArticleId IdType="pubmed">27986644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayaru L, Ypsilantis P P, Nanapragasam A et al.Prediction of outcome in acute lower gastrointestinal bleeding using gradient boosting. PLoS One. 2015;10(07):e0132485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4501707</ArticleId><ArticleId IdType="pubmed">26172121</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogutu J O, Schulz-Streeck T, Piepho H P. Genomic selection using regularized linear regression models: ridge regression, lasso, elastic net and their extensions. BMC Proc. 2012;6 02:S10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3363152</ArticleId><ArticleId IdType="pubmed">22640436</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalilia M, Choi M, Henderson A, Iyengar S, Braunstein M, Sun J. Clinical predictive modeling development and deployment through FHIR web services. AMIA Annu Symp Proc. 2015;2015:717&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765683</ArticleId><ArticleId IdType="pubmed">26958207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J H, Dindorf J, Eberhardt M et al.Innate extracellular vesicles from melanoma patients suppress &#x3b2;-catenin in tumor cells by miRNA-34a. Life Sci Alliance. 2019;2(02):e201800205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6406044</ArticleId><ArticleId IdType="pubmed">30846484</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke J D, Shah N H et al.Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Povey S, Lovering R, Bruford E, Wright M, Lush M, Wain H. The HUGO Gene Nomenclature Committee (HGNC) Hum Genet. 2001;109(06):678&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">11810281</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Lang L, Storf H et al.Towards implementation of OMOP in a German University Hospital Consortium. Appl Clin Inform. 2018;9(01):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>McCormack J L, Ash J S.Clinician perspectives on the quality of patient data used for clinical decision support: a qualitative studyIn, AMIA Annual Symposium Proceedings: American Medical Informatics Association;20121302</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540542</ArticleId><ArticleId IdType="pubmed">23304409</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooke J. SUS-A quick and dirty usability scale. Usabil Eval Ind. 1996;189:4&#x2013;7.</Citation></Reference><Reference><Citation>Unberath P.2019. Available at:https://github.com/Unberath/WebAPI/tree/v2.4.0-custom. Accessed April 16, 2020</Citation></Reference><Reference><Citation>Bellazzi R, Zupan B. Predictive data mining in clinical medicine: current issues and guidelines. Int J Med Inform. 2008;77(02):81&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17188928</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon D, Ahn E K, Park M Y et al.Conversion and data quality assessment of electronic health record data at a Korean tertiary teaching hospital to a common data model for distributed network research. Healthc Inform Res. 2016;22(01):54&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756059</ArticleId><ArticleId IdType="pubmed">26893951</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H et al.An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Saf. 2013;36(02):119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamer A, Depas N, Doutreligne M et al.Transforming French electronic health records into the Observational Medical Outcome Partnership's common data model: a feasibility study. Appl Clin Inform. 2020;11(01):13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949163</ArticleId><ArticleId IdType="pubmed">31914471</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch K E, Deppen S A, DuVall S L et al.Incrementally transforming electronic medical records into the Observational Medical Outcomes Partnership common data model: a multidimensional quality assurance approach. Appl Clin Inform. 2019;10(05):794&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6811349</ArticleId><ArticleId IdType="pubmed">31645076</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, Resnic F S, Robbins S L et al.Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl Clin Inform. 2015;6(03):536&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy S N, Weber G, Mendis M et al.Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) J Am Med Inform Assoc. 2010;17(02):124&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender D, Sartipi K.HL7 FHIR: an agile and RESTful approach to healthcare information exchangeIn, Proceedings of the 26th IEEE international symposium on computer-based medical systems: IEEE;2013326&#x2013;331.</Citation></Reference><Reference><Citation>Shin S J, You S C, Park Y R et al.Genomic common data model for seamless interoperation of biomedical data in clinical practice: retrospective study. J Med Internet Res. 2019;21(03):e13249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454347</ArticleId><ArticleId IdType="pubmed">30912749</ArticleId></ArticleIdList></Reference><Reference><Citation>Virzi R A. Refining the test phase of usability evaluation: how many subjects is enough? Hum Factors. 1992;34:457&#x2013;468.</Citation></Reference><Reference><Citation>Bangor A, Kortum P, Miller J. Determining what individual SUS scores mean: adding an adjective rating scale. J Usability Stud. 2009;4:114&#x2013;123.</Citation></Reference><Reference><Citation>O'Sullivan D, Fraccaro P, Carson E, Weller P. Decision time for clinical decision support systems. Clin Med (Lond) 2014;14(04):338&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4952821</ArticleId><ArticleId IdType="pubmed">25099829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates D W, Kuperman G J, Wang S et al.Ten commandments for effective clinical decision support: making the practice of evidence-based medicine a reality. J Am Med Inform Assoc. 2003;10(06):523&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC264429</ArticleId><ArticleId IdType="pubmed">12925543</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32500272</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure with the Use of Paracetamol Compared with Ibuprofen.</ArticleTitle><Pagination><StartPage>927</StartPage><EndPage>942</EndPage><MedlinePgn>927-942</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-020-00950-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Observational studies estimating severe outcomes for paracetamol versus ibuprofen use have acknowledged the specific challenge of channeling bias. A previous study relying on negative controls suggested that using large-scale propensity score (LSPS) matching may mitigate bias better than models using limited lists of covariates.</AbstractText><AbstractText Label="OBJECTIVE">The aim was to assess whether using LSPS matching would enable the evaluation of paracetamol, compared to ibuprofen, and increased risk of myocardial infarction, stroke, gastrointestinal (GI) bleeding, or acute renal failure.</AbstractText><AbstractText Label="STUDY DESIGN AND SETTING">In a new-user cohort study, we used two propensity score model strategies for confounder controls. One replicated the approach of controlling for a hand-picked list. The second used LSPSs based on all available covariates for matching. Positive and negative controls assessed residual confounding and calibrated confidence intervals. The data source was the Clinical Practices Research Datalink (CPRD).</AbstractText><AbstractText Label="RESULTS">A substantial proportion of negative controls were statistically significant after propensity score matching on the publication covariates, indicating considerable systematic error. LSPS adjustment was less biased, but residual error remained. The calibrated estimates resulted in very wide confidence intervals, indicating large uncertainty in effect estimates once residual error was incorporated.</AbstractText><AbstractText Label="CONCLUSIONS">For paracetamol versus ibuprofen, when using LSPS methods in the CPRD, it is only possible to distinguish true effects if those effects are large (hazard ratio&#x2009;&gt;&#x2009;2). Due to their smaller hazard ratios, the outcomes under study cannot be differentiated from null effects (represented by negative controls) even if there were a true effect. Based on these data, we conclude that we are unable to determine whether paracetamol is associated with an increased risk of myocardial infarction, stroke, GI bleeding, and acute renal failure compared to ibuprofen, due to residual confounding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weinstein</LastName><ForeName>Rachel B</ForeName><Initials>RB</Initials><Identifier Source="ORCID">0000-0002-0023-9578</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, 1125 Harbourton-Trenton Rd, Titusville, NJ, 08560, USA. Rweinst1@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, 1125 Harbourton-Trenton Rd, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berlin</LastName><ForeName>Jesse A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Johnson and Johnson, 1125 Harbourton-Trenton Rd, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, 1125 Harbourton-Trenton Rd, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, 1125 Harbourton-Trenton Rd, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fife</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, 1125 Harbourton-Trenton Rd, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>362O9ITL9D</RegistryNumber><NameOfSubstance UI="D000082">Acetaminophen</NameOfSubstance></Chemical><Chemical><RegistryNumber>WK2XYI10QM</RegistryNumber><NameOfSubstance UI="D007052">Ibuprofen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000082" MajorTopicYN="N">Acetaminophen</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007052" MajorTopicYN="N">Ibuprofen</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="Y">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="N">Stroke</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Jesse A. Berlin, Daniel Fife, Patrick B. Ryan, Martijn J. Schuemie, Joel Swerdel, and Rachel B. Weinstein were full-time employees of Johnson &amp; Johnson, or a subsidiary, at the time the study was conducted. Johnson &amp; Johnson manufactures several medications that contain paracetamol or ibuprofen. Jesse A. Berlin, Daniel Fife, Patrick B. Ryan, Martijn J. Schuemie, Joel Swerdel, and Rachel B. Weinstein own stock, stock options, and pension rights from the company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32500272</ArticleId><ArticleId IdType="pmc">PMC7434801</ArticleId><ArticleId IdType="doi">10.1007/s40264-020-00950-3</ArticleId><ArticleId IdType="pii">10.1007/s40264-020-00950-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, Doherty M, Zhang W, Birrell F, Porcheret M, Dziedzic K, Bernstein I, Wise E, Conaghan PG. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2015;0:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4789700</ArticleId><ArticleId IdType="pubmed">25732175</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipworth L, Friis S, Mellemkjaer L, et al. A population-based cohort study of mortality among adults prescribed paracetamol in Denmark. J Clin Epidemiol. 2003;56:796&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">12954473</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries F, Setakis E, van Staa TP, et al. Concomitant use of ibuprofen and paracetamol and the risk of major clinical safety outcomes. Br J Clin Pharmacol. 2010;70:429&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949916</ArticleId><ArticleId IdType="pubmed">20716244</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AT, Manson JE, Albert CM, et al. Nonsteroidal anti-inflammatory drugs, paracetamol, and the risk of cardiovascular events. Circulation. 2006;113:1578&#x2013;1587.</Citation><ArticleIdList><ArticleId IdType="pubmed">16534006</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med. 1989;320(19):1238&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pubmed">2651928</ArticleId></ArticleIdList></Reference><Reference><Citation>Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med. 1994;331(25):1675&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969358</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurth T, Glynn RJ, Walker AM, et al. Analgesic use and change in kidney function in apparently healthy men. Am J Kidney Dis. 2003;42:234&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">12900803</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans M, Fored CM, Bellocco R, et al. Acetaminophen, aspirin and progression of advanced chronic kidney disease. Nephrol Dial Transplant. 2009;24:1908&#x2013;1918.</Citation><ArticleIdList><ArticleId IdType="pubmed">19155536</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedier J, Stampfer M, Hankinson S, et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;40:604&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">12411450</ArticleId></ArticleIdList></Reference><Reference><Citation>Curhan GC, Willett WC, Rosner B, et al. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002;162:2204&#x2013;2208.</Citation><ArticleIdList><ArticleId IdType="pubmed">12390063</ArticleId></ArticleIdList></Reference><Reference><Citation>Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164(14):1519&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">15277282</ArticleId></ArticleIdList></Reference><Reference><Citation>Fored CM, Ejerblad E, Lindblad P. Acetaminophen, aspirin and chronic renal failure. N Engl J Med. 2001;345:1801&#x2013;1808.</Citation><ArticleIdList><ArticleId IdType="pubmed">11752356</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein RB, Ryan P, Berlin JA, et al. Channeling in the use of nonprescription paracetamol and ibuprofen in an electronic medical records database: evidence and implications. Drug Saf. 2017;40(12):1279&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688206</ArticleId><ArticleId IdType="pubmed">28780741</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33(2):209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci USA. 2018;115(11):2571&#x2013;2577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Cepeda MS, Suchard MA, Yang J, Tian Y, Schuler A, et al. How confident are we about observational findings in health care: a benchmark study. Harvard Data Sci Rev. 2020</Citation></Reference><Reference><Citation>Herret E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data resource profile: Clinical Practice Research Datalink (CPRD) Int J Epidemiol. 2015;44(3):827&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a Clinical Practice Research Datalink conversion to the OMOP common data model. Drug Saf. 2014;37:945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(3):553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the premier perspective hospital database into the observational medical outcomes partnership (OMOP) common data model. EGEMS (Wash DC). 2014;2(1):1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul Publ Assoc Comput Mach. 2013;23(1):1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc B. 1996;58(1):267&#x2013;288.</Citation></Reference><Reference><Citation>Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. J Clin Epidemiol. 2015;68:627&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">25704724</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AM, Patrick AR, Lauer MS, Hornbrook MC, Marin MG, Platt R, Roger VL, Stang P, Schneeweiss S. A tool for assessing the feasibility of comparative effectiveness research. Comp Effect Res. 2013;2013(3):11&#x2013;20.</Citation></Reference><Reference><Citation>Dusetzina SB, Brookhart MA, Maciejewski ML. Control outcomes and exposures for improving internal validity of nonrandomized studies. Health Serv Res. 2015;50:1432&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4600355</ArticleId><ArticleId IdType="pubmed">25598384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology (Cambridge, Mass) 2010;21:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2017;66:72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D) Diabetes Obes Metab. 2018;20(11):2585&#x2013;2597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6220807</ArticleId><ArticleId IdType="pubmed">29938883</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Ryan PB, Suchard MA, et al. Risk of angioedema associated with levetiracetam compared with phenytoin: findings of the observational health data sciences and informatics research network. Epilepsia. 2017;58(8):e101&#x2013;e106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632067</ArticleId><ArticleId IdType="pubmed">28681416</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" VersionID="2" Owner="NLM"><PMID Version="2">32511443</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Jun</Month><Day>28</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Deep phenotyping of 34,128 patients hospitalised with COVID-19 and a comparison with 81,596 influenza patients in America, Europe and Asia: an international network study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2020.04.22.20074336</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2020.04.22.20074336</ELocationID><Abstract><AbstractText>Background In this study we phenotyped individuals hospitalised with coronavirus disease 2019 (COVID-19) in depth, summarising entire medical histories, including medications, as captured in routinely collected data drawn from databases across three continents. We then compared individuals hospitalised with COVID-19 to those previously hospitalised with influenza. Methods We report demographics, previously recorded conditions and medication use of patients hospitalised with COVID-19 in the US (Columbia University Irving Medical Center [CUIMC], Premier Healthcare Database [PHD], UCHealth System Health Data Compass Database [UC HDC], and the Department of Veterans Affairs [VA OMOP]), in South Korea (Health Insurance Review &amp; Assessment [HIRA]), and Spain (The Information System for Research in Primary Care [SIDIAP] and HM Hospitales [HM]). These patients were then compared with patients hospitalised with influenza in 2014-19. Results 34,128 (US: 8,362, South Korea: 7,341, Spain: 18,425) individuals hospitalised with COVID-19 were included. Between 4,811 (HM) and 11,643 (CUIMC) unique aggregate characteristics were extracted per patient, with all summarised in an accompanying interactive website (http://evidence.ohdsi.org/Covid19CharacterizationHospitalization/). Patients were majority male in the US (CUIMC: 52%, PHD: 52%, UC HDC: 54%, VA OMOP: 94%,) and Spain (SIDIAP: 54%, HM: 60%), but were predominantly female in South Korea (HIRA: 60%). Age profiles varied across data sources. Prevalence of asthma ranged from 4% to 15%, diabetes from 13% to 43%, and hypertensive disorder from 24% to 70% across data sources. Between 14% and 33% were taking drugs acting on the renin-angiotensin system in the 30 days prior to hospitalisation. Compared to 81,596 individuals hospitalised with influenza in 2014-19, patients admitted with COVID-19 were more typically male, younger, and healthier, with fewer comorbidities and lower medication use. Conclusions We provide a detailed characterisation of patients hospitalised with COVID-19. Protecting groups known to be vulnerable to influenza is a useful starting point to minimize the number of hospital admissions needed for COVID-19. However, such strategies will also likely need to be broadened so as to reflect the particular characteristics of individuals hospitalised with COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9286-1128</Identifier></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Abedtash</LastName><ForeName>Hamed</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Abrahao</LastName><ForeName>Maria Tereza F</ForeName><Initials>MTF</Initials></Author><Author ValidYN="Y"><LastName>Alberga</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Aragon</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Banda</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Jaehyeong</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Culhane</LastName><ForeName>Aedin C</ForeName><Initials>AC</Initials></Author><Author ValidYN="Y"><LastName>Davydov</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Fernandez-Bertolin</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Weihua</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hardin</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Hokyun</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Yonghua</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Chi Young</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Kaas-Hansen</LastName><ForeName>Benjamin Skov</ForeName><Initials>BS</Initials></Author><Author ValidYN="Y"><LastName>Kaduk</LastName><ForeName>Denys</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Seamus</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeesuk</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kolovos</LastName><ForeName>Spyros</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyejin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paras</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jimyung</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rho</LastName><ForeName>Yeunsook</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials></Author><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Seokyoung</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vizcaya</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Volpe</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Haini</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Yimer</LastName><ForeName>Belay B</ForeName><Initials>BB</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zhuk</LastName><ForeName>Oleg</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Nat Commun. 2020 Oct 6;11(1):5009</RefSource><PMID Version="1">33024121</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32511443</ArticleId><ArticleId IdType="pmc">PMC7239064</ArticleId><ArticleId IdType="doi">10.1101/2020.04.22.20074336</ArticleId><ArticleId IdType="pii">2020.04.22.20074336</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32524701</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Empirical assessment of case-based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (SNDS).</ArticleTitle><Pagination><StartPage>890</StartPage><EndPage>903</EndPage><MedlinePgn>890-903</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.5038</ELocationID><Abstract><AbstractText Label="PURPOSE">Upper gastrointestinal bleeding (UGIB) is a severe and frequent drug-related event. In order to enable efficient drug safety alert generation in the French National Healthcare System database (SNDS), we assessed and calibrated empirically case-based designs to identify drug associated with UGIB risk.</AbstractText><AbstractText Label="METHODS">All cases of UGIB were extracted from SNDS (2009-2014) using two definitions. Positive and negative drug controls were used to compare 196 self-controlled case series (SCCS), case-control (CC) and case-population (CP) design variants. Each variant was evaluated in a 1/10<sup>th</sup> population sample using area under the receiver operating curve (AUC) and mean square error (MSE). Parameters that had major impacts on results were identified through logistic regression. Optimal designs were replicated in the unsampled population.</AbstractText><AbstractText Label="RESULTS">Using a specific UGIB definition, AUCs ranged from 0.64 to 0.80, 0.44 to 0.61 and 0.50 to 0.67, for SCCS, CC and CP, respectively. MSE ranged from 0.07 to 0.39, 0.83 to 1.33 and 1.96 to 4.6, respectively. Univariate regressions showed that high AUCs were achieved with SCCS with multiple drug adjustment and a 30-day risk window starting at exposure. The top-performing SCCS variant in the unsampled population yielded an AUC = 0.84 and MSE = 0.14, with 10/36 negative controls presenting significant estimates.</AbstractText><AbstractText Label="CONCLUSIONS">SCCS adjusting for multiple drugs and using a 30-day risk window has the potential to generate UGIB-related alerts in the SNDS and hypotheses on its potential population impact. Negative control implementation highlighted that low systematic error was generated but that protopathic bias and confounding by indication remained unaddressed issues.</AbstractText><CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thurin</LastName><ForeName>Nicolas H</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0003-3589-0819</Identifier><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1219, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lassalle</LastName><ForeName>R&#xe9;gis</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;nichon</LastName><ForeName>Marine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagne</LastName><ForeName>Joshua J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rassen</LastName><ForeName>Jeremy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Aetion, Inc., New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benichou</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1181, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weill</LastName><ForeName>Alain</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8687-9092</Identifier><AffiliationInfo><Affiliation>Caisse Nationale de l'Assurance Maladie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blin</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1212-2817</Identifier><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1219, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Droz-Perroteau</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bordeaux PharmacoEpi, INSERM CIC1401, Universit&#xe9; de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="Y">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009313" MajorTopicYN="N">National Health Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">calibration</Keyword><Keyword MajorTopicYN="N">case-control</Keyword><Keyword MajorTopicYN="N">case-population</Keyword><Keyword MajorTopicYN="N">claims database</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">self-controlled case series</Keyword><Keyword MajorTopicYN="N">upper gastrointestinal bleeding</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32524701</ArticleId><ArticleId IdType="doi">10.1002/pds.5038</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. BMJ. 2019;364:l536.</Citation></Reference><Reference><Citation>Hearnshaw SA, Logan RF, Lowe D, Travis SP, Murphy MF, Palmer KR. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut. 2011;60:1327-1335.</Citation></Reference><Reference><Citation>Nahon S, Hagege H, Latrive JP, et al. Epidemiological and prognostic factors involved in upper gastrointestinal bleeding: results of a French prospective multicenter study. Endoscopy. 2012;44:998-1008.</Citation></Reference><Reference><Citation>Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093-2099.</Citation></Reference><Reference><Citation>Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015;11:1061-1075.</Citation></Reference><Reference><Citation>Wilcox CM, Alexander LN, Cotsonis G. A prospective characterization of upper gastrointestinal hemorrhage presenting with hematochezia. Am J Gastroenterol. 1997;92:231-235.</Citation></Reference><Reference><Citation>Henry DA, Johnston A, Dobson A, Duggan J. Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin, and corticosteroids. Br Med J (Clin Res Ed). 1987;295:1227-1229.</Citation></Reference><Reference><Citation>Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35:1127-1146.</Citation></Reference><Reference><Citation>Valkhoff VE. Use and Safety of Non-Steroidal Inflammatory Drugs and Aspirin, Erasmus University Rotterdam; 2012.</Citation></Reference><Reference><Citation>Coloma PM, Avillach P, Salvo F, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36:13-23.</Citation></Reference><Reference><Citation>Trifiro G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18:1176-1184.</Citation></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med. 2012;31:4401-4415.</Citation></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(Suppl 1):S33-S47.</Citation></Reference><Reference><Citation>Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954-962.</Citation></Reference><Reference><Citation>Schuemie MJ, Gini R, Coloma PM, et al. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. Drug Saf. 2013;36(Suppl 1):S159-S169.</Citation></Reference><Reference><Citation>Thurin NH, Lassalle R, Schuemie M, et al. Empirical assessment of case-based methods for drug safety alert identification in the French National Healthcare System database (SNDS): methodology of the ALCAPONE project. Pharmacoepidemiol Drug Saf. 2020;29:1-8.</Citation></Reference><Reference><Citation>Armstrong B. A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies. Am J Epidemiol. 1987;126:356-358.</Citation></Reference><Reference><Citation>Cantor SB, Kattan MW. Determining the area under the ROC curve for a binary diagnostic test. Med Decis Making. 2000;20:468-470.</Citation></Reference><Reference><Citation>Bezin J, Bosco-Levy P, Pariente A. False-positive results in pharmacoepidemiology and pharmacovigilance. Therapie. 2017;72:415-420.</Citation></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33:209-218.</Citation></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust empirical calibration of p-values using observational data. Stat Med. 2016;35:3883-3888.</Citation></Reference><Reference><Citation>Gruber S, Tchetgen E. Limitations of empirical calibration of p-values using observational data. Stat Med. 2016;35:3869-3882.</Citation></Reference><Reference><Citation>Yola M, Lucien A. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994;47:731-737.</Citation></Reference><Reference><Citation>Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. BMJ. 2016;354:i4515.</Citation></Reference><Reference><Citation>Terdiman JP, Ostroff JW. Risk of persistent or recurrent and intractable upper gastrointestinal bleeding in the era of therapeutic endoscopy. Am J Gastroenterol. 1997;92:1805-1811.</Citation></Reference><Reference><Citation>Whitaker HJ, Steer CD, Farrington CP. Self-controlled case series studies: just how rare does a rare non-recurrent outcome need to be? Biom J. 2018;60:1110-1120.</Citation></Reference><Reference><Citation>Suchard MA, Zorych I, Simpson SE, Schuemie MJ, Ryan PB, Madigan D. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S83-S93.</Citation></Reference><Reference><Citation>Moore N, Gulmez SE, Larrey D, et al. Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. Pharmacoepidemiol Drug Saf. 2013;22:160-167.</Citation></Reference><Reference><Citation>Moore N, Gulmez SE, Blin P, et al. Relative risks from case-population data. Epidemiology. 2013;24:935-936.</Citation></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Man KKC, Wong ICK, Suchard MA, Hripcsak G. A plea to stop using the case-control design in retrospective database studies. Stat Med. 2019;38:4199-4208.</Citation></Reference><Reference><Citation>Schneeweiss S, Suissa S. Discussion of Schuemie et al: &#x201c;a plea to stop using the case-control design in retrospective database studies&#x201d;. Stat Med. 2019;38:4209-4212.</Citation></Reference><Reference><Citation>Cook EF, Goldman L. Performance of tests of significance based on stratification by a multivariate confounder score or by a propensity score. J Clin Epidemiol. 1989;42:317-324.</Citation></Reference><Reference><Citation>Sturmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005;161:891-898.</Citation></Reference><Reference><Citation>Clissold SP, Heel RC. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs. 1985;29:189-207.</Citation></Reference><Reference><Citation>Horwitz RI, Feinstein AR. The problem of &#x201c;protopathic bias&#x201d; in case-control studies. Am J Med. 1980;68:255-258.</Citation></Reference><Reference><Citation>Al Sibae MR, McGuire BM. Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manag. 2009;5:617-626.</Citation></Reference><Reference><Citation>Strom BL. Pharmacoepidemiology. 4th ed. Chichester; Hoboken, NJ: J. Wiley; 2005.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32530430</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study.</ArticleTitle><Pagination><StartPage>e17353</StartPage><MedlinePgn>e17353</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e17353</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/17353</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Immune checkpoint inhibitors are associated with unique immune-related adverse events (irAEs). As most of the immune checkpoint inhibitors are new to the market, it is important to conduct studies using real-world data sources to investigate their safety profiles.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of the study was to develop a framework for signal detection and filtration of novel irAEs for 6 Food and Drug Administration-approved immune checkpoint inhibitors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In our framework, we first used the Food and Drug Administration's Adverse Event Reporting System (FAERS) standardized in an Observational Health Data Sciences and Informatics (OHDSI) common data model (CDM) to collect immune checkpoint inhibitor-related event data and conducted irAE signal detection. OHDSI CDM is a standard-driven data model that focuses on transforming different databases into a common format and standardizing medical terms to a common representation. We then filtered those already known irAEs from drug labels and literature by using a customized text-mining pipeline based on clinical text analysis and knowledge extraction system with Medical Dictionary for Regulatory Activities (MedDRA) as a dictionary. Finally, we classified the irAE detection results into three different categories to discover potentially new irAE signals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">By our text-mining pipeline, 490 irAE terms were identified from drug labels, and 918 terms were identified from the literature. In addition, of the 94 positive signals detected using CDM-based FAERS, 53 signals (56%) were labeled signals, 10 (11%) were unlabeled published signals, and 31 (33%) were potentially new signals.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We demonstrated that our approach is effective for irAE signal detection and filtration. Moreover, our CDM-based framework could facilitate adverse drug events detection and filtration toward the goal of next-generation pharmacovigilance that seamlessly integrates electronic health record data for improved signal detection.</AbstractText><CopyrightInformation>&#xa9;Yue Yu, Kathryn Ruddy, Aaron Mansfield, Nansu Zong, Andrew Wen, Shintaro Tsuji, Ming Huang, Hongfang Liu, Nilay Shah, Guoqian Jiang. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 12.06.2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3900-1217</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruddy</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-6298-332X</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mansfield</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9483-6903</Identifier><AffiliationInfo><Affiliation>Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zong</LastName><ForeName>Nansu</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0066-9524</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9090-8028</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Shintaro</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2809-2122</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ming</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7367-3626</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongfang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2570-3741</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nilay</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-8597-3447</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Guoqian</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2940-0019</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse drug reaction reporting systems/standards</Keyword><Keyword MajorTopicYN="N">drug-related side effects and adverse reactions</Keyword><Keyword MajorTopicYN="N">immunotherapy/adverse effects</Keyword><Keyword MajorTopicYN="N">pharmacovigilance</Keyword><Keyword MajorTopicYN="N">text mining</Keyword></KeywordList><CoiStatement>Conflicts of Interest: AM reports research support from Novartis and Verily; remuneration to his institution for participation on advisory boards for AbbVie, Astra Zeneca, BMS, and Genentech; and travel support from Roche and is a nonremunerated director of the Mesothelioma Applied Research Foundation.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32530430</ArticleId><ArticleId IdType="pmc">PMC7320306</ArticleId><ArticleId IdType="doi">10.2196/17353</ArticleId><ArticleId IdType="pii">v8i6e17353</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011 Dec 21;480(7378):480&#x2013;9. doi: 10.1038/nature10673.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10673</ArticleId><ArticleId IdType="pmc">PMC3967235</ArticleId><ArticleId IdType="pubmed">22193102</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016 Oct 1;2(10):1346&#x2013;53. doi: 10.1001/jamaoncol.2016.1051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2016.1051</ArticleId><ArticleId IdType="pubmed">27367787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser J, Couzin-Frankel J. Cancer immunotherapy sweeps nobel for medicine. Science. 2018 Oct 5;362(6410):13. doi: 10.1126/science.362.6410.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.362.6410.13</ArticleId><ArticleId IdType="pubmed">30287641</ArticleId></ArticleIdList></Reference><Reference><Citation>Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018 Jan 11;378(2):158&#x2013;68. doi: 10.1056/NEJMra1703481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1703481</ArticleId><ArticleId IdType="pubmed">29320654</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015 Apr 9;161(2):205&#x2013;14. doi: 10.1016/j.cell.2015.03.030.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.03.030</ArticleId><ArticleId IdType="pmc">PMC5905674</ArticleId><ArticleId IdType="pubmed">25860605</ArticleId></ArticleIdList></Reference><Reference><Citation>Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015 Jun 10;33(17):1974&#x2013;82. doi: 10.1200/JCO.2014.59.4358.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.59.4358</ArticleId><ArticleId IdType="pmc">PMC4980573</ArticleId><ArticleId IdType="pubmed">25605845</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlh&#xe4;ufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crin&#xf2; L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627&#x2013;39. doi: 10.1056/NEJMoa1507643.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1507643</ArticleId><ArticleId IdType="pmc">PMC5705936</ArticleId><ArticleId IdType="pubmed">26412456</ArticleId></ArticleIdList></Reference><Reference><Citation>Reck M, Rodr&#xed;guez-Abreu D, Robinson AG, Hui R, Cs&#x151;szi T, F&#xfc;l&#xf6;p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, KEYNOTE-024 Investigators Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823&#x2013;33. doi: 10.1056/NEJMoa1606774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1606774</ArticleId><ArticleId IdType="pubmed">27718847</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012 Jun;91(6):1010&#x2013;21. doi: 10.1038/clpt.2012.50.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2012.50</ArticleId><ArticleId IdType="pmc">PMC3675775</ArticleId><ArticleId IdType="pubmed">22549283</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . The Safety of Medicines in Public Health Programmes - Pharmacovigilance: An Essential Tool. Geneva, Switzerland: WHO Publications; 2006.</Citation></Reference><Reference><Citation>Garcia CR, Cox JN, Villano JL. Myasthenia gravis and Guillain-Barr&#xe9; syndrome adverse events with immune checkpoint inhibitors. J Clin Oncol. 2018 Feb 10;36(5_suppl):37. doi: 10.1200/jco.2018.36.5_suppl.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2018.36.5_suppl.37</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias R, Rider J, Tan X, Rahma OE. Single agent and combination checkpoint inhibitors therapy: a post marketing safety analysis. J Clin Oncol. 2018 Feb 10;36(5_suppl):125. doi: 10.1200/jco.2018.36.5_suppl.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2018.36.5_suppl.125</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Moslehi JJ, Salem J, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30533-6</ArticleId><ArticleId IdType="pmc">PMC6668330</ArticleId><ArticleId IdType="pubmed">29536852</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kindi SG, Oliveira GH. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet. 2018 Aug 4;392(10145):382&#x2013;3. doi: 10.1016/S0140-6736(18)31542-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31542-3</ArticleId><ArticleId IdType="pubmed">30102167</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018 Aug 1;4(8):1112&#x2013;5. doi: 10.1001/jamaoncol.2017.4526.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2017.4526</ArticleId><ArticleId IdType="pmc">PMC5885195</ArticleId><ArticleId IdType="pubmed">29327061</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauben M, Aronson JK. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32(2):99&#x2013;110. doi: 10.2165/00002018-200932020-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200932020-00003</ArticleId><ArticleId IdType="pubmed">19236117</ArticleId></ArticleIdList></Reference><Reference><Citation>Council for International Organizations of Medical Sciences . Practical Aspects of Signal Detection in Pharmacovigilance: Report of CIOMS Working Group VIII. Geneva, Switzerland: WHO Publications; 2010.</Citation></Reference><Reference><Citation>Coloma PM, Trifir&#xf2; G, Patadia V, Sturkenboom M. Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Saf. 2013 Mar;36(3):183&#x2013;97. doi: 10.1007/s40264-013-0018-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0018-x</ArticleId><ArticleId IdType="pubmed">23377696</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J, Zhang X, Tong J, Du J, Duan R, Yang L, Moore JH, Tao C, Chen Y. Comparing drug safety of hepatitis C therapies using post-market data. BMC Med Inform Decis Mak. 2019 Aug 8;19(Suppl 4):147. doi: 10.1186/s12911-019-0860-6.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-019-0860-6</ArticleId><ArticleId IdType="doi">10.1186/s12911-019-0860-6</ArticleId><ArticleId IdType="pmc">PMC6686214</ArticleId><ArticleId IdType="pubmed">31391106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MM, Alatawi Y, Cheng N, Qian J, Peissig PL, Berg RL, Page DC, Hansen RA. Methodological considerations for comparison of brand versus generic versus authorized generic adverse event reports in the US food and drug administration adverse event reporting system (FAERS) Clin Drug Investig. 2017 Dec;37(12):1143&#x2013;52. doi: 10.1007/s40261-017-0574-4.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-017-0574-4</ArticleId><ArticleId IdType="pmc">PMC5842081</ArticleId><ArticleId IdType="pubmed">28933038</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Nayernama A, Jones SC, Kordestani LA, Fedenko K, Prowell T, Bersoff-Matcha SJ. Fatal neutropenic enterocolitis associated with docetaxel use: a review of cases reported to the United States food and drug administration adverse event reporting system. J Oncol Pharm Pract. 2019 Oct 8;:-. doi: 10.1177/1078155219879494. epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1078155219879494</ArticleId><ArticleId IdType="pubmed">31594460</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R, Wang Q. Large-scale combining signals from both biomedical literature and the FDA adverse event reporting system (FAERS) to improve post-marketing drug safety signal detection. BMC Bioinformatics. 2014 Jan 15;15:17. doi: 10.1186/1471-2105-15-17.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-15-17</ArticleId><ArticleId IdType="doi">10.1186/1471-2105-15-17</ArticleId><ArticleId IdType="pmc">PMC3906761</ArticleId><ArticleId IdType="pubmed">24428898</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu R, Wang Q. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA adverse event reporting system (FAERS) J Biomed Inform. 2014 Mar;47:171&#x2013;7. doi: 10.1016/j.jbi.2013.10.008.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2013.10.008</ArticleId><ArticleId IdType="pmc">PMC4452013</ArticleId><ArticleId IdType="pubmed">24177320</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeleswarapu S, Rao A, Joseph T, Saipradeep VG, Srinivasan R. A pipeline to extract drug-adverse event pairs from multiple data sources. BMC Med Inform Decis Mak. 2014 Mar 24;14:13. doi: 10.1186/1472-6947-14-13.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-14-13</ArticleId><ArticleId IdType="doi">10.1186/1472-6947-14-13</ArticleId><ArticleId IdType="pmc">PMC3936866</ArticleId><ArticleId IdType="pubmed">24559132</ArticleId></ArticleIdList></Reference><Reference><Citation>openFDA.  [2020-05-06].  FDA Adverse Event Reporting System https://open.fda.gov/data/faers/</Citation></Reference><Reference><Citation>OHDSI: Observational Health Data Sciences and Informatics.  [2020-05-06].  OHDSI Common Data Model https://ohdsi.org/</Citation></Reference><Reference><Citation>DailyMed.  [2020-05-06].  DailyMed: NIH https://dailymed.nlm.nih.gov/dailymed/</Citation></Reference><Reference><Citation>PubMed-NCBI.  [2020-05-06].  PubMed https://www.ncbi.nlm.nih.gov/pubmed/</Citation></Reference><Reference><Citation>Yu Y, Ruddy KJ, Hong N, Tsuji S, Wen A, Shah ND, Jiang G. ADEpedia-on-OHDSI: a next generation pharmacovigilance signal detection platform using the OHDSI common data model. J Biomed Inform. 2019 Mar;91:103119. doi: 10.1016/j.jbi.2019.103119.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103119</ArticleId><ArticleId IdType="pmc">PMC6432939</ArticleId><ArticleId IdType="pubmed">30738946</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016 May 10;3:160026. doi: 10.1038/sdata.2016.26.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.26</ArticleId><ArticleId IdType="pmc">PMC4872271</ArticleId><ArticleId IdType="pubmed">27193236</ArticleId></ArticleIdList></Reference><Reference><Citation>Athena: OHDSI.  [2020-05-06].  License Agreement http://athena.ohdsi.org.</Citation></Reference><Reference><Citation>van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3&#x2013;10. doi: 10.1002/pds.668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.668</ArticleId><ArticleId IdType="pubmed">11998548</ArticleId></ArticleIdList></Reference><Reference><Citation>Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009 Jun;18(6):427&#x2013;36. doi: 10.1002/pds.1742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1742</ArticleId><ArticleId IdType="pubmed">19358225</ArticleId></ArticleIdList></Reference><Reference><Citation>Savova GK, Masanz JJ, Ogren PV, Zheng J, Sohn S, Kipper-Schuler KC, Chute CG. Mayo clinical text analysis and knowledge extraction system (cTAKES): architecture, component evaluation and applications. J Am Med Inform Assoc. 2010;17(5):507&#x2013;13. doi: 10.1136/jamia.2009.001560.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.001560</ArticleId><ArticleId IdType="pmc">PMC2995668</ArticleId><ArticleId IdType="pubmed">20819853</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977 Mar;33(1):159&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassel JC, Heinzerling L, Aberle J, B&#xe4;hr O, Eigentler TK, Grimm M, Gr&#xfc;nwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017 Jun;57:36&#x2013;49. doi: 10.1016/j.ctrv.2017.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2017.05.003</ArticleId><ArticleId IdType="pubmed">28550712</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Ruddy KJ, Tsuji S, Hong N, Liu H, Shah N, Jiang G. Coverage evaluation of CTCAE for capturing the immune-related adverse events leveraging text mining technologies. AMIA Jt Summits Transl Sci Proc. 2019;2019:771&#x2013;8.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568118</ArticleId><ArticleId IdType="pubmed">31259034</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Xu R. Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis. JAMIA Open. 2019 Apr;2(1):173&#x2013;8. doi: 10.1093/jamiaopen/ooy045.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooy045</ArticleId><ArticleId IdType="pmc">PMC6447026</ArticleId><ArticleId IdType="pubmed">30976759</ArticleId></ArticleIdList></Reference><Reference><Citation>Zini EM, Lanzola G, Quaglini S, Cornet R. Standardization of immunotherapy adverse events in patient information leaflets and development of an interface terminology for outpatients' monitoring. J Biomed Inform. 2018 Jan;77:133&#x2013;44. doi: 10.1016/j.jbi.2017.12.009.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2017.12.009</ArticleId><ArticleId IdType="pubmed">29269275</ArticleId></ArticleIdList></Reference><Reference><Citation>Lois M, Noppen M. Bronchopleural fistulas: an overview of the problem with special focus on endoscopic management. Chest. 2005 Dec;128(6):3955&#x2013;65. doi: 10.1378/chest.128.6.3955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.128.6.3955</ArticleId><ArticleId IdType="pubmed">16354867</ArticleId></ArticleIdList></Reference><Reference><Citation>Harpaz R, Vilar S, Dumouchel W, Salmasian H, Haerian K, Shah NH, Chase HS, Friedman C. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2013 May 1;20(3):413&#x2013;9. doi: 10.1136/amiajnl-2012-000930.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2012-000930</ArticleId><ArticleId IdType="pmc">PMC3628045</ArticleId><ArticleId IdType="pubmed">23118093</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Ruddy K, Wen A, Zong N, Shintaro T, Chen J, Shah N, Jiang G. Integrating electronic health record data into the ADEpedia-on-OHDSI platform for improved signal detection: a case study of immune-related adverse events. AMIA 2020 Informatics Summit. 2019:710&#x2013;9. (forthcoming) </Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233056</ArticleId><ArticleId IdType="pubmed">32477694</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32531725</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8243</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of medical informatics</Title><ISOAbbreviation>Int J Med Inform</ISOAbbreviation></Journal><ArticleTitle>Establishment and evaluation of a multicenter collaborative prediction model construction framework supporting model generalization and continuous improvement: A pilot study.</ArticleTitle><Pagination><StartPage>104173</StartPage><MedlinePgn>104173</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijmedinf.2020.104173</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1386-5056(20)30136-2</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE">In recent years, an increasing number of clinical prediction models have been developed to serve clinical care. Establishing a data-driven prediction model based on large-scale electronic health record (EHR) data can provide a more empirical basis for clinical decision making. However, research on model generalization and continuous improvement is insufficiently focused, which also hinders the application and evaluation of prediction models in real clinical environments. Therefore, this study proposes a multicenter collaborative prediction model construction framework to build a prediction model with greater generalizability and continuous improvement capabilities while preserving patient data security and privacy.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Based on a multicenter collaborative research network, such as the Observational Health Data Sciences and Informatics (OHDSI), a multicenter collaborative prediction model construction framework is proposed. Based on the idea of multi-source transfer learning, in each source hospital, a base classifier was trained according to the model research setting. Then, in the target hospital with missing calibration data, a prediction model was established through weighted integration of base classifiers from source hospitals based on the smoothness assumption. Moreover, a passive-aggressive online learning algorithm was used for continuous improvement of the prediction model, which can help to maintain a high predictive performance to provide reliable clinical decision-making abilities. To evaluate the proposed prediction model construction framework, a prototype system for colorectal cancer prognosis prediction was developed. To evaluate the performance of models, 70,906 patients were screened, including 70,090 from 5 US hospital-specific datasets and 816 from a Chinese hospital-specific dataset. The area under the receiver operating characteristic curve (AUC) and the estimated calibration index (ECI) were used to evaluate the discrimination and calibration of models.</AbstractText><AbstractText Label="RESULTS">Regarding the colorectal cancer prognosis prediction in our prototype system, compared with the reference models, our model achieved a better performance in model calibration (ECI = 9.294 [9.146, 9.441]) and a similar ability in model discrimination (AUC = 0.783 [0.780, 0.786]). Furthermore, the online learning process provided in this study can continuously improve the performance of the prediction model when patient data with specified labels arrive (the AUC value increased from 0.709 to 0.715 and the ECI value decreased from 13.013 to 9.634 after 650 patient instances with specified labels from the Chinese hospital arrived), enabling the prediction model to maintain a good predictive performance during clinical application.</AbstractText><AbstractText Label="CONCLUSIONS">This study proposes and evaluates a multicenter collaborative prediction model construction framework that can support the construction of prediction models with better generalizability and continuous improvement capabilities without the need to aggregate multicenter patient-level data.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Engineering Research Center of EMR and Intelligent Expert System, Ministry of Education, College of Biomedical Engineering and Instrument Science, Zhejiang University, No. 38 Zheda Road, Hangzhou 310027, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weiguo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Engineering Research Center of EMR and Intelligent Expert System, Ministry of Education, College of Biomedical Engineering and Instrument Science, Zhejiang University, No. 38 Zheda Road, Hangzhou 310027, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Tianshu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Engineering Research Center of EMR and Intelligent Expert System, Ministry of Education, College of Biomedical Engineering and Instrument Science, Zhejiang University, No. 38 Zheda Road, Hangzhou 310027, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 31009, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Kefeng</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 31009, Zhejiang Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jingsong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Engineering Research Center of EMR and Intelligent Expert System, Ministry of Education, College of Biomedical Engineering and Instrument Science, Zhejiang University, No. 38 Zheda Road, Hangzhou 310027, Zhejiang Province, China; Research Center for Healthcare Data Science, Zhejiang Lab, Hangzhou, China. Electronic address: ljs@zju.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Int J Med Inform</MedlineTA><NlmUniqueID>9711057</NlmUniqueID><ISSNLinking>1386-5056</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Model generalization</Keyword><Keyword MajorTopicYN="N">Multicenter collaborative research</Keyword><Keyword MajorTopicYN="N">Prognosis prediction</Keyword><Keyword MajorTopicYN="N">Transfer learning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32531725</ArticleId><ArticleId IdType="doi">10.1016/j.ijmedinf.2020.104173</ArticleId><ArticleId IdType="pii">S1386-5056(20)30136-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32568364</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>180</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Chlorthalidone and Hydrochlorothiazide for Treatment of Patients With Hypertension-Reply.</ArticleTitle><Pagination><StartPage>1133</StartPage><EndPage>1134</EndPage><MedlinePgn>1133-1134</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2020.1736</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterian Hospital, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shea</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, New York.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0J48LPH2TH</RegistryNumber><NameOfSubstance UI="D006852">Hydrochlorothiazide</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q0MQD1073Q</RegistryNumber><NameOfSubstance UI="D002752">Chlorthalidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Intern Med. 2020 Apr 1;180(4):542-551</RefSource><PMID Version="1">32065600</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Intern Med. 2020 Aug 1;180(8):1133</RefSource><PMID Version="1">32568361</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>JAMA Intern Med. 2020 Aug 1;180(8):1132-1133</RefSource><PMID Version="1">32568375</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002752" MajorTopicYN="Y">Chlorthalidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006852" MajorTopicYN="N">Hydrochlorothiazide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32568364</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2020.1736</ArticleId><ArticleId IdType="pii">2767646</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32570362</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><PubDate><Year>2020</Year><Month>Jun</Month><Day>16</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Data Integration into OMOP CDM for Heterogeneous Clinical Data Collections via HL7 FHIR Bundles and XSLT.</ArticleTitle><Pagination><StartPage>138</StartPage><EndPage>142</EndPage><MedlinePgn>138-142</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI200138</ELocationID><Abstract><AbstractText>Data integration is an important task in medical informatics and highly impacts the gain out of existing health information data. These tasks are using implemented as extract transform and load processes. By introducing HL7 FHIR as an intermediate format, our aim was to integrate heterogeneous data from a German pulmonary hypertension registry into an OMOP Common Data Model. First, domain knowledge experts defined a common parameter set, which was subsequently mapped to standardized terminologies like LOINC or SNOMED-CT. Data was extracted as HL7 FHIR Bundle to be transformed to OMOP CDM by using XSLT. We successfully transformed the majority of data elements to the OMOP CDM in a feasible time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Medical Informatics, Faculty of Medicine, Justus-Liebig-University, Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xf6;hr</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>UGMLC, German Center for Lung Research (DZL), Justus-Liebig-University, Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gall</LastName><ForeName>Henning</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UGMLC, German Center for Lung Research (DZL), Justus-Liebig-University, Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michel-Backofen</LastName><ForeName>Achim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Data-Integration-Center, Faculty of Medicine, Justus-Liebig-University, Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Majeed</LastName><ForeName>Raphael W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>UGMLC, German Center for Lung Research (DZL), Justus-Liebig-University, Giessen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039703" MajorTopicYN="N">Logical Observation Identifiers Names and Codes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039061" MajorTopicYN="Y">Systematized Nomenclature of Medicine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">HL7 FHIR</Keyword><Keyword MajorTopicYN="N">LOINC</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">SNOMED-CT</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32570362</ArticleId><ArticleId IdType="doi">10.3233/SHTI200138</ArticleId><ArticleId IdType="pii">SHTI200138</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32570366</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><PubDate><Year>2020</Year><Month>Jun</Month><Day>16</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Design for a Modular Clinical Trial Recruitment Support System Based on FHIR and OMOP.</ArticleTitle><Pagination><StartPage>158</StartPage><EndPage>162</EndPage><MedlinePgn>158-162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI200142</ELocationID><Abstract><AbstractText>The MIRACUM consortium is developing a Clinical Trials Recruitment Support System to support the data-driven recruitment of patients for clinical trials. The design of the prototype includes both open source solutions (OMOP CDM, Atlas) and open standards for interoperability (FHIR). The aim of the prototype is to create a patient screening list of potential participants for a clinical study. The paper shows the modular structure and functionality of the prototype building the foundation for the practical implementation of the CTRSS and, at the same time, demonstrating the use of open source solutions and standards for the development of clinical support systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reinecke</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gulden</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Informatics, Univ. of Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>K&#xfc;mmel</LastName><ForeName>Mich&#xe9;le</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nassirian</LastName><ForeName>Azadeh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasini</LastName><ForeName>Romina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Informatics, Univ. of Giessen, Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Carl Gustav Carus Faculty of Medicine, Center for Medical Informatics, Institute for Medical Informatics and Biometry, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="Y">Patient Selection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">automation</Keyword><Keyword MajorTopicYN="N">clinical trial recruitment support system</Keyword><Keyword MajorTopicYN="N">decision support systems</Keyword><Keyword MajorTopicYN="N">open standards</Keyword><Keyword MajorTopicYN="N">secondary use of electronic health records</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32570366</ArticleId><ArticleId IdType="doi">10.3233/SHTI200142</ArticleId><ArticleId IdType="pii">SHTI200142</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32570675</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><PubDate><Year>2020</Year><Month>Jun</Month><Day>16</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Specification and Distribution of Vocabularies Among Consortial Partners.</ArticleTitle><Pagination><StartPage>1393</StartPage><EndPage>1394</EndPage><MedlinePgn>1393-1394</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI200458</ELocationID><Abstract><AbstractText>Due to the variety of different software systems and disparate observational databases, the need for a uniform data representation rises. Common data models (CDM) support the harmonisation of data. A powerful but compact software setup and a minimum vocabulary set has been composed via Docker to facilitate analysis of data across ten university hospitals. The presented approach also creates the possibility to use a concise database which is easy to deploy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gruhl</LastName><ForeName>Mirko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Medical Informatics, Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinecke</LastName><ForeName>Ines</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Center for Medical Informatics, Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Medical Informatics, Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014825" MajorTopicYN="Y">Vocabulary</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Docker</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">data sharing</Keyword><Keyword MajorTopicYN="N">reproducible</Keyword><Keyword MajorTopicYN="N">vocabulary</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32570675</ArticleId><ArticleId IdType="doi">10.3233/SHTI200458</ArticleId><ArticleId IdType="pii">SHTI200458</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32626900</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Learning from local to global: An efficient distributed algorithm for modeling time-to-event data.</ArticleTitle><Pagination><StartPage>1028</StartPage><EndPage>1036</EndPage><MedlinePgn>1028-1036</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocaa044</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We developed and evaluated a privacy-preserving One-shot Distributed Algorithm to fit a multicenter Cox proportional hazards model (ODAC) without sharing patient-level information across sites.</AbstractText><AbstractText Label="MATERIALS AND METHODS">Using patient-level data from a single site combined with only aggregated information from other sites, we constructed a surrogate likelihood function, approximating the Cox partial likelihood function obtained using patient-level data from all sites. By maximizing the surrogate likelihood function, each site obtained a local estimate of the model parameter, and the ODAC estimator was constructed as a weighted average of all the local estimates. We evaluated the performance of ODAC with (1) a simulation study and (2) a real-world use case study using 4 datasets from the Observational Health Data Sciences and Informatics network.</AbstractText><AbstractText Label="RESULTS">On the one hand, our simulation study showed that ODAC provided estimates nearly the same as the estimator obtained by analyzing, in a single dataset, the combined patient-level data from all sites (ie, the pooled estimator). The relative bias was &lt;0.1% across all scenarios. The accuracy of ODAC remained high across different sample sizes and event rates. On the other hand, the meta-analysis estimator, which was obtained by the inverse variance weighted average of the site-specific estimates, had substantial bias when the event rate is &lt;5%, with the relative bias reaching 20% when the event rate is 1%. In the Observational Health Data Sciences and Informatics network application, the ODAC estimates have a relative bias &lt;5% for 15 out of 16 log hazard ratios, whereas the meta-analysis estimates had substantially higher bias than ODAC.</AbstractText><AbstractText Label="CONCLUSIONS">ODAC is a privacy-preserving and noniterative method for implementing time-to-event analyses across multiple sites. It provides estimates on par with the pooled estimator and substantially outperforms the meta-analysis estimator when the event is uncommon, making it extremely suitable for studying rare events and diseases in a distributed manner.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press on behalf of the American Medical Informatics Association. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Chongliang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Janssen Research and Development LLC, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>C Jason</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Howard H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Mary Regina</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Informatics and eHealth Core, University of Florida Health Cancer Center, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>John H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morton</LastName><ForeName>Sally C</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Statistics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berlin</LastName><ForeName>Jesse A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahoney</LastName><ForeName>Kevin B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>University of Pennsylvania Health System, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA246418</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012607</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001427</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG061431</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM010098</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI116794</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066264" MajorTopicYN="N">Datasets as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016013" MajorTopicYN="N">Likelihood Functions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="Y">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cox proportional hazards model</Keyword><Keyword MajorTopicYN="N">data integration</Keyword><Keyword MajorTopicYN="N">distributed algorithm</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32626900</ArticleId><ArticleId IdType="pmc">PMC7647322</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocaa044</ArticleId><ArticleId IdType="pii">5867658</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence&#x2014;what is it and what can it tell us. N Engl J Med 2016; 375 (23): 2293&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman CP, Wong AK, Blumenthal D.. Achieving a nationwide learning health system. Sci Transl Med 2010; 2 (57): 57cm29.</Citation><ArticleIdList><ArticleId IdType="pubmed">21068440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagar Y, Albers D, Pivovarov R, et al. Survival analysis with electronic health record data: experiments with chronic kidney disease. Stat Anal Data Mining 2014; 7 (5): 385&#x2013;403.</Citation></Reference><Reference><Citation>Ranganath R, Perotte A, Elhadad N, Blei D. Deep survival analysis. arXiv preprint arXiv: 1608.02158, 2016.</Citation></Reference><Reference><Citation>Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol 1972; 34 (2): 187&#x2013;202.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL, Curtis LH, Califf RM, et al. Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc 2014; 21 (4): 578&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashisht R, Jung K, Schuler A, et al. Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated with metformin: analysis from the observational health data sciences and informatics initiative. JAMA Netw Open 2018; 1 (4): e181755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6324274</ArticleId><ArticleId IdType="pubmed">30646124</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland MR, Parhi P, Li L, et al. Uncovering exposures responsible for birth season&#x2013;disease effects: a global study. J Am Med Inform Assoc 2018; 25 (3): 275&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282503</ArticleId><ArticleId IdType="pubmed">29036387</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JD, Ryan PB, Suchard MA, et al. Risk of angioedema associated with levetiracetam compared with phenytoin: findings of the observational health data sciences and informatics research network. Epilepsia 2017; 58 (8): e101&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632067</ArticleId><ArticleId IdType="pubmed">28681416</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A 2016; 113 (27): 7329&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. Regression cubes with lossless compression and aggregation. IEEE Trans Knowl Data Eng 2006; 18 (12): 1585&#x2013;99.</Citation></Reference><Reference><Citation>Wu Y, Jiang X, Kim J, et al. Grid Binary LOgistic REgression (GLORE): building shared models without sharing data. J Am Med Inform Assoc 2012; 19 (5): 758&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422844</ArticleId><ArticleId IdType="pubmed">22511014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-L, Wang S, Ji Z, et al. WebDISCO: a web service for distributed cox model learning without patient-level data sharing. J Am Med Inform Assoc 2015; 22 (6): 1212&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009917</ArticleId><ArticleId IdType="pubmed">26159465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Kolar M, Srebro N, Zhang T.. Efficient distributed learning with sparsity . Proc Int Conf Mach Learn 2017; 70: 3636&#x2013;45.</Citation></Reference><Reference><Citation>Jordan MI, Lee JD, Yang Y.. Communication-efficient distributed statistical inference. J Am Stat Assoc 2019; 114 (526): 668&#x2013;81.</Citation></Reference><Reference><Citation>Duan R, Boland MR, Moore JH, Chen Y.. ODAL: a one-shot distributed algorithm to perform logistic regressions on electronic health records data from multiple clinical sites In: Altman RB, Dunker AK, Hunter L, Ritchie MD, Murray T, Klein TE, eds. Pacific Symposium on Biocomputing 2019. Singapore: World Scientific; 30&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417819</ArticleId><ArticleId IdType="pubmed">30864308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno-Machado L, Agha Z, Bell DS, et al. pSCANNER: patient-centered Scalable National Network for Effectiveness Research. J Am Med Inform Assoc 2014; 21 (4): 621&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078293</ArticleId><ArticleId IdType="pubmed">24780722</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc 2012; 19 (1): 54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008; 29 (7): 932&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">18334475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanas F, Avezum A, Bautista LE, et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation 2007; 115 (9): 1067&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">17339564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokotailo RA, Hill MD.. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke 2005; 36 (8): 1776&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16020772</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest CB, Margolis PA, Bailey LC, et al. PEDSnet: a national pediatric learning health system. J Am Med Inform Assoc 2014; 21 (4): 602&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="pubmed">24821737</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest CB, Margolis P, Seid M, et al. PEDSnet: how a prototype pediatric learning health system is being expanded into a national network. Health Aff (Millwood) 2014; 33 (7): 1171&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25006143</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenkman E, Hurt M, Hogan W, et al. OneFlorida Clinical Research Consortium: linking a clinical and translational science institute with a community-based distributive medical education model. Acad Med 2018; 93 (3): 451&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839715</ArticleId><ArticleId IdType="pubmed">29045273</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. OHDSI Network Research 2019 In: The Book of OHDSI. Chapter 20. 
New York, NY: 
OHDSI; 
https://ohdsi.github.io/TheBookOfOhdsi/NetworkResearch.html Accessed October 13, 2019.</Citation></Reference><Reference><Citation>PCORnet Distributed Research Network Data-Driven Common Model. https://pcornet.org/data-driven-common-model/ Accessed October 13, 2019.</Citation></Reference><Reference><Citation>PopMedNet. 2012; https://www.popmednet.org/ Accessed October 13, 2019.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32632237</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jul</Month><Day>06</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.</ArticleTitle><Pagination><StartPage>11115</StartPage><MedlinePgn>11115</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11115</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-68037-8</ELocationID><Abstract><AbstractText>Alendronate and raloxifene are among the most popular anti-osteoporosis medications. However, there is a lack of head-to-head comparative effectiveness studies comparing the two treatments. We conducted a retrospective large-scale multicenter study encompassing over 300 million patients across nine databases encoded in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The primary outcome was the incidence of osteoporotic hip fracture, while secondary outcomes were vertebral fracture, atypical femoral fracture (AFF), osteonecrosis of the jaw (ONJ), and esophageal cancer. We used propensity score trimming and stratification based on an expansive propensity score model with all pre-treatment patient characteritistcs. We accounted for unmeasured confounding using negative control outcomes to estimate and adjust for residual systematic bias in each data source. We identified 283,586 alendronate patients and 40,463 raloxifene patients. There were 7.48 hip fracture, 8.18 vertebral fracture, 1.14 AFF, 0.21 esophageal cancer and 0.09 ONJ events per 1,000 person-years in the alendronate cohort and 6.62, 7.36, 0.69, 0.22 and 0.06 events per 1,000 person-years, respectively, in the raloxifene cohort. Alendronate and raloxifene have a similar hip fracture risk (hazard ratio [HR] 1.03, 95% confidence interval [CI] 0.94-1.13), but alendronate users are more likely to have vertebral fractures (HR 1.07, 95% CI 1.01-1.14). Alendronate has higher risk for AFF (HR 1.51, 95% CI 1.23-1.84) but similar risk for esophageal cancer (HR 0.95, 95% CI 0.53-1.70), and ONJ (HR 1.62, 95% CI 0.78-3.34). We demonstrated substantial control of measured confounding by propensity score adjustment, and minimal residual systematic bias through negative control experiments, lending credibility to our effect estimates. Raloxifene is as effective as alendronate and may remain an option in the prevention of osteoporotic fracture.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeesuk</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, College of Medicine, Hanyang University, Seoul, 04763, Republic of Korea. estone96@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yuxi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Computational Medicine, University of California, Los Angeles, CA, 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jianxiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Computational Medicine, University of California, Los Angeles, CA, 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, MD, 20894, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Christophe G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, 87131, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hojun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University, Suwon, 16499, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University, Suwon, 16499, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University, Suwon, 16499, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, 3000, Rotterdam, CA, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Zandt</LastName><ForeName>Mui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Real World Insights, IQVIA, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real World Insights, IQVIA, Cambridge, MA, 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vashisht</LastName><ForeName>Rohit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yonghui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duke</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Health Analytics and Informatics, Georgia Tech Research Institute, Atlanta, GA, 30332, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, 10032, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, NewYork-Presbyterian Hospital, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, NY, 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research &amp; Development, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Computational Medicine, University of California, Los Angeles, CA, 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA, 90095, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, University of California, Los Angeles, CA, 90095, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31LM012636-01</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM101430</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F86W47BR6</RegistryNumber><NameOfSubstance UI="D020849">Raloxifene Hydrochloride</NameOfSubstance></Chemical><Chemical><RegistryNumber>X1J18R4W8P</RegistryNumber><NameOfSubstance UI="D019386">Alendronate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019386" MajorTopicYN="N">Alendronate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015519" MajorTopicYN="N">Bone Density</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010024" MajorTopicYN="N">Osteoporosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020849" MajorTopicYN="N">Raloxifene Hydrochloride</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32632237</ArticleId><ArticleId IdType="pmc">PMC7338498</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-68037-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-68037-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bone HG, et al. Ten years&#x2019; experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 2004;350:1189&#x2013;1199. doi: 10.1056/NEJMoa030897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa030897</ArticleId><ArticleId IdType="pubmed">15028823</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen B, Hoshino H, Togawa D, Matsuyama Y. Cortical thickness index of the proximal femur: A radiographic parameter for preliminary assessment of bone mineral density and osteoporosis status in the age 50 years and over population. Clin. Orthop. Surg. 2018;10:149&#x2013;56. doi: 10.4055/cios.2018.10.2.149.</Citation><ArticleIdList><ArticleId IdType="doi">10.4055/cios.2018.10.2.149</ArticleId><ArticleId IdType="pmc">PMC5964262</ArticleId><ArticleId IdType="pubmed">29854337</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster SA, et al. Fractures in women treated with raloxifene or alendronate: A retrospective database analysis. BMC Womens Health. 2013;13:15. doi: 10.1186/1472-6874-13-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6874-13-15</ArticleId><ArticleId IdType="pmc">PMC3626542</ArticleId><ArticleId IdType="pubmed">23521803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernlund E, et al. Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteop. 2013;8:136. doi: 10.1007/s11657-013-0136-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-013-0136-1</ArticleId><ArticleId IdType="pmc">PMC3880487</ArticleId><ArticleId IdType="pubmed">24113837</ArticleId></ArticleIdList></Reference><Reference><Citation>Park EJ, et al. Prevalence of osteoporosis in the Korean population based on Korea National Health and Nutrition Examination Survey (KNHANES), 2008&#x2013;2011. Yonsei Med. J. 2014;55:1049&#x2013;57. doi: 10.3349/ymj.2014.55.4.1049.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2014.55.4.1049</ArticleId><ArticleId IdType="pmc">PMC4075366</ArticleId><ArticleId IdType="pubmed">24954336</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T, et al. Alendronate versus raloxifene for postmenopausal women: A meta-analysis of seven head-to-head randomized controlled trials. Int. J. Endocrinol. 2014;2014:796510. doi: 10.1155/2014/796510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/796510</ArticleId><ArticleId IdType="pmc">PMC3912893</ArticleId><ArticleId IdType="pubmed">24511313</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller PD, Derman RJ. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteop. Int. 2010;21:1793&#x2013;802. doi: 10.1007/s00198-010-1208-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-010-1208-3</ArticleId><ArticleId IdType="pubmed">20309524</ArticleId></ArticleIdList></Reference><Reference><Citation>Black DM, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med. 2010;362:1761&#x2013;71. doi: 10.1056/NEJMoa1001086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1001086</ArticleId><ArticleId IdType="pubmed">20335571</ArticleId></ArticleIdList></Reference><Reference><Citation>Ettinger B, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. multiple outcomes of raloxifene evaluation (more) investigators. JAMA. 1999;282:637&#x2013;45. doi: 10.1001/jama.282.7.637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.282.7.637</ArticleId><ArticleId IdType="pubmed">10517716</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadarette SM, et al. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann. Intern. Med. 2008;148:637&#x2013;46. doi: 10.7326/0003-4819-148-9-200805060-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-148-9-200805060-00003</ArticleId><ArticleId IdType="pmc">PMC3285566</ArticleId><ArticleId IdType="pubmed">18458276</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka S, Yamamoto T, Oda E, Nakamura M, Fujiwara S. Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: Retrospective analysis of a hospital claims database. J. Bone Miner. Metab. 2018;36:87&#x2013;94. doi: 10.1007/s00774-016-0809-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00774-016-0809-0</ArticleId><ArticleId IdType="pubmed">28028633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Observational health data sciences and informatics (OHDSI): Opportunities for observational researchers. Stud. Health Technol. Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: Why empirical calibration is needed to correct p-values. Stat. Med. 2014;33:209&#x2013;18. doi: 10.1002/sim.5925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Gruber S, Zorych I, Madigan D. Empirical performance of a new user cohort method: Lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S59&#x2013;72. doi: 10.1007/s40264-013-0099-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-013-0099-6</ArticleId><ArticleId IdType="pubmed">24166224</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J. Am. Med. Inform. Assoc. 2012;19:54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzHenry F, et al. Creating a common data model for comparative effectiveness with the observational medical outcomes partnership. Appl. Clin. Inform. 2015;6:536&#x2013;547. doi: 10.4338/ACI-2014-12-CR-0121.</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/ACI-2014-12-CR-0121</ArticleId><ArticleId IdType="pmc">PMC4586341</ArticleId><ArticleId IdType="pubmed">26448797</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: A systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826. doi: 10.1016/S0140-6736(19)32317-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P. Statistical challenges in systematic evidence generation through analysis of observational healthcare data networks. Stat. Methods Med. Res. 2013;22:3&#x2013;6. doi: 10.1177/0962280211403601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280211403601</ArticleId><ArticleId IdType="pubmed">23439684</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie, M.&#xa0;J., Suchard, M.&#xa0;A. &amp; Ryan, P.&#xa0;B. Cohortmethod: New-user cohort method with large scale propensity and outcome models. https://github.com/OHDSI/CohortMethod (2015). Accessed 21 June 2020.</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans. Model Comput. Simul. 2013 doi: 10.1145/2414416.2414791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/2414416.2414791</ArticleId><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score inobservational studies for causal effects. Biometrika. 1983;70:41&#x2013;55. doi: 10.1093/biomet/70.1.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/70.1.41</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int. J. Epidemiol. 2018;47:2005&#x2013;2014. doi: 10.1093/ije/dyy120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold BF, Ercumen A. Negative control outcomes: A tool to detect bias in randomized trials. JAMA. 2016;316:2597&#x2013;2598. doi: 10.1001/jama.2016.17700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.17700</ArticleId><ArticleId IdType="pmc">PMC5428075</ArticleId><ArticleId IdType="pubmed">28027378</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, et al. Accuracy of an automated knowledge base for identifying drug adverse reactions. J. Biomed. Inform. 2017;66:72&#x2013;81. doi: 10.1016/j.jbi.2016.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.12.005</ArticleId><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie, M. J., Hripcsak, G., Ryan, P. B., Madigan, D. &amp; Suchard, M. A. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proceedings of the National Academy of Sciences201708282, (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ensrud KE, et al. Effects of raloxifene on fracture risk in postmenopausal women: The raloxifene use for the heart trial. J. Bone Miner. Res. 2008;23:112&#x2013;20. doi: 10.1359/jbmr.070904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1359/jbmr.070904</ArticleId><ArticleId IdType="pubmed">17892376</ArticleId></ArticleIdList></Reference><Reference><Citation>Khosla S. Increasing options for the treatment of osteoporosis. N. Engl. J. Med. 2009;361:818&#x2013;20. doi: 10.1056/NEJMe0905480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe0905480</ArticleId><ArticleId IdType="pmc">PMC3901579</ArticleId><ArticleId IdType="pubmed">19671654</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLean C, et al. Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann. Intern. Med. 2008;148:197&#x2013;213. doi: 10.7326/0003-4819-148-3-200802050-00198.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-148-3-200802050-00198</ArticleId><ArticleId IdType="pubmed">18087050</ArticleId></ArticleIdList></Reference><Reference><Citation>Murad MH, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: A systematic review and network meta-analysis. J. Clin. Endocrinol. Metab. 2012;97:1871&#x2013;80. doi: 10.1210/jc.2011-3060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2011-3060</ArticleId><ArticleId IdType="pubmed">22466336</ArticleId></ArticleIdList></Reference><Reference><Citation>Wells GA, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Datab. Syst. Rev. 2008 doi: 10.1002/14651858.CD001155.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001155.pub2</ArticleId><ArticleId IdType="pubmed">18253985</ArticleId></ArticleIdList></Reference><Reference><Citation>Luckey M, et al. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause. 2004;11:405&#x2013;15. doi: 10.1097/01.GME.0000119981.77837.1F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.GME.0000119981.77837.1F</ArticleId><ArticleId IdType="pubmed">15243278</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambrook PN, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: Results of effect (efficacy of fosamax versus evista comparison trial) international. J. Intern. Med. 2004;255:503&#x2013;11. doi: 10.1111/j.1365-2796.2004.01317.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2004.01317.x</ArticleId><ArticleId IdType="pubmed">15049885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002&#x2013;2012. Bone. 2013;57:423&#x2013;8. doi: 10.1016/j.bone.2013.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bone.2013.09.008</ArticleId><ArticleId IdType="pubmed">24063946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J. Bone. Miner. Res. 2011;26:993&#x2013;1001. doi: 10.1002/jbmr.288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.288</ArticleId><ArticleId IdType="pmc">PMC3179299</ArticleId><ArticleId IdType="pubmed">21542002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis. J. Bone. Miner. Res. 2013;28:1729&#x2013;37. doi: 10.1002/jbmr.1893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.1893</ArticleId><ArticleId IdType="pmc">PMC3713078</ArticleId><ArticleId IdType="pubmed">23408697</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N. Engl. J. Med. 2011;364:1728&#x2013;37. doi: 10.1056/NEJMoa1010650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1010650</ArticleId><ArticleId IdType="pubmed">21542743</ArticleId></ArticleIdList></Reference><Reference><Citation>Shane E, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 2010;25:2267&#x2013;94. doi: 10.1002/jbmr.253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbmr.253</ArticleId><ArticleId IdType="pubmed">20842676</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelmalek MF, Douglas DD. Alendronate-induced ulcerative esophagitis. Am. J. Gastroenterol. 1996;91:1282&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">8651202</ArticleId></ArticleIdList></Reference><Reference><Citation>Castell DO. &#x201c;Pill esophagitis&#x201d;&#x2014;The case of alendronate. N. Engl. J. Med. 1996;335:1058&#x2013;1059. doi: 10.1056/NEJM199610033351412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199610033351412</ArticleId><ArticleId IdType="pubmed">8793934</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groen PC, et al. Esophagitis associated with the use of alendronate. N. Engl. J. Med. 1996;335:1016&#x2013;21. doi: 10.1056/NEJM199610033351403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199610033351403</ArticleId><ArticleId IdType="pubmed">8793925</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberman UI, Hirsch LJ. Esophagitis and alendronate. N. Engl. J. Med. 1996;335:1069&#x2013;70. doi: 10.1056/NEJM199610033351416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199610033351416</ArticleId><ArticleId IdType="pubmed">8801453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N. Engl. J. Med. 2009;360:89&#x2013;90. doi: 10.1056/NEJMc0808738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc0808738</ArticleId><ArticleId IdType="pubmed">19118315</ArticleId></ArticleIdList></Reference><Reference><Citation>Green J, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: Case&#x2013;control analysis within a UK primary care cohort. BMJ. 2010;341:c4444. doi: 10.1136/bmj.c4444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c4444</ArticleId><ArticleId IdType="pmc">PMC2933354</ArticleId><ArticleId IdType="pubmed">20813820</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LX, et al. The carcinogenicity of alendronate in patients with osteoporosis: Evidence from cohort studies. PLoS One. 2015;10:e0123080. doi: 10.1371/journal.pone.0123080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0123080</ArticleId><ArticleId IdType="pmc">PMC4399980</ArticleId><ArticleId IdType="pubmed">25881304</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo GH, Choi HJ. Oral bisphosphonate and risk of esophageal cancer: A nationwide claim study. J Bone Metab. 2015;22:77&#x2013;81. doi: 10.11005/jbm.2015.22.2.77.</Citation><ArticleIdList><ArticleId IdType="doi">10.11005/jbm.2015.22.2.77</ArticleId><ArticleId IdType="pmc">PMC4466448</ArticleId><ArticleId IdType="pubmed">26082917</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K, Liu JM, Sun HX, Lu N, Ning G. Bisphosphonate treatment and risk of esophageal cancer: A meta-analysis of observational studies. Osteoporos Int. 2013;24:279&#x2013;86. doi: 10.1007/s00198-012-2158-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00198-012-2158-8</ArticleId><ArticleId IdType="pubmed">23052941</ArticleId></ArticleIdList></Reference><Reference><Citation>Madigan D, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol. 2013;178:645&#x2013;51. doi: 10.1093/aje/kwt010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwt010</ArticleId><ArticleId IdType="pmc">PMC3736754</ArticleId><ArticleId IdType="pubmed">23648805</ArticleId></ArticleIdList></Reference><Reference><Citation>King G, Nielsen R. Why propensity scores should not be used for matching. Political Analysis. 2019;27:435&#x2013;454. doi: 10.1017/pan.2019.11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/pan.2019.11</ArticleId></ArticleIdList></Reference><Reference><Citation>Qaseem A, Forciea MA, McLean RM, Denberg TD. Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the american college of physicians. Ann Intern Med. 2017;166:818&#x2013;839. doi: 10.7326/M15-1361.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M15-1361</ArticleId><ArticleId IdType="pubmed">28492856</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32691386</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2568</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Digestive diseases and sciences</Title><ISOAbbreviation>Dig Dis Sci</ISOAbbreviation></Journal><ArticleTitle>Real-World Use of Colonoscopy in an Older Population: A Nationwide Standard Cohort Study Using a Common Data Model.</ArticleTitle><Pagination><StartPage>2227</StartPage><EndPage>2234</EndPage><MedlinePgn>2227-2234</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10620-020-06494-x</ELocationID><Abstract><AbstractText Label="BACKGROUNDS AND AIMS">Rapid population aging is considered to be a major factor in increased colonoscopy use in Korea. However, real-world use of colonoscopy in older populations is rarely evaluated using Korean databases.</AbstractText><AbstractText Label="METHODS">We conducted a retrospective, observational cohort study of individuals aged over 20&#xa0;years between 2012 and 2017. We used the Health Insurance Review and Assessment-National Patient Samples database, previously converted to the standardized Observational Medical Outcomes Partnership-Common Data Model. The use of diagnostic colonoscopy and colonoscopic polypectomy was evaluated, stratified by age group and sex.</AbstractText><AbstractText Label="RESULTS">During the study period, we captured data from the database on 240,406 patients who underwent diagnostic colonoscopy and 88,984 who underwent colonoscopic polypectomy. During the study period, use of diagnostic colonoscopy and colonoscopic polypectomy steadily increased, but both procedures were most significantly increased in the 65- to 85-year group compared to other age groups (p&#x2009;&lt;&#x2009;0.05). Average ages for both procedures significantly increased in the most recent 3&#xa0;years (p&#x2009;&lt;&#x2009;0.05). Polypectomy rates for men plateaued in the 50- to 64-year age group, but rates for women steadily increased up to the 65- to 85-year group. Polypectomy rates were higher for men than for women in all index years.</AbstractText><AbstractText Label="CONCLUSIONS">The use of diagnostic colonoscopy and colonoscopic polypectomy significantly increased in the 65- to 85-year age group. Our findings suggest that more available colonoscopy resources should be allocated to older populations, considering the aging society in Asian countries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ha Il</ForeName><Initials>HI</Initials><Identifier Source="ORCID">0000-0002-5471-7790</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jin Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-5280-0443</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwak</LastName><ForeName>Min Seob</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-8988-7423</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Jae Myung</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-9403-230X</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Korea. drcha@khu.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea. drcha@khu.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dig Dis Sci</MedlineTA><NlmUniqueID>7902782</NlmUniqueID><ISSNLinking>0163-2116</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003113" MajorTopicYN="N">Colonoscopy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Colonoscopy</Keyword><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">Polypectomy</Keyword><Keyword MajorTopicYN="N">Population</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32691386</ArticleId><ArticleId IdType="doi">10.1007/s10620-020-06494-x</ArticleId><ArticleId IdType="pii">10.1007/s10620-020-06494-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/CA.2007.0018</ArticleId></ArticleIdList></Reference><Reference><Citation>Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. multi-society task force on colorectal cancer. Am J Gastroenterol. 2017;112:1016&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2017.174</ArticleId></ArticleIdList></Reference><Reference><Citation>Schussele Filliettaz S, Gonvers JJ, Peytremann-Bridevaux I, et al. Appropriateness of colonoscopy in Europe (EPAGE II). Functional bowel disorders: pain, constipation and bloating. Endoscopy. 2009;41:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0028-1119625</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-149-9-200811040-00243</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BI, Hong SP, Kim SE, et al. Korean guidelines for colorectal cancer screening and polyp detection. Clin Endosc. 2012;45:25&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="doi">10.5946/ce.2012.45.1.25</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha JM, Suh M, Kwak MS, et al. Risk of interval cancer in fecal immunochemical test screening significantly higher during the summer months: results from the national cancer screening program in Korea. Am J Gastroenterol. 2018;113:611&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2018.23</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68:250&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21457</ArticleId></ArticleIdList></Reference><Reference><Citation>Audibert C, Perlaky A, Glass D. Global perspective on colonoscopy use for colorectal cancer screening: a multi-country survey of practicing colonoscopists. Contemp Clin Trials Commun. 2017;7:116&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conctc.2017.06.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha JM, Kwak MS, Kim HS, et al. Real-world national colonoscopy volume in Korea: a nationwide population-based study over 12 years. Gut Liver. 2020;14:338&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="doi">10.5009/gnl19108</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation. Proposed working definition of an older person in Africa for the MDS Project, 2002. https://www.who.int/healthinfo/survey/ageingdefnolder/en/ . Accessed 12th June, 2020.</Citation></Reference><Reference><Citation>Asge Standards of Practice Committee, Chandrasekhara V, Early DS, et al. Modifications in endoscopic practice for the elderly. Gastrointest Endosc. 2013;78:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2013.04.161</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyun K-R, Kang S, Lee S. Population aging and healthcare expenditure in Korea. Health Econ. 2016;25:1239&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hec.3209</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017;32:718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2017.32.5.718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pubmed">26262116</ArticleId><ArticleId IdType="pmc">4815923</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedia P, Waye JD. Colon polypectomy: a review of routine and advanced techniques. J Clin Gastroenterol. 2013;47:657&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e31829ebda7</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn DK, Kim MJ, Park Y, et al. The Korean guideline for colorectal cancer screening. J Korean Med Assoc. 2015;58:420&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="doi">10.5124/jkma.2015.58.5.420</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin OS, Kozarek RA, Schembre DB, et al. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. JAMA. 2006;295:2357&#x2013;2365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.295.20.2357</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin OS. Performing colonoscopy in elderly and very elderly patients: risks, costs and benefits. World J Gastrointest Endosc. 2014;6:220&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="doi">10.4253/wjge.v6.i6.220</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Albeniz X, Hsu J, Bretthauer M, Hernan MA. Effectiveness of screening colonoscopy to prevent colorectal cancer among medicare beneficiaries aged 70 to 79&#xa0;years: a prospective observational study. Ann Intern Med. 2017;166:18&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M16-0758</ArticleId></ArticleIdList></Reference><Reference><Citation>Nee J, Chippendale RZ, Feuerstein JD. Screening for colon cancer in older adults: risks, benefits, and when to stop. Mayo Clin Proc. 2020;95:184&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2019.02.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Benard F, Barkun AN, Martel M, von Renteln D. Systematic review of colorectal cancer screening guidelines for average-risk adults: summarizing the current global recommendations. World J Gastroenterol. 2018;24:124&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v24.i1.124</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontis V, Bennett JE, Mathers CD, et al. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. Lancet. 2017;389:1323&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)32381-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014;370:1298&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1309086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski MF, Wieszczy P, Rupinski M, et al. Increased rate of adenoma detection associates with reduced risk of colorectal cancer and death. Gastroenterology. 2017;153:98&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zauber AG, Winawer SJ, O&#x2019;Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366:687&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1100370</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel NC, Islam RS, Wu Q, et al. Measurement of polypectomy rate by using administrative claims data with validation against the adenoma detection rate. Gastrointest Endosc. 2013;77:390&#x2013;394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2012.09.032</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JE, Holub JL, Faigel DO. Polypectomy rate is a valid quality measure for colonoscopy: results from a national endoscopy database. Gastrointest Endosc. 2012;75:576&#x2013;582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2011.12.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Gohel TD, Burke CA, Lankaala P, et al. Polypectomy rate: a surrogate for adenoma detection rate varies by colon segment, gender, and endoscopist. Clin Gastroenterol Hepatol. 2014;12:1137&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2013.11.023</ArticleId></ArticleIdList></Reference><Reference><Citation>Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2006;63:S16&#x2013;S28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gie.2006.02.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieszczy P, Regula J, Kaminski MF. Adenoma detection rate and risk of colorectal cancer. Best Pract Res Clin Gastroenterol. 2017;31:441&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpg.2017.07.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard MA, Shea S, et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med. 2020;180:542&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2019.7454</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Reps JM, Kostka KF, et al. Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network. PLoS ONE. 2020;15:e0226718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0226718</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32771540</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><PubDate><Year>2020</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>The Counterfactual &#x3c7;-GAN: Finding comparable cohorts in observational health data.</ArticleTitle><Pagination><StartPage>103515</StartPage><MedlinePgn>103515</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2020.103515</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(20)30143-X</ELocationID><Abstract><AbstractText>Causal inference often relies on the counterfactual framework, which requires that treatment assignment is independent of the outcome, known as strong ignorability. Approaches to enforcing strong ignorability in causal analyses of observational data include weighting and matching methods. Effect estimates, such as the average treatment effect (ATE), are then estimated as expectations under the re-weighted or matched distribution, P. The choice of P is important and can impact the interpretation of the effect estimate and the variance of effect estimates. In this work, instead of specifying P, we learn a distribution that simultaneously maximizes coverage and minimizes variance of ATE estimates. In order to learn this distribution, this research proposes a generative adversarial network (GAN)-based model called the Counterfactual &#x3c7;-GAN (cGAN), which also learns feature-balancing weights and supports unbiased causal estimation in the absence of unobserved confounding. Our model minimizes the Pearson &#x3c7;<sup>2</sup>-divergence, which we show simultaneously maximizes coverage and minimizes the variance of importance sampling estimates. To our knowledge, this is the first such application of the Pearson &#x3c7;<sup>2</sup>-divergence. We demonstrate the effectiveness of cGAN in achieving feature balance relative to established weighting methods in simulation and with real-world medical data.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Averitt</LastName><ForeName>Amelia J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Biomedical Informatics, Columbia University, New York, NY, United States. Electronic address: amelia.averitt@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanitchanant</LastName><ForeName>Natnicha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranganath</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Courant Institute, Center for Data Science, New York University, New York, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perotte</LastName><ForeName>Adler J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM009886</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="Y">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Causal inference</Keyword><Keyword MajorTopicYN="N">Deep learning</Keyword><Keyword MajorTopicYN="N">GANs</Keyword><Keyword MajorTopicYN="N">Health</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Observational studies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32771540</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2020.103515</ArticleId><ArticleId IdType="pii">S1532-0464(20)30143-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32781983</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States.</ArticleTitle><Pagination><StartPage>296</StartPage><MedlinePgn>296</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">296</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-020-01882-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The treatment landscape for multiple sclerosis (MS) is quickly evolving. Understanding real-world treatment patterns of patients is necessary to identifying potential gaps in care.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with incident MS were identified from a large national claims database during 1/1/2014-6/30/2019. Patients had &#x2265;2 diagnoses for MS or an inpatient hospitalization with a primary diagnosis of MS. Patients were required to have enrollment in the database &#x2265;1&#x2009;year prior to and&#x2009;&#x2265;&#x2009;1&#x2009;year following their first MS diagnosis. Treatment sequences were captured for all available disease modifying therapies (DMTs) during all available follow-up. Presence of comorbid conditions were captured during the one year prior to and following (and including) the index date; absolute change in prevalence from the pre- to post-index periods was calculated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 5691 patients with incident MS. Common comorbidities included physical symptoms (e.g., pain, weakness, fatigue), mental health conditions (anxiety, depression), and cardiovascular/metabolic conditions (hypertension, hyperlipidemia, diabetes, obesity). Just 1994 (35.0%) of patients received a DMT at any time during follow-up. Of those receiving a DMT, 28.2% went on to receive a second line of therapy, 5.8% received a third, and just 0.9% went on to a fourth line. Use of more than one DMT concomitantly occurred in just 1.8% of all treated patients. Glatiramer and dimethyl fumarate were by far the most common first-line treatments received accounting for nearly 62% of patients receiving a DMT.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Approximately two-thirds of patients newly diagnosed with MS did not receive a DMT and the disease is accompanied by a significant comorbid burden.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0001-5417-3925</Identifier><AffiliationInfo><Affiliation>Janssen Research and Development, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA. dkern2@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cepeda</LastName><ForeName>M Soledad</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, 1125 Trenton Harbourton Rd, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5M691HL4BO</RegistryNumber><NameOfSubstance UI="D000068717">Glatiramer Acetate</NameOfSubstance></Chemical><Chemical><RegistryNumber>FO2303MNI2</RegistryNumber><NameOfSubstance UI="D000069462">Dimethyl Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069462" MajorTopicYN="N">Dimethyl Fumarate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068717" MajorTopicYN="N">Glatiramer Acetate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Administrative claims</Keyword><Keyword MajorTopicYN="N">Comorbidity</Keyword><Keyword MajorTopicYN="N">Disease modifying therapy</Keyword><Keyword MajorTopicYN="N">Multiple sclerosis</Keyword><Keyword MajorTopicYN="N">Treatment patterns</Keyword></KeywordList><CoiStatement>All authors are employees of Janssen Research &amp; Development, LLC, which markets and develops treatments for depression, and are stockholders of Johnson &amp; Johnson, Janssen&#x2019;s parent company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32781983</ArticleId><ArticleId IdType="pmc">PMC7418327</ArticleId><ArticleId IdType="doi">10.1186/s12883-020-01882-2</ArticleId><ArticleId IdType="pii">10.1186/s12883-020-01882-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Compston A, Coles A. Multiple sclerosis. Lancet (London, England) 2002;359(9313):1221&#x2013;1231.</Citation><ArticleIdList><ArticleId IdType="pubmed">11955556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A, Munger KL. Epidemiology of multiple sclerosis: from risk factors to prevention-an update. Semin Neurol. 2016;36(2):103&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">27116717</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodin DS. The epidemiology of multiple sclerosis: insights to a causal cascade. Handb Clin Neurol. 2016;138:173&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637959</ArticleId></ArticleIdList></Reference><Reference><Citation>Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol. 2016;172(1):3&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">26718593</ArticleId></ArticleIdList></Reference><Reference><Citation>Gehr S, Kaiser T, Kreutz R, Ludwig WD, Paul F. Suggestions for improving the design of clinical trials in multiple sclerosis-results of a systematic analysis of completed phase III trials. EPMA J. 2019;10(4):425&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6883016</ArticleId><ArticleId IdType="pubmed">31832116</ArticleId></ArticleIdList></Reference><Reference><Citation>Freedman MS, Rush CA. Severe, highly active, or aggressive multiple sclerosis. Continuum (Minneapolis, Minn) 2016;22(3):761&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pubmed">27261681</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart FM, Bainbridge J. Current and emerging treatment of multiple sclerosis. Am J Manag Care. 2016;22(6 Suppl):s159&#x2013;s170.</Citation><ArticleIdList><ArticleId IdType="pubmed">27356025</ArticleId></ArticleIdList></Reference><Reference><Citation>National Multiple Sclerosis Society. Disease-modifying therapies for MS 2020 [Last Accessed: May 18, 2020]. Available from: http://www.nationalmssociety.org/nationalmssociety/media/msnationalfiles/brochures/brochure-the-ms-disease-modifying-medications.pdf.</Citation></Reference><Reference><Citation>Sanchirico M, Caldwell-Tarr A, Mudumby P, Hashemi L, Dufour R. Treatment patterns, healthcare resource utilization, and costs among Medicare patients with multiple sclerosis in relation to disease-modifying therapy and corticosteroid treatment. Neurol Therapy. 2019;8(1):121&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6534679</ArticleId><ArticleId IdType="pubmed">30565050</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010;9(3):299&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">20170843</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede MM, Johnson BH, Wenten M, Watson C. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Clin Ther. 2013;35(10):1501&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pubmed">24139422</ArticleId></ArticleIdList></Reference><Reference><Citation>Visaria J, Thomas N, Gu T, Singer J, Tan H. Understanding the Patient's journey in the diagnosis and treatment of multiple sclerosis in clinical practice. Clin Ther. 2018;40(6):926&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">29803533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst FR, Barr P, Elmor R, Wong SL. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon beta-1a or dimethyl fumarate: a real-world study. Curr Med Res Opin. 2017;33(12):2099&#x2013;2106.</Citation><ArticleIdList><ArticleId IdType="pubmed">28906152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholas J, Ko JJ, Park Y, Navaratnam P, Friedman HS, Ernst FR, et al. Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients. Multiple Scleros J- Exper Transl Clin. 2017;3(1):2055217317696114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5459267</ArticleId><ArticleId IdType="pubmed">28607751</ArticleId></ArticleIdList></Reference><Reference><Citation>Setayeshgar S, Kingwell E, Zhu F, Zhang T, Carruthers R, Marrie RA, et al. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: a population-based study. Mult Scler Relat Disord. 2019;27:364&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">30476872</ArticleId></ArticleIdList></Reference><Reference><Citation>Oleen-Burkey M, Cyhaniuk A, Swallow E. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years. J Med Econ. 2013;16(3):397&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">23301877</ArticleId></ArticleIdList></Reference><Reference><Citation>Widdifield J, Ivers NM, Young J, Green D, Jaakkimainen L, Butt DA, et al. Development and validation of an administrative data algorithm to estimate the disease burden and epidemiology of multiple sclerosis in Ontario, Canada. Multiple Sclerosis (Houndmills, Basingstoke, England) 2015;21(8):1045&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">25392338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Levine ME, Shang N, Ryan PB. Effect of vocabulary mapping for conditions on phenotype cohorts. J Am Med Inform Assoc: JAMIA. 2018;25(12):1618&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289550</ArticleId><ArticleId IdType="pubmed">30395248</ArticleId></ArticleIdList></Reference><Reference><Citation>SNOMED CT, SNOMED CT. 5-step briefing. 2019.</Citation></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Sintzel MB, Rametta M, Reder AT. Vitamin D and multiple sclerosis: a comprehensive review. Neurol Therapy. 2018;7(1):59&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5990512</ArticleId><ArticleId IdType="pubmed">29243029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitnis T, Giovannoni G, Trojano M. Complexity of MS management in the current treatment era. Neurology. 2018;90(17):761&#x2013;762.</Citation><ArticleIdList><ArticleId IdType="pubmed">29686111</ArticleId></ArticleIdList></Reference><Reference><Citation>Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Rep Guideline Dev Dissemination, Implement Subcommittee Am Acad Neurol. 2018;90(17):777&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">29686116</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England) 2018;24(2):96&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">29353550</ArticleId></ArticleIdList></Reference><Reference><Citation>Corboy JR, Weinshenker BG, Wingerchuk DM. Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. Neurology. 2018;90(24):1106&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pubmed">29685920</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrie RA, Hanwell H. General health issues in multiple sclerosis: comorbidities, secondary conditions, and health behaviors. Continuum (Minneapolis, Minn) 2013;19(4 Multiple Sclerosis):1046&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">23917100</ArticleId></ArticleIdList></Reference><Reference><Citation>Berrigan LI, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, et al. Health-related quality of life in multiple sclerosis. Direct indirect Effects Comorbidity. 2016;86(15):1417&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4831037</ArticleId><ArticleId IdType="pubmed">26962068</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda MS, Reps J, Kern DM, Stang P. Medical conditions predictive of self-reported poor health: retrospective cohort study. JMIR Public Health Surveill. 2020;6(1):e13018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6996740</ArticleId><ArticleId IdType="pubmed">31913130</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Tremlett H, Leung S, Zhu F, Kingwell E, Fisk JD, et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology. 2016;86(14):1287&#x2013;1295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826339</ArticleId><ArticleId IdType="pubmed">26944268</ArticleId></ArticleIdList></Reference><Reference><Citation>Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, et al. Natural history of multiple sclerosis symptoms. Int J MS care. 2013;15(3):146&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883021</ArticleId><ArticleId IdType="pubmed">24453777</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch-Henriksen N, S&#xf8;rensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9(5):520&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">20398859</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazareth T, Datar M, Yu T-C. Treatment effectiveness for resolution of multiple sclerosis relapse in a US health plan population. Neurology Therapy. 2019;8(2):383&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858912</ArticleId><ArticleId IdType="pubmed">31564036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander MA. Epidemiology of multiple sclerosis: results from a large observational study in the UK. J Neurol. 2015;262(9):2033&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4768220</ArticleId><ArticleId IdType="pubmed">26067217</ArticleId></ArticleIdList></Reference><Reference><Citation>National Multiple Sclerosis Society. Types of MS 2020 [Last Accessed: May 18, 2020]. Available from: https://www.nationalmssociety.org/What-is-MS/Types-of-MS.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM"><PMID Version="2">32805036</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment.</ArticleTitle><Pagination><StartPage>427</StartPage><EndPage>443</EndPage><MedlinePgn>427-443</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocaa196</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Coronavirus disease 2019 (COVID-19) poses societal challenges that require expeditious data and knowledge sharing. Though organizational clinical data are abundant, these are largely inaccessible to outside researchers. Statistical, machine learning, and causal analyses are most successful with large-scale data beyond what is available in any given organization. Here, we introduce the National COVID Cohort Collaborative (N3C), an open science community focused on analyzing patient-level data from many centers.</AbstractText><AbstractText Label="MATERIALS AND METHODS">The Clinical and Translational Science Award Program and scientific community created N3C to overcome technical, regulatory, policy, and governance barriers to sharing and harmonizing individual-level clinical data. We developed solutions to extract, aggregate, and harmonize data across organizations and data models, and created a secure data enclave to enable efficient, transparent, and reproducible collaborative analytics.</AbstractText><AbstractText Label="RESULTS">Organized in inclusive workstreams, we created legal agreements and governance for organizations and researchers; data extraction scripts to identify and ingest positive, negative, and possible COVID-19 cases; a data quality assurance and harmonization pipeline to create a single harmonized dataset; population of the secure data enclave with data, machine learning, and statistical analytics tools; dissemination mechanisms; and a synthetic data pilot to democratize data access.</AbstractText><AbstractText Label="CONCLUSIONS">The N3C has demonstrated that a multisite collaborative learning health network can overcome barriers to rapidly build a scalable infrastructure incorporating multiorganizational clinical data for COVID-19 analytics. We expect this effort to save lives by enabling rapid collaboration among clinicians, researchers, and data scientists to identify treatments and specialized care and thereby reduce the immediate and long-term impacts of COVID-19.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Oregon Clinical and Translational Research Institute, Oregon Health and Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational and Integrative Sciences Center, Department of Molecular Toxicology, Oregon State University, Corvallis, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Schools of Medicine, Public Health, and Nursing, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Section of Informatics and Data Science, Department of Pediatrics, University of Colorado School of Medicine, University of Colorado, Aurora, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichmann</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>School of Library and Information Science, The University of Iowa, Iowa City, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guinney</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kibbe</LastName><ForeName>Warren A</ForeName><Initials>WA</Initials><AffiliationInfo><Affiliation>Duke University, Durham,North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Payne</LastName><ForeName>Philip R O</ForeName><Initials>PRO</Initials><AffiliationInfo><Affiliation>Institute for Informatics, Washington University in St. Louis, Saint Louis,Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>North Carolina Translational and Clinical Sciences Institute (NC TraCS), University of North Carolina at Chapel Hill, Chapel Hill,North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Peter N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Jackson Laboratory, Bar Harbor, Maine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saltz</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Stony Brook University, Stony Brook, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spratt</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Texas Medical Branch, Galveston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suver</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilbanks</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilcox</LastName><ForeName>Adam B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Tufts Medical Center Clinical and Translational Science Institute, Tufts Medical Center, Boston,Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chunlei</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, LLC, Raritan, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradford</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>North Carolina Translational and Clinical Sciences Institute (NC TraCS), University of North Carolina at Chapel Hill, Chapel Hill,North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cimino</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>University of Alabama-Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Marshall</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>North Carolina Translational and Clinical Sciences Institute (NC TraCS), University of North Carolina at Chapel Hill, Chapel Hill,North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colmenares</LastName><ForeName>Evan W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill, Chapel Hill,North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Davera</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graves</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Iowa Institute for Clinical and Translational Science, The University of Iowa, Iowa City, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemadri</LastName><ForeName>Raju</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Science, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Stephanie S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripscak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Dazhi</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klann</LastName><ForeName>Jeffrey G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Harvard Medical School, Boston,Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>IQVIA, Durham, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>University of North Carolina at Chapel Hill, Chapel Hill,North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Harold P</ForeName><Initials>HP</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lingrey</LastName><ForeName>Lora</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>TriNetX, Cambridge,Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Robert T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Tufts Clinical and Translational Science Institute, Tufts University, Boston,Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh,Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Shawn N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Mass General Brigham, Boston,Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Irving Medical Center, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palchuk</LastName><ForeName>Matvey B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>TriNetX, Cambridge,Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Usman</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Science, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solbrig</LastName><ForeName>Harold</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visweswaran</LastName><ForeName>Shyam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh,Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walden</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oregon Clinical and Translational Research Institute, Oregon Health and Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sage Bionetworks, Seattle, Washington, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walters</LastName><ForeName>Kellie M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>North Carolina Translational and Clinical Sciences Institute (NC TraCS), University of North Carolina at Chapel Hill, Chapel Hill,North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Griffin M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston,Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaohan Tanner</ForeName><Initials>XT</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amor</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girvin</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manna</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Nabeel</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurilla</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Division of Clinical Innovation, National Center for Advancing Translational Science, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michael</LastName><ForeName>Sam G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portilla</LastName><ForeName>Lili M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Office of Strategic Alliances, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutter</LastName><ForeName>Joni L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Office of the Director, National Center for Advancing Translational Science, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Austin</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gersing</LastName><ForeName>Ken R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Science, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>N3C Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013345</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016494" MajorTopicYN="N">Computer Security</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078332" MajorTopicYN="N">Data Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="N">Data Science</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028744" MajorTopicYN="N">Ethics Committees, Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033161" MajorTopicYN="N">Government Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070516" MajorTopicYN="Y">Intersectoral Collaboration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009316" MajorTopicYN="N">National Institutes of Health (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">EHR data</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">clinical data model harmonization</Keyword><Keyword MajorTopicYN="N">collaborative analytics</Keyword><Keyword MajorTopicYN="N">open science</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Haendel</LastName><ForeName>Melissa A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9114-8737</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Chute</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0001-5437-2545</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials><Identifier Source="ORCID">0000-0003-1483-4236</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Eichmann</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">00000-0003-3150-8758</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Guinney</LastName><ForeName>Justin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1477-1888</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Kibbe</LastName><ForeName>Warren A</ForeName><Initials>WA</Initials><Identifier Source="ORCID">0000-0001-5622-7659</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Payne</LastName><ForeName>Philip R O</ForeName><Initials>PRO</Initials><Identifier Source="ORCID">0000-0002-9532-2998</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Pfaff</LastName><ForeName>Emily R</ForeName><Initials>ER</Initials><Identifier Source="ORCID">0000-0002-6840-9756</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Peter N</ForeName><Initials>PN</Initials><Identifier Source="ORCID">0000-0002-0736-9199</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Saltz</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-3451-2165</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Spratt</LastName><ForeName>Heidi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9420-5028</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Suver</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2986-385X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Wilbanks</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4510-0385</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Wilcox</LastName><ForeName>Adam B</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0002-6305-735X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0002-0692-412X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chunlei</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2629-6124</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2570-2124</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Bradford</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0003-0908-1428</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Cimino</LastName><ForeName>James J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-4101-1622</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>Marshall</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colmenares</LastName><ForeName>Evan W</ForeName><Initials>EW</Initials><Identifier Source="ORCID">0000-0002-4993-2269</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Francis</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials><Identifier Source="ORCID">0000-0001-9612-5702</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Davera</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9041-4597</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Graves</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2193-9987</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Hemadri</LastName><ForeName>Raju</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hong</LastName><ForeName>Stephanie S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hripscak</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2664-7614</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Jiao</LastName><ForeName>Dazhi</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5052-3836</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Klann</LastName><ForeName>Jeffrey G</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2595-8736</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehmann</LastName><ForeName>Harold P</ForeName><Initials>HP</Initials><Identifier Source="ORCID">0000-0002-7698-219X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Lingrey</LastName><ForeName>Lora</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Robert T</ForeName><Initials>RT</Initials><Identifier Source="ORCID">0000-0002-1787-2855</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Michele</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3255-5727</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>Shawn N</ForeName><Initials>SN</Initials><Identifier Source="ORCID">0000-0002-1905-8806</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9066-9431</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Palchuk</LastName><ForeName>Matvey B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0002-7737-8752</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Usman</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-1434-0888</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Solbrig</LastName><ForeName>Harold</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5928-3071</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Visweswaran</LastName><ForeName>Shyam</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2079-8684</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Walden</LastName><ForeName>Anita</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3327-7423</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Walters</LastName><ForeName>Kellie M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-7473-1709</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>Griffin M</ForeName><Initials>GM</Initials><Identifier Source="ORCID">0000-0002-2597-881X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaohan Tanner</ForeName><Initials>XT</Initials><Identifier Source="ORCID">0000-0002-4843-9077</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>Richard L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0002-4289-7632</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Amor</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girvin</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><Identifier Source="ORCID">0000-0002-2031-9209</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Manna</LastName><ForeName>Amin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4711-2128</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Qureshi</LastName><ForeName>Nabeel</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3177-5314</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Kurilla</LastName><ForeName>Michael G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michael</LastName><ForeName>Sam G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Portilla</LastName><ForeName>Lili M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rutter</LastName><ForeName>Joni L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-6502-2361</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Austin</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><Identifier Source="ORCID">0000-0001-7770-0708</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Gersing</LastName><ForeName>Ken R</ForeName><Initials>KR</Initials><Identifier Source="ORCID">0000-0003-3897-3409</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Al-Shukri</LastName><ForeName>Shaymaa</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8587-9189</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Alaoui</LastName><ForeName>Adil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Connor</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-9313-0431</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Crandall</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0002-0836-3389</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Deacy</LastName><ForeName>Mariam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8307-5208</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Dietz</LastName><ForeName>Racquel R</ForeName><Initials>RR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobbins</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baghal</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0389-0021</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Banning</LastName><ForeName>Pamela D</ForeName><Initials>PD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbour</LastName><ForeName>Edward M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-2962-607X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Becich</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-5998-8074</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Beheshti</LastName><ForeName>Afshin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4643-531X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Bernard</LastName><ForeName>Gordon R</ForeName><Initials>GR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhattacharyya</LastName><ForeName>Sharmodeep</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5011-4119</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Bissell</LastName><ForeName>Mark M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boulware</LastName><ForeName>L Ebony</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bozzette</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Donald E</ForeName><Initials>DE</Initials><Identifier Source="ORCID">0000-0002-9140-2632</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-9723-3876</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Bush</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Callahan</LastName><ForeName>Tiffany J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-8169-9049</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Campion</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casiraghi</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">00000-0003-2024-7572</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Chaudhry</LastName><ForeName>Ammar A</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0000-0002-2126-0587</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Guanhua</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Anjun</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1528-1928</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Clifford</LastName><ForeName>Gari D</ForeName><Initials>GD</Initials><Identifier Source="ORCID">0000-0002-5709-201X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Coffee</LastName><ForeName>Megan P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-4581-111X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Conlin</LastName><ForeName>Tom</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-0355-5581</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Elkin</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials><Identifier Source="ORCID">0000-0001-9616-6811</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Embi</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-7733-0847</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Facelli</LastName><ForeName>Julio C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">00000-0003-1449-477X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Fecho</LastName><ForeName>Karamarie</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6704-9306</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Feng</LastName><ForeName>Xue</ForeName><Initials>X</Initials><Identifier Source="ORCID">00000-0002-2181-9889</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Foraker</LastName><ForeName>Randi E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gal</LastName><ForeName>Tamas S</ForeName><Initials>TS</Initials><Identifier Source="ORCID">0000-0002-6525-092X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Ge</LastName><ForeName>Linqiang</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-0817-8850</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Golovko</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-4609-2767</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Gouripeddi</LastName><ForeName>Ramkiran</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4345-9669</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Greene</LastName><ForeName>Casey S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>Sangeeta</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>Ashish</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4593-3261</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Hajagos</LastName><ForeName>Janos G</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0001-6251-9586</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Hanauer</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harper</LastName><ForeName>Jeremy Richard</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0003-1244-8948</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Nomi L</ForeName><Initials>NL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassan</LastName><ForeName>Mehadi R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>He</LastName><ForeName>Yongqun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9189-9661</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>Elaine L</ForeName><Initials>EL</Initials><Identifier Source="ORCID">0000-0003-2494-317X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Hoatlin</LastName><ForeName>Maureen E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmes</LastName><ForeName>Kristi L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0001-8420-5254</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Hughes</LastName><ForeName>LaRon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jawa</LastName><ForeName>Randeep S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jiang</LastName><ForeName>Guoqian</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jing</LastName><ForeName>Xia</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-1916-4588</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Joachimiak</LastName><ForeName>Marcin P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0001-8175-045X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0002-2983-6384</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Kamaleswaran</LastName><ForeName>Rishikesan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8366-4811</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Kannampallil</LastName><ForeName>Thomas George</ForeName><Initials>TG</Initials><Identifier Source="ORCID">0000-0003-4119-4836</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Kanter</LastName><ForeName>Andrew S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-4019-7894</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Kavuluru</LastName><ForeName>Ramakanth</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1238-9378</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Khanipov</LastName><ForeName>Kamil</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-3881-737X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Kharrazi</LastName><ForeName>Hadi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Dongkyu</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9221-2507</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Knosp</LastName><ForeName>Boyd M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0002-3834-3135</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Krishnan</LastName><ForeName>Arunkumar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurc</LastName><ForeName>Tahsin</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lai</LastName><ForeName>Albert M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-9241-2656</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Lambert</LastName><ForeName>Christophe G</ForeName><Initials>CG</Initials><Identifier Source="ORCID">0000-0003-1994-2893</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Larionov</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8067-7817</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Stephen B</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0000-0002-6253-293X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Lesh</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><Identifier Source="ORCID">00000-0001-6177-0103</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Lichtarge</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-4057-7122</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Sijia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9763-1164</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongfang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2570-3741</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Loomba</LastName><ForeName>Johanna J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-3673-5423</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Mallipattu</LastName><ForeName>Sandeep K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0002-6324-7807</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Mamillapalli</LastName><ForeName>Chaitanya K</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mason</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathew</LastName><ForeName>Jomol P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>McClay</LastName><ForeName>James C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0002-3404-0671</Identifier></Investigator><Investigator ValidYN="Y"><LastName>McMurry</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-9353-5498</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paras P</ForeName><Initials>PP</Initials><Identifier Source="ORCID">0000-0002-0233-9871</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Mendelevitch</LastName><ForeName>Ofer</ForeName><Initials>O</Initials><Identifier Source="ORCID">00000-0003-1082-7047</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Meystre</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7632-9625</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Moffitt</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morizono</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9678-5564</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Mungall</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munoz-Torres</LastName><ForeName>Monica C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-8430-6039</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Neumann</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0002-4809-6289</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Ning</LastName><ForeName>Xia</ForeName><Initials>X</Initials><Identifier Source="ORCID">00000-0002-6842-1165</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Nyland</LastName><ForeName>Jennifer E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">00000-0002-4549-3617</Identifier></Investigator><Investigator ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Neil</LastName><ForeName>Shawn T</ForeName><Initials>ST</Initials><Identifier Source="ORCID">0000-0001-6220-7080</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Obeid</LastName><ForeName>Jihad S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0002-7193-7779</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Ogburn</LastName><ForeName>Elizabeth L</ForeName><Initials>EL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phuong</LastName><ForeName>Jimmy</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0956-8404</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Posada</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0003-3864-0241</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Prasanna</LastName><ForeName>Prateek</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prior</LastName><ForeName>Fred</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-6314-5683</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Prosser</LastName><ForeName>Justin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6358-5507</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Purnell</LastName><ForeName>Amanda Lienau</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rahnavard</LastName><ForeName>Ali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9710-0248</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Ramadas</LastName><ForeName>Harish</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9818-1625</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Reese</LastName><ForeName>Justin T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0001-7389-3047</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Rubin</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rutherford</LastName><ForeName>Cody D</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0001-8556-4013</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Sadhu</LastName><ForeName>Eugene M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saha</LastName><ForeName>Amit</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3542-4319</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Saltz</LastName><ForeName>Mary Morrison</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaffter</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8242-9462</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Schleyer</LastName><ForeName>Titus KL</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0003-1829-971X</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Setoguchi</LastName><ForeName>Soko</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharafeldin</LastName><ForeName>Noha</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8835-8899</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Sholle</LastName><ForeName>Evan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-9518-4399</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Silverstein</LastName><ForeName>Jonathan C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solomonides</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solway</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0898-8530</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Su</LastName><ForeName>Jing</ForeName><Initials>J</Initials><Identifier Source="ORCID">00000-0003-4917-6173</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Subbian</LastName><ForeName>Vignesh</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-9974-8382</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Tak</LastName><ForeName>Hyo Jung</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0003-1925-3190</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Bradley W</ForeName><Initials>BW</Initials><Identifier Source="ORCID">0000-0002-6414-4172</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Thessen</LastName><ForeName>Anne E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Jason A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-3892-7197</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Topaloglu</LastName><ForeName>Umit</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-3241-8773</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Unni</LastName><ForeName>Deepak R</ForeName><Initials>DR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vogelstein</LastName><ForeName>Joshua T</ForeName><Initials>JT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Volz</LastName><ForeName>Andr&#xe9;a M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-1438-5664</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0002-5052-4895</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>Kelli M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0003-2636-2766</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Clark B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5274-4672</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Yan</LastName><ForeName>Yao</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zak</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0021-0027</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lanjing</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chengda</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1616-4715</Identifier></Investigator><Investigator ValidYN="Y"><LastName>Zheng</LastName><ForeName>Jingyi</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32805036</ArticleId><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocaa196</ArticleId><ArticleId IdType="pii">5893482</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johns Hopkins Coronavirus Resource Center. COVID-19 Map. https://coronavirus.jhu.edu/map.html Accessed July 12, 2020.</Citation></Reference><Reference><Citation>Kissler SM, Tedijanto C, Goldstein E, et al.Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020; 368 (6493): 860&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164482</ArticleId><ArticleId IdType="pubmed">32291278</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al.Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Visweswaran S, Becich MJ, D&#x2019;Itri VS, et al.Accrual to Clinical Trials (ACT): A Clinical and Translational Science Award Consortium Network. JAMIA Open 2018; 1 (2): 147&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6241502</ArticleId><ArticleId IdType="pubmed">30474072</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL, Curtis LH, Califf RM, et al.Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc 2014; 21 (4): 578&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al.Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>
Findlay S. The FDA&#x2019;s Sentinel Initiative. Health Policy Brief. Health Affairs2015. https://www.healthaffairs.org/do/10.1377/hpb20150604.936915/full/healthpolicybrief_139.pdf Accessed June 7, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hpb20150604.936915/full/healthpolicybrief_139.pdf</ArticleId></ArticleIdList></Reference><Reference><Citation>Topaloglu U, Palchuk MB.. Using a federated network of real-world data to optimize clinical trials operations. JCO Clin Cancer Inform 2018; 2 (2): 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6816049</ArticleId><ArticleId IdType="pubmed">30652541</ArticleId></ArticleIdList></Reference><Reference><Citation>Brat GA, Weber GM, Gehlenborg N, et al.International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. npj Digit Med 2020; 3: 109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Carton TW, Marsolo K, Block JP.. PCORnet COVID-19 common data model design and results. Zenodo 2020. Jun 16; doi: 10.5281/zenodo.3897398.</Citation></Reference><Reference><Citation>Rajkomar A, Dean J, Kohane I.. Machine learning in medicine. N Engl J Med 2019; 380 (14): 1347&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">30943338</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu K-H, Beam AL, Kohane IS.. Artificial intelligence in healthcare. Nat Biomed Eng 2018; 2 (10): 719&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">31015651</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer WG, Perentesis G, Affrime MB, et al.Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers. Am J Cardiol 1989; 63 (19): 7I&#x2013;11I.</Citation><ArticleIdList><ArticleId IdType="pubmed">2729127</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeyer Z, Emanuel EJ.. Predicting the future&#x2014;big data, machine learning, and clinical medicine. N Engl J Med 2016; 375 (13): 1216&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070532</ArticleId><ArticleId IdType="pubmed">27682033</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhao Y, Therneau TM, et al.Unsupervised machine learning for the discovery of latent disease clusters and patient subgroups using electronic health records. J Biomed Inform 2020; 102: 103364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028517</ArticleId><ArticleId IdType="pubmed">31891765</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Sahu AK, Talwalkar A, et al.Federated learning: challenges, methods, and future directions. IEEE Signal Process Mag 2020; 37 (3): 50&#x2013;60.</Citation></Reference><Reference><Citation>Zerka F, Barakat S, Walsh S, et al.Systematic review of privacy-preserving distributed machine learning from federated databases in health care. JCO Clin Cancer Inform 2020; 4 (4): 184&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113079</ArticleId><ArticleId IdType="pubmed">32134684</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Qi J, et al.Federated machine learning: concept and applications. ACM Trans Intell Syst Technol 2019; 10 (6): 1&#x2013;19.</Citation></Reference><Reference><Citation>Brisimi TS, Chen R, Mela T, et al.Federated learning of predictive models from federated Electronic Health Records. Int J Med Inform 2018; 112: 59&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5836813</ArticleId><ArticleId IdType="pubmed">29500022</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020 May 22; doi: 10.1016/S0140-6736(20)31180-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255293</ArticleId><ArticleId IdType="pubmed">32450107</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehra MR, Desai SS, Kuy S, et al.Retraction: cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020; 382 (25): e102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206931</ArticleId><ArticleId IdType="pubmed">32356626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson MD, Dumontier M, Aalbersberg IJJ, et al.The FAIR Guiding Principles for scientific data management and stewardship. Sci Data 2016; 3 (1): 160018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4792175</ArticleId><ArticleId IdType="pubmed">26978244</ArticleId></ArticleIdList></Reference><Reference><Citation>CTSA Program Hubs. National Center for Advancing Translational Sciences. 2015. https://ncats.nih.gov/ctsa/about/hubs Accessed June 13, 2020.</Citation></Reference><Reference><Citation>
Phenotype_Data_Acquisition. GitHub https://github.com/National-COVID-Cohort-Collaborative/Phenotype_Data_Acquisition Accessed June 20, 2020.</Citation></Reference><Reference><Citation>National Center for Advancing Translational Sciences. https://ncats.nih.gov/ Accessed June 7, 2020.</Citation></Reference><Reference><Citation>CD2H. https://ctsa.ncats.nih.gov/cd2h/ Accessed June 7, 2020.</Citation></Reference><Reference><Citation>All of Us Research Hub. https://www.researchallofus.org/ Accessed June 18, 2020.</Citation></Reference><Reference><Citation>Human Tumor Atlas Network. https://humantumoratlas.org/ Accessed June 18, 2020.</Citation></Reference><Reference><Citation>Grayson S, Suver C, Wilbanks J, et al. Open Data Sharing in the 21st Century: Sage Bionetworks&#x2019; Qualified Research Program and Its Application in mHealth Data Release. SSRN2019. Jan 19 [E-pub ahead of print]. doi: 10.2139/ssrn.3502410.</Citation></Reference><Reference><Citation>Global Alliance for Genomics and Health. Regulatory &amp; Ethics Toolkit. https://www.ga4gh.org/genomic-data-toolkit/regulatory-ethics-toolkit/ Accessed June 18, 2020.</Citation></Reference><Reference><Citation>Data Access Compliance Office. https://icgc.org/daco Accessed June 18, 2020.</Citation></Reference><Reference><Citation>i2b2: Informatics for Integrating Biology and the Bedside. https://www.i2b2.org/ Accessed June 18, 2020.</Citation></Reference><Reference><Citation>US Code of Federal Regulations. govinfo&#xa0;. https://www.govinfo.gov/app/details/CFR-2011-title45-vol1/CFR-2011-title45-vol1-part164 Accessed June 7, 2020.</Citation></Reference><Reference><Citation>HIPAA Privacy Rule and Its Impacts on Research. https://privacyruleandresearch.nih.gov/pr_08.asp Accessed June 18, 2020.</Citation></Reference><Reference><Citation>Raab GM, Nowok B, Dibben C. Guidelines for Producing Useful Synthetic Data. arXiv: 1712.04078; 2017.</Citation></Reference><Reference><Citation>Snoke J, Raab GM, Nowok B, et al.General and specific utility measures for synthetic data. J R Stat Soc A 2018; 181 (3): 663&#x2013;88.</Citation></Reference><Reference><Citation>Office for Civil Rights. Methods for De-identification of PHI. 2015. https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-identification/index.html Accessed June 20, 2020.</Citation></Reference><Reference><Citation>Certificates of Confidentiality (CoC)&#x2014;Human Subjects. https://grants.nih.gov/policy/humansubjects/coc.htm Accessed June 15, 2020.</Citation></Reference><Reference><Citation>Office for Human Research Protections. 
The Revised Common Rule&#x2019;s Cooperative Research Provision (45 CFR 46.114). 2019. https://www.hhs.gov/ohrp/regulations-and-policy/single-irb-requirement/index.html Accessed June 20, 2020.</Citation></Reference><Reference><Citation>SMART IRB. National IRB Reliance Initiative. https://smartirb.org/ Accessed April 14, 2020.</Citation></Reference><Reference><Citation>Sprague ER. ORCID. J Med Libr Assoc 2017; 105: 207.</Citation></Reference><Reference><Citation>Haendel M, Su A, McMurry J.. FAIR-TLC: Metrics to Assess Value of Biomedical Digital Repositories: Response to RFI NOT-OD-16-133. Zenodo2016. Dec 15; doi: 10.5281/zenodo.203295.</Citation></Reference><Reference><Citation>Welcome to the Contributor Attribution Model&#x2014;Contributor Attribution Model Documentation. https://contributor-attribution-model.readthedocs.io/en/latest/ Accessed June 20, 2020.</Citation></Reference><Reference><Citation>Katz DS, Smith AM. Transitive credit and JSON-LD J Open Res Soft 2015; 3: 14.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. ICD-10-CM Official Coding Guidelines&#x2014;Supplement Coding Encounters Related to COVID-19 Coronavirus Outbreak. 2020. https://cdc.gov/nchs/data/icd/interim-coding-advice-coronavirus-March-2020-final.pdf Accessed June 7, 2020.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. ICD-10-CM Official Coding and Reporting Guidelines April 1, 2020 through September 30, 2020. 2020. https://www.cdc.gov/nchs/data/icd/COVID-19-guidelines-final.pdf Accessed June 7, 2020.</Citation></Reference><Reference><Citation>PCORnet. COVID-19 Common Data Model Launched, Enabling Rapid Capture of Insights on Patients Infected with the Novel Coronavirus. 2020. https://pcornet.org/news/pcornet-covid-19-common-data-model-launched-enabling-rapid-capture-of-insights/ Accessed June 8, 2020.</Citation></Reference><Reference><Citation>Burn E, You SC, Sena AG, et al. An international characterisation of patients hospitalised with COVID-19 and a comparison with those previously hospitalised with influenza. medRxiv2020. doi: 10.1101/2020.04.22.20074336.</Citation></Reference><Reference><Citation>SARS-CoV-2 and COVID-19 Related LOINC Terms&#x2014;LOINC. LOINC. https://loinc.org/sars-cov-2-and-covid-19/ Accessed June 8, 2020.</Citation></Reference><Reference><Citation>National COVID Cohort Collaborative. GitHub. https://github.com/National-COVID-Cohort-Collaborative Accessed June 14, 2020.</Citation></Reference><Reference><Citation>Weber GM, Murphy SN, McMurry AJ, et al.The Shared Health Research Information Network (SHRINE): a prototype federated query tool for clinical data repositories. J Am Med Inform Assoc 2009; 16 (5): 624&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744712</ArticleId><ArticleId IdType="pubmed">19567788</ArticleId></ArticleIdList></Reference><Reference><Citation>Patient-Centered Outcomes Research Institute (PCORI). https://www.pcori.org/ Accessed April 12, 2020.</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. https://ohdsi.org/ Accessed April 12, 2020.</Citation></Reference><Reference><Citation>TriNetX. https://www.trinetx.com/ Accessed April 12, 2020.</Citation></Reference><Reference><Citation>PCORnet. PCORnet Common Data Model v5.1 Specification. 2019. https://pcornet.org/wp-content/uploads/2019/09/PCORnet-Common-Data-Model-v51-2019_09_12.pdf Accessed June 7, 2020.</Citation></Reference><Reference><Citation>University of Pittsburgh. Box. https://pitt.app.box.com/s/qoj5afssw4oz3v27ipmfidhitmgya9nt Accessed June 21, 2020.</Citation></Reference><Reference><Citation>
CommonDataModel. GitHub https://github.com/OHDSI/CommonDataModel Accessed June 21, 2020.</Citation></Reference><Reference><Citation>Chute CG. Clinical classification and terminology: some history and current observations. J Am Med Inform Assoc 2000; 7 (3): 298&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61433</ArticleId><ArticleId IdType="pubmed">10833167</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Robinson PN.. Classification, ontology, and precision medicine. N Engl J Med 2018; 379 (15): 1452&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6503847</ArticleId><ArticleId IdType="pubmed">30304648</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Level 7 (HL7). Fast Healthcare Interoperability Resources (FHIR). https://www.hl7.org/fhir/ Accessed May 21, 2020.</Citation></Reference><Reference><Citation>Chute CG, Huff SM.. The pluripotent rendering of clinical data for precision medicine. Stud Health Technol Inform 2017; 245: 337&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295111</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Data to Health (CD2H). https://ctsa.ncats.nih.gov/cd2h/ Accessed April 12, 2020.</Citation></Reference><Reference><Citation>Health Level 7 (HL7). Vulcan Accelerator Home&#x2014;Vulcan Accelerator&#x2014;Confluence. https://confluence.hl7.org/display/VA/Vulcan+Accelerator+Home Accessed May 21, 2020.</Citation></Reference><Reference><Citation>CDM v5.3.1. https://ohdsi.github.io/CommonDataModel/cdm531.html Accessed June 21, 2020.</Citation></Reference><Reference><Citation>Kahn MG, Batson D, Schilling LM.. Data model considerations for clinical effectiveness researchers. Med Care 2012; 50: S60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824370</ArticleId><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunyemi OI, Meeker D, Kim H-E, et al.Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems. Med Care 2013; 51 (8 Suppl 3): S45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774519</ArticleId></ArticleIdList></Reference><Reference><Citation>HHS Office of the National Coordinator. Common Data Model Harmonization | HealthIT.gov. https://www.healthit.gov/topic/scientific-initiatives/pcor/common-data-model-harmonization-cdm Accessed June 7, 2020.</Citation></Reference><Reference><Citation>CDISC. BRIDG. https://www.cdisc.org/standards/domain-information-module/bridg Accessed April 13, 2020.</Citation></Reference><Reference><Citation>Data-Ingestion-and-Harmonization. GitHub https://github.com/National-COVID-Cohort-Collaborative/Data-Ingestion-and-Harmonization Accessed June 14, 2020.</Citation></Reference><Reference><Citation>
Banga J, Tyagi MR, Hans S. B2B Integration Platform for Next-gen Business Connectivity | Adeptia. https://adeptia.com/ Accessed April 13, 2020.</Citation></Reference><Reference><Citation>Kahn MG, Brown JS, Chun AT, et al.Transparent reporting of data quality in distributed data networks. EGEMS (Wash DC) 2015; 3 (1): 1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4434997</ArticleId><ArticleId IdType="pubmed">25992385</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare R, Utidjian L, Ruth BJ, et al.A longitudinal analysis of data quality in a large pediatric data research network. J Am Med Inform Assoc 2017; 24 (6): 1072&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6259665</ArticleId><ArticleId IdType="pubmed">28398525</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Hripcsak G, Swaminathan S, et al.Defining and measuring completeness of electronic health records for secondary use. J Biomed Inform 2013; 46 (5): 830&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3810243</ArticleId><ArticleId IdType="pubmed">23820016</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Weng C.. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. J Am Med Inform Assoc 2013; 20 (1): 144&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Zozus M. The Data Book: Collection and Management of Research Data. Boca Raton, FL: CRC Press; 2017.</Citation></Reference><Reference><Citation>Kahn MG, Eliason BB, Bathurst J.. Quantifying clinical data quality using relative gold standards. AMIA Annu Symp Proc 2010; 2010: 356&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041459</ArticleId><ArticleId IdType="pubmed">21347000</ArticleId></ArticleIdList></Reference><Reference><Citation>Execute and View Data Quality Checks on OMOP CDM Database. https://ohdsi.github.io/DataQualityDashboard/ Accessed June 20, 2020.</Citation></Reference><Reference><Citation>PCORnet: The National Patient-Centered Clinical Research Network. PCORnet Data Checks v8. The National Patient-Centered Clinical Research Network. 2020. https://pcornet.org/wp-content/uploads/2020/03/PCORnet-Data-Checks-v8.pdf Accessed June 20, 2020.</Citation></Reference><Reference><Citation>Wikipedia Contributors. Smoke Testing (software). Wikipedia, the Free Encyclopedia. 2020. https://en.wikipedia.org/w/index.php?title=Smoke_testing_(software)&amp;oldid=962025059 Accessed July 12, 2020.</Citation></Reference><Reference><Citation>Hans S. Adeptia. Explore B2B Process Automation Solutions for Integration Needs. https://adeptia.com/solutions/b2b-process-automation Accessed June 20, 2020.</Citation></Reference><Reference><Citation>ETL Data Integration Software for Connecting Business Data. https://adeptia.com/products/etl-data-integration Accessed June 20, 2020.</Citation></Reference><Reference><Citation>ATLAS. https://atlas.ohdsi.org/#/home Accessed June 20, 2020.</Citation></Reference><Reference><Citation>Creates Descriptive Statistics Summary for an Entire OMOP CDM Instance. https://ohdsi.github.io/Achilles/ Accessed June 20, 2020.</Citation></Reference><Reference><Citation>Eagleton MJ, Kashyap VS.. Introduction. J Vasc Surg 2020; 72 (1): e4&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7295701</ArticleId><ArticleId IdType="pubmed">32553410</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X, Li J, Soysal E.. COVID-19 TestNorm&#x2014;a tool to normalize COVID-19 testing names to LOINC codes. J Am Med Inform Assoc 2020; 27 (9): 1437&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337837</ArticleId><ArticleId IdType="pubmed">32569358</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane J, Schur C.. Balancing access to health data and privacy: a review of the issues and approaches for the future. Health Serv Res 2010; 45 (5p2): 1456&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965886</ArticleId><ArticleId IdType="pubmed">21054366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, et al.Facilitating phenotype transfer using a common data model. J Biomed Inform 2019; 96: 103253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Hripcsak G, Ryan PB.. PheValuator: development and evaluation of a phenotype algorithm evaluator. J Biomed Inform 2019; 97: 103258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736922</ArticleId><ArticleId IdType="pubmed">31369862</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Schuemie MJ, Suchard MA, et al.Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. J Am Med Inform Assoc 2018; 25 (8): 969&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Cepede MS, Suchard MA, et al.How confident are we about observational findings in health care: a benchmark study. Harv Data Sci Rev 2020; 2 (1); doi: 10.1162/99608f92.147cc28e</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, et al.Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci 2018; 376:20170356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, et al.Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci U S A 2018; 115 (11): 2571&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang XA, Yates A, Vasilevsky N, et al.Semantic integration of clinical laboratory tests from electronic health records for deep phenotyping and biomarker discovery. NPJ Digit Med 2019; 2:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6527418</ArticleId><ArticleId IdType="pubmed">31119199</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomedical Data Translator Consortium. Toward a universal biomedical data translator. Clin Transl Sci 2019; 12: 86&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6440568</ArticleId><ArticleId IdType="pubmed">30412337</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomedical Data Translator Consortium. The biomedical data translator program: conception, culture, and community. Clin Transl Sci 2019; 12(2): 91&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6440573</ArticleId><ArticleId IdType="pubmed">30412340</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin CP, Colvis CM, Southall NT.. Deconstructing the translational tower of babel. Clin Transl Sci 2019; 12 (2): 85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6440561</ArticleId><ArticleId IdType="pubmed">30412342</ArticleId></ArticleIdList></Reference><Reference><Citation>Biolink Model. https://biolink.github.io/biolink-model Accessed June 21, 2020.</Citation></Reference><Reference><Citation>
kg-covid-19. GitHub. https://github.com/Knowledge-Graph-Hub/kg-covid-19 Accessed June 20, 2020.</Citation></Reference><Reference><Citation>Dobbins NJ, Spital CH, Black RA, et al.Leaf: an open-source, model-agnostic, data-driven web application for cohort discovery and translational biomedical research. J Am Med Inform Assoc 2020; 27 (1): 109&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6913227</ArticleId><ArticleId IdType="pubmed">31592524</ArticleId></ArticleIdList></Reference><Reference><Citation>FedRAMP.gov. https://www.fedramp.gov/ Accessed June 21, 2020.</Citation></Reference><Reference><Citation>Brito JJ, Li J, Moore JH, et al.Recommendations to enhance rigor and reproducibility in biomedical research. GigaScience 2020; 9 (6): giaa056</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7263079</ArticleId><ArticleId IdType="pubmed">32479592</ArticleId></ArticleIdList></Reference><Reference><Citation>Walonoski J, Kramer M, Nichols J, et al.Synthea: an approach, method, and software mechanism for generating synthetic patients and the synthetic electronic health care record. J Am Med Inform Assoc 2018; 25 (3): 230&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7651916</ArticleId><ArticleId IdType="pubmed">29025144</ArticleId></ArticleIdList></Reference><Reference><Citation>Baowaly MK, Lin C-C, Liu C-L, et al.Synthesizing electronic health records using improved generative adversarial networks. J Am Med Inform Assoc 2019; 26 (3): 228&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647178</ArticleId><ArticleId IdType="pubmed">30535151</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Chun D, Patel M, et al.The validity of synthetic clinical data: a validation study of a leading synthetic data generator (Synthea) using clinical quality measures. BMC Med Inform Decis Mak 2019; 19 (1): 44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416981</ArticleId><ArticleId IdType="pubmed">30871520</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hayes J, Melis L, Danezis G, et al. LOGAN: membership inference attacks against generative models. arXiv: 1705.07663; 2017.</Citation></Reference><Reference><Citation>Erez L. Computer system of computer servers and dedicated computer clients specially programmed to generate synthetic non-reversible electronic data records based on real-time electronic querying and methods of use thereof. U.S. Patent 10,235,537. 2019. https://patents.google.com/patent/US10235537B2/en Accessed June 7, 2020.</Citation></Reference><Reference><Citation>Foraker R, Mann DL, Payne PRO.. Are synthetic data derivatives the future of translational medicine? J Am Coll Cardio Basic Trans Sci 2018; 3 (5): 716&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234614</ArticleId><ArticleId IdType="pubmed">30456342</ArticleId></ArticleIdList></Reference><Reference><Citation>Head ML, Holman L, Lanfear R, et al.The extent and consequences of p-hacking in science. PLoS Biol 2015; 13 (3): e1002106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4359000</ArticleId><ArticleId IdType="pubmed">25768323</ArticleId></ArticleIdList></Reference><Reference><Citation>Shickel B, Tighe PJ, Bihorac A, et al.Deep EHR: a survey of recent advances in deep learning techniques for electronic health record (EHR) analysis. IEEE J Biomed Health Inform 2018; 22 (5): 1589&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6043423</ArticleId><ArticleId IdType="pubmed">29989977</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, Wang F, Szolovits P.. Tensor factorization toward precision medicine. Brief Bioinform 2017; 18 (3): 511&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6078180</ArticleId><ArticleId IdType="pubmed">26994614</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AE, Ranard BL, Wei Y, et al.Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure. JAMA Intern Med 2020 Jun 17 [E-pub ahead of print]; doi: 10.1001/jamainternmed.2020.3030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301298</ArticleId><ArticleId IdType="pubmed">32584946</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, et al.COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395 (10229): 1033&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Suo Q, Ma F, Yuan Y, et al.Deep patient similarity learning for personalized healthcare. IEEE Trans Nanobiosci 2018; 17 (3): 219&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">29994534</ArticleId></ArticleIdList></Reference><Reference><Citation>Belhadjer Z, M&#xe9;ot M, Bajolle F, et al.Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020; 142: 429&#x2013;36. doi: 10.1161/CIRCULATIONAHA.120.048360.</Citation><ArticleIdList><ArticleId IdType="pubmed">32418446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KJ, Rosenthal GE, Murphy SN, et al.External validation of an algorithm to identify patients with high data-completeness in electronic health records for comparative effectiveness research. Clin Epidemiol 2020; 12: 133&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7007793</ArticleId><ArticleId IdType="pubmed">32099479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharrazi H, Lasser EC, Yasnoff WA, et al.A proposed national research and development agenda for population health informatics: summary recommendations from a national expert workshop. J Am Med Inform Assoc 2017; 24 (1): 2&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5201177</ArticleId><ArticleId IdType="pubmed">27018264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharrazi H, Chi W, Chang H-Y, et al.Comparing population-based risk-stratification model performance using demographic, diagnosis and medication data extracted from outpatient electronic health records versus administrative claims. Med Care 2017; 55 (8): 789&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28598890</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DR, Cooper LA.. COVID-19 and health equity-a new kind of &#x2018;herd immunity&#x2019;. JAMA 2020; 323 (24): 2478.</Citation><ArticleIdList><ArticleId IdType="pubmed">32391852</ArticleId></ArticleIdList></Reference><Reference><Citation>Glover RE, van Schalkwyk MC, Akl EA, et al.A framework for identifying and mitigating the equity harms of COVID-19 policy interventions. J Clin Epidemiol 2020; 128: 35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280094</ArticleId><ArticleId IdType="pubmed">32526461</ArticleId></ArticleIdList></Reference><Reference><Citation>Price-Haywood EG, Burton J, Fort D, et al.Hospitalization and mortality among Black patients and White patients with Covid-19. N Engl J Med 2020; 382 (26): 2534&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269015</ArticleId><ArticleId IdType="pubmed">32459916</ArticleId></ArticleIdList></Reference><Reference><Citation>Millett GA, Jones AT, Benkeser D, et al.Assessing differential impacts of COVID-19 on Black communities. Ann Epidemiol 2020; 47: 37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224670</ArticleId><ArticleId IdType="pubmed">32419766</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamache R, Kharrazi H, Weiner JP.. Public and population health informatics: the bridging of big data to benefit communities. Yearb Med Inform 2018; 27 (1): 199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6115205</ArticleId><ArticleId IdType="pubmed">30157524</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeyer Z, Powers B, Vogeli C, et al.Dissecting racial bias in an algorithm used to manage the health of populations. Science 2019; 366 (6464): 447&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">31649194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimino JJ, Ayres EJ, Remennik L, et al.The National Institutes of Health&#x2019;s Biomedical Translational Research Information System (BTRIS): design, contents, functionality and experience to date. J Biomed Inform 2014; 52: 11&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026354</ArticleId><ArticleId IdType="pubmed">24262893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh WR, Weiner MG, Embi PJ, et al.Caveats for the use of operational electronic health record data in comparative effectiveness research. Med Care 2013; 51 (8 Suppl 3): S30&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748381</ArticleId><ArticleId IdType="pubmed">23774517</ArticleId></ArticleIdList></Reference><Reference><Citation>Hersh W, Cimino J, Payne PRO, et al.Recommendations for the use of operational electronic health record data in comparative effectiveness research. EGEMS (Wash DC) 2013; 1 (1): 1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371471</ArticleId><ArticleId IdType="pubmed">25848563</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBL-EBI Launches COVID-19 Data Portal. https://www.ebi.ac.uk/about/news/press-releases/embl-ebi-launches-covid-19-data-portal Accessed June 21, 2020.</Citation></Reference><Reference><Citation>ELIXIR Support to COVID-19 Research | ELIXIR. https://elixir-europe.org/services/covid-19 Accessed June 21, 2020.</Citation></Reference><Reference><Citation>Chute CG. National COVID Cohort Collaborative (N3C) institutional review board protocol. Zenodo 2020. Apr 22. doi: 10.5281/zenodo.3902948.</Citation></Reference><Reference><Citation>N3C Consortium. Attribution and Publication Principles for N3C (National Covid Cohort Collaborative). Zenodo 2020 August 25; doi: 10.5281/zenodo.3992394.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32819037</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2093-3681</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Healthcare informatics research</Title><ISOAbbreviation>Healthc Inform Res</ISOAbbreviation></Journal><ArticleTitle>Toolkit to Compute Time-Based Elixhauser Comorbidity Indices and Extension to Common Data Models.</ArticleTitle><Pagination><StartPage>193</StartPage><EndPage>200</EndPage><MedlinePgn>193-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4258/hir.2020.26.3.193</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The time-dependent study of comorbidities provides insight into disease progression and trajectory. We hypothesize that understanding longitudinal disease characteristics can lead to more timely intervention and improve clinical outcomes. As a first step, we developed an efficient and easy-to-install toolkit, the Time-based Elixhauser Comorbidity Index (TECI), which pre-calculates time-based Elixhauser comorbidities and can be extended to common data models (CDMs).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A Structured Query Language (SQL)-based toolkit, TECI, was built to pre-calculate time-specific Elixhauser comorbidity indices using data from a clinical data repository (CDR). Then it was extended to the Informatics for Integrating Biology and the Bedside (I2B2) and Observational Medical Outcomes Partnership (OMOP) CDMs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At the University of Arkansas for Medical Sciences (UAMS), the TECI toolkit was successfully installed to compute the indices from CDR data, and the scores were integrated into the I2B2 and OMOP CDMs. Comorbidity scores calculated by TECI were validated against: scores available in the 2015 quarter 1-3 Nationwide Readmissions Database (NRD) and scores calculated using the comorbidities using a previously validated algorithm on the 2015 quarter 4 NRD. Furthermore, TECI identified 18,846 UAMS patients that had changes in comorbidity scores over time (year 2013 to 2019). Comorbidities for a random sample of patients were independently reviewed, and in all cases, the results were found to be 100% accurate.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">TECI facilitates the study of comorbidities within a time-dependent context, allowing better understanding of disease associations and trajectories, which has the potential to improve clinical outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Syed</LastName><ForeName>Shorabuddin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baghal</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prior</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zozus</LastName><ForeName>Meredith</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Shukri</LastName><ForeName>Shaymaa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syeda</LastName><ForeName>Hafsa Bareen</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garza</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Begum</LastName><ForeName>Salma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Information Technology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gates</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syed</LastName><ForeName>Mahanazuddin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sexton</LastName><ForeName>Kevin W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy and Management, University of Arkansas for Medical Sciences, Little Rock, AR, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TR003107</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Healthc Inform Res</MedlineTA><NlmUniqueID>101534553</NlmUniqueID><ISSNLinking>2093-3681</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Comorbidity</Keyword><Keyword MajorTopicYN="N">Data Warehouse</Keyword><Keyword MajorTopicYN="N">Multimorbidity</Keyword><Keyword MajorTopicYN="N">Quality of Care</Keyword><Keyword MajorTopicYN="N">Retrospective Studies</Keyword><Keyword MajorTopicYN="N">Risk Adjustment</Keyword><Keyword MajorTopicYN="N">Risk Assessments</Keyword></KeywordList><CoiStatement><b>Conflict of Interest</b>. No potential conflict of interest relevant to this article was reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32819037</ArticleId><ArticleId IdType="pmc">PMC7438698</ArticleId><ArticleId IdType="doi">10.4258/hir.2020.26.3.193</ArticleId><ArticleId IdType="pii">hir.2020.26.3.193</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009;7(4):357&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2713155</ArticleId><ArticleId IdType="pubmed">19597174</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein RH, Dexter F. Development and validation of a structured query language implementation of the Elixhauser comorbidity index. J Am Med Inform Assoc. 2017;24(4):845&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7651966</ArticleId><ArticleId IdType="pubmed">28339644</ArticleId></ArticleIdList></Reference><Reference><Citation>Kattoor AJ, Pothineni NV, Goel A, Syed M, Syed S, Paydak H, et al. Prescription patterns and outcomes of patients with atrial fibrillation treated with direct oral anticoagulants and warfarin: a real-world analysis. J Cardiovasc Pharmacol Ther. 2019;24:428&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">31035795</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinker A.  How to improve patient outcomes for chronic diseases and comorbidities [Internet] Salt Lake City (UT): HealthCatalyst; 2017.  [cited at 2020 Apr 15]. Available from:  http://www.healthcatalyst.com/wp-content/uploads/2014/04/How-to-Improve-Patient-Outcomes.pdf.</Citation></Reference><Reference><Citation>Zulman DM, Asch SM, Martins SB, Kerr EA, Hoffman BB, Goldstein MK. Quality of care for patients with multiple chronic conditions: the role of comorbidity interrelatedness. J Gen Intern Med. 2014;29(3):529&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3930789</ArticleId><ArticleId IdType="pubmed">24081443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12418941</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraccaro P, Kontopantelis E, Sperrin M, Peek N, Mallen C, Urban P, et al. Predicting mortality from changeover-time in the Charlson Comorbidity Index: a retrospective cohort study in a data-intensive UK health system. Medicine (Baltimore) 2016;95(43):e4973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5089087</ArticleId><ArticleId IdType="pubmed">27787358</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoula A, Gutierrez-Sacristan A, Bravo A, Sanz F, Furlong LI. Identifying temporal patterns in patient disease trajectories using dynamic time warping: a population-based study. Sci Rep. 2018;8(1):4216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5844976</ArticleId><ArticleId IdType="pubmed">29523868</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen AB, Moseley PL, Oprea TI, Ellesoe SG, Eriksson R, Schmock H, et al. Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nat Commun. 2014;5:4022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090719</ArticleId><ArticleId IdType="pubmed">24959948</ArticleId></ArticleIdList></Reference><Reference><Citation>McPhail SM. Multimorbidity in chronic disease: impact on health care resources and costs. Risk Manag Healthc Policy. 2016;9:143&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4939994</ArticleId><ArticleId IdType="pubmed">27462182</ArticleId></ArticleIdList></Reference><Reference><Citation>Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">9431328</ArticleId></ArticleIdList></Reference><Reference><Citation>Menendez ME, Neuhaus V, van Dijk CN, Ring D. The Elixhauser comorbidity method outperforms the Charlson index in predicting inpatient death after orthopaedic surgery. Clin Orthop Relat Res. 2014;472(9):2878&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117875</ArticleId><ArticleId IdType="pubmed">24867450</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47(6):626&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433995</ArticleId></ArticleIdList></Reference><Reference><Citation>Healthcare Cost and Utilization Project. Creation of Elixhauser comorbidity variables (ICD-10-CM Elixhauser comorbidity software, version 2020. 1) [Internet] Rockville (MD): Healthcare Cost and Utilization Project; 2019.  [cited at 2020 Apr 15]. Available from:  https://www.hcup-us.ahrq.gov/toolssoftware/comorbidityicd10/comoanaly_icd10cm_2020_1.txt.</Citation></Reference><Reference><Citation>Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality [Internet] Rockville (MD): Healthcare Cost and Utilization Project; 2019. Nationwide HCUP databases [Internet] [cited at 2020 Apr 15]. Available from:  https://www.hcup-us.ahrq.gov/databases.jsp.</Citation></Reference><Reference><Citation>Wang CY, Baldwin LM, Saver BG, Dobie SA, Green PK, Cai Y, et al. The contribution of longitudinal comorbidity measurements to survival analysis. Med Care. 2009;47(7):813&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2701975</ArticleId><ArticleId IdType="pubmed">19536031</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C, Ellis JL, Steiner JF, Shoup JA, McQuillan DB, Bayliss EA. Assessment of morbidity over time in predicting health outcomes. Med Care. 2014 Mar;52(Suppl 3):S52&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">24561759</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss VY, Jones PW, Kadam UT, Jordan KP. Distinct trajectories of multimorbidity in primary care were identified using latent class growth analysis. J Clin Epidemiol. 2014;67(10):1163&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4165436</ArticleId><ArticleId IdType="pubmed">25063556</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus MN. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann JG, Phillips LC, Herrick C, Joss MA, Wagholikar KB, Murphy SN. Web services for data warehouses: OMOP and PCORnet on i2b2. J Am Med Inform Assoc. 2018;25(10):1331&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6188504</ArticleId><ArticleId IdType="pubmed">30085008</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann JG, Joss MAH, Embree K, Murphy SN. Data model harmonization for the All Of Us Research Program: transforming i2b2 data into the OMOP common data model. PLoS One. 2019;14(2):e0212463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16224307</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann JG, Abend A, Raghavan VA, Mandl KD, Murphy SN. Data interchange using i2b2. J Am Med Inform Assoc. 2016;23(5):909&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997035</ArticleId><ArticleId IdType="pubmed">26911824</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ryan P, Belenkaya R, Natarajan K, Blacketer C.  OMOP Common Data Model v6.0 Specifications [Internet] [place unknown]: Github.com; 2018.  [cited at 2020 Apr 15]. Available from:  https://github.com/OHDSI/CommonDataModel/wiki.</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. Athena standardized vocabularies [Internet] Bethesda (MD): Observational Health Data Sciences and Informatics; 2018.  [cited at 2020 Apr 15]. Available from:  http://athena.ohdsi.org/search-terms/terms?conceptClass=Staging+%2F+Scales&amp;page=1&amp;pageSize=15&amp;query=comorbid.</Citation></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the premier perspective hospital database into the Observational Medical Outcomes Partnership (OMOP) common data model. EGEMS (Wash DC) 2014;2(1):1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Healthcare Cost and Utilization Project. NRD file specifications-2013 [Internet] Rockville (MD): Healthcare Cost and Utilization Project; 2015.  [cited at 2020 Apr 15]. Available from:  https://www.hcup-us.ahrq.gov/db/nation/nrd/nrdfilespecs.jsp.</Citation></Reference><Reference><Citation>Healthcare Cost and Utilization Project. NRD file specifications-2015 [Internet] Rockville (MD): Healthcare Cost and Utilization Project; 2015.  [cited at 2020 Apr 15]. Available from:  https://www.hcup-us.ahrq.gov/db/nation/nrd/nrdfilespecs.jsp.</Citation></Reference><Reference><Citation>Duncan I, Ahmed T, Dove H, Maxwell TL. Medicare cost at end of life. Am J Hosp Palliat Care. 2019;36(8):705&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6610551</ArticleId><ArticleId IdType="pubmed">30884954</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright A, Feblowitz J, Maloney FL, Henkin S, Bates DW. Use of an electronic problem list by primary care providers and specialists. J Gen Intern Med. 2012;27(8):968&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3403130</ArticleId><ArticleId IdType="pubmed">22426706</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32823317</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2364-0502</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Yearbook of medical informatics</Title><ISOAbbreviation>Yearb Med Inform</ISOAbbreviation></Journal><ArticleTitle>Clinical Research Informatics.</ArticleTitle><Pagination><StartPage>203</StartPage><EndPage>207</EndPage><MedlinePgn>203-207</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0040-1702007</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To summarize key contributions to current research in the field of Clinical Research Informatics (CRI) and to select best papers published in 2019.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A bibliographic search using a combination of MeSH descriptors and free-text terms on CRI was performed using PubMed, followed by a double-blind review in order to select a list of candidate best papers to be then peer-reviewed by external reviewers. After peer-review ranking, a consensus meeting between the two section editors and the editorial team was organized to finally conclude on the selected three best papers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 517 papers, published in 2019, returned by the search, that were in the scope of the various areas of CRI, the full review process selected three best papers. The first best paper describes the use of a homomorphic encryption technique to enable federated analysis of real-world data while complying more easily with data protection requirements. The authors of the second best paper demonstrate the evidence value of federated data networks reporting a large real world data study related to the first line treatment for hypertension. The third best paper reports the migration of the US Food and Drug Administration (FDA) adverse event reporting system database to the OMOP common data model. This work opens the combined analysis of both spontaneous reporting system and electronic health record (EHR) data for pharmacovigilance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The most significant research efforts in the CRI field are currently focusing on real world evidence generation and especially the reuse of EHR data. With the progress achieved this year in the areas of phenotyping, data integration, semantic interoperability, and data quality assessment, real world data is becoming more accessible and reusable. High quality data sets are key assets not only for large scale observational studies or for changing the way clinical trials are conducted but also for developing or evaluating artificial intelligence algorithms guiding clinical decision for more personalized care. And lastly, security and confidentiality, ethical and regulatory issues, and more generally speaking data governance are still active research areas this year.</AbstractText><CopyrightInformation>Georg Thieme Verlag KG Stuttgart.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Daniel</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Information Technology Department, AP-HP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne University, University Paris 13, Sorbonne Paris Cit&#xe9;, INSERM UMR_S 1142, LIMICS, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Dipak</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The University of Gent, Gent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Section Editors for the IMIA Yearbook Section on Clinical Research Informatics</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Yearb Med Inform</MedlineTA><NlmUniqueID>9312666</NlmUniqueID><ISSNLinking>0943-4747</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016494" MajorTopicYN="Y">Computer Security</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068598" MajorTopicYN="N">Data Accuracy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079803" MajorTopicYN="N">Data Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32823317</ArticleId><ArticleId IdType="pmc">PMC7442510</ArticleId><ArticleId IdType="doi">10.1055/s-0040-1702007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Denaxas S, Gonzalez-Izquierdo A, Direk K, Fitzpatrick N K, Fatemifar G, Banerjee A et al.UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER. J Am Med Inform Assoc. 2019;26(12):1545&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6857510</ArticleId><ArticleId IdType="pubmed">31329239</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M A, Schuemie M J, Krumholz H M, You S C, Chen R, Pratt Net al.Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis Lancet 2019394102111816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Rosner G L. A Bayesian nonparametric causal inference model for synthesizing randomized clinical trial and real-world evidence. Stat Med. 2019;38(14):2573&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">30883861</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Ruddy K J, Hong N, Tsuji S, Wen A, Shah N D, Jiang G. ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model. J Biomed Inform. 2019;91:103119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6432939</ArticleId><ArticleId IdType="pubmed">30738946</ArticleId></ArticleIdList></Reference><Reference><Citation>Glicksberg B S, Oskotsky B, Giangreco N, Thangaraj P M, Rudrapatna V, Datta D et al.ROMOP: a light-weight R package for interfacing with OMOP-formatted electronic health record data. JAMIA Open. 2019;2(01):10&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6800657</ArticleId><ArticleId IdType="pubmed">31633087</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasser F, Kohlbacher O, Mansmann U, Bauer B, Kuhn K A.Data Integration for Future Medicine (DIFUTURE) Methods Inf Med 201857(S01):e57&#x2013;e65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6178202</ArticleId><ArticleId IdType="pubmed">30016812</ArticleId></ArticleIdList></Reference><Reference><Citation>Paddock S, Abedtash H, Zummo J, Thomas S. Proof-of-concept study: Homomorphically encrypted data can support real-time learning in personalized cancer medicine. BMC Med Inform Decis Mak. 2019;19(01):255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6894133</ArticleId><ArticleId IdType="pubmed">31801535</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Chun D, Patel M, Chiang E, James J. The validity of synthetic clinical data: a validation study of a leading synthetic data generator (Synthea) using clinical quality measures. BMC Med Inform Decis Mak. 2019;19(01):44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416981</ArticleId><ArticleId IdType="pubmed">30871520</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;ssler-Fiorenza Rose S M, Contrepois K, Moneghetti K J, Zhou W, Mishra T, Mataraso S et al.A longitudinal big data approach for precision health. Nat Med. 2019;25(05):792&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6713274</ArticleId><ArticleId IdType="pubmed">31068711</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang G, Annis I E, Elston-Lafata J, Cykert S.Applying machine learning to predict real-world individual treatment effects: insights from a virtual patient cohort J Am Med Inform Assoc 201926(10):977&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647181</ArticleId><ArticleId IdType="pubmed">31220274</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Cai T, Yu S, Cho K, Hong C, Sun J et al.High-throughput phenotyping with electronic medical record data using a common semi-supervised approach (PheCAP) Nat Protoc. 2019;14(12):3426&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323894</ArticleId><ArticleId IdType="pubmed">31748751</ArticleId></ArticleIdList></Reference><Reference><Citation>Meystre S M, Heider P M, Kim Y, Aruch D B, Britten C D. Automatic trial eligibility surveillance based on unstructured clinical data. Int J Med Inf. 2019;129:13&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717538</ArticleId><ArticleId IdType="pubmed">31445247</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller H N, Gleason K T, Juraschek S P, Plante T B, Lewis-Land C, Woods B et al.Electronic medical record-based cohort selection and direct-to-patient, targeted recruitment: early efficacy and lessons learned. J Am Med Inform Assoc. 2019;26(11):1209&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6798572</ArticleId><ArticleId IdType="pubmed">31553434</ArticleId></ArticleIdList></Reference><Reference><Citation>Claerhout B, Kalra D, Mueller C, Singh G, Ammour N, Meloni L et al.Federated electronic health records research technology to support clinical trial protocol optimization: Evidence from EHR4CR and the InSite platform. J Biomed Inform. 2019;90:103090.</Citation><ArticleIdList><ArticleId IdType="pubmed">30611012</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrigan G, Whipple S, Capra W B, Taylor M D, Brown J S, Lu M et al.Using Electronic Health Records to Derive Control Arms for Early Phase Single-Arm Lung Cancer Trials: Proof-of-Concept in Randomized Controlled Trials. Clin Pharmacol Ther. 2020;107(02):369&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7006884</ArticleId><ArticleId IdType="pubmed">31350853</ArticleId></ArticleIdList></Reference><Reference><Citation>Beier K, Schweda M, Schicktanz S. Taking patient involvement seriously: a critical ethical analysis of participatory approaches in data-intensive medical research. BMC Med Inform Decis Mak. 2019;19(01):90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482526</ArticleId><ArticleId IdType="pubmed">31023321</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32827027</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study.</ArticleTitle><Pagination><StartPage>1268</StartPage><EndPage>1277</EndPage><MedlinePgn>1268-1277</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocaa124</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To demonstrate the application of the Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND) principles described in our companion article to hypertension treatments and assess internal and external validity of the generated evidence.</AbstractText><AbstractText Label="MATERIALS AND METHODS">LEGEND defines a process for high-quality observational research based on 10 guiding principles. We demonstrate how this process, here implemented through large-scale propensity score modeling, negative and positive control questions, empirical calibration, and full transparency, can be applied to compare antihypertensive drug therapies. We assess internal validity through covariate balance, confidence-interval coverage, between-database heterogeneity, and transitivity of results. We assess external validity through comparison to direct meta-analyses of randomized controlled trials (RCTs).</AbstractText><AbstractText Label="RESULTS">From 21.6 million unique antihypertensive new users, we generate 6&#xa0;076&#xa0;775 effect size estimates for 699&#xa0;872 research questions on 12&#xa0;946 treatment comparisons. Through propensity score matching, we achieve balance on all baseline patient characteristics for 75% of estimates, observe 95.7% coverage in our effect-estimate 95% confidence intervals, find high between-database consistency, and achieve transitivity in 84.8% of triplet hypotheses. Compared with meta-analyses of RCTs, our results are consistent with 28 of 30 comparisons while providing narrower confidence intervals.</AbstractText><AbstractText Label="CONCLUSION">We find that these LEGEND results show high internal validity and are congruent with meta-analyses of RCTs. For these reasons we believe that evidence generated by LEGEND is of high quality and can inform medical decision-making where evidence is currently lacking. Subsequent publications will explore the clinical interpretations of this evidence.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>RuiJun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medical College, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterian Hospital, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomathematics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Am Med Inform Assoc. 2021 Jan 15;28(1):196</RefSource><PMID Version="1">33099616</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003195" MajorTopicYN="N">Computer Communication Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="Y">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019370" MajorTopicYN="N">Observation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">empirical calibration</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">observational studies</Keyword><Keyword MajorTopicYN="N">open science</Keyword><Keyword MajorTopicYN="N">treatment effects</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32827027</ArticleId><ArticleId IdType="pmc">PMC7481033</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocaa124</ArticleId><ArticleId IdType="pii">5895564</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hripcsak. G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N, et al. Principles of Large-Scale Evidence Generation and Evaluation across a Network of Databases (LEGEND). J&#xa0;Am Med Inform Association. 27(8):1331--1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JPA. Why Most Published Research Findings Are False. CHANCE 2019; 32: 4&#x2013;13. doi:10.1080/09332480.2019.1579573</Citation></Reference><Reference><Citation>Rush CJ, Campbell RT, Jhund PS, et al. Association is not causation: treatment effects cannot be estimated from observational data in heart failure. Eur Heart J 2018; 39: 3417&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166137</ArticleId><ArticleId IdType="pubmed">30085087</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein HC, McMurray J, Holman RR. Real-world studies no substitute for RCTs in establishing efficacy. Lancet 2019; 393: 210&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663582</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, et al. Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci 2018; 376. doi: 10.1098/rsta.2017.0356</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol 2018; 47 (6): 2005&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, et al. Empirical CI calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci USA 2018; 115 (11): 2571&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, et al. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med 2014; 33 (2): 209&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018; 138: e595&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">30354656</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71 (6): 1269&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">29133354</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams B, Mancia G, Spiering W, et al. ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 2018; 36 (10): 1953&#x2013;2041.</Citation><ArticleIdList><ArticleId IdType="pubmed">30234752</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019; 394 (10211): 1816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Suchard MA, Ryan PB. CohortMethod: New-user cohort method with large scale propensity and outcome models. 2018.&#xa0;https://ohdsi.github.io/CohortMethod/</Citation></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, et al. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul 2013; 23 (1): 1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The Central Role of the Propensity Score in Observational Studies for Causal Effects.Biometrika 1983;70:41&#x2013;55.; doi: 10.21236/ada114514.</Citation></Reference><Reference><Citation>Walker A, Lauer Patrick, et al. A tool for assessing the feasibility of comparative effectiveness research. Comparative Effect Res 2013; 3: 11&#x2013;20.</Citation></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, et al. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform 2017; 66: 72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (3): 177&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Soledad Cepede M, Suchard MA, et al. How Confident Are We about Observational Findings in Health Care: A Benchmark Study. 2.1. 2020; doi: 10.1162/99608f92.147cc28e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28 (25): 3083&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen BB. The prognostic analogue of the propensity score. Biometrika 2008; 95 (2): 481&#x2013;8.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32864472</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-6352</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>NPJ digital medicine</Title><ISOAbbreviation>NPJ Digit Med</ISOAbbreviation></Journal><ArticleTitle>International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium.</ArticleTitle><Pagination><StartPage>109</StartPage><MedlinePgn>109</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">109</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41746-020-00308-0</ELocationID><Abstract><AbstractText>We leveraged the largely untapped resource of electronic health record data to address critical clinical and epidemiological questions about Coronavirus Disease 2019 (COVID-19). To do this, we formed an international consortium (4CE) of 96 hospitals across five countries (www.covidclinical.net). Contributors utilized the Informatics for Integrating Biology and the Bedside (i2b2) or Observational Medical Outcomes Partnership (OMOP) platforms to map to a common data model. The group focused on temporal changes in key laboratory test values. Harmonized data were analyzed locally and converted to a shared aggregate form for rapid analysis and visualization of regional differences and global commonalities. Data covered 27,584 COVID-19 cases with 187,802 laboratory tests. Case counts and laboratory trajectories were concordant with existing literature. Laboratory tests at the time of diagnosis showed hospital-level differences equivalent to country-level variation across the consortium partners. Despite the limitations of decentralized data generation, we established a framework to capture the trajectory of COVID-19 disease in patients and their response to interventions.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Brat</LastName><ForeName>Gabriel A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0003-3928-5931</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Weber</LastName><ForeName>Griffin M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gehlenborg</LastName><ForeName>Nils</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avillach</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0235-7543</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Nathan P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiovato</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IRCCS ICS Maugeri, Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.</Affiliation><Identifier Source="GRID">grid.8982.b</Identifier><Identifier Source="ISNI">0000 0004 1762 5736</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cimino</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4101-1622</Identifier><AffiliationInfo><Affiliation>UAB Informatics Institute, Birmingham, AL USA.</Affiliation><Identifier Source="GRID">grid.265892.2</Identifier><Identifier Source="ISNI">0000000106344187</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waitman</LastName><ForeName>Lemuel R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Medical Informatics, University of Kansas Medical Center, Kansas City, KS USA.</Affiliation><Identifier Source="GRID">grid.412016.0</Identifier><Identifier Source="ISNI">0000 0001 2177 6375</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omenn</LastName><ForeName>Gilbert S</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0002-8976-6074</Identifier><AffiliationInfo><Affiliation>Department of Computational Medicine &amp; Bioinformatics, University of Michigan, Ann Arbor, MI USA.</Affiliation><Identifier Source="GRID">grid.214458.e</Identifier><Identifier Source="ISNI">0000000086837370</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malovini</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS ICS Maugeri, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.</Affiliation><Identifier Source="GRID">grid.25879.31</Identifier><Identifier Source="ISNI">0000 0004 1936 8972</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.</Affiliation><Identifier Source="GRID">grid.25879.31</Identifier><Identifier Source="ISNI">0000 0004 1936 8972</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beaulieu-Jones</LastName><ForeName>Brett K</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0000-0002-6700-1468</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tibollo</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>IRCCS ICS Maugeri, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Shawn N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.32224.35</Identifier><Identifier Source="ISNI">0000 0004 0386 9924</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Sehi L'</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0001-7720-2848</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellazzi</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>IRCCS ICS Maugeri, Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Electrical Computer and Biomedical Engineering, University of Pavia, Pavia, Italy.</Affiliation><Identifier Source="GRID">grid.8982.b</Identifier><Identifier Source="ISNI">0000 0004 1762 5736</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanauer</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-6931-3791</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI USA.</Affiliation><Identifier Source="GRID">grid.214458.e</Identifier><Identifier Source="ISNI">0000000086837370</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serret-Larmande</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2642-2514</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutierrez-Sacristan</LastName><ForeName>Alba</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-1245-198X</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.</Affiliation><Identifier Source="GRID">grid.25879.31</Identifier><Identifier Source="ISNI">0000 0004 1936 8972</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI USA.</Affiliation><Identifier Source="GRID">grid.214458.e</Identifier><Identifier Source="ISNI">0000000086837370</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Douglas S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0002-5063-8294</Identifier><AffiliationInfo><Affiliation>Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA USA.</Affiliation><Identifier Source="GRID">grid.19006.3e</Identifier><Identifier Source="ISNI">0000 0000 9632 6718</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandl</LastName><ForeName>Kenneth D</ForeName><Initials>KD</Initials><Identifier Source="ORCID">0000-0002-9781-0477</Identifier><AffiliationInfo><Affiliation>Computational Health Informatics Program, Boston Children's Hospital, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.2515.3</Identifier><Identifier Source="ISNI">0000 0004 0378 8438</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Follett</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-1618-2817</Identifier><AffiliationInfo><Affiliation>Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA USA.</Affiliation><Identifier Source="GRID">grid.19006.3e</Identifier><Identifier Source="ISNI">0000 0000 9632 6718</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klann</LastName><ForeName>Jeffrey G</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0003-2043-1601</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.32224.35</Identifier><Identifier Source="ISNI">0000 0004 0386 9924</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murad</LastName><ForeName>Douglas A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA USA.</Affiliation><Identifier Source="GRID">grid.19006.3e</Identifier><Identifier Source="ISNI">0000 0000 9632 6718</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scudeller</LastName><ForeName>Luigia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7240-9567</Identifier><AffiliationInfo><Affiliation>Scientific Direction, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bucalo</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0407-6120</Identifier><AffiliationInfo><Affiliation>BIOMERIS (BIOMedical Research Informatics Solutions), Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirchoff</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC USA.</Affiliation><Identifier Source="GRID">grid.259828.c</Identifier><Identifier Source="ISNI">0000 0001 2189 3475</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craig</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC USA.</Affiliation><Identifier Source="GRID">grid.259828.c</Identifier><Identifier Source="ISNI">0000 0001 2189 3475</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obeid</LastName><ForeName>Jihad</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7193-7779</Identifier><AffiliationInfo><Affiliation>Biomedical Informatics Center, Medical University of South Carolina, Charleston, SC USA.</Affiliation><Identifier Source="GRID">grid.259828.c</Identifier><Identifier Source="ISNI">0000 0001 2189 3475</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jouhet</LastName><ForeName>Vianney</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5272-2265</Identifier><AffiliationInfo><Affiliation>Bordeaux University Hospital, Bordeaux, France.</Affiliation><Identifier Source="GRID">grid.42399.35</Identifier><Identifier Source="ISNI">0000 0004 0593 7118</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffier</LastName><ForeName>Romain</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1096-137X</Identifier><AffiliationInfo><Affiliation>Bordeaux University Hospital, Bordeaux, France.</Affiliation><Identifier Source="GRID">grid.42399.35</Identifier><Identifier Source="ISNI">0000 0004 0593 7118</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cossin</LastName><ForeName>Sebastien</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3845-8127</Identifier><AffiliationInfo><Affiliation>Bordeaux University Hospital, Bordeaux, France.</Affiliation><Identifier Source="GRID">grid.42399.35</Identifier><Identifier Source="ISNI">0000 0004 0593 7118</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moal</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Bordeaux University Hospital, Bordeaux, France.</Affiliation><Identifier Source="GRID">grid.42399.35</Identifier><Identifier Source="ISNI">0000 0004 0593 7118</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Lav P</ForeName><Initials>LP</Initials><Identifier Source="ORCID">0000-0002-8626-137X</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Medical Informatics, University of Kansas Medical Center, Kansas City, KS USA.</Affiliation><Identifier Source="GRID">grid.412016.0</Identifier><Identifier Source="ISNI">0000 0001 2177 6375</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellasi</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7830-1645</Identifier><AffiliationInfo><Affiliation>UOC Ricerca, Innovazione e Brand Reputation, ASST Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prokosch</LastName><ForeName>Hans U</ForeName><Initials>HU</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, University of Erlangen-N&#xfc;rnberg, Erlangen, Germany.</Affiliation><Identifier Source="GRID">grid.5330.5</Identifier><Identifier Source="ISNI">0000 0001 2107 3311</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraska</LastName><ForeName>Detlef</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Medical Information and Communication Technology, University Hospital Erlangen, Erlangen, Germany.</Affiliation><Identifier Source="GRID">grid.411668.c</Identifier><Identifier Source="ISNI">0000 0000 9935 6525</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sliz</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6522-0835</Identifier><AffiliationInfo><Affiliation>Computational Health Informatics Program, Boston Children's Hospital, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.2515.3</Identifier><Identifier Source="ISNI">0000 0004 0378 8438</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Amelia L M</ForeName><Initials>ALM</Initials><Identifier Source="ORCID">0000-0003-0623-6623</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngiam</LastName><ForeName>Kee Yuan</ForeName><Initials>KY</Initials><Identifier Source="ORCID">0000-0001-5676-2520</Identifier><AffiliationInfo><Affiliation>National University Health Systems, Singapore, Singapore.</Affiliation><Identifier Source="GRID">grid.410759.e</Identifier><Identifier Source="ISNI">0000 0004 0451 6143</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zambelli</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology, ASST Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mowery</LastName><ForeName>Danielle L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0003-3802-4457</Identifier><AffiliationInfo><Affiliation>Institute for Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA.</Affiliation><Identifier Source="GRID">grid.25879.31</Identifier><Identifier Source="ISNI">0000 0004 1936 8972</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI USA.</Affiliation><Identifier Source="GRID">grid.214458.e</Identifier><Identifier Source="ISNI">0000000086837370</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiver</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Penn Medicine, Data Analytics Center, Philadelphia, PA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devkota</LastName><ForeName>Batsal</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA USA.</Affiliation><Identifier Source="GRID">grid.239552.a</Identifier><Identifier Source="ISNI">0000 0001 0680 8770</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradford</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials><Identifier Source="ORCID">0000-0003-0908-1428</Identifier><AffiliationInfo><Affiliation>North Carolina Translational and Clinical Sciences (NC TraCS) Institute, UNC Chapel Hill, Chapel Hill, NC USA.</Affiliation><Identifier Source="GRID">grid.10698.36</Identifier><Identifier Source="ISNI">0000000122483208</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniar</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Computational Health Informatics Program, Boston Children's Hospital, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.2515.3</Identifier><Identifier Source="ISNI">0000 0004 0378 8438</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniel</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benoit</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bey</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paris</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serre</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orlova</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubiel</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilka</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jannot</LastName><ForeName>Anne Sophie</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, HEGP, APHP Greater Paris University Hospital, Paris, France.</Affiliation><Identifier Source="GRID">grid.414093.b</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breant</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leblanc</LastName><ForeName>Judith</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0323-6671</Identifier><AffiliationInfo><Affiliation>Clinical Research Unit, Saint Antoine Hospital, APHP Greater Paris University Hospital, Paris, France.</Affiliation><Identifier Source="GRID">grid.412370.3</Identifier><Identifier Source="ISNI">0000 0004 1937 1100</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffon</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-9602-6429</Identifier><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgun</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, HEGP, APHP Greater Paris University Hospital, Paris, France.</Affiliation><Identifier Source="GRID">grid.414093.b</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernaux</LastName><ForeName>Melodie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Strategy and Transformation Department, APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandrin</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salamanca</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cormont</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>WIND Department APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganslandt</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6864-8936</Identifier><AffiliationInfo><Affiliation>Heinrich-Lanz-Center for Digital Health, University Medicine Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation><Identifier Source="GRID">grid.411778.c</Identifier><Identifier Source="ISNI">0000 0001 2162 1728</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gradinger</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8049-2900</Identifier><AffiliationInfo><Affiliation>Heinrich-Lanz-Center for Digital Health, University Medicine Mannheim, Heidelberg University, Mannheim, Germany.</Affiliation><Identifier Source="GRID">grid.411778.c</Identifier><Identifier Source="ISNI">0000 0001 2162 1728</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Champ</LastName><ForeName>Julien</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2042-0411</Identifier><AffiliationInfo><Affiliation>INRIA Sophia-Antipolis-ZENITH Team, LIRMM, Montpellier, France.</Affiliation><Identifier Source="GRID">grid.464638.b</Identifier><Identifier Source="ISNI">0000 0004 0599 0488</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeker</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2972-2042</Identifier><AffiliationInfo><Affiliation>Institute of Medical Biometry and Statistics, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany.</Affiliation><Identifier Source="GRID">grid.5963.9</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martel</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Paris Saclay, APHP Greater Paris University Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esteve</LastName><ForeName>Loic</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>SED/SIERRA, Inria Centre de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gramfort</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, Inria, CEA, Paris, France.</Affiliation><Identifier Source="GRID">grid.5583.b</Identifier><Identifier Source="ISNI">0000 0001 2299 8025</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grisel</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, Inria, CEA, Paris, France.</Affiliation><Identifier Source="GRID">grid.5583.b</Identifier><Identifier Source="ISNI">0000 0001 2299 8025</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leprovost</LastName><ForeName>Damien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clevy.io, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreau</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, Inria, CEA, Paris, France.</Affiliation><Identifier Source="GRID">grid.5583.b</Identifier><Identifier Source="ISNI">0000 0001 2299 8025</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varoquaux</LastName><ForeName>Gael</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, Inria, CEA, Paris, France.</Affiliation><Identifier Source="GRID">grid.5583.b</Identifier><Identifier Source="ISNI">0000 0001 2299 8025</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vie</LastName><ForeName>Jill-J&#xea;nn</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0002-9304-2220</Identifier><AffiliationInfo><Affiliation>SequeL, Inria Lille, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassermann</LastName><ForeName>Demian</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5194-6056</Identifier><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, Inria, CEA, Paris, France.</Affiliation><Identifier Source="GRID">grid.5583.b</Identifier><Identifier Source="ISNI">0000 0001 2299 8025</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mensch</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ENS, PSL University, Paris, France.</Affiliation><Identifier Source="GRID">grid.5607.4</Identifier><Identifier Source="ISNI">0000000121105547</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caucheteux</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, Inria, CEA, Paris, France.</Affiliation><Identifier Source="GRID">grid.5583.b</Identifier><Identifier Source="ISNI">0000 0001 2299 8025</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haverkamp</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8165-4783</Identifier><AffiliationInfo><Affiliation>Institute of Digitalization in Medicine, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany.</Affiliation><Identifier Source="GRID">grid.5963.9</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemaitre</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, Inria, CEA, Paris, France.</Affiliation><Identifier Source="GRID">grid.5583.b</Identifier><Identifier Source="ISNI">0000 0001 2299 8025</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bosari</LastName><ForeName>Silvano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krantz</LastName><ForeName>Ian D</ForeName><Initials>ID</Initials><Identifier Source="ORCID">0000-0003-2442-1128</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA USA.</Affiliation><Identifier Source="GRID">grid.239552.a</Identifier><Identifier Source="ISNI">0000 0001 0680 8770</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>South</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3204-4142</Identifier><AffiliationInfo><Affiliation>Brenner Children's Hospital, Wake Forest School of Medicine, Winston-Salem, NC USA.</Affiliation><Identifier Source="GRID">grid.241167.7</Identifier><Identifier Source="ISNI">0000 0001 2185 3318</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Tianxi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5379-2502</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohane</LastName><ForeName>Isaac S</ForeName><Initials>IS</Initials><Identifier Source="ORCID">0000-0003-2192-5160</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Harvard Medical School, Boston, MA USA.</Affiliation><Identifier Source="GRID">grid.38142.3c</Identifier><Identifier Source="ISNI">000000041936754X</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 HL148394</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013345</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HG002295</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Digit Med</MedlineTA><NlmUniqueID>101731738</NlmUniqueID><ISSNLinking>2398-6352</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Databases</Keyword><Keyword MajorTopicYN="N">Outcomes research</Keyword><Keyword MajorTopicYN="N">Viral infection</Keyword></KeywordList><CoiStatement>Competing interestsR.B. and A.M. are shareholders of Biomeris s.r.l.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32864472</ArticleId><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="doi">10.1038/s41746-020-00308-0</ArticleId><ArticleId IdType="pii">308</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019&#x2014;United States, February 12&#x2212;March 28, 2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:382&#x2013;386. doi: 10.15585/mmwr.mm6913e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6913e2</ArticleId><ArticleId IdType="pmc">PMC7119513</ArticleId><ArticleId IdType="pubmed">32240123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, A. H. Does Covid-19 hit women and men differently? U.S. isn&#x2019;t keeping track. The New York Times (April 3, 2020).</Citation></Reference><Reference><Citation>Bonow, R. O., Fonarow, G. C., O&#x2019;Gara, P. T. &amp; Yancy, C. W. Association of Coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol. 10.1001/jamacardio.2020.1105 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32219362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadpoor, P. &amp; Rostaing, L. Why the immune system fails to mount an adaptive immune response to a Covid-19 infection. Transpl. Int. 10.1111/tri.13611 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32236983</ArticleId></ArticleIdList></Reference><Reference><Citation>Thachil, J. The versatile heparin in COVID-19. J. Thromb. Haemost. 10.1111/jth.14821 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906146</ArticleId><ArticleId IdType="pubmed">32239799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, Tong Q. Rhabdomyolysis as potential late complication associated with COVID-19. Emerg. Infect. Dis. 2020;26:1618&#x2013;1620. doi: 10.3201/eid2607.200445.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2607.200445</ArticleId><ArticleId IdType="pmc">PMC7323559</ArticleId><ArticleId IdType="pubmed">32197060</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, C., Shi, L. &amp; Wang, F. S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol.10.1016/S2468-1253(20)30057-1 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30057-1</ArticleId><ArticleId IdType="pmc">PMC7129165</ArticleId><ArticleId IdType="pubmed">32145190</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan, X. W. et al. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Intensive Care Med. 10.1007/s00134-020-06026-1 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7106051</ArticleId><ArticleId IdType="pubmed">32236644</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chim. Acta. 2020;505:190&#x2013;191. doi: 10.1016/j.cca.2020.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.03.004</ArticleId><ArticleId IdType="pmc">PMC7094472</ArticleId><ArticleId IdType="pubmed">32145275</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, et al. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2) J. Am. Med. Inform. Assoc. 2010;17:124&#x2013;130. doi: 10.1136/jamia.2009.000893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.000893</ArticleId><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Sacristan A, et al. Rcupcake: an R package for querying and analyzing biomedical data through the BD2K PIC-SURE RESTful API. Bioinformatics. 2018;34:1431&#x2013;1432. doi: 10.1093/bioinformatics/btx788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btx788</ArticleId><ArticleId IdType="pmc">PMC5905576</ArticleId><ArticleId IdType="pubmed">29267850</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandl KD, et al. The Genomics Research and Innovation Network: creating an interoperable, federated, genomics learning system. Genet. Med. 2020;22:371&#x2013;380. doi: 10.1038/s41436-019-0646-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41436-019-0646-3</ArticleId><ArticleId IdType="pmc">PMC7000325</ArticleId><ArticleId IdType="pubmed">31481752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandl KD, et al. Scalable collaborative infrastructure for a learning healthcare system (SCILHS): architecture. J. Am. Med. Inform. Assoc. 2014;21:615&#x2013;620. doi: 10.1136/amiajnl-2014-002727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002727</ArticleId><ArticleId IdType="pmc">PMC4078286</ArticleId><ArticleId IdType="pubmed">24821734</ArticleId></ArticleIdList></Reference><Reference><Citation>McMurry AJ, et al. SHRINE: enabling nationally scalable multi-site disease studies. PLoS ONE. 2013;8:e55811. doi: 10.1371/journal.pone.0055811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0055811</ArticleId><ArticleId IdType="pmc">PMC3591385</ArticleId><ArticleId IdType="pubmed">23533569</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber GM, et al. The Shared Health Research Information Network (SHRINE): a prototype federated query tool for clinical data repositories. J. Am. Med. Inform. Assoc. 2009;16:624&#x2013;630. doi: 10.1197/jamia.M3191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M3191</ArticleId><ArticleId IdType="pmc">PMC2744712</ArticleId><ArticleId IdType="pubmed">19567788</ArticleId></ArticleIdList></Reference><Reference><Citation>Visweswaran S, et al. Accrual to Clinical Trials (ACT): a clinical and translational science award consortium network. JAMIA Open. 2018;1:147&#x2013;152. doi: 10.1093/jamiaopen/ooy033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooy033</ArticleId><ArticleId IdType="pmc">PMC6241502</ArticleId><ArticleId IdType="pubmed">30474072</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohane IS, Churchill SE, Murphy SN. A translational engine at the national scale: informatics for integrating biology and the bedside. J. Am. Med. Inform. Assoc. 2012;19:181&#x2013;185. doi: 10.1136/amiajnl-2011-000492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000492</ArticleId><ArticleId IdType="pmc">PMC3277623</ArticleId><ArticleId IdType="pubmed">22081225</ArticleId></ArticleIdList></Reference><Reference><Citation>Onder, G., Rezza, G. &amp; Brusaferro, S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA.10.1001/jama.2020.4683 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32203977</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong, E., Du, H. &amp; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 10.1016/S1473-3099(20)30120-1 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynants L, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ. 2020;369:m1328. doi: 10.1136/bmj.m1328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1328</ArticleId><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin. Chem. Lab. Med. (CCLM) 2020;58:1131&#x2013;1134. doi: 10.1515/cclm-2020-0198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0198</ArticleId><ArticleId IdType="pubmed">32119647</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamache RE, Dixon BE, Grannis S, Vreeman DJ. Impact of selective mapping strategies on automated laboratory result notification to public health authorities. AMIA Annu. Symp. Proc. 2012;2012:228&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540490</ArticleId><ArticleId IdType="pubmed">23304292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon BE, Hook J, Vreeman DJ. Learning from the crowd in terminology mapping: the LOINC experience. Lab. Med. 2015;46:168&#x2013;174. doi: 10.1309/LMWJ730SVKTUBAOJ.</Citation><ArticleIdList><ArticleId IdType="doi">10.1309/LMWJ730SVKTUBAOJ</ArticleId><ArticleId IdType="pmc">PMC4832593</ArticleId><ArticleId IdType="pubmed">25918199</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan AN, et al. Standardizing laboratory data by mapping to LOINC. J. Am. Med. Inform. Assoc. 2006;13:353&#x2013;355. doi: 10.1197/jamia.M1935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M1935</ArticleId><ArticleId IdType="pmc">PMC1513656</ArticleId><ArticleId IdType="pubmed">16501183</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Finnell JT, Vreeman DJ. Evaluating congruence between laboratory LOINC value sets for quality measures, public health reporting, and mapping common tests. AMIA Annu. Symp. Proc. 2013;2013:1525&#x2013;1532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900163</ArticleId><ArticleId IdType="pubmed">24551424</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MR, et al. Early vision for the CTSA Program Trial Innovation Network: a perspective from the National Center for Advancing Translational Sciences. Clin. Transl. Sci. 2017;10:311&#x2013;313. doi: 10.1111/cts.12463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12463</ArticleId><ArticleId IdType="pmc">PMC5593163</ArticleId><ArticleId IdType="pubmed">28271602</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL, et al. Launching PCORnet, a national patient-centered clinical research network. J. Am. Med. Inform. Assoc. 2014;21:578&#x2013;582. doi: 10.1136/amiajnl-2014-002747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002747</ArticleId><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Semler SC, Wissing F, Heyder R. German medical informatics initiative. Methods Inf. Med. 2018;57:e50&#x2013;e56. doi: 10.3414/ME18-03-0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME18-03-0003</ArticleId><ArticleId IdType="pmc">PMC6178199</ArticleId><ArticleId IdType="pubmed">30016818</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson, P. C. &amp; Yazdany, J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat. Rev. Rheumatol. 10.1038/s41584-020-0418-0 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7117553</ArticleId><ArticleId IdType="pubmed">32242121</ArticleId></ArticleIdList></Reference><Reference><Citation>Global research on coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov (World Health Organization, 2020).</Citation></Reference><Reference><Citation>Bodenreider O, Cornet R, Vreeman DJ. Recent developments in clinical terminologies&#x2014;SNOMED CT, LOINC, and RxNorm. Yearb. Med. Inform. 2018;27:129&#x2013;139. doi: 10.1055/s-0038-1667077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1667077</ArticleId><ArticleId IdType="pmc">PMC6115234</ArticleId><ArticleId IdType="pubmed">30157516</ArticleId></ArticleIdList></Reference><Reference><Citation>i2b2: Informatics for Integrating Biology &amp; the Bedside. https://www.i2b2.org/ (World Health Organization, 2020).</Citation></Reference><Reference><Citation>CTSA ACT Consortium. CTSA ACT Network i2b2 and SHRINE Ontology with 1-1 SHRINE Adapter Mapping File (Github) (2020).</Citation></Reference><Reference><Citation>Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res. 2004;32:D267&#x2013;D270. doi: 10.1093/nar/gkh061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh061</ArticleId><ArticleId IdType="pmc">PMC308795</ArticleId><ArticleId IdType="pubmed">14681409</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" VersionID="2" Owner="NLM"><PMID Version="2">32864627</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2665-9913</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet. Rheumatology</Title><ISOAbbreviation>Lancet Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study.</ArticleTitle><Pagination><StartPage>e698</StartPage><EndPage>e711</EndPage><MedlinePgn>e698-e711</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2665-9913(20)30276-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hydroxychloroquine, a drug commonly used in the treatment of rheumatoid arthritis, has received much negative publicity for adverse events associated with its authorisation for emergency use to treat patients with COVID-19 pneumonia. We studied the safety of hydroxychloroquine, alone and in combination with azithromycin, to determine the risk associated with its use in routine care in patients with rheumatoid arthritis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this multinational, retrospective study, new user cohort studies in patients with rheumatoid arthritis aged 18 years or older and initiating hydroxychloroquine were compared with those initiating sulfasalazine and followed up over 30 days, with 16 severe adverse events studied. Self-controlled case series were done to further establish safety in wider populations, and included all users of hydroxychloroquine regardless of rheumatoid arthritis status or indication. Separately, severe adverse events associated with hydroxychloroquine plus azithromycin (compared with hydroxychloroquine plus amoxicillin) were studied. Data comprised 14 sources of claims data or electronic medical records from Germany, Japan, the Netherlands, Spain, the UK, and the USA. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate calibrated hazard ratios (HRs) according to drug use. Estimates were pooled where the <i>I</i> <sup>2</sup> value was less than 0&#xb7;4.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The study included 956&#x2008;374 users of hydroxychloroquine, 310&#x2008;350 users of sulfasalazine, 323&#x2008;122 users of hydroxychloroquine plus azithromycin, and 351&#x2008;956 users of hydroxychloroquine plus amoxicillin. No excess risk of severe adverse events was identified when 30-day hydroxychloroquine and sulfasalazine use were compared. Self-controlled case series confirmed these findings. However, long-term use of hydroxychloroquine appeared to be associated with increased cardiovascular mortality (calibrated HR 1&#xb7;65 [95% CI 1&#xb7;12-2&#xb7;44]). Addition of azithromycin appeared to be associated with an increased risk of 30-day cardiovascular mortality (calibrated HR 2&#xb7;19 [95% CI 1&#xb7;22-3&#xb7;95]), chest pain or angina (1&#xb7;15 [1&#xb7;05-1&#xb7;26]), and heart failure (1&#xb7;22 [1&#xb7;02-1&#xb7;45]).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Hydroxychloroquine treatment appears to have no increased risk in the short term among patients with rheumatoid arthritis, but in the long term it appears to be associated with excess cardiovascular mortality. The addition of azithromycin increases the risk of heart failure and cardiovascular mortality even in the short term. We call for careful consideration of the benefit-risk trade-off when counselling those on hydroxychloroquine treatment.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, NIHR Senior Research Fellowship programme, US National Institutes of Health, US Department of Veterans Affairs, Janssen Research and Development, IQVIA, Korea Health Industry Development Institute through the Ministry of Health and Welfare Republic of Korea, Versus Arthritis, UK Medical Research Council Doctoral Training Partnership, Foundation Alfonso Martin Escudero, Innovation Fund Denmark, Novo Nordisk Foundation, Singapore Ministry of Health's National Medical Research Council Open Fund Large Collaborative Grant, VINCI, Innovative Medicines Initiative 2 Joint Undertaking, EU's Horizon 2020 research and innovation programme, and European Federation of Pharmaceutical Industries and Associations.</AbstractText><CopyrightInformation>&#xa9; 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Jennifer C E</ForeName><Initials>JCE</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahao</LastName><ForeName>Maria Tereza F</ForeName><Initials>MTF</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Islamic University of Gaza, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biedermann</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Actelion Pharmaceuticals, Allschwil, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banda</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Computer Science, Georgia State University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casajust</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Real-World Evidence, Trial Form Support, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conover</LastName><ForeName>Mitchell M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Culhane</LastName><ForeName>Aedin C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Data Sciences, Dana-Farber Cancer Institute, Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davydov</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Ontology Solutions, Odysseus Data Services, Cambridge MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Western Institute for Biomedical Research, Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dymshyts</LastName><ForeName>Dmitry</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical Ontology Solutions, Odysseus Data Services, Cambridge MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Bertolin</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fi&#x161;ter</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Medicine, Andrija &#x160;tampar School of Public Health, University of Zagreb, Zagreb, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardin</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hester</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaas-Hansen</LastName><ForeName>Benjamin Skov</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NNF Centre for Protein Research, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Seamus</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Institute for Health and Care Excellence, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khosla</LastName><ForeName>Sajan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Real World Science and Digital, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolovos</LastName><ForeName>Spyros</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Christophe G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Center for Global Health and Division of Translational Informatics, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lei</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Western Institute for Biomedical Research, Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margulis</LastName><ForeName>Andrea V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>RTI Health Solutions, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Geriatrics Research Education and Clinical Care Center, Tennessee Valley Healthcare System VA, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paras</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>College of Medicine, University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan-Stewart</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosseveld</LastName><ForeName>Mees</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newby</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon-si Gyeonggi-do, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sathappan</LastName><ForeName>Selva Muthu Kumaran</ForeName><Initials>SMK</Initials><AffiliationInfo><Affiliation>Saw Swee Hock School of Public Health, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seager</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biomathematics and Department of Human Genetics, David Geffen School of Medicine at UCLA, and Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre</LastName><ForeName>Carmen O</ForeName><Initials>CO</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizcaya</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Bayer Pharmaceuticals, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Haini</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wilde</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Junqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon-si Gyeonggi-do, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Population Medicine and Public Health, Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne School of Population and Global Health, University of Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuk</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Medical Ontology Solutions, Odysseus Data Services, Cambridge MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la Recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>OHDSI-COVID-19 consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG059307</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RES 13-457</GrantID><Acronym>RD</Acronym><Agency>ORD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Rheumatol</MedlineTA><NlmUniqueID>101765308</NlmUniqueID><ISSNLinking>2665-9913</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32864627</ArticleId><ArticleId IdType="pmc">PMC7442425</ArticleId><ArticleId IdType="doi">10.1016/S2665-9913(20)30276-9</ArticleId><ArticleId IdType="pii">S2665-9913(20)30276-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135139</ArticleId><ArticleId IdType="pubmed">32145363</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003;3:722&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128816</ArticleId><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference><Reference><Citation>Vigerust DJ, Shepherd VL. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 2007;15:211&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127133</ArticleId><ArticleId IdType="pubmed">17398101</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118659</ArticleId><ArticleId IdType="pubmed">32171740</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102549</ArticleId><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuro NJ, Yen CF, Shim DJ. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1834. published online May 1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.1834</ArticleId><ArticleId IdType="pmc">PMC7195692</ArticleId><ArticleId IdType="pubmed">32936252</ArticleId></ArticleIdList></Reference><Reference><Citation>Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTC in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation. 2020;141:e906&#x2013;e907.</Citation><ArticleIdList><ArticleId IdType="pubmed">32267732</ArticleId></ArticleIdList></Reference><Reference><Citation>Chorin E, Dai M, Shulman E. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med. 2020;26:808&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">32488217</ArticleId></ArticleIdList></Reference><Reference><Citation>Borba MGS, Val FFA, Sampaio VS. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3</Citation><ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY  Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020. June 5, 2020. https://www.ox.ac.uk/news/2020-06-05-no-clinical-benefit-use-hydroxychloroquine-hospitalised-patients-covid-19</Citation></Reference><Reference><Citation>WHO  &#x201c;Solidarity&#x201d; clinical trial for COVID-19 treatments update on hydroxychloroquine. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments</Citation></Reference><Reference><Citation>Hofschneider PH, Winter U, Lemmel E-M. Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis. Rheumatol Int. 1992;12:175&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1290019</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency  COVID-19: reminder of the risks of chloroquine and hydroxychloroquine. April 23, 2020. https://www.ema.europa.eu/en/news/covid-19-reminder-risk-serious-side-effects-chloroquine-hydroxychloroquine</Citation></Reference><Reference><Citation>US Food and Drug Administration  FDA revokes Emergency Use Authorization for chloroquine phosphate and hydroxychloroquine sulfate. June 15, 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and</Citation></Reference><Reference><Citation>Sepriano A, Kerschbaumer A, Smolen JS. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79:760&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">32033941</ArticleId></ArticleIdList></Reference><Reference><Citation>Costello R, David T, Jani M. Impact of adverse events associated with medications in the treatment and prevention of rheumatoid arthritis. Clin Ther. 2019;41:1376&#x2013;1396.</Citation><ArticleIdList><ArticleId IdType="pubmed">31196653</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo MH, Hu Q, Guirong X, Wu F, Wu B, Xu T. Data mining and safety analysis of drugs for novel coronavirus pneumonia treatment based on FAERS: chloroquine phosphate. Herald Med. 2020;39:505&#x2013;512.</Citation></Reference><Reference><Citation>Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41:919&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pubmed">29858838</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K, Deeb M, Gladman DD, Harvey P, Urowitz MB. Antimalarial-induced cardiomyopathy: a systematic review of the literature. Lupus. 2018;27:591&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">28992800</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo D, Cai Y, Chai D, Liang B, Bai N, Wang R. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65:631&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">21038838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881&#x2013;1890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3374857</ArticleId><ArticleId IdType="pubmed">22591294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu ZK, Yuan J, Li M. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf. 2015;14:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404501</ArticleId><ArticleId IdType="pubmed">25494485</ArticleId></ArticleIdList></Reference><Reference><Citation>European Network of Centres for Pharmacoepidemiology and Pharmacovigilance  ENCePP guide on methodological standards in pharmacoepidemiology, revision 8. July, 2020. http://www.encepp.eu/standards_and_guidances/documents/GuideMethodRev8.pdf</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics . Observational Health Data Sciences and Informatics; 2020. The book of OHDSI.</Citation></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2017;66:72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801982</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47:2005&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083&#x2013;3107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust empirical calibration of p-values using observational data. Stat Med. 2016;35:3883&#x2013;3888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5108459</ArticleId><ArticleId IdType="pubmed">27592566</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33:209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23:1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson SE, Madigan D, Zorych I, Schuemie MJ, Ryan PB, Suchard MA. Multiple self-controlled case series for large-scale longitudinal observational databases. Biometrics. 2013;69:893&#x2013;902.</Citation><ArticleIdList><ArticleId IdType="pubmed">24117144</ArticleId></ArticleIdList></Reference><Reference><Citation>European Network of Centres for Pharmacoepidemiology and Pharmacovigilance  EU PAS registration: hydroxychloroquine safety and potential efficacy as an antiviral prophylaxis in light of potential wide-spread use in COVID-19: a multinational, large-scale network cohort and self-controlled case series study. April 2, 2020. http://www.encepp.eu/encepp/viewResource.htm%3Fid=34498</Citation></Reference><Reference><Citation>Shinjo SK, Bonf&#xe1; E, Wojdyla D. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62:855&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pubmed">20131238</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YM, Lin CH, Lan TH. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology. 2015;54:1244&#x2013;1249.</Citation><ArticleIdList><ArticleId IdType="pubmed">25587177</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasko MC, Hubert HB, Lingala VB. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298:187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">17622600</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" VersionID="4" Owner="NLM"><PMID Version="4">32908948</PMID><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2331-8422</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Jul</Month><Day>13</Day></PubDate></JournalIssue><Title>ArXiv</Title><ISOAbbreviation>ArXiv</ISOAbbreviation></Journal><ArticleTitle>COVID-19 SignSym: a fast adaptation of a general clinical NLP tool to identify and normalize COVID-19 signs and symptoms to OMOP common data model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">arXiv:2007.10286v4</ELocationID><Abstract><AbstractText>The COVID-19 pandemic swept across the world rapidly, infecting millions of people. An efficient tool that can accurately recognize important clinical concepts of COVID-19 from free text in electronic health records (EHRs) will be valuable to accelerate COVID-19 clinical research. To this end, this study aims at adapting the existing CLAMP natural language processing tool to quickly build COVID-19 SignSym, which can extract COVID-19 signs/symptoms and their 8 attributes (body location, severity, temporal expression, subject, condition, uncertainty, negation, and course) from clinical text. The extracted information is also mapped to standard concepts in the Observational Medical Outcomes Partnership common data model. A hybrid approach of combining deep learning-based models, curated lexicons, and pattern-based rules was applied to quickly build the COVID-19 SignSym from CLAMP, with optimized performance. Our extensive evaluation using 3 external sites with clinical notes of COVID-19 patients, as well as the online medical dialogues of COVID-19, shows COVID-19 Sign-Sym can achieve high performance across data sources. The workflow used for this study can be generalized to other use cases, where existing clinical natural language processing tools need to be customized for specific information needs within a short time. COVID-19 SignSym is freely accessible to the research community as a downloadable package (https://clamp.uth.edu/covid/nlp.php) and has been used by 16 healthcare organizations to support clinical research of COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jingqi</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Abu-El-Rub</LastName><ForeName>Noor</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Josh</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pham</LastName><ForeName>Huy Anh</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yujia</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Manion</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mei</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xing</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hua</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Rouhizadeh</LastName><ForeName>Masoud</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yaoyun</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R44 TR003254</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ArXiv</MedlineTA><NlmUniqueID>101759493</NlmUniqueID><ISSNLinking>2331-8422</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>J Am Med Inform Assoc. 2021 Jun 12;28(6):1275-1283</RefSource><PMID Version="1">33674830</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>CONFLICT OF INTEREST STATEMENT. Dr Hua Xu, Mr Jingqi Wang, and The University of Texas Health Science Center at Houston have financial related research interest in Melax Technologies, Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32908948</ArticleId><ArticleId IdType="pmc">PMC7480086</ArticleId><ArticleId IdType="pii">2007.10286</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/ Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>Coronavirus in the U.S.:Latest Map and Case Count. https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html Accessed
February 23, 2021.</Citation></Reference><Reference><Citation>Kupferschmidt K, Cohen J. WHO launches global megatrial of the four most promising coronavirus treatments. Science j AAAS; 2020. https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>Open science initiatives related to the COVID-19. OECD. https://community.oecd.org/docs/DOC-172520 Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>COVID-19 Datasets and Machine Learning Projects. https://www.kaggle.com/tags/covid19/ Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>COVID-19 Open Research Dataset Challenge (CORD-19). https://kaggle.com/allen-institute-for-ai/CORD-19-research-challenge Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>Wang LL, Lo K, Chandrasekhar Y, et al. CORD-19: The Covid-19 Open Research Dataset. ArXiv200410706 Cs; 2020.</Citation></Reference><Reference><Citation>LitCovid. https://www.ncbi.nlm.nih.gov/research/coronavirus/ Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>AlRahman AlMomani A, Bollt E. Informative Ranking of Stand Out Collections of Symptoms: A New Data-Driven Approach to Identify the Strong Warning Signs of COVID 19. arXiv arXiv&#x2013;2004; 2020.</Citation></Reference><Reference><Citation>Wagner T, Shweta FN, Murugadoss K, et al.
Augmented Curation of Clinical Notes from a Massive EHR System Reveals Symptoms of Impending COVID-19 Diagnosis; 2020. http://medrxiv.org/lookup/doi/10.1101/2020.04.19.20067660 Accessed
January 10, 2020. doi: 10.1101/2020.04.19.20067660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.19.20067660</ArticleId><ArticleId IdType="doi">10.1101/2020.04.19.20067660</ArticleId><ArticleId IdType="pmc">PMC7410498</ArticleId><ArticleId IdType="pubmed">32633720</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. COVID-19 Updates Page. https://www.ohdsi.org/covid-19-updates/ Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>National COVID Cohort Collaborative (N3C). National Center for Advancing Translational Sciences; 2020. https://ncats.nih.gov/n3c Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>International Electronic Health Record-Derived COVID-19 Clinical Course Profiles: The 4CE Consortium medRxiv. https://www.medrxiv.org/content/10.1101/2020.04.13.20059691v5 Accessed
January 10, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.13.20059691v5</ArticleId><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X, Li J, Soysal E, et al. COVID-19 TestNorm: a tool to normalize COVID-19 testing names to LOINC codes. J. Am. Med. Inform. Assoc 2020; 27 (9): 1437&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337837</ArticleId><ArticleId IdType="pubmed">32569358</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen A, Fu S, Moon S, et al. Desiderata for delivering NLP to accelerate healthcare AI advancement and a Mayo Clinic NLP-as-a-service implementation. NPJ Digit Med 2019; 2 (1): 1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6917754</ArticleId><ArticleId IdType="pubmed">31872069</ArticleId></ArticleIdList></Reference><Reference><Citation>OHNLP/MedTagger. GitHub
https://github.com/OHNLP/MedTagger Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>Soysal E, Wang J, Jiang M, et al. CLAMP&#x2014;a toolkit for efficiently building customized clinical natural language processing pipelines. J Am Med Inform Assoc 2018; 25 (3): 331&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378877</ArticleId><ArticleId IdType="pubmed">29186491</ArticleId></ArticleIdList></Reference><Reference><Citation>Savova GK, Masanz JJ, Ogren PV, et al. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation, and applications. J Am Med Inform Assoc 2010; 17 (5): 507&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995668</ArticleId><ArticleId IdType="pubmed">20819853</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. OMOP Common Data Model. https://www.ohdsi.org/data-standardization/the-common-data-model/ Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>Garibaldi BT, Fiksel J, Muschelli J, et al. Patient trajectories among persons hospitalized for COVID-19: a cohort study. Ann Intern Med 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7530643</ArticleId><ArticleId IdType="pubmed">32960645</ArticleId></ArticleIdList></Reference><Reference><Citation>iCliniq. Common &#x2018;Covid-19&#x2019; queries answered by top doctors. https://www.icliniq.com/qa/covid-19 Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>Elhadad N, Pradhan S, Gorman S, et al. SemEval-2015 task 14: analysis of clinical text. In: proceedings of the 9th International Workshop on Semantic Evaluation (SemEval 2015); June 4&#x2013;5, 2015; Denver, CO.</Citation></Reference><Reference><Citation>World Health Organization. Case management. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>List of COVID-19 Signs and Symptoms; 2020. https://github.com/Medical-NLP/COVID-19-Sign-Symptom Accessed
January 10, 2020.</Citation></Reference><Reference><Citation>Uzuner &#xd6;, South BR, Shen S, DuVall SL. 2010 i2b2/VA challenge on concepts, assertions, and relations in clinical text. J Am Med Inform Assoc 2011; 18 (5): 552&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3168320</ArticleId><ArticleId IdType="pubmed">21685143</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z, Xu W, Yu K. Bidirectional LSTM-CRF Models for Sequence Tagging. ArXiv150801991 Cs; 2015.</Citation></Reference><Reference><Citation>Wei Q, Ji Z, Li Z, et al. A study of deep learning approaches for medication and adverse drug event extraction from clinical text. J Am Med Inform Assoc 2020; 27 (1): 13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6913210</ArticleId><ArticleId IdType="pubmed">31135882</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezen-Can A. A Comparison of LSTM and BERT for Small Corpus. ArXiv Prepr. ArXiv200905451; 2020.</Citation></Reference><Reference><Citation>Zhang Y, Wang J, Tang B, et al. UTH_CCB: A report for SemEval 2014 &#x2013; task 7 analysis of clinical text. In: proceedings of the 8th International Workshop on Semantic Evaluation (SemEval 2014). Association for Computational Linguistics; August 23&#x2013;24, 2014; Dublin, Ireland. doi: 10.3115/v1/S14-2142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3115/v1/S14-2142</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. documentation:cdm:note_nlp. https://www.ohdsi.org/web/wiki/doku.php?id=documentation:cdm:note_nlp Accessed
January 10, 2020.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32909033</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND).</ArticleTitle><Pagination><StartPage>1331</StartPage><EndPage>1337</EndPage><MedlinePgn>1331-1337</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocaa103</ELocationID><Abstract><AbstractText>Evidence derived from existing health-care data, such as administrative claims and electronic health records, can fill evidence gaps in medicine. However, many claim such data cannot be used to estimate causal treatment effects because of the potential for observational study bias; for example, due to residual confounding. Other concerns include P hacking and publication bias. In response, the Observational Health Data Sciences and Informatics international collaborative launched the Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND) research initiative. Its mission is to generate evidence on the effects of medical interventions using observational health-care databases while addressing the aforementioned concerns by following a recently proposed paradigm. We define 10 principles of LEGEND that enshrine this new paradigm, prescribing the generation and dissemination of evidence on many research questions at once; for example, comparing all treatments for a disease for many outcomes, thus preventing publication bias. These questions are answered using a prespecified and systematic approach, avoiding P hacking. Best-practice statistical methods address measured confounding, and control questions (research questions where the answer is known) quantify potential residual bias. Finally, the evidence is generated in a network of databases to assess consistency by sharing open-source analytics code to enhance transparency and reproducibility, but without sharing patient-level information. Here we detail the LEGEND principles and provide a generic overview of a LEGEND study. Our companion paper highlights an example study on the effects of hypertension treatments, and evaluates the internal and external validity of the evidence we generate.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2020. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>RuiJun</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medical College, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Yale University School of Medicine, New Haven, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Statistics, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterian Hospital, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomathematics, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003195" MajorTopicYN="Y">Computer Communication Networks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="Y">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019370" MajorTopicYN="N">Observation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">empirical calibration</Keyword><Keyword MajorTopicYN="N">observational studies</Keyword><Keyword MajorTopicYN="N">open science</Keyword><Keyword MajorTopicYN="N">treatment effects</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>10</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32909033</ArticleId><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocaa103</ArticleId><ArticleId IdType="pii">5895561</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gerstein HC, McMurray J, Holman RR.. Real-world studies no substitute for RCTs in establishing efficacy. Lancet 2019; 393: 210&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663582</ArticleId></ArticleIdList></Reference><Reference><Citation>Rush CJ, Campbell RT, Jhund PS, Petrie MC, McMurray JJV. Association is not causation: treatment effects cannot be estimated from observational data in heart failure. Eur Heart J 2018; 39: 3417&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6166137</ArticleId><ArticleId IdType="pubmed">30085087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannidis JPA. Why most published research findings are false. PLOS Med 2005; 2(8): e124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182327</ArticleId><ArticleId IdType="pubmed">16060722</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al.Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform 2015; 216: 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci 2018; 376&#xa0;. doi:10.1098/rsta.2017.0356</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Pratt N. et al Large-Scale Evidence Generation and Evaluation across a Network of Databases (LEGEND): Assessing Validity Using Hypertension as a Case Study. J Am Med Inform Assoc. 27(8):1268--1277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7481033</ArticleId><ArticleId IdType="pubmed">32827027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct P-values. Stat Med 2014; 33: 209&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Natl Acad Sci USA 2018; 115: 2571&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad V, Jena AB.. Prespecified falsification end points: can they validate true observational associations? JAMA 2013; 309: 241&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">23321761</ArticleId></ArticleIdList></Reference><Reference><Citation>Dusetzina SB, Brookhart MA, Maciejewski ML.. Control outcomes and exposures for improving internal validity of nonrandomized studies. Health Serv Res 2015; 50: 1432&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4600355</ArticleId><ArticleId IdType="pubmed">25598384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen E, Cohen T.. Negative controls: a tool for detecting confounding and bias in observational studies. &#xa0;Epidemiology 2010; 21: 383&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform 2017; 66: 72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM.. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 2016; 183: 758&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA.. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol 2018; 47: 2005&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Soledad Cepede M, Suchard MA, et al. How confident are we about observational findings in health care: a benchmark study. 2020; 2 (1). doi: 10.1162/99608f92.147cc28e</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/99608f92.147cc28e</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25: 1768&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">16220518</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Kunz R, et al.What is &#x2018;quality of evidence&#x2019; and why is it important to clinicians? BMJ 2008; 336: 995&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2364804</ArticleId><ArticleId IdType="pubmed">18456631</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, et al.Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet&#xa0;2019; 394 (10211): 1816&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32916988</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Association between Use of Hydrochlorothiazide and Nonmelanoma Skin Cancer: Common Data Model Cohort Study in Asian Population.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2910</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm9092910</ELocationID><Abstract><AbstractText Label="UNLABELLED">Although hydrochlorothiazide (HCTZ) has been suggested to increase skin cancer risk in white Westerners, there is scant evidence for the same in Asians. We analyzed the association between the use of hydrochlorothiazide and non-melanoma in the Asian population using the common data model.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective multicenter observational study was conducted using a distributed research network to analyze the effect of HCTZ on skin cancer from 2004 to 2018. We performed Cox regression to evaluate the effects by comparing the use of HCTZ with other antihypertensive drugs. All analyses were re-evaluated using matched data using the propensity score matching (PSM). Then, the overall effects were evaluated by combining results with the meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Positive associations were observed in the use of HCTZ with high cumulative dose for non-melanoma skin cancer (NMSC) in univariate analysis prior to the use of PSM. Some negative associations were observed in the use of low and medium cumulative doses.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although many findings in our study were inconclusive, there was a non-significant association of a dose-response pattern with estimates increasing in cumulative dose of HCTZ. In particular, a trend with a non-significant positive association was observed with the high cumulative dose of HCTZ.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Seung Min</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0001-5762-2618</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kwangsoo</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4586-5062</Identifier><AffiliationInfo><Affiliation>Transdisciplinary Department of Medicine &amp; Advanced Technology, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Jihoon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine in St. Louis, St. Louis, MO 63110-1010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sue K</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0001-5002-9707</Identifier><AffiliationInfo><Affiliation>Department of Preventive Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Seoul National University, Seoul 03080, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Convergence Graduate Program in Innovative Medical Science, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moon</LastName><ForeName>Sungji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Research Institute, Seoul National University, Seoul 03080, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Interdisciplinary Program in Cancer Biology Major, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang Eun</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>JiSeon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics Health Innovation Big Data Center, Asan Medical Center, Seoul 05505, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Healthcare ICT Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam 13620, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kwang-Il</ForeName><Initials>KI</Initials><Identifier Source="ORCID">0000-0002-6658-047X</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Hyung-Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hae-Young</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0002-9521-4102</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IITP-2020-2018-0-01833</GrantID><Agency>MSIT(Ministry of Science and ICT), Korea</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cox regression</Keyword><Keyword MajorTopicYN="N">dose-response relationship</Keyword><Keyword MajorTopicYN="N">hydrochlorothiazide</Keyword><Keyword MajorTopicYN="N">melanoma</Keyword><Keyword MajorTopicYN="N">non-melanoma</Keyword><Keyword MajorTopicYN="N">skin cancer</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>12</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32916988</ArticleId><ArticleId IdType="pmc">PMC7563303</ArticleId><ArticleId IdType="doi">10.3390/jcm9092910</ArticleId><ArticleId IdType="pii">jcm9092910</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xie X., Atkins E., Lv J., Bennett A., Neal B., Ninomiya T., Woodward M., MacManon S., Turnbull F., Hillis G.S., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis. Lancet. 2016;387:435&#x2013;443. doi: 10.1016/S0140-6736(15)00805-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(15)00805-3</ArticleId><ArticleId IdType="pubmed">26559744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R., Xavier D. Hypertension: The most important non communicable disease risk factor in India. Indian Heart J. 2018;70:565&#x2013;572. doi: 10.1016/j.ihj.2018.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ihj.2018.02.003</ArticleId><ArticleId IdType="pmc">PMC6116711</ArticleId><ArticleId IdType="pubmed">30170654</ArticleId></ArticleIdList></Reference><Reference><Citation>Whelton P.K., Carey R.M., Aronow W.S., Casey N.E., Collins K.J., Himmelfarb C.R.D., DePalma S.M., Gidding S., Jamerson K.A., Jones D.W., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American college of Cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2018;71:e113&#x2013;e115.</Citation><ArticleIdList><ArticleId IdType="pubmed">29133356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchey M.D., Gillespie C., Wozniak G., Shay C.M., Thompson-Paul A.M., Loustalot F., Hong Y. Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC/AHA Hypertension Guideline. J. Clin. Hypertens. Greenwich. 2018;20:1377&#x2013;1391. doi: 10.1111/jch.13364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jch.13364</ArticleId><ArticleId IdType="pubmed">30194806</ArticleId></ArticleIdList></Reference><Reference><Citation>Hisamatsu T. Control rates of systolic and diastolic blood pressure among hypertensive adults in Korea. Korean Circ. J. 2019;49:1049&#x2013;1051. doi: 10.4070/kcj.2019.0197.</Citation><ArticleIdList><ArticleId IdType="doi">10.4070/kcj.2019.0197</ArticleId><ArticleId IdType="pmc">PMC6813153</ArticleId><ArticleId IdType="pubmed">31456366</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J., Cho M.-C. Updated reasons and clinical implications of New Korean Hypertension Guidelines for cardiologists. Korean Circ. J. 2020;50:476&#x2013;484. doi: 10.4070/kcj.2019.0338.</Citation><ArticleIdList><ArticleId IdType="doi">10.4070/kcj.2019.0338</ArticleId><ArticleId IdType="pmc">PMC7234851</ArticleId><ArticleId IdType="pubmed">32281319</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung B.M.Y., Or B., Fei Y., Tsoi M.F. A 2020 vision of hypertension. Korean Circ. J. 2020;50:469&#x2013;475. doi: 10.4070/kcj.2020.0067.</Citation><ArticleIdList><ArticleId IdType="doi">10.4070/kcj.2020.0067</ArticleId><ArticleId IdType="pmc">PMC7234844</ArticleId><ArticleId IdType="pubmed">32281321</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S.M.J., Lee H., Pyun W.B., Kim H.C. Differential control rate of systolic and diastolic blood pressure among Korean adults with Hypertension: The sixth Korean national health and nutrition examination survey, 2013&#x2013;2015 (KNHANES VI) Korean Circ. J. 2019;49:1035&#x2013;1048. doi: 10.4070/kcj.2019.0049.</Citation><ArticleIdList><ArticleId IdType="doi">10.4070/kcj.2019.0049</ArticleId><ArticleId IdType="pmc">PMC6813160</ArticleId><ArticleId IdType="pubmed">31190479</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwun J.-S., Kim S.-H., Kang S.-H., Yoon C.-H., Lee H.-Y., Kim K.-I., Youn T.-J., Chae I.-H., Kim C.-H. Potential impact of 2018 Korean society of Hypertension guidelines on Korean population: A population-based cohort study. Clin. Hypertens. 2020;26:3&#x2013;8. doi: 10.1186/s40885-020-0137-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-020-0137-5</ArticleId><ArticleId IdType="pmc">PMC6995175</ArticleId><ArticleId IdType="pubmed">32021699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.C., Ihm S.-H., Kim G.-H., Kim J.H., Kim K.-I., Lee H.-Y., Lee J.H., Park J.-M., Park S., Pyun W.B., et al. 2018 Korean Society of Hypertension guidelines for the management of hypertension: Part I-epidemiology of hypertension. Clin. Hypertens. 2019;25:1&#x2013;16. doi: 10.1186/s40885-019-0121-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-019-0121-0</ArticleId><ArticleId IdType="pmc">PMC6670210</ArticleId><ArticleId IdType="pubmed">31388451</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.-I., Ihm S.-H., Kim G.-H., Kim H.C., Kim J.H., Lee H.-Y., Lee J.H., Park J.-M., Park S., Pyun W.B., et al. 2018 Korean society of hypertension guidelines for the management of hypertension: Part III-hypertension in special situations. Clin. Hypertens. 2019;25:1&#x2013;14. doi: 10.1186/s40885-019-0123-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-019-0123-y</ArticleId><ArticleId IdType="pmc">PMC6670160</ArticleId><ArticleId IdType="pubmed">31388452</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.-Y., Shin J., Kim G.-H., Park S., Ihm S.-H., Kim H.C., Kim K.-I., Kim J.H., Lee J.H., Park J.-M., et al. 2018 Korean society of Hypertension guidelines for the management of hypertension: Part II-diagnosis and treatment of hypertension. Clin. Hypertens. 2019;25:20. doi: 10.1186/s40885-019-0124-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40885-019-0124-x</ArticleId><ArticleId IdType="pmc">PMC6670135</ArticleId><ArticleId IdType="pubmed">31388453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.R., Alexander G.C., Stafford R.S. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch. Intern. Med. 2007;167:141&#x2013;147. doi: 10.1001/archinte.167.2.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.167.2.141</ArticleId><ArticleId IdType="pubmed">17242314</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen S.A., Schmidt SA J., H&#xf6;lmich L.R., Friis S., Potteg&#xe5;rd A., Gaist D. Hydrochlorothiazide use and risk for Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study. J. Am. Acad. Dermatol. 2019;80:460&#x2013;465. doi: 10.1016/j.jaad.2018.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2018.06.014</ArticleId><ArticleId IdType="pubmed">29913261</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen S.A., Gaist D., Schmidt M., H&#xf6;lmich L.R., Friis S., Potteg&#xe5;rd A. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J. Am. Acad. Dermatol. 2018;78:673&#x2013;681. doi: 10.1016/j.jaad.2017.11.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2017.11.042</ArticleId><ArticleId IdType="pubmed">29217346</ArticleId></ArticleIdList></Reference><Reference><Citation>Potteg&#xe5;rd A., Pedersen S.A., Schmidt S.A.J., H&#xf6;lmich L.R., Friis S., Gaist D. Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern. Med. 2018;178:1120&#x2013;1122. doi: 10.1001/jamainternmed.2018.1652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2018.1652</ArticleId><ArticleId IdType="pmc">PMC6143099</ArticleId><ArticleId IdType="pubmed">29813157</ArticleId></ArticleIdList></Reference><Reference><Citation>Su K., Habel L., Achacoso N., Friedman G., Asgari M.M. Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma. Br. J. Dermatol. 2018;179:1088&#x2013;1094. doi: 10.1111/bjd.16713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.16713</ArticleId><ArticleId IdType="pmc">PMC6223125</ArticleId><ArticleId IdType="pubmed">29723931</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandini S., Palli M., Spadola G., Bendinelli B., Cocorocchio E., Stanganelli I., Miligi L., Masala G., Caini S. Anti-hypertensive drugs and skin cancer risk: A review of the literature and meta-analysis. Crit. Rev. Oncol. Hematol. 2018;122:1&#x2013;9. doi: 10.1016/j.critrevonc.2017.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2017.12.003</ArticleId><ArticleId IdType="pubmed">29458778</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottegaard A., Pedersen S.A., Schmidt S.A.J., Lee C.-N., Hsu C.-K., Liao T.-C., Shao S.-C., Lai E.C.-C. Use of hydrochlorothiazide and risk of skin cancer: A nationwide Taiwanese case-control study. Br. J. Cancer. 2019;121:973&#x2013;978. doi: 10.1038/s41416-019-0613-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-019-0613-4</ArticleId><ArticleId IdType="pmc">PMC6889460</ArticleId><ArticleId IdType="pubmed">31673105</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh C.-M., Cho H., Won Y.-J., Kong H.-J., Roh Y.H., Jeong K.-H., Jung K.-W. Nationwide trends in the incidence of melanoma and non-melanoma skin cancers from 1999 to 2014 in South Korea. Cancer Res. Treat. 2018;50:729&#x2013;737. doi: 10.4143/crt.2017.166.</Citation><ArticleIdList><ArticleId IdType="doi">10.4143/crt.2017.166</ArticleId><ArticleId IdType="pmc">PMC6056982</ArticleId><ArticleId IdType="pubmed">28707459</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuoppala J., Lamminp&#xe4;&#xe4; A., Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur. J. Cancer. 2008;44:2122&#x2013;2132. doi: 10.1016/j.ejca.2008.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2008.06.025</ArticleId><ArticleId IdType="pubmed">18707867</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinau D., Surber C., Jick S.S., Meier C.R. Nonsteroidal anti-inflammatory drugs and the risk of nonmelanoma skin cancer. Int. J. Cancer. 2015;137:144&#x2013;153. doi: 10.1002/ijc.29357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.29357</ArticleId><ArticleId IdType="pubmed">25418602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Cheng Y., Luo R.-C., Li A.-M. Aspirin for the primary prevention of skin cancer: A meta-analysis. Oncol. Lett. 2015;9:1073&#x2013;1080. doi: 10.3892/ol.2015.2853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2015.2853</ArticleId><ArticleId IdType="pmc">PMC4314970</ArticleId><ArticleId IdType="pubmed">25663859</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen S.K., Christiansen C.F., Christensen S., Lash T.L., S&#xf8;rensen H.T. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med. Res. Methodol. 2011;11:83. doi: 10.1186/1471-2288-11-83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-11-83</ArticleId><ArticleId IdType="pmc">PMC3125388</ArticleId><ArticleId IdType="pubmed">21619668</ArticleId></ArticleIdList></Reference><Reference><Citation>Littnerova S., Jarkovsky J., Parenica J., Pavlik T., Spinar J., Dusek L. Why to use propensity score in observational studies? Case study based on data from the Czech clinical database AHEAD 2006&#x2013;2009. Cor. et Vasa. 2013;55:e383&#x2013;e390. doi: 10.1016/j.crvasa.2013.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crvasa.2013.04.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Huedo-Medina T.B., S&#xe1;nchez-Meca J., Mar&#xed;n-Mart&#xed;nez F., Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol. Methods. 2006;11:193&#x2013;206. doi: 10.1037/1082-989X.11.2.193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/1082-989X.11.2.193</ArticleId><ArticleId IdType="pubmed">16784338</ArticleId></ArticleIdList></Reference><Reference><Citation>Park E., Lee Y., Jue M.-S. Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: A nationwide retrospective cohort study from Korea. Korean J. Intern. Med. 2019;35:906. doi: 10.3904/kjim.2019.218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2019.218</ArticleId><ArticleId IdType="pmc">PMC7373969</ArticleId><ArticleId IdType="pubmed">31842528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreutz R., AlGharably E.A.H., Douros A. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. J. Hypertens. 2019;37:1950&#x2013;1958. doi: 10.1097/HJH.0000000000002136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HJH.0000000000002136</ArticleId><ArticleId IdType="pubmed">31145177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G., Duke J.D., Shah N.H., Reich C.G., Huser V., Schuemie M.J., A Suchard M., Park R.W., Wong I.C.K., Rijnbeek P.R., et al. Observational health data sciences and informatics (OHDSI): Opportunities for observational researchers. Stud. Health Technol. Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R., Wilson M., Chan K.A., Benner J.S., Marchibroda J., McClellan M. The new Sentinel Network--improving the evidence of medical-product safety. N. Engl. J. Med. 2009;361:645&#x2013;647. doi: 10.1056/NEJMp0905338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp0905338</ArticleId><ArticleId IdType="pubmed">19635947</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D., Lee E.S., Kim J., Guerra L., Naik D., Prida X. Association Between the use of thiazide diuretics and the risk of skin cancers: A meta-analysis of observational studies. J. Clin. Med. Res. 2019;11:247&#x2013;255. doi: 10.14740/jocmr3744.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jocmr3744</ArticleId><ArticleId IdType="pmc">PMC6436572</ArticleId><ArticleId IdType="pubmed">30937114</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert X., Dolladille C., Chr&#xe9;tien B., Sassier M., Fedrizzi S., Puddu P.-E., Alexandre J. Thiazides and nonmelanoma skin cancer: Is it a class effect? J. Am. Acad. Dermatol. 2020;82:e25&#x2013;e26. doi: 10.1016/j.jaad.2019.08.086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaad.2019.08.086</ArticleId><ArticleId IdType="pubmed">31520661</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32947205</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>131</Volume><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Incidence, prevalence and prescription patterns of antipsychotic medications use in Asia and US: A cross-nation comparison with common data model.</ArticleTitle><Pagination><StartPage>77</StartPage><EndPage>84</EndPage><MedlinePgn>77-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2020.08.025</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(20)30937-7</ELocationID><Abstract><AbstractText>The use of antipsychotic medications (APMs) could be different among countries due to availability, approved indications, characteristics and clinical practice. However, there is limited literature providing comparisons of APMs use among countries. To examine trends in antipsychotic prescribing in Taiwan, Hong Kong, Japan, and the United States, we conducted a cross-national study from 2002 to 2014&#xa0;b&#xa0;y using the distributed network approach with common data model. We included all patients who had at least a record of antipsychotic prescription in this study, and defined patients without previous exposure of antipsychotics for 6 months before the index date as new users for incidence estimation. We calculated the incidence, prevalence, and prescription rate of each medication by calendar year. Among older patients, sulpiride was the most incident [incidence rate (IR) 11.0-23.3) and prevalent [prevalence rate (PR) 11.9-14.3) APM in Taiwan, and most prevalent (PR 2.5-3.9) in Japan. Quetiapine and haloperidol were most common in the United States (IR 8.1-9.5; PR 18.0-18.4) and Hong Kong (PR 8.8-13.7; PR 10.6-12.7), respectively. The trend of quetiapine use was increasing in Taiwan, Hong Kong and the United States. As compared to older patients, the younger patients had more propensity to be prescribed second-generation APM for treatment in four countries. Trends in antipsychotic prescribing varied among countries. Quetiapine use was most prevalent in the United States and increasing in Taiwan and Hong Kong. The increasing use of quetiapine in the elderly patients might be due to its safety profile compared to other APMs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Chien-Chou</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; School of Pharmacy And, College of Medicine National Cheng Kung University, Tainan, Taiwan; Health Outcome Research Center, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chia-Cheng Lai</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; School of Pharmacy And, College of Medicine National Cheng Kung University, Tainan, Taiwan; Health Outcome Research Center, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kao Yang</LastName><ForeName>Yea-Huei</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; School of Pharmacy And, College of Medicine National Cheng Kung University, Tainan, Taiwan; Health Outcome Research Center, National Cheng Kung University, Tainan, Taiwan. Electronic address: yhkao@mail.ncku.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Kenneth K C</ForeName><Initials>KKC</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong; Research Department of Practice and Policy, UCL School of Pharmacy, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubota</LastName><ForeName>Kiyoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>NPO Drug Safety Research Unit Japan, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stang</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Titusville, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>Chantelle</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Durham, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yinghong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Durham, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Shinya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Japan Medical Data Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamijima</LastName><ForeName>Yukari</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Japan Medical Data Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Ian C K</ForeName><Initials>ICK</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong; Research Department of Practice and Policy, UCL School of Pharmacy, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Setoguchi</LastName><ForeName>Soko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Rutgers Robertood Johnson Medical School and Institute for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health Sciences, New Jersey, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055656" MajorTopicYN="N">Prescriptions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antipsychotic agents</Keyword><Keyword MajorTopicYN="N">Pharmacoepidemiology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>20</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32947205</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2020.08.025</ArticleId><ArticleId IdType="pii">S0022-3956(20)30937-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33008368</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6947</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>BMC medical informatics and decision making</Title><ISOAbbreviation>BMC Med Inform Decis Mak</ISOAbbreviation></Journal><ArticleTitle>Prediction of incident myocardial infarction using machine learning applied to harmonized electronic health record data.</ArticleTitle><Pagination><StartPage>252</StartPage><MedlinePgn>252</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">252</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12911-020-01268-x</ELocationID><Abstract><AbstractText Label="BACKGROUND">With cardiovascular disease increasing, substantial research has focused on the development of prediction tools. We compare deep learning and machine learning models to a baseline logistic regression using only 'known' risk factors in predicting incident myocardial infarction (MI) from harmonized EHR data.</AbstractText><AbstractText Label="METHODS">Large-scale case-control study with outcome of 6-month incident MI, conducted using the top 800, from an initial 52&#x2009;k procedures, diagnoses, and medications within the UCHealth system, harmonized to the Observational Medical Outcomes Partnership common data model, performed on 2.27 million patients. We compared several over- and under- sampling techniques to address the imbalance in the dataset. We compared regularized logistics regression, random forest, boosted gradient machines, and shallow and deep neural networks. A baseline model for comparison was a logistic regression using a limited set of 'known' risk factors for MI. Hyper-parameters were identified using 10-fold cross-validation.</AbstractText><AbstractText Label="RESULTS">Twenty thousand Five hundred and ninety-one patients were diagnosed with MI compared with 2.25 million who did not. A deep neural network with random undersampling provided superior classification compared with other methods. However, the benefit of the deep neural network was only moderate, showing an F1 Score of 0.092 and AUC of 0.835, compared to a logistic regression model using only 'known' risk factors. Calibration for all models was poor despite adequate discrimination, due to overfitting from low frequency of the event of interest.</AbstractText><AbstractText Label="CONCLUSIONS">Our study suggests that DNN may not offer substantial benefit when trained on harmonized data, compared to traditional methods using established risk factors for MI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mandair</LastName><ForeName>Divneet</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiwari</LastName><ForeName>Premanand</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Colorado Center for Personalized Medicine, University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Cardiology and Cardiac Electrophysiology, University of Colorado School of Medicine, 12631 E. 17th Avenue, Mail Stop B130, Aurora, CO, 80045, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colborn</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-6708-1648</Identifier><AffiliationInfo><Affiliation>Division of Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA. michael.a.rosenberg@cuanschutz.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology and Cardiac Electrophysiology, University of Colorado School of Medicine, 12631 E. 17th Avenue, Mail Stop B130, Aurora, CO, 80045, USA. michael.a.rosenberg@cuanschutz.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 HL127296</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 HL123413</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL146824</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Inform Decis Mak</MedlineTA><NlmUniqueID>101088682</NlmUniqueID><ISSNLinking>1472-6947</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009203" MajorTopicYN="N">Myocardial Infarction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Electronic health records</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Myocardial infarction</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>3</Day><Hour>5</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33008368</ArticleId><ArticleId IdType="pmc">PMC7532582</ArticleId><ArticleId IdType="doi">10.1186/s12911-020-01268-x</ArticleId><ArticleId IdType="pii">10.1186/s12911-020-01268-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Burden of Cardiovascular Diseases Collaboration et al. The Burden of Cardiovascular Diseases Among US States, 1990&#x2013;2016. JAMA Cardiol. 2018;3:375&#x2013;389. doi: 10.1001/jamacardio.2018.0385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2018.0385</ArticleId><ArticleId IdType="pmc">PMC6145754</ArticleId><ArticleId IdType="pubmed">29641820</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, et al. Risk factors associated with major cardiovascular events 1 year after acute myocardial infarction. JAMA Netw Open. 2018;1:e181079. doi: 10.1001/jamanetworkopen.2018.1079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2018.1079</ArticleId><ArticleId IdType="pmc">PMC6324290</ArticleId><ArticleId IdType="pubmed">30646102</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh RW, Go AS. Rethinking the epidemiology of acute myocardial infarction: challenges and opportunities. Arch Intern Med. 2010;170:759&#x2013;764. doi: 10.1001/archinternmed.2010.88.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2010.88</ArticleId><ArticleId IdType="pubmed">20458082</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, et al. Prediction of adverse cardiac events in emergency department patients with chest pain using machine learning for variable selection. BMC Med Inform Decis Mak. 2014;14:75. doi: 10.1186/1472-6947-14-75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-14-75</ArticleId><ArticleId IdType="pmc">PMC4150554</ArticleId><ArticleId IdType="pubmed">25150702</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele AJ, Denaxas SC, Shah AD, Hemingway H, Luscombe NM. Machine learning models in electronic health records can outperform conventional survival models for predicting patient mortality in coronary artery disease. PLoS One. 2018;13:e0202344. doi: 10.1371/journal.pone.0202344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0202344</ArticleId><ArticleId IdType="pmc">PMC6118376</ArticleId><ArticleId IdType="pubmed">30169498</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay D, Poh CL, Van Reeth E, Kitney RI. The effect of sample age and prediction resolution on myocardial infarction risk prediction. IEEE J Biomed Health Inform. 2015;19:1178&#x2013;1185. doi: 10.1109/JBHI.2014.2330898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/JBHI.2014.2330898</ArticleId><ArticleId IdType="pubmed">24951711</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC, Lee DS, Steyerberg EW, Tu JV. Regression trees for predicting mortality in patients with cardiovascular disease: what improvement is achieved by using ensemble-based methods? Biom J. 2012;54:657&#x2013;673. doi: 10.1002/bimj.201100251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bimj.201100251</ArticleId><ArticleId IdType="pmc">PMC3470596</ArticleId><ArticleId IdType="pubmed">22777999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansoor H, Elgendy IY, Segal R, Bavry AA, Bian J. Risk prediction model for in-hospital mortality in women with ST-elevation myocardial infarction: a machine learning approach. Heart Lung. 2017;46:405&#x2013;411. doi: 10.1016/j.hrtlng.2017.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrtlng.2017.09.003</ArticleId><ArticleId IdType="pubmed">28992993</ArticleId></ArticleIdList></Reference><Reference><Citation>Shouval R, et al. Machine learning for prediction of 30-day mortality after ST elevation myocardial infraction: an acute coronary syndrome Israeli survey data mining study. Int J Cardiol. 2017;246:7&#x2013;13. doi: 10.1016/j.ijcard.2017.05.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2017.05.067</ArticleId><ArticleId IdType="pubmed">28867023</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallert J, Tomasoni M, Madison G, Held C. Predicting two-year survival versus non-survival after first myocardial infarction using machine learning and Swedish national register data. BMC Med Inform Decis Mak. 2017;17:99. doi: 10.1186/s12911-017-0500-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-017-0500-y</ArticleId><ArticleId IdType="pmc">PMC5499032</ArticleId><ArticleId IdType="pubmed">28679442</ArticleId></ArticleIdList></Reference><Reference><Citation>LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521:436&#x2013;444. doi: 10.1038/nature14539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14539</ArticleId><ArticleId IdType="pubmed">26017442</ArticleId></ArticleIdList></Reference><Reference><Citation>Morav&#x10d;&#xed;k M, et al. DeepStack: expert-level artificial intelligence in heads-up no-limit poker. Science. 2017;356:508&#x2013;513. doi: 10.1126/science.aam6960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aam6960</ArticleId><ArticleId IdType="pubmed">28254783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooi T, et al. Large scale deep learning for computer aided detection of mammographic lesions. Med Image Anal. 2017;35:303&#x2013;312. doi: 10.1016/j.media.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.media.2016.07.007</ArticleId><ArticleId IdType="pubmed">27497072</ArticleId></ArticleIdList></Reference><Reference><Citation>Song X, Mitnitski A, Cox J, Rockwood K. Comparison of machine learning techniques with classical statistical models in predicting health outcomes. Stud Health Technol Inform. 2004;107:736&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pubmed">15360910</ArticleId></ArticleIdList></Reference><Reference><Citation>Payrovnaziri SN, Barrett LA, Bis D, Bian J, He Z. Enhancing prediction models for one-year mortality in patients with acute myocardial infarction and post myocardial infarction syndrome. Stud Health Technol Inform. 2019;264:273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6785831</ArticleId><ArticleId IdType="pubmed">31437928</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey JA, Schwartz BS, Stewart WF, Adler NE. Using electronic health Records for Population Health Research: a review of methods and applications. Annu Rev Public Health. 2016;37:61&#x2013;81. doi: 10.1146/annurev-publhealth-032315-021353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-publhealth-032315-021353</ArticleId><ArticleId IdType="pmc">PMC6724703</ArticleId><ArticleId IdType="pubmed">26667605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. Building bridges across electronic health record systems through inferred phenotypic topics. J Biomed Inform. 2015;55:82&#x2013;93. doi: 10.1016/j.jbi.2015.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.03.011</ArticleId><ArticleId IdType="pmc">PMC4464930</ArticleId><ArticleId IdType="pubmed">25841328</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, et al. Privacy-preserving predictive modeling: harmonization of contextual Embeddings from different sources. JMIR Med Inform. 2018;6:e33. doi: 10.2196/medinform.9455.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/medinform.9455</ArticleId><ArticleId IdType="pmc">PMC5981054</ArticleId><ArticleId IdType="pubmed">29769172</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett LA, Payrovnaziri SN, Bian J, He Z. Building computational models to predict one-year mortality in ICU patients with acute myocardial infarction and post myocardial infarction syndrome. AMIA Jt Summits Transl Sci Proc. 2019;2019:407&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568079</ArticleId><ArticleId IdType="pubmed">31258994</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherazi SWA, Jeong YJ, Jae MH, Bae J-W, Lee JY. A machine learning-based 1-year mortality prediction model after hospital discharge for clinical patients with acute coronary syndrome. Health Informatics J. 2019:1460458219871780. 10.1177/1460458219871780.</Citation><ArticleIdList><ArticleId IdType="pubmed">31566458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu D, et al. Evidential MACE prediction of acute coronary syndrome using electronic health records. BMC Med Inform Decis Mak. 2019;19:61. doi: 10.1186/s12911-019-0754-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-019-0754-7</ArticleId><ArticleId IdType="pmc">PMC6454666</ArticleId><ArticleId IdType="pubmed">30961585</ArticleId></ArticleIdList></Reference><Reference><Citation>Asaria M, et al. Using electronic health records to predict costs and outcomes in stable coronary artery disease. Heart. 2016;102:755&#x2013;762. doi: 10.1136/heartjnl-2015-308850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2015-308850</ArticleId><ArticleId IdType="pmc">PMC4849559</ArticleId><ArticleId IdType="pubmed">26864674</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss JC, Natarajan S, Peissig PL, McCarty CA, Page D. Machine learning for personalized medicine: predicting primary myocardial infarction from electronic health records. AI Mag. 2012;33:33. doi: 10.1609/aimag.v33i4.2438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1609/aimag.v33i4.2438</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, Kiefer RC, Sharma DK, Prud&#x2019;hommeaux E, Solbrig HR. A consensus-based approach for harmonizing the OHDSI common data model with HL7 FHIR. Stud Health Technol Inform. 2017;245:887&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939955</ArticleId><ArticleId IdType="pubmed">29295227</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang G, et al. Harmonization of detailed clinical models with clinical study data standards. Methods Inf Med. 2015;54:65&#x2013;74. doi: 10.3414/ME13-02-0019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3414/ME13-02-0019</ArticleId><ArticleId IdType="pubmed">25426730</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Ryan PB. Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) Common Data Model. EGEMS (Washington, DC) 2014;2:1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Blagus R, Lusa L. SMOTE for high-dimensional class-imbalanced data. BMC Bioinform. 2013;14:106. doi: 10.1186/1471-2105-14-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-14-106</ArticleId><ArticleId IdType="pmc">PMC3648438</ArticleId><ArticleId IdType="pubmed">23522326</ArticleId></ArticleIdList></Reference><Reference><Citation>Agresti A, Coull BA. Approximate is better than &#x2018;exact&#x2019; for interval estimation of binomial proportions. Am Stat. 1998;52:119&#x2013;126.</Citation></Reference><Reference><Citation>Lakhani P, Langlotz CP. Automated detection of radiology reports that document non-routine communication of critical or significant results. J Digit Imaging. 2010;23:647&#x2013;657. doi: 10.1007/s10278-009-9237-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10278-009-9237-1</ArticleId><ArticleId IdType="pmc">PMC2978900</ArticleId><ArticleId IdType="pubmed">19826871</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson S, Rosengren A, Young K, et al. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord. 2017;17:53. doi: 10.1186/s12872-017-0482-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-017-0482-9</ArticleId><ArticleId IdType="pmc">PMC5297173</ArticleId><ArticleId IdType="pubmed">28173750</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss JC, Page D, Peissig PL, Natarajan S, McCarty C. Statistical relational learning to predict primary myocardial infarction from electronic health records. Proc Innov Appl Artif Intell Conf. 2012;2012:2341&#x2013;2347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4211289</ArticleId><ArticleId IdType="pubmed">25360347</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue S, et al. Circulating MiR-17-5p, MiR-126-5p and MiR-145-3p are novel biomarkers for diagnosis of acute myocardial infarction. Front Physiol. 2019;10:123. doi: 10.3389/fphys.2019.00123.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2019.00123</ArticleId><ArticleId IdType="pmc">PMC6387945</ArticleId><ArticleId IdType="pubmed">30833907</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross DS, McCarty CA, Steinhubl SR, Carey DJ, Erlich PM. Development of a multi-institutional cohort to facilitate cardiovascular disease biomarker validation using existing biorepository samples linked to electronic health records. Clin Cardiol. 2013;36:486&#x2013;491. doi: 10.1002/clc.22146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.22146</ArticleId><ArticleId IdType="pmc">PMC3970767</ArticleId><ArticleId IdType="pubmed">23740530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusunose K, et al. A deep learning approach for assessment of Regional Wall motion abnormality from echocardiographic images. JACC Cardiovasc Imaging. 2019. 10.1016/j.jcmg.2019.02.024.</Citation><ArticleIdList><ArticleId IdType="pubmed">31103590</ArticleId></ArticleIdList></Reference><Reference><Citation>Androulakis AFA, et al. Entropy as a novel measure of myocardial tissue heterogeneity for prediction of ventricular arrhythmias and mortality in post-infarct patients. JACC Clin Electrophysiol. 2019;5:480&#x2013;489. doi: 10.1016/j.jacep.2018.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2018.12.005</ArticleId><ArticleId IdType="pubmed">31000102</ArticleId></ArticleIdList></Reference><Reference><Citation>Zadrozny, B. &amp; Elkan, C. Transforming Classifier Scores into Accurate Multiclass Probability Estimates. Proceed Eighth ACM SIGKDD Int Conf Knowl Discov Data Mining 694&#x2013;699 (ACM, 2002). 10.1145/775047.775151.</Citation></Reference><Reference><Citation>Niculescu-Mizil, A. &amp; Caruana, R. Obtaining Calibrated Probabilities from Boosting.</Citation></Reference><Reference><Citation>Gibson WJ, et al. Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis. J Thromb Thrombolysis. 2019. 10.1007/s11239-019-01940-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31535314</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiwari, Premanand, Colborn, Katie, Smith, Derek, Xing, Fuyong, Gosh, Debashis, Rosenberg Michael. Development of a Prediction Model for Incident Atrial Fibrillation using Machine Learning Applied to Harmonized Electronic Health Record Data. BioRxiv [Preprint]. January 18, 2019. Available from: 10.1101/520866.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33011645</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-0772</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Healthcare (Amsterdam, Netherlands)</Title><ISOAbbreviation>Healthc (Amst)</ISOAbbreviation></Journal><ArticleTitle>The Longitudinal Epidemiologic Assessment of Diabetes Risk (LEADR): Unique 1.4&#xa0;M patient Electronic Health Record cohort.</ArticleTitle><Pagination><StartPage>100458</StartPage><MedlinePgn>100458</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hjdsi.2020.100458</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-0764(20)30057-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Longitudinal Epidemiologic Assessment of Diabetes Risk (LEADR) study uses a novel Electronic Health Record (EHR) data approach as a tool to assess the epidemiology of known and new risk factors for type 2 diabetes mellitus (T2DM) and study how prevention interventions affect progression to and onset of T2DM. We created an electronic cohort of 1.4 million patients having had at least 4 encounters with a healthcare organization for at least 24-months; were aged &#x2265;18 years in 2010; and had no diabetes (i.e., T1DM or T2DM) at cohort entry or in the 12 months following entry. EHR data came from patients at nine healthcare organizations across the U.S. between January 1, 2010-December 31, 2016.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Approximately 5.9% of the LEADR cohort (82,922 patients) developed T2DM, providing opportunities to explore longitudinal clinical care, medication use, risk factor trajectories, and diagnoses for these patients, compared with patients similarly matched prior to disease onset.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">LEADR represents one of the largest EHR databases to have repurposed EHR data to examine patients' T2DM risk. This paper is first in a series demonstrating this novel approach to studying T2DM.</AbstractText><AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">Chronic conditions that often take years to develop can be studied efficiently using EHR data in a retrospective design.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">While much is already known about T2DM risk, this EHR's cohort's 160&#xa0;M data points for 1.4&#xa0;M people over six years, provides opportunities to investigate new unique risk factors and evaluate research hypotheses where results could modify public health practice for preventing T2DM.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fishbein</LastName><ForeName>Howard A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA. Electronic address: HowardFishbein@westat.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birch</LastName><ForeName>Rebecca Jeffries</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathew</LastName><ForeName>Sunitha M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawyer</LastName><ForeName>Holly L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulver</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Colorado Anschutz Medical Campus, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poling</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cherokee Health Systems Inc, Knoxville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaelber</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The MetroHealth System and Case Western Reserve University, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mardon</LastName><ForeName>Russell</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Maurice C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pace</LastName><ForeName>Wilson</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>DARTNet, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umbel</LastName><ForeName>Keith D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Westat, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuanping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Karen R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imperatore</LastName><ForeName>Giuseppina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrestha</LastName><ForeName>Sundar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proia</LastName><ForeName>Krista</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yiling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKeever Bullard</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregg</LastName><ForeName>Edward W</ForeName><Initials>EW</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolka</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavkov</LastName><ForeName>Meda E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Division of Diabetes Translation, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Healthc (Amst)</MedlineTA><NlmUniqueID>101622189</NlmUniqueID><ISSNLinking>2213-0764</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011236" MajorTopicYN="N">Prediabetic State</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Big data</Keyword><Keyword MajorTopicYN="N">Chronic disease</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Electronic health records</Keyword><Keyword MajorTopicYN="N">Epidemiologic methods</Keyword><Keyword MajorTopicYN="N">Epidemiologic research design</Keyword><Keyword MajorTopicYN="N">Public health informatics</Keyword><Keyword MajorTopicYN="N">Public health practice</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>4</Day><Hour>20</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33011645</ArticleId><ArticleId IdType="doi">10.1016/j.hjdsi.2020.100458</ArticleId><ArticleId IdType="pii">S2213-0764(20)30057-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33021486</PMID><DateRevised><Year>2020</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2291-9694</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>JMIR medical informatics</Title><ISOAbbreviation>JMIR Med Inform</ISOAbbreviation></Journal><ArticleTitle>Implementation of a Cohort Retrieval System for Clinical Data Repositories Using the Observational Medical Outcomes Partnership Common Data Model: Proof-of-Concept System Validation.</ArticleTitle><Pagination><StartPage>e17376</StartPage><MedlinePgn>e17376</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e17376</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/17376</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Widespread adoption of electronic health records has enabled the secondary use of electronic health record data for clinical research and health care delivery. Natural language processing techniques have shown promise in their capability to extract the information embedded in unstructured clinical data, and information retrieval techniques provide flexible and scalable solutions that can augment natural language processing systems for retrieving and ranking relevant records.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In this paper, we present the implementation of a cohort retrieval system that can execute textual cohort selection queries on both structured data and unstructured text-Cohort Retrieval Enhanced by Analysis of Text from Electronic Health Records (CREATE).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">CREATE is a proof-of-concept system that leverages a combination of structured queries and information retrieval techniques on natural language processing results to improve cohort retrieval performance using the Observational Medical Outcomes Partnership Common Data Model to enhance model portability. The natural language processing component was used to extract common data model concepts from textual queries. We designed a hierarchical index to support the common data model concept search utilizing information retrieval techniques and frameworks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our case study on 5 cohort identification queries, evaluated using the precision at 5 information retrieval metric at both the patient-level and document-level, demonstrates that CREATE achieves a mean precision at 5 of 0.90, which outperforms systems using only structured data or only unstructured text with mean precision at 5 values of 0.54 and 0.74, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The implementation and evaluation of Mayo Clinic Biobank data demonstrated that CREATE outperforms cohort retrieval systems that only use one of either structured data or unstructured text in complex textual cohort queries.</AbstractText><CopyrightInformation>&#xa9;Sijia Liu, Yanshan Wang, Andrew Wen, Liwei Wang, Na Hong, Feichen Shen, Steven Bedrick, William Hersh, Hongfang Liu. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 06.10.2020.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Sijia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9763-1164</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yanshan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4433-7839</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9090-8028</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Liwei</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-9970-8604</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Na</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-6798-1761</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Feichen</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7803-2331</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedrick</LastName><ForeName>Steven</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0163-9397</Identifier><AffiliationInfo><Affiliation>Department of Computer Science and Electrical Engineering, Oregon Health &amp; Science University, Portland, OR, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hersh</LastName><ForeName>William</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-4114-5148</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics and Clinical Epidemiology, Oregon Health &amp; Science University, Portland, OR, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongfang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-2570-3741</Identifier><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EB019403</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011829</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011934</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR002062</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Med Inform</MedlineTA><NlmUniqueID>101645109</NlmUniqueID></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cohort retrieval</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">information retrieval</Keyword><Keyword MajorTopicYN="N">natural language processing</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>6</Day><Hour>12</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33021486</ArticleId><ArticleId IdType="pmc">PMC7576539</ArticleId><ArticleId IdType="doi">10.2196/17376</ArticleId><ArticleId IdType="pii">v8i10e17376</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Weiskopf NG, Weng C. Methods and dimensions of electronic health record data quality assessment: enabling reuse for clinical research. Journal of the American Medical Informatics Association. 2013 Jan 01;20(1):144&#x2013;151. doi: 10.1136/amiajnl-2011-000681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000681</ArticleId><ArticleId IdType="pmc">PMC3555312</ArticleId><ArticleId IdType="pubmed">22733976</ArticleId></ArticleIdList></Reference><Reference><Citation>Accrual to Clinical Trials (ACT) Network. Clinical and Translational Science Institute.  [2020-08-20].   https://www.ctsi.umn.edu/consultations-and-services/multi-site-study-support/accrual-clinical-trials-act-network.</Citation></Reference><Reference><Citation>Gottesman O, Kuivaniemi H, Tromp G, Faucett WA, Li R, Manolio TA, Sanderson SC, Kannry J, Zinberg R, Basford MA, Brilliant M, Carey DJ, Chisholm RL, Chute CG, Connolly JJ, Crosslin D, Denny JC, Gallego CJ, Haines JL, Hakonarson H, Harley J, Jarvik GP, Kohane I, Kullo IJ, Larson EB, McCarty C, Ritchie MD, Roden DM, Smith ME, B&#xf6;ttinger EP, Williams MS. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet Med. 2013 Jun 6;15(10):761&#x2013;771. doi: 10.1038/gim.2013.72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2013.72</ArticleId><ArticleId IdType="pmc">PMC3795928</ArticleId><ArticleId IdType="pubmed">23743551</ArticleId></ArticleIdList></Reference><Reference><Citation>PCORnet: the National Patient-Centered Clinical Research Network.  [2020-08-20].   https://pcornet.org/clinical-research-network/</Citation></Reference><Reference><Citation>Meystre SM, Lovis C, B&#xfc;rkle T, Tognola G, Budrionis A, Lehmann CU. Clinical Data Reuse or Secondary Use: Current Status and Potential Future Progress. Yearb Med Inform. 2017 Aug;26(1):38&#x2013;52. doi: 10.15265/IY-2017-007.  </Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2017-007</ArticleId><ArticleId IdType="pmc">PMC6239225</ArticleId><ArticleId IdType="pubmed">28480475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O&#x2019;Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen N, Donnelly P, Marchini J. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018 Oct 10;562(7726):203&#x2013;209. doi: 10.1038/s41586-018-0579-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-018-0579-z</ArticleId><ArticleId IdType="pmc">PMC6786975</ArticleId><ArticleId IdType="pubmed">30305743</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Wang Y, Hong N, Shen F, Wu S, Hersh W, Liu H. On Mapping Textual Queries to a Common Data Model. 2017 IEEE International Conference on Healthcare Informatics (ICHI); 23-26 Aug. 2017; Park City, UT, USA. 2017. pp. 21&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/ICHI.2017.63</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang L, Rastegar-Mojarad M, Moon S, Shen F, Afzal N, Liu S, Zeng Y, Mehrabi S, Sohn S, Liu H. Clinical information extraction applications: A literature review. Journal of Biomedical Informatics. 2018 Jan;77:34&#x2013;49. doi: 10.1016/j.jbi.2017.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2017.11.011</ArticleId><ArticleId IdType="pmc">PMC5771858</ArticleId><ArticleId IdType="pubmed">29162496</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu P-Y, Cheng C-W, Kaddi CD, Venugopalan J, Hoffman R, Wang MD. -Omic and Electronic Health Record Big Data Analytics for Precision Medicine. IEEE Trans Biomed Eng. 2017 Feb;64(2):263&#x2013;273. doi: 10.1109/TBME.2016.2573285.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TBME.2016.2573285</ArticleId><ArticleId IdType="pmc">PMC5859562</ArticleId><ArticleId IdType="pubmed">27740470</ArticleId></ArticleIdList></Reference><Reference><Citation>Murff HJ, FitzHenry F, Matheny ME, Gentry N, Kotter KL, Crimin K, Dittus RS, Rosen AK, Elkin PL, Brown SH, Speroff T. Automated identification of postoperative complications within an electronic medical record using natural language processing. JAMA. 2011 Aug 24;306(8):848&#x2013;55. doi: 10.1001/jama.2011.1204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2011.1204</ArticleId><ArticleId IdType="pubmed">21862746</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddox TM, Albert NM, Borden WB, Curtis LH, Ferguson TB, Kao DP, Marcus GM, Peterson ED, Redberg R, Rumsfeld JS, Shah ND, Tcheng JE. The Learning Healthcare System and Cardiovascular Care: A Scientific Statement From the American Heart Association. Circulation. 2017 Apr 04;135(14) doi: 10.1161/cir.0000000000000480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/cir.0000000000000480</ArticleId><ArticleId IdType="pubmed">28254835</ArticleId></ArticleIdList></Reference><Reference><Citation>Savova GK, Masanz JJ, Ogren PV, Zheng J, Sohn S, Kipper-Schuler KC, Chute CG. Mayo clinical Text Analysis and Knowledge Extraction System (cTAKES): architecture, component evaluation and applications. J Am Med Inform Assoc. 2010 Sep 01;17(5):507&#x2013;513. doi: 10.1136/jamia.2009.001560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.001560</ArticleId><ArticleId IdType="pmc">PMC2995668</ArticleId><ArticleId IdType="pubmed">20819853</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronson AR, Lang F. An overview of MetaMap: historical perspective and recent advances. J Am Med Inform Assoc. 2010 May 01;17(3):229&#x2013;236. doi: 10.1136/jamia.2009.002733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jamia.2009.002733</ArticleId><ArticleId IdType="pmc">PMC2995713</ArticleId><ArticleId IdType="pubmed">20442139</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan S, Elhadad N, Chapman Wendy, Manandhar Suresh, Savova Guergana. SemEval-2014 Task 7: Analysis of Clinical Text. 8th International Workshop on Semantic Evaluation (SemEval 2014); August 23-24, 2014; Dublin, Ireland. 2014. pp. 54&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="doi">10.3115/v1/s14-2007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan Sameer, Elhadad Noemie, South Brett, Martinez David, Christensen Lee, Vogel Amy, Suominen Hanna, Chapman Wendy, Savova Guergana. Task 1: ShARe/CLEF eHealth Evaluation Lab 2013. CLEF (Working Notes); ShARe/CLEF eHealth Evaluation Lab; September 23-26, 2013; Valencia, Spain. 2013.</Citation></Reference><Reference><Citation>Carroll R, Thompson Will K, Eyler Anne E, Mandelin Arthur M, Cai Tianxi, Zink Raquel M, Pacheco Jennifer A, Boomershine Chad S, Lasko Thomas A, Xu Hua, Karlson Elizabeth W, Perez Raul G, Gainer Vivian S, Murphy Shawn N, Ruderman Eric M, Pope Richard M, Plenge Robert M, Kho Abel Ngo, Liao Katherine P, Denny Joshua C. Portability of an algorithm to identify rheumatoid arthritis in electronic health records. J Am Med Inform Assoc. 2012 Jun;19(e1):e162&#x2013;9. doi: 10.1136/amiajnl-2011-000583.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000583</ArticleId><ArticleId IdType="pmc">PMC3392871</ArticleId><ArticleId IdType="pubmed">22374935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrabi S, Krishnan A, Roch AM, Schmidt H, Li D, Kesterson J, Beesley C, Dexter P, Schmidt M, Palakal M, Liu H. Identification of Patients with Family History of Pancreatic Cancer--Investigation of an NLP System Portability. Stud Health Technol Inform. 2015;216:604&#x2013;8.  </Citation><ArticleIdList><ArticleId IdType="pmc">PMC5863760</ArticleId><ArticleId IdType="pubmed">26262122</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin Travis R, Harabagiu Sanda M. Multi-modal Patient Cohort Identification from EEG Report and Signal Data. Annual Symposium proceedings; American Medical Informatics Association; Nov 12-16, 2016; Chicago, IL, USA. 2016. pp. 1794&#x2013;1803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333290</ArticleId><ArticleId IdType="pubmed">28269938</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanauer DA, Mei Q, Law J, Khanna R, Zheng K. Supporting information retrieval from electronic health records: A report of University of Michigan&#x2019;s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE) Journal of Biomedical Informatics. 2015 Jun;55:290&#x2013;300. doi: 10.1016/j.jbi.2015.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.05.003</ArticleId><ArticleId IdType="pmc">PMC4527540</ArticleId><ArticleId IdType="pubmed">25979153</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford E, Carroll JA, Smith HE, Scott D, Cassell JA. Extracting information from the text of electronic medical records to improve case detection: a systematic review. J Am Med Inform Assoc. 2016 Feb 05;23(5):1007&#x2013;1015. doi: 10.1093/jamia/ocv180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv180</ArticleId><ArticleId IdType="pmc">PMC4997034</ArticleId><ArticleId IdType="pubmed">26911811</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Liu S, Wang Y, Timmons T, Uppili H, Bedrick S, Hersh W, Liu H. Intrainstitutional EHR collections for patient-level information retrieval. Journal of the Association for Information Science and Technology. 2017 Sep 18;68(11):2636&#x2013;2648. doi: 10.1002/asi.23884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/asi.23884</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson JE, Ryu E, Johnson KJ, Koenig BA, Maschke KJ, Morrisette JA, Liebow M, Takahashi PY, Fredericksen ZS, Sharma RG, Anderson KS, Hathcock MA, Carnahan JA, Pathak J, Lindor NM, Beebe TJ, Thibodeau SN, Cerhan JR. The Mayo Clinic Biobank: A Building Block for Individualized Medicine. Mayo Clinic Proceedings. 2013 Sep;88(9):952&#x2013;962. doi: 10.1016/j.mayocp.2013.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2013.06.006</ArticleId><ArticleId IdType="pmc">PMC4258707</ArticleId><ArticleId IdType="pubmed">24001487</ArticleId></ArticleIdList></Reference><Reference><Citation>Biron P, Metzger M, Pezet C, Sebban C, Barthuet E, Durand T. An information retrieval system for computerized patient records in the context of a daily hospital practice: the example of the L&#xe9;on B&#xe9;rard Cancer Center (France) Appl Clin Inform. 2017 Dec 20;05(01):191&#x2013;205. doi: 10.4338/aci-2013-08-cr-0065.</Citation><ArticleIdList><ArticleId IdType="doi">10.4338/aci-2013-08-cr-0065</ArticleId><ArticleId IdType="pmc">PMC3974255</ArticleId><ArticleId IdType="pubmed">24734133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanauer DA, Mei Q, Law J, Khanna R, Zheng K. Supporting information retrieval from electronic health records: A report of University of Michigan&#x2019;s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE) Journal of Biomedical Informatics. 2015 Jun;55:290&#x2013;300. doi: 10.1016/j.jbi.2015.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.05.003</ArticleId><ArticleId IdType="pmc">PMC4527540</ArticleId><ArticleId IdType="pubmed">25979153</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcelon N, Neuraz A, Salomon R, Faour H, Benoit V, Delapalme A, Munnich A, Burgun A, Rance B. A clinician friendly data warehouse oriented toward narrative reports: Dr. Warehouse. Journal of Biomedical Informatics. 2018 Apr;80:52&#x2013;63. doi: 10.1016/j.jbi.2018.02.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2018.02.019</ArticleId><ArticleId IdType="pubmed">29501921</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H, Toti Giulia, Morley Katherine I, Ibrahim Zina M, Folarin Amos, Jackson Richard, Kartoglu Ismail, Agrawal Asha, Stringer Clive, Gale Darren, Gorrell Genevieve, Roberts Angus, Broadbent Matthew, Stewart Robert, Dobson Richard J B. SemEHR: A general-purpose semantic search system to surface semantic data from clinical notes for tailored care, trial recruitment, and clinical research. J Am Med Inform Assoc. 2018 May 01;25(5):530&#x2013;537. doi: 10.1093/jamia/ocx160.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocx160</ArticleId><ArticleId IdType="pmc">PMC6019046</ArticleId><ArticleId IdType="pubmed">29361077</ArticleId></ArticleIdList></Reference><Reference><Citation>FHIR (Fast Healthcare Interoperability Resources)  FHIR Overview.   https://www.hl7.org/fhir/overview.html.</Citation></Reference><Reference><Citation>Stubbs A, Filannino Michele, Soysal Ergin, Henry Samuel, Uzuner &#xd6;zlem. Cohort selection for clinical trials: n2c2 2018 shared task track 1. J Am Med Inform Assoc. 2019 Nov 01;26(11):1163&#x2013;1171. doi: 10.1093/jamia/ocz163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocz163</ArticleId><ArticleId IdType="pmc">PMC6798568</ArticleId><ArticleId IdType="pubmed">31562516</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Tu SW, Sim I, Richesson R. Formal representation of eligibility criteria: A literature review. Journal of Biomedical Informatics. 2010 Jun;43(3):451&#x2013;467. doi: 10.1016/j.jbi.2009.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2009.12.004</ArticleId><ArticleId IdType="pmc">PMC2878905</ArticleId><ArticleId IdType="pubmed">20034594</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Wu X, Luo Z, Boland MR, Theodoratos D, Johnson SB. EliXR: an approach to eligibility criteria extraction and representation. Journal of the American Medical Informatics Association. 2011 Dec 01;18(Supplement 1):i116&#x2013;i124. doi: 10.1136/amiajnl-2011-000321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000321</ArticleId><ArticleId IdType="pmc">PMC3241167</ArticleId><ArticleId IdType="pubmed">21807647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang T, Zhang S, Tang Y, Hruby GW, Rusanov A, Elhadad N, Weng C. EliIE: An open-source information extraction system for clinical trial eligibility criteria. Journal of the American Medical Informatics Association. 2017;24(6):1062&#x2013;1071. doi: 10.1093/jamia/ocx019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocx019</ArticleId><ArticleId IdType="pmc">PMC6259668</ArticleId><ArticleId IdType="pubmed">28379377</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP Common Data Model v5.3.1. GitHub.  [2020-08-20].   https://github.com/OHDSI/CommonDataModel/tree/v5.3.1.</Citation></Reference><Reference><Citation>Metathesaurus. UMLS.  [2020-08-20].   https://www.nlm.nih.gov/research/umls/knowledge_sources/metathesaurus/index.html.</Citation></Reference><Reference><Citation>ATHENA standardized vocabularies - OHDSI.  [2020-08-20].   https://www.ohdsi.org/analytic-tools/athena-standardized-vocabularies/</Citation></Reference><Reference><Citation>Elasticsearch: The Official Distributed Search &amp; Analytics Engine.  [2020-08-20].   https://www.elastic.co/elasticsearch/</Citation></Reference><Reference><Citation>Wang Yanshan, Wen Andrew, Liu Sijia, Hersh William, Bedrick Steven, Liu Hongfang. Test collections for electronic health record-based clinical information retrieval. JAMIA Open. 2019 Oct;2(3):360&#x2013;368. doi: 10.1093/jamiaopen/ooz016.  </Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooz016</ArticleId><ArticleId IdType="pmc">PMC6824517</ArticleId><ArticleId IdType="pubmed">31709390</ArticleId></ArticleIdList></Reference><Reference><Citation>Huser V, DeFalco FJ, Schuemie M, Ryan PB, Shang N, Velez M, Park RW, Boyce RD, Duke J, Khare R, Utidjian L, Bailey C. Multisite Evaluation of a Data Quality Tool for Patient-Level Clinical Datasets. eGEMs. 2016 Nov 30;4(1):24. doi: 10.13063/2327-9214.1239.</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1239</ArticleId><ArticleId IdType="pmc">PMC5226382</ArticleId><ArticleId IdType="pubmed">28154833</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson KJ. Mining Hierarchies Similarity Clusters from Value Set Repositories. AMIA Annu Symp Proc; AMIA Annual Symposium; Nov 4-8, 2017; Washington, DC, USA. 2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977603</ArticleId><ArticleId IdType="pubmed">29854206</ArticleId></ArticleIdList></Reference><Reference><Citation>Marling C, Whitehouse P. Case-Based Reasoning in the Care of Alzheimer's Disease Patients. In: Aha DW, Watson I, editors. International Conference on Case-Based Reasoning. Lecture Notes in Computer Science. Berlin: Springer; 2001. pp. 702&#x2013;715.</Citation></Reference><Reference><Citation>van den Branden M, Wiratunga N, Burton D, Craw S. Integrating case-based reasoning with an electronic patient record system. Artificial Intelligence in Medicine. 2011 Feb;51(2):117&#x2013;123. doi: 10.1016/j.artmed.2010.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.artmed.2010.12.004</ArticleId><ArticleId IdType="pubmed">21232927</ArticleId></ArticleIdList></Reference><Reference><Citation>Miotto R, Weng C. Case-based reasoning using electronic health records efficiently identifies eligible patients for clinical trials. Journal of the American Medical Informatics Association. 2015 Mar 13;22(e1):e141&#x2013;e150. doi: 10.1093/jamia/ocu050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu050</ArticleId><ArticleId IdType="pmc">PMC4428438</ArticleId><ArticleId IdType="pubmed">25769682</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckley C, Singhal A, Mitra M, Salton G. New Retrieval Approaches Using SMART: TREC 4. The Fourth Text REtrieval Conference (TREC-4); Fourth text retrieval conference (TREC-4); November 1-3; Gaithersburg, Maryland. NIST Special Publication 500-236; 1995. pp. 25&#x2013;48.  </Citation></Reference><Reference><Citation>Cao Z, Wei F, Dong L, Li S, Zhou M. Ranking with recursive neural networks and its application to multi-document summarization. Proceedings of the Twenty-Ninth AAAI Conference on Artificial Intelligence; 2015; Austin, TX, USA. 2015. pp. 2153&#x2013;2159.</Citation></Reference><Reference><Citation>Chen J, Yu H. Unsupervised ensemble ranking of terms in electronic health record notes based on their importance to patients. Journal of Biomedical Informatics. 2017 Apr;68:121&#x2013;131. doi: 10.1016/j.jbi.2017.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2017.02.016</ArticleId><ArticleId IdType="pmc">PMC5505865</ArticleId><ArticleId IdType="pubmed">28267590</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Lasko TA, Mei Q, Denny JC, Xu H. A study of active learning methods for named entity recognition in clinical text. Journal of Biomedical Informatics. 2015 Dec;58:11&#x2013;18. doi: 10.1016/j.jbi.2015.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2015.09.010</ArticleId><ArticleId IdType="pmc">PMC4934373</ArticleId><ArticleId IdType="pubmed">26385377</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33023798</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Risk of Mortality in Elderly Coronavirus Disease 2019 Patients With Mental Health Disorders: A Nationwide Retrospective Study in South Korea.</ArticleTitle><Pagination><StartPage>1308</StartPage><EndPage>1316</EndPage><MedlinePgn>1308-1316</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2020.09.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(20)30498-X</ELocationID><Abstract><AbstractText Label="OBJECTIVE">This study aimed to investigate the different clinical characteristics among elderly coronavirus disease 2019 (COVID-19) patients with and without mental disorders in South Korea and determine if these characteristics have an association with underlying mental disorders causing mortality.</AbstractText><AbstractText Label="METHOD">A population-based comparative cohort study was conducted using the national claims database. Individuals aged &#x2265;65 years with confirmed COVID-19 between January 1, 2020 and April 10, 2020 were assessed. The endpoints for evaluating mortality for all participants were death, 21 days after diagnosis, or April 10, 2020. The risk of mortality associated with mental disorders was estimated using Cox hazards regression.</AbstractText><AbstractText Label="RESULTS">We identified 814 elderly COVID-19 patients (255 [31.3%] with mental disorder and 559 [68.7%] with nonmental disorder). Individuals with mental disorders were found more likely to be older, taking antithrombotic agents, and had diabetes, hypertension, chronic obstructive lung disease, and urinary tract infections than those without mental disorders. After propensity score stratification, our study included 781 patients in each group (236 [30.2%] with mental disorder and 545 [69.8%] with nonmental disorder). The mental disorder group showed higher mortality rates than the nonmental disorder group (12.7% [30/236] versus 6.8% [37/545]). However, compared to patients without mental disorders, the hazard ratio (HR) for mortality in elderly COVID-19 patients with mental disorders was not statistically significant (HR: 1.57, 95%CI: 0.95-2.56).</AbstractText><AbstractText Label="CONCLUSION">Although the association between mental disorders in elderly individuals and mortality in COVID-19 is unclear, this study suggests that elderly patients with comorbid conditions and those taking psychiatric medications might be at a higher risk of COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Yun</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ajou University School of Medicine (DYL, CHH, HWR, SJS), Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Jaehyeong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Graduate School of Ajou University (JC, RWP, CSK), Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine (SCY, RWP, EYL, BP), Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Graduate School of Ajou University (JC, RWP, CSK), Suwon, South Korea; Department of Biomedical Informatics, Ajou University School of Medicine (SCY, RWP, EYL, BP), Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chung Soo</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Graduate School of Ajou University (JC, RWP, CSK), Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun Young</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine (SCY, RWP, EYL, BP), Suwon, South Korea; Office of Biostatistics, Medical Research Collaborating Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center (EYL, BP), Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine (HA, CA, HK), PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreescu</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine (HA, CA, HK), PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karim</LastName><ForeName>Helmet</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine (HA, CA, HK), PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Chang Hyung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ajou University School of Medicine (DYL, CHH, HWR, SJS), Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rho</LastName><ForeName>Hyun Woong</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ajou University School of Medicine (DYL, CHH, HWR, SJS), Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Bumhee</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine (SCY, RWP, EYL, BP), Suwon, South Korea; Office of Biostatistics, Medical Research Collaborating Center, Ajou Research Institute for Innovative Medicine, Ajou University Medical Center (EYL, BP), Suwon, South Korea. Electronic address: bhpark@ajou.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Sang Joon</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ajou University School of Medicine (DYL, CHH, HWR, SJS), Suwon, South Korea. Electronic address: sjsonpsy@ajou.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008603" MajorTopicYN="N">Mental Health</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Elderly</Keyword><Keyword MajorTopicYN="N">mental disorder</Keyword><Keyword MajorTopicYN="N">mortality</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33023798</ArticleId><ArticleId IdType="pmc">PMC7521355</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2020.09.016</ArticleId><ArticleId IdType="pii">S1064-7481(20)30498-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yang W, Cao Q, Qin L. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infection. 2020;80:388&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102539</ArticleId><ArticleId IdType="pubmed">32112884</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Coronavirus disease 2019 (COVID-19) Wkly Epidemiol Updat. 2020:1&#x2013;2.</Citation></Reference><Reference><Citation>Applegate WB, Ouslander JG. COVID-19 presents high risk to older persons. J Am Geriatr Soc. 2020;68:681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166412</ArticleId><ArticleId IdType="pubmed">32154911</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Guan X, Wu P. Early transmission dynamics in Wuhan, China, of novel coronavirus&#x2013;infected pneumonia. N Engl J Med. 2020;382:1199&#x2013;1207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121484</ArticleId><ArticleId IdType="pubmed">31995857</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Li W, Zhang Q. Mental health services for older adults in China during the COVID-19 outbreak. Lancet Psychiatry. 2020;7:e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128970</ArticleId><ArticleId IdType="pubmed">32085843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd-Sherlock P, Ebrahim S, Geffen L. Bearing the brunt of covid-19: older people in low and middle income countries. BMJ. 2020;368:m1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">32169830</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiloha R. COVID-19 and mental health. Epidem Int. 2020;5:7&#x2013;9.</Citation></Reference><Reference><Citation>Brown EE, Kumar S, Rajji TK. Anticipating and mitigating the impact of COVID-19 pandemic on Alzheimer's disease and related dementias. Am J Geriatr Psychiatry. 2020;28:712&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165101</ArticleId><ArticleId IdType="pubmed">32331845</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip PS, Cheung Y, Chau PH. The impact of epidemic outbreak: the case of severe acute respiratory syndrome (SARS) and suicide among older adults in Hong Kong. Crisis. 2010;31:86&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">20418214</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahia IV, Blazer DG, Smith GS. COVID-19, mental health and Aging: A need for new knowledge to bridge science and service. Am J Geriatr Psychiatry. 2020;28:695&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142692</ArticleId><ArticleId IdType="pubmed">32278745</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JH, Kim KW, Kim M-H. A nationwide survey on the prevalence and risk factors of late life depression in South Korea. J Affect Disord. 2012;138:34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22284016</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim E, Tariq A, Choi W. Transmission potential and severity of COVID-19 in South Korea. Int J Infect Dis. 2020;93:339&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118661</ArticleId><ArticleId IdType="pubmed">32198088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Yoon S, Kim L-Y. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017;32:718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5383602</ArticleId><ArticleId IdType="pubmed">28378543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394:1816&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Suchard MA, Shea S. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med. 2020;180:542&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042845</ArticleId><ArticleId IdType="pubmed">32065600</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AM, Patrick AR, Lauer MS. A tool for assessing the feasibility of comparative effectiveness research. Comp Eff Res. 2013;3:11&#x2013;20.</Citation></Reference><Reference><Citation>Cohort Method: New-user cohort method with large scale propensity and outcome models. Martijn J: Observational Health Data Sciences and Informatics (OHDSI) network; 2014. Available at: https://github.com/ohdsi/cohortmethod. Accessed March 25, 2020</Citation></Reference><Reference><Citation>Jin J-M, Bai P, He W. Gender differences in patients with COVID-19: Focus on severity and mortality. Front Public Health. 2020;8:152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201103</ArticleId><ArticleId IdType="pubmed">32411652</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Luo R, Wang K. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110296</ArticleId><ArticleId IdType="pubmed">32247631</ArticleId></ArticleIdList></Reference><Reference><Citation>Paranjpe I, Fuster V, Lala A. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76:122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202841</ArticleId><ArticleId IdType="pubmed">32387623</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayers G, Igoe D, Carr M. High morbidity and mortality associated with an outbreak of influenza A (H3N2) in a psycho-geriatric facility. Epidemiol Infect. 2013;141:357&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">22672856</ArticleId></ArticleIdList></Reference><Reference><Citation>World Wide Web Domestic Occurrence Status [KCDC COVID-19 Web site]. 2020. Available at:http://ncov.mohw.go.kr/bdBoardList_Real.do?brdId=1&amp;brdGubun=11&amp;ncvContSeq=&amp;contSeq=&amp;board_id=&amp;gubun=Accessed 21 March, 2020</Citation></Reference><Reference><Citation>Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K, Zheng J, Mok Y. SARS: prognosis, outcome and sequelae. Respirology. 2003;8:S36&#x2013;S40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169213</ArticleId><ArticleId IdType="pubmed">15018132</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakafero G, Sanders RD, Nguyen&#x2010;Van&#x2010;Tam JS. The association between benzodiazepines and influenza&#x2010;like illness&#x2010;related pneumonia and mortality: a survival analysis using UK Primary Care data. Pharmacoepidemiol Drug Saf. 2016;25:1263&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pubmed">27215827</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S-W, Su K-P. Using psychoneuroimmunity against COVID-19. Brain Behav Immun. 2020;87:4&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194899</ArticleId><ArticleId IdType="pubmed">32234338</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H, Chen J-H, Xu Y-F. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7:e21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269717</ArticleId><ArticleId IdType="pubmed">32199510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33024121</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study.</ArticleTitle><Pagination><StartPage>5009</StartPage><MedlinePgn>5009</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5009</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-020-18849-z</ELocationID><Abstract><AbstractText>Comorbid conditions appear to be common among individuals hospitalised with coronavirus disease 2019 (COVID-19) but estimates of prevalence vary and little is known about the prior medication use of patients. Here, we describe the characteristics of adults hospitalised with COVID-19 and compare them with influenza patients. We include 34,128 (US: 8362, South Korea: 7341, Spain: 18,425) COVID-19 patients, summarising between 4811 and 11,643 unique aggregate characteristics. COVID-19 patients have been majority male in the US and Spain, but predominantly female in South Korea. Age profiles vary across data sources. Compared to 84,585 individuals hospitalised with influenza in 2014-19, COVID-19 patients have more typically been male, younger, and with fewer comorbidities and lower medication use. While protecting groups vulnerable to influenza is likely a useful starting point in the response to COVID-19, strategies will likely need to be broadened to reflect the particular characteristics of individuals being hospitalised with COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9286-1128</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5052-6399</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sena</LastName><ForeName>Anthony G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2595-8736</Identifier><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abedtash</LastName><ForeName>Hamed</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9139-5452</Identifier><AffiliationInfo><Affiliation>Eli Lilly and Company, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrah&#xe3;o</LastName><ForeName>Maria Tereza F</ForeName><Initials>MTF</Initials><Identifier Source="ORCID">0000-0003-2701-670X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alberga</LastName><ForeName>Amanda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics Network, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alghoul</LastName><ForeName>Heba</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8234-5843</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alser</LastName><ForeName>Osaid</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6743-803X</Identifier><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Medication Safety Research Chair, King Saud University, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aragon</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Areia</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4668-7069</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banda</LastName><ForeName>Juan M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-8499-824X</Identifier><AffiliationInfo><Affiliation>Department of Computer Science, Georgia State University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Jaehyeong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Culhane</LastName><ForeName>Aedin C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0002-1395-9734</Identifier><AffiliationInfo><Affiliation>Data Science, Dana-Farber Cancer Institute. Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davydov</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Microbiology, Virology and Immunology, Belarusian State Medical University, Minsk, Belarus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez-Bertolin</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Weihua</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research, AbbVie, North Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4243-155X</Identifier><AffiliationInfo><Affiliation>Pharmacoepidemiology, Regeneron, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Johns Hopkins School of Public, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardin</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Library of Medicine, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Hokyun</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-6220-4207</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jing</LastName><ForeName>Yonghua</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Health Economics and Outcomes Research, AbbVie, North Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Chi Young</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaas-Hansen</LastName><ForeName>Benjamin Skov</ForeName><Initials>BS</Initials><Identifier Source="ORCID">0000-0003-1023-0371</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology Unit, Zealand University Hospital, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NNF Centre for Protein Research, University of Copenhagen, K&#xf8;benhavn, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaduk</LastName><ForeName>Denys</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics &#x2116; 2, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Seamus</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Science Policy and Research, National Institute for Health and Care Excellence, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeesuk</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4956-0693</Identifier><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, College of Medicine, Hanyang University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolovos</LastName><ForeName>Spyros</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Jennifer C E</ForeName><Initials>JCE</Initials><Identifier Source="ORCID">0000-0002-1729-8654</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyejin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Bigdata Department, Health Insurance Review &amp; Assessment Service, Wonju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lynch</LastName><ForeName>Kristine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>GRECC, Tennessee Valley Healthcare System VA, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paras P</ForeName><Initials>PP</Initials><Identifier Source="ORCID">0000-0002-0233-9871</Identifier><AffiliationInfo><Affiliation>College of Medicine-Tucson, University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee, Dundee, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9066-9431</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nyberg</LastName><ForeName>Fredrik</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0892-5668</Identifier><AffiliationInfo><Affiliation>School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jimyung</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6998-2546</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posada</LastName><ForeName>Jose D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0003-3864-0241</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rho</LastName><ForeName>Yeunsook</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Data Science to Patient Value Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Nigam H</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0001-9385-7158</Identifier><AffiliationInfo><Affiliation>Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Seokyoung</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5653-7005</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology and Pain Medicine, Catholic University of Daegu, School of Medicine, Gyeongsan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, UCLA Fielding School of Public Health, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizcaya</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0248-7636</Identifier><AffiliationInfo><Affiliation>Bayer Pharmaceuticals, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volpe</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Haini</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><Identifier Source="ORCID">0000-0002-0692-412X</Identifier><AffiliationInfo><Affiliation>Tufts Institute for Clinical Research and Health Policy Studies, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yimer</LastName><ForeName>Belay B</ForeName><Initials>BB</Initials><Identifier Source="ORCID">0000-0001-8621-6539</Identifier><AffiliationInfo><Affiliation>Centre for Epidemiology Versus Arthritis, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2064-8440</Identifier><AffiliationInfo><Affiliation>School of Public Health, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuk</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, Oxford, UK. daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG059307</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K501256/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>SRF-2018-11-ST2-004</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>21605</GrantID><Acronym>VAC_</Acronym><Agency>Versus Arthritis</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2020 Jun 28;:</RefSource><PMID Version="1">32511443</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed the ICMJE uniform disclosure form, with the following declarations made: D.P.A. reports grants and other from AMGEN, grants, non-financial support and other from UCB Biopharma, grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programmes organised by DPA&#x2019;s department and open for external participants. D.V. reports personal fees from Bayer, outside the submitted work, and he is a full-time employee at a pharmaceutical company. DM reports funding support from the Wellcome Trust, NIHR, Scottish CSO and Tenovus Scotland for research unrelated to this work. S.C.Y. reports grants from Korean Ministry of Health &amp; Welfare, grants from Korean Ministry of Trade, Industry &amp; Energy, during the conduct of the study. A.G. reports personal fees from Regeneron Pharmaceuticals, outside the submitted work, and she a full-time employee at Regeneron Pharmaceuticals. This work was not conducted at Regeneron Pharmaceuticals. Y.J. reports employee of AbbVie and owns company stock. A.A. reports that he is currently employed at Alberta Health Services (AHS) as a Data Science Lead redeployed as an epidemiologist to aid in the COVID-19 response. This work was not conducted at AHS, within AHS working hours, or with AHS staff. He contributed and conducted this work as an Independent Epidemiologist, as a member of the Observational Health Data Sciences and Informatics (OHDSI) Network. P.R. reports grants from Innovative Medicines Initiative, grants from Janssen Research and Development, during the conduct of the study. M.S. reports grants from US National Science Foundation, grants from US National Institutes of Health, grants from IQVIA, personal fees from Janssen Research and Development, during the conduct of the study. G.H. reports grants from US NIH National Library of Medicine, during the conduct of the study; grants from Janssen Research, outside the submitted work. A.P.U. reports grants from Fundacion Alfonso Martin Escudero, grants from Medical Research Council, outside the submitted work. H.A. reports personal fees from Eli Lilly and Company, outside the submitted work. A.S. reports personal fees from Janssen Research &amp; Development, during the conduct of the study; personal fees from Janssen Research &amp; Development, outside the submitted work. A.S. is a full-time employee of Janssen and shareholder of Johnson &amp; Johnson. G.R. is a full-time employee of Janssen and shareholder of Johnson &amp; Johnson. F.D. reports personal fees from Janssen Research &amp; Development, during the conduct of the study; personal fees from Janssen Research &amp; Development, outside the submitted work. R.W.P. reports grants from Korean Ministry of Health &amp; Welfare, grants from Korean Ministry of Trade, Industry &amp; Energy, during the conduct of the study. J.P. reports grants from Korean Ministry of Health &amp; Welfare, grants from Korean Ministry of Trade, Industry &amp; Energy, during the conduct of the study. J.C. reports grants from Korean Ministry of Health &amp; Welfare, grants from Korean Ministry of Trade, Industry &amp; Energy, during the conduct of the study. S.D. reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Biomedical Research outside the submitted work. H.J. reports grants from Korean Ministry of Health &amp; Welfare, grants from Korean Ministry of Trade, Industry &amp; Energy, during the conduct of the study. B.S.K.H. reports grants from Innovation Fund Denmark (5153-00002B) and the Novo Nordisk Foundation (NNF14CC0001), outside the submitted work. K.K. reports she is an employee of IQVIA. CR reports he is an employee of IQVIA. J.S. reports other from Janssen R&amp;D, during the conduct of the study; other from Janssen R&amp;D, outside the submitted work; and J.S. was a full-time employee of Johnson &amp; Johnson, or a subsidiary, at the time the study was conducted. J.S. owns stock, stock options, and pension rights from the company. R.M. reports and is an employee of Janssen Research and Development. W.G. is an AbbVie employee. P.R. reports and is an employee of Janssen Research and Development and shareholder of Johnson &amp; Johnson. M.S. is a full-time employee of Janssen R&amp;D, and a shareholder of Johnson &amp; Johnson. J.H. reports other from Janssen Research &amp; Development, during the conduct of the study; other from Janssen Research &amp; Development, outside the submitted work; and full-time employee of Janssen and shareholder of Johnson &amp; Johnson. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33024121</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pii">10.1038/s41467-020-18849-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507&#x2013;513. doi: 10.1016/S0140-6736(20)30211-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x2013;infected pneumonia in Wuhan, China. JAMA. 2020;323:1061&#x2013;1069. doi: 10.1001/jama.2020.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatraju, P. K. et al. Covid-19 in critically ill patients in the seattle region&#x2014;case series. N. Engl. J. Med. 10.1056/NEJMoa2004500 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7143164</ArticleId><ArticleId IdType="pubmed">32227758</ArticleId></ArticleIdList></Reference><Reference><Citation>Verity R, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet. 2020;3099:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158570</ArticleId><ArticleId IdType="pubmed">32240634</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertz D, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ Br. Med. J. 2013;347:f5061. doi: 10.1136/bmj.f5061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.f5061</ArticleId><ArticleId IdType="pmc">PMC3805492</ArticleId><ArticleId IdType="pubmed">23974637</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed C, et al. Complications among adults hospitalized with influenza: a comparison of seasonal influenza and the 2009 H1N1 pandemic. Clin. Infect. Dis. 2014;59:166&#x2013;174. doi: 10.1093/cid/ciu285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu285</ArticleId><ArticleId IdType="pmc">PMC7314251</ArticleId><ArticleId IdType="pubmed">24785230</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan, W. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 10.1056/NEJMoa2002032 (2020).</Citation></Reference><Reference><Citation>Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli, C. M. et al. Factors associated with hospitalization and critical illness among 4103 patients with COVID-19 disease in New York City. medRxiv10.1101/2020.04.08.20057794 (2020).</Citation></Reference><Reference><Citation>Garg, S., Kim, L., Whitaker, M., O&#x2019;Halloran, A. &amp; Cummings, C. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019&#x2014;COVID-NET, 14 States, March 1&#x2013;30, 2020. MMWR Morb. Mortal Wkly Rep.10.15585/mmwr.mm6915e3 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755063</ArticleId><ArticleId IdType="pubmed">32298251</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting P, et al. What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis. BMJ Open. 2017;7:e012674. doi: 10.1136/bmjopen-2016-012674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-012674</ArticleId><ArticleId IdType="pmc">PMC5541442</ArticleId><ArticleId IdType="pubmed">28389482</ArticleId></ArticleIdList></Reference><Reference><Citation>Horby, P. et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv10.1101/2020.06.22.20137273 (2020).</Citation></Reference><Reference><Citation>Vogelstein, J. T. et al. Alpha-1 adrenergic receptor antagonists for preventing acute respiratory distress syndrome and death from cytokine storm syndrome. Preprint at https://arxiv.org/abs/2004.10117 (2020).</Citation></Reference><Reference><Citation>CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019&#x2014;United States, February 12&#x2013;March 28, 2020. MMWR Morb. Mortal Wkly Rep.69, 382 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7119513</ArticleId><ArticleId IdType="pubmed">32240123</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli, G. et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA10.1001/jama.2020.5394 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J. Am. Med. Inf. Assoc. 2015;22:553&#x2013;564. doi: 10.1093/jamia/ocu023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud. Health Technol. Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Gil MDM, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP) Inform. Prim. Care. 2011;19:135&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">22688222</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-A, Yoon S, Kim L-Y, Kim D-S. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J. Korean Med. Sci. 2017;32:718&#x2013;728. doi: 10.3346/jkms.2017.32.5.718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2017.32.5.718</ArticleId><ArticleId IdType="pmc">PMC5383602</ArticleId><ArticleId IdType="pubmed">28378543</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta, S. et al. A new paradigm for accelerating clinical data science at Stanford Medicine. Preprint at https://arxiv.org/abs/2003.10534 (2020).</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J. Am. Med. Inform. Assoc. 2011;19:54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. The Book of OHDSI (Independently published, 2019).</Citation></Reference><Reference><Citation>Brat GA, et al. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. npj Digit. Med. 2020;3:109. doi: 10.1038/s41746-020-00308-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00308-0</ArticleId><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Melissa, H., Christopher, C. &amp; Kenneth, G. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J. Am. Med. Informatics Assoc. 10.1093/jamia/ocaa196 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 2011;46:399&#x2013;424. doi: 10.1080/00273171.2011.568786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00273171.2011.568786</ArticleId><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn, E. et al. Deep phenotyping of 34,128 patients hospitalised with COVID-19 and a comparison with 81,596 influenza patients in America, Europe and Asia: an international network study. medRxiv10.1101/2020.04.22.20074336 (2020).</Citation></Reference><Reference><Citation>OHDSI. CohortDiagnostics. https://github.com/OHDSI/CohortDiagnostics.</Citation></Reference><Reference><Citation>OHDSI. FeatureExtraction. https://github.com/OHDSI/FeatureExtraction.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33027834</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1869-0327</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Applied clinical informatics</Title><ISOAbbreviation>Appl Clin Inform</ISOAbbreviation></Journal><ArticleTitle>Content Coverage Evaluation of the OMOP Vocabulary on the Transplant Domain Focusing on Concepts Relevant for Kidney Transplant Outcomes Analysis.</ArticleTitle><Pagination><StartPage>650</StartPage><EndPage>658</EndPage><MedlinePgn>650-658</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0040-1716528</ELocationID><Abstract><AbstractText Label="BACKGROUND">Improving outcomes of transplant recipients within and across transplant centers is important with the increasing number of organ transplantations being performed. The current practice is to analyze the outcomes based on patient level data submitted to the United Network for Organ Sharing (UNOS). Augmenting the UNOS data with other sources such as the electronic health record will enrich the outcomes analysis, for which a common data model (CDM) can be a helpful tool for transforming heterogeneous source data into a uniform format.</AbstractText><AbstractText Label="OBJECTIVES">In this study, we evaluated the feasibility of representing concepts from the UNOS transplant registry forms with the Observational Medical Outcomes Partnership (OMOP) CDM vocabulary to understand the content coverage of OMOP vocabulary on transplant-specific concepts.</AbstractText><AbstractText Label="METHODS">Two annotators manually mapped a total of 3,571 unique concepts extracted from the UNOS registry forms to concepts in the OMOP vocabulary. Concept mappings were evaluated by (1) examining the agreement among the initial two annotators and (2) investigating the number of UNOS concepts not mapped to a concept in the OMOP vocabulary and then classifying them. A subset of mappings was validated by clinicians.</AbstractText><AbstractText Label="RESULTS">There was a substantial agreement between annotators with a kappa score of 0.71. We found that 55.5% of UNOS concepts could not be represented with OMOP standard concepts. The majority of unmapped UNOS concepts were categorized into transplant, measurement, condition, and procedure concepts.</AbstractText><AbstractText Label="CONCLUSION">We identified categories of unmapped concepts and found that some transplant-specific concepts do not exist in the OMOP vocabulary. We suggest that adding these missing concepts to OMOP would facilitate further research in the transplant domain.</AbstractText><CopyrightInformation>Georg Thieme Verlag KG Stuttgart &#xb7; New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sin</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsapepas</LastName><ForeName>Demetra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Transplantation, New York Presbyterian Hospital, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Leigh-Anne</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Columbia University Medical Center, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Husain</LastName><ForeName>Syed A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohan</LastName><ForeName>Sumit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Medicine, Columbia University Medical Center, New York, New York, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 DK114893</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MD014161</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DK116066</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR002062</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Appl Clin Inform</MedlineTA><NlmUniqueID>101537732</NlmUniqueID><ISSNLinking>1869-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016030" MajorTopicYN="Y">Kidney Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="Y">Vocabulary, Controlled</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>S.M. reports grants and other from Angion Pharmaceuticals, personal fees from Kidney International Reports, outside the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>7</Day><Hour>20</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33027834</ArticleId><ArticleId IdType="pmc">PMC7557323</ArticleId><ArticleId IdType="doi">10.1055/s-0040-1716528</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abecassis M, Bartlett S T, Collins A J. Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin J Am Soc Nephrol. 2008;3(02):471&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390948</ArticleId><ArticleId IdType="pubmed">18256371</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonelli M, Wiebe N, Knoll G. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093&#x2013;2109.</Citation><ArticleIdList><ArticleId IdType="pubmed">21883901</ArticleId></ArticleIdList></Reference><Reference><Citation>United Network for Organ Sharing  US organ transplants, deceased donors set record in 2016Available at:https://www.unos.org/us-organ-transplants-set-record-in-2016/. Published 2017. Accessed June 21, 2020</Citation></Reference><Reference><Citation>Howard R J, Cornell D L, Schold J D. CMS oversight, OPOs and transplant centers and the law of unintended consequences. Clin Transplant. 2009;23(06):778&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">20447183</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivas T R, Taber D J, Su Z. Big data, predictive analytics and quality improvement in kidney transplantation- a proof of concept. Am J Transplant. 2017;17(03):671&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">27804279</ArticleId></ArticleIdList></Reference><Reference><Citation>Massie A B, Kucirka L M, Segev D L. Big data in organ transplantation: registries and administrative claims. Am J Transplant. 2014;14(08):1723&#x2013;1730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4387865</ArticleId><ArticleId IdType="pubmed">25040084</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Mohan S, Husain S A, Natarajan K. Expanding transplant outcomes research opportunities through the use of a common data model. Am J Transplant. 2018;18(06):1321&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6070138</ArticleId><ArticleId IdType="pubmed">29687963</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnbeek P R. Converting to a common data model: what is lost in translation?: commentary on &#x201c;fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model&#x201d;. Drug Saf. 2014;37(11):893&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">25187018</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunyemi O I, Meeker D, Kim H-E, Ashish N, Farzaneh S, Boxwala A. Identifying appropriate reference data models for comparative effectiveness research (CER) studies based on data from clinical information systems. Med Care. 2013;51(08) 03:S45&#x2013;S52.</Citation><ArticleIdList><ArticleId IdType="pubmed">23774519</ArticleId></ArticleIdList></Reference><Reference><Citation>Steindel S J. International classification of diseases, 10th edition, clinical modification and procedure coding system: descriptive overview of the next generation HIPAA code sets. J Am Med Inform Assoc. 2010;17(03):274&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995704</ArticleId><ArticleId IdType="pubmed">20442144</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E A, Makadia R, Matcho A. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015;22(03):553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann J G, Joss M AH, Embree K, Murphy S N. Data model harmonization for the All Of Us Research Program: transforming i2b2 data into the OMOP common data model. PLoS One. 2019;14(02):e0212463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn M G, Batson D, Schilling L M.Data model considerations for clinical effectiveness researchers Med Care 201250(Suppl):S60&#x2013;S67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3824370</ArticleId><ArticleId IdType="pubmed">22692260</ArticleId></ArticleIdList></Reference><Reference><Citation>Garza M, Del Fiol G, Tenenbaum J, Walden A, Zozus M N. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6810649</ArticleId><ArticleId IdType="pubmed">27989817</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  Software toolsAvailable at:https://www.ohdsi.org/software-tools/. Accessed June 20, 2020</Citation></Reference><Reference><Citation>Maier C, Christoph J, Schmidt D. Experiences of transforming a complex nephrologic care and research database into i2b2 using the IDRT tools. J Healthc Eng. 2019;2019:5.640685E6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6360056</ArticleId><ArticleId IdType="pubmed">30800257</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X, Murugesan S, Bhullar H. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. Drug Saf. 2013;36(02):119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23329543</ArticleId></ArticleIdList></Reference><Reference><Citation>Matcho A, Ryan P, Fife D, Reich C. Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model. Drug Saf. 2014;37(11):945&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4206771</ArticleId><ArticleId IdType="pubmed">25187016</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale L-A, Mohan S, Natarajan K.Advancing outcomes analysis within and across transplant centers using the OMOP CDMOHDSI Symposium. Available at:https://www.ohdsi.org/web/wiki/lib/exe/fetch.php?media=resources:unos_mapping.pdf. Published 2016. Accessed June 20, 2020</Citation></Reference><Reference><Citation>Ryan P, Duke J, Hripcsak G.Open-source big data analytics in healthcareAvailable at:https://www.ohdsi.org/wp-content/uploads/2014/07/OHDSI-Tutorial-PreFinal-mod.pdf. Accessed June 21, 2020</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  USAGIAvailable at:http://www.ohdsi.org/web/wiki/doku.php?id=documentation:software:usagi. Published 2017. Accessed June 21, 2020</Citation></Reference><Reference><Citation>United Network for Organ Sharing (UNOS)  Data collection formsAvailable at:https://transplantpro.org/technology/data-collection-forms/. Accessed June 21, 2020</Citation></Reference><Reference><Citation>Reich C, Ostropolets A.Chapter 5: Standardized vocabularies 2019. Accessed August 12, 2020 at:https://ohdsi.github.io/TheBookOfOhdsi/StandardizedVocabularies.html#fn25</Citation></Reference><Reference><Citation>Maier C, Lang L, Storf H. Towards Implementation of OMOP in a German University Hospital Consortium. Appl Clin Inform. 2018;9(01):54&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics . ATHENA. http://athena.ohdsi.org http://athena.ohdsi.org</Citation></Reference><Reference><Citation>McHugh M L. Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 2012;22(03):276&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3900052</ArticleId><ArticleId IdType="pubmed">23092060</ArticleId></ArticleIdList></Reference><Reference><Citation>US National Library of Medicine  NIH common data elements (CDE) repositoryAvailable at:https://cde.nlm.nih.gov/home. Accessed June 21, 2020</Citation></Reference><Reference><Citation>Common Data Element Repository (CDER) Library . Available at:https://repository.usaspending.gov/cder_library/. Accessed June 21, 2020</Citation></Reference><Reference><Citation>Cho S, Sin M, Tsapepas D.UNOS-to-OMOP GitHub repositoryAvailable at:https://github.com/sylviacho/UNOS-to-OMOP/wiki. Published 2020. Accessed July 12, 2020</Citation></Reference><Reference><Citation>Cimino J J.Desiderata for controlled medical vocabularies in the twenty-first century Methods Inf Med 199837(4&#x2013;5):394&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415631</ArticleId><ArticleId IdType="pubmed">9865037</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  Common data model: Measurement table OHDSI; Published 2017. Accessed June 21, 2020 at:http://www.ohdsi.org/web/wiki/doku.php?id=documentation:cdm:measurement</Citation></Reference><Reference><Citation>Observational Health Data Sciences and Informatics  Common data model: Procedure_occurrence table OHDSI; Published 2017. Accessed June 21, 2020 at:http://www.ohdsi.org/web/wiki/doku.php?id=documentation:cdm:procedure_occurrence</Citation></Reference><Reference><Citation>Lee D, Cornet R, Lau F, de Keizer N. A survey of SNOMED CT implementations. J Biomed Inform. 2013;46(01):87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7185627</ArticleId><ArticleId IdType="pubmed">23041717</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman C PA. A &#x201c;fundamental theorem&#x201d; of biomedical informatics. J Am Med Inform Assoc. 2009;16(02):169&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649317</ArticleId><ArticleId IdType="pubmed">19074294</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsapepas D, King K L, Husain S A, Mohan S. Evaluation of kidney allocation critical data validity in the OPTN registry using dialysis dates. Am J Transplant. 2020;20(01):318&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">31550418</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsolo K. Dordrecht: Springer; 2012. EHR-linked registries for studies of populations; pp. 133&#x2013;148.</Citation></Reference><Reference><Citation>Seneviratne M G, Seto T, Blayney D W, Brooks J D, Hernandez-Boussard T. Architecture and implementation of a clinical research data warehouse for prostate cancer. EGEMS (Wash DC) 2018;6(01):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6078122</ArticleId><ArticleId IdType="pubmed">30094285</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33083538</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2379-6146</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Learning health systems</Title><ISOAbbreviation>Learn Health Syst</ISOAbbreviation></Journal><ArticleTitle>Toward cross-platform electronic health record-driven phenotyping using Clinical Quality Language.</ArticleTitle><Pagination><StartPage>e10233</StartPage><MedlinePgn>e10233</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e10233</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/lrh2.10233</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Electronic health record (EHR)-driven phenotyping is a critical first step in generating biomedical knowledge from EHR data. Despite recent progress, current phenotyping approaches are manual, time-consuming, error-prone, and platform-specific. This results in duplication of effort and highly variable results across systems and institutions, and is not scalable or portable. In this work, we investigate how the nascent Clinical Quality Language (CQL) can address these issues and enable high-throughput, cross-platform phenotyping.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We selected a clinically validated heart failure (HF) phenotype definition and translated it into CQL, then developed a CQL execution engine to integrate with the Observational Health Data Sciences and Informatics (OHDSI) platform. We executed the phenotype definition at two large academic medical centers, Northwestern Medicine and Weill Cornell Medicine, and conducted results verification (n = 100) to determine precision and recall. We additionally executed the same phenotype definition against two different data platforms, OHDSI and Fast Healthcare Interoperability Resources (FHIR), using the same underlying dataset and compared the results.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CQL is expressive enough to represent the HF phenotype definition, including Boolean and aggregate operators, and temporal relationships between data elements. The language design also enabled the implementation of a custom execution engine with relative ease, and results verification at both sites revealed that precision and recall were both 100%. Cross-platform execution resulted in identical patient cohorts generated by both data platforms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CQL supports the representation of arbitrarily complex phenotype definitions, and our execution engine implementation demonstrated cross-platform execution against two widely used clinical data platforms. The language thus has the potential to help address current limitations with portability in EHR-driven phenotyping and scale in learning health systems.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Learning Health Systems published by Wiley Periodicals LLC on behalf of the University of Michigan.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brandt</LastName><ForeName>Pascal S</ForeName><Initials>PS</Initials><Identifier Source="ORCID">0000-0001-5116-0555</Identifier><AffiliationInfo><Affiliation>Biomedical Informatics and Medical Education University of Washington Seattle Washington USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiefer</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research Mayo Clinic Rochester Minnesota USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacheco</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Feinberg School of Medicine Northwestern University Chicago Illinois USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adekkanattu</LastName><ForeName>Prakash</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Information Technologies and Services Weill Cornell Medicine New York New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sholle</LastName><ForeName>Evan T</ForeName><Initials>ET</Initials><AffiliationInfo><Affiliation>Information Technologies and Services Weill Cornell Medicine New York New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Faraz S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Feinberg School of Medicine Northwestern University Chicago Illinois USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5291-5198</Identifier><AffiliationInfo><Affiliation>Department of Population Health Sciences Weill Cornell Medicine New York New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhenxing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences Weill Cornell Medicine New York New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ancker</LastName><ForeName>Jessica S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences Weill Cornell Medicine New York New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences Weill Cornell Medicine New York New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Feinberg School of Medicine Northwestern University Chicago Illinois USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Guoqian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research Mayo Clinic Rochester Minnesota USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathak</LastName><ForeName>Jyotishman</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences Weill Cornell Medicine New York New York USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rasmussen</LastName><ForeName>Luke V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Feinberg School of Medicine Northwestern University Chicago Illinois USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM105688</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Learn Health Syst</MedlineTA><NlmUniqueID>101708071</NlmUniqueID><ISSNLinking>2379-6146</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical Quality Language</Keyword><Keyword MajorTopicYN="N">common data models</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">phenotyping</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33083538</ArticleId><ArticleId IdType="pmc">PMC7556419</ArticleId><ArticleId IdType="doi">10.1002/lrh2.10233</ArticleId><ArticleId IdType="pii">LRH210233</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Institute of Medicine (IOM) . The Learning Healthcare System. Washington, DC: National Academies Press; 2007. doi:10.17226/11903</Citation><ArticleIdList><ArticleId IdType="doi">10.17226/11903</ArticleId></ArticleIdList></Reference><Reference><Citation>Banda JM, Seneviratne M, Hernandez&#x2010;Boussard T, Shah NH. Advances in electronic phenotyping: from rule&#x2010;based definitions to machine learning models. Annu Rev Biomed Data Sci. 2018;1:53&#x2010;68. 10.1146/annurev-biodatasci.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biodatasci</ArticleId><ArticleId IdType="pmc">PMC6583807</ArticleId><ArticleId IdType="pubmed">31218278</ArticleId></ArticleIdList></Reference><Reference><Citation>
Rasmussen LV, Kiefer RC, Mo H, et al. A modular architecture for electronic health record&#x2010;driven phenotyping. AMIA Jt Summits Transl Sci Proc. 2015;2015:147&#x2010;151. http://www.ncbi.nlm.nih.gov/pubmed/26306258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525215</ArticleId><ArticleId IdType="pubmed">26306258</ArticleId></ArticleIdList></Reference><Reference><Citation>
CQL Documentation: Introduction
. https://cql.hl7.org/01-introduction.html.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2010;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics&#x2010;2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56&#x2010;e528.</Citation><ArticleIdList><ArticleId IdType="pubmed">30700139</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak J, Kho AN, Denny JC. Electronic health records&#x2010;driven phenotyping: challenges, recent advances, and perspectives. J Am Med Informatics Assoc. 2013;20(e2):e206&#x2010;e211. 10.1136/amiajnl-2013-002428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2013-002428</ArticleId><ArticleId IdType="pmc">PMC3861925</ArticleId><ArticleId IdType="pubmed">24302669</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton KM, Peissig PL, Kho AN, et al. Validation of electronic medical record&#x2010;based phenotyping algorithms: results and lessons learned from the eMERGE network. J Am Med Inform Assoc. 2013;20(E1):147&#x2010;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3715338</ArticleId><ArticleId IdType="pubmed">23531748</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, et al. Facilitating phenotype transfer using a common data model. J Biomed Inform. 2019;96:103253 10.1016/j.jbi.2019.103253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103253</ArticleId><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang N, Liu C, Rasmussen LV, et al. Making work visible for electronic phenotype implementation: lessons learned from the eMERGE network. J Biomed Inform. 2019;99:103293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6894517</ArticleId><ArticleId IdType="pubmed">31542521</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo H, Thompson WK, Rasmussen LV, et al. Desiderata for computable representations of electronic health records&#x2010;driven phenotype algorithms. J Am Med Inform Assoc. 2015;22(6):1220&#x2010;1230. 10.1093/jamia/ocv112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocv112</ArticleId><ArticleId IdType="pmc">PMC4639716</ArticleId><ArticleId IdType="pubmed">26342218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross TR, Ng D, Brown JS, et al. The HMO Research Network Virtual Data Warehouse: a public data model to support collaboration. EGEMS (Wash DC). 2014;2(1):1049 Published March 24, 2014. 10.13063/2327-9214.1049.</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1049</ArticleId><ArticleId IdType="pmc">PMC4371424</ArticleId><ArticleId IdType="pubmed">25848584</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt R, Brown JS, Robb M, et al. The FDA sentinel initiative&#x2014;an evolving national resource. N Engl J Med. 2018;379(22):2091&#x2010;2093.</Citation><ArticleIdList><ArticleId IdType="pubmed">30485777</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarty CA, Chisholm RL, Chute CG, et al. The eMERGE network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics. 2011;4(1):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038887</ArticleId><ArticleId IdType="pubmed">21269473</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman O, Kuivaniemi H, Gerard T, et al. The electronic medical records and genomics (eMERGE) network: past, present, and future. Genet Med. 2013;15(10):761&#x2010;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795928</ArticleId><ArticleId IdType="pubmed">23743551</ArticleId></ArticleIdList></Reference><Reference><Citation>Zouk H, Venner E, Lennon NJ, et al. Harmonizing clinical sequencing and interpretation for the eMERGE III network. Am J Hum Genet. 2019;105(3):588&#x2010;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6731372</ArticleId><ArticleId IdType="pubmed">31447099</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. Launching PCORnet, a national patient&#x2010;centered clinical research network. J Am Med Inform Assoc. 2014;21(4):578&#x2010;582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>
The ACT Network
. https://www.actnetwork.us/national.</Citation></Reference><Reference><Citation>
Rasmussen LV, Brandt PS, Jiang G, et al. Considerations for improving the portability of electronic health record&#x2010;based phenotype algorithms. AMIA Annu Symp Proc. 2020;2019:755&#x2013;764. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153055/. </Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153055</ArticleId><ArticleId IdType="pubmed">32308871</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma H, Mao C, Zhang Y, et al. Developing a portable natural language processing based phenotyping system. BMC Med Inform Decis Mak. 2019;19:78 10.1186/s12911-019-0786-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-019-0786-z</ArticleId><ArticleId IdType="pmc">PMC6448187</ArticleId><ArticleId IdType="pubmed">30943974</ArticleId></ArticleIdList></Reference><Reference><Citation>
Li D, Endle CM, Murthy S, et al. Modeling and executing electronic health records driven phenotyping algorithms using the NQF quality data Model and JBoss&#xae; drools engine. AMIA Annu Symp Proc. 2012;2012:532&#x2010;541. http://www.ncbi.nlm.nih.gov/pubmed/23304325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540464</ArticleId><ArticleId IdType="pubmed">23304325</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mo H, Pacheco JA, Rasmussen LV, et al. A prototype for executable and portable electronic clinical quality measures using the KNIME analytics platform. AMIA Jt Summits Transl Sci Proc. 2015;2015(Icd):127&#x2010;131. http://www.ncbi.nlm.nih.gov/pubmed/26306254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4525225</ArticleId><ArticleId IdType="pubmed">26306254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco JA, Rasmussen LV, Kiefer RC, et al. A case study evaluating the portability of an executable computable phenotype algorithm across multiple institutions and electronic health record environments. J Am Med Inform Assoc. 2018;25(11):1540&#x2010;1546. 10.1093/jamia/ocy101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocy101</ArticleId><ArticleId IdType="pmc">PMC6213083</ArticleId><ArticleId IdType="pubmed">30124903</ArticleId></ArticleIdList></Reference><Reference><Citation>Fast Healthcare Interoperability Resources (FHIR) Specification. http://hl7.org/fhir/Accessed January 27, 2020.</Citation></Reference><Reference><Citation>Measure Authoring Tool (MAT). https://www.emeasuretool.cms.gov/Accessed January 23, 2020.</Citation></Reference><Reference><Citation>CDS Authoring Tool | CDS Connect. https://cds.ahrq.gov/cdsconnect/authoringAccessed January 23, 2020.</Citation></Reference><Reference><Citation>Savarese G, Vedin O, D'Amario D, et al. Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail. 2019;7(4):306&#x2010;317. 10.1016/j.jchf.2018.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2018.11.019</ArticleId><ArticleId IdType="pubmed">30852236</ArticleId></ArticleIdList></Reference><Reference><Citation>Tison GH, Chamberlain AM, Pletcher MJ, et al. Identifying heart failure using EMR&#x2010;based algorithms. Int J Med Inform. 2018;120:1&#x2010;7. 10.1016/j.ijmedinf.2018.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2018.09.016</ArticleId><ArticleId IdType="pmc">PMC6233734</ArticleId><ArticleId IdType="pubmed">30409334</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhinav G, Norton CR, Thomas TN, et al. Predictors of incident heart failure in a large insured population. Circ Heart Fail. 2010;3(6):698&#x2010;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3113516</ArticleId><ArticleId IdType="pubmed">20798277</ArticleId></ArticleIdList></Reference><Reference><Citation>HL7 International&#x2010;Biomedical Research, and Regulation Work Group. Common Data Models Harmonization. https://build.fhir.org/ig/HL7/cdmh/cdmh-overview.html.</Citation></Reference><Reference><Citation>Clinical Quality Language Community Projects Github. https://github.com/cqframework/clinical_quality_language/wiki/Community-Projects Accessed January 31, 2020.</Citation></Reference><Reference><Citation>PhEMA Heart Failure Use Case. Github. https://github.com/PheMA/heart-failure-use-case. Accessed January 23, 2020.</Citation></Reference><Reference><Citation>Bodenreider O, Nguyen D, Chiang P, et al. The NLM value set authority center. Stud Health Technol Inform. 2013;192:1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4300102</ArticleId><ArticleId IdType="pubmed">23920998</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Level Seven Reference Implementation Model, Version 3 &#x2013; ActCode &#x2013; Classes | NCBO BioPortal. http://bioportal.bioontology.org/ontologies/HL7?p=classes&amp;conceptid=C1553812.</Citation></Reference><Reference><Citation>Encounter &#x2013; FHIR. https://www.hl7.org/fhir/encounter-definitions.html#Encounter.class. Accessed January 31, 2020.</Citation></Reference><Reference><Citation>Circe Github. https://github.com/OHDSI/circe-be. Accessed January 23, 2020.</Citation></Reference><Reference><Citation>CQL on OMOP Github. https://github.com/PheMA/cql-on-omopAccessed January 23, 2020.</Citation></Reference><Reference><Citation>CQL Logical Specification. https://cql.hl7.org/04-logicalspecification.htmlAccessed January 23, 2020.</Citation></Reference><Reference><Citation>
Parr T. Language Implementation Patterns: Create your Own Domain&#x2010;Specific and General Programming Languages. Raleigh, North Carolina: Pragmatic Bookshelf; 2009. 
https://www.linkedin.com/company/the-pragmatic-programmers/.</Citation></Reference><Reference><Citation>Wiley L. Luke Rasmussen Laurakwiley/ReviewR: ReviewR November 2018. doi: 10.5281/zenodo.1488535</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.1488535</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical Quality Language Evaluation Engine Github. https://github.com/DBCG/cql_engineAccessed January 27, 2020.</Citation></Reference><Reference><Citation>HAPI FHIR &#x2013; The Open Source FHIR API for Java. https://hapifhir.io/Accessed January 27, 2020.</Citation></Reference><Reference><Citation>CMS 2008&#x2013;2010 Data Entrepreneurs' Synthetic Public Use File (DE&#x2010;SynPUF) | CMS. https://www.cms.gov/Research-Statistics-Data-and-Systems/Downloadable-Public-Use-Files/SynPUFs/DE_Syn_PUF.</Citation></Reference><Reference><Citation>OHDSI CMS SynPUF ETL Github. https://github.com/OHDSI/ETL-CMS.</Citation></Reference><Reference><Citation>
Khalilia M, Choi M, Henderson A, Iyengar S, Braunstein M, Sun J. Clinical predictive modeling development and deployment through FHIR web services. AMIA Annu Symp Proc. 2015;2015:717&#x2010;726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765683/.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765683</ArticleId><ArticleId IdType="pubmed">26958207</ArticleId></ArticleIdList></Reference><Reference><Citation>Peissig PL, Rasmussen LV, Berg RL, et al. Importance of multi&#x2010;modal approaches to effectively identify cataract cases from electronic health records. J Am Med Inform Assoc. 2012;19(2):225&#x2010;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277618</ArticleId><ArticleId IdType="pubmed">22319176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby JC, Speltz P, Rasmussen LV, et al. PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability. J Am Med Inform Assoc. 2016;23(6):1046&#x2010;1052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070514</ArticleId><ArticleId IdType="pubmed">27026615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong N, Wen A, Shen F, et al. Developing a scalable FHIR&#x2010;based clinical data normalization pipeline for standardizing and integrating unstructured and structured electronic health record data. JAMIA Open. 2019;2(4):570&#x2010;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6993992</ArticleId><ArticleId IdType="pubmed">32025655</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SN, Weber G, Mendis M, et al. Serving the enterprise and beyond with informatics for integrating biology and the bedside (i2b2). J Am Med Inform Assoc. 2010;17(2):124&#x2010;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000779</ArticleId><ArticleId IdType="pubmed">20190053</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33097389</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1545-7214</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry</Title><ISOAbbreviation>Am J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Stroke Risk Among Elderly Users of Haloperidol and Typical Antipsychotics Versus Atypical Antipsychotics: A Real-World Study From a US Health Insurance Claims Database.</ArticleTitle><Pagination><StartPage>499</StartPage><EndPage>510</EndPage><MedlinePgn>499-510</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jagp.2020.09.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1064-7481(20)30499-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">We estimated stroke risk associated with new exposure to haloperidol, or any typical antipsychotic, versus atypical antipsychotic among patients aged &#x2265;65 years regardless of dementia status.</AbstractText><AbstractText Label="METHODS">IBM MarketScan Medicare Supplemental Database data (January 1, 2001 to December 31, 2017) were used. Stroke risk for new users of typical antipsychotics (T1 cohort) or haloperidol (T2 cohort) was compared with new users of atypical antipsychotics (C1 cohort) aged &#x2265;65 years. Crude incidence rate (IR) and incidence proportion of stroke were estimated within each cohort and gender subgroup. Three propensity score (PS) matching strategies were employed: Unadjusted (crude), Sentinel PS replication, and a large-scale regularized regression model (adapted PS).</AbstractText><AbstractText Label="RESULTS">Overall, 36,734 (T1), 24,074 (T2), and 226,990 (C1) patients were included. Crude IRs for stroke per 1000 person-years were 17.67 (T1), 23.74 (T2), and 14.17 (C1). In preplanned analyses, PS-matched calibrated hazard ratio (cHR) for stroke T1 versus C1 cohort was 1.08 (95% calibrated confidence interval [cCI]&#x202f;=&#x202f;0.75, 1.55) with Sentinel PS strategy and 1.31 (95% cCI&#x202f;=&#x202f;1.07, 1.60) with adapted PS strategy. The cHR for stroke in patients of T2 versus C1 was 1.69 (95% cCI&#x202f;=&#x202f;1.08, 2.75) with Sentinel PS strategy and 1.45 (95% cCI&#x202f;=&#x202f;1.17, 1.80) with adapted PS strategy.</AbstractText><AbstractText Label="CONCLUSION">Stroke risk in elderly new users of haloperidol was elevated compared to new users of atypical antipsychotics and was elevated for typical antipsychotics using the adapted PS strategy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fife</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Janssen Research and Development, LLC (DF, CB, JW), Titusville, NJ. Electronic address: DFife@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Janssen Research and Development, LLC (DF, CB, JW), Titusville, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>R Karl</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Established Products, Janssen Research and Development, LLC (RKK), Titusville, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Janssen Research and Development, LLC (DF, CB, JW), Titusville, NJ.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Geriatr Psychiatry</MedlineTA><NlmUniqueID>9309609</NlmUniqueID><ISSNLinking>1064-7481</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Haloperidol</Keyword><Keyword MajorTopicYN="N">atypical antipsychotics</Keyword><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">stroke risk</Keyword><Keyword MajorTopicYN="N">typical antipsychotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>24</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33097389</ArticleId><ArticleId IdType="doi">10.1016/j.jagp.2020.09.017</ArticleId><ArticleId IdType="pii">S1064-7481(20)30499-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33099616</PMID><DateRevised><Year>2021</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Erratum to: Large-Scale Evidence Generation and Evaluation across a Network of Databases (LEGEND): Assessing Validity Using Hypertension as a Case Study.</ArticleTitle><Pagination><StartPage>196</StartPage><MedlinePgn>196</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocaa256</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>RuiJun</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016425">Published Erratum</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumFor"><RefSource>J Am Med Inform Assoc. 2020 Aug 1;27(8):1268-1277</RefSource><PMID Version="1">32827027</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>25</Day><Hour>20</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33099616</ArticleId><ArticleId IdType="pmc">PMC7810446</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocaa256</ArticleId><ArticleId IdType="pii">5939805</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33099844</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Empirical assessment of case-based methods for identification of drugs associated with acute liver injury in the French National Healthcare System database (SNDS).</ArticleTitle><Pagination><StartPage>320</StartPage><EndPage>333</EndPage><MedlinePgn>320-333</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.5161</ELocationID><Abstract><AbstractText Label="PURPOSES">Drug induced acute liver injury (ALI) is a frequent cause of liver failure. Case-based designs were empirically assessed and calibrated in the French National claims database (SNDS), aiming to identify the optimum design for drug safety alert generation associated with ALI.</AbstractText><AbstractText Label="METHODS">All cases of ALI were extracted from SNDS (2009-2014) using specific and sensitive definitions. Positive and negative drug controls were used to compare 196 self-controlled case series (SCCS), case-control (CC), and case-population (CP) design variants, using area under the receiver operating curve (AUC), mean square error (MSE) and coverage probability. Parameters that had major impacts on results were identified through logistic regression.</AbstractText><AbstractText Label="RESULTS">Using a specific ALI definition, AUCs ranged from 0.78 to 0.94, 0.64 to 0.92 and 0.48 to 0.85, for SCCS, CC and CP, respectively. MSE ranged from 0.12 to 0.40, 0.22 to 0.39 and 1.03 to 5.29, respectively. Variants adjusting for multiple drug use had higher coverage probabilities. Univariate regressions showed that high AUCs were achieved with SCCS using exposed time as the risk window. The top SCCS variant yielded an AUC = 0.93 and MSE = 0.22 and coverage = 86%, with 1/7 negative and 13/18 positive controls presenting significant estimates.</AbstractText><AbstractText Label="CONCLUSIONS">SCCS adjusting for multiple drugs and using exposed time as the risk window performed best in generating ALI-related drug safety alert and providing estimates of the magnitude of the risk. This approach may be useful for ad-hoc pharmacoepidemiology studies to support regulatory actions.</AbstractText><CopyrightInformation>&#xa9; 2020 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thurin</LastName><ForeName>Nicolas H</ForeName><Initials>NH</Initials><Identifier Source="ORCID">0000-0003-3589-0819</Identifier><AffiliationInfo><Affiliation>Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lassalle</LastName><ForeName>R&#xe9;gis</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Epidemiology Analytics, Janssen Research and Development, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;nichon</LastName><ForeName>Marine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagne</LastName><ForeName>Joshua J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-5428-9733</Identifier><AffiliationInfo><Affiliation>Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rassen</LastName><ForeName>Jeremy A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Aetion, Inc., New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benichou</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>INSERM U1181, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weill</LastName><ForeName>Alain</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8687-9092</Identifier><AffiliationInfo><Affiliation>Caisse Nationale de l'Assurance Maladie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blin</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-1212-2817</Identifier><AffiliationInfo><Affiliation>Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Droz-Perroteau</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Univ. Bordeaux, INSERM CIC-P1401, Bordeaux PharmacoEpi, Bordeaux, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017891" MajorTopicYN="Y">Pharmacoepidemiology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SNDS</Keyword><Keyword MajorTopicYN="N">acute liver injury</Keyword><Keyword MajorTopicYN="N">calibration</Keyword><Keyword MajorTopicYN="N">case-control</Keyword><Keyword MajorTopicYN="N">case-population</Keyword><Keyword MajorTopicYN="N">claims database</Keyword><Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">self-controlled case series</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>25</Day><Hour>20</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33099844</ArticleId><ArticleId IdType="doi">10.1002/pds.5161</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Zimmerman HJ. The spectrum of hepatotoxicity. Perspect Biol Med. 1968;12:135-161.</Citation></Reference><Reference><Citation>Zimmerman HJ. Drug-induced liver disease. Drugs. 1978;16:25-45.</Citation></Reference><Reference><Citation>Hadem J, Tacke F, Bruns T, et al. Etiologies and outcomes of acute liver failure in Germany. Clin Gastroenterol Hepatol. 2012;10:664-669.e662.</Citation></Reference><Reference><Citation>Ostapowicz G, Fontana RJ, Schi&#xf8;dt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-954.</Citation></Reference><Reference><Citation>Wei G, Bergquist A, Broome U, et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med. 2007;262:393-401.</Citation></Reference><Reference><Citation>Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419-1425. 1425.e1411-1413; quiz e1419-1420.</Citation></Reference><Reference><Citation>Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451-455.</Citation></Reference><Reference><Citation>Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731-739.</Citation></Reference><Reference><Citation>Chen M, Zhang J, Wang Y, et al. The liver toxicity Knowledge Base: a systems approach to a complex end point. Clin Pharmacol Ther. 2013;93:409-412.</Citation></Reference><Reference><Citation>Gulmez SE, Larrey D, Pageaux GP, et al. Liver transplant associated with paracetamol overdose: results from the seven-country SALT study. Br J Clin Pharmacol. 2015;80:599-606.</Citation></Reference><Reference><Citation>Gulmez SE, Larrey D, Pageaux GP, et al. Methodology for a multinational case-population study on liver toxicity risks with NSAIDs: the study of acute liver transplant (SALT). Eur J Clin Pharmacol. 2013;69:605-616.</Citation></Reference><Reference><Citation>Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther. 2011;89:788-790.</Citation></Reference><Reference><Citation>Moore N, Duret S, Grolleau A, et al. Previous drug exposure in patients hospitalised for acute liver injury: a case-population study in the French National Healthcare Data System. Drug Saf. 2019;42:559-572.</Citation></Reference><Reference><Citation>Coloma PM, Avillach P, Salvo F, et al. A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases. Drug Saf. 2013;36:13-23.</Citation></Reference><Reference><Citation>Trifiro G, Pariente A, Coloma PM, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18:1176-1184.</Citation></Reference><Reference><Citation>Pacurariu AC, Straus SM, Trifiro G, et al. Useful interplay between spontaneous ADR reports and electronic healthcare Records in Signal Detection. Drug Saf. 2015;38:1201-1210.</Citation></Reference><Reference><Citation>Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, Hartzema AG. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the observational medical outcomes partnership. Stat Med. 2012;31:4401-4415.</Citation></Reference><Reference><Citation>Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(Suppl 1):S33-S47.</Citation></Reference><Reference><Citation>Abbing-Karahagopian V, Kurz X, de Vries F, et al. Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project. Curr Clin Pharmacol. 2014;9:130-138.</Citation></Reference><Reference><Citation>Brauer R, Douglas I, Garcia Rodriguez LA, et al. Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. Pharmacoepidemiol Drug Saf. 2016;25:29-38.</Citation></Reference><Reference><Citation>Brauer R, Ruig&#xf3;mez A, Klungel O, et al. The risk of acute liver injury among users of antibiotic medications: a comparison of case-only studies. Pharmacoepidemiol Drug Saf. 2016;25(Suppl 1):39-46.</Citation></Reference><Reference><Citation>Udo R, Tcherny-Lessenot S, Brauer R, et al. The risk of acute liver injury associated with the use of antibiotics-evaluating robustness of results in the pharmacoepidemiological research on outcomes of therapeutics by a European consortium (PROTECT) project. Pharmacoepidemiol Drug Saf. 2016;25(Suppl 1):47-55.</Citation></Reference><Reference><Citation>Madigan D, Schuemie MJ, Ryan PB. Empirical performance of the case-control method: lessons for developing a risk identification and analysis system. Drug Safety. 2013;36(Suppl 1):S73-S82.</Citation></Reference><Reference><Citation>Ryan P, Stang P, Overhage J, et al. A comparison of the empirical performance of methods for a risk identification system. Drug Saf. 2013;36(Suppl 1):S143-S158.</Citation></Reference><Reference><Citation>Suchard MA, Zorych I, Simpson SE, Schuemie MJ, Ryan PB, Madigan D. Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system. Drug Saf. 2013;36(Suppl 1):S83-S93.</Citation></Reference><Reference><Citation>Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26:954-962.</Citation></Reference><Reference><Citation>Gulmez SE, Unal US, Lassalle R, Chartier A, Grolleau A, Moore N. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: preliminary results from the EPIHAM study. Pharmacoepidemiol Drug Saf. 2018;27:1174-1181.</Citation></Reference><Reference><Citation>Schuemie MJ, Gini R, Coloma PM, et al. Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases. Drug Saf. 2013;36(Suppl 1):S159-S169.</Citation></Reference><Reference><Citation>Thurin NH, Lassalle R, Schuemie M, et al. Empirical assessment of case-based methods for identification of drugs associated with upper gastrointestinal bleeding in the French National Healthcare System database (SNDS). Pharmacoepidemiol Drug Saf. 2020;29:890-903.</Citation></Reference><Reference><Citation>Thurin NH, Lassalle R, Schuemie M, et al. Empirical assessment of case-based methods for drug safety alert identification in the French National Healthcare System database (SNDS): methodology of the ALCAPONE project. Pharmacoepidemiol Drug Saf. 2020;29(9):993-1000.</Citation></Reference><Reference><Citation>Armstrong B. A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies. Am J Epidemiol. 1987;126:356-358.</Citation></Reference><Reference><Citation>Cantor SB, Kattan MW. Determining the area under the ROC curve for a binary diagnostic test. Med Decis Mak. 2000;20:468-470.</Citation></Reference><Reference><Citation>Bezin J, Bosco-Levy P, Pariente A. False-positive results in pharmacoepidemiology and pharmacovigilance. Therapie. 2017;72:415-420.</Citation></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med. 2014;33:209-218.</Citation></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, Suchard MA. Robust empirical calibration of p-values using observational data. Stat Med. 2016;35:3883-3888.</Citation></Reference><Reference><Citation>Gruber S, Tchetgen Tchetgen E. Limitations of empirical calibration of p-values using observational data. Stat Med. 2016;35:3869-3882.</Citation></Reference><Reference><Citation>Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51:228-235.</Citation></Reference><Reference><Citation>Petersen I, Douglas I, Whitaker H. Self controlled case series methods: an alternative to standard epidemiological study designs. Br Med J. 2016;354:i4515.</Citation></Reference><Reference><Citation>Zimmerman HJ. Hepatotoxicity: the Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia: Lippincott Williams &amp; Wilkins; 1999.</Citation></Reference><Reference><Citation>Andrade RJ, Aithal GP, Bj&#xf6;rnsson ES, et al. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70:1222-1261.</Citation></Reference><Reference><Citation>Hoofnagle JH, Bjornsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med. 2019;381:264-273.</Citation></Reference><Reference><Citation>Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148:1340-1352 e1347.</Citation></Reference><Reference><Citation>Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol. 2010;16:5651-5661.</Citation></Reference><Reference><Citation>Schmeltzer PA, Kosinski AS, Kleiner DE, et al. Drug-induced liver injury N. liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int. 2016;36:603-609.</Citation></Reference><Reference><Citation>Simpson SE, Madigan D, Zorych I, Schuemie MJ, Ryan PB, Suchard MA. Multiple self-controlled case series for large-scale longitudinal observational databases. Biometrics. 2013;69:893-902.</Citation></Reference><Reference><Citation>Moore N, Gulmez SE, Larrey D, et al. Choice of the denominator in case population studies: event rates for registration for liver transplantation after exposure to NSAIDs in the SALT study in France. Pharmacoepidemiol Drug Saf. 2013;22:160-167.</Citation></Reference><Reference><Citation>Shahbaz A, Aziz K, Umair M, Sharifzadeh M, Sachmechi I. Acute liver injury induced by Sitagliptin: report of two cases and review of literature. Cureus. 2018;10:e2776.</Citation></Reference><Reference><Citation>Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol. 1977;105:488-495.</Citation></Reference><Reference><Citation>Secrest MH, Platt RW, Dormuth CR, et al. Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 2020;29(Suppl 1):26-34.</Citation></Reference><Reference><Citation>Timmer A, de Sordi D, Kappen S, et al. Validity of hospital ICD-10-GM codes to identify acute liver injury in Germany. Pharmacoepidemiol Drug Saf. 2019;28:1344-1352.</Citation></Reference><Reference><Citation>Al Sibae MR, McGuire BM. Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manag. 2009;5:617-626.</Citation></Reference><Reference><Citation>Gr&#xf8;nbaek L, Watson H, Vilstrup H, Jepsen P. Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites. United European Gastroenterol J. 2018;6:407-412.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>